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Foreword
The interest in wound healing goes back to the beginning of history and has not dimin-
ished throughout the centuries also because practical implications of wound healing 
studies have remained very relevant for public health. During the last century, much 
progress has been made in the understanding of basic mechanisms of skin wound heal-
ing, and it has been realized that healing processes evolve similarly in various organs. It 
has been established that fibrotic diseases are regulated by analogous mechanisms, 
albeit less controlled, compared to those regulating wound healing. Moreover, many 
advances, such as the use of antiseptics and, later, of antibiotics, as well as the intro-
duction of skin transplants have facilitated the treatment of wounds. It has been shown 
that wound healing evolution depends on several factors including the type of injury 
causing the damage, the tissue and/or organ affected, and the genetic or epigenetic 
background of the patient.
This Compendium has the merit of discussing a broad spectrum of topics, including 
the general biology of wound healing, modern diagnostic approaches, and therapeutic 
tools, applied to many different clinical situations. It should be of interest to teachers, 
students, and clinicians working in different aspects of wound healing biology and 
pathology. I am sure that it will rapidly become an important reference book in these 
fields.
Giulio Gabbiani
Emeritus Professor of Pathology  
University of Geneva  
Geneva, Switzerland
Preface
Scars represent the indelible cutaneous signature of aggression, surgery, traumas, and 
other events occurring during life. Most of them cause no problem, but some of them 
become sources of social exclusion, especially in a world where beauty is glorified. The 
psychosocial aspects surrounding culture, religion, and uses may be determinant. Even 
a transient redness may become source of suffering. Paradoxically, major keloids or 
massive contractures cause definitive loss of function or social problems leading to 
exclusion in developing countries, whereas simultaneously, we assist a rapid extension 
of laser technology indications for minor scar problems in the same countries. When 
we founded the Scar Club in 2006 together with Prof. Tom Mustoe, the aim was and 
still is the diffusion of knowledge and the development of all types of mechanical 
devices and antiscarring drugs.
Important financial support for researches in the field of growth factors and antis-
carring agents was recruited, aiming at controlling cell proliferation and secretion using 
chemical compounds, but the results were modest. Mechanical control of keloids or 
hypertrophic scars is proposed and reimbursed in some countries, applying medical 
devices capable to exert forces over the suture during the post-operative period or over 
post-burn scars.
This small group formed the Scar Club, composed of passionate colleagues who 
attracted surgeons and dermatologists, researchers, and physiotherapists, becoming an 
upmost scientific biannual rendezvous attracting colleagues from all over the world. 
The Scar Club group is built like a club, focusing on researches, new organizations and 
collaborations, new strategies, and development of guidelines.
The need for a larger educational initiative appeared since 2015 and the GScarS was 
founded in 2016. In October 2018, the first GScarS meeting was held in Shanghai with 
a successful event, grouping more than 600 colleagues. The idea came from the Board 
to provide an educational book free of charge, open source, and downloadable from 
anywhere. Patients and caregivers suffer most of the time from an insufficient profes-
sional training, and scar science is poorly represented in teaching courses at universi-
ties. Most of the proposed treatments are still based on cultural or anecdotal medicine. 
It is time to propose a structuration of the scar knowledge based on evidence-based 
medicine, consensus, guidelines, and key opinion leaders’ expertise.
This Compendium on scar management proposes a synthesis of the basic principles 
in scar management, including the large armamentarium of medical devices having 
proven efficacy and considered as the standards of care, and also the most recent tech-
niques accessible in scar management, provided by the most prominent specialists com-
ing from all over the world. It will be completed by a series of illustrations, schematic 
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Wound healing is a complex and tightly regulated pro-
cess and can be divided in three different overlapping 
phases: the inflammatory phase, the proliferation phase, 
and the remodeling phase. The first phase begins directly 
after wounding and is characterized by hemostasis and 
inflammation. Platelets play an important role in the 
formation of the blood clot to stop the bleeding, and 
through the secretion of chemokines, they recruit differ-
ent inflammatory cells such as neutrophils and mono-
cytes to the wound. The inflammatory cells clean the 
wound by phagocytosis of invading microorganisms 
and damaged tissue. The inflammatory cells also secrete 
chemotactic signals which attract fibroblasts and endo-
thelial cells to the wound which, together with the 
inflammatory cells, form the granulation tissue. This is 
the proliferation phase during which the destroyed tis-
sue is replaced. During this phase, the keratinocytes 
migrate over the granulation tissue to form a new epi-
dermis to close the skin defect.
The last phase in wound healing is the remodeling 
phase which is characterized by a decrease in cellularity 
and vascularity by apoptosis and an increase of synthesis 
and deposition of the components of the extracellular 
matrix (ECM). In adults, this process results is scar for-
mation, whereas in fetal skin, complete regeneration of 
the skin, including the formation of skin appendices such 
as hairs and sebaceous and sweat glands, takes place.
Since the 1950, studies on scarless healing in fetal 
skin in animals have been published, and in the late 
1970s of the last century, the first publications appeared 
describing scarless healing of fetal skin wounds in 
humans. Since then, several experimental studies on this 
subject have been published. From experimental animal 
and human studies it is known that scarless healing only 
occurs during the first period of gestation. Human 
fetuses lose the ability of skin regeneration around 
22 weeks of gestation.
Animal experiments in which adult, late gestational, 
and early gestational fetal skin were transplanted on 
early gestational fetuses showed clear differences in 
wound healing outcome. Incision wounds created in 
these transplants showed scar formation in adult and 
late gestational fetal skin, whereas the wound created in 
the fetal skin resulted in complete regeneration [1]. 
These experiments show not only that this phenomenon 
is an intrinsic property of the fetal skin itself  but also 
that scarless healing is not triggered by the intrauterine 
environment. Interestingly, the wounds at the fetal-adult 
interface also healed without scar formation implicating 
that direct contact of a wound with fetal skin is suffi-
cient to induce regeneration of the tissue [2].
Several mechanisms have been suggested to be 
responsible for the scarless healing in fetal skin, e.g., a 
diminished inflammatory reaction, differences in com-
position and architecture of the extracellular matrix, 
and mechanical load in fetal skin. Furthermore, fetal 
skin differs from adult skin in many factors commonly 
associated with scar formation such as proteolytic activ-
ity and TGF-β secretion and sensitivity. This chapter 
will discuss the different mechanisms during the three 
phases of wound healing proposed in the literature to be 
involved in scarless healing.
1.2  Inflammation
Several studies have shown that the inflammatory 
response to injury is strongly reduced in fetal skin 
wounds, and induction of the local inflammation causes 
scar formation in early fetal skin.
The inflammatory reaction involves recruitment of 
inflammatory cells which produce inflammatory media-
tors such as growth factors and cytokines. The growth 
factors and cytokines subsequently recruit more inflam-
matory cells.
Inflammation in adult wound healing starts off  with 
a pro-inflammatory cytokine and immune cell response 
and the activation of the acute phase response. During 
this period, invading microorganisms and injured tissue 
are cleared from the wound bed. Subsequently, the 
inflammatory reaction is skewed to an anti- inflammatory 
profile which initiates the healing response. Although 
the exact role of inflammatory cells in scar formation is 
not entirely elucidated, it is evident that they play an 
important role in the derailed wound healing process 
leading to scar formation. It was shown that in severely 
scarred wounds such as burn wounds, the acute (pro-)
inflammatory status is continued for a very long time.
Cells involved in the pro-inflammatory reaction are 
neutrophils and the M1 subtype macrophages, while 
macrophages of the M2 subtypes and regulatory T cells 
are anti-inflammatory, pro-healing cells.
Platelets are the first cells involved in the induction of 
the inflammatory reaction. The platelets are activated 
and aggregate during the coagulation phase forming the 
hemostatic plug. The activated platelets release cyto-
kines such as platelet-derived growth factor (PDGF), 
interleukins (IL) 1 and 6, and transforming growth fac-
tor beta (TGF-β) into the wound environment. It was 
shown that fetal platelets aggregate poorly when exposed 
to higher levels of hyaluronic acid, a component of the 
extracellular matrix, which is more abundantly expressed 
in fetal skin than in adult skin, and subsequently release 
lower levels of platelet-derived cytokines.
The lower platelet-derived cytokines are most likely 
responsible for the reduced inflammatory cell infiltra-
tion, such as neutrophils, macrophages, and lympho-
cytes, seen in fetal wounds at early gestational age [3].
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Not only recruitment of inflammatory cells from the 
circulation to the fetal wound is reduced, but also the 
number of resident macrophages, mast cells, Langerhans 
cells, dendritic cells and T cells in uninjured fetal skin is 
reduced. Moreover, the immune cells present in the fetal 
skin have the anti-inflammatory, pro-healing phenotype 
as fetal skin contains higher numbers of regulatory T 
cells and macrophages of the M2 phenotype. In addi-
tion, chemoattractant cytokines such as CCL17, CCL21, 
and CCL27 involved in recruitment of T cells and den-
dritic cells are reduced in fetal skin [4].
Although the inflammatory growth factor TGF-β 
plays an important role in scar formation, it is also 
involved in the resolution of the inflammatory reaction. 
In fetal skin, high levels of all the components of the 
TGF-β pathway are present, and moreover, the pathway 
seems to be highly activated. This highly activated 
TGF-β pathway might also result in fast suppression of 
the pro-inflammatory reaction in fetal wounds [4].
These findings indicate that indeed the (pro-)inflam-
matory immune reactions is reduced in fetal wound heal-
ing. However, the inflammatory component cannot be 
the key link to scarless healing since wounding of trans-
planted adult sheep skin to a sheep fetus resulted in scar 
formation despite the diminished inflammatory state of 
the fetus itself and the intrauterine environment.
1.3  Extracellular Matrix
The extracellular matrix of fetal skin is distinctly differ-
ent than adult skin matrix. Early gestational fetal skin 
contains higher amounts of collagen type III, fibronec-
tin EIIIA, and hyaluronic acid (HA) and is deficient in 
elastin. Similar expression profiles for ECM compo-
nents were demonstrated for the (adult) oral mucosa, a 
tissue also known for reduced scar formation.
Although collagen type I is the major component in 
both adult and fetal skin, in fetal skin, collagen type III/
collagen type I ratio is higher compared to adult skin. The 
higher levels of collagen type III have effects on the ECM 
organization and collagen fiber diameter. Downregulation 
of collagen type III expression results in increased scar 
formation and differentiation of fibroblasts into myofi-
broblasts, the main cell type involved in scar formation [5].
The properties of the ECM network do not depend 
only on the presence and percentage of the different col-
lagen subtypes and other ECM components but also on 
cross-linking of the ECM components. Increased cross- 
linking results in ECM accumulation and increased 
rigidity. In fetal skin, most of the collagen fibers are not 
cross-linked [5]. One of the enzymes involved in collagen 
and elastin cross-linking is lysyl oxidase (LOX). Early 
gestational fetal wounds show reduced LOX expression 
in comparison to late gestational wounds.
Other important components of the ECM which are 
differentially expressed between fetal and adult skin are 
glycosaminoglycans (GAGs) and proteoglycans. The 
GAGs like hyaluronic acid (HA) contain long polysaccha-
ride chains which can absorb large amounts of water and 
are important for hydration of the skin and determine the 
viscoelasticity of the skin. HA is thought to play an impor-
tant role in regulation of the inflammatory reaction during 
wound healing. However, its effect is dependent on the 
length of the polysaccharides. High- molecular- weight 
(HMW) HA suppresses the inflammatory reaction, while 
low-molecular-weight (LMW) HA fragments are immu-
nostimulatory and induce the inflammatory reaction [6].
Expression of HA in fetal skin is high and during 
wound healing the expression is induced in adults. The 
positive effect in fetal wound healing might be related to 
the balance between HMW and LMW HA, which may be 
caused by differential expression of enzymes  synthesizing 
HA (hyaluronan synthases) and enzymes degrading HA 
(hyaluronidases) between adult and fetal tissue. It was 
shown that addition of hyaluronidases to fetal wounds 
can induce fibroplasia, collagen deposition, and neovascu-
larization, processes involved in scar formation.
Besides the abovementioned component, elastin is also 
an important component of the ECM.  This protein is 
responsible for connective tissue pliability in the adult der-
mis; however, it is absent in early gestational skin, and its 
role in scarless wound healing is not clear [7] (. Fig. 1.1).
1.4  Angiogenesis
Several studies have shown that reduced angiogenesis dur-
ing adult wound healing reduces scar formation. However, 
indisputable evidence that this also plays a role during 
fetal wound healing has not been provided although sev-
eral studies suggested lack of strong neovascularization 
and reduced proangiogenic factors in fetal wounds.
Angiogenesis is much more prominent in adult 
wound healing compared to fetal wound healing. Early 
in adult wound healing, a dense capillary bed is created. 
However, this capillary tangle lacks the assembly of a 
functional network which is able to provide nutrition 
and oxygen to the wound bed [8].
It was shown that HA degradation products induce 
angiogenesis; therefore, the reduced synthesis of hyal-
uronidases not only has a positive effect on suppression 
of the inflammatory reaction but also reduces the exag-
gerated neovascularization seen in adult wounds.
However, this could also be attributed to reduced 
levels of  angiogenic growth factors such as basic fibro-
blast growth factor and PDGF. Addition of  angiogenic 
factors such as hyaluronidase and PDGF to fetal 






One of the factors thought to play a role in scar forma-
tion is delayed wound closure by reepithelialization. 
Wound closure in fetal wounds is much faster in com-
parison to adult wounds.
Fetal keratinocytes not only have a higher prolifera-
tion rate; also the mechanism of reepithelialization was 
found to be distinctly different between adult and fetal 
wounds. In adult wound healing reepithelialization, the 
basal keratinocytes at the wound edge undergo morpho-
logical changes. They form actin containing cytoplasmic 
elongations called lamellipodia through which they 
crawl over the extracellular matrix of the wound bed. To 
be able to migrate, the cells lose their ECM binding 
structures (hemidesmosomes) and the cell-cell binding 
sites (desmosomes). Fetal keratinocytes do not form 






  . Fig. 1.1 Expression of  different ECM components in adult and fetal skin. The specific ECM components are stained in brown
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cables through the front keratinocytes at the wound edge 
[9]. This cable runs from cell to cell most likely through 
the adherens junctions, another form of cell-cell junc-
tion similar to the desmosome. The cable is formed 
within hours after wounding and by contraction pulls 
the keratinocytes together to close the wound.
Integrins may also play a role in faster reepithelial-
ization in fetal wound healing. Integrins are heterodi-
meric transmembrane receptors which can bind to 
specific ECM components. Different combinations of 
the subunit determine the specificity for the different 
ECM components, and they determine cellular pro-
cesses like cell proliferation and migration. In the fetus, 
it was shown that specific integrins were rapidly upregu-
lated upon wounding and that this occurred much faster 
than in adult keratinocytes.
It is evident that there is an interaction between kera-
tinocytes and fibroblasts in the dermis. In vitro experi-
ments have shown that fetal keratinocytes suppress 
proliferation, myofibroblast differentiation, and ECM 
production, in fibroblasts derived from hypertrophic 
scar, whereas fetal keratinocytes promote proliferation 
and migration in fetal and adult healthy skin-derived 
fibroblasts.
1.6  Fibroblasts
Fibroblasts are the main cell type of the dermis; they 
produce the ECM and therefore play an important role 
in wound healing and scar formation. During wound 
healing, this cell type differentiates into myofibroblasts. 
These latter cells produce high levels of ECM compo-
nents and contain the contractile protein alpha smooth 
muscle actin (αSMA) which is involved in tissue con-
traction seen in scar formation. The transition to a myo-
fibroblast population in the wound healing environment 
and especially the persistence of this cell population are 
seen as the most important contributor to scar forma-
tion. Transforming growth factor beta (TGF-β) plays an 
important role in this process. However, TGF-β also 
plays an important role during embryonic and fetal 
development and thus is abundantly present in the fetus. 
TGF-β is stored as an inactive compound in the ECM. 
In order to execute its role in the many processes this 
growth factor is involved in, it has to be activated which 
ultimately leads to the induction of various genes 
 including genes involved in fibrosis and the process of 
scar formation. It was shown that all of the components 
are abundantly present in the fetal skin. In addition, the 
TGF-β pathway was also shown to be highly activated in 
healthy fetal skin in comparison to adult skin, but this 
does not result in fibrotic skin or scar formation. It was 
suggested that differential expression in TGF-β isoforms 
plays a crucial role in this. TGF-β1 and TGF-β2 are 
thought to be profibrotic, whereas TGF-β3 has antifi-
brotic properties. However, this segmentation is not 
completely indisputable. The balance between the profi-
brotic and antifibrotic TGF-β isoforms in fetal skin is 
shifted in comparison to adult skin: 99.5%:0.5% in adult 
to 97.4%:2.6% in fetal skin. However, the absolute con-
centrations of all TGF-β isoforms are much higher in 
fetal skin in comparison to adult skin.
Several differences were observed between fetal skin 
fibroblasts and adult dermal fibroblasts: The fetal cells 
migrated much faster than adult fibroblasts and exhib-
ited a “hyperactive morphology.” They produced higher 
amounts of extracellular matrix components. 
Furthermore, fetal cells produced a larger contraction 
effect when cultured in fibroblast-populated collagen 
lattices compared to adult fibroblasts.
As in fetal keratinocytes, it was shown that fetal 
fibroblasts express different integrins which results in 
higher proliferation and migration rates. Inhibition of 
one of the specific fetal integrins resulted in a more 
adultlike fibroblast phenotype.
Stimulation of fetal fibroblasts in vitro also induced 
myofibroblast differentiation and shows higher contrac-
tion of fibroblast-seeded collagen matrices [4].
Studies in which fetal skin cells have been applied to 
burn wounds show improved wound healing. Since it 
was shown that the fetal cells were not incorporated into 
the newly formed skin, it is thought that the cells secrete 
growth factors or in any other form interact with the 
host organism to accelerate wound healing.
1.7  Mechanical Forces
Mechanical forces, extracellular as well as intracellular, 
play an important role in skin homeostasis as it directs 
cell function and activity through a process called mech-
anotransduction. In this process, the composition, vis-
coelasticity, and stiffness of the ECM play an important 
role. Adult skin contains thick collagen bundles mainly 
consisting of type I fibrils, whereas fetal skin contains 
thin collagen fibers which are high in collagen type III 
fibrils and show reduced resting stress.
Through adhesion molecules on the surface of the 
skin, the integrins, the ECM is connected to the cyto-
skeleton of the cell. The link between the ECM and the 
cytoskeleton is a dynamic complex, called focal adhe-
sions (FA), which are constantly assembled and disas-
sembled. The FA are able to direct not only cell function 
such as gene expression but also cellular adhesion and 
cell migration. Fibroblasts exposed to mechanical stress 
form supermature FA displaying a specific composition 




were shown to have reduced FA protein expression 
among which Pax and different integrin subunits [4].
Also from clinical data, there is evidence that 
mechanical stress plays an important role in scar forma-
tion. Collagen fibers in the ECM of the skin are aligned 
in a specific pattern depending on the location of the 
body. This pattern forms the so-called Langer lines and 
determines the direction of the tension in the skin. From 
surgery, it is known that incisions made parallel to these 
lines heal with less scar formation than incisions perpen-
dicular to the Langer lines, suggesting that mechanical 
load to the wound influences scar formation [10]. In 
fetal skin, the ECM is organized in a loose reticular net-
work of collagen, while in adult skin, there are thicker 
more compact collagen fibers. In fetal wound healing, 
the same reticular ECM network is formed indistin-
guishable from the unaffected surrounding, whereas in 
adult wound healing, the collagen fibers are arranged in 
dense parallel bundles [11].
1.8  Remodeling
The last phase in wound healing is the remodeling phase. 
During this phase, cellularity decreases by apoptosis, 
and the degradation of the excessive extracellular matrix 
takes place. In adult wound healing, the predominant 
type III collagen is replaced by type I collagen. However, 
in fetal recovered skin, type III collagen remains the 
main subtype.
The deposition of extracellular matrix is an interplay 
between synthesis and degradation of the components 
of the ECM. Matrix metalloproteinases (MMPs) and 
tissue inhibitors of metalloproteinases (TIMPs) play an 
important role in this process. The MMP family consists 
of more than 20 members which are able to degrade 
most of the components of the ECM with different spe-
cific activities toward the different components. The 
process of ECM degradation is controlled by specific 
tissue inhibitors of metalloproteinases (TIMPs). 
Currently, four TIMPs have been identified which pos-
sess varying affinity to specific MMPs. An imbalance 
between MMPs and TIMPs affects the deposition of 
ECM.  In scarring, reduced collagen degradation as a 
result of reduced MMP expression and increased TIMP 
expression causes accumulation of ECM components. 
Early gestational fetal skin and middle gestational fetal 
skin express lower MMP and TIMP levels than late ges-
tational skin and adult skin. During fetal wound heal-
ing, several MMPs were increased in early gestational 
fetal wounds, whereas later during gestation, when 
wounds heal with scar formation, MMP levels were 
reduced, and TIMP levels were increased [12]. This later 
finding may explain the accumulation of ECM seen in 
scar formation.
1.9  Skin Appendix Formation
Early gestational wound healing results not only in res-
toration of the dermis and epidermis but also in the 
regeneration of skin appendages such as hair follicles 
and sebaceous and sweat glands.
Hair follicles contain several stem cell niches and 
play an important role in adult wound healing. In 
partial- thickness wounds in which part of the hair folli-
cle is still intact, healing can occur without scar forma-
tion.
Hair follicle development during embryogenesis 
starts, depending on the anatomical location, between 
weeks 9 and 15. One could envision that early gesta-
tional skin contains stem cells and still has the mecha-
nisms available to induce skin appendage development 
and create the stem niches but that these stem cells can 
also regenerate the skin. It was shown that allogeneic 
cells derived from fetal skin could enhance burn wound 
healing and reduce scar formation.
1.10  Conclusions
The fact that adult skin in an intrauterine environment 
still heal with scar formation despite the low inflamma-
tory milieu, the presence of fetal growth factors, and 
even fetal cells able to migrate into the adult tissue shows 
that the processes leading to scarless healing or scar for-
mation cannot be attributed to single individual mecha-
nisms, cells, or other factors but that it is a result of 
complex of interconnected processes.
Take-Home Messages
 5 Early to midgestational skin wounds result in skin 
regeneration instead of scar formation.
 5 The exact mechanism behind scarless healing is 
still unknown.
 5 Several mechanisms have been indicated: reduced 
inflammation, altered cytokine profile, and 
different ECM composition.
 5 The process of scarless healing is a result of a 
complex of interconnected processes.
 5 Several characteristics of fetal skin are shared with 
oral mucosa which is also known for its reduced 
scar formation.
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The last phase of  cutaneous wound healing produces 
the scar. Scars mainly consist of  dermal-like collagens 
that are covered by the epidermis. The early stage of 
scarring is marked by inflammation, whose purpose is 
to close the wound gap. The source of  the inflamma-
tion in the wound is the blood vessels, which exhibit 
vascular permeability after wounding. This allows the 
influx of  inflammatory soluble factors and many types 
of  immune cells from the circulation into the wound 
bed. Moreover, in the early stages of  wound healing, 
resident cells, including collagen-secreting fibroblasts, 
accumulate in the damaged area. Finally, collagens, 
blood vessels, and nerve fibers are produced, resulting 
in an immature scar that is red, elevated, hard, and 
painful.
2.2  Role of Mechanobiology in Cutaneous 
Scarring
Under normal circumstances, the immature scar then 
undergoes the scar maturation process over several 
months. This process involves tissue remodeling, which 
associates with a natural decrease in the inflammation 
and the numbers of blood vessels, collagen fibers, and 
fibroblasts. However, sometimes the scar maturation 
process is not properly engaged because inflammation 
continues in the scar. Consequently, the immature scar 
stage is prolonged. This results in the pathological scars 
called hypertrophic scars and keloids. Many factors that 
prolong the inflammatory stage have been identified [1]. 
However, multiple lines of evidence acquired in recent 
years suggest that mechanical force can be an important 
cause of pathological scar development (some of these 
lines of evidence will be described in more detail below) 
[2]. This notion is also supported by the empirically 
acquired clinical understanding that noticeable scarring 
can be prevented by stabilizing surgical wounds with 
sutures and postsurgical dressings: the sutures help to 
approximate the wound edges with a small amount of 
intrinsic tension, while the dressings suppress the extrin-
sic mechanical forces on the wound/scar edges [3]. When 
the mechanical forces on and in the scar are imbalanced, 
a heavy scar can result.
2.3  Cellular and Tissue Responses 
to Mechanical Forces
The mechanical forces on scars/wounds include stretch-
ing tension, shear force, scratch, compression, hydro-
static pressure, and osmotic pressure. These forces are 
perceived by mechanosensors on and in the cells that 
reside in the extracellular matrix as well as by nerve fiber 
mechanoreceptors at the tissue level [4, 5].
The cellular mechanosensors include mechanosen-
sitive cell membrane molecules such as ATP hemi-
channels, Ca2+ ion channels, and cell adhesion 
molecules such as integrin (. Fig. 2.1). Cytoskeletal 
components such as actin filaments also sense mechan-
ical force: when they do, actin polymerization and 
depolymerization occur [6]. Thus, when the extracel-
lular matrix is distorted by mechanical forces such as 
skin tension, the cellular mechanosensors are trig-
gered and initiate mechanosignaling pathways that 
lead to a variety of  molecular biological changes [7], 
including gene expression, cell proliferation, angio-
genesis, and epithelialization. The key mechanosignal-
ing pathways [8] that are involved in scarring at the 
cellular level appear to be the integrin, MAPK/G 
 protein, TNF-α/NF-κB, Wnt/β-catenin, interleukin, 
calcium ion, TGFβ/Smad, and FAK signaling path-
ways [9] (. Fig. 2.2).
At the tissue level, sensory nerve fibers, namely, 
mechanosensitive nociceptors, in the skin act as mecha-
noreceptors and thereby produce the somatic sensation 
of mechanical force [5]. Thus, when mechanical stimuli 
are received by mechanosensitive nociceptors some-
where on the body, electrical signals are transmitted to 
the dorsal root ganglia, which contain the neuronal cell 
bodies of  the afferent spinal nerves (. Fig. 2.3). This 




  . Fig. 2.1 Schematic depiction of  the mechanosensors that allow 
cells to sense extrinsic mechanical forces. (A) Mechanosensitive ATP 
hemichannels and Ca2+ ion channels. (B) Mechanosensitive mole-
cules on the cell membrane, including cell adhesion molecules. (C) 
Cytoskeletal elements, including the actin filaments. When the extra-
cellular matrix is distorted by mechanical forces such as skin tension 
(purple, blue, and orange triangles indicate different mechanical 
forces), mechanosensors on and in the resident cells sense the forces 
and initiate mechanosignaling pathways that lead to a large variety 
of  molecular biological changes, including gene expression. The 
mechanosensors include mechanosensitive cell membrane molecules 
such as ATP hemichannels and Ca2+ ion channels (A, blue, red, and 
green cylinder pairs). Others are cell adhesion molecules such as inte-
grin (B, purple cylinder pairs). Cytoskeletal elements such as the 
actin filaments (C, the beige ropelike bundles within the cell) also 




sensory neurons that innervate the skin to release neu-
ropeptides, including substance P, calcitonin gene-based 
peptide (CGRP), neurokinin A, vasoactive intestinal 
peptide, and somatostatin. Since the peripheral termi-
nals of  the neuropeptide-releasing neurons are often in 
physical contact with cells in the wound/scar, the neuro-
peptides can directly target keratinocytes, fibroblasts, 
Langerhans, mast, dermal microvascular endothelium, 
and infiltrating immune cells. This can alter cell prolif-
eration, cytokine production, antigen presentation, sen-
sory neurotransmission, mast cell degradation, and 
vasodilation. The triggering of  mechanonociceptors is 
particularly known to increase vascular permeability 
under both physiological and pathophysiological condi-
tions. All of  these pro-inflammatory responses produce 
what is termed neurogenic inflammation [4, 5]. Notably, 
substance P and CGRP, which, respectively, act through 
the neurokinin 1 receptor and CGRP1 receptor, are 
synthesized during nerve growth factor regulation. It 
has been suggested that neurogenic inflammation/neu-
ropeptide activity plays a role in the development of 
burn and abnormal scars such as keloids and hypertro-
phic scars [10].
2.4  Role of Mechanobiology 
in the Development of Pathological 
Scars
Traditionally, hypertrophic scars and keloids are diag-
nosed as separate clinical and pathological entities, even 
though both are characterized by prolonged and aber-
rant extracellular matrix accumulation. The so-called 
typical keloids grow beyond the confines of their origi-
nal wounds and exhibit accumulation of dermal thick 
eosinophilic collagen bundles with dermal nodules 
under the microscope. By contrast, hypertrophic scars 
generally grow within the boundaries of wounds and are 
characterized histologically by dermal nodules alone. 
  . Fig. 2.2 Mechanosignaling pathways in cells subjected to 
mechanical forces. When the mechanosensors in or on the cells are 
triggered, they activate various mechanosignaling pathways that 
then regulate cell proliferation, angiogenesis, and epithelialization. 
(This figure is from reference [8] with copyright permission from the 




One of the reasons why hypertrophic scars and keloids 
are considered to be separate clinical and pathological 
entities is that keloids are relatively rare in the Caucasian 
population, which may have limited clinical experience 
with these scars. However, even senior clinicians some-
times have difficulty in differentiating between the two 
conditions, particularly with the so-called atypical cases 
that bear characteristics of both scar types. This is par-
ticularly true in Asian countries, where keloids are very 
common. We currently believe that hypertrophic scars 
and keloids represent successive stages or alternative 
forms of the same underlying fibroproliferative patho-
logical lesion and that their progression or development 
into one or the other classical form may be determined 
by a variety of pro-inflammatory risk factors (. Fig. 2.4) 
[11, 12]. One of these is mechanical forces. The impor-
tance of this factor in pathological scarring is supported 
by a number of observations, including the fact that 
hypertrophic scars can be generated in experimental ani-
mal models by mechanical forces [13]. Moreover, an 
analysis of Asian patients showed that keloids tend to 
occur at specific sites (the anterior chest, shoulder, scap-
ular, and lower  abdomen- suprapubic regions) that are 
constantly or frequently subjected to mechanical forces, 
including skin stretching due to daily body movements 
[14]. Thus, the anterior chest skin is regularly stretched 
horizontally by the upper limb movements, the shoulder 
and scapula skin is constantly stretched by upper limb 
movements and body bending motions, and the lower 
abdomen and suprapubic skin regions are stretched 
hundreds of time a day by sitting and standing motions. 
Conversely, heavy scars rarely develop on the scalp, 
upper eyelid, and anterior lower leg, even in patients 
with extensive keloids or hypertrophic scars that cover 
much of the body. This pattern is likely to reflect the 
absence of tension on the skin in these regions. Thus, 
even in cases of deep wounding on the scalp and ante-
rior lower leg, there is little tension on the wound 
because the skin on these regions is stabilized by the 
bones that lie directly below it. Moreover, there is little 
tension on the upper eyelid during the opening and clos-
ing of the eyes.
Another key piece of evidence that indicates the 
importance of mechanical forces in pathological scar 
formation and progression is the fact that keloids grow 




  . Fig. 2.3 Mechanosensitive nociceptors shape somatic sensations 
and tissue responses to mechanical forces. Tissues such as skin 
respond to external mechanical forces such as tension via mechano-
sensitive nociceptors, whose neuronal cell bodies are located in the 
dorsal root ganglia in the spinal cord c. Thus, when a mechanical 
force is placed on a scar, the mechanosensitive nociceptors in and 
around the scar convert the mechanical stimuli into electrical signals 
that travel to the dorsal root ganglia in the spinal cord and then to 
the brain a. This produces the somatic sensations to the mechanical 
force (e.g., pain and/or itch). Simultaneously, electrical signals return 
from the dorsal root ganglia to the skin mechanosensitive nocicep-
tors b. This causes them to release neuropeptides from their periph-
eral terminals. Since these terminals are often in physical contact 
with cells in the scar, including epidermal and dermal cells, the neu-
ropeptides can induce neurogenic inflammation, thereby promoting 
pathological scar formation and progression
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forces on the wound/scar. This results in characteristic 
keloid shapes on specific locations. For example, keloids 
on the anterior chest grow in a “crab’s claw” or “butter-
fly” shape, whereas upper arm keloids grow in a 
“dumbbell”-like shape along the long axis of the limb 
(. Fig. 2.5).
Keloids exhibit stronger and more prolonged inflam-
mation than hypertrophic scars. This together with all 
of the mechanobiological observations described above 
suggests that keloid and hypertrophic scars largely differ 
because of the degree of skin tension on the wound/scar, 
which in turn determines the degree of inflammation 
(. Fig.  2.4). Thus, pronounced and highly repetitive 
skin tension on the wound may lead to greater inflam-
mation and keloid formation, while less strong or differ-
ent mechanical forces lead to a weaker or qualitatively 
different inflammation that leads to hypertrophic scar 
formation. This is supported by our previous finite ele-
ment analysis of the mechanical force distribution 
around keloids [15], which showed that both the skin 
tension on the keloid and the inflammation within the 
keloid are particularly high at the leading keloid edges 
(. Fig. 2.6). Thus, the mechanical forces coming from 
the predominant direction(s) drive high inflammation at 
the leading keloid edges: this provokes local collagen 
production, which in turn causes the keloid to invade 
further in the direction of the skin tension.
It should be noted, however, it is highly likely that the 
inflammatory status in heavy scars is also shaped by 
many other risk factors, including local, genetic, and 
systemic factors such as hypertension (high blood pres-
sure) [16].
a
  . Fig. 2.4 Difference between hypertrophic scars and keloids. The main difference between keloids and hypertrophic scars is that keloids 
have stronger and more prolonged inflammation.  a depicts the strength and/or duration of  inflammation
a b c
  . Fig. 2.5 Typical shape of 
keloids on specific regions of  the 
body. a The “butterfly” shape on 
the anterior chest. b The “crab’s 
claw” shape on the anterior 
chest. c The “dumbbell” shape 
on the upper arm. These 
site-specific keloid shapes reflect 
the predominant directions of 




2.5  A Pathological Scar Animal Model that 
Is Based on Mechanotransduction
Many researchers have sought to develop animal 
models of  heavy scars by using mice, rats, and rab-
bits. It should be noted that the scars of  all of  these 
models, especially the keloid models, seem to be 
driven more by an acute inflammatory response than 
by chronic inflammation: consequently, the resulting 
scars are largely immature. Nevertheless, an interest-
ing model is the hypertrophic scar mouse model in 
which heavy scars are induced by placing a mechani-
cal force on the edges of  a cutaneous incision. 
Analysis of  this model shows that when scars are sub-
jected to tension, they exhibit less apoptosis and that 
inflammatory cells and mechanical forces promote 
fibrosis [13]. In addition, studies with this model 
show that during pathological scar development, cel-
lular mechanosignaling pathways interact actively 
with the extracellular matrix and crosstalk exten-
sively with the hypoxia, inflammation, and angiogen-
esis pathways.
2.6  Mechanotherapy for Scar Prevention 
and Treatment
2.6.1  Stabilization Materials
To limit skin stretching and external mechanical stimuli 
during wound healing/scarring, wounds and scars 
should be covered by fixable materials such as tape, ban-
dages, garments, and silicone gel sheets. Several ran-
domized controlled trials have shown that such wound 
stabilization reduces the incidence of hypertrophic scars 
or keloids. Our computer analysis of the mechanical 
forces around scars also showed that silicone gel  sheeting 
reduces the tension at the scar edges [17].
2.6.2  Sutures
The fact that mechanical tension promotes keloid 
and hypertrophic scar development together with the 
fact that these scars arise from the dermis (especially 
the reticular dermis) suggests that closing surgical 
a
b
  . Fig. 2.6 Distribution of  the 
mechanical forces around 
keloids. a A scapular keloid. 
b Finite element analysis of  the 
mechanical force on the scapular 
keloid. The inflamed and 
elevated portions of  the keloid 
a match with the areas of  high 
tension in the keloid (red color 
in b). This suggests that high 
skin tension prolongs and 
amplifies the inflammation in the 
periphery of  keloids. (The figure 
is from reference [15] with 
copyright permission from the 
publisher. © All rights reserved)
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wounds with sutures that place little tension on the 
wound dermis may reduce the risk of  pathological 
scar formation after surgery. Therefore, we use sub-
cutaneous/fascial tensile reduction sutures that place 
the tension on the deep fascia and superficial fascia 
layer rather than the dermis (see 7  Chap. 21). This 
minimizes the use of  dermal sutures; in fact, dermal 
sutures can be avoided altogether if  the wound edges 
approximate each other closely after the fascial 
sutures are placed.
2.6.3  Z-Plasty, Skin Grafting, and  
Local Flaps
In scar revision surgery, it is important to choose the 
surgical approach that most effectively reduces tension 
on the scar. An excellent choice is the Z-plasty, which 
disrupts the line of tension on linear scars (see 
7 Chap. 21). Another choice is to use skin grafts. Full-
thickness skin grafts (FTSG) are a better choice than 
split-thickness skin grafts (STSG) because the latter 
associate with a greater risk of secondary contracture. 
However, if  adjacent normal skin is available, it is better 
to use local flaps rather than FTSG because they have a 
much lower risk of contracture and better esthetic out-
comes. Once the decision to use a local flap has been 
made, one then has to decide between an island flap and 
a skin-pedicled flap. While this choice depends some-
what on the scar geometry and other patient-specific 
variables, skin-pedicled flaps are generally the better 
choice because they have greater extensibility than island 
flaps and are therefore good for releasing the tension of 
a scar (see 7 Chap. 21). This greater extensibility prob-
ably reflects the fact that the entire perimeter of the 
island flap is surrounded by new scar whereas the skin-
pedicled flap maintains a connection with normal skin, 
which is much more elastic than scar tissue.
2.7  Conclusion
It is suggested that mechanical forces on the skin strongly 
influence the cellular behavior that leads to scarring. 
These observations led us to focus on the importance of 
reducing skin tension when keloids and hypertrophic 
scars are surgically removed to prevent their recurrence. 
Clinical studies revealed that subcutaneous/fascial ten-
sile reduction sutures, which apply minimal tension on 
the dermis, are effective in reducing recurrence. 
Moreover, we have found that by using Z-plasty and 
skin flaps, which release tension on the wound, huge 
scars can be successfully treated.
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Tissue repair after injury is a complex phenomenon 
involving intricate and coordinated mechanisms. Even 
though during the last decade, many studies have 
increased our knowledge on the different cellular players 
involved in this process [16], many gray areas remain, 
particularly concerning the dialogue between different 
cell populations acting during wound healing and scar 
formation. Interestingly, an abnormal course of the 
inflammatory phase at the beginning of the healing pro-
cess appears to have effects long after scar formation. In 
addition, the relationships between cells and the extra-
cellular matrix remain a key aspect in understanding the 
normal development and remodeling of scars.
3.2  Introduction
The skin provides the primary protection against exter-
nal injuries for the body and is also essential in the 
maintenance of general homeostasis. Located beneath 
the epidermis, the dermis represents the thickest com-
partment of the skin and is composed mainly of a dense 
extracellular matrix network of collagen fibers sup-
porting the specific dermal appendages, including hair 
follicles, sebaceous glands, and sweat glands. Dermal 
(myo)fibroblasts play a major role in the synthesis and 
maintenance of the extracellular matrix as well as in the 
wound- healing process [4]. During healing, fibroblasts 
proliferate and migrate into the wound space, though 
the origin of these cells remains to be clearly eluci-
dated. Moreover, research on progenitor cells present 
in the skin, which can differentiate into many different 
cell types, represents an interesting source of cells that 
may be able to promote (when correctly stimulated) 
wound healing, improve the repair process in impaired 
or difficult- to-heal wounds or be able to modify the pro-
cess of excessive scarring. In this chapter, these different 
aspects will be expanded on, including the biochemical, 
cellular, and physical factors that are involved in regulat-
ing healing and scarring in skin wounds (e.g., cytokines, 
mechanical tension, and innervation).
3.3  General Mechanisms of Scar Formation
Immediately after wounding, the healing process com-
mences leading to (partial) restoration of the injured tis-
sue. Wound healing passes through three dynamic and 
interrelated phases which temporally overlap [3]. Based 
on morphological changes seen in the wound tissue dur-
ing the course of the healing process, these phases are 
defined as the inflammatory phase, the proliferative 
phase (with the development of the granulation tissue) 
and reepithelialization phase, and the remodeling phase 
which includes maturation and scar formation. The 
inflammatory phase begins with capillary damage, 
where blood loss results in a clot forming, which consists 
of fibrin and fibronectin and stops further blood loss. 
The wound space is thus filled with a provisional matrix 
that provides a scaffold into which various cells can 
migrate. The initial source of chemokines in the wound 
is platelets that are present in the clot, and these degran-
ulate and provide multiple factors that stimulate the 
recruitment of inflammatory cells, neutrophils, and 
macrophages. At the same time, fibroblasts and endo-
thelial cells are attracted by growth factors that are 
 chemotactic for these cells. The proliferative phase of 
healing which follows includes angiogenesis, the growth 
of new vessels into the wound. Angiogenesis is vital for 
tissue repair since it provides vascular perfusion of the 
wound, delivering oxygen and nutrients and thus con-
tributing to cell proliferation, including the proliferation 
of fibroblasts. The wound is initially hypoxic, as it lacks 
normal perfusion, and hypoxia itself  is an important 
stimulus for the release of growth factors, including 
those that regulate angiogenesis. During the prolifera-
tive phase, angiogenesis proceeds and eventually rees-
tablishes a more normal level of perfusion. The 
regulation of angiogenesis may represent a target for 
improving wound repair, particularly in those cases 
where delayed or abnormal angiogenesis has been sug-
gested to play a role in healing impairment. Fibroblasts 
present in the granulation tissue become activated and 
are then termed myofibroblasts. These myofibroblasts 
are responsible for the synthesis and deposition of extra-
cellular matrix components which progressively replace 
the provisional matrix [6]. Myofibroblasts also show 
contractile properties, playing a major role in the con-
traction and maturation of the granulation tissue. Scar 
formation, which is the third phase of healing, involves 
progressive remodeling of the granulation tissue 
(. Fig. 3.1). A major role in this process is played by 
proteolytic enzymes, particularly the family of matrix 
metalloproteinases (MMPs) and their inhibitors (tissue 
inhibitor of metalloproteinases [TIMPs]). Synthesis of 
extracellular matrix is then reduced, though not com-
pletely stopped, and the components that make up the 
matrix are modified as the matrix is remodeled. Collagen 
type III, the major collagen present in granulation tis-
sue, is progressively replaced by collagen type I, the main 
structural protein in normal unwounded dermis. Finally, 
elastin which is largely responsible for the elasticity of 
the skin and which is absent in granulation tissue also 
reappears. In deep human wounds, elastin fibers do not 
show complete regeneration after wound healing being 
both deficient and not showing normal structural 
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 organization. During the resolution phase of wound 
healing, apoptosis of both vascular cells and myofibro-
blasts results in a significant reduction in cell number in 
the granulation tissue. Whether myofibroblasts can reac-
quire a quiescent phenotype thus returning to a “nor-
mal” dermal fibroblast phenotype is still open to 
question.
3.4  Morphological and Biochemical 
Characteristics of Myofibroblast 
Phenotype
The earliest descriptions of  myofibroblasts, based on 
their electron microscopic morphology, identified ultra-
structural specializations showing some similarity to 
those of  smooth muscle cells, in particular prominent 
bundles of  cytoplasmic microfilaments. Further ultra-
structural and molecular markers that define myofibro-
blasts have since been identified, including cell-cell and 
cell-matrix adhesions, stress fibers, and expression of 
α-smooth muscle actin [9]. Both in vivo and in vitro, the 
presence of  fibroblasts exhibiting prominent microfila-
ment bundles in their cytoplasm (known as stress fibers) 
can be observed; however, these cells do not necessarily 
contain α-smooth muscle actin-positive microfilaments. 
In vitro, these fibroblasts can also be shown to secrete a 
splice-variant form of fibronectin, ED-A fibronectin. 
These cells have been termed proto-myofibroblasts, and 
their stress fibers contain only β- and γ-cytoplasmic 
actin. Proto-myofibroblasts can exert tractional forces 
in connective tissue, and they may be induced by 
mechanical stress; however, to undergo full differentia-
tion into myofibroblasts, they require stimulation with 
transforming growth factor (TGF)-β1 (see below). Fully 
differentiated myofibroblasts are then capable of  exert-
ing increased force due to contraction. The expression 
pattern of  myofibroblasts and smooth muscle cells 
shows several differences. Smooth muscle cells express 
smooth muscle myosin heavy chain, smoothelin, and 
h- caldesmon, while myofibroblasts are generally nega-
tive for these markers. Desmin, an intermediate fila-
ment protein which is normally expressed in muscle 
cells, has also been used as a negative marker of  myofi-
broblasts, since during normal wound healing myofi-
broblasts have been found to be desmin-negative. In 
some conditions of  pathological scarring, myofibro-
blasts have been observed to be desmin-positive. Overall 
though α-smooth muscle actin is also expressed in 
smooth muscle cells and pericytes, it still represents the 
most reliable phenotypic marker of  myofibroblast phe-
notype.
Given the important roles of  myofibroblasts in tis-
sue repair and scarring, in particular their role in con-
traction, the exact mechanisms regulating contraction 
in such tissues need to be clearly identified. 
Examination of  spontaneous intracellular Ca2+ oscil-
lations has shown that intracellular Ca2+ oscillations 
are coordinated between contracting myofibroblasts 
via adherens junctions but occur randomly between 
fibroblasts and non- contacting cells. Therefore the fol-
lowing model of  mechanical coupling for myofibro-
blasts can be proposed: individual cell contraction is 
transmitted via adherens junctions leading to the 
opening of   mechanosensitive ion channels in adjacent 
cells. The resulting Ca2+ influx induces a contraction 
that can feed back on the first cell and/or stimulate 
other contacting cells allowing the cells to work like a 
syncytium. This mechanism of  coordination of  myofi-
broblast activity may improve the remodeling of  cell-
dense tissue [8].
3.5  Cellular Origins of Myofibroblasts
Recruitment of  fibroblasts from the local connective 
tissue is generally accepted to be the major source of 
myofibroblasts in the wound. Dermal fibroblasts that 
are located at the wound margins can acquire a myo-
fibroblastic phenotype and then play a role in tissue 
repair. However, there is considerable heterogeneity in 
fibroblastic cell subpopulations. These fibroblast sub-
populations are present in different locations within 
the skin and have specific activation and deactivation 



























  . Fig. 3.1 The various phases of  the healing process. After dam-
age, inflammation leads to the formation of  granulation tissue dur-
ing which myofibroblasts appear. A significant neoangiogenesis is 
also observed. A new epidermis can then develop over this granula-
tion tissue. Subsequently, remodeling of  this granulation tissue 
occurs via apoptosis of  the cells present in the granulation tissue 
(myofibroblasts and vascular cells), and the extracellular matrix is 
gradually reorganized
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identified in the dermis: superficial (or papillary) 
fibroblasts (the papillary dermis is approximately 
300–400 μm in depth and is arranged as a ridgelike 
structure), reticular fibroblasts which are present in 
the deep dermis (which consists of  thick collagen and 
elastin fibers that are arranged parallel to the surface 
of  the skin), and fibroblasts which are associated with 
hair follicles. These cell subpopulations can be iso-
lated for cell culture and then, depending on the age 
and nature of  the skin sample, show distinct differ-
ences in phenotype in vitro.
It has been recently suggested that local mesenchy-
mal stem cells may also be involved in the tissue repair 
process. These progenitor cells have been identified in 
the dermal sheath that surrounds the exterior of hair 
follicles, facing the epithelial stem cells. These cells are 
involved in regeneration of the dermal papilla and can 
also differentiate into wound-healing myofibroblasts 
after damage or injury.
Recent data has also suggested a role for circulating 
cells, termed fibrocytes, in the tissue repair process. 
Fibrocytes may enter damaged skin together at the same 
time as inflammatory cells and may then acquire a myo-
fibroblastic phenotype. In burn wound, fibrocytes may 
infiltrate the wound where they both stimulate a local 
inflammatory response and additionally secrete extra-
cellular matrix proteins, thus contributing to the patho-
logical (hypertrophic) scarring that can be seen postburn 
injury.
Another bone marrow-derived circulating cell has 
also been suggested to play a role in tissue repair. 
Mesenchymal stem cells are bone marrow-derived non- 
hematopoietic precursor cells that may be present in 
both normal and damaged connective tissue, where they 
infiltrate the tissue and then contribute to the mainte-
nance and repair of the tissue. Indeed, these cells have 
the capacity to seed into several organs and then differ-
entiate into myofibroblasts, similar to those seen during 
wound healing. The degree to which damaged tissues or 
organs are infiltrated by these cells is dependent on the 
severity of tissue injury.
Lastly, epithelial- or endothelial-to-mesenchymal 
transition of either differentiated or malignant epithe-
lium (or endothelium) can result in a phenotypic change 
to fibroblasts or myofibroblasts that are then responsible 
for extracellular matrix production. Although this 
mechanism is now accepted as playing an important role 
in fibrogenesis after tissue injury, it appears to play a less 
prominent role in normal tissue repair. Overall, myofi-
broblasts derived from circulating fibrocytes, mesenchy-
mal stem cells, epithelial- or endothelial-to-mesenchymal 
transition, or bone marrow-derived cells may supple-
ment local fibroblast recruitment and differentiation 
where their numbers are insufficient for the repair and 
remodeling process [14].
3.6  Regulation of Myofibroblast 
Phenotype
Wound healing and skin homeostasis are regulated by a 
number of cytokines and growth factors. Some growth 
factors act directly on granulation tissue formation and 
fibroblasts activity, while others have effects on vascular 
and epithelial cells. Of the factors with direct effects on 
fibroblasts, TGF-β1 is notable as it is a potent inducer of 
myofibroblast differentiation [18]. In addition to its role 
in inducing expression of α-smooth muscle actin, TGF- 
β1 also powerfully stimulates the synthesis of extracel-
lular matrix proteins. TGF-β1 also favors the deposition 
of matrix by an effect on the balance between MMPs 
and their inhibitors, TIMPs, by reducing MMP activity 
while stimulating TIMP expression. The action of TGF- 
β1 on fibroblast to myofibroblast differentiation requires 
the presence of ED-A fibronectin, underlining the close 
relationship between growth factor activation, the extra-
cellular matrix, and regulation of cellular function 
(. Fig.  3.2). It is interesting to note that granulocyte 
macrophage colony stimulating factor can also increase 
the number of myofibroblasts in vivo; however, this is 
most likely due to its activation and recruitment of mac-
rophages which in turn increases the levels and availabil-
ity of TGF-β1 [15]. Finally, microRNAs (miRNAs) have 
also been implicated in the induction of myofibroblasts 
in both fibrotic conditions and in cancer. Specifically, 
expression of miR-21 appears to be correlated with high 
levels of TGF-β1 stimulation of the myofibroblast phe-
notype. A recent study has suggested that the mecha-
nism underlying this may be through effects on TGF-β1 
inhibitory pathways. Improvements in our understand-
ing of the effects of miRNAs in regulating fibrosis, 
potentially through actions on myofibroblast differenti-
ation and activity, may allow miRNAs to be targeted in 
therapies aimed at inhibition of fibrosis and scarring.
3.7  Role of Myofibroblasts in Pathological 
Scarring and Fibrosis
In some cases, wound healing proceeds in a pathological 
course resulting in pathological scarring [17]. Such 
abnormal repair processes may be the result of impaired 
remodeling of the granulation tissue resulting in, for 
example, abnormal repair of the skin in the form of 
hypertrophic or keloid scars and to fibrosis in internal 
organs. In the case of excessive scarring in the skin such 
as hypertrophic scars, normal healing fails and the gran-
ulation tissue continues to expand, likely due to abnor-
mal and excessive secretion of growth factors and/or to 
a lack of molecules that in normal healing are responsi-
ble for induction of apoptosis or remodeling of the 
 I. A. Darby and A. Desmoulière
23 3
extracellular matrix. When the stimulus driving the 
response to injury persists in internal organs, excessive 
deposition of extracellular matrix then leads to organ 
fibrosis. As is observed in pathological healing in the 
skin, the occurrence of fibrosis and its chronic nature 
may be a consequence of an imbalance between matrix 
deposition and matrix degradation. The mechanism 
underlying this is most likely an imbalance in the levels 
of MMPs and their inhibitors, TIMPs.
Hypertrophic scars and keloids are both character-
ized by an abnormal accumulation of extracellular 
matrix; however, they represent two very different cuta-
neous pathologies. In the case of hypertrophic scars, 
these do not extend beyond the periphery of the lesion, 
while keloids do extend beyond the margins of the orig-
inal lesion. α-Smooth muscle-positive myofibroblasts 
are abundant in hypertrophic scars, and these cells con-
tract, inducing retraction of the scar, particularly when 
the scar tissue is located in a region that is subjected to 
mechanical tension. This is particularly the case when 
the scar is adjacent to joints including the shoulders, 
elbows, wrists, knees, and ankles. Conversely, retraction 
does not occur in keloids. The development of hypertro-
phic scars is frequently observed after severe burns, and 
it appears that prolonged inflammation contributes to 
the increased risk of hypertrophic scarring. Conversely 
chronic wounds, such as venous leg ulcers, can also show 
prolonged inflammation with the mixture of pro- 
inflammatory cytokines and MMPs leading to a failure 
of matrix deposition and repair. It is therefore suggested 
that after cleansing of the wound, treatment should be 
aimed at producing the most rapid recovery possible 
with the aim of limiting the time spent in the inflamma-
tory stage of healing.
3.8  The Role of Mechanical Tension
Due to both their contractile nature and their intimate 
relationship with the extracellular matrix, myofibro-
blasts are sensitive to their mechanical environment, and 
mechanical signaling has been shown to play important 
roles in regulating the activity of myofibroblasts [10]. 
Differentiation markers of myofibroblasts, including 
stress fibers, ED-A fibronectin, and α-smooth muscle 



























  . Fig. 3.2 Illustration showing the evolution of the fibroblast phe-
notype during normal and pathological conditions. Changes observed 
in fibroblast phenotype as cells differentiate towards a myofibroblast 
phenotype begin with the appearance of proto- myofibroblasts. These 
cells possess stress fibers composed of β- and γ-cytoplasmic actins. 
These then evolve, at least in some cases, into fully differentiated myo-
fibroblasts. These cells possess stress fibers containing α-smooth mus-
cle actin. Soluble factors such as transforming growth factor-β1 
(TGF-β1), extracellular matrix (ECM) components such as ED-A 
fibronectin, and/or the mechanical microenvironment are all involved 
in myofibroblastic differentiation. The myofibroblast may then disap-
pear by apoptosis, while deactivation, leading to a quiescent pheno-
type, has not been clearly demonstrated at least in  vivo. If  the 
remodeling phase of the granulation tissue does not occur (with no 
apoptosis of the myofibroblasts and vascular cells present in the gran-
ulation tissue nor reorganization of the extracellular matrix), myofi-
broblasts may then persist, leading to pathological conditions 
characterized by excessive scarring
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that is subjected to increased mechanical tension. This 
has been shown in experiments using splinting of a full- 
thickness wound with a plastic frame and comparing 
this to unsplinted, normally healing granulation tissue. 
Additionally, mechanical forces can be altered by cultur-
ing fibroblasts on substrates of varying stiffness, and 
these experiments have shown alterations in fibroblast 
phenotype dependent on substrate compliance. In cul-
ture, fibroblasts grown on soft, compliant substrates do 
not show stress fiber expression, while increasing the 
stiffness of the substrate induces a rapid change in mor-
phology and the appearance of stress fibers. In cultured 
fibroblasts, shear forces, from movement of fluid, are 
also able to increase TGF-β1 synthesis and thus stimu-
late fibroblast differentiation to a myofibroblast pheno-
type. Shear forces are able to affect fibroblast 
differentiation in the absence of other stimuli that are 
normally involved in their differentiation, for example, 
exposure to cytokines or pre-straining of the extracel-
lular matrix which regulates TGF-β1 bioavailability. As 
mentioned above, the role of mechanical stress in stimu-
lating myofibroblast activity has also been shown in 
experiments using mechanically stressed skin wounds in 
mice. These wounds are stretched or splinted, resulting 
in an increased mechanical load that in turn increases 
myofibroblast activity and results in increased scar for-
mation. These models to some extent mimic hypertro-
phic scarring that is sometimes observed in humans. The 
mechanical environment of the wound and the tension 
present are thus essential factors that need to be taken 
into account and managed in order to reduce scarring. 
To this end controlled immobilization of the wound 
should be employed. Interestingly, devices that manage 
the mechanical environment and tension of the wound 
are now appearing on the market (e.g., Embrace® from 
Neodyne Biosciences, Inc. or Zip® from ZipLine 
Medical, Inc.).
3.9  Role of Innervation in Skin Healing
Recently it has been shown that innervation of the skin 
plays an important role in both normal and pathological 
wound healing. However, the precise roles of sensory 
and autonomic innervation during wound healing 
remain to be clearly established [12]. Keratinocytes, 
melanocytes, fibroblasts, and myofibroblasts have all 
been shown to express a variety of neurotrophins includ-
ing nerve growth factor, neurotophin-3, brain-derived 
neurotrophic factor, as well as their receptors, and these 
promote cellular proliferation and differentiation. 
Neuropeptides including calcitonin gene-related pep-
tide, substance P, and vasoactive intestinal peptide are 
able to modulate the activity of MMP-2 and MMP-9, 
both of which play important roles in granulation tissue 
remodeling and scar formation. Additionally, these neu-
ropeptides also act on collagen type I and type III syn-
thesis during skin wound healing, promoting dermal 
fibroblast adhesion and their differentiation into myofi-
broblasts. The effects of these neuropeptides on the 
composition of the extracellular matrix and its organi-
zation are certainly essential since it is well-established 
that the mechanical microenvironment, which is depen-
dent on the organization of the extracellular matrix, can 
affect fibroblast to myofibroblast differentiation. Lastly, 
regulation of MMPs can also affect the subsequent acti-
vation of latent TGF-β1 which involves MMPs.
Injury to the skin induces the release of a number of 
inflammatory mediators, from both immune cells and 
sensory nerve endings. These include interleukin-1β, 
tumor necrosis factor-α, bradykinin, substance P, calci-
tonin gene-related peptide, nerve growth factor, and 
prostaglandins, and their release by these cells contrib-
utes to the “inflammatory soup” present in the wound. 
It has been suggested that changes in substance P levels 
may be involved in the aberrant wound-healing response 
seen in hypertrophic scarring. Furthermore, it has been 
observed that in cocultures of fibroblasts and neurites, 
the direct contact of these cells is able to induce myofi-
broblast differentiation leading to increased retraction 
of collagen lattices, mimicking the contraction seen in 
wound repair.
In keloids, nerve fiber density is significantly higher 
than in normal skin samples, and symptoms including 
itch, pain, abnormal thermal sensory thresholds to heat 
as well as cold, and pain associated with heat sensation 
are all reported suggesting the involvement of small 
nerve fibers in the pathogenesis of this disease. In hyper-
trophic scars, published data are inconsistent with either 
a decrease or an increase of the number nerve fibers hav-
ing been reported. Nevertheless, in burn patients with 
chronic pain, abnormal cutaneous innervation has been 
reported. A recent pilot study has been published which 
compared healthy skin versus postburn scars from the 
same patient [2]. These authors examined the expression 
of genes involved in regulation of innervation and addi-
tionally looked at the intraepidermal density of nerve 
endings. Significant differences in the patterns of expres-
sion were observed when comparing healthy skin and 
postburn scars. Based on studies of a mouse model of 
hypertrophic scarring induced by mechanical loading, it 
has been suggested that innervation of the skin and the 
level of inflammation present may both play roles in the 
development of hypertrophic scars.
The role of the sensory nervous system in wound 
healing in the skin has been examined using several ani-
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mal models of denervation. Surgical denervation has 
been employed, as has chemical denervation, and mice 
with genetic modifications resulting in denervation have 
also been used. Studies using surgical denervation have 
shown that wound healing is retarded in these animals, 
with a reduction observed in the number of inflamma-
tory cells infiltrating the wound, delayed contraction of 
the wound, and a delay in reepithelialization. Another 
skin denervation model, which used chemical sympa-
thectomy induced by intraperitoneal administration of 
6-hydroxydopamine, also showed that denervation 
interfered with wound healing. 6-Hydroxydopamine- 
induced sympathectomy has also been shown to modify 
wound healing with an increase in wound contraction, a 
reduction in mast cell migration and delayed reepitheli-
alization. These alterations in healing are associated 
with a decrease in neurogenic inflammation. Lastly, 
these studies have definitively shown that neuropeptides 
released by sensory fibers play an important role during 
wound healing, affecting the granulation tissue in 
 particular.
3.10  Therapeutic Options
It has been recently shown, in human pulmonary fibro-
sis, that mechanical stretching of tissue can contribute 
to the development of fibrosis via mechanical activation 
of TGF-β1 [5]. Stretching of the extracellular matrix in 
the lungs, due either to breathing or to mechanical ven-
tilation that is employed to support breathing in cases of 
lung injury or lung disease, may contribute to TGF-β1- 
driven disease progression. Since it is not possible to 
stop breathing to avoid mechanical TGF-β1 activation 
from established fibrotic tissue, therapeutic intervention 
might however be possible aimed at the cellular side of 
mechanical TGF-β1 activation. Thus, in organs that are 
subjected to mechanical stress, such as the lungs and 
skin, the role of TGF-β1 in excessive scarring and fibro-
sis is clearly crucial, and the mechanisms involved in 
activation of TGF-β1 represent an important therapeu-
tic target.
The presence and activity of fibroblasts is vital for 
normal skin homeostasis, while the presence of myofi-
broblasts is crucial for tissue repair and has evolved to 
speed the process of normal tissue repair [1]. The impor-
tance of fibroblast activity in normal repair has been 
very well documented using in vitro models of dermal 
substitutes. For example, a living dermal equivalent 
(containing fibroblasts) that has been applied to skin 
graft beds was found to reduce pain, improve hemosta-
sis, and also improve the mechanical and cosmetic prop-
erties of the graft, in particular, producing a normal 
undulating dermal-epidermal junction by 3–4  months 
after grafting and also leading to the presence of elastic 
fibers, which were detectable 6–9 months after grafting. 
Therefore, it seems apparent that tissue engineering 
approaches to normal repair require fibroblasts and 
myofibroblasts to be effective [7]. It is, however, very 
important to keep in mind that many different popula-
tions of fibroblasts exist and that these have different 
properties. These recent observations thus offer new per-
spectives for skin repair and for tissue engineering. In 
addition, promotion of normal reinnervation and ade-
quate levels of neuropeptides during the healing process 
certainly appear to be crucial for improving skin healing 
and to avoid the occurrence of pathological repair pro-
cesses and scarring [13]. Despite the existence of many 
areas that still require elucidation in myofibroblast biol-
ogy, it seems clear that myofibroblasts are pivotal cells 
for the control of extracellular matrix deposition and 
remodeling during normal repair and are also important 
in pathological conditions such as excessive scarring. 
Myofibroblasts thus definitively represent an essential 
target to be considered when developing new therapeu-
tic strategies.
3.11  Conclusion
Myofibroblasts are key cells during wound healing. It 
has become increasingly evident that a lack of myofibro-
blast apoptosis is a major mechanism leading to exces-
sive scarring [11]. Blocking pro-survival mechanisms, 
particularly those linked to the mechanical environment, 
and modifying the myofibroblast phenotype to obtain 
cells able to remodel the excessive deposition of extra-
cellular matrix certainly represent new ways to develop 
therapeutic options that could positively modulate scar 
formation.
Take-Home Messages
 5 Myofibroblasts play a major role during granula-
tion tissue formation with transforming growth 
factor-β1 being the main soluble factor involved in 
myofibroblastic differentiation.
 5 Myofibroblasts, through mechanotransduction 
pathways, are very sensitive to their mechanical 
environment.
 5 Myofibroblast apoptosis and extracellular matrix 
remodeling are necessary for normal scar forma-
tion.
 5 Abnormal mechanical tension facilitates the devel-
opment of hypertrophic scars.
 5 Normal innervation and neuropeptide secretion 
are necessary to maintain skin homeostasis and 
normal wound healing.
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 5 Despite the fact that keloids are common through-
out the world, their epidemiology has not been 
adequately investigated.
 5 The demographic distribution of keloids, mainly 
on the geographical regions and ethnic racies.
 5 Genetic risk factors can shape keloid rates, in 
particular certain diseases appear to amplify or 
suppress keloid formations.
 5 Environmental factors also contribute to keloid 
development and progression and therefore shape 
keloid rates, such as local mechanical stimuli.
4.1  Background
Keloids are pathological scars that are characterized 
histologically by an overwhelming aggregation of fibro-
blasts and collagen type I within the inflammatory retic-
ular dermis [1]. Their clinical characteristics include 
continuous growth and invasion into the neighboring 
healthy skin beyond the original wound boundary via 
an erythematous and pruritic leading edge. They also 
show a strong tendency to recur when they are surgi-
cally excised in the absence of  adjuvant therapies. 
Despite the fact that keloids are common throughout 
the world, their epidemiology has not been adequately 
investigated.
In this chapter, we will summarize the limited epide-
miological data on keloids that exists to date. Most of 
these data are from English language papers that are 
listed in PubMed. Below, we will describe what is known 
about (1) the demographic distribution of keloids, 
mainly on the geographical regions and ethnic races; (2) 
the internal genetic factors that shape keloid rates; and 
(3) the external environmental factors that influence 
keloid epidemiology. The aim of the chapter is to facili-
tate a greater understanding of the complexity and 
diversity of keloids from an epidemiological perspective, 
thereby potentiating further and deeper explorations 
into individualized strategies that prevent and treat 
keloids.
4.2  Demographic Risk Factors That Shape 
Keloid Rates
The studies on the demographic distribution of keloids 
in the world are sparse and occasionally contradictory. 
However, keloid rates can be affected by geography and 
ethnicity.
In terms of geographical distribution, it has long 
been cited that the incidence of keloids ranges widely 
from 0.09% in England to 16% in Zaire [2, 3]. While 
these reviews did not indicate how these incidences were 
determined, they are somewhat supported by the few 
large-scale studies on geographical incidence that have 
been performed. One of these was a review of the 5735 
patients who underwent surgery in the 33 surgical facili-
ties in Zambia between 1993 and 2008: the study showed 
that of the 5774 surgical diagnoses, 514 are related to 
keloids. Thus, keloids accounted for nearly 9% of all 
those surgical cases in Zambia during the study period 
[4]. Moreover in Kenya, the keloid prevalence is 8.5% 
among people with normally pigmented skins [5]. By 
contrast, the keloid incidence in Japan is around 0.1% [6] 
(. Table 4.1). Considering that the keloid incidence data 
is limited and scattered, which can hardly be comparable 
in a strictly defined background covering key factors 
such as statistical period/cycle, population size/composi-
tion, and diagnostic criteria on scar type/severity, it is 
still difficult to depict an accurate keloid distribution 
map at this time. And the average keloid incidence can 
only be estimated as 5–10% in African, 0–0.1% in Asian, 
and <0.1% in other countries, as seen in . Fig. 4.1.
It is suspected that this large geographical variation 
in keloid rate may reflect racial differences in skin pig-
mentation (. Fig.  4.2). However, the data on keloid 
prevalence in various races is conflicting. First, Louw 
states that both Blacks and Asians are more susceptible 
to keloid formation than Caucasians [3]. Indeed, the 
Black/Caucasian ratio was reported varying from 14:1 
to 2:1 [7]. However, the above reports may suggest that 
Asians could have similarly low incidences of keloid as 
Caucasians (0.1% in Japan versus 0.09% in England) [2, 
3, 6]. Two studies also suggest that at least one specific 
type of keloid, acne keloidalis nuchae (AKN), is much 
more common in Blacks than in Asians. Na et al. showed 
that of 254,785 patients who attended the dermatology 
department of a Korean hospital in 2005–2017, 17 had 
AKN (0.007%) [8]. By contrast, another study showed 
that of 13,422 new patients who visited a large univer-
sity hospital in Benin in 1993–2002, 0.7% (90 cases) had 
AKN, and the prevalence was reported as 0.37% (90 
  . Table 4.1 The incidences of  keloid reported in different 
countries
Country Keloid incidence (%) Reference




Zaire 16% [2, 3]
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cases out of 26,522 patients overall) [9]. The latter study 
is supported by several other studies that show that 
AKN is common in Blacks. For example, as high as 
4.7% of Black boys in the last year of high school in 
South Africa can develop AKN [10]. Moreover, the pos-
tulated relationship between high skin pigmentation and 
greater susceptibility to keloid formation is not borne 
out by two studies. One is a cross-sectional study on ran-
domly selected villages in Kenya and people with albi-
nism who were recruited via an albino association in 
Kenya and  dermatology training center clinics and spe-
cial schools in Tanzania. Of the 1416 African people 
who were recruited, 1185 had normally pigmented skin, 
and 231 had albinism. And 954 among the 1416 people 
have scars on their body. For them, the total prevalence 
of keloid was 8.3%. The subjects with normal pigmenta-
tion did not differ significantly from the subjects with 
albinism in terms of keloid prevalence (8.5% versus 
7.8%; P = 0.599) [5]. The second study described the 175 
keloid patients who visited the General Hospital in 
Kuala Lumpur in West Malaysia in 1959–1967. West 





  . Fig. 4.1 Heatmap of  keloid epidemiology in the world. The average keloid incidence can only be estimated as 5–10% in African, 0–0.1% 
in Asian, and <0.1% in other countries
  . Fig. 4.2 Chest and shoulder keloids in different racial groups of 
Asians, Africans, and Caucasians. 4.2.1 The images are from Huang 
et al. with permission (Huang et al. [11]). 4. 2.2 The images are from 
Bayat et al. with permission (Bayat et al. [12]). 4. 2.3 The images are 





the ethnicities of the keloid patient cohort showed that 
keloid was more common in the relatively fair-skinned 
Chinese: while 56% of the keloid patients were Chinese, 
this ethnicity accounted for only 47.47% of the popula-
tion. By contrast, 22.86% and 17.14% of the keloid 
patients were darker-skinned Indians and Malays, 
respectively; these ethnicities accounted for 19.52% and 
29.58% of the population, respectively [7].
4.3  Genetic Risk Factors That Shape Keloid 
Rates
The effect of ethnicity on keloidogenesis suggests that 
keloid formation is somewhat underpinned by genetic 
variation. This is borne out by multiple genetic studies 
that show that keloidogenesis associates with certain 
gene mutations or polymorphism [14]. Keloids also 
show a familial tendency [15]. Here, we will discuss less 
well-known genetic associations with keloids, namely, 
certain diseases that appear to amplify or, conversely, 
suppress keloid rates.
The diseases that associate with an increased risk of 
keloid include the Rubinstein-Taybi syndrome (RSTS), 
the Ehlers-Danlos syndrome, the Lowe syndrome, and 
the novel X-linked syndrome, and others (. Table 4.2). 
RSTS is also called broad thumb-hallux syndrome. It is 
characterized by broad thumbs and toes, facial abnor-
malities, and short stature [16]. The etiological mutation 
lies in gene encoding the cyclic AMP response element-
binding protein (CBP) on chromosome 16p13.3 [17] and 
E1A- binding protein (EP300) gene which encodes p300 
protein (a cAMP response element-binding protein 
homologue) [18]. Keloid is reported to occur in 24% 
(15/62) of RSTS patients, either spontaneously or sec-
ondary to minor trauma [19]. The Ehlers-Danlos syn-
drome type IV (the vascular subtype) is an inherited 
disorder of connective tissue that is characterized by 
acrogeria, translucent skin, propensity to bruising, and 
significant arterial, digestive, and uterine complications 
[20]. The causative mutation is in COL3A1 gene, which 
encodes the pro-α1(III) chain of collagen type III [21]. 
Several case reports show that this syndrome can para-
doxically associate with extensive keloid formation [22]. 
The Lowe syndrome (also called the oculocerebrorenal 
syndrome of Lowe [OCRL]) affects the eyes, nervous 
system, and kidneys [23]. It is caused by a mutation in 
the OCRL gene that reduces the amount of the OCRL-1 
protein [24]. The formation of corneal keloids in patients 
with Lowe syndrome is relatively common. It is gener-
ally provoked by corneal contact lens use or after intra-
ocular lens implantation [25]. Novel X-linked syndrome 
is characterized by symptoms of cardiac valvular dis-
ease, spontaneous keloid scarring, and reduced joint 
mobility. The causal mutation is filamin A (FLNA) sub-
stitution G1576R [26]. Other syndromes that may asso-
ciate with spontaneous keloid formation include the 
Dubowitz syndrome [27], the Noonan syndrome [28], 
and the Goeminne syndrome [29], which are inherited in 
autosomal recessive, autosomal dominant, and sex-
linked incomplete dominant ways, respectively, though 
the actual gene mutation remained unclear.
The diseases that associate with protection from 
severe pathological scarring are Hansen’s disease and von 
Recklinghausen’s disease. Hansen’s disease (also known 
as leprosy) is a chronic disease that arises after infec-
tion with Mycobacterium leprae and Mycobacterium 
lepromatosis. It is characterized by granulomas of the 
nerves, respiratory tract, skin, and eyes and the grad-
ual destruction of the intraepidermal innervation. 
Extensive scarring is extremely rare in patients with 
Hansen’s disease [30, 31]. von Recklinghausen’s disease 
is also known as neurofibromatosis type I (NF-I). It is 
characterized by the growth of tumors on the nerves. 
A study of 30 Nigerian patients with neurofibromato-
sis who underwent surgery showed that none of them 
developed keloid or hypertrophic scars after surgery, 
even though their wound healing was poor and some of 
their wounds were closed under tension [32]. Similarly, 
a worldwide multicenter study on 57 patients with 
von Recklinghausen’s disease showed that none of the 
patients developed hypertrophic scar or keloid after sur-
gery: in general, their wounds healed remarkably well. 
The main complications were the development of hema-
toma and wide white scar in six patients. By contrast, 
two of the 35 patients with a solitary neurofibroma who 
were included in the study developed hypertrophic scars 
after surgery [33].
4.4  Environmental Risk Factors That Shape 
Keloid Rates
Environmental factors also contribute to keloid devel-
opment and progression and therefore shape keloid 
rates. One such factor is local mechanical stimulus. An 
interesting feature of  keloids is that they show a distinct 
site specificity. When we analyzed 1500 keloids in 
483 Japanese patients (the keloids generated from arti-
ficially created wounds, namely, those created by sur-
gery and piercing, were excluded), we found they tended 
to occur on the anterior chest region (48.9%), scapular 
regions (26.9%), lower jaw/neck region (12.1%), upper 
arm (4.8%), dorsal regions (2.5%), lower abdomen 
(1.9%), femoral regions (1.7%), knee (0.5%) and upper 
abdomen (0.5%) [34]. All of  these regions are charac-
terized by high skin tension/friction. That skin tension 
promotes keloid development is also shown by the fact 
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that the keloids on certain regions grow into specific 
shapes. Thus, anterior chest keloids form symmetrical 
butterfly shapes that reflect the predominant stretching 
directions of  the chest skin that are caused by the upper 
arm movements. By contrast, keloids on the scapula 
form dumbbell shapes that run down the long axis of 
the arm and are caused by the skin stretching caused by 
the hanging upper arm. Moreover, earlobe keloids 
often grow into balls that reflect the circular nocturnal 
friction on the earlobe from the head moving on the 
pillow [34]. This role of  mechanical tension in keloid 
growth is further supported by the recent case of  a 
patient in our center whose symmetrically distributed 
butterfly keloid on the chest was accidentally split in 
half  at the midline. The patient was right-handed. In 
the subsequent 2 years, the right half  butterfly of  the 
keloid continued to progress as usual. By contrast, the 
left half  butterfly grew much less strongly and indeed 
exhibited signs of  amelioration [11].
4.5  Conclusion
Regardless of whether keloids occur spontaneously or 
after trauma, these lesions are clearly the result of both 
internal genetic and external environmental factors. 
These factors underlie the association between keloids 
and various demographic risk factors, namely, geo-
graphical region and ethnicity. However, our under-
standing of these demographic factors is limited by the 
paucity of and inconsistencies in the epidemiological 
research on keloids. To identify the respective contribu-
tions of genetic and environment factors to keloid for-
mation, it will be necessary to conduct large-scale 
investigations with specific study designs, such as studies 
on twin cohorts or cross-sectional studies on the mem-
bers of families that show a predilection toward keloido-
genesis. Such explorations will help to orient further 
keloid research, thereby aiding the development of 
effective therapeutic approaches.
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5.1  Burn Injuries and Their Treatment
Burn injuries are a global public health problem. 
According to estimates of the WHO, burn injuries cause 
180,000 deaths every year. The majority of these deaths 
occur in low- and middle-income countries. Two-third 
of these deaths occur in the WHO regions of Africa and 
Southeast Asia.
The nonfatal burns are a leading cause of morbidity, 
including long hospitalizations, disability and problems 
in returning to normal life. In the United States annu-
ally, 486,000 burn injuries receive medical treatment. In 
addition, 40,000 hospitalizations are related to burn 
injuries.
National burn injury incidence data are scarce. In 
Europe, incidence rates of hospitalized burn injuries are 
reported between 2 and 29 per 100,000 inhabitants; in 
Australia, 36 per 100,000 has been reported.
Reviews on burn injury incidence data describe a 
decline in the incidence rates of  burn-related hospital 
admissions in both low- and middle-income coun-
tries. In high-income countries, a similar trend is 
observed.
5.1.1  Burn Care
In the past decades, there has been a shift in focus from 
mortality to morbidity in burn care in high-income coun-
tries. Recently, the European Burns Association stated in 
its guidelines that “the main goal of burn care is to ensure 
optimum resuscitation in the emergency period and then 
to reach re-epithelialization of injured or destroyed skin 
either by support of spontaneous healing or by surgical 
necrectomy and grafting with split thickness skin graft. 
Subsequent treatment is to ensure the optimum post 
burn quality of life”. This goal only includes the mini-
mum surgical procedure. In nowadays burn care, other 
surgical techniques including skin substitutes, full skin 
transplantations and ReCell are also applied.
In high-income countries, a trend is described 
towards a growing specialized burn care. In the 
Netherlands, the majority of these hospital admissions 
are seen in specialized burn centres. This is in line with 
the trend towards further specialization of health care in 
general and also because of limited travel distances in 
our country. In addition, it has been suggested that 
many patients are transferred towards tertiary care facil-
ities because of a lack of basic skills in the assessment 
and care of burn wounds at community and rural hospi-
tals.
5.1.2  Acute Phase
The acute treatment of burn injuries is guided by their 
severity, indicated by the burn size and the burn depth. 
Burn size is represented by the percentage of the total 
body surface area burned (TBSA). The burn depth is 
related to the dermal layers which are affected by the 
burn injury. Accurate diagnosis of both burn size and 
burn depth is crucial to start appropriate treatment at 
the correct level of care required. It guides the initiation 
of fluid resuscitation, acute escharotomy in case of cir-
cumferential deep burns and the decision for conserva-
tive or surgical wound treatment. Burn size also has an 
important prognostic value in predicting burn-related 
mortality. Both burn size and burn depth are of prog-
nostic value for eventual burn scar pathology.
The most widely used classification for burn injuries 
divides burns into three categories of increasing depth: 
superficial partial-thickness, deep partial-thickness and 
full-thickness burns. Superficial partial-thickness burns 
involve only the epidermal layer and the superficial part 
of the dermis. In deep partial-thickness burns, the epider-
mis and the majority of the dermis are destroyed, with 
damage to deeper skin structures such as blood vessels, 
nerves and hair follicles. In full-thickness burns, all layers 
of the skin are destroyed, and there may also be damage 
to subdermal structures, such as the muscle, cartilage or 
bone. In these wounds, no viable epidermal appendages 
remain in the bottom of the wound, which makes sponta-
neous healing from the wound bed impossible.
In superficial partial-thickness burns, conservative 
treatment will be chosen to support spontaneous wound 
healing, which is expected within 10–14  days. In deep 
partial-thickness burns, surgical treatment is sometimes 
necessary to reach wound closure. In full-thickness 
burns, surgical wound closure will be necessary in the 
majority of wounds, except in the very small-sized ones. 
Background
This chapter focuses on the epidemiology of burn scars 
and their consequences. Burn scars are the result of a 
pathological healing process in specific burn injuries.
The occurrence of burn injuries and resulting scars 
and their consequences will be discussed. This includes 
scar contractures and reconstructive surgery. Next, the 
predisposing factors for the occurrence of burn scars 
will be addresses. The chapter ends with the clinical im-
plications.
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Other important parts of burn care include oedema 
management, early mobilization and scar management.
Treatment protocols vary between burn centres, 
including wound dressings, early mobilization and tim-
ing of surgery. According to Dokter et  al., in the 
Netherlands, 45% of all burn injury patients admitted to 
burn centres receive surgery approximately 15 days post 
burn. In burn centres in Australia and New Zealand, a 
similar proportion is operated upon (47.2%) in general 
within 1 week post burn (mean 6 days post burn).
5.2  Prevalence of Burn Scars and Their 
Consequences
5.2.1  Definition of Scars
The consequences of burns can be severe, affecting mul-
tiple domains. The focus in this chapter is on the preva-
lence of pathological physical scar formation and its 
consequences.
Burn scars can cause aesthetic and functional prob-
lems, resulting in limitations in activities of daily living, 
the return to normal social roles and impacted quality 
of life. The psychological consequences will be further 
elucidated elsewhere in this book.
Early studies on pathological scarring in burn 
wounds have distinguished between hypertrophic scars 
and contractures (Magliacani (1997) in [1]).
Hypertrophic scars are a dominant type of patho-
logical scar formation after burns. Nowadays, hypertro-
phic scarring is described as “the greatest unmet 
challenge after burn injury.”
Hypertrophic scars are generally elevated, firm and 
erythematous. They can also tend to be pruritic and ten-
der. By definition, they are limited to the site of the orig-
inal wound and grow in size by pushing out the scar 
margins. Hypertrophic scarring is known to decrease 
with time.
Next to hypertrophic scars, contractures are another 
important type of pathological scar formation after 
burns. A contracture is defined as the pathological result 
of excessive scarring and ongoing scar contraction that 
results in loss of range of motion (ROM) over joint 
areas. Scar contractures may limit daily functioning and 
as a result affect health-related quality of life after burns.
Modern scar assessment addresses a broader range 
of scar features from both the patients’ perspective and 
the perspective of the health-care professional. Scar 
quality from a patient perspective depends on the pres-
ence or absence of several visual, tactile and sensational 
features [2]. For research purposes, an ideal scar evalua-
tion protocol should include both subjective and objec-
tive measurements. These different perspectives will 
result in different scar assessment tools and different scar 
outcomes. Results indicate the level of scar morbidity 
and not the mere presence or absence of scar pathology.
Examples of frequently used scar assessment scales 
are the Vancouver Scar Scale and the Patient and 
Observer Scar Assessment Scale (POSAS; see 7 www. 
posas. org).
A final approximation of burn scarring is the occur-
rence of reconstructive surgery after burns. The need for 
reconstructive surgery after burn injuries can be viewed 
upon as an indicator for problematic scar development, 
requiring a surgical intervention to relieve scar morbid-
ity.
5.2.2  Prevalence of Hypertrophic Scarring
The estimates of prevalence of scarring vary widely. 
Prevalences of hypertrophic scarring between 8% and 
67% are reported [3]. These data are all related to burn 
centre populations in high-income countries.
One of the first reports was written by Deitch et al. in 
1983, based on a combined retrospective and  prospective 
study in a mixed population of children and adults. 
They reported hypertrophic scars after conservative 
wound healing in 30% of their patients with a dark skin 
and in 15% of their Caucasian/White patients at 9 to 
18  months post burn. Hypertrophic scars were docu-
mented in case of increased thickness or elevation of the 
burn wound; changes in colour or pigmentation alone 
were not classified as hypertrophy.
Two decades later, Bombardo reported a prevalence 
of 67% of hypertrophic scars in a dominantly Caucasian 
sample of patients after major burns. Again, data were 
based on retrospective chart analysis in patients after 
major burns, examining the mentioning of the word 
hypertrophic in the charts. No description was provided 
on the timing of the scar assessments.
More recently, estimates of prevalence of hypertro-
phic scars are derived on assessments using validated 
instruments. The Vancouver Scar Scale is traditionally a 
well-known scale to evaluate burn scars. In 2017, Wallace 
et  al. assessed the prevalence of hypertrophic scars, 
using the Modified Vancouver Scar Scale. Raised hyper-
trophic scarring over 1 mm was reported in 7.8% of the 
patients treated in a Western Australian burns unit up to 
1 year post burn [4].
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5.2.3  Prevalence of Contractures
Although contractures are a dominant feature after 
burn injuries, data on prevalence of burn scar contrac-
tures are scarce. In a recent review by Oosterwijk [5] 
et al., only 10 relevant studies were available for inclu-
sion. The prevalence at discharge was 38–54% and 
decreased with an increasing time post burns.
The included studies indicated an elevated risk for 
contractures in deep or surgically treated burn injuries, 
in females and children. In addition, contractures 
seemed to occur more frequently in the upper extremity 
joints, specifically in the shoulder and elbows.
Assessment of  scar contractures was based on 
range of  motion measurement in six studies; in four 
studies, the method of  scar contracture assessment was 
not described. In addition, study design, study period, 
study population and timing of  scar contracture 
assessment varied largely. Consequently, the authors 
concluded that “prevalence of  scar contractures after 
burn is insufficiently reported and varies considerably 
between studies.” This impedes the analysis of  deter-
minants of  scar contractures and possible interven-
tions [5].
Recently, Schouten et al. assessed scar contractures 
in a prospective cohort study using passive ROM assess-
ments up to 12 months. Scar contractures one year post 
burn were only found in operated burned joints. Scar 
contractures at discharge in non-operated joints all 
returned back to normal in 6 to 9 months. Again, scar 
contractures were more often seen in the upper part of 
the body, especially in the shoulder [6].
5.2.4  Scar Quality Assessment
In contrast to the assessment of scar hypertrophy or scar 
contractures, scar quality assessment addresses a 
broader assessment of scar-related characteristics, 
including colour, thickness, relief, pliability, pain and 
pruritus. The Patient Scar Assessment Scale and the 
Patient and Observer Scar Assessment Scale (POSAS), 
for example, consist of the two six-item numeric scales 
reflecting the patient’s perspective and the observer’s 
perspective. This is in contrast to another frequently 
used scale, the Vancouver Scar Scale, which reflects the 
observer perspective only and has some methodological 
difficulties, especially concerning the item “pigmenta-
tion.”
The POSAS was introduced in 2004. Both the self- 
reported mean patient POSAS and the observer POSAS 
are based on scores on six individual scar characteristics. 
These scar characteristics are scored on a numerical 
10-point scale, in which 1 represents a scar comparable 
with “normal skin” whereas 10 represents the “worst 
scar imaginable.”
Using the POSAS, substantial scar morbidity is 
reported, even several years after the burn injury. In 
patients after mild to intermediate burn injuries, mean 
self-reported patient POSAS scores varied between 1.8 
and 2.9 more than 2 years post [7]. In a similar sample 5 
years post burn, these patient POSAS scores were even 
higher, reflecting more scar morbidity. The mean patient 
POSAS was 3.0, and 7% had a POSAS score above 4 (on 
a scale from 1 to 10) on all six scar characteristics.
In patients after severe burns (with a mean TBSA of 
24.0%), scar morbidity was higher, with a patient 
POSAS of 4.5 (SD 2.0) [8].
5.2.5  Prevalence of Reconstructive Surgery
The need for reconstructive surgery after burn injuries 
can be viewed upon as an indicator for problematic scar 
development, requiring a surgical intervention to relieve 
scar morbidity. Of course, the possibilities to perform 
reconstructive surgery will influence the occurrence of 
reconstructive surgery.
Recent studies in patients after a burn centre admis-
sion in the Netherlands showed that 13.0% of these 
patients received reconstructive surgery in a ten-year 
follow-up period after burn injuries. In patients with 
head and neck burns, the prevalence of reconstructive 
surgery was 8.9% [9]. Vlies et al. reported a prevalence of 
15% in patients after hand burns. These prevalences are 
lower than the one reported in the early 1990s by Prasad 
et al. (19.9%). This can probably be related not only to 
improvements in acute burn care between the 1970–1985 
and 1990 but also to the more frequent use of non-surgi-
cal therapies in the rehabilitation phase, like silicones 
and laser therapy. Another explanation for these differ-
ences may be the higher burn size in the study of Prasad 
with a mean TBSA of 16.4% and 5.8% full- thickness 
burns, compared to our sample (9.8 and 3.4%). Also 
follow-up time differed; patients in the study of Prasad 
were followed for a variable period of 5 to 20 years.
Another Dutch study by Hoogewerf et al. in patients 
after head and neck burns described a prevalence of 
5.3% reconstructive surgery. This prevalence is lower 
than the one found in the 10-year follow-up period, 
probably because of the shorter follow-up period of 
2–7 years post burn.
5.2.6  Maturation Pattern
In general, hypertrophic scars develop in the first months 
after the burn injury. Then, scar hypertrophy is described 
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to increase up to 6 months. At 12 months, there is a ten-
dency to regress, according to several studies [2].
Individual scar characteristics have an individual 
maturation pattern. Vascularization shows a continuous 
decrease from 3 months post burn onwards, and relief  
and thickness show increased scar morbidity during at 
least the first year post injury (. Fig. 5.1).
5.3  Factors Predicting Scar Outcome  
After Burns
Several studies investigated the predictors of pathologi-
cal scar formation after burn injuries.
Some groups of predictors can be distinguished, 
including patient, injury and treatment characteristics.
5.3.1  Patient Characteristics
A few patient characteristics are recognized for their 
predictive value in pathological scar formation.
Sex: The relation between sex and scar quality is 
ambiguous.
There are several studies reporting a poorer scar 
quality in females. In Dutch studies using the Patient 
and Observer Scar Assessment Scale (POSAS), a poorer 
scar quality was reported in females two and five years 
after burns. Observers reported a poorer scar quality in 
female participants two years post burn, but the females 
themselves reported similar scar quality, compared to 
their male counterparts. However, after taking skin type 
and surgical treatment into account, scar quality was 
similar [7].
In patients five years after burns, female participants 
reported a similar overall patient POSAS score but a 
poorer overall scar opinion, compared to men. This sex 
differences remained, also after controlling for other rel-
evant factors including length of hospital stay [8].
In an Australian study predicting raised scars 
(<1  mm) in adults, based on the Modified Vancouver 
Scar Scale, females had an increased risk of raised scars, 
also after taking into account other relevant factors [4]. 
In a similar study in children, no gender differences were 
found.
However, in earlier studies, using a variety of 
scar assessments, this gender difference was not 
observed [1].
Age: An older age has been shown to reduce the risk 
for pathological scarring in several studies. The risk for 
raised scars was reduced in patients over 45 years of age, 
compared to patients 30 years of age and under [2]. In a 
paediatric study, the youngest children (0–5 years) were 
at higher risk to develop raised scars [10].
Skin type: Skin type is a well-known factor influenc-
ing the scar formation and scar quality. In one of the 
first studies on prediction of scar quality from Deitch in 
1983, scar hypertrophy was more often reported in 
patients with a darker skin. In recent studies, skin type is 
often classified using the Fitzpatrick skin type test. This 
score classifies skin types in six categories, from type I 
(palest) to type VI (deeply pigmented dark brown to 
darkest brown). Having skin types V or VI was associ-
ated with a poorer scar quality, based on both the patient 
and observer POSAS [7]. In addition, darker skin (skin 
types IV–VI) has an increased risk on raised scars [4]. In 
children, this association was not reported [10].
5.3.2  Injury and Treatment Characteristics
Several injury and treatment characteristics have been 
documented to influence scar formation and scar 
quality.
These include several burn severity indicators, 
including increased burn size (percentage of total body 
surface area burned (TBSA)), high %TBSA full thick-
ness, wound complications and a longer time to wound 
healing.
In addition, several treatment characteristics have 
been described to be related to poor scar quality, 
 including a prolonged hospital stay, type of surgery 
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  . Fig. 5.1 Maturation pattern after burn injuries, assessed with 
observer scales of  POSAS (Van der Wal et al., personal communica-
tion; see also Wound Repair Regen. 2012;20:676–87)
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ple surgeries, repeated surgery in the same wound, 
reconstructive surgery and artificial ventilation [4, 10]. 
Again, all these treatment features are related to the 
severity of the burn injuries, complexity of wound heal-
ing and possible complications. Length of stay in these 
analyses is the representation or proxy for the severity of 
the burn injuries and the complexity of the burn care 
process including wound healing and possible complica-
tions.
5.3.3  Patient, Injury and Treatment 
Characteristics Combined
To identify the independent predictors of  poor scar 
outcome, the potential predictors have to be taken into 
account together in one analysis, which requires ade-
quate numbers to reach significant power of  the analy-
sis. Some examples of  such studies are summarized 
here.
Raised scars in children up to 16 years of age, one 
year post burn, could be predicted by greater burn size 
(%TBSA), a prolonged healing time (over 14 days) and 
multiple surgical procedures. Patient characteristics did 
not contribute to this prediction of scars after burn inju-
ries in children [10].
Raised scars in adults one year post burn could be 
predicted again by increasing burn size (%TBSA) and by 
the type of surgical intervention (as a proxy for burn 
depth), wound complications and prolonged hospital 
stay. In addition, patient predictors were found, being a 
young age (<30), the female gender and darker skin were 
for raised scars in adults [4].
Reported scar quality 2 years post burn could be 
predicted by one patient-related and one injury/
treatment- related characteristic: a dark skin type and 
more than one operation in the same wound were inde-
pendently related to lower long-term scar quality, 
2 years after the injury [7]. Self-reported scar quality 5 
years post burn was predicted by length of  hospital 
stay. In addition, the female gender predicted the over-
all scar opinion. Thus, all other patient-, injury- or 
treatment-related potential risk factor predictors did 
no longer predict scar quality, after taking these predic-
tors into account [8].
Some general remarks can be made based on these 
findings. Firstly, injury- and treatment-related charac-
teristics are the main predictors of  scar outcomes after 
burn injury. These characteristics are related to burn 
size (total body surface area burned) and burn depth 
(number or type of  surgery) or the overall healing pro-
cess in general (length of  stay, wound healing complica-
tions). Intrinsic patient-related risk factors seem to play 
a role as well but are less consistent predictors of  scar 
outcome. This includes the risk factors the female gen-
der and also a younger age and darker skin.
An important limitation of three of the aforemen-
tioned studies is the sample size. In sample sizes up to 
251 patients, only a limited number of predictors can be 
revealed in multivariate analysis. This was illustrated by 
the results of the adult study from Wallace et al.; their 
analyses on 616 people after burns revealed seven sig-
nificant predictors [4, 10], compared to the maximum of 
three predictors in the other smaller-sized studies.
5.4  Clinical Relevance
Knowledge on risk factors for poor scar outcome can be 
used to tailor treatment, aftercare and scar prevention 
to these patients with a high-risk profile.
Current evidence shows that injury- and treatment- 
related characteristics are the main predictors of scar 
outcomes after burn injury. These characteristics are 
related to burn size (%TBSA) and burn depth (number 
or type of surgery) or the overall healing process in gen-
eral (length of stay, wound healing complications). 
Intrinsic patient-related risk factors seem to play a role 
as well but are less consistent predictors of scar out-
come. This includes the risk factors the female gender 
and also a younger age and darker skin.
Future studies, with greater sample sizes, will proba-
bly reveal additional predictors for scar outcome. 
Especially, paediatric scar outcome is not yet well 
studied.
5.5  Conclusion
Early studies on pathological scarring in burn wounds 
have distinguished between hypertrophic scars and con-
tractures. Prevalences of hypertrophic scarring after 
burn injuries are reported between 8% and 67%; a recent 
prospective study revealed a prevalence of 8%. Data on 
prevalence of burn scar contractures are limited; 
reported prevalence at discharge varied between 38 and 
54% and decreased with an increasing time post burn. 
Prevalence of reconstructive surgery after burn varied 
between 5 and 20%, up to 10 years post injury.
Factors predicting pathological scar formation after 
burn injuries include patient, injury and treatment char-
acteristics. Injury- and treatment-related characteristics 
are the main predictors of scar outcomes after burn 
injury. These characteristics are related to burn size 
(total body surface area burned) and burn depth (num-
ber or type of surgery) or the overall healing process in 
general (length of stay, wound healing complications). 
Intrinsic patient-related risk factors seem to play a role 
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as well but are less consistent predictors of scar  outcome. 
This includes the risk factors the female gender and also 
a younger age and darker skin.
Knowledge on risk factors for poor scar outcome 
can be used to tailor treatment, aftercare and scar pre-
vention to these patients with a high-risk profile.
Take-Home Messages
 5 Pathological scarring in burn wounds can result in 
hypertrophic scars and/or contractures.
 5 Reported prevalence of hypertrophic scarring 
after burn injuries varied between 8% and 67%.
 5 Reported prevalence of burn scar contractures 
varied between 38 and 54%.
 5 About 5 to 20% of patient after burn injuries 
receive reconstructive surgery, reflecting scar 
pathology.
 5 Factors predicting pathological scar formation 
after burn injuries include patient, injury and 
treatment characteristics.
 5 Injury- and treatment-related characteristics are 
the main predictors of scar outcomes after burn 
injury, including burn size (TBSA burned), burn 
depth (number of type of surgery) or the overall 
healing process in general (length of stay, wound 
healing complications).
 5 Intrinsic patient-related risk factors, including the 
female gender and also a younger age and darker 
skin, are less consistent predictors of scar outcome.
 5 Knowledge on risk factors for poor scar outcome 
should be used to tailor treatment, aftercare and 
scar prevention to these patients with a high-risk 
profile.
References
 1. Gangemi EN, Gregori D, Berchialla P, et al. Epidemiology and 
risk factors for pathologic scarring after burn wounds. Arch 
Facial Plast Surg. 2008;10:93–102. https://doi.org/10.1001/arch-
faci.10.2.93.
 2. van der Wal MB, Verhaegen PD, Middelkoop E, et al. A clini-
metric overview of  scar assessment scales. J Burn Care Res: 
Official Publication of  the American Burn Association. 
2012;33:e79–87. https://doi.org/10.1097/
BCR.0b013e318239f5dd.
 3. Bombaro KM, Engrav LH, Carrougher GJ, et  al. What is the 
prevalence of  hypertrophic scarring following burns? Burns. 
2003;29:299–302. DOI: S0305417903000676 [pii].
 4. Wallace HJ, Fear MW, Crowe MM, et al. Identification of  fac-
tors predicting scar outcome after burn in adults: a prospective 
case–control study. Burns. 2017;43:1271–83.
 5. Oosterwijk AM, Mouton LJ, Schouten H, et al. Prevalence of 
scar contractures after burn: a systematic review. Burns. 
2017;43:41–9.
 6. Schouten HJ, Nieuwenhuis MK, van Baar M E, et al. The preva-
lence and development of  burn scar contractures. A prospective 
multicentre cohort study. Submitted.
 7. Goei H, van der Vlies CH, Hop MJ, et al. Long-term scar quality 
in burns with three distinct healing potentials: a multicenter pro-
spective cohort study. Wound Repair Regen. 2016;24:721–30.
 8. Spronk I, Polinder S, Haagsma J, et  al. Patient-reported scar 
quality of  adults after burn injuries: a five-year multicenter fol-
low-up study. Wound Repair Regen Acc. 
 9. Hop MJ, Langenberg LC, Hiddingh J, et al. Reconstructive sur-
gery after burns: a 10-year follow-up study. Burns. 2014;40:1544–
51. https://doi.org/10.1016/j.burns.2014.04.014.
 10. Wallace HJ, Fear MW, Crowe MM, et al. Identification of  fac-
tors predicting scar outcome after burn injury in children: a pro-
spective case-control study. Burns Trauma. 2017;5:19.
Further Reading
Finnerty CC, Jeschke MG, Branski LK, Barret JP, Dziewulski P, 
Herndon DN. Hypertrophic scarring: the greatest unmet chal-
lenge after burn injury. Lancet. 2016;388:1427–36.
Open Access This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons. 
org/licenses/by/4. 0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appro-
priate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if  changes were made.
The images or other third party material in this chapter are included in the chapter’s Creative Commons license, unless indicated otherwise 
in a credit line to the material. If  material is not included in the chapter’s Creative Commons license and your intended use is not permitted by 
statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
Epidemiology of Scars and Their Consequences: Burn Scars
45
© The Author(s) 2020





6.1  Introduction and Background – 46
6.2  Reminder of the Spectrum of Scars – 46
6.2.1  Contractures – 46
6.2.2  Extended Scar – 46
6.2.3  Atrophic Scar – 46
6.2.4  Hypertrophic Scar – 46
6.2.5  Keloid Scar – 46
6.3  Hypertrophic Scars – 46
6.4  Basic Epidemiology – 46
6.4.1  Risk Factors – 47
6.5  Keloid Scars – 47
6.5.1  Basic Epidemiology – 47
6.5.2  Risk Factors – 47
6.6  Specific Situation: The Burnt Patient Healing – 47
6.6.1  Scarred Hypertrophy in Burned Patients: Epidemiology – 48
6.6.2  Retracted Scars – 48
6.7  Impact of Scars – 48
6.8  Conclusion – 48




6.1  Introduction and Background
Cutaneous scarring is a dynamic process following a 
physical alteration of the cutaneous barrier. It is a slow 
process, taking place in three phases: debridement, gran-
ulation and epidermization, each of these phases bring-
ing into play different cellular mediators. Then comes 
the maturation phase of the scar, which reaches its final 
appearance usually after two years of evolution.
It is important to distinguish between defective scars, 
which may result out of poor surgical technique, issuing 
to a dermal separation, keeping the epidermal layer in 
continuity. These scars are stable over time and do not 
belong to the same category than pathological scars, 
which are true evolutionary abnormalities of cutaneous 
scarring, linked to abnormal cell proliferation of myofi-
broblasts, with different scenarios depending on the 
degree of anarchy of the collagenic bundles.
6.2  Reminder of the Spectrum of Scars
6.2.1  Contractures
Located generally opposite the joints or when a wound 
is perpendicular to the lines of Langer, they can alter 
considerably the function according to their importance 
and their localization. They are particularly common in 
burned patients or after a thin or semi-thick skin graft.
6.2.2  Extended Scar
They are mainly observed from the first postoperative 
weeks. Most often pale, asymptomatic, they pose mostly 
aesthetic problems without functional discomfort. 
Stretch marks (often abdominal) are a type of enlarged 
scar and a consequence of a rupture of the dermis, with-
out epidermal alteration. The absence of elevation or 
thickening differentiates them from hypertrophic scars.
6.2.3  Atrophic Scar
The plan of these scars lies under the plan of healthy 
peripheral skin. They are usually small. Frequent on the 
face, they are mostly consequences of acne or chicken pox.
6.2.4  Hypertrophic Scar
They are characterized clinically by an elevation of the 
plane of the scar which is thickened, inflammatory, but 
which remains limited to the cicatricial banks. They 
never invade the healthy peripheral skin. They are also 
distinguished from keloid scars by their spontaneous 
regression within two years of the onset of the wound. 
They are often itchy and even painful.
6.2.5  Keloid Scar
Unlike hypertrophic scars, keloid scars extend beyond 
the margins and also affect healthy skin around the scar. 
Functional symptoms (itching and pain) are very com-
mon and hinder quality of life. They have no tendency 
to regress. After excision, the rate of recurrence is major, 
making the management of these scars, which must be 
multimodal, complex.
Pathological (hypertrophic or keloid) healing is a 
complex process, resulting from many factors. During 
normal healing, the myofibroblasts participating in the 
cutaneous contraction enter apoptosis. A lack of apop-
tosis of these myofibroblasts, and consequently their 
excessive accumulation, explains the occurrence of 
raised and inflammatory scars [1]. Another factor con-
tributing to the pathogenesis of these scars is an accu-
mulation of immature collagen [2].
6.3  Hypertrophic Scars
Hypertrophic scars are the result of excessive prolifera-
tion of myofibroblasts and increased deposition of colla-
gen within the scar [1, 2]. The scar then exceeds to the 
surface of the healthy peripheral skin, can be inflamma-
tory and itchy, and even painful. They differ from keloid 
scars due to their tendency to regress within two years and 
because they never exceed the scarred margins [3, 4, 5]. 
However, diagnostic errors are still common in practice.
6.4  Basic Epidemiology
The frequent confusion between hypertrophic scars and 
keloids (despite the above definitions) means that there 
is little data on their epidemiology. The studies found 
are often of low level of evidence, centered on a given 
geographic population. Mahdavian Belavary et  al [5] 
studied the rate of hypertrophic scars after breast reduc-
tion or median sternotomy. At three months, 60% of 
patients developed hypertrophic scars. At one year, there 
was persistent hypertrophy in 32% of patients included. 
These figures are consistent with previous studies, found 
between 38% and 68% postoperative hypertrophic scars 
[6]. An analysis of data over time would be interesting, 
in order to evaluate the average duration of evolution of 
these scars. No sex ratio was found in the literature, as 
men and women were similarly affected by the occur-
rence of hypertrophic scars.
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6.4.1  Risk Factors
Many risk factors for the occurrence of scarring hyper-
trophy are admitted. There are many studies in the litera-
ture but many are of a low level of proof (levels IV–V). 
Butzelaar et al. [7] found as major risk factors the age, the 
existence of allergic terrain, the existence of bacterial 
colonization (with or without infection) within the 
wound, and cutaneous tension. Most of the hypertrophic 
scars are found between the ages of 11 and 30 years. This 
can be explained by the presence of sagging skin with age 
and a decrease in the inflammatory response [8]. It is 
often accepted that a dark phototype (African skin) is a 
risk factor for hypertrophic scars. Nevertheless, in the lit-
erature, the studies are of a low level of proof and the 
opinion of the authors is partaged, not allowing to bring 
a valid and reliable conclusion to this idea. Unlike keloid 
scars, there does not appear to be a genetic cause for the 
occurrence of hypertrophic scars [9]. Butzelaar et al [7] 
found a protective trend of smoking for the development 
of hypertrophic scars. Cancer chemotherapy also seems 
to be a protective factor; however, there are many con-
founding factors to consider in the studies in question 
(role of cancer itself, possible undernutrition).
6.5  Keloid Scars
The keloid scar is an abnormality of cutaneous healing 
specific to humans. The main problems, apart from their 
unattractive and annoying appearance, are their non- 
improvement in the time and frequency of recurrence 
despite the medical and surgical treatments undertaken. 
They can even be aggravated by surgical resection if  it is 
not strictly intra-lesional.
6.5.1  Basic Epidemiology
Again, few studies have investigated the prevalence or 
incidence of keloid scars. Yet each year, it is estimated 
that about 100 million scars are developed, and among 
them 11 million would become keloids [10].
In the literature, the prevalence varies widely accord-
ing to the population studied [3, 11].The estimations are 
as follows:
 5 4.5 to 16% in black and Hispanic populations of 
American origin
 5 16% in Zaire
 5 only 0.09% in England
They are responsible for pruritus or pain in 20–40% of 
cases [3].
6.5.2  Risk Factors
Keloid scars may be found on all localizations, but are 
more frequent in some areas [11, 12]:
 5 Ear lobe
 5 Pre-stern and deltoid region
 5 Under umbilical area (pubic area)
These are areas where skin tension is important, thus 
joining the frequent locations of  hypertrophic scars. 
By definition, they do not touch the mucous mem-
branes.
They can be observed at any age but peak frequency 
is between 10 and 30 years [13, 18]. Some authors 
explain this by the role of  cutaneous tension which is 
more important in young subjects [3]. There also 
appears to be a hormonal factor, keloid scars being 
more frequent in the pubertal period [3]. The hor-
monal role is still discussed: if  they are actually more 
common in pubertal period, keloids that appear at 
these ages also have a tendency to hyperpigmentation. 
During pregnancy, some authors have observed a 
more frequent appearance or enlargement of  keloid 
scars [14].
It is also accepted that subjects with a dark photo-
type are more frequently affected, although we may 
experience keloid scars in all phototypes [15, 16].
The hypothesis of  a genetic predisposition is begin-
ning to be well anchored. It is estimated that 5 to 10% 
of  cases have family keloids [17]. Marneros et al. [18] 
found that transmission is autosomal-dominant mode, 
the clinical penetrance is incomplete, and the expres-
sion is highly variable. There appears to be susceptibil-
ity to the development of  keloids in Japanese and 
African-American families in relation to chromosomes 
2 and 7 [19].
There are cases of spontaneous keloids in the litera-
ture, but these would ultimately be due to undetected 
microtrauma [20]
6.6  Specific Situation: The Burnt Patient 
Healing
Hypertrophic scarring after a burn (whether it has 
healed spontaneously or required skin grafting) is a 
common problem in clinical practice. In addition to 
being dysgraculous, these scars are generally itchy and 
even painful and can significantly alter function and 
quality of life, especially if  they are responsible for skin 
retraction. Since this type of healing is quite specific to 





6.6.1  Scarred Hypertrophy in Burned 
Patients: Epidemiology
The data of the literature are very variable on this sub-
ject. In the majority of cases, the studies are small, and 
few distinctions are made between the different popula-
tions (adults vs. children, light phototype vs. dark pho-
totype, spontaneously scarred burn vs. transplanted).
Deitch et al [21] found a prevalence of 15% (white 
patients) to 30% (black patients) in burn patients who 
healed spontaneously.
Mc Donald and Deitch [22] analyzed the prevalence 
of scar hypertrophy in patients treated with thin skin 
grafts. Of the children included, 75% had cicatricial 
hypertrophy. In adults, the prevalence was 50% in 
patients with black skin, compared to 7% in patients 
with fair skin.
Spurr and Shakespeare [23] followed 82 children and 
found 65% hypertrophic scars. Bombaro et  al. [24] 
reported an average of 67% cicatricial hypertrophy (up 
to 100% in children with non-white skin). Finally, 
Delavary et  al. [25] found a rate of 60% hypertrophic 
scars in burn patients, mainly in the first three months 
after the onset of the burn. According to them, young 
and non- smoking subjects are more likely to develop 
hypertrophic scars. In each of these studies, the number 
of patients remains low and the population monocen-
tric. Further and larger studies would be needed to bet-
ter identify populations at risk. The risk factors identified 
to date are young age, location of the upper limbs or 
neck, dark phototype, repetition of surgical procedures, 
initial severity of burn, and time to heal [25]. Lawrence 
et al [26] also find these risk factors in the literature, in 
addition to the female sex and skin grafts that required 
expansion (mesh-graft). Their review of the literature 
found a prevalence of hypertrophic scars ranging 
between 32 and 72%.
6.6.2  Retracted Scars
Retraction or contraction of the skin following a burn 
results from an excessive, hypertrophic scarring, of 
which we have just spoken. Functional consequences 
can be major and threaten the socio-professional future 
of patients. They are frequent and particularly disabling 
in the articular areas. The prevalence is very variable 
according to the studies, one finds on average between 
38 and 54% of contraction in the years following the 
occurrence of the burn [27]. According to the authors, 
these would be more common in severely burned 
patients, children, women, and upper limb. Gangemi 
et  al. [28] analyzed 703 burned patients and found on 
average 77% of pathological scars (44% hypertrophy, 5% 
contractures, 28% combining both). They also found as 
risk factors the female sex, the young age, localization of 
the burning of the upper limb or the neck, the repetition 
of the surgical procedures, and the expansion of the skin 
grafts when these are realized.
6.7  Impact of Scars
Although many studies concern the epidemiology and 
management of scars, very few have been interested in 
the consequences of these scars. However, it is estimated 
that more than one in two patients are not satisfied with 
the appearance of their scars, 20% of patients suffer 
from anxiety, and more than 50% feel that their privacy 
is affected by the presence of their scars [29].
6.8  Conclusion
Few studies have really focused on the epidemiology of 
scars and their consequences. When studies are con-
ducted, they often concentrate around a given geo-
graphic population and report only a small number of 
patients. There are probably many lost sight, since many 
patients live surely with their scars (hypertrophic, 
keloids) without consulting. Larger scale studies should 
be carried out to determine the frequency of occurrence 
of these scarring abnormalities, in order to better iden-
tify them and, consequently, to better treat them.
Take Home Message
The epidemiology of  pathologic scars is diverse. 
Sixty percent of  scars located on the thorax may 
become hypertrophic, and a patient from Zaire has 
100% more risks to develop a keloid than a patient 
native from England. Burns may issue up to 77% of 
pathologic scars, combining hypertrophic, retractile, 
and keloid scars. The role of  hormonal status, 
nutrition, and many other factors has been suspected 
in keloids.
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Cleft lip and palate are facial and oral malformation due 
to failures in the embryologic craniofacial development 
during early pregnancy. They occur in approximately 
1 in 750/1000 births in Europe, which makes it the most 
common congenital craniofacial abnormality. Different 
variations in phenotype of this malformation exist. It 
can occur unilateral (left or right) or bilateral, with 
involvement of lip and/or alveolus and/or palate and 
can be microform, incomplete, or complete. Unilateral 
cleft lip and palate are the most common type, whereby 
the upper lip, the orbicularis muscle, the alveolar bone, 
the floor of the nose, and the hard and soft palate are 
interrupted, creating an open communication between 
nasopharynx and oropharynx.
Patients with a cleft lip and palate are treated in spe-
cialized cleft centers by a multidisciplinary team, con-
sisting of geneticists; (plastic) surgeons; orthodontists; 
dentists; ear, nose, and throat (ENT) doctors; speech 
and language therapists; and psychologists. All surgical 
interventions aimed at closure of the cleft lip and palate 
induce restriction of maxillary growth. Surgical timing, 
staging, and techniques differ between treatment cen-
ters. The lip is usually closed at 3–6 months after birth 
and the soft palate at 6–12 months. In some cleft centers, 
the hard palate is closed before 12 months after birth in 
either a one-stage or two-stage procedure. Other cleft 
centers prefer to close the hard palate later in life, at 
18 months to 3 years, or during the closure of the alveo-
lar gap at the age of 8–11 years.
Having cleft lip and/or palate has a noteworthy 
impact on quality of life and psychosocial functioning. 
Postoperative scarring is a common cause of patient dis-
satisfaction. The degree of postoperative scarring in 
cleft patients is associated with symptoms of anxiety, 
depression, and a lower self-esteem. For cleft surgeons, 
every possible measure to optimize functional and aes-
thetic outcome is important.
7.2  Objectives of Cleft Lip Surgery
The goal of cleft lip surgery is to close the lip separation, 
provide optimal function in terms of speech, mastica-
tion, dental protection, breathing and feeding, and pro-
vide an aesthetically pleasing facial scar and optimal 
shape of nose and nostril. The visible facial scar and its 
effect on nose and lip aesthetics are a daily reminder to 
the patient of its underlying cause. Over the years, dif-
ferent surgical techniques have been described regarding 
surgical closure of the cleft lip. The ideal technique 
should create a balanced lip, allow for easy adjustments, 
and produce a favorable scar pattern combined with a 
symmetrical shape of the nose. Closure of a cleft lip, 
also called “cheilorrhaphy,” is a functional and aesthetic 
reconstruction of the upper lip, orbicularis muscle, nasal 
floor, and ala.
7.3  Treatment Protocol
As stated above, surgical timing, staging, and techniques 
differ between treatment centers. In . Table 7.1, a short 
overview of the “surgical treatment of cleft patients” 
protocol of the Amsterdam University Medical Center 
is provided.
7.4  Cleft Lip Reconstruction: Surgical 
Techniques
Precise surgical technique and adequate aligning of ana-
tomical structures is important for the postoperative 
aesthetic result and scar formation. Patients with a cleft 
lip have, besides the obvious interrupted upper lip, a 
typical flared nostril and a septum deviation. As stated 
above, different surgical techniques are used to recon-
struct this defect, each with its pros and cons. Though 
many approaches exist, the Millard (rotation advance-
ment) and Fisher (anatomic subunit) approaches are 
historically most frequently performed.
  . Table 7.1 Short overview of  the “surgical treatment of 
cleft patients” protocol of  the Amsterdam University 
Medical Center
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7.4.1  Unilateral Cleft Lip
7.4.1.1  Millard Lip Closure
Since the 1950s, the Millard rotation advancement tech-
nique for surgical lip closure was the most popular 
among cleft surgeons. It consists of downward rotation 
of the medial cleft component and a lateral lip advance-
ment flap. The majority of the scar can be placed at the 
philtral column. A disadvantage of this approach is that 
the superior part of the scar crosses the philtrum per-
pendicularly at the columellar base. Various modifica-
tions of the traditional Millard technique have been 
developed to overcome this disadvantage.
7.4.1.2  Fisher Lip Closure
In 2005, Fisher published his lip closure technique, in 
which the anatomical subunit principles guide lip 
repair. In this technique, a circumferential incision at 
the cleft side of  the columella is continued to the 
Cupid’s bow top in a straight manner. This mirrors the 
unaffected philtral ridge. To lengthen the medial flap, 
small inlet incisions are frequently necessary. To pre-
vent upper lip shortening, a triangular flap above the 
cutaneous roll can be incorporated (. Figs. 7.1, 7.2, 
and 7.3).
7.4.2  Bilateral Cleft Lip
“Bilateral cleft lip” can manifest in different ways, in 
which symmetrical complete bilateral
cleft lip–cleft palate is the most prevalent. When 
looking at the lip alone, the bilateral symmetrical com-
plete variant accounts for 50% of cases, bilateral incom-
plete for 25%, and asymmetrical bilateral (complete/
incomplete) for 25%. A one-stage surgical approach is 
advocated in most centers.
The Millard–Mulliken technique is frequently 
employed. A cranially based philtrum flap is created, the 
gap is closed, and orbicularis oris continuity and lip 
continuity are restored. Ideally, both scars are posi-
tioned symmetrically at the philtral ridge.
In several cleft centers these surgical techniques are 
combined with preoperative nasoalveolar molding 
(NAM). The aim of NAM is to improve the shape and 
form of the alveolar wall and nose and to bring the 
divided lip together with an orthodontic plate, nasal 
spring, and tape (Plaatje). In our center NAM is only 
used in cases with bilateral cleft lips. Furthermore, a 
nasal conformer is used in unilateral cases to improve 
the shape of the affected nostril postoperative.
7.4.3  Additional Measures to Improve 
Scarring
Visible facial scarring after cleft lip repair is inevitable. 
There are however some perioperative measures that can 
be taken to minimize scar morbidity in terms of hyper-
trophy and contraction.
7.4.3.1  Perioperative Botulinum Toxin
After surgical correction of the lip and philtrum, the 
underlying orbicularis oris muscle contracts in a direction 
perpendicular to the cutaneous scar. This results in accen-
tuation of dynamic rhytides, which may slowly result in 
widening of the surgical scar. Some surgical teams tempo-
rarily paralyze the orbicularis oris muscle, by intraopera-
tively injecting it with botulinum toxin. Several studies 
showed a beneficial effect on  postoperative scar width; 
however, the sample size is relatively small in most studies, 
and objective assessment tools are scarcely employed.
7.4.3.2  Sutureless Skin Closure
Using (too many) cutaneous sutures in a facial wound 
may cause a foreign body reaction and subsequent sub-
optimal scarring. The possibility of visible cross- 
hatching of sutures is unappealing.
  . Fig. 7.1 Preoperative planning for Millard (left) and Fisher (right) lip closure
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  . Fig. 7.2 Postoperative scar pattern after Millard (left) and Fisher (right) lip closure. Note, different surgeons use different modifications 
of  both techniques
  . Fig. 7.3 Preoperative (upper), 
planning (middle), and direct 
postoperative (lower) result of  the 
Fisher lip closing technique in a 
patient with complete unilateral 
cleft lip and palate
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Some advocate the use of sutureless skin closure, in 
which the cutaneous layer approximation is performed 
using surgical glue, such as butyl cyanoacrylate or amc-
rylate. An additional advantage is that is generally faster 
to perform, which reduces intraoperative time. No large, 
prospective comparative studies are performed on this 
subject.
7.4.3.3  Silicone Application
Topical silicone application is used for treating/prevent-
ing hypertrophic scars in different body locations. This 
is also the case for cheiloplasty scars. To which extent 
hypertrophic cheiloplasty scars can be treated/prevented 
with this application is unknown. Side effects of this 
treatment comprise skin rash and fusibility problems, 
such as loss of adhesiveness. Using silicone gel seems to 
be non-inferior to silicone sheeting.
7.4.3.4  Postoperative Laser Therapy
Use of carbon dioxide fractional laser, sometimes com-
bined with intense pulsed light treatment, in the direct 
postoperative phase is shown to improve scars in terms 
of pliability and color. Though proven safe, pain during 
the session and crust formation are frequently reported.
7.4.3.5  Hair Transplantation
In male cleft patients, limited or missing moustache 
growth may be noticeable in the scarred area, especially 
in men with dark hair and ample hair growth. Hair graft 
transplantation can be performed; however, the poor 
vascularization of scar tissue poses a problem, because 
this is not a good bed for graft survival. Some use fat 
grafting of the scar before hair transplantation to opti-
mize graft survival.
7.5  Secondary Cleft Lip Reconstruction
Secondary cleft lip reconstruction is frequently per-
formed due to scar contracture, which has a negative 
impact on lip, philtrum, and nose aesthetics. The exact 
incidence of secondary lip correction is unknown and 
dependent on many factors, for example, patient factors, 
treatment protocol, access to health care services, etc. In 
the Western world, the estimated incidence is 40–60%. 
Conservative management of these cases is seldom suc-
cessful. Surgical correction typically employs use of the 
Rose–Thompson effect (in which a scar is lengthened by 
using concave excisions of the scar, which is subse-
quently closed in a straight line), one or multiple 
Z- plasties, or a combination of these strategies. Some 
perform fat grafting of the scar to loosen it and provide 
more length. Remaining volume deficiencies, for exam-
ple, volume deficiencies of the lip, can be restored in the 
same procedure with lipofilling or dermal fat grafts.
7.6  Evaluation of Aesthetic Outcome
One of the goals in the treatment of cleft lip (and palate) 
repair is improving nasolabial aesthetics by restoring 
symmetry and proportion of the nose and lip. 
Traditionally, aesthetic assessment is performed by sym-
metry measurements with a caliper. The last two decades, 
several scoring systems have been proposed for a simpler 
and quicker assessment. Most of these scoring systems 
use two-dimensional (2D) photographs in combination 
with Likert or visual analog (VAS) scales. The most fre-
quently used method is the Asher–McDade (AMD) sys-
tem, which utilizes a five-point Likert scale ranging from 
“excellent” to “very poor” to grade four anatomical 
nasal and lip structures. In 2016, the Cleft Aesthetic 
Rating Scale (CARS) was developed as a new tool to 
allow rapid assessment of the nose and lip separately.
The majority of assessment methods are focusing on 
symmetry and on the shape of the nose and lip, whereas 
the scar appears to be of secondary importance. In 2010, 
the Patient and Observer Scar Assessment Scale 
(POSAS) was proposed to assess the scar after cleft lip 
repair. Nevertheless, it remains unknown to which 
extend visible scarring plays a role in facial aesthetics 
after cleft surgery.
To determine the aesthetic outcome in a more objec-
tive way, measurements using three-dimensional (3D) 
photographs seem to be promising nowadays. These 
methods show a high reliability, but these techniques 
require expertise and costly equipment and are therefore 
not readily available worldwide. To compromise, 
computer- based programs, like SymNose, have been 
developed. These programs allow symmetry measure-
ments on 2D images of the nose and lip by tracing the 
outline of the upper lip and the lower border of the 
nose. By reflecting the left side of the midline over the 
right, the percentage mismatch of the nonoverlapping 
area is calculated.
However, an internationally accepted assessment 
method for the aesthetic evaluation of cleft lips is still 
not available.
7.6.1  Palatal Scarring
7.6.1.1  Palatal Closure
Both the hard palate and soft palate can be involved in 
palatal clefts, resulting in a gap from anterior to poste-
rior, affecting the maxilla, the mucosa, the levator veli 
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palatini muscle, the tensor veli palatini muscle, and uvula 
muscle. An open communication between the nasophar-
ynx and oropharynx prevents the infant to create an 
intraoral negative pressure, which is mandatory for pro-
ductive suckling during (breast)feeding. A positive oro-
pharyngeal pressure and elevation of the palate allows 
for the normal articulation of the oral consonants, most 
notably the oral stop-plosives, [p, t, k, b, d, g] in English. 
This can only be achieved by partitioning the orophar-
ynx from the nasopharynx. Therefore, the aim of palatal 
closure, also called “palatography” or “palatoplasty,” is 
functional reconstruction of structures that are neces-
sary for feeding and speech development early in life. 
Different types of palatoplasties have been described to 
close the soft and the hard palate whereby several surgi-
cal considerations must be addressed. The most impor-
tant anatomical structure, which should not be harmed 
during surgery is the greater palatine neurovascular bun-
dle, proceeding through the greater palatine foramen 
through the lateral posterior hard palate. It is essential to 
obtain a tension-free closure of the palatal flaps, prevent-
ing compression or stretching of the neurovascular bun-
dle. Releasing incisions may be necessary to achieve 
complete closure from anterior to posterior.
7.6.1.2  Timing of Palatal Closure
Impaired maxillary growth and an abnormal speech 
development are common findings in
patients after repaired cleft lip and palate. Delayed 
closure of the palate beyond 12 years or no closure at all 
minimizes abnormal facial growth, yet early closure of 
the palate, that is, before 12 months after birth, is neces-
sary for normal speech development. Studies on speech 
development, maxillary growth, and timing of palatal 
closure show different results due to confounding vari-
ables as surgical technique, surgeon’s experience level, 
and lack of standardized speech outcome or standard-
ized indications for secondary maxillary surgery. 
Therefore, consensus on the optimal timing of palatal 
closure has not yet been reached.
7.6.1.3  Maxillary Growth
Impaired maxillary growth in cleft patients often results 
in typical features as crowding, lateral crossbite, and 
open bite. The exact pathophysiology of abnormal facial 
growth after cleft lip and palate repair remains unclear. 
It is a widely accepted hypothesis that abnormal maxil-
lary growth has an iatrogenic cause and is secondary to 
surgical intervention due to scarring. However, other 
studies suggest that intrinsic maxillary underdevelop-
ment contribute to impaired facial growth as well. It is 
most likely that a combination of intrinsic and iatro-
genic factors is responsible, making it mandatory for a 
surgeon to minimize scarring in the oral cavity.
7.6.1.4  Speech Development
Due to a congenital short palate, hypernasal speech, 
and nasal air emission during speech are common 
findings in children after a cleft palate repair. 
Hypernasality and nasal air leakage are often the 
result of  velopharyngeal insufficiency, which means 
that the velopharyngeal valve does not close com-
pletely and consistently during the production of  oral 
sounds. As scarring tissue tends to contract in longi-
tudinal direction, the palate frequently becomes even 
shorter or movement of  the soft palate becomes inad-
equate, preventing the soft palate to make contact 
with the pharyngeal wall. Several techniques have 
been described to create more length of  the palate, 
such as the V–Y pushback repair (Veau–Wardill–
Kilner), the buccal mucosal flap, the double opposing 
Z-plasty (Furlow), or the lengthening of  the soft pal-
ate with a pharyngoplasty.
7.7  Conclusion
Cleft lip and palate scars influence lip, philtrum, and 
nose aesthetics, as well as speech and growth of the max-
illa. Optimal scar management can be divided in surgi-
cal (precise surgical technique, planning, and adequate 
aligning of anatomical structures) and nonsurgical 
methods (botulinum toxin, silicone application, carbon 
dioxide fractional laser).
Take-Home Message
 5 Cleft lip and palate are facial and oral malforma-
tion due to failures in the embryologic craniofacial 
development during early pregnancy.
 5 The goal of cleft lip surgery is to close the lip 
separation; provide optimal function in terms of 
speech, mastication, dental protection, breathing 
and feeding; and provide an aesthetically pleasing 
facial scar.
 5 Cleft lip scars influence lip, philtrum, and nose 
aesthetics.
 5 Optimal scar management can be divided in 
surgical (precise surgical technique, planning, and 
adequate aligning of anatomical structures).
 5 And nonsurgical methods (botulinum toxin, 
silicone application, carbon dioxide fractional 
laser).
 5 In secondary lip correction, cleft surgeons typically 
make use of the Rose–Thompson effect, one or 
multiple Z-plasties, or a combination of these 
strategies.
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Overview Keloid disease (KD) is an aesthetically and 
physically distressing skin disorder [74]. KD is considered 
a benign tumor of the dermis that develops as a result of 
a dysregulated healing response to cutaneous wounding 
[88]. Phenotypically, it is an exophytic proliferative fibrous 
growth of ill-defined etiopathogenesis [15, 17]. Keloid 
scarring is an enigma and a challenge to clinicians espe-
cially dermatologists and surgeons [87], due to its poor 
response to clinical management [88].
Keloids are reported to have a high incidence in 
darker skin races and certain ethnicities of Afro- 
Caribbean origin [4]. The incidence of keloid cases is 
16% in black Africans [15] and keloid predominance in 
females as compared to the males might be due to more 
piercing trends in females [82].
This benign skin disease can either occur sporadi-
cally, or can exhibit a familial pattern. Keloid disease 
is considered a genetic disease due to a strong genetic 
susceptibility to keloid formation as it occurs predomi-
nantly in people of  African and Asian descent, runs 
in families, and has been found in twins. However, a 
well-defined comprehensive mode of  inheritance still 
remains unknown due to insufficient studies to uncover 
the genetic basis of  keloid formation. Nevertheless, 
inheritance patterns for X-Linked or autosomal domi-
nant trait have been found in families with keloids 
[71]. Although no specific genes have been identified, 
that is directly linked to the development of  keloids, 
a few genetic loci have been reported to have a poten-
tial role in disease susceptibility. A study conducted in 
a Japanese population revealed four potential SNPs 
(single- nucleotide polymorphisms) in three chromo-
somal regions [76]. Anatomical sites affected with KD 
also vary in different keloid-prone families [9]. Keloid 
scarring may comprise of  multiple genes, and affected 
individuals could possess variable genetic susceptibil-
ity for a set of  genes or gene mutations associated with 
keloid phenotype [4]. Association studies for keloids 
such as gene polymorphisms and mutations have been 
conducted for some genes including SMAD3, SMAD7, 
and SMAD6, TGF-β1–3, and TGF-βRI-III to inves-
tigate the respective genetic basis of  disease pathol-
ogy. Some genetic networks such as cellular apoptosis, 
MAPKs, TGF-β, IL-6 and PAI-1 have also been stud-
ied in keloid pathology [8, 10–13, 15, 99] and also found 
associated with immunogenic processes as well as other 
biological pathways  (PAI-1, Bcl-2, p53, and collagen 
deposition) [88]. Complexity and differences in the 
inheritance modes and familial keloid scarring reflect 
the variability and heterogeneity in genetic susceptibil-
ity, family history, twin genetic makeup, inheritance 
patterns, linkage, genetic associations, variation in gene 
expression and respective gene pathways, HLA (human 
leukocyte antigen) polymorphism, epigenetics, and eth-
nic populations [88]. Currently, none of  hypothesized 
mechanisms can directly explain the disease pathol-
ogy. Moreover, the lack of  effective treatment options 
underlines the lack of  understanding about disease pro-
cess and complex and multivariable pathogenesis [74].
Objectives The objectives of this review are to investi-
gate the evidence related to the genetic basis and its asso-
ciation with keloid disease. A comprehensive literature 
search was performed using PubMed, Google Scholar, 
CNKI and Embase databases, by applying combinations 
of relevant MeSH (Medical Subject Headings) words as 
title. The key search terms included “Keloid, HLA immu-
nogenetics, Linkage, and Large scale population SNP 
analysis.” The appropriate keywords included “Keloid, 
RNA Sequence analysis, Microarray, Micro RNA, 
Methylation, Mutation, Epigenetics, and FISH.” All 
retrieved records were compiled in the study for compre-
hensive review and evaluated based on significance, meth-
odology, evidence, and reproducibility (. Fig. 8.1).
8.2  HLA Immunogenetics
Human leukocyte antigen (HLA) is the only complex 
genetic polymorphic system present on the 6th chromo-
some (short arm) and is involved in presentation and pro-
cessing of peptide antigens via HLA class I and II [23]. 
The association or involvement of HLA in keloid etiol-
ogy remains elusive as the pathology of dermal fibrosis 
and poor wound-healing remain ill understood [74].
A study conducted in Caucasians and Chinese Hans 
populations demonstrated the involvement of immuno-
genetics (HLA alleles) in keloid etiology. Generally, 
environmental exposure during the wound-healing pro-
cess alters the antigen presentation and expression levels 
of HLA molecules that trigger respective immune 
response including prolonged inflammation and subse-
quent release of profibrotic cytokine/chemokines con-
tributing to the excessive extracellular matrix (ECM) 
deposition, leading to the development of the keloid 
phenotype. The presence of (altered) immune cells in 
keloids, provides the insight into the disease pathology. 
Variable/altered gene and protein expression in keloids 
supports the contribution of a dysregulated immune 
system for disease progression or development [4]. The 
association of immunogenic molecules with the keloid 
phenotype, has been shown by a study, in which periph-
eral blood mononuclear cells of keloid patient exhibited 
increased expression levels of HLA-DR, -DQ, -DP and 
CD1a molecules in keloid patients [57].
The association of keloids with HLA-I alleles, has 
been studied in Chinese Han population (192 patients 
and 252 healthy individuals) to find out the HLA status 
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as a potential contributor to the keloids formation. The 
frequencies of HLA-A*03, A*25, Cw*0802, and B*07 
were significantly high in keloid group but, the frequency 
of HLA-A*01 was highly decreased in comparison 
with healthy individuals. This study described high risk 
haplotypes (A*03-B*07, A*25-B*07, A*03-Cw*0802, 
A*25-Cw*0802, and B*07-Cw*0802) as contributing 
components in keloid formation. Interestingly, keloid 
site specificities, number, severity and details of fam-
ily inheritance were also associated with specific alleles 
of HLA class. It shows that maybe these alleles are 
linked (linkage) with genes, which are responsible for 
keloid susceptibility [65]. Of note, HLA-I alleles (A*01, 
A*03, A*25, B*07 and Cw*08:02, HLA-DQA1 and 
DQB1)  previously associated with KD in participants 
of Chinese ethnicity were shown to have no significant 
differences in allele frequencies in keloid cases from 
Jamaican Afro-Caribbean ethnic group [4].
Keloid patients were also found to have an association 
with blood type A and human leukocyte antigens HLA-
B14, HLA-B21, HLA-BW35, HLA−DR5, HLA- DRB1, 
HLA−DQA1, HLA-DQB1, and HLA-DQW3 [78, 88, 
110]. The association of HLA-I histocompatibility anti-
gens, patient’s family history with earlobe keloids pathol-
ogy, has been studied in females of Black ethnic group. 
This study revealed some factors that appear in high fre-
quency and acts as a risk factor when associated with: (i) 
HLA-A 9, (ii) HLA-A 23, (iii) HLA-Aw 34, (iv) HLA-Cw 
2 antigens, history of (v) hypertension and (vi) post-ear 
piercing infection [29].
Association between HLA-DRB1 phenotype and 
keloid etiology has been studied in Caucasians popu-
lations of Northern European origin (keloid cases n = 
67, control n = 537). It was revealed that frequency of 
HLA-DRB1*15 was high (38.8%) in Caucasians keloid 
cases, which appeared as a risk factor of developing KD 
following injury [17]. Frequencies of serologically detect-
able HLA antigens, i.e., HLA-B14 and HLA- Bw16, 
were subsequently found to be more (25%) common as 
compared to the control, which further suggests that, the 
individuals having HLA-B14 or HLABwl6 phenotype 
may be at risk for keloid formation [51].
It seems that most likely there is an association 
between alleles of HLA class and/or shield against der-
mal fibrosis, because allele loci (DQ and DR) from class 
II is a promising genetic marker owing significance con-
tribution in poor wound healing and fibrosis [74]. All of 
these investigations deliver a strong statement about sig-
nificant involvement of immunogenic component in 
keloid pathogenesis [19, 23].
8.3  Linkage
The prevalence of KD in identical twins, in families, in 
certain ethnicities, and at multiple sites strongly sup-
ports a genetic predisposition in the development of 
keloid phenotype [9, 71]. Certainly, the risk of KD 
occurrence is higher in genetically susceptible individu-
als (Bayat et al. [8, 12, 16]). In addition to that, recur-
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rence rate (50%) is also higher in the African population 
with family history having positive keloid cases [9]. The 
linkage loci of KD were initially found to be on chromo-
somes 2q23 and 7p11 by Marneros et al. [72], but no 
putative gene target was further identified.
Single-nucleotide polymorphisms (commonly found 
to be useful genetic markers in various association stud-
ies) may also confer a risk for keloid disease develop-
ment, such as PTEN (The phosphatase and tensin 
homolog) gene polymorphisms at rs2299939, rs17431184, 
rs555895, and rs701848) were found significantly related 
with high risk of keloid development in Chinese Han 
population. In addition, it was found that CC genotype 
from rs2299939 appeared as a risk factor in keloid 
patients as compared to ACTC haplotype prevalence in 
population, which seems protective factor against keloid 
formation [55, 56].
The GWAS (genome-wide association study) identi-
fied three keloid susceptibility loci (rs873549 at 1q41, 
rs8032158 at 15p21.3 and rs940187 and rs1511412 at 
3q22.3) in a Japanese population. Furthermore, an asso-
ciation study of these susceptibility loci was also investi-
gated in keloid patients from Chinese Han population. 
The SNPs 1q41 (rs873549, and rs1442440,) and 15q21.3 
(rs2271289 present in NEDD4) revealed significant 
association with keloid in the Chinese Han population. 
In addition, AG haplotype was identified as risk factor 
whereas, GA and AA haplotypes appeared as protective 
factors from rs1442440 and rs873549 SNPs. It is also 
suggested that 15q21.3 and 1q41 loci shows genetic 
association and predisposition for keloid formation in 
Japanese and Chinese Han populations [116].
Predisposing genes also showed linkage association 
with keloid susceptibility genes. A study conducted in a 
selected Han Chinese keloid pedigree, mapped to the 
region about 1 Mbp on chromosomes 10q23.31, between 
Fas gene marker D10S1765 and D10S1735, provides the 
first genetic evidence of a predisposing Fas gene linkage 
association with keloid susceptibility genes [22].
Another genome-wide association research study 
(keloid cases =824, Healthy cases= 3205) found strong 
association of keloid cases with four more SNP loci pres-
ent at three chromosomal locations (3q22.3–23, 1q41, 
and 15q21.3) in a Japanese population. It was found that 
SNP rs873549 at chromosome 1 showed the most signifi-
cant association with keloid cases [76].
The linkage between the susceptibility locus (18q21.1, 
SMAD, and PIAS2) to keloid and two loci, 18q21.1and 
15q22.31-q23, was also investigated through pedigree 
linkage analysis in a five-generation Han Chinese keloid 
family. Seven critical regions of microsatellite markers on 
chromosomes 18q21.1 and 15q22.31-q23 and were 
included in analysis. Out of the seven markers, only two 
(D18S460, D18S467) showed linkage to the disease locus 
[108]. SMAD genes 3, 6, and 7 are known to be involved 
in fibrotic disorders, and their association with keloid dis-
ease susceptibility was also studied in Jamaican keloid 
patients. Thirty-five SNPs across these genes were geno-
typed using  time-of- flight mass spectrometry (MALDI-
TOF MS) and iPLEX assay. Linkage disequilibrium (LD) 
was established between several of the SNPs investigated. 
These findings indicated that the SMAD SNPs were not 
significantly associated with high risk of keloid formation 
in the Jamaican population. This study also highlighted 
the importance of identification of genetic bio-markers as 
a candidate such as SMAD, which can be helpful diagnos-
tic, prognostic tool and can provide hope for development 
of new therapeutics for keloid scar management [15].
Keloid predisposition loci at chromosome 7p11 was 
studied in a Chinese population pedigree [21] consist-
ing of  5 affected generations and a total of  32 mem-
bers. Four microsatellites on chromosome 7p11 were 
selected as the genetic markers. This study provided the 
first genetic indication that keloid predisposition loci 
did not locate on chromosome 7p11 in Chinese popula-
tion, furthermore, it suggested that familial keloid pre-
disposition loci are heterogeneous.
Recently in another research study, analysis was con-
ducted through whole genome sequence data, and identi-
fied “Leu401Pro variant” in ASAH1 (N-acylsphingosine 
amidohydrolase) gene, that revealed co-segregation pat-
tern with keloid phenotype in a large population of 
Yoruba family. This genetic variant is known to play a 
role in tumor formation, inflammation and cell prolif-
eration, which suggested that it may be involve in keloid 
development through various other mechanisms. This 
study also found some rare coding variants but their sus-
ceptibility for non-syndromic development of keloid is 
not known [85].
8.4  Large-Scale Population 
Single-Nucleotide Polymorphism (SNP)
Researchers have started to investigate deeper into the 
human genome by using high-throughput microarray 
genotyping technologies with an objective to develop 
high-density SNPs map arrays in families with keloid 
history. Previously genome-wide case-control associa-
tion study described three susceptibility loci (i) 1q41, (ii) 
3q22.3-23, and (iii) 15q21.3 in association with keloid 
disease, in a Japanese population [76]. NEDD4 gene 
present in 15q21.3 chromosomal locus, is involve in up 
regulation of collagen type 1 and fibronectin, that result 
in extracellular matrix formation [24].
An independent case-control study was conducted to 
find correlation between SNPS i: e rs2118610, rs873549, 
rs2271289, rs1511412) and phenotypes of keloid cases in 
Chinese Han population. This study revealed that inheri-
tance patterns of four SNPs (particularly SNP rs2271289) 
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were dominant in severe keloid cases, in comparison with 
mild cases and control groups. Similar pattern of associa-
tion of SNP rs2271289 with keloid cases, appeared in 
family with no case history of keloids as well as in groups 
having multiple keloid sites. These associations revealed 
that SNP rs2271289 is a strong contributing factor and a 
likely candidate in keloid pathology [114].
Association of  FOXL2 gene, keloid and SNP 
rs1511412 have also been identified in Japanese 
 population [76], but this association wasn’t significant 
in the Chinese Han population [116] may be due to low 
frequency of  this variant. Another SNP rs1511412 
showed significant association with FOXL2 gene and 
keloid cases, which appeared as genetic risk factor for 
keloid development in various ethnic groups of  Asian 
population  [64].
A comprehensive study of  familial keloids, based 
on genetic and clinical parameters, was conducted in 
mostly African Americans, White, Japanese, and 
African Caribbean families. Individuals affected with 
keloids exhibited a variable pattern of  expression 
within the families, for example some family members 
had minor keloids on earlobes and other had large 
body areas highly affected with severe keloids. In same 
family, seven members were identified as unaffected 
but obligate carriers for keloid phenotype. The genetic 
analysis revealed an autosomal dominant inheritance 
pattern along with variable phenotypic expression [71].
8.5  Gene Expression
Gene regulation and unique genetic components have 
also been studied in keloid dermal fibroblasts (KDF). 
Studies revealed up-/downregulated expression of vari-
ous genes (. Table 8.1). The specific genes and their dif-
ferentially regulated expression may have direct 
implications toward understanding the keloid develop-
ment [25].
8.6  MicroRNAs (miRNA)
MicroRNAs are 21–23 nucleotide molecules, targeting 
the 3’UTR of mRNA and microRNA deregulation 
may indicate a potential need for clinical intervention 
[2]. Role of  various miRNAs has been established for 
activation of  fibroblasts. A study reported 32 microR-
NAs differentially expressed in keloid tissues [63], in 
which total 23 miRNAs (e.g. miR-4269, miR-21, miR-
382) were up-regulated and 9 miRNAs (e.g. miR-205, 
miR-203, miR-200b/c) were down-regulated. These 
miRNAs are involved in various cellular signaling net-
works particularly wound- healing, development of 
scar and collagen synthesis [39]. Various studies 
revealed that microRNAs play a key regulatory role in 
keloid fibroblasts, for instance, miR200b was found 
associated with abnormal proliferation in fibroblasts 
and miR200c was involved in radiation-induced cell 
apoptosis pathway [50, 55, 56, 61, 117]. These microR-
NAs may be considered potential candidates for thera-
peutic targets for keloids [33]. Three common miRNAs, 
has-miR-21, has-miR-199a-5p and has-miR-214 were 
found in some studies [69, 104, 105] among them, has-
miRNA-21 exhibited variable expression [40]. 
Comparative expression profiles study of  miRNA was 
further extended and found that, keloid derived fibro-
blasts have total nine different miRNAs as compared to 
the normal skin fibroblasts. Out of  nine, six were up-
regulated (hsv1-miR- H7, miR-320c, miR-31- 5p, miR-
23b-3p, miR-152, miR-30a-5p) and three (miR-143-3p, 
miR-4328 and miR-145-5p) were down-regulated [54, 
66]. Some of  the key miRNAs that appear differentially 
expressed in keloid cells have been assessed in more 
detail the table below (. Table 8.2).
8.7  Long noncoding RNA (lncRNA)
Long noncoding RNA, remains uncovered with 
respect to their association with keloid pathology. 
The advanced microarray technology was used first 
time to investigate the keloids in 2015 by Liang et al. 
group that demonstrated constantly up-regulated (total 
1,731) and down-regulated (782) lncRNAs in keloids. 
In this study, a total of  55 pathways were highlighted: 
out of  which 11 pathways were related to the upregu-
lated transcripts and 44 with downregulated transcripts 
in keloids. In addition to that, it has been found that 
the CACNA1G-AS1, as one of  the selected lncRNA, 
may have a potential role in keloid development [58]. 
The lncRNAs regulating encoding transcripts/genes are 
considered to participate in Wnt signaling pathway in 
keloids [95]. The lncRNA H19 stimulate cell prolifera-
tion in keloid fibroblasts which reversed by H19 siRNA 
treatment on keloid fibroblasts [113].
8.8  Small Interfering RNA (siRNA)
RNA interference is an evolutionally conserved genetic 
regulatory mechanism involving inhibition of target 
gene expression at transcriptional, or translational level, 
or by degrading the mRNA [101]. Advances in gene 
silencing [102] provide the opportunity to apply RNA 
interference technology to uncover the details of molec-
ular mechanisms  maintain keloid tissue growth [6]. It is 
found that β-catenin expression significantly increased in 
keloid tissue [18] and has been shown to have a role in 
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β-catenin/siRNA inhibits cell proliferation and induces 
arrest in G0/G1 phase of cell cycle. It also induces apop-
tosis in fibroblasts via down-regulation of cyclin D1 and 
Wnt2 pathways. Keloid fibroblasts (KFs) overexpress 
AMF (autocrine motility factor), which acts through 
RhoA/ROCK1 signaling network, to enhance their cell 
migration and proliferation. Knocking down AMF/
siRNA significantly reduces the migration as well as pro-
liferation potential of KFs that ultimately reduces keloid 
size [98].
TIMP-1 and small interfering RNA regulation has an 
important role in keloid pathology. Generally, it is known 
that keloid phenotype appears as a result of dispropor-
tion between synthesis and degradation of extracellular 
matrix. There are two main vital components (i) Matrix 
metalloproteinase (ii) Tissue inhibitors of metallopro-
teinase, which regulate the process of synthesis degrada-
tion and remodeling of ECM. Knockdown of TIMPs 
(siTIMP-1 or siTIMP-2)/siRNA resulted in suppression 
of MMP-1/TIMP-1 and MMP-1/TIMP-2 complex mol-
ecules but upregulation of MMP-2 and increased colla-
gen type I degradation. KFs also showed increased 
apoptosis and reduced cell viability [3].
The role of siRNA during TGF-β-induced regula-
tion of of PTB (Polypyrimidine Tract-Binding Protein)
in keloid pathophysiology has been demonstrated 
recently [43]. It is a splicing regulator and known to play 
an important role in tumor cell proliferation, invasion 
and metastasis. TGF-β1 stimulation caused over expres-
sion of PTB along with its upstream regulatory compo-
nent (C-MYC) in keloid derived fibroblasts, resulting in 
dysregulation of alternative splicing events, leads to 
enhanced fibroblast proliferation and deposition of 
fibronectin in keloid. PTB/siRNA knockdown shift the 
alternative splicing of RTN4 and USP, and caused sig-
nificant reduction in fibroblasts proliferation and depo-
sition of COL3A1 and FN1, that resulting in the fast 
regression of keloid tissues.
Silencing the Smad2 (Sma and Drosophila mothers 
against decapentaplegic homolog 2) downregulate the 
TGF-β-induced synthesis of procollagen, in keloid 
derived fibroblasts [35]. The role of siRNA during 
Smad3 (Sma and Drosophila mothers against decapen-
taplegic homolog 3)-induced TGF-β signaling in keloid 
pathogenesis has been studied. Smad3 is recently char-
acterized as an intracellular effector of TGF-β signaling 
pathway. TGF-β participate as key component in fibrotic 
pathology by stimulating keloid fibroblasts to synthesize 
extracellular matrix excessively, including collagen I and 
III. The knockdown of Smad3/siRNA expression 
caused significantly and uniquely decrease in types I and 
III procollagen level. Thus Smad3 is thought to play a 
significant role in the TGF-β-induced keloid fibrosis 
[101].
Keloid derived fibroblasts over expressed NLRC5 
(NOD-like receptor family CARD domain containing 
5) belongs to the family of nucleotide-binding domain 
and leucine-rich repeat. It has been shown that silencing 
of NLRC5 results inhibition of proliferation and expres-
sion of ECM in keloid derived fibroblasts via inhibition 
of TGF-β1/Smad signaling network, suggesting poten-
tial therapeutic target keloids [67]. Increased expression 
of Stat3 (signal transducer and activator of transcrip-
tion 3) was also found in keloid tissue. Stat3 is a latent 
transcription factor activated under the stimulation of 
various growth factors and cytokines during wound-
  . Table 8.2 Differential expression of  miRNAs and their effects on keloid fibroblasts
S. No Type of microRNA Expression level 
in keloid 
fibroblasts
Role in keloid phenotype Reference
1. miR- 7 Low Induce excessive collagen expression [31]
2. miR- 29a Low Collagen I and III expression regulation,
TGF-β/Smad signaling pathway, fibrosis
[73, 41, 112]
3. miR- 199a Low Influence proliferation of  keloid fibroblasts via cell 
cycle regulation
[104, 105, 109]
4. miR- 21 High Stimulate fibroblast proliferation and apoptosis via 
P13K/AKT pathway and synthesis of  extracellular 
matrix
[62, 75, 100]
5. miR- 196a High Regulates the stabilized elevated expression of 
COL1A1 and COL3A1 genes
[1, 48, 54]






healing process. Short interfering RNA inhibited its 
expression and subsequent phosphorylation and 
resulted in reduction of collagen synthesis, cell prolifera-
tion and migration in keloid derived fibroblasts, hence 
suggesting another therapeutic candidate for the treat-
ment of keloids [59].
Keloid fibroblasts characteristically showed overex-
pression of collagen and PAI-1. Short interfering RNA 
targeted treatment results in reduction the collagen 
deposition, which showed that PAI-1-targeted siRNA 
interference may offer therapeutic alternative in keloid 
formation  [99]. Another study showed that silencing of 
PAI-1 caused significant reduction in keloid volume up 
to 28% in fourth week. It also decreased the synthesis of 
collagen I and III and resulted in shrinkage of keloid 
tissue mass [96].
VEGF (vascular endothelial growth factor) plays vital 
roles in the regulation of inflammation and angiogenesis 
during wound-healing process. The role of vector-based 
RNAi (shRNA) for inhibition of VEGF expression in 
keloid fibroblasts has been studied. siRNA sequences 
(clone of three potential short interfering RNA sequences) 
were used to silence the VEGF gene in keloid fibroblasts 
that resulted in significantly inhibited VEGF gene expres-
sion and fibroblasts growth. In addition, the expression of 
plasminogen activator inhibitor-1 (PAI-1) was also down-
regulated. This study provides the insight about the modu-
lation of VEGF production as a potential therapeutic 
strategy for keloid [111].
Silencing by HIF-1α siRNA in keratinocytes resulted 
in decreased expression levels of fibronectin and vimen-
tin, whereas ZO-1 and E-cadherin expression levels were 
restored. This indicated that HIF-1α stimulation can 
regulate the respective mesenchymal changes, caused by 
hypoxia in the keloid derived keratinocytes during keloid 
development [68].
Knockdown of PAI-2, Hsp27, α2β1-integrin/siRNA 
also cause significant reduction in ECM deposition, cell 
anchorage, and mobility in keloid derived fibroblasts 
[94]. Hsp70/siRNA and Hsp47-shRNA knockdown 
decreased collagen synthesis in keloid derived fibroblasts 
[20, 90]. hTERT gene regulates telomere length homeo-
stasis and influences cell cycle of fibroblasts. Knockdown 
of hTERT-siRNA in keloid fibroblasts was shown to 
reduce telomere length and fibroblast growth [87].
The role of siRNA in apoptosis of keloid fibroblasts 
has also been investigated. Keloids exhibited increased 
reactive oxygen species (ROS) production and disrupted 
apoptosis mechanisms. ROS plays an important role in 
the induction of apoptosis under pathological conditions. 
Cellular defense mechanisms against oxidative stress and 
apoptosis are regulated by nuclear factor erythroid 
2-related factor 2 (Nrf2) through activation of B-cell lym-
phoma 2 (Bcl-2) protein. Transfection of fibroblasts with 
the Nrf2-specific siRNA resulted in increased apoptosis 
and decreased cell viability [53]. NRG1/ErbB2/Src/PTK2 
signaling pathway in fibroblast migration and the role of 
siRNA have been investigated in keloid development. 
Keloid fibroblasts exhibit upregulation of the polypep-
tide growth factor neuregulin-1 (NRG1) and receptor 
tyrosine-protein kinase erbB-2 (ErbB2) oncogene that 
contributes to altered cytokine expression profiles, 
increased Src and protein tyrosine kinase 2 (PTK2/FAK) 
gene expression, and migration in keloid fibroblast. 
siRNA knockdown of ErbB2 gene resulted in reduced 
migration and Src/PTK2 expression but didn’t affect the 
NRG/ErbB2/Src/PTK2 network, revealing the possibility 
that this network may affect migrating potential of keloid 
fibroblasts indirectly [47]. Therefore, siRNA silencing on 
various  targeted mechanisms such as Smad2,3-TGF-β, 
HIF-1α- EMT, PAI-1-VEGF production, and NRG1/
ErbB2/Src/PTK2 signaling pathway in keloid pathogene-
sis, proposes that their production can be modulated by 
using siRNA based regulation, and this strategy seems 
promising candidate for keloid therapeutics.
8.9  Microarray Analysis
Various advanced molecular biology techniques such as 
PCR, cDNA approaches, cloning, whole genome 
sequencing provides the huge platform to investigate the 
differentially regulated genes in term of microarray 
analysis from variety of biological samples [70]. 
Functional genomic provides a tool to probe and moni-
tor the genetic interactions [27]. Complex pattern of 
genotypic differences and respective multiple fibrosis-
related pathways in keloid fibroblasts have been studied 
by microarray approach. Comparative Affymetrix- 
based microarray analysis was carried out on keloid 
fibroblast RNA. Approximately 500 genes were found 
differentially regulated out of total the total 38,000 
genes observed. Interestingly, study also revealed that 
increase in expression of various IGF-binding protein 
and related protein in comparison with set of protein 
related to Wnt signaling pathway, who exhibited 
decrease in expression [91]. Total 2,215 differentially 
expressed genes (DEGs) have been found in compara-
tive analysis of after and before normal wound, and sur-
prisingly total 3,161 DEGs have been identified in 
keloid- prone individuals. Among those genes, only 513 
genes were related to normal individuals, total set of 
1,449 genes were found specifically related to keloid phe-
notype. Moreover, hierarchical distribution of differen-
tially expressed keloid- specific genes resulted into two 
distinct clusters. Further probing into keloid-specific 
pathways revealed 24 pathways linked with differentially 
activated genes. Most importantly, some other vital sig-
naling pathways like NOTCH, MAPKs, TLRs and insu-
lin regulation, have also been found altered during 
post-wounding analysis in keloid prone individuals. 
Furthermore, Genetic association network analysis 
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revealed, divergent gene expression profile of key genes 
that contribute in cytokines signaling pathways [79, 83].
8.10  Epigenetics
Study of inheritable characteristics of genome that 
doesn’t affect the genetic sequences but only gene func-
tion, comes under the term of epigenetics. It is also 
known to contribute significantly in regulation of vari-
ous gene expressions. Recently, there is further extension 
to this terminology that is epigenetic modification, 
which is currently being applied to get comprehension 
of molecular aspects of keloid pathology. This study 
revealed that there are some evidences pointing the 
involvement of epigenetic changes/modifications trig-
gering the constant activation of fibroblasts in keloid 
[30]. These epigenetic alterations include changes in 
microRNAs, DNA methylation as well as histone modi-
fications. These three event are well known crucial events 
that involve in early cellular growth, differentiation and 
development, hence these aspects of molecular features 
have also been included as an important candidate for 
investigations to understand their role/associations in 
keloid pathology [28]. Recent studies are coming up 
with findings about the epigenetic mechanisms that may 
contribute in keloid formation [42].
8.10.1  Methylation
DNA methylation is the well-known aspect of epigene-
tic modification [103]. It has been hypothesized that 
DNA methylation is responsible to maintain the myofi-
broblats transformation of fibroblasts during the pro-
cess of fibrosis in wound healing events, this modification 
set the basis for deviation from normal wound-healing 
mechanism. Gene expression profile acquired by myofi-
broblasts is significantly differ from fibroblasts [81, 97]. 
Therefore it is crucial to understand respective epigene-
tic modifications that resulted in acquiring highly dif-
ferentiated gene expression profile in my myofibroblasts 
that will help to trace the respective network leading to 
fibrotic phenotype in keloids [77]. Previous research 
study found that keloid fibroblasts showed alternations 
in DNA methylation [84]. Involvement and significance 
of epigenetic modification in keloid pathology has been 
revealed in recent study, that showed reversal of expres-
sion profile in TGF-β1, phosphor-smad2, 3 (down-regu-
lation) and smad7 (up-regulation) by the treatment of 
5-aza-dC (5-aza-2 deoxycytidine), which is an inhibitor 
of DNA methyltransferase [118].
Expression of DNA methyltransferase 1 (DNMT1) 
was found 100% elevated in keloid as compared to the 
fibroblast (8%) from normal skin samples [32], suggesting 
its involvement in keloid scar formation. Furthermore, 
different DNA methylation patterns have also been stud-
ied in keloid vs normal cells and tissue and analyzed via 
large scale genome profiling using advanced approach 
(Infinium Human Methylation 450 BeadChip), results 
explained that 152 unique genes showed total 192 dif-
ferent methylation patterns in promoter region CpGs. 
Moreover respective gene network analysis, revealed four 
common hierarchical regulatory networks, consisting of 
four key regulators, (i) PENK (ii) PRKG2, (iii) pryox-
amide (iv) tributyrin, and total 19 intermediate regula-
tory molecules. This analysis highlighted the involvement 
of regulatory networks in keloid phenotype development 
[36, 45] and with the development of this study approach 
in recent research since last five years, methylome of 
keloid have been characterized as most hypo-methylated 
rather than hyper-methylated [45].
List of hyper-methylated genes includes CACNB2, 
ACTR3C, PAQR4, SLCO2B1, C1orf109, LRRC61, 
AHDC1, FYCO1, CMKLR1 and CCDC34 as com-
pared to hypo-methylated group of genes, which are 
GHDC, DENND1C, MX2, ANKRD11, SCML4, 
GALNT3, IFFO1, WIPF1, PPP1R13L and CFH. 
Recently, further analysis was carried out using bioinfor-
matics approach by applying Ingenuity Pathway Analysis 
(IPA) software on data set, obtained from keloid sam-
ples, revealed some key pathways shows significant asso-
ciation with keloids. These pathways include (i) histidine 
degradation VI (ii) metastasis signaling pathway of 
colorectal cancer (iii) phospholipase C signaling (iv) P2Y 
purinergic receptor signaling and (v) Gai signaling path-
way [44]. Keloid fibroblasts having multiple genes with 
differential methylation, exhibited significant difference 
in expression profile of genes related to fibrosis such as 
IGFBP5 (IGF/IGF-binding protein 5), JAG1 (Jagged 1), 
SFRP1 (secreted frizzled-related protein1), MMP3 
(matrix mettallopeptidase 3), CTGF (connective tissue 
growth factor) and DPT (dermatopontin) [84]. These 
finding support the statement about the involvement of 
DNA methylation in keloid formation, but needs further 
extension of research studies to explore respective key 
changes/modification that leads subsequent stages of 
development resulted in keloid pathogenesis [36, 44, 45].
8.10.2  Histone Modifications
Histone modifications include changes in distal N-amino 
acids specifically, phosphorylation at Threonine or 
Serine, ubiquitination at Arginine or Lysine and acetyla-
tion at Lysine amino acid. There are some enzyme such 
as histone deacetylases (HDACs) and acetyltransferases 
(HATs), which are involve in these modifications, and 
result in altered gene expression profile [7]. Interestingly, 




in keloid tissue. This over expression pattern has also 
been observed under TGF-β1 induced stimulation in 
normal fibroblasts and murine Swiss 3T3 fibroblasts 
[34]. In vitro research study showed that treating the 
keloid fibroblasts with HDAC inhibitor resulted in 
decreased production of collagen [92]. Inhibition of his-
tone acetyltransferases caused anti-fibrotic affects, 
increased expression of p300 (which is a cofactor, essen-
tial for acetylase activity) in fibroblasts (isolated from 
scleroderma patients samples) [37].
These studies suggest that both DNA methylation and 
histone modification are crucial to cause differential gene 
expression profile, exhibited by keloid fibroblasts, further-
more, as such, any sustainable modification responsible to 
deliver epigenetic changes, can leads towards phenotypic 
alteration of keloid fibroblasts. This scenario recommend-
ing that inhibitors of histone modification can be an 
important candidate to consider with therapeutic point of 
view for management of keloid pathology [5, 80, 84].
8.11  Mutations
Role of mutations was investigated in a study conducted in 
keloid cases from a Caucasian population (95 cases). 
Large scale genome wide analysis in the exon (1–7) and 
promoter regions showed presence of some novel muta-
tions in Caucasian population [13]. But up till now, none 
of the gene mutations have been found associated with 
keloid cases [88]. One in vitro study reported a p53 muta-
tion that was found in keloid fibroblasts from cultured 
cells [26], that may suggest the role of acquired inheritable 
gene changes in keloid cells [88].
8.12  Copy Number Variation
Copy number variations (CNVs) are known to be asso-
ciated with various human disorders including skin dis-
eases. Research study conducted in keloid cases from 
Caucasian population revealed that CNVs found at 
11q11, 8p23.1, 19p13.1, 22q13.1, 17q12, and 2q14.3, 
specifically 6p21.32 (that contain HLA-DRB5 region) 
are associated with keloid pathology [89].
8.13  FISH (Fluorescence In Situ 
Hybridization)
Keloid derived fibroblasts exhibited differential pheno-
typic and genotypic expression as compared to neigh-
boring normal skin fibroblasts. Real-time RT-PCR and 
proteomics tools (2-DAGE, immunoblot analysis, and 
immunohistochemistry) have been used to investigate 
these differentially expressed specific set of  genes and 
proteins in keloid derived fibroblasts. Proteomic analy-
sis revealed that there are sixteen different spots which 
differentiate keloid fibroblasts from normal fibroblasts, 
among all, Hsp70 was most up-regulated protein in 
keloid derived fibroblasts. These results were also vali-
dated by immunohistochemical and western blot anal-
ysis conducted on keloid vs normal skin tissue. This 
study indicated that Hsp70 overexpression may be 
associated with keloid pathology and its inhibition can 
be studied for therapeutic purpose  [52].
8.14  Conclusions
Keloids are benign dermal tumors that develop as a 
result of a dysregulated cutaneous wound-healing pro-
cess. Several research findings support the idea that 
there is an association between various genetic elements 
such as linkage, autosomal-dominant, oligo-genic or 
additive inheritance in families and keloid development, 
predominantly in people of African and Asian descent. 
In addition to that, differential gene expression studies 
in families and keloid fibroblasts indicate heterogeneous 
genetic events, revealing complexity of underlying 
genetic basis of keloids. Therefore, it’s quite obvious 
that single gene phenomena is not a possible causative 
factor for keloid formation. To address this complexity, 
a likely scenario may involve the understanding of 
genetic pathway interactions including environmental 
factors, healing mechanisms, wound matrix degrada-
tion, and immunologic response.
Take-Home Messages
1. Keloid is a complex skin pathology with varied 
susceptibilities and ethnicities. This disease is a 
clinical challenge because it lacks effective treat-
ment and often recurs after excision.
2. Well-defined comprehensive mode of  inheritance 
is still not known because of  insufficient genetic 
investigations.
3. HLA system represents the highest level of  diver-
sity of  any functional genetic association with 
keloid disease. 
4. Recent advanced approaches like high-throughput 
microarray facilitating the genetics and epigenetic 
investigations may be helpful in understanding the 
underlying complex basis of keloid formation.
5. There could be a possibility to identifying poten-
tial candidate set of  genetic markers for diagnos-
tic or prognostic purpose.
6. There is need to uncover the specific biological 
mechanism and respective signaling networks of 
keloid fibroblasts.
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There has been a wide variety of therapies proposed for 
the treatment of scars, most of them with a lack of firm 
randomized controlled clinical trials to support their 
efficacy, and among other deficiencies, there has been 
often a lack of appropriate labeling or classification of 
scars to allow optimal evaluation of existing literature. 
There is a real benefit to a consistent classification of 
different types of scars so that different clinicians use a 
consistent vocabulary allowing a systematic evaluation 
of treatments and outcomes. One problem has always 
been the changes in scars over time so that improve-
ments may not necessarily be due to the treatment inter-
vention but simply scar maturation.
Scar classifications have previously been published 
including notably the 2002 publication in PRS which 
gained widespread acceptance because it represented the 
consensus of 12 experts from an international group 
incorporating Europe, North America, and Australia. 
In subsequent publications, this classification has been 
found to sound and not needing further modification. 
We will use this classification again in this updated text-
book.
Scarring is the inevitable consequence of  tissue 
injury as opposed to tissue regeneration which is the 
true restoration of  the normal architecture of  the skin. 
True tissue regeneration after injury occurs only in the 
fetus during the first two trimesters and in amphibians 
who can even regenerate amputated limbs. In the opti-
mal outcome of  a thin flat thin linear scar, the sequence 
of  tissue repair after injury is tightly regulated. After 
initial platelet aggegation, provisional matrix is depos-
ited, followed by influx of  inflammatory cells and sub-
sequent cell proliferation including fibroplasia and 
angiogenesis. Wound healing overlap, and are followed 
by cellular apoptosis with resolution of  inflammation. 
Permanent matrix deposition (collagen) begins within 
3 days. Maximal collagen deposition occurs in the first 
few weeks with a combination of  type 1 and type 3, fol-
lowed by many months of  collagen breakdown and 
synthesis with increasing type 1 collagen with increased 
organization and scar strength. These phases of  inflam-
mation, cell proliferation and collagen remodeling 
result in a fine line scar in the scenario of  an incison 
(“normal” scar), and a wider flat scar in the scenario of 
an injury over a broader area.
9.1  Immature Scar
Even a normal scar goes through a period when it is 
immature, meaning it is pink, often with a healing ridge 
(edema plus collagen synthesis). Collagen accumulation 
typically peaks about 3  weeks after surgery and then 
goes through about 6  months of remodeling with 
steadily increasing collagen organization, conversion 
from a mix of type 1 and type 3 collagen to almost 
entirely type 1 collagen with increased cross-linking, and 
continued increase in tensile strength. The gains in scar 
strength are due to improvement in collagen organiza-
tion and cross-linking rather than an increase in colla-
gen. A useful analogy is to compare the difference 
between raw wool from a sheared sheep, versus the fine 
knit of a woolen coat. The amount of wool is the same, 
but the woven wool is far stronger. However, although 
the strength of a scar is maximal in approximately 
6  months, complete scar maturation as measured by 
resolution of erythema typically takes a year or even 
longer. In a human volunteer study conducted by 
Renovo, superficial scars took longer than a year for the 
erythema to fully resolve in one-third of patients. In 
scars in thicker skin with more depth, or in a group of 
patients with more active scarring process, it probably 
takes even longer. In my own clinical practice with 
approximately 20,000 patients of all ages and ethnic 
backgrounds, my experience mirrors the study by 
Renovo (. Table 9.1).
The resolution of erythema is a useful marker of scar 
maturity (. Fig. 9.1). In all scars, erythema eventually 
resolves, but in a few percent of patients, I have seen it 
take longer than 2 years and in a rare hypertrophic scar 
as long as 10 years. In a study we conducted on burn 
patients, we found that the average scar elasticity (a 
measure of collagen remodeling), as measured by a 
device that applied a constant force to the skin and mea-
sured how much it stretched, continued to increase over 
5 years (Bartell et  al). Although the patients were not 
followed longitudinally, we simply correlated elasticity 
to the age of the scar, and it can be inferred that it can 
take a long time indeed for a scar to reach full maturity.
In an immature scar histologically, there are an 
increased number of inflammatory cells. After 2 weeks 
or so, the predominant inflammatory cells are macro-
phages with scattered lymphocytes and an occasional 
mast cell. There are increased numbers of fibroblasts 
including myofibroblasts, increased numbers of blood 
vessels, and for a period of up to a few months epider-
mal hyperplasia. The visual appearance is a scar that is 
erythematous and slightly raised due to increased fluid 
in the tissues and increased collagen as well as increased 
cellularity.
9.2  Mature Scar
In undergoing the transition from an immature scar to a 
mature scar, the key visual marker is resolution of ery-
thema (. Fig.  9.2). At this point, the inflammatory 
cells, endothelial cells, and most of the fibroblasts have 
undergone apoptosis, and the epithelium looks com-
pletely normal as compared to the adjacent unwounded 
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skin. What is left is a band of collagen fibers that are 
clearly demarcated from the surrounding dermis histo-
logically lacking the completely ordered collagen orga-
nization characteristic of normal skin. The collagen 
fibers go in multiple directions giving the scar stiffer bio-
mechanical properties and are of variable width depend-
ing on the genetics of the patient and the underlying 
tension placed on the healing immature scar. There is no 
longer any increased fluid in the tissues (edema) and so 
the scar is flat. The color of the scar ranges from white 
(absence of melanocytes) to hyperpigmented (often 
characteristic of ethnicities with increased melanocytes 
  . Fig. 9.1 Immature scar
  . Fig. 9.2 Mature scar






Firm but not hard
Begins soon after injury, months to resolve
Peaks at a few weeks after injury
Mature flat 
scar




Ropy (elevated) and pink or red
Evolves from immature scar within several 
weeks
Progressive enlargement for months before 
slow decrease in activity
Often itchy or slightly sore to touch
Resolution results in a persistently elevated 
scar that is no longer pink
Hypertrophic 
wide scar
Elevated, pink or red
Arises from widespread injury such as a burn
Frequently with severe pruritis and can be 
tender
Very stiff  with limitation of  mobility across 
joint surface
Minor keloid Round or elevated, extends beyond scar
Most often at site of  pierced earring or 
surgical incision
Strong genetic component which is different 
than hypertrophic scars
Simple surgical excision with very high rate 
of  recurrence
Major keloid Elevated, large often irregular in shape (i.e., 
butterfly appearance)
Frequently seen in multiple locations on 
person
Initial injury can be very minor
Often symptoms of  pain and pruritis are 
debilitating
Treatment options are limited
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in the basal layer of the epidermis such as Asian, South 
Asian, Middle Eastern, Mediterranean, and Latin 
American or patients with brown skin).
9.3  Atrophic Scar
In some cases, a scar will become depressed or thinned 
as it transitions from an immature scar (. Fig.  9.3). 
This can occur when collagen synthesis is depressed and 
inflammation is less than usual. Examples of atrophic 
scars are the stretch marks or striae that can be a com-
plication of systemic steroid excess either from exoge-
nous steroids or Cushing’s disease or in some scars after 
radiation therapy.
9.4  Linear Hypertrophic Scar
In many cases, scars fail to transition normally from 
immature to mature with resolution of inflammation 
and an equilibrium of collagen synthesis and break-
down. Collagen continues to accumulate, and the scar 
widens and becomes elevated or ropy in appearance and 
the erythema fails to resolve. This active process of scar 
growth can continue for many months but eventually 
slowly resolves, with resolution of erythema that can 
take years. The collagen accumulation stabilizes but 
with a residual scar that is elevated and wider than a 
normal mature scar (. Fig. 9.4). During the period of 
active collagen accumulation and erythema, the scar can 
be itchy and/or painful. The residual scar is less elastic 
(stiffer) than normal skin and, if  it crosses a joint, can 
limit motion. A key feature of hypertrophic scar (versus 
keloid) is that the scar tissue remains within the confines 
of the original scar (although it may be widened). 
Hypertrophic scars are more common in patients of 
color, particularly East Asians, and the susceptibility to 
hypertrophic scars is often inherited. Prolonged inflam-
mation for any reason (delays in epithelization, blocked 
sebaceous glands, ingrown hairs, and tension) contrib-
utes significantly to the incidence of hypertrophic scars. 
Frequently portions of a scar will be hypertrophic in 
hair-bearing areas, while the adjacent scars evolve into 
normal mature scars.
9.5  Widespread Hypertrophic Scar
In many cases, most notably from burns, the initial 
injury is not linear but covers a larger area (. Fig. 9.5). 
In general, when epithelization (complete epithelial 
resurfacing) is not completed within 2 weeks, the risk of 
  . Fig. 9.4 Linear hypertrophic scar
  . Fig. 9.3 Atrophic mature scar
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hypertrophic scar increases, particularly in children and 
in adults under the age of 40. In a hypertrophic scar, the 
period of collagen accumulation is prolonged up to 
6–12  months resulting in a scar that is elevated and 
thickened and is very stiff. Erythema will be prolonged 
and the scars are often intensely pruritic or even painful.
9.6  Keloid
A keloid unlike a hypertrophic scar behaves more like a 
tumor in that growth can occur even years after the orig-
inal injury and extend far beyond the confines of the 
original scar. The keloid often has a mushroom or cauli-
flower type of appearance. Keloids are frequently symp-
tomatic with pain or itch. The genetics of keloids are 
quite complex and beyond the scope of this chapter, but 
many are familial and are much more common among 
many African tribes and to a lesser degree among 
Asians. The central portion of a keloid is very dense 
fibers with a characteristic pattern histologically and 
relatively acellular, while the active spreading edge has a 
significant inflammatory and cellular component.
9.6.1  Minor Keloid
Most keloids arise from localized injuries such as a 
pierced ear (the most common location of minor keloid), 
and although they extend beyond the margins of the 
original scar, their growth stabilizes and allows more 
options for treatment including surgical excision com-
bined with other modalities such as steroid injections or 
radiation therapy (. Fig. 9.6).
9.6.2  Major Keloid
In extreme situations in patients with a very strong 
genetic predisposition, keloids can extend into large 
plagues with a very actively growing outer edge that in 
some areas has a characteristic butterfly pattern 
(. Fig. 9.7a) due to forces on the keloid exerted by the 
surrounding skin. The peripheral edge of the keloid is 
active, while the central portion is less active with less 
cell proliferation. Often the original injury can be as 
minor as a scratch or seemingly spontaneous 
(. Fig.  9.7b Keloid arising from small tracheotomy   . Fig. 9.5 Hypertrophic broad scar
  . Fig. 9.6 Minor keloid
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scar), and the unfortunate patients with major keloids 
can form them all over their body. These are extraordi-
narily difficult to treat and are both deforming and 
debilitating. Intensive research on the defining genetic 
characteristics and pathogenesis of keloids continues, 
and in a few cases genetic loci have been identified, but 
the genetics are complex, as well as the pathogenesis.
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10
10.1   Pain: Definition and Subtypes
Pain is defined as a distressing sensory experience asso-
ciated with potential or actual tissue damage with cogni-
tive, emotional, and social components [1]. Pain can be 
classified into acute and chronic, based on the duration 
of symptoms as well as nociceptive and non-nociceptive 
subtypes with regards to the neurophysiological pro-
cesses involved.
Acute pain is the predicted physiological response 
to an adverse mechanical, thermal, or chemical stimu-
lus and most frequently occurs after traumatic injury/
surgery as part of the inflammatory response. Chronic 
pain is defined as pain lasting for three or more months 
showing no resolution to treatment [1].
Nociceptive pain can be defined as pain arising from 
the sensitization/activation of peripheral nociceptors and 
will only continue if  the inciting stimulus is maintained 
[2]. Non-nociceptive pain can be classified into neuro-
pathic and psychogenic pain. Neuropathic pain denotes 
a primary anatomical or biochemical abnormality aris-
ing within the CNS, resulting in persistent and chronic 
sensory disturbance following the initial injury [3]. It 
occurs as a result of damage to neural tissue in periph-
eral and central nervous system and relates to aberrant 
somatosensory processing. While a detailed account of 
psychogenic pain is outside the remit for this review, we 
will elaborate extensively on neuropathic phenomena 
since they are frequently observed in scar practice.
10.2   Pain Pathway
10.2.1   Peripheral Receptor Activation
Specialized sensory nociceptor fibers in peripheral tis-
sues are activated by a broad spectrum of stimuli includ-
ing mechanical, thermal as well as chemical with the 
most frequent being acetylcholine, bradykinin, adenos-
ine triphosphate, and prostaglandins [4].
10.2.2   Ascending Pathway
First-order neuron pathways are responsible for car-
rying impulses to the dorsal column initially and then 
other parts of the CNS as part of the ascending pathway 
and comprise the following different subtypes [5].
A-beta fibers: These are low stimulation threshold, 
myelinated fibers, activated by vibration and touch; 
under normal conditions, they convey nonpainful 
stimuli; nevertheless, they play a crucial role in carrying 
painful sensations in chronic neuropathic pain.
A-delta fibers: These thinly myelinated fibers have a 
high threshold potential and are involved in the initia-
tion of the reflex response associated with painful stim-
uli; they transmit pain faster than unmyelinated C fibers 
and contain the neurotransmitter L-glutamate.
C-fibers: These fibers are unmyelinated, have a high 
threshold for activation, and their stimulation causes 
delayed perception of pain that is often described as dif-
fuse stabbing or burning. As well as glutamate, they con-
tain other neurotransmitters like substance P (SP) and 
calcitonin gene-related peptide (CGRP).
Second-order neurons start from the dorsal horn 
and cross over to the contralateral side of the ascend-
ing spinothalamic tract to reach the thalamus and pons. 
The components of the dorsal horn involved in noci-
ception express several receptors including α-amino-3- 
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), 
voltage-gated calcium channels, N-methyl-D-aspartate 
(NMDA), as well as gamma-aminobutyric acid–alpha 
(GABA-A) receptors [4].
Third-order neurons start at the thalamus and end at 
a number of different cerebral loci.
Processing regarding the magnitude and spatial char-
acteristics of painful stimuli is provided by the somato-
sensory cortex and the ventral posterior  thalamic nuclei. 
At the same time affective and motivational aspects of 
pain are processed by the ventromedial posterior tha-
lamic nucleus and its cortical connections [6].
Furthermore, positron emission tomography stud-
ies have proposed that pain-related activation of  ante-
rior cingulate cortex (ACC) has a direct relationship 
with an individual’s emotional and behavioural reac-
tions to pain [7]. Midbrain periaqueductal gray mat-
ter, the region responsible for fight or flight response 
has also been shown to have interconnections with the 
ACC [8].
10.2.3   Descending Pathway
The dorsal horn of the spinal cord receives input from 
higher centers, which can modulate the peripheral noci-
ceptor input barrage by the descending pathway.
The descending pathway starts at the limbic system 
of the brain area, namely the periaqueductal gray/para-
brachial area, rostral ventromedial medulla, and nucleus 
raphae magnus, whose stimulation, in turn, inhibit noci-
ceptors in the laminae of the spinal cord. Key transmit-
ters involved include noradrenaline, serotonin, as well as 
endogenous endorphins and encephalins [9].
Aside from descending signals, nociceptive impulses 
can also be modulated by segmental input from A-beta 
fibers under the gate control theory of pain. In other 
words, non-nociceptive fiber signals carried by the large 
diameter A fibers can interrupt the transmission of pain 
indirectly by inhibiting the effect of pain fibers (“closing 
the gate”) [10].
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Neuropathic pain refers to a type of non-nociceptive 
pain, which has many neurophysiological phenomena cen-
tral to its genesis and symptom maintenance. These can 
involve the central nervous system primarily or second-
arily due to changes to the peripheral nervous system com-
ponents (sensitization). . Figure 10.1 provides a pictorial 
representation of key processes involving the peripheral 
and central nervous system in neuropathic states.
10.2.4   Peripheral Sensitization
Different mechanisms have been proposed for the occur-
rence of abnormal signals in the peripheral nervous sys-
tem capable of ultimately sensitizing the central system, 
including:
 5 Injured afferent hypothesis: According to this the-
ory, a neuroma formed by injury to the peripheral 
afferent fibers causes growth of unmyelinated C 
fibers from damaged axons and results in abnormal 
excitability. This spontaneous activity occurs due to 
increased sensitivity to mechanical, chemical, and 
thermal stimuli [11, 12].
 5 Intact nociceptor hypothesis: This concept proposes 
that intact nociceptors (i.e., those surviving the origi-
nal injury in the periphery and innervating the region 
affected by the transected nerve fibers) develop sponta-
neous activity [11]. Changes in ion channels, expression 
of receptors, and secretion of agents like prostaglan-
din, bradykinin, and tumor necrosis factor-alpha have 
the potential to sensitize nociceptors, thereby altering 
the properties of uninjured afferents [12].
Loss of afferent Aβ


















  . Fig. 10.1 Schematic diagram of  several mechanisms of  periph-
eral and central nervous system neuropathies. Peripheral sensitiza-
tion include injured afferent hypothesis when a neuroma formed 
by injury to peripheral afferent fibres causes increased sesitvity to 
different stimuli resulting in abnormal excitability [11]; intact nocio-
ceptor hypothesis in which spontaneous activity may develop in the 
nocioceptors that survived peripherally after injury innervating the 
region of  the transected nerve secreting agents altering the activity 
of  uninjured afferents [12] Central sensitization include increased 
activity in of  the dorsal horn projection neurons in the dorsal root 
ganglion after a peripheral nerve injury causing the release of  excit-
atory neurotransmitter glutamate [13]; loss of  Aβ-myelinated fibers 
input causing loss of  afferent inhibition resulting in more noxious 
stimuli reaching the CNS (Deafferentation theory) [14]; degenra-
tion of  inhibitory CNS neurons (GABA interneurons) in the dorsal 
horn resulting in decreased inhibtion of  nociceptive pathways caus-
ing chronic pain [15]; loss of  anti-nociceptive descending pathways 
resulting in increased excitability to the CNS resulting in increased 
pain [16]; abnormal cotical input as a result of  misdirected axonal 
growths at the site of  injury causing reorganization of  the somato-
sensory cortex with distorted skin mapping of  the area innervated by 
the injured afferent [17]
Scar Symptoms: Pruritus and Pain
90
10
10.2.5   Central Sensitization
The following mechanisms have been proposed to 
underlie central sensitization:
 5 Increased activity of dorsal horn projection neurons: 
There is an upregulation of α2δ subunit of calcium 
channels in the dorsal root ganglion and spinal 
cord after a peripheral nerve injury; this results in 
increased release of excitatory neurotransmitter glu-
tamate [13].
 5 Deafferentation theory (loss of afferent inhibition): 
Tissue injury causes loss of Aβ-myelinated fibers 
input, which is the primary mechanism promoting 
hypoactivity of interneurons. These interneurons 
primarily inhibit nociceptive afferents resulting in 
more noxious stimuli reaching the CNS centers [14].
 5 Loss of CNS inhibitory neurons: γ-Aminobutyric 
acid (GABA) interneurons in the dorsal horn nerve 
fibers undergo degeneration, causing decreased inhi-
bition of the nociceptive pathway contributing to 
chronic pain and hypersensitivity [15].
 5 Loss of descending inhibition: Inhibition of the 
anti-nociceptive descending pathways can result in 
increased excitability of the CNS, and this is thought 
to cause loss of sensory input following peripheral 
nerve injury [16].
 5 Synaptic reorganization: Acute deafferentation in 
the nervous system is thought to stem from periph-
eral nerve transection resulting in a misdirected axo-
nal growth at the site of injury and cause abnormal 
cortical input. This mediates somatosensory cortex 
reorganization with distorted skin mapping origi-
nally innervated by the injured afferent [17].
The sensitization phenomena described above appear 
to play a key role in the generation and maintenance 
of  chronic sensory phenomena in burn scars (see the 
following section) as well as keloid scars. It is inter-
esting to note that the clinical profile of  symptoms in 
keloids is such that pain in keloid is felt at the center 
while itch is mostly felt at the periphery raising the 
suspicion of  a small fiber neuropathic state. Its sever-
ity has been suggested to correlate with pruritic inten-
sity with a disproportionate number of  regenerating 
unmyelinated C fibers at the periphery causing itch. 
Keloids with itch have also demonstrated an overall 
lower epidermal innervation density pointing toward 
mechanisms of  peripheral nervous sensitization [18, 
19]. Another study reporting a large number of  thin-
ner nerve fibers in deeper layers of  keloidal skin has 
hypothesized the presence of  the intensive fibrous 
compression (entrapment neuropathy) accounting for 
painful symptoms [20].
10.2.6   Pruritus: Definition and Subtypes
Pruritus is derived from the Latin word prurio, which 
means “to itch” and can be defined as the unpleasant 
sensation, which leads to the desire to scratch [21]. It 
can be divided into acute and chronic as well as into 
different subtypes based on the pathophysiological 
processes involved. In terms of  chronicity, the acute 
itch has been proposed to last up to 6  months post-
injury/insult to the skin in burns patients, correspond-
ing to the early remodeling phase of  wound healing 
[22]. Pruritic sensations in the healing wound could 
potentially be explained on the basis of  histamine 
release as part of  the inflammatory response and partly 
by virtue of  abundant mast cell present in hypertro-
phic scars [23]. Nevertheless, the persistence of  these 
symptoms beyond the wound healing and into scarring 
phase could not be solely explained on a histaminergic 
basis (see below).
Twycross et  al. [24] has classified pruritus into the 
following four main subtypes:
 5 Pruritogenic: Arising in the skin because of injury/
inflammation
 5 Neuropathic: Stemming from within the afferent 
neurologic pathway
 5 Neurogenic: Having a central nervous system origin 
in the absence of neurologic pathology
 5 Psychogenic: Associated with psychiatric conditions
While a number of non-skin pruritic disorders may 
appear to consistently fit in one discreet category, the 
scar- related itch is thought to have a number of non- 
pruritogenic origins.
10.2.7   Pruritic Pathway
10.2.7.1   Peripheral Receptor Activation
A wide variety of substances have been implicated in 
the generation and propagation of antegrade pruritic 
stimuli including:
Histamine
A number of histamine receptors have been described in 
the literature. The surface of sensory nerve endings have 
H1 and H2 receptors that are activated by histamine 
stored in the keratinocytes and mast cells [25]; H3 and 
H4 receptors are also found on peripheral and central 
neurons regulating neurotransmitter release and mast 
cells [26, 27]. As a by-product of collagen production, 
histamine synthesis is increased in the healing wound, 
and this can account for the generation of pruritic stim-
uli in the healing wound/freshly formed scar [28].
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Acetylcholine
Human keratinocytes have been shown to synthesize, 
store, and release acetylcholine, which, through the acti-
vation of M3 muscarinic receptors in the skin, can pro-
duce an itch-associated response [29, 30].
Bradykinin
Histamine release can be caused by bradykinin secretion 
through mast cell degranulation [31]. It also stimulates 
the release of calcitonin gene-related peptide, substance 
P, and prostaglandin E2 at the site of tissue injury result-
ing in inflammation [32].
Proteinases
Dermal mast cells synthesize proteinases, including 
tryptase and chymase, which interact with proteinase- 
activated- receptor-2 located on C fibers neurons, con-
tributing to impulse generation [33].
10.2.8   Peripheral Nerve Fibers (PNF)
A specific group of “unmyelinated C fibers” appears to 
be responsible for the transmission of itch; they start 
at the dermo-epidermal junction and reach the spinal 
cord via the dorsal root ganglion. These fibers have a 
characteristic slow conduction velocity (0.5 m/sec) with 
a prolonged histamine response and extensive termi-
nal branching. The main transmitters released include 
 substance P and calcitonin gene-related peptide [34].
10.2.9   Spinal Cord/Itch Specific Neurons
Andrew and Craig, in their experiments on cats, showed 
“itch-specific” neurons to be located in the superficial 
part of the dorsal lamina I of spinothalamic tract [35]. 
They are characterized by their lack of ongoing dis-
charge and low conduction velocities and terminate at 
the thalamus before crossing over to the contralateral 
side in the spinal cord.
10.2.10   Thalamocortical Level
The exact parts of the brain activated by the pruritic 
pathway are still not fully characterized; lamina I of the 
spinothalamic tract was originally postulated to termi-
nate in the medial dorsal and ventral medial nucleus of 
the thalamus in primates [36]. However, positron emis-
sion tomography studies have failed to show any subcor-
tical activation in healthy individuals and instead show 
significant activation in contralateral somatosensory 
cortex and in both ipsilateral and contralateral motor 
areas (premotor cortex, primary motor cortex, and 
supplementary motor area). The cingulate gyrus and 
prefrontal cortex have also been implicated in neuronal 
transmission and this may potentially be the reason for 
the associated emotional component seen in scratching 
behaviour of patients suffering from pruritus [37].
The generation and maintenance of pruritic symp-
toms into a chronic state has been postulated to relate 
to a state of central nervous system sensitization, based 
on a combination of clinical, neurophysiological, as well 
as pharmacological data [38]. The salient observations 
supporting a neuropathic state in chronic pruritus in 
burns patients are summarized below.
 (a) Emerging pharmacological evidence behind the 
effectiveness of antihistamines at different time-
points during rehabilitation indicates that in the 
later phases of healing, wounds and scars become 
unresponsive to antihistamine therapy [39, 40, 41]. 
This may point toward the involvement of the cen-
tral nervous system in the maintenance of these 
symptoms and is further supported by the superior-
ity of centrally acting agents including gabapentin 
and pregabalin [34, 35, 42, 43] and transcutaneous 
electrical nerve stimulation modalities in symptom 
management [41, 44].
 (b) Neurophysiological studies in burn scars show that 
phenomena similar to those occurring in chronic 
neuropathic pain exist in terms of the presence of 
increased sensitivity to stimuli (hyperalgesia/hyper-
kinesis) on the background of otherwise overall 
decreased sensibility. This finding provides some 
evidence of possible deafferentation as a mechanism 
for CNS sensitization [44, 45].
 (c) Clinical presentation highlights a pattern of symp-
tom exacerbation at night time, which is found typi-
cally in neuropathic states [46, 47].
 (d) The neurological pathways of both symptoms share 
common features including the role of substance P 
and CGRP as well as similar areas of the central 
nervous system activated in the generation of symp-
toms as in neuropathic pain [48, 49].
 (e) Neuropeptide expression data. Hypertrophic scar 
biopsies in patients with pain and itch demonstrated 
a higher density of neuropeptides (SP and CGRP) 
compared to controls, whereas these were absent 
in non-hypertrophic scars providing a link between 
neuropeptide expression and impulse transmission. 
Interestingly, SP immunoreactivity was present in 
the densely packed areas of scar hypertrophy [50].
Another study in grafted burn skin showed the 
coexistence of overall decrease in axonal population 
and a preferential increase in SP fibers correlating 
with pruritic symptoms; this provides a link between 
a state of SP hyperinnervation in a milieu of deaf-
ferentation possibly leading to a neuropathic state 
[32]. Furthermore, neuropeptides like SP are thought 
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to play a key role in perpetuating fibroproliferative 
pathology establishing a cycle of nociception and 
scar hypertrophy [50, 51].
Other authors have proposed the role of opioids in the 
generation of pruritic impulses in hypertrophic burn 
scars [52].
10.2.10.1   Incidence/Prevalence of Pain 
and Itch in Scars
Pain is a major sensory disturbance and has been 
described as contributing to the “hidden cost” of cutane-
ous scars. According to a study based on semi- structured 
interviews in a UK scar specialist service, it has been 
identified that 26% and 44% of patients reported pain 
and itch in association with their scars, affecting their 
physical comfort and functioning [53].
In a corroborative study, pain and itch have been 
found to correlate with physical impairment (P ≤ 0.001) 
in a study of 100 patients with keloid and hypertro-
phic scarring attending a German dermatology depart-
ment using the Questionnaire on Experience with Skin 
Complaints. Similar work utilizing the Dermatology 
Life Quality Index (DLQI) tool confirmed that keloids 
have a statistically significant effect on the quality of 
life compared to physiologic scars (p < 0.001); addition-
ally, they are associated with a statistically significant 
increase in pain and itch disturbances (P  <  0.01 and 
0.001  respectively) [54].
A cross-sectional health-related quality of life 
(HRQL) assessment study focused on indicators of the 
burden for 106 keloid patients using one disease-specific 
(Skindex-29) and two generic (SF-36 and EQ-5D-5L) 
HRQL measures; results indicated that pain and itch 
were the strongest predictors of impairment and related 
to low mental and emotional status [55].
A study evaluating chronic pain due to central sen-
sitization in burn scars showed a 35% prevalence of 
pain in scarred tissue one or more years after injury [56, 
57]. Additionally, work evaluating 98 burn survivors, 
reported 25% of patients having painful scars and 20% 
experiencing shooting pain more than 30  years post-
injury [21]. A retrospective review involving 72 patients 
suggested that the first complaint of neuropathic pain 
presents on average at 4.3 months after injury and that 
there is a qualitative progression pattern; symptoms 
are initially reported as “pins and needles,” then being 
predominantly stabbing or burning pain followed by 
“shooting” sensory qualities [58].
A multicenter cohort involving 510 patients was used 
to evaluate the incidence and prevalence of burns itch. 
In this long-term prospective study, 64% of individuals 
reported itch to be a significant problem over a 2-year 
period. At three  months, 87% of individuals reported 
severe itching; this fell to 70% at 12 and 64% at 24 months 
respectively. Predictors of itch at three  months post-
burn included total burned surface area (TBSA), female 
gender, number of surgical procedures (deep dermal 
injury), and post- traumatic stress disorder (PTSD) 
symptoms at two  weeks post-injury. Interestingly, at 
24 months the only predictors for itch complaints were 
the latter two (PTSD at two weeks post-injury and the 
presence of deep dermal injury). The authors proposed 
that acute itch (up to 6 months) corresponding to the 
early remodeling phase of wound healing effects, both 
partial and full-thickness burn injuries. Chronic itch, on 
the other hand, affects patients with certain predispos-
ing factors, providing a link between the chronicity of 
symptoms and markers of injury severity as well as psy-
chological stress [59].
Another multicenter, large cohort study of adult 
burn survivors, reported high prevalence and severity 
of post-burn pruritus. Two cohorts of individual with 
burns were studied; the first included 637 patients fol-
lowed prospectively over a 2-year period and identified 
that pruritus initially affected more than 90% of individ-
uals and persisted in more than 40% of burn survivors in 
the long term. The second cohort comprised 336 patients 
who sustained burn injury 4–10 years before assessment 
using the 5-D itch scale. Pruritus was reported as severe 
in 76% patients within this group, moderate in 29%, and 
mild in 52% [60].
Schneider et al. [61] conducted a retrospective review 
of 430 pediatric burn survivors with a mean TBSA of 
40.8%. Findings included that pruritus is present in most 
children (93%) and is of moderate intensity at discharge. 
The frequency and intensity of symptoms decreased over 
time; nevertheless continued to affect 63% of children at 
two  years post-injury; furthermore, regression analysis 
showed significant correlations between pain and itch 
intensity at each time point. Most interestingly, no asso-
ciation was identified between pruritic intensity and burn 
etiology, age, gender, or burn size.
10.2.10.2   Management of Symptoms
Sensory symptoms in scars can be managed using a 
variety of approaches; undoubtedly, the most important 
initial step toward successful management relies on reli-
able and consistent monitoring of symptoms. A pleth-
ora of clinical measurement scales have been described 
in the literature; some of the most commonly utilized 
mono- dimensional scales include verbal, visual, as well 
as numerical analogue scales [62]. Other evaluation 
methods like the “itch man scale” incorporate a picto-
rial element, which makes them more suitable for pediat-
ric patients or those unable to complete analogue scales 
[63]. Multidimensional tools including the 5-D Pruritus 
Scale have the advantage of incorporating components 
of the sensory experience other than intensity, including 
duration and disability, hence offering the opportunity 
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to capture the degree of disturbance in a more compre-
hensive manner [64].
A variety of pharmacological and non-pharma-
cological adjuncts are available and frequently using a 
combination of modalities provides an optimal thera-
peutic approach.
10.2.11   Non-pharmacological Adjuncts
10.2.11.1   Psychological Support
A multidisciplinary approach toward treating sensory 
disturbances in scars is vital, and psychological support 
has been suggested as an integral part of the manage-
ment plan [65]. This is particularly pertinent given the 
association between psychological stress and persever-
ance of sensory symptoms into a chronic state [38].
10.2.11.2   Cooling
The application of cooling agents as part of wound care 
and scar management can help temporarily relieve pru-
ritic sensations. The beneficial effect of cooling can be 
explained by the temperature-sensitive activation of cer-
tain excitatory ion channels, including vanilloid receptor 
1 as well as ascending pathway C fibers [34, 66].
10.2.11.3   Hydration/Moisturization
Two recent literature reviews have found that there is lim-
ited and low-level evidence behind the optimal choice of 
a moisturizing and hydrating product for burn scars [67], 
with a small number of studies investigating the value of 
different products available. The rationale for moistur-
ization of a scar relates to addressing the increased rate 
of transepidermal water loss (TEWL) seen in scars and 
potentially inhibits the fibrogenic action of fibroblasts by 
virtue of the hydrating effect [68].
The ideal moisturizer should have both occlusive as 
well as humectant ingredients. Occlusive substances (e.g., 
oils) function to impede water loss, whereas humectants 
(e.g., glycerin, propylene glycol, etc.) attract water from the 
dermis into the stratum corneum. The presence of a defec-
tive barrier against transepidermal water loss in scarred 
skin implies that a humectant-only-based preparation 
would enhance fluid loss, hence should be avoided [69].
A small randomized study has indicated that mugwort 
lotion is a promising topical agent for the relief of an itch 
in burns hypertrophic scarring [70]; additionally, a non-
prescription moisturizer containing a blend of protease 
enzymes (Provase) applied every 8 hours for four weeks 
has been shown to reduce itch severity parameters as well 
as the affective burden significantly [71].
A similar randomized controlled study among 
52  patients with postburn itch found that a prepara-
tion of beeswax and herbal oil had a statistically signifi-
cant better effect on itch compared to aqueous cream 
(P = 0.001); additionally, symptoms recurred later com-
paratively (P ≤ 0.001), and the use of antipruritic medi-
cations was lower (P = 0.023) [72].
A different literature report compared the effects of 
hydrocolloid dressing versus moisturizer in 20 patients 
with keloid and hypertrophic scars over a 2-month 
period in a randomized controlled prospective manner. 
Results indicate that both products achieved a similar 
reduction in itch (P < 0.03) and pain (P < 0.08) presum-
ably by virtue of scar hydration [73].
One of  the most interesting reports in the litera-
ture focused on the comparison between a hydrat-
ing gel- cream and three fluid silicones in a group of 
healthy volunteers. The moisturizer Alhydran (BAP 
Medical, Belgium) has been found to have an equiva-
lent effect on hydration and occlusion suggesting that 
these may be the most important in topical scar care 
preparations as opposed to active substances like sili-
cone, which have become extremely popular in recent 
decades [74].
10.2.11.4   Massage
Massage has been shown to be effective for the manage-
ment of pain, itch, and anxiety associated with scars in 
a number of studies [75–77]. The first randomized study 
included 20 patients in the remodeling phase of scar 
formation; these were divided into either a 30-minute 
massage with cocoa butter to a moderate-sized scar tis-
sue area twice a week for five weeks or standard therapy 
(cocoa butter application to scars applied by physical 
therapists without massage motions). The massage ther-
apy group showed reduced pain, itch (both measured 
using visual analogue scales), as well as anxiety scores 
consistently throughout the study period [75]. Similar 
results were obtained in a study with a comparable 
design with regards to pain, itch, and anxiety in adoles-
cent burn victims [78].
A Korean group investigated the effects of skin reha-
bilitation massage for three months in a group of 18 burn 
survivors; this involved the combination of light stroking 
movements followed by acupressure using oil as a medium 
applied for 30  minutes once a week for three  months. 
Results indicated a statistically significant improvement 
of pruritus in the massage group (t = −2.942, p = 0.006) 
as well as depression (t = −2.920, p = 0.007) [76]. The 
underlying mechanisms of action of massage include the 
principles of the “gate theory” of pain modulation as 
well as the increased vagal activity, reducing stress hor-
mone levels in the recipient [10, 79, 80].
10.2.11.5   Silicone Gels/Sheets
Silicone is widely used for the treatment of symptomatic 
hypertrophic scars. The proposed beneficial mechanisms 
involved include increased skin hydration (by virtue of 
occlusion) and a decrease in fibroblastic activity [81, 82].
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The literature contains a number of high-quality 
studies regarding the role of silicone for the preven-
tion of hypertrophy including a randomized placebo- 
controlled, double-blind prospective trial on sternotomy 
wounds showing a statistically significant effect on pain 
and itch symptoms [83].
Topical application of silicone gel versus placebo gel 
has been investigated in a randomized within-subject 
comparative clinical trial. Results suggested that sili-
cone gel promoted maturation of early burn scars (mean 
age of scars in the study 4 months) and a decrease in 
itch symptoms in a statistically significant manner [84]. 
Similar beneficial effects were reproduced in a differ-
ent study employing silicone gel application to burns 
hypertrophic scarring showing a significant difference in 
terms of scar vascularity starting at the first month of 
application [85].
Another study utilized silicone gel sheets in the 
conservative management of six keloid patients for 
24 weeks. Symptoms of pain and itch showed a decrease 
after four weeks of the gel sheeting application and dis-
appeared after 12  weeks. After 24  weeks, a histologi-
cal decrease in the number of mast cells was observed, 
which may explain the therapeutic benefit seen by vir-
tue of a decreased concentration of mast cells derived 
mediators [86].
A number of comparative studies exist in the litera-
ture, which aimed to elucidate the role of silicone prod-
ucts in the scar care arena.
A randomized clinical trial of 45 post-traumatic 
hypertrophic scars found that silicone gel sheeting 
applied 24  hours/day for six  months was superior to 
15-minute-long daily massage in reducing scar thickness 
in a statistically significant manner (p < 0.001); of par-
ticular note is that pain and itch reduction did not reach 
statistical significance in this study [87].
A separate prospective single-blinded study com-
pared the efficacy of 585 nm flashlamp-pumped pulsed 
dye laser and silicone gel sheeting and control in the 
management of 20 patients with hypertrophic scars; 
results showed an overall reduction of blood flow, vol-
ume, and pruritus for all the study subgroups but failed 
to show any statistically significant difference between 
treatment and control groups [88].
A prospective split sternotomy scar study [89] 
involving 14 patients randomized to treat one-half  
of the scar with triamcinolone acetonide (TAC) and 
the other with silicone gel sheeting worn for 12  hours 
for 12  weeks. The primary outcome of patient prefer-
ence was analyzed, and recruitment was terminated 
after 11 patients had completed the study, 10 of whom 
favoured silicone gel treatment. The average time for the 
symptomatic improvement of silicone-treated patients 
was 3.9 days as compared to triamcinolone acetonide, 
which was 6.8  days (p  <  0.05). The authors proposed 
that the enhanced compliance to silicone-based treat-
ments relates to the painless and noninvasive nature of 
silicone-based adjuncts.
10.2.12   Transcutaneous Electrical Nerve 
Stimulation (TENS)
TENS involves the application of low-voltage electrical 
impulses to the nervous system by means of electrodes 
placed on the skin [90]. The underlying mechanism of 
action involves the stimulation of rapidly conducting 
A-fibers, which inhibit the transmission of noxious stim-
uli carried by the slower C fibers according to the “gate 
theory of pain” [10].
A pilot study involving 20 patients with healed burns 
complaining of severe itch following burns demon-
strated a statistically significant change in the reported 
visual analogue scale compared with placebo over a 
3-week period [90].
10.2.13   Pharmacological Adjuncts
10.2.13.1   Capsaicin
This is a naturally occurring alkaloid compound, which 
interacts with the transient receptor potential V1 recep-
tor resulting in the depletion of neuropeptides from 
peripheral nerves. Despite the fact that capsaicin forms 
one of the mainstay topical agents in many chronic pain 
services, a double-blind placebo-controlled random-
ized trial using 0.025% capsaicin cream on 30 patients 
with pruritic wounds revealed no significant effects on 
pruritic symptom relief  [91, 92, 93]. Further work is 
warranted involving preparations with different concen-
trations of this agent in order to elucidate its exact role 
in the management of symptomatic scars.
10.2.13.2   Antihistamines
Antihistamines have traditionally been used as first-line 
agents for the management of pruritus. First-generation 
compounds (diphenhydramine, hydroxyzine, cyprohep-
tadine, and chlorphenamine) act on histaminic, sero-
tonergic, muscarinic, and alpha-adrenergic receptors. 
Second-generation compounds, like cetirizine, have 
minimal activity on non-histaminic receptors and hence 
have a more favourable side effect profile as well as a 
longer duration of action [94, 95]. The pharmacologi-
cal action of antihistamine relates primarily to a reverse 
agonist action at histaminic receptors as well a central 
nervous system sedative effect (the latter action refers to 
first-generation compounds).
One of the initial studies involving 35 burns patient 
complaining of severe itching after discharge assessed 
the efficacy of three first-generation antihistamines, 
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namely chlorpheniramine, hydroxyzine, and diphen-
hydramine. The results of the study pointed toward no 
significant difference in therapeutic efficacy between the 
three compounds and only a 20% complete relief  of 
symptoms in the cohort [96].
10.2.13.3   Gabapentin/Pregabalin
Gabapentin is a useful agent for the management of 
neuropathic pain associated with a variety of condi-
tions, including post-herpetic neuralgia [97].
The mechanism of action of gabapentin involves a 
number of mechanisms, including:
 1. Blockade of the α2δ subunits of voltage- gated Ca 
channels resulting in a reduced release of excitatory 
neurotransmitters [98].
 2. Increased synthesis and release of γ-aminobutyric 
acid in the CNS [99].
A comparative study appraised two different therapeu-
tic protocols for the management of burns pruritus in 
patients with healing and healed burns in a UK burn 
center incorporating a mixture of antihistamines and 
gabapentin; the authors concluded that gabapentin as 
monotherapy as well as in combination with another 
two antihistamines was more efficacious compared 
to chlorpheniramine alone and in combination with 
another two antihistamines (t = 3.70, df = 89, P < 0.001 
for monotherapy and x2 = 12.2, df = 1, P = 0.001 for 
polytherapy). Additionally, patients with higher initial 
pruritus scores needed a combination of pharmacologi-
cal agents for effective symptomatic relief. This study 
raised the value of centrally acting agents in itch man-
agement and proposed the combination of peripherally 
and centrally acting agents in the treatment for burns 
pruritus [41].
Another landmark study comprised a four-arm, 
double-blind, randomized and placebo-controlled study 
of pregabalin in the management of postburn pruritus. 
Pregabalin is a newer analogue of gabapentin with com-
paratively better anxiolytic and pharmacokinetic prop-
erties. The study compared the following four groups: 
pregabalin; cetirizine and pheniramine maleate; the 
combination of pregabalin, cetirizine, and pheniramine 
maleate; and placebo. Results indicated that for moder-
ate to severe pruritus (VAS 6-10) a centrally acting agent 
like pregabalin is indicated to significantly decrease itch; 
patients with milder itch (VAS 4-5) are best served with 
the addition of pregabalin even if massage and antihista-
mines can provide some control because of quicker, pre-
dictable response with the added benefit of anxiolysis [77].
10.2.13.4   Steroids
Steroid delivery to hypertrophic and keloidal scars is 
a well-established modality for the alleviation of scar- 
related symptoms, including pain and itch, and their 
beneficial effects were first recorded in literature in the 
1950s [100]. The international advisory panel in 2002 
recommended triamcinolone acetonide (TAC) as the 
first- line treatment modality for keloid and second-line 
treatment for linear hypertrophic scar in reducing sub-
jective symptoms associated with keloid and hypertro-
phic scar like pain and pruritus [101].
In 2014, a protocol re-evaluation was undertaken, 
which reinforced the prominent position of steroids in 
scar management albeit supported a combined approach 
incorporating the use of other agents including 5 fluo-
rouracil, cryotherapy, laser, and silicone products [102].
Darvi evaluated the use of intralesional triamcino-
lone acetonide in treating hypertrophic and keloid scars 
in 65 patients with a 10-year follow- up. The dosage of 
TAC for 1–2 cm2 of scar surface area was determined to 
be 20–40 mg, 40–80 mg for 2–3 cm2, and 60–120 mg for 
scar surface area of 4–6 cm2. In this study four injections 
of TAC were given for the total dose delivered to the 
scar at 1–2-week intervals with an ensuing symptomatic 
relief  seen in 71% of patients; furthermore, a dramatic 
improvement of symptoms with full flattening of hyper-
trophic scars was seen in 50% and 71% in patients with 
keloid scars [103].
Manuskiatti [104] and colleagues performed a ran-
domized controlled trial comparing the effects of intra-
lesional triamcinolone acetonide with 5-fluorouracil or 
alone with 585 nm pulse dye laser. TAC-treated scars had 
better improvements in clinical symptoms (pain, itching) 
and scar induration, although the results were not statis-
tically significant. Intralesional triamcinolone acetonide 
treatment, however, did produce side effects, including 
skin atrophy, telangiectasia, and hypopigmentation 
in 50% of the TAC-treated group. Boutli-Kasapidou 
and colleagues [105] evaluated a polytherapy protocol, 
including three triamcinolone acetonide intralesional 
injections every month combined with 12 monthly 
cycles of cryotherapy and 12-hour silicone dressing for 
12 months. Patient satisfaction scale was used to grade 
the appearance cosmetically and subjective symptoms 
(pain, burning, and tension post 12 months). Similarly, 
an investigator satisfaction scale was used as well. The 
results showed that compared to monotherapy, poly-
therapy group had a major improvement in control of 
symptoms and appearance, reported by the patient and 
observed by the physician (P < 0.01). They concluded 
the beneficial effects of each treatment acting synergis-
tically: Steroids downregulating the excessive collagen 
expression in keloids and making it softer, ischemic 
destruction and subsequent necrosis of keloids with 
cryotherapy, and silicon downregulating mastocytes.
Tan and colleagues [106] conducted a patient- 
controlled prospective study for 12 weeks with patients 
receiving intralesional triamcinolone acetonide (40 mg/
mL), silicone gel sheeting, or no treatment (control). 
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The dose of triamcinolone acetonide varied between 
0.1 ml to 0.5 ml of 40 mg/mL of TAC depending upon 
the size of the lesion. In this trial, 12% of silicone-
treated keloids showed a significant reduction (>50%) 
in size compared with 94% of triamcinolone acetonide 
group (RR: 33.00, 95% CI: 2.14–509.33). There was also 
a significant improvement in erythema (RR: 21.00, 95% 
CI: 1.33–332.06). The improvement in itch and pain was 
not statistically significant when compared to control.
Martin et  al. studied the combination of carbon 
dioxide fractional laser (10,600 nm), a pulsed dye laser 
(585 nm), and triamcinolone acetonide (40 mg/ml) injec-
tions monthly for seven sessions in a cohort of keloid 
scars; they reported favourable results in regards to pru-
ritic relief  [107].
Steroids can also be delivered to scars in the form of 
tape application. Advantages of this modality include the 
noninvasive nature and the ability to maintain a continu-
ous level of steroid concentration to the symptomatic scar, 
which can ameliorate the inflammatory milieu responsible 
for the bulk as well as sensory symptoms [108].
10.2.13.5   Botulinum Toxin
Botulinum toxin is a protein neurotoxin produced by 
the spore-forming bacteria Clostridium Botulinum; it 
works by preventing the release of acetylcholine at the 
neuromuscular junction and causing chemoimmobiliza-
tion as well as affecting a variety of cell types including 
fibroblasts [109]. It is an established adjunct in a variety 
of medical and aesthetic interventions and over the last 
number of years has been trialed in the scar manage-
ment arena. The rationale for its use rests on the ability 
to decrease muscular tension underlying a scar as well as 
the ability to alter a host of fibroblast related pathways, 
including their proliferation and cell cycle [110].
A randomized, double-blind comparative trial [111] 
involving 24 females with idiopathic or post-traumatic 
keloids employed the use of either intralesional triam-
cinolone (10 mg/cc), given every four weeks for six ses-
sions or 5  IU/cm3 intralesional botulinum toxin every 
eight weeks for three sessions; in both groups, therapy 
was continued until complete improvement of keloid 
was noted. The authors concluded that the effects of 
intralesional botulinum toxin A comparable to that of 
intralesional steroids with a significant reduction in vol-
ume height and redness of scar in both groups (p < 0.01). 
In the 7-month follow up both treated groups had a sta-
tistically significant reduction in subjective symptoms of 
pain and itching with a statistically significant difference 
in favour of the botulinum toxin A treated group with 
the added advantage of no side effects which were typi-
cally seen in steroid- treated patients.
Another blind study compared the effect of triam-
cinolone acetonide (maximum of 40 mg dose) plus pla-
cebo versus triamcinolone acetonide and botulinum 
toxin (20IU) for keloid scars injected every four weeks 
for a total of 12  weeks. Although the difference in 
height, vascularization, and the pliability were not sig-
nificant between the two groups, there was a significant 
difference in favour of the botulinum group in terms of 
pain and pruritus control ((p < 0.001) at the end of the 
study [112].
Similar results in terms of the superior alleviating 
effect of botulinum toxin have been reached in another 
randomized, single-blind study in 32 keloid patients [113].
The use of  botulinum toxin has been reported in the 
burns literature as part of  a pilot study involving nine 
patients, eight of  which had skin grafts for deep par-
tial-thickness to full-thickness burns, with an average 
TBSA of  24%. At the beginning of  the study, 87.5% of 
patients rated their burns itch as being severe (>7/10), 
which fell to 0 at four weeks following the administra-
tion of  toxin [114].
Further studies are warranted to delineate the exact 
role of botulinum toxin in scar symptom management.
10.2.14   Emerging Modalities
10.2.14.1   Autologous Fat Grafting
Autologous fat grafting has been widely used for the treat-
ment of contour deformities and increasingly employed 
to remodel and regenerate tissue by virtue of mesenchy-
mal stem cells present in adipose tissue [115, 116].
The proposed mechanism supporting the alleviation 
of scar symptoms is suggested to relate to the mechanical 
release of adhesions, neovascularization, and remodel-
ing of scar tissue architecture [117]. Other mechanisms 
proposed for controlling neuropathic pain symptoms 
include blockade of nociceptive impulses and an overall 
reduction of the signal input to the central nervous sys-
tem [118].
Fredman et  al. [119] in a retrospective case review 
evaluated the effectiveness of fat grafting in neuropathic 
burn scars using the patient-reported outcome mea-
surement information system (PROMIS) to assess pain 
following two fat-grafting sessions eight  weeks apart. 
Results showed a statistically significant improvement in 
subjective outcomes at 1-year follow-up.
Huang et al. [120] evaluated autologous fat grafting 
in 13 patients with neuropathic scar pain. Pain evalua-
tions were undertaken using the Visual Analogue Scale 
(VAS) and Neuropathic Pain Symptom Inventory 
(NPSI) preoperatively and at 1, 4, and 24  weeks 
postoperatively. Both VAS and NPSI scores showed 
a significant decrease starting at one  week, alleviat-
ing neuropathic scar pain in the short term, which 
were statistically significant (P = 0.009 and P = 0.007 
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respectively). The NPSI score continued to decrease 
at four weeks (P = 0.0009) till 24 weeks (P = 0.0008) 
with the most significant improvement in paresthesia, 
dysesthesia and evoked pain (P  <  0.001). They con-
cluded the autologous fat provides insulation and acts 
as a cushion to block abnormal sensations and prevent 
stimulation.
Two systematic reviews of the literature pertaining 
to the use of fat grafting and adipose-derived stem cells 
in scarring have shown improvements in scar character-
istics including texture and size, improved pain profiles, 
increased angiogenesis, and an earlier return to function 
[121, 122]. It is clear that the use of fat-derived cells will 
play an important role in the future of scar treatments in 
the field of regenerative medicine.
10.2.14.2   Lasers
Laser stands for “Light Amplification by Stimulated 
Emission of Radiation” and exerts its effect on the tis-
sue through photochemical/thermal/mechanical mecha-
nisms [123].
The photothermal effect or photothermolysis is the 
most relevant mechanism in scar treatment with the 
main target being either blood vessels (pulsed dye laser) 
or water (CO2 and Er:YAG laser). Lasers can be fur-
ther subdivided into ablative and non-ablative based on 
whether the epidermis is affected or not and fractional 
and non-fractional: based on whether intact columns of 
skin are left behind or not after the treatment [124].
Pulsed Dye Laser is a vascular specific laser with 
haemoglobin being the target chromophore. Selective 
photothermolysis [125] with a short pulse duration leads 
to selective absorption of heat by haemoglobin, leading 
to thrombosis and vasculitis [126].
Ebid et  al. [127] in a double-blind, randomized, 
placebo- controlled trial, compared the effects of pulsed 
high-intensity laser in the treatment of post-burn pruri-
tus. They showed that a combination of a long period of 
high- intensity pulsed laser, antihistamine, and massage 
could effectively control moderate to severe burn pruri-
tus, raising the value of incorporating laser modalities in 
antipruritic protocols.
Vasheghani and colleagues [128] showed that low- 
level laser therapy in second-degree cutaneous burns 
decreases the total number of mast cells in the remod-
eling phase while increasing the number of mast cells 
in the proliferative and inflammatory phases. Increased 
level of growth factors and anti-inflammatory cytokines 
and decreased level of pro-inflammatory cytokines 
like interleukin alpha and beta have been shown after 
treatment with laser therapy [129] elucidating potential 
mechanisms for the action of laser on pruritic pathways. 
Other proposed mechanisms include the direct action 
on reactive oxygen species, inhibition of cyclooxygenase 
(COX) and prostaglandin E2 [130], as well as the fast 
axonal flow and microtubule disruption of Aδ and C 
fibers transmission [131].
Alster and Williams [132], in an investigator-blinded 
split scar study of patients with keloid scarring, per-
formed two sessions of flash pump 585 nm pulse-dyed 
laser treatment to half  of the scar at 6–8-week intervals. 
They reported a significant improvement in the texture 
of the skin surface, scar height, erythema, pruritus with 
coarse, loose collagen, and increase number of mast 
cells seen histologically in the laser-treated side.
A prospective randomized controlled trial investi-
gated the outcomes following ablative fractional CO2 
laser on 19 patients with burn scars (minimum age of 
scars for inclusion six  months). Results demonstrated 
that three treatments of ablative fractional CO2 laser 
(Deep FX setting on UltraPulse®, Lumenis; treatment 
parameters: single pass of 300 Hz, 5% density, and 50 mJ 
energy) significantly improved scar pain, itch based on 
Patient and Observer Scar Assessment Scale (POSAS) 
scores (p  =  0.047 and <0.01 respectively). Additional 
findings included an improved dermal architecture at 
six weeks post-treatment [133].
10.3   Conclusion
Pain and itch represent the most common sensory symp-
toms accompanying scars and can have a significant 
impact on patients’ quality of life. Over the last number 
of decades, our understanding of the pertinent patho-
physiological mechanisms has improved considerably, 
especially with regards to the contribution of the central 
nervous system in the generation and maintenance of 
nociceptive and pruritic stimuli. Consistent and reliable 
monitoring of symptoms combined with a multimodal 
approach to treatment should be integral parts of holis-
tic scar management.
Take-Home Messages
 5 Itch and pain can have a significant impact on 
individuals with scars.
 5 The contribution of the central nervous system in 
the generation and maintenance of symptoms is 
paramount.
 5 Accurate assessment and monitoring of symptoms 
are central to successful scar management.
 5 Multimodal approaches which target both periph-
eral and central nervous system components and 
incorporate non-pharmacological adjuncts are 
recommended.
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Erythema is derived from the Greek erythros, which 
refers to the redness of skin or mucous membrane. 
Erythema is common in pathological scars (hypertrophic 
scar and keloid) and premature physiological scars where 
inflammation-induced angiogenesis and capillary dilation 
are mostly responsible. Different from the temporary and 
self-relieving redness in normal skin caused by allergy or 
mechanical friction (such as massage), the existence and 
severity of erythema in scar tissues are consistent with 
their maturity and inflammation state inside, serving as a 
convenient monitor of scar quality and treatment 
response. Scar thickness indirectly reflects the extent of 
scar development by collagen deposition.
11.1   Mechanisms of Erythema in Scar
In general, the common causes of erythema can be 
roughly categorized into four  groups: inflammation, 
mechanical stimulation (massage, waxing, and tweezing 
of hairs), radiation (sunburn, radiotherapy), allergies 
and other chemical agents. Despite the pervasive nature 
of erythema in both physiological and pathological 
scars, the development mechanisms remain to be rela-
tively less explored and therefore limited effective treat-
ment options are available. However, previous studies 
demonstrated that inflammation, vascularization, and 
sometimes epidermis defect are the three major mecha-
nisms that contribute to the erythema in scars.
11.1.1   Inflammation-Induced Capillary 
Perfusion Is Crucial for Erythema 
Initiation
Accumulated studies have confirmed that the inflamma-
tion induced by various reasons (infection, foreign body, 
immune dysfunction, etc.) is greatly associated with the 
formation of scars, especially hypertrophic scars and 
keloids [1]. Stimulated by inflammatory cytokines, capil-
laries constrict to increase the local blood flow and ves-
sel permeability, resulting in erythema and sometimes 
elevated skin temperature [2]. It was shown that signifi-
cant increase of blood flow values was detected in ery-
thematous scars when compared to healthy skin [3, 4]. 
Besides, erythema (measured by colorimetry) is often 
interpreted as an indirect measurement of the blood 
flow in clinical practice as it indicates the hyperemia in 
superficial capillaries. Bae-Harboe et al. first introduced 
the term “postinflammatory erythema” (PIE) in 2013 to 
describe erythema often seen after the resolution of 
inflammatory acne or other inflammatory skin condi-
tions [5]. To be specific, the symptom of erythema per-
sists all along the inflammatory stage of wound healing 
and plays multiple roles in this process.
11.1.2   Vascularization Dynamically 
Participates in the Erythema 
Development
The chronic inflammatory stimulation and hyperprolif-
eration of scar tissues deteriorate the local hypoxia and 
promote the secretion of angiogenic factors, such as vas-
cular endothelial growth factor (VEGF), basic fibro-
blast growth factor (BFGF), and hypoxia-induced 
factor 1 (HIF-1) [2, 6]. As reported by Amadeu et al., 
hypertrophic scars contain an increased number of 
dilated vessels in papillary and reticular dermis com-
pared to normal skin [7]. The increased capillary density 
and dilated vessel diameter then contribute to the for-
mation of erythema, in line with the study of Fullerton, 
who stated that erythema is determined by the blood 
volume under a given area, and not by the product of 
erythrocyte velocity and concentration [8]. Clinically, 
erythema disappears on finger pressure (blanching), 
which also suggests that the vascular remodeling is 
involved.
Scar erythema, blood flow, microvessels, and redness 
are four features of scar that are often interchangeably 
used under the item “vascularization” or “vascularity.” 
However, by directly measuring erythema with colorim-
etry, blood flow with laser Doppler imaging (LDI), ves-
sels with immunohistochemistry, and subjective scale of 
redness with POSAS, respectively, Jaspers et  al. found 
only significant relevance between erythema and subjec-
tive redness, but no correlations between the others. In 
contrast, Mermans et al. found that erythema was asso-
ciated with blood flow, but this correlation was not con-
sistent at different test moments [9]. Moreover, Kischer 
et al. reported that most microvessels were occluded in 
hypertrophic scars due to an excessive number of endo-
thelial cells [10, 11]. And the higher hematocrit and the 
enlarged vessels would then result in a more sluggish 
blood velocity and lower blood flow values. Taken 
together, it is now understood that the term “vascular-
ity” describes a dynamic process, and the four criteria 
mentioned above can attribute to the redness either 
independently or interact with each other at different 
stages of scar development. These exploration studies 
express well the complexity of erythema formation and 
enlighten us to view this process dynamically instead of 
simply putting them under the umbrella of “vasculariza-
tion,” especially in clinical practice.
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11.1.3   Thinner Epidermis Is Directly 
Responsible for the Transparency 
in Erythematous Scars with Skin 
Barrier Defect
The epidermal thickness and collagen synthesis are 
directly associated with the transparency of skin. 
Oliveira et al. and Busch et al. identified a thinned-out 
skin texture in burn scar that makes the intense circula-
tion of blood becoming more apparent [3, 12]. They 
argued that increased skin redness is not only considered 
as an inflammatory symptom but also the structural 
modification of subdermal components. And the induc-
tion of percutaneous collagen (IPC) and angiogenesis 
therapies (medical needling and fractional laser) has 
been proven to be effective to adjust the skin color after 
repetitive treatments [12].
Different from the thinner epidermis in physiological 
scars resulting from normal wound-healing process, 
keloids and hypertrophic scars are characterized by 
extra collagen deposition and increased epidermal thick-
ness [13]. But recent studies also hypothesized a skin 
barrier defect in keloid scars, which may possibly alter 
the opacity of epidermis [14].
11.2   Contributions of Erythema to Scar 
Development and Associated Clinical 
Symptoms
The wound-healing process contains three chrono-
logical but partially overlapped phases: inflammatory 
stage (day 1–6), proliferation stage (day 4–week 3), 
and remodeling stage (week 3–1  year). Parallel with 
this process, Van Der Wal et al. reported that the ery-
thema index scores of  scars reduce significantly within 
12 months [15] as a result of  the common pathological 
mechanisms they shared. To be specific, the allevia-
tion and deterioration of  erythema are closely associ-
ated with the scar development since they indirectly 
reflect the inflammatory state and angiogenic activity 
beneath the skin. And since the redness of  erythema 
(from pink to scarlet to purple) is the result of  dif-
ferent proportion of  hemoglobin (the red oxygenated 
state, absorbed at 660  nm) and deoxyhemoglobin 
(dark red, absorbed at 940  nm) in the capillaries of 
the dermis, the color of  scarred skin can serve as a 
monitor of  local hypoxia, angiogenesis, and microcir-
culation.
Although the most commonly used principles for 
measuring scar color are narrow-band reflectance spec-
trophotometry and tristimulus reflectance colorimetry 
[4], researchers found statistically significant correlation 
between erythema values (colorimetry) and subjective 
redness assessment (Patient and Observer Scar 
Assessment Scale, POSAS) (r  =  0.403, p  =  0.030) [4], 
proving the reliability of subjective erythema measure-
ment in clinical practice.
Similarly, erythematous scars are more likely to suf-
fer from pain or pruritus as a result of inflammatory 
stimulation and suspicious vulnerability of scar fibro-
blasts (previous studies detected an elevation of 
α-adrenoreceptors expression on keloid fibroblasts and 
predicted that it might be related to paresthesia in scar 
tissues [16]).
Elevated temperature is directly associated with 
overperfusion of vessels especially arteries in deeper 
layer of the skin [4] and is not common in thickened scar 
tissues, but the existence of which could be explained as 
a sign of infection or active inflammatory state.
Generally, erythema reflects the inflammation and 
angiogenesis activity, as well as structural remodeling of 
scar tissues to serve as a monitor of scar maturation and 
quality. Since patients and clinicians often determine the 
success of treatment by the visual appearance of a scar, 
erythema measured by POSAS could be an accessible 
method to evaluate the treatment response and help to 
set the endpoint for the course.
11.3   Scar Erythema and Scar Thickness
There is no direct relation between scar erythema and 
scar thickness, because the former reflects the level 
of inflammation and angiogenesis process, whereas 
the latter indicates the extent of cell proliferation and 
extracellular matrix production and deposition. Such 
phenomenon has been frequently observed in clinical 
practice that a highly inflamed scar with sever erythema 
might be thin and soft in texture, whereas a dark-col-
ored keloid could be thick and abundant with collagen. 
However, enhanced erythema by strong angiogenesis 
provides nutrition for fibroblast proliferation and matrix 
production, and therefore reducing erythema also helps 
to prevent scar thickening.
11.4   Clinical Measurement of Scar Redness 
and Thickness
Colorimetric plate along with photography is the con-
ventional methodology to semi-objectively measure the 
redness of scars. Doppler ultrasound can detect blood 
flow inside a scar, but it reflects activity in a relatively 
deep blood vessel. For superficial blood flow inside the 
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surface capillaries, laser speckle might be the technique 
to quantitatively measure the erythema change.
Manual measurement is the conventional way to 
assess scar thickness. With advances in technology, 
ultrasound and nuclear magnetic resonance can quanti-
tatively provide data of scar thickness. In addition, 3D 
scanner not only provides the gross view of a thick scar, 
but also provides quantitative data of scar thickness and 
volume.
11.5   Clinical Relevance
11.5.1  Clinical Treatment Strategies 
of Erythema in Scars
Traditional clinical treatments of erythema in scar tissues 
mainly target on anti-inflammation and anti- proliferation, 
such as topical glucocorticoid and compression garments. 
The spreading applications of laser treatments and medi-
cal needling provide therapists with powerful arms that 
can interfere with erythema formation from various per-
spectives. Besides, systematic elements including imbal-
anced diets, stressful lifestyles, and even genetic 
predisposition may also be responsible.
11.5.1.1   Anti-inflammation Strategies 
to Alleviate Erythema and Hinder 
Scars Development
Inflammation is one of the major risk factors of both 
scar development and erythema. Since corticoid can 
effectively reduce the production of pro-inflammatory 
mediators and inhibit inflammatory processes in the 
dermis, the intralesional triamcinolone acetonide (TCA) 
injection has been widely used alone or as an adjuvant 
therapy to treat hypertrophic scars and keloids [17]. 
Besides, although the application of triamcinolone tapes 
is limited by its penetrating ability, it can be stuck to the 
scar area and release the drug all day long. Moreover, 
clinical studies observed a better performance of triam-
cinolone when combined with 5-Fluorouracil [17]. Other 
topical anti-inflammation treatment such as silicone gel 
sheeting that increases the elasticity of burn scar tissue 
also showed a reduction in pruritus, erythema, and scar 
thickness [18]. Systematic glucocorticoid application is 
not recommended for risks of complications such as dia-
betes, infections, and Cushing’s syndrome.
11.5.1.2   Laser Treatments to Interfere 
with Erythema from Multiple 
Perspective
Laser therapy is one of  the most widely used methods 
to treat erythema in scars. Ablative fractional lasers 
that create columns of  vaporized tissue with surround-
ing eschar and coagulated tissue can improve various 
features of  burn scars including erythema. Kawecki 
et  al. observed that 31% of hypertrophic burn scar 
patients had resolution of  erythema with resulting nor-
mal skin tone after ablative fractional laser treatment 
[19]. Coagulating microvessels with the selective photo-
thermolysis of  wavelengths around 595 nm, pulsed dye 
laser (PDL) can decrease inflammation and edema in 
erythematous scars and shows satisfactory outcomes in 
color repair. Similarly, Q-switched Nd:YAG lasers with 
a wavelength of  1064 nm in very short pulses are prom-
ising solutions to superficial angiogenesis of  erythema-
tous skin, especially in decreasing the vascular 
prominence in PIE [17, 18, 20]. Studies have demon-
strated minimal side effects including atrophic scarring 
(0.8%), hyperpigmentation (1%), hypopigmentation 
(2.6%), and dermatitis (2%), among 500 patients treated 
with PDL [21]. Notably, although PDL and Nd:YAG 
have shown good results in reducing the red color of 
scars, skin erythema itself  is one common adverse effect 
of  laser treatment, which suggests that the laser therapy 
should be carefully selected and be practiced with cau-
tions especially in patients with a history of  post-treat-
ment erythema or scar constitution.
11.5.1.3   Compression Therapy
Compression therapy (or occlusive dressings) has 
been widely applied to hypertrophic scar patients as 
a first- line agent with good results in decreasing ery-
thema, thickness, and hardness of  burn scars [22, 
23]. A total of  60% of  patients treated with compres-
sion devices showed 75–100% enhancement in scar 
condition according to previous studies [17]. The 
anti-scar effects of  occlusive garments are thought to 
be related to occlusion and hydration [7, 17]. Some 
literature reported that this change is likely because 
of  the inhibition of  transforming growth factor 
(TGF)-β1 release and ultimately decreased fibroblast 
activity [24].
11.5.1.4   Medical Needling
Although sounding contradictory, the bleeding process 
of medical needling can influence vascularization by 
stimulating angiogenesis in the post-wound healing cas-
cade and improve the vital thickness of the epidermis 
(directly related to skin transparency) by inducing per-
cutaneous collagen synthesis.
Based on the outcomes of objective measurements, 
medical needling achieves a normalization of the skin 
color and an adjustment to healthy skin after repetitive 
treatments [12], and it has clinically shown to improve the 
abnormal vascular proliferation that occurs in 
PIE. Similarly, fractional resurfacing lasers have been used 
to induce structural remodeling and skin regeneration.
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11.6   Clinical Treatment for Thick Scar
Contracture  and functional disability caused by hyper-
trophic scars need surgical interventions. As for thick 
keloids, surgical therapy is also preferred. In addition, 
intralesional injection with 5-fluorouracil and steroid, 
cryotherapy, pressure therapy, and radiotherapy are all 
potential therapeutic options for thick scars, and these 
will be introduced in various chapters of this book and 
thus will not be the focus of this chapter.
11.7   Conclusion
The scar erythema is a burden for patients, as it amplifies 
the cosmetic problems and is associated with other 
unpleasant feelings such as pain and itching. Moreover, 
the development of erythema parallels with the dynamic 
process of inflammation, angiogenesis, scar formation, 
and thickening. Although most studies consider erythema 
as a concomitant byproduct following wound healing, it 
also promotes scar development via enhancing angiogen-
esis to provide scar fibroblasts essential nutrition for col-
lagen production and deposition, and thus it has become 
an important therapeutic target as well. Although many 
issues remain to be explored such as what determines ery-
thema presence, persistence, and disappearance, the ery-
thema/redness itself can serve as a visible symptom 
reflecting treatment response and thus help both patients 
and therapists to set a relevant endpoint.
Take-Home Messages
Both erythema and thickness are key characteristics 
of scar, which can be used to monitor scar development 
and therapy efficacy. Angiogenesis represented by scar 
redness is a key contributor to pathological scar 
development due to enhanced inflammation, which 
can also serve as an important therapeutic target.
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To a significant degree, vascularization and pigmentation 
determine the color of scars. Pigmentation problems 
are  often even more persistent than deviations in 
vascularization. Pigmentation problems are a common 
consequence after partial and full-thickness burns, skin 
pathology such as vitiligo, other skin trauma, and surgical 
procedures. Almost all these patients experience at least 
some pigmentation problems. Both hypopigmentation 
and hyperpigmentation can cause esthetic and 
psychological issues which affect the quality of life of 
patients. Information on the role and pathways of 
melanocytes in pigmentation problems and the changes 
that occur during scar maturation is increasingly more 
understood. Different subjective and objective methods 
are available to determine scar color. Hypo- and hyperpig-
mentation management options include surgical and 
nonsurgical techniques.
12.1   Pathophysiology and Epidemiology
Altered skin pigmentation, or pigmentation disorders, 
can result from increased or decreased melanin, abnor-
mal melanin distribution, decreased hemoglobin, or 
deposition of exogenous substances. Melanin is pro-
duced by melanocytes, specialized cells of neural crest 
origin that reside in the basal layer of the epidermis. The 
biosynthesis of melanin occurs in lysosome-like organ-
elles called melanosomes, which are transported to the 
cell periphery and transferred from the dendritic tips of 
the melanocytes to the surrounding keratinocytes. Each 
melanocyte is associated with approximately 36 basal 
keratinocytes to form the so-called “epidermal melanin 
unit.”
12.1.1   Hypopigmentation
Hypopigmentation is characterized by skin becoming 
lighter than the individuals own color, but not com-
pletely lacking pigment (. Fig. 12.1). This should not 
be confused with depigmentation, which is the absence 
of all pigment. Hypopigmentation is common and 
approximately 1 in 20 have at least one hypopigmented 
macule [1]. Common causes include vitiligo, postinflam-
matory hypopigmentation, pityriasis versicolor, pityria-
sis alba, and halo naevi. Hypopigmentation disorders 
may be congenital or acquired. Acquired hypopigmen-
tation may be the result of inflammatory conditions or 
trauma like a burn injury. In burn scars, hypopigmen-
tation is a frequent pathology. Although the condition 
often improves over time with scar maturation, lasting 
depigmented or hypopigmented lesions may remain. 
Data on the prevalence of these conditions after burn 
injury are scarce.
Vitiligo is an autoimmune disease where melano-
cytes are affected. The condition affects approximately 
0.5–1% of the population, occurs in patients of all ages, 
equally affects men and women, with an early onset in 
many cases (<20 years). There is no difference in preva-
lence with respect to skin type or race. 
12.1.2   Hyperpigmentation
Hyperpigmentation is the darkening or increase in the 
natural color of the skin and results from overproduc-
tion or abnormal release of melanin in the epidermis 
and/or dermis in response to either endogenous or exog-
enous inflammatory conditions [2]. Superficial hyper-
pigmentation is located in the epidermis and causes a 
light- to dark-brown discoloration. As soon as the pig-
ment lies deeper in the skin (dermal pigmentation), the 
hyperpigmentation acquires a gray-brown to gray-blue 
glow. Like hypopigmentation, hyperpigmentation disor-
ders may be congenital or acquired.
Postinflammatory hyperpigmentation is a reactive 
hypermelanosis of the skin that occurs as a sequela of 
cutaneous inflammation. Common causes of include 
acne vulgaris, eczematous dermatoses, and burn injury. 
Postinflammatory hyperpigmentation may also occur as 
a complication of a chemical peeling.
Although this pigmentary change can be observed 
in all skin types, it more frequently affects individu-
als with higher degrees of skin pigmentation (meaning 
Fitzpatrick skin types IV–VI) due to increased reactivity 
of melanocytes within the skin. The modified Fitzpatrick 
skin type classification system contains six categories 
with types I–IV describing different types of white skin 
and type V “brown” and type VI “black” skin.
Severe burns significantly affect the process of pig-
mentation as it is tightly regulated by cell proliferation 
  . Fig. 12.1 Hypopigmentation in a hand after burn injury
 A. Pijpe et al.
111 12
and differentiation of melanocytes and melanocyte stem 
cells which are located in the epidermis and hair follicles 
of the skin. Almost all burn patients with deep partial- 
thickness wounds and full-thickness wounds experience 
at least some pigmentation problems (. Fig.  12.2). 
Superficial burn wounds generally heal without pigmen-
tation problems. Although scar-related hypo- and hyper-
pigmentation are not harmful, it can cause significant 
cosmetic problems and become a great psychological 
burden for patients which influences their quality of life.
12.1.3   Maturation
Maturation is the fourth and final stage of the wound 
healing process and is commonly referred to as remodel-
ing. The cellular changes that occur during scar matu-
ration are increasingly understood. They are associated 
with remodeling of the extracellular matrix as well as 
normalization of the ratio of type III to type I collagen. 
However, the process of scar maturation with regard 
to changes in clinical appearance over time is the least 
understood part of wound healing. Most studies suggest 
a mean maturation period of 1, 2, or several years. In 
this active stage it can be difficult to determine to what 
extent deviant skin color is caused by vascularization 
and/or pigmentation. By pressing the scar with a finger 
or transparent ruler like made from plexiglass, the blood 
flow is reduced and degree of pigmentation can be better 
established (. Fig. 12.3). 
Van der Wal et al. performed the first longitudinal 
study on the maturation pattern of individual scar char-
acteristics and predictors of severe scarring in a repre-
sentative burn population [3]. They conducted a detailed 
analysis on the clinical changes of burn scars in 474 
patients following a longitudinal scar assessment proto-
col. The observations of the POSAS Observer Scale (see 
7 Sect. 2.2) showed that all scar parameters, except vas-
cularization, become more apparent in the first 6 months 
after the injury. After 12 months, mean POSAS scores 
were significantly lower for vascularization, pigmenta-
tion, and pliability compared with the 6-month follow-
 up. Statistical significant improvement at 12 months was 
also found for the parameters vascularization and pig-
mentation compared with the 3-month evaluation.
12.2   Measurement Techniques
For the diagnosis, evaluation of progress of disease 
and/or therapy it is of major importance to be able to 
measure skin or scar color in a noninvasive, valid, and 
reliable way. Outcome measures receive more and more 
attention to evaluate therapies on an individual basis as 
  . Fig. 12.2 Burn scar with hyperpigmented and hypopigmented areas
  . Fig. 12.3 (a) Pressure on the scar with a finger reduces blood 
flow in the scar. (b) Immediately after release of  the pressure, level of 
pigmentation of  the scar is visible
a
b
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well as at group level for efficacy studies. For this, vali-
dated techniques are a prerequisite.
To determine scar color, different subjective and 
objective methods are developed and available.
12.2.1  Objective Measurement Instruments
Several instruments are available to measure skin or scar 
color. The output is generally a combination of redness 
(erythema) and melanin (pigment). Most instruments 
use either narrow band spectrophotometry or reflec-
tance colorimetry. The tristimulus reflectance colorim-
etry measures color through three broad wavelengths 
filters representing brightness, redness, and pigmen-
tation. This system is suitable to measure any kind of 
color in the standard color space defined by Commission 
Internationale de l’Eclairage (CIE), where the output in 
L∗a∗b coordinates is defined as CIELAB color space 
values [4]. The LAB values express color as three values: 
L∗ for the lightness (black to white), a∗ from green to 
red, and b∗ from blue to yellow.
Narrow-band reflectance spectrophotometers mea-
sure erythema and melanin index, representing vas-
cularization and pigmentation, based on differences 
in light absorption by hemoglobin and melanocytes, 
respectively, in selected bands of the light spectrum 
corresponding to hemoglobin and melanin absorption 
spectra.
Van der Wal et al. performed a study where the reli-
ability, validity, and feasibility of narrow-band reflec-
tance spectrophotometry and tristimulus reflectance 
colorimetry on normal skin and scar tissue were studied 
[5]. All three devices included in this study, Mexameter 
(narrow band spectrophotometer) and Colorimeter 
 (tristimulus reflectance) (both from Courage & Khazaka 
Electronic GmbH, Cologne, Germany) and DSM II 
ColorMeter (narrow band spectrophotometer) (Cortex 
Technology, Hadsund, Denmark), obtained reliable 
results after a single measurement, performed by one 
observer.
Some aspects of these measurements need to be 
considered when using skin color data for therapeutic 
evaluation: Skin color is generally adapted to seasonal 
differences and is likely to be different on various ana-
tomical regions of the body. Therefore, measurements 
of skin or scar lesions on specific locations need to be 
compared to the relevant normal skin of a nearby or 
contralateral comparative anatomical region. For nar-
row band spectrophotometric measurements, this needs 
to be performed by subtraction of the data of the normal 
skin from the lesional data. Furthermore, for the nar-
row band spectrophotometers, some caution is needed 
in interpretation of the data from highly pigmented 
skin: There is some influence on the erythema index by 
the melanin index, in that the erythema index appar-
ently increases with increasing melanin index. Also, the 
melanin index is influenced by the oxygen saturation 
level of hemoglobin, since reduced hemoglobin absorbs 
more red light than oxyhemoglobin. For example, low-
ering the arm of a subject to be measured will lower the 
oxygenation, and give an increase in both erythema and 
melanin indices. Therefore, a standardized position for 
the measurements is recommended.
12.2.2   Scar Assessment Scales
Today, many scales exist to evaluate skin and scar char-
acteristics [6]. One of the earliest and frequently reported 
is the Vancouver Scar Scale (VSS) [7]. Despite the fact 
that it is frequently used as a scale, especially the items 
“erythema” and “pigmentation” are nominal categories 
rather than ordinal ones. For the item “pigmentation” 
categories are normal, hypo, mixed, or hyper pigmen-
tation; and for the item ‘erythema’ they are normal, 
pink, red, and purple. The VSS gives no intensity value 
of these parameters and therefore the numbers that are 
often attributed to these categories cannot be added to 
give a “severity score” for total scar characteristics. This 
is specifically important for pigmentation problems, 
since “hypopigmentation” cannot generally be consid-
ered to be less severe than “hyperpigmentation,” which 
would be a consequence if  the VSS categories would be 
used as a true scale.
To overcome these difficulties, the Patient and 
Observer Scar Assessment Scale (POSAS) was designed 
and validated [8]. The POSAS questionnaire represent 
the severity of burn scar quality including parameters 
that indicate skin color and pigmentation on a numeri-
cal 10-point rating scale. Furthermore, the categories 
“pale, pink, red, purple, mix” and “hypo, hyper, mix” 
are added for each assessment. Within these categories, 
the numerical data can be added to present an overall 
scar severity score.
12.3   Therapies
12.3.1  Hypopigmentation
12.3.1.1   Nonsurgical Techniques
Laser Therapy
Laser therapy can be used to treat pigment disorders in 
a scar. If  there is hypopigmentation of a scar, it can be 
treated with the Excimer laser (308 nm) [9]. This laser 
produces a stimulation of melanocytes, thereby correct-
ing hypopigmentation in the scar tissue.
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Other pigment lasers mainly focus on the presence of 
hyperpigmentation and induce pigment reduction.
Dermatography
Dermatography, also known as medical tattooing, is an 
alternative method to improve the scar color, particu-
larly in hypopigmented areas. Chemical-based pigments 
are injected into the dermis, as with other sorts of tat-
tooing. Dermatography can be repeated if  the color 
fades over time.
Camouflage Therapy
Camouflage therapy offers a temporary solution to hide 
a (hypopigmented) scar or make it less visible. Often a 
cream, spray, or powder that is close to the original skin 
color is used. Once the correct color has been deter-
mined, the application can be used independently in the 
home situation.
12.3.1.2   Surgical Techniques
Dermabrasion
Dermabrasion can help to treat the hypopigmentation 
of a scar.
By abrasion, the epidermis and a very small layer 
of the dermis are removed layer by layer, resulting in a 
superficial wound.
Normally, the abrasia is done until the whitish der-
mal layer is exposed with no more than fractional bleed-
ing present.
Dermabrasion is performed as a single treatment 
modality or in combination with other treatments such 
as skin transplantation or cell spray. If  it is used as a 
single treatment modality, the superficial wound has to 
recover by itself. In those cases abrasia must be carried 
out carefully to prevent wound-healing problems if  the 
wound becomes too deep. This method is mainly used in 
case of hyperpigmentation where the excess pigment is 
shaved off  and the new epidermis hopefully has a more 
balanced pigment and therefore color (see below).
In hypopigmentation the dermabrasion is mostly 
combined with a method to transplant melanocytes 
from healthy skin to the depigmented regions like skin 
grafting or cell therapy.
Skin Grafting
Skin-grafting techniques include split-thickness skin 
grafts, full-thickness skin grafts, punch-grafting, and 
epidermal grafts, such as grafts from suction blisters.
The split skin graft (SSG) contains the entire epider-
mis with only a thin layer of dermis. The skin is har-
vested with a dermatome preferably from a suitable, 
color-matching concealed donor site. A pigmented 
donor area with a thickness of 0.15 mm is identified to 
achieve optimal outcomes as the basal layer of the epi-
dermis and a complement of melanocytes remain intact.
The full-thickness graft provides better functional 
and cosmetic outcomes in terms of scarring compared 
to the SSG. The entire epidermis and dermis are trans-
planted. For correction of pigment disorders, this is 
only indicated if  the general quality of the scar is unac-
ceptable/problematic and the scar area is limited.
In skin grafting, selecting a donor site of healthy skin 
with suitable normal pigmentation is key to ensure opti-
mal outcomes.
Small full-thickness punch biopsies are harvested 
from healthy skin from a concealed body part, normally 
the upper arm or upper leg. The size of the biopsies 
can be 1–4 mm in diameter. Repigmentation occurs in 
70% of the cases. Melanocytes migrate from the punch 
biopsies into the adjacent area in a centrifugal manner. 
A disadvantage of punch grafting is the cobblestone 
appearance that may remain in the long term.
Grafting of suction blisters is an interesting and suc-
cessful technique for the treatment of hypopigmentation 
disorders. Negative pressure is exerted on healthy skin 
of the patient to create epidermal blisters. Devices such 
as a suction pump, vacuum bottle, hoses, or suction cups 
can be used for harvesting. This blister is harvested sub-
sequently and transplanted to the depigmented area.
The donor site generally heals spontaneously with 
no or minimal scarring. Minor adverse effects such as 
donor site hyperpigmentation and color mismatching 
may be encountered.
Cell Therapy
An autologous epidermal cell suspension spray can be 
used to enhance repigmentation. The suspension can 
be sprayed on top of the wound after dermabrasion or 
injected in the hypopigmented area. This was studied by 
Falabella et al. already in 1971 and measured both by 
clinical score and by melanocyte counts, but the differ-
ence between the groups was not statistically significant 
in either case [10].
Later the RECELL® Autologous Cell Harvesting 
Device (AVITA Medical Europe Ltd., Melbourne, 
UK) became available, which uses an on-site device to 
isolate epidermal cells from a small piece of  split skin 
graft.
Similar to the treatment of vitiligo, melanocytes are 
directly isolated and harvested from skin grafts prior to 
transplantation to the depigmented injured area. These 
cell-based treatments can be divided into (i) non- cultured 
cell suspension, (ii) cultured melanocyte suspension, 
(iii) cultured keratinocyte/melanocyte suspension, (iv) 
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tissue-engineered melanocyte grafts. For current clinical 
practice mainly the non-cultured cell suspension is used. 
The other, more sophisticated options may be interest-
ing but are rarely used as clinical therapy so far. These 
therapies are expensive and laborious and currently it 
has not been conclusively demonstrated that they are 
cost effective.
A limitation of cell transplantation is a poten-
tially uneven cell dispersion across the recipient site. 
Furthermore, poor attachment of transplanted melano-
cytes to the recipient skin and unfavorable wound condi-
tions may also affect cell survival and outcome.
Microneedling
Microneedling is a relatively new therapeutic modal-
ity in dermatology. It has shown promising results as 
an adjuvant therapy for enhanced drug delivery in the 
treatment of atrophic scars, alopecia, actinic keratoses, 
and disorders of pigmentation such as melisma [11]. The 
efficacy in treatment of vitiligo remains limited.
Excision
Excision of the hypopigmented area can be performed 
and needs to be combined with a technique for wound 
closure. For small areas direct wound closure is the first 
choice. For larger areas and in the case of considerable 
tension on the wound edges, additional closing tech-
niques such as the skin stretching technique or tissue 
expansion can be performed.
The skin stretch technique is suitable for closing 
defects after excision of scars and wounds of limited size. 
The skin stretcher is a device that can stretch two widely 
spaced wound edges together. The force with which this 
goes can be set, but is usually in the order of 30 Newton. 
The best result is obtained when working in cycles of 
4  minutes of stretch and 1  minute of rest. After a few 
cycles, the wound tension has dropped and the wound 
can be closed under acceptable tension. In a large study, 
the number of wound dehiscence was limited [12].
With the help of a tissue expander large areas of scar 
can be normally excised. The tissue expander technique 
is widespread and is frequently used for reconstruction 
of large scar areas such as alopecia areas of the hairy 
head. During the first operation, an expander is placed 
under flexible skin in the area of  the scar area that needs 
to be reconstructed. This extension is a special balloon 
with a filling port. The filling port is also placed under 
the skin. The fill port can be triggered through the skin so 
the balloon can be filled in tempi until sufficient texture 
has been expanded for the scar reconstruction. However, 
despite good results, two interventions are needed, the 
total procedure may take several weeks to months with 
frequent visits to the clinic to fill the balloon.
12.3.2   Hyperpigmentation
12.3.2.1   Nonsurgical Treatment
Topical Treatments
Hydroquinone, either as monotherapy or in combination 
with alpha-hydroxy acid, ascorbic acid, retinoids, corti-
costeroids, and antioxidants, is a commonly used depig-
menting agent [2]. Its working mechanism is thought to 
inhibit melanogenesis by acting as an alternative substrate 
for the enzyme tyrosinase. Hydroquinone may also result 
in inhibition of DNA/RNA synthesis, destruction of 
melanocytes, and degradation of melanosomes.
Topical retinoids, including tretinoin (all-trans- 
retinoic acid), tazarotene, and adapalene, are also used 
as monotherapy for treatment of hyperpigmented 
lesions. Retinoids are supposed to act by inhibition 
of tyrosinase, induction of melanocyte apoptosis, and 
acceleration of epidermal cell turnover.
Also azelaic acid is thought to inhibit tyrosinase and 
decrease melanogenesis.
Chemical Peels
A commonly used acid against hyperpigmentation is the 
use of lactic acid. Lactic acid is particularly known to 
prevent the formation of tyrosinase so that pigment cells 
can form less pigment. In addition, the accelerated exfo-
liation of the skin cells fades the pigment cells present. 
The mechanism of this effect might be due to epidermal 
remodeling and accelerated desquamation, which would 
result in quick pigment dispersion.
Laser Therapy
Hyperpigmentation can be treated with laser therapy, 
based on selective photothermolysis. Selecting the right 
wavelength can tackle pigment selectively. Selective pho-
tothermolysis suggests that laser therapy would allow 
discriminating destruction of pigment without injuring 
the surrounding tissue. Selective melanin photother-
molysis can be obtained with any laser light having a 
wavelength in the absorption spectrum of melanin and 
sufficient energy levels to target melanosomes (mostly 
used: the Q-switched ruby laser (694  nm), Q-switched 
Nd:YAG laser (532 nm, 1064 nm), and the Q-switched 
alexandrite laser (755 nm)). Laser induces extreme heat-
ing of melanosomes with subsequent thermal expan-
sion, local vaporization and generation of acoustic 
waves that damage the nucleus and eventually destroy 
the pigment-laden cells. The released melanin is then 
removed through transepidermal elimination or phago-
cytosis by dermal macrophages. To be effective and spe-
cific, wavelengths that avoid absorption by other skin 
chromophores and penetrate to the desired depth have 
to be used [13].
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12.3.2.2   Surgical Treatment
Dermabrasion
As mentioned above, dermabrasion can help to reduce 
hypo- and hyperpigmentation of a scar. In the case of 
hyperpigmentation, dermabrasion is usually performed 
as a single treatment modality, that is, it is not combined 
with another treatment such as skin transplantation. The 
idea is to easily remove the epidermis including the mela-
nocytes and the pigment and let it heal spontaneously 
resulting in an epidermis with a lower concentration 
of melanocytes. It is not recommended to go too deep 
because the regeneration capacity of the skin is limited 
in scars, due to lowered presence or even absence of hair 
follicles and sweat glands. If the wounds are too deep and 
stay open too long, problematic new scars can occur.
It is advisable to perform dermabrasion in the fall or 
winter season to anticipate low UV light exposure to reduce 
the risk of excessive new pigmentation. It is also recom-
mended to start dermabrasion with a small test area, pref-
erably in an area that can be easily evaluated by the patient.
Excision
Excision and closure is also a feasible therapeutic option 
for hyperpigmented lesions that are limited in size (see 
above under hypopigmentation). It should be taken into 
account that a (linear) scar will remain and that  outcome 
may be more severe than the original situation.
12.4   Conclusion
Pigmentation problems are an important feature of scar 
quality and partly determine the visual characteristics 
of a scar. Both hypopigmentation and hyperpigmenta-
tion can cause aesthetic and psychological issues which 
influences quality of life. Pigmentation disorders are 
difficult to treat. Treatment options include camouflage 
therapy, topical treatments, chemical peels, laser ther-
apy, dermatography, dermabrasion, microneedling, skin 
grafting, cell therapy, and excision. It is advised to first 
try the conservative options and to dose the treatment to 
prevent overshoot and complications.
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Take-Home Messages
 5 Pigment abnormalities are divided into hyperpig-
mentation and hypopigmentation.
 5 Pigmentation disorders are difficult to treat.
 5 Nonsurgical and surgical options are available.
 5 Wait until the area has matured.
 5 First try the conservative options. If  possible, first 
test the response to the therapy in a test area.
 5 Dose the treatment to prevent overshoot and com-
plications.
Scar Symptoms: Pigmentation Disorders
117
© The Author(s) 2020





13.1  Introduction – 118
13.2  General Features – 118
13.3  Contractures of the Neck – 118
13.4  Axillar Contractures – 119
13.5  Hand Contractures – 119
13.6  Other Anatomical Sites of Scar Contractures – 120
13.7  Rehabilitation Programs – 120
13.8  Surgical Strategies – 121
13.9  Z Plasties – 121
13.10  Skin Grafts – 121
13.11  Dermal Substitutes – 121
13.12  Flaps – 121
13.13  Conclusion – 122
 References – 122
118
13
13.1   Introduction
The prevalence of contractures is high, especially after 
burns and may vary, depending on the age, the depth of the 
initial burns, and the time between burns and the occur-
rence of the contractures. Young patients and children are 
more likely candidates to develop contractures. When skin 
grafting after burn is performed in due time, the prevalence 
is lower. Contractures are more likely to occur in more 
severe burns, flame burns, children, females, on the cervical 
spine and in the upper extremity. The absence of physio-
therapy and an abnormal long period awaiting spontane-
ous healing without skin grafting will progressively induce 
severe contractures. This is still frequently observed on the 
upper limbs in burn patients in developing countries. Early 
excision and skin grafting is the best option to reduce the 
incidence of contractures. Other causes of contractures are 
less frequently observed, but may be seen after trauma or 
infection, linked to noncompliance, a too long immobili-
zation, a joint destruction, an epiphysiodesis in children. 
This chapter proposes to give an overview of the func-
tional limitations of the skin contractures and the need for 
an adapted early rehabilitation program starting during 
the healing stage and carried on during the next 2 years 
post burns and other causes of skin limitation.
13.2   General Features
Incidence of contractures has been recently analyzed [1, 2] 
on patients presenting acute burns across or adjacent to the 
neck, shoulder, elbow, wrist, hip, knee, and ankle. Passive 
range of motion was measured at 3–6–9–12 months after 
burn. Limited range of motion of non- operated burned 
joints was restored back to normal within 6–9  months. 
From the operated burned joints, 58.6% demonstrated a 
limited range of motion at 3–6 weeks declining to 20.9% 
at 12 months. The upper part of the body was affected 
more often by scar contracture than the lower part. 
Reconstructive surgery was performed in 13.3% of the 
operated burned joints. This study confirms that a quick 
skin grafting is a good option to prevent severe contrac-
tures, but not enough to prevent all of them.
Contractures may clinically present with differ-
ent characteristics, like bands of skin partially limiting 
the range of joint movements to a complete impossi-
bility to move, all joints being glued in deep stiffness. 
Contractures are more or less severe, depending if  the 
deep structures (tendons, aponeurosis, subcutaneous 
muscles, or fascia) are involved in the process, and the 
type of contracture, static or dynamic.
Skin capacity is particularly limited in burns of the 
dorsal aspect of the hand, if  an adapted rehabilitation 
program including staged splinting of the hand before, 
during, and after skin grafting, as well as slow move-
ments during the inflammation stage and more active 
after some months is not properly done. The usual 
limitation is observed at the level of the metartarso- 
phalangeal joints (in flexion) and the grip is impacted.
Contractures may variably limit the amplitude of 
movements, some of them being only observed during 
full movements, others imposing a severe stiffness and 
a blockade of any movement. Neck contractures may 
simply affect the extreme degrees of lateral movements 
or realize a vertical contracture (chin to thorax) impos-
ing strong difficulties to maintain the horizontal sight, a 
situation extremely difficult to live with.
Web contractures may limit multidirectional move-
ments on the neck or the shoulder, others will limit 
opening of orifices (mouth, nostrils, perineal areas) with 
concentric contractures, a cause of difficulties to feeding.
Contractures may vary along time. An early inflam-
mation is frequently observed in children or young adults 
after burns, lasting some months especially on mobile 
areas like the thorax and the upper limb. This situation 
may be transiently observed during the first 2 years and 
may disappear afterward. This period should be covered 
by adapted physiotherapy programs, aiming at an aug-
mented range of movements and a less red skin.
13.3   Contractures of the Neck
Neck skin is extremely mobile over the underlying struc-
tures. This mobility will be quickly limited in burns, due 
to a skin retraction linked to wound healing and par-
ticularly to the mechanical action of myofibroblasts, but 
also to the pain during movements inducing a voluntary 
restriction of movement during the healing stage. These 
combined factors induce a centripetal retraction and may 
lead to different situations, ranging from a single line of 
skin tension in the lateral movements (. Fig.  13.1) to 
severe vertical and horizontal loss of movements. The 
subcutaneous muscles, embedded in the scarring process, 
  . Fig. 13.1 Neck contracture persistent in spite of  several surgical 
procedures
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contribute to skin limitation. In severe situations the hor-
izontal sight may be impacted, bending permanently the 
neck and imposing a difficult surgery.
13.4   Axillar Contractures
Three different areas may be impacted by retractile scars, 
the anterior and posterior pillars, and the central axilla. 
Skin contractures may affect any one or the three of these 
areas, with different possible extensions on the anterior or 
posterior thorax. The shoulder is mobile anteriorly, pos-
teriorly, and laterally, needing a full skin mobility in all 
aspects of the region. A large range of functional deficits 
may be encountered in burns, with a good reactivity to early 
physiotherapy and specifically to range axilla orthotic, as 
demonstrated [3] (. Figs. 13.2, 13.3, and 13.4).
13.5   Hand Contractures
Burns usually affect the dorsal aspect of  the hand, with 
a centripetal retraction impairing the complete com-
bined flexion of  all digits together. The deficit in terms 
of  grip may be crucial; other situations may limit one 
or two digits in flexion. When the situation has become 
chronic, tendon shortening and bone deformities may 
be observed, imposing complex surgical procedures 
including bone shortening, joint arthrodesis, and ten-
don lengthening to restore function.
The dorsal aspects of the interdigital webs are 
frequently involved, with consequences on the sepa-
rate movements of each digit, a quadrige effect often 
observed in poorly managed deep burns.
The palmar aspect of the hand is less frequently 
touched but more frequent in children, but the very deep 
scarring tissues may sometimes reach more than 2  cm 
depth, inducing tendons blockade. Usually these severe 
scars embed totally the underlying structures, nerves, 
vessels, tendons, and muscles (. Fig. 13.5).
Persistent contractures observed in young adults 
having been submitted to burns that occurred during 
childhood, with retracted wrists and elbows or com-
pletely locked axillas, which sometimes require bone 
resection or amputation, are less observed now with the 
development and diffusion of NGO programs acting in 
underdeveloped countries.
  . Figs. 13.2 and 13.3 Postburn axillar contracture treated by an 
orthotic orlen realized at fashion
  . Fig. 13.4 Severe postburn neck contracture on a young female 





13.6   Other Anatomical Sites of Scar 
Contractures
Lower limbs may develop contractures at the level of 
hips (in flexion), knee, and foot (dorsal positioning of 
toes). These contractures are better managed by an 
adapted rehabilitation, completed by surgical proce-
dures if  needed.
13.7   Rehabilitation Programs
During the wound-healing stage, splinting of the burned 
hands, the neck, the axillar, and the lower limbs are 
needed to prevent contractures. Most of the burns cen-
ters benefit of a specific rehabilitation team included in 
the organization of the center. Passive movements dur-
ing the dressing change and positioning of joints into 
adapted customized splints in position of maximum 
extension capacity will efficiently limit the develop-
ment of contractures (. Fig. 13.6). Exercise is allowed 
as soon as the inflammatory period is under control, 
immobilization being the most anti-inflammatory agent.
After skin closure, active and passive movements will 
be encouraged but it is essential not to exert an exces-
sive mechanical tension on contractures, relayed and 
completed by the design of compressive garments, and 
mechanical compression of the involved areas. Specific 
rehabilitation centers for severely burned patients exist 
in some countries, proposing multiprograms to soften 
the scar, manipulate joints, and efficiently prevent the 
occurrence of the contractures using positioning, espe-
cially on the axillar region, the neck, and the hands 
(. Figs. 13.7 and 13.8).
Pruritus and the risk of stretching are prevented 
using hydration and drugs. Capsaicin and cooling 
are frequently used to limit pain and inflammation. 
These programs are long, painful, and psychologically 
demanding. A limited compliance of the patients may 
explain some of the poor results sometimes observed, 
but most of the patients get benefit of these treatments.
Once the inflammation stage is completed, more 
active compressive techniques like endermology, motor-
ized skin manipulations (LPG), stretching posture, high 
power jets, or other types of physiotherapy are pro-
posed, with good results at 2 years. More than 90% of 
the patients come back to a normal function if  the pro-
gram is done properly.
  . Fig. 13.6 Hand splint in complete digital flexion used for 
mechanical tension over the dorsal aspect
  . Fig. 13.7 Hand splint in complete digital extension used for 
mechanical tension on the palmar aspect. In case of  contracture 
touching both the aspects of  the hand, alternative positioning in flex-
ion during night and in extension during the day may be proposed
  . Fig. 13.5 Palmar contracture embedding the whole palmar area, 
creating a maximal web between the I and the IV. Surgery is needed
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Despite clear international recommendations [4] the 
studies on the modalities of application and the type of 
splints cover only a limited number of cases, therefore 
the evidence for these strategies is limited [5].
13.8   Surgical Strategies
Contracture release creates a large skin defect, and the 
aim of surgery is to restore as far as possible a full skin 
disponibility after surgery and to prevent recurrence.
13.9   Z Plasties
Z plasty is the most frequently used surgical technique 
[6]. Based on the principle of skin disponibility and 
softness of adjacent areas, the triangles designed by 
the Z-shape incisions break the linear scar contracture 
with a new scar without any mechanical tension. The 
cosmetic result is usually acceptable. Linear contrac-
tures are better managed using Z plasties, multiple Z 
plasties. Web contracture may be treated using W–Y 5 
plasties combing 2 Z plasties and an advancement flap, 
or omega plasties using the contracted skin but needing 
two small full skin grafts on the edges.
13.10   Skin Grafts
Skin grafts are by definition free skin transfers from 
one site to another without any vascular connection. 
Depending on their thickness, skin grafts form two dif-
ferent techniques, split-thickness skin grafts (STG) lim-
ited to epidermis and a thin layer of dermis, harvested 
using a dermatome and full-thickness skin grafts (FTG), 
which include the epidermis and the entire dermis; har-
vested with a scalpel and needing a defatting before 
application. The donor sites of STG heal by rapid re- 
epithelialization (like a superficial abrasion) while the 
donor site of FTG must be closed primarily for healing, 
so their use is limited to smaller defects. The main disad-
vantage of STG is the lack of dermal component, mean-
ing a risk of recurrence higher than when using a flap.
13.11   Dermal Substitutes
Since three decades the introduction of acellular dermal 
substitute has changed the profile of skin grafting. The 
dermal component brought by the use of collagen (and 
elastin) inside the dermal substitute limits the secondary 
retraction of the thin skin graft applied to cover it, even 
if  some shrinking is sometimes observed [7]. Different 
devices are proposed, with or without elastin, the col-
lagen coming from different animals like cows, sharks, 
or pigs with different combination with elastin, and with 
or without a protective film in silicone, depending if  the 
product is immediately covered by skin graft or sec-
ondarily after 3 weeks, the device being slowly incorpo-
rated in the new dermis before skin coverage. Hori et al. 
recently compared the contraction capacity, pores size, 
and shape of the different proposed devices [7] which 
may induce a secondary contraction.
13.12   Flaps
Large contractures have to be excised and replacement 
using different types of flaps.
Random skin flaps are frequently used [8], coming 
from the adjacent area when scar-free, but pedicled 
fasciocutaneous flaps bring a rich vascular network. 
Branches from this plexus reach the skin as direct or 
indirect perforators. They can be used locally or region-
ally, and rotated into the defect [9].
Perforator flaps, more recently developed, are based 
on a fine dissection of the perforator vessels going 
through the fascia to vascularize the overlying skin 
island. This increases the range of motion of these 
pedicled flaps and it reduces significantly the donor site 
morbidity.
Free flaps enlarge even further the armamentarium 
for tissue transfer. In principle, all axial flaps can be 
transferred as a free vascularized flap: the artery and 
the vein (eventually also the nerve) are transected at 
the donor site and re-anastomosed microsurgically 
with a recipient vessel at another part of the body. Till 
recently, free fasciocutaneous flaps and perforator flaps 
were most frequently used for coverage of contracture 
defects. Both can however result in significant donor site 
morbidity by harvesting structurally important fascia.
  . Fig. 13.8 Bilateral contracture of  the mouth web, combined 
with a red lip loss of  substance. Surgery using W–Y-5 plasties, plus 




13.13   Conclusion
In summary, contractures after burns are difficult to pre-
vent, some areas like axilla, neck, and upper limbs being 
predominantly affected. Early skin grafting may prevent 
contractures, but an adapted rehabilitation program 
should be established and redefined during the regular 
check-up done by the burns team. When constituted, 
a precise analysis of the lacking skin surface should be 
done by the surgical team, issuing to a covering program 
depending on the area involved and the expertise of the 
team. Function may efficiently be restored using dif-
ferent techniques, skin grafting and dermal substitutes 
being more adapted in term of volumes, flap providing 
a suppler skin.
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Take-Home Message
Contractures may form a severe functional deficit. 
Early prevention is mandatory, with a combination 
of  exercise and positioning to prevent skin retraction. 
In specific situations like the burned hand immobili-
zation can be done in both positions: flexion during 
the night and extension during the day. Treatment 
is difficult, and a balance should be sought between 
surgery, which always means a restart in the reha-
bilitation process, and the rehabilitation limits which 
should be established in close conjunction together 
with the team in charge. Recurrence is a risk if  the 
postoperative management is not properly realized.
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14.1   Background
Over the last decades, standardized measurements of 
medical treatment outcome have become increasingly 
important. First of all, application of evidence-based 
medicine requires that the research field evaluates the 
effectiveness of new and existing treatments. Therefore, 
no clinical trial can exist without the appropriate out-
come measurement instruments to determine the study 
outcomes in a reliable and valid way. These outcome 
measurement instruments are not only vital in the 
research setting but also indispensable in daily clinical 
practice to monitor scars in individual patients. 
Furthermore, standardized scar measurements are per-
formed and recorded in clinical registries with the aim to 
improve the quality of care and patient health outcomes.
Scar outcome measurement instruments can be 
either measurement devices or scar assessment scales. 
Measurement devices are often seen as objective instru-
ments that provide solid quantitative analyses of scar 
characteristics. However, measurement devices have to 
be purchased for sometimes high prices and can only be 
used at one place at a time. Another disadvantage may 
be that most devices are only able to evaluate one scar 
characteristic. In addition, cutting-edge measurement 
technologies often involve time-consuming measure-
ments and analyses that require training of the observer, 
which might be appropriate in research settings but is 
less suitable in clinical practice. Contrary to measure-
ment devices, scar assessment scales are qualitative eval-
uations of multiple scar characteristics provided by an 
individual, either the patient or the clinician/researcher. 
Scar assessment scales are sometimes criticized by their 
subjective nature. However, advantages of scar assess-
ment scales are their ability to provide fast evaluation of 
multiple scar characteristics, their (usually) free and easy 
accessibility, and their ability to capture the patient’s 
view on their scars. The latter is especially important as 
nowadays patients are receiving more information about 
treatment options and are getting more involved in mak-
ing treatment decisions and in reporting treatment out-
comes. In this chapter, an overview of the content and 
development of most frequently used scar assessment 
scales is provided.
14.2   Domains
Scars can influence patients in several health domains, 
ranging from appearance to quality of life. These differ-
ent domains require different levels of measurements. 
Measurements acquired with clinician-reported scales 
are limited to observable aspects of the scar, such as 
appearance, physical characteristics, and functional 
impairment of the scar. On the other hand, patient- 
reported scar scales allow for the evaluation of addi-
tional health domains that cannot be observed by 
clinicians, such as scar symptoms and quality of life.
14.3   Scar Assessment Scales
. Table 14.1 provides an overview of consecutive devel-
oped scar assessment scales, the constructs measured, 
and whether it is reported by the patient or clinician. 
. Table 14.2 shows which scar aspects are assessed in 
the most frequently used scales. The first concepts of 
scar assessment scales were reported in the late 1980s, 
but the first widely used, validated scar scale was devel-
oped in 1990 by Sullivan et  al., which became widely 
known as the Vancouver Scar Scale (VSS) [1]. The VSS 
consists of four items: vascularity, pigmentation, thick-
ness, and pliability. Since this first introduction to scar 
assessment scales, the development of many other scales 
followed. Various authors modified the original version 
of the VSS by adding extra items to the scale or altering 
the answering categories of the existing items [2–4]. This 
resulted in an abundance of modified VSS versions—of 
which the modified VSS by Baryza et  al. is the most 
widely used [2]. The Seattle, Hamilton, and Manchester 
scar scales were consecutively developed from 1997 to 
1998 [5–7]. The Seattle and Hamilton scales were both 
developed for photographic evaluation of scar [5, 6]. 
The Manchester scar scale introduced two new items: an 
“overall assessment,” rated on a VAS scale (0–10), and if  
the scar appeared matte or shiny [7]. Until 2000, the 
focus remained on the clinician/observer, as all  developed 
scales were clinician-reported, focusing on visual and 
physical scar characteristics. This changed when Nedelec 
et  al. added a symptomatic assessment (i.e., items of 
pain and itch) to the original VSS [3]. However, it was 
not until 2004 that in addition to symptoms such as pain 
and itch, the patient’s opinion on visual and physical 
scar characteristics was incorporated into a scar assess-
ment scale called the Patient and Observer Scar 
Assessment Scale (POSAS) [8]. The POSAS captures 
both the clinician’s (observer’s) and the patient’s per-
spective on multiple-characteristics scar quality. A few 
years after the introduction of the POSAS, Bock et al. 
made it possible to evaluate the quality of life of patients 
with keloid and hypertrophic scars by the development 
of the Bock Quality of Life Scale [9]. This was the first 
patient-reported scar scale measuring at the level of 
quality of life. Around the same time, the Stony Brooks 
Scar Evaluation Scale was introduced, which is a 
clinician- reported scar scale specifically designed for the 
assessment of surgical scars [10]. Therefore, it included 
an item to evaluate the presence of suture marks. The 
Patient Scar Assessment Questionnaire, Patient-Reported 
Impact of Scars Measure (PSAQ), and Brisbane Burn 
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  . Table 14.1 Overview of  consecutive developed scar assessment scales




Type of scars Construct
Vancouver Scar Scale 1990 X Burn Physical characteristics and appearance
Modified Vancouver Scar Scale 
by Baryza et al.
1995 X Burn Physical characteristics and appearance
Seattle Scar Scale 1997 X Burn Physical characteristics and appearance
Hamilton Scar Scale 1998 X Mix Physical characteristics and appearance
Manchester Scar Scale 1998 X Mix Physical characteristics and appearance
Modified Vancouver Scar Scale 
by Nedelec et al.
2000 (X) Burn Physical characteristics and appearance, 
scar sensation
Patient and Observer Scar 
Assessment Scale
2004 X X Mix Physical characteristics and appearance, 
scar sensation
Bock Quality of  Life 2006 X Hypertrophic/
keloid
Quality of  life
Stony Brooks Scar Evaluation 
Scale
2007 X Surgical Scar characteristics and appearance
Patient Scar Assessment 
Questionnaire
2009 X Surgical Scar characteristics and appearance, 
scar sensation
Consciousness (body image and 
confidence)
Patient-Reported Impact of 
Scars Measure
2010 X Surgical Scar sensation
Quality of  life
Brisbane Burn Scar Impact 
Profile
2016 X Burns Scar characteristics and appearance
Scar sensation
Quality of  life
Scar Cosmesis Assessment and 
Rating scale
2016 (X) Surgical Scar characteristics and appearance
Scar sensation
Scar Q 2018 X Mix Scar characteristics and appearance
Symptoms
Psychological problems
(X) = Clinician-reported scale in which the presence of  pain and itch is included
Scar Impact Profile (BSSIP) are more recently devel-
oped patient-reported scales which measure aspects of 
quality of life, in addition visual and physical scar char-
acteristics, symptoms, and/or satisfaction [11–13]. Most 
recently, the Scar Q was developed for the evaluation of 
physical characteristics, scar appearance, symptoms, 
and physiological problems [14].
14.4   Measurement Properties/Clinimetrics
To evaluate the quality of available scar assessment 
scales, several measurement properties must be consid-
ered, i.e. ,validity, reliability, and responsiveness [15]. 
The most important property is content validity. Content 
validity is the degree to which the content of a measure 
is an adequate reflection of the construct to be measured 
[15]. Good content validity means that all items included 
in the scale are relevant and no relevant items are miss-
ing for the construct of interest (within a specific popu-
lation and context of use). Furthermore, it means that 
patients should understand the content as intended. 
Lack of content validity can influence all other mea-
surement properties [16]. To ensure good content valid-
ity, it is important that well-designed scale development 
studies are performed that use qualitative methods to 
gain patient/professional input on the content of the 
scale. In addition, the draft scale must be pilot tested to 
ensure its content is relevant, comprehensive, and com-







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 M. E. Carrière et al.
131 14
these requirements were met for the included scar assess-
ment scales. Besides content validity, reliability is an 
important clinimetric property. Reliability refers to the 
extent to which scores for patients who have not changed 
are the same for repeated measurements [15]. Reliability 
and measurement error are related but distinct measure-
ment properties. Reliability refers to the ability of a 
measure to distinguish between patients, and measure-
ment error refers to the systematic and random error 
attributed to the measurement instrument [17]. The 
responsiveness is the ability of a scale to detect changes 
over time in the construct to be measured (e.g., scar 
quality) [15]. All measurement properties should be 
evaluated in the specific population in which it will be 
used. The context of use, referring to the application of 
use (i.e., discriminative, evaluative, or diagnostic appli-
cation) and to the setting (e.g., hospital or at home), 
should also be taken into account. Furthermore, the 
instrument must be practical and user-friendly in order 
to be easily applicable in clinical practice: an aspect 
which is defined as feasibility [18]. It is crucial to con-
sider the measurement properties, the context of use, 
and the feasibility when choosing a measurement instru-
ment. Measurements obtained by poor-quality or non- 
validated instruments are not trustworthy, and thus, 
studies that utilize these instruments yield unreliable 
results and invalid conclusions.
14.5   Conclusion
Scar assessment scales are useful tools to measure vari-
ous domains of scars. This chapter provides an overview 
of the most frequently used scar scales, including their 
content and development. It is of paramount impor-
tance to evaluate the clinimetric properties of an instru-
ment prior to using it for scar assessments for clinical or 
research purposes in order to prevent measurements 
obtained by poor-quality instruments.
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Patient 
interviews
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Pilot testing X X X X X
VSS Vancouver Scar Scale, POSAS Patient and Observer Scar Assessment Scale, SBSES Stony Brooks Scar Evaluation Scale, PSAQ 
Patient Scar Assessment Questionnaire, PRISM Patient-Reported Impact of Scars Measure, BBSIP Brisbane Burn Scar Impact Profile
Take-Home Messages
 5 Scar assessment scales are important to evaluate 
the effectiveness of scar treatments and to monitor 
patients over time.
 5 Traditional scar scales are clinician/researcher- 
reported, focusing on the appearance and physical 
characteristics of the scar, while more recently, devel-
oped scales are patient-reported scales which mea-
sure aspects of quality of life.
 5 (Content) Validity, reliability, and responsiveness 
are important measurement properties which must 
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15.1   Background
The Vancouver scar scale [1], the Manchester scar scale 
[2], and the Patient and Observer Scar Assessment Scale 
(POSAS) [3] are all very well-known scar evaluation 
methods. These tools are based on a number of scar 
variables, including color, height, and pliability. 
However, since all were mainly developed to evaluate 
burn scars, they are difficult to use in clinical practice for 
keloids and hypertrophic scars. This is because these 
pathological scars require both differential diagnosis 
and a way to evaluate their response to therapy. Since 
the Japan Scar Workshop (JSW) was established in 
2006, it has sought to develop a scar assessment scale 
that meets these clinical needs. The first version of this 
scar assessment tool was named the JSW scar scale 
(JSS), and it was reported in 2011 [4]. In 2015, the revised 
second version was reported (. Table  15.1 and 
. Figs. 15.1, 15.2, 15.3, 15.4, 15.5, 15.6, and 15.7) [5]. 
This chapter introduces the JSS and discusses its clinical 
importance and usefulness in scar research.
15.2   JSW Scar Scale (JSS) 2015
The JSS consists of two tables. One is a scar classifica-
tion table that is used to determine whether the scar is a 
normal mature scar, a hypertrophic scar, or a keloid. 
This grading system helps the user to select the most 
appropriate treatment method for the scar. The other 
table in the JSS is an evaluation table that is used to 
judge the response to treatment and for follow-up. Both 
tables contain sample images of each subjective keloid/
hypertrophic scar item that allow the user to evaluate 
each item without hesitation (. Figs.  15.1, 15.2, 15.3, 
15.4, 15.5, 15.6, and 15.7). Japanese guidelines for the 
prevention and treatment of keloids and hypertrophic 
scars [6] include JSS 2015.
15.3   Classification Table
The classification table consists of  two parts: risk fac-
tors and the present symptoms. The risk factors con-
sists of  six items, each of  which has 2–3 categories: (1) 
human race (African, Other, Caucasian), (2) whether 
there is a familial tendency (Clearly exists, Does not 
clearly exist), (3) the number of  scars (Multiple, 
Solitary), (4) the body region the scar is on (Anterior 
chest/scapular-shoulder/suprapubic, Other), (5) the age 
at onset (0–30, 31–60, ≥60 years), and (6) the cause(s) 
(Unknown/minute, Specific type of  wounding such as 
surgery). The present symptoms also consist of  six 
items, each of  which has 2–3 categories: (7) scar size 
(>20 cm2, <20 cm2), (8) whether there is vertical growth 
(Clearly exists, Does not clearly exist), (9) whether 
there is horizontal growth (Clearly exists, Does not 
clearly exist), (10) the shape of  the scar (Characteristic 
shape, Others), (11) whether there is erythema around 
the scar (Clearly exists, Does not clearly exist), and (12) 
whether there are subjective symptoms (Always exist, 
Intermittent, None). Thus, the classification table con-
sists of  12 items in total. The categories in each item are 
weighted: for example, in Human race, African, 
Caucasian, and Other races are weighted 2, 0, and 1 
points, respectively. The minimum and maximum num-
ber of  points in the classification table are 0 and 25, 
respectively. If  the classification score is 0–5, the scar is 
deemed to have mature scar characteristics. If  the score 
is 6–15 or 16–25, the scar is deemed to be a hypertro-
phic scar and a keloid, respectively.
This grading system is thus used to differentially 
diagnose keloid and hypertrophic scars. It is necessary 
to have this system because there are many cases in 
which the scar bears the growth and histological features 
of both hypertrophic scars and keloids; as a result, it can 
be difficult to differentially diagnose these scars in real 
clinical practice. This reality is not mirrored by the cur-
rent dogma about pathological scars. Thus, many classi-
cal textbooks consider keloids and hypertrophic scars to 
be completely different types of scar. Clinicians define 
hypertrophic scars as scars that do not grow beyond the 
boundaries of the original wound, whereas keloids are 
defined as scars that spread into the surrounding normal 
skin. Pathologists have their own definitions; they make 
a histological distinction between keloids and hypertro-
phic scars on the basis of thick eosinophilic (hyalinizing) 
collagen bundles called “keloidal collagen”: these are 
present in the former scar type but rarer in the latter. 
However, we have observed many cases that do not fit 
these dichotomic definitions. For example, scars with 
hypertrophic growth characteristics can bear consider-
able keloidal collagen. Indeed, it is possible that hyper-
trophic scars and keloids are manifestations of the same 
fibroproliferative skin disorder and just differ in the 
intensity and duration of inflammation. These inflam-
matory features may be shaped by genetic, systemic, and 
local risk factors [7].
15.4   Evaluation Table
The evaluation table consists of six items: (1) Induration, 
(2) Elevation, (3) Redness of the scar, (4) Erythema 
around the scar, (5) Spontaneous and pressing pain, and 
(6) Itch. Each item has four intensity categories, namely, 
None, Weak, Mild, and Strong. These categories are 
weighted 0, 1, 2, and 3, respectively. There are sample 
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  . Table 15.1 JSW Scar Scale (JSS) 2015 (Classification and Evaluation of  Keloids and Hypertrophic Scars)
Classification (for grading and selection of  appropriate treatment 
methods)
Evaluation (for judging treatment results and for 
following-up)
Risk factors 1. Induration
1. Human race Africans 2 0: None 1: Weak 2: Mild 3: Strong
Others 1
Caucasians 0 2. Elevation (. Fig. 15.5)
2. Familial tendency Clearly exists 1 0: None 1: Weak 2: Mild 3: Strong
Not clearly 0
3. Number Multiple 2 3. Redness of  scars (. Fig. 15.6)
Solitary 0 0: None 1: Weak 2: Mild 3: Strong
4. Region Anterior chest, scapular-shoulder, 
suprapubic
2
Others 0 4. Erythema around scars (. Fig. 15.7)
5. Age at onset 0–30 y/o 2 0: None 1: Weak 2: Mild 3: Strong
31–60 y/o 1
60 y/o 0 5. Spontaneous and pressing pain
6. Causes Unknown or minute 3 0: None 1: Weak 2: Mild 3: Strong
Specific wound type such as surgery 0
Present symptoms 6. Itch
7. Size (cm2) Over 20 cm2 1 0: None 1: Weak 2: Mild 3: Strong
Under 20 cm2 0
8. Vertical growth 
(elevation) (. Fig. 15.1)
Clearly exists 2 Total 0–18
Not clearly 0 Remarks
9. Horizontal growth 
(. Fig. 15.2)
Clearly exists 3 Weak: symptoms exist in less than 1/3 of  the area, or are 
intermittently
Not clearly 0 Strong: symptoms exist in the entire region, or are 
continuous
10. Shape (. Fig. 15.3) Characteristic shape 3 Mild: between weak and strong
Others 0











0–5 Character like matured scars (intractability, 
low risk)
6–1 Character like hypertrophic scars 
(intractability, middle risk)
16–25 Character like keloids (intractability, high risk)
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images of each category in each item that helps the user 
judge the items. The minimum and maximum total 
points in the evaluation table are thus 0 and 18, respec-
tively. When the symptoms improve, the total score 
decreases.
15.5   Clinical Suitability and Usefulness 
of the JSS
We evaluated the clinical suitability of the classification 
table of JSS2015 with 50 consecutive scar patients in our 
clinic. The scores of the patients were evenly distributed 
between 0 and 25 points (. Fig. 15.8). This distribution 
closely reflects our subjective experiences in our scar 
clinic and those of other Japanese plastic surgeons. As a 
result, the JSS became a standard classification and 
evaluation tool for keloid and hypertrophic scars in 
Japan. The JSS has since been used to evaluate scar 
severity in several clinical research projects [8–10]. It was 
also used in a study in Taiwan [9]. However, in our expe-
rience, different regions of the world vary in terms of the 
severity of keloids and hypertrophic scars: in particular, 
keloids appear to be singularly severe in Africa and 
East-South Asia, while being rare in western countries. 
Therefore, in the future, the JSS2015 should be modified 
to cover other regions of the world.
15.6   Conclusion
The Japan Scar Workshop (JSW) developed the JSW scar 
scale (JSS) to evaluate keloids and hypertrophic scars. 
The JSS consists of two tables; one is a scar classification 
table that is used to determine whether the scar is a nor-
mal mature scar, a hypertrophic scar, or a keloid, and the 
other table is an evaluation table that is used to judge the 
response to treatment and for follow-up. The JSS became 
a standard classification and evaluation tool for keloid 
and hypertrophic scars in Japan. In the future, the JSS5 
should be modified to cover other regions of the world.
Clearly exists
Not clear
  . Fig. 15.1 Vertical growth (elevation)
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Clearly exists Not clear
  . Fig. 15.2 Horizontal growth
Characteristic shape Others
  . Fig. 15.3 Shape





  . Fig. 15.5 Elevation
Clearly present Not present





  . Fig. 15.6 Redness of  scars
WeakMildStrong None
  . Fig. 15.7 Erythema around scars




 5 The Vancouver scar scale, the Manchester scar 
scale, and the Patient and Observer Scar Assessment 
Scale (POSAS) were mainly developed to evaluate 
burn scars.
 5 The Japan Scar Workshop (JSW) developed the 
JSW scar scale (JSS) to evaluate keloids and hyper-
trophic scars.
 5 The JSS consists of two tables; one is a scar clas-
sification table that is used to determine whether the 
scar is a normal mature scar, a hypertrophic scar, or 
a keloid, and the other table is an evaluation table 
that is used to judge the response to treatment and 
for follow-up.
 5 The JSS contains sample images of each subjective 
keloid/hypertrophic scar item that allow the user to 
evaluate each item without hesitation.
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16.1   Background
Comprehensive scar treatment is becoming more and 
more readily available. Both the awareness of medical 
professionals regarding the impairments of severely 
scarred patients and their knowledge of treatment 
options for scars have increased significantly during 
recent years. Those developments have been made pos-
sible by extensive research of new treatment options and 
continued reevaluation of long-established ones.
However, large numbers of studies continue to rely 
predominantly on subjective evaluation methods like 
scales and questionnaires to gauge the success of their 
treatment. Objective scar evaluation technology, too, 
has shown an immense development throughout recent 
years, and researchers and clinicians alike can now 
choose from a large arsenal of options to document 
treatment progress and failure [1].
But while this newfound selection of tools for objec-
tive scar analysis has helped to improve research, it has 
also introduced new problems.
With many different manufacturers offering many dif-
ferent devices for analysis of a vast number of parameters, 
researchers are left with the dilemma to choose the right 
tools for their individual projects with little evidence- based 
recommendations available. Oftentimes, devices will not 
be able to measure in standardized units but will provide 
measurement results in the manufacturer’s own propri-
etary format that offers little comparability with results 
from different research groups with different measurement 
tools. The process of measuring the desired parameters 
reliably in the oftentimes hectic environment of everyday 
clinical routine can be daunting too and can lead to prob-
lems with recreating measurements and making sure that 
repeated measurements yield comprehensible results.
In this chapter, we want to focus on the basics of 
objective measurement technologies that allow research-
ers and clinicians to find the right tools for their desired 
analyses, to make comprehensive plans about how to 
document their patients’ scars in a way that can both 
easily and reliably be reproduced, and to understand the 
value and impact of the results of their measurements.
Obtaining and cultivating this knowledge can then 
not only lead to improving the level of evidence in scar 
research but also help in everyday clinical treatment sce-
narios where in-depth scar analysis might provide physi-
cians with a sensitive gauge for the success or failure of 
their applied treatment.
16.2   Choosing the Right Tools for Each Scar
Before planning a research project or the documenta-
tion of clinical results in scar therapy based on objective 
assessment technology, care must be taken to identify 
the tools best suited for each specific undertaking. Since 
scar documentation as well as the consecutive sort-
ing, assessment, and evaluation of data is considerably 
time- consuming, superfluous measurements should be 
avoided.
The first step is identifying the scar parameters that 
require documentation and afterward choosing the 
tools suitable to assess the development of the chosen 
parameters. When trying to assess the influence of a cer-
tain treatment option on scars, parameters most likely 
affected positively or negatively (e.g., side effects) should 
be selected.
When choosing the most suitable assessment technol-
ogy, a thorough literature research should be performed 
to identify assessment options that have been well estab-
lished and are used by other researchers as well to ensure 
both the suitability for the task and, later, comparability 
of the results between different research groups.
Ideally, comparability does not require different 
researchers to use identical hardware but rather that dif-
ferent hardware uses the same units of measurement. 
While this is common in ultrasound technology where 
most, if  not all, units are able to perform measurements 
based on SI units, more specialized tools for profilom-
etry or colorimetry specifically designed for application 
in aesthetic medicine often employ proprietary units of 
measurement that are difficult to compare with other 
researches.
While this does not necessarily mean those options 
are unsuited for research applications, it should be taken 
into consideration beforehand.
16.3   Optimizing the Measurement Process
16.3.1   Preparing the Surroundings
The room where measurements are conducted should 
be light, cool, and dry. Illumination through natural 
light should be minimized so that it does not influence 
photographic and colorimetric testing where changing 
outside lighting could act as a disruptive factor. The 
ambient temperature should neither be too warm or 
too cool since physiological reactions to extreme tem-
perature (e.g., sweating, goose bumps) can influence 
measurements, especially regarding physiological skin 
parameters. Furthermore, extreme temperatures, just 
like humidity, could also influence the functionality 
and longevity of the measurement instruments. Some 
manufacturers even provide ambient condition sensors 
to monitor parameters like temperature or humidity and 
save the values together with the measured results. This 
can guarantee both superior awareness of the lab ambi-
ence as well as improve comparability of the achieved 
measurement results.
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16.3.2   Configuring and Calibrating 
the Assessment Tools
Reliable measurements are paramount in every clinical 
and/or research setting. This starts with making sure 
that the assessment instruments are properly cared for 
and calibrated.
Most devices come with extensive instructions on 
how to calibrate them, and adhering to those recom-
mendations is important since even small discrepan-
cies in the measurement process can yield significantly 
altered results, especially with modern, highly sensitive 
equipment.
Instruments that have direct contact with the skin, 
for example, devices that measure skin elasticity, color, 
or physiological properties, should be cleaned regularly 
as sebum, hairs, and makeup can accumulate on the 
measuring probes and alter measurements as well as 
hinder successful calibration.
Photography-based systems require regular cleaning 
too, so that there are no specks on the lens or projector 
systems (e.g., PRIMOS system).
Most devices allow for a variety of parameters to 
be configured that can greatly influence how the mea-
surements are conducted and what the results are going 
to be. Those parameters need to be defined before-
hand and require standardization so that subsequent 
measurements can be compared. Photography-based 
devices that use different exposure times or white bal-
ances during measurements will result in significantly 
different looking images, skin elasticity values will dif-
fer greatly when on and off  times of the suction probes 
of the Cutometer are changed, and the same is true for 
many other devices, too. Especially when more than one 
researcher is working with a certain device, care should 
be taken to check all the relevant parameters before 
measurements are performed.
16.3.3   Preparing the Patient
The areas to be measured should be clean and free of 
makeup, skin-care products, or therapeutic agents (like 
ointments, gels, silicon sheets).
Throughout the measurement process, patients 
should remain in a neutral, predefined position so as 
not to alter certain measurement results due to their 
pose. Especially during measurements regarding skin 
texture and relief  or elasticity, identical positioning for 
subsequent measurements is crucial in ensuring com-
parability of the results. Scars that run close to or over 
joints are greatly affected when those joints are moved, 
and elasticity results, for example, might reveal drasti-
cally different results when said joints are fully flexed 
or extended. It can therefore help when the positioning 
of the patient is predefined (e.g., patient standing, arms 
hanging loosely on his sides) and said positioning is kept 
throughout all measurements (. Fig. 16.1).
16.3.4   Performing the Measurements
After all the preparations have been made, calibrations 
have been performed, and configurations have been 
checked, the measurements are performed. Here, it is 
important to ensure subsequent measurements are per-
formed similarly. Camera-based systems often provide 
integrated overlay functions that allow the examiner to 
achieve identical captures during successive assessments, 
and some devices offer integrated software solutions to 
stack subsequently taken images to only measure the 
common areas; however sometimes, such solutions are 
not offered. It can therefore help to define anatomical 
landmarks for orientation and to fashion templates so 
that positioning of the measuring probe or the camera 
system remains constant [2].
a b c
  . Fig. 16.1 Canfield Vectra X3 imaging before a, 3 months after 
b, and 6 months after c one session of  fractional ablative laser treat-
ment of  the upper right chest. The patient had been instructed to 
maintain a standardized pose (standing upright, arms hanging 
loosely by his sides, facing forward) to ensure comparability between 
subsequent images
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Devices that measure skin elasticity or color often rely 
on small probes with relatively small openings through 
which the individual parameters are measured. This often 
proves challenging for the examiner since exact reposition-
ing for a subsequent measurement often is difficult if not 
impossible. Furthermore, especially in widespread scar-
ring, getting representative results from only one measure-
ment is virtually impossible, especially if one cannot ensure 
that measurements are always taken at the same spot.
These problems, unfortunately, cannot be addressed 
satisfactorily with devices that are not able to measure 
the entire scarred surface, and therefore, a compromise 
that will allow for as great an approximation as possible 
is necessary. Using an increased number of measuring 
points in a randomized fashion is a method that has been 
used in current research, thus ensuring that extreme val-
ues do not dramatically alter the overall measurements 
and including more parts of the oftentimes inhomoge-
neous scar surface into the measurement [3]. There is, 
however, no consensus on how many measurements are 
necessary to adequately represent the results of a larger 
area. In their research, the authors have commonly used 
three measurements for an area of 10 cm by 10 cm when 
measuring skin elasticity or other parameters that rely 
on assessment through small probes (. Fig. 16.2).
16.4   Interpreting Therapeutic Success 
with Objective Scar Assessment 
Technologies
16.4.1   Data Assessment and Evaluation
After the measurements, the resultant data needs to 
be sorted and analyzed. To present the most objective 
results possible, it is necessary to use the raw abso-
lute data for further analyses. Only including relative 
changes makes it hard for outside observers to interpret 
the importance of the findings when absolute baseline 
values are not known. Furthermore, the level of mea-
surement that is required for certain statistical tests is 
not sufficient when using relative data.
Then, tests can be performed to elucidate the statisti-
cal significance of the findings.
16.4.2   Clinically Important Difference
After performing statistical testing, one must consider 
whether the results of the measurements constitute a 
clinically important difference. Currently, there are no 
clear recommendations on what constitutes a clinically 
important difference in objective scar assessment in the 
literature. However, ideally, every modern study on scar 
treatment and its effects can include its own control to 
evaluate whether the results are clinically important.
After all, scar treatment should alleviate the patients’ 
symptoms, improve functional impairments, and 
address aesthetic disfigurements. Therefore, patient- 
derived questionnaires like the POSAS Patient Scale 
or the Dermatology Life Quality Index (DLQI) can be 
included in the research as a control for patient satisfac-
tion [4]. Should those questionnaires show statistically 
significant improvements, just like the objective assess-
ment tools, then a clinically important difference has 
been achieved. While the lack of statistically significant 
results does not necessarily rule out a clinically impor-
tant difference, it is important to consider just how sen-
sitive modern assessment tools have become. Surface 
profilometry can measure changes at the micrometer 
scale, and other technologies boast similar sensitivities. 
But even if  changes can be documented on such a fine 
scale, statistical significance of such results does not 
help the patients if  they do not register improvements 
regarding their impairments.
Therefore, defining an absolute clinically impor-
tant difference for objective scar assessment is neither 
possible nor sensible. The importance of documented 
improvements should always be compared to the 
patients’ assessment of the therapeutic results to gauge 
the overall success.
16.5   Conclusion
Objective scar assessment has come a long way during the 
recent years. Today, a multitude of options for the docu-
mentation of scar treatment is available. From this variety 
of options, researchers and clinicians have to choose the 
tools best suited for their individual analysis based on the 
scar parameters that require documentation and the indi-
vidual devices’ features. Care should be taken to choose 
  . Fig. 16.2 Severe burn scars on the abdomen of  a female patient. 
Note the marked squares where one has been defined as the treat-
ment and the other as the control area. By using a foil template 
and anatomical landmarks, those areas can be retraced for follow-
up measurements which are always conducted within the marked 
squares to avoid confounding of  the results. This course of  action 
ensures that surface profilometry and skin elasticity measurements 
are always performed on the same area
 J. Poetschke and G. G. Gauglitz
147 16
assessment technology that does not rely on proprietary 
assessment and evaluation formats but that is able to 
export results in standardized units of measurement so 
that comparability with other research groups and studies 
is ensured. Measurements should be performed in a stan-
dardized environment with well- maintained and well-cal-
ibrated tools, and conditions as well as patient positioning 
should not differ between measurements.
Objective scar assessment relies on using the most 
accurate values to represent the results which is why 
absolute values should always be preferred to relative 
values. Not only does this ensure comparability of the 
results, it allows for more complex statistical testing, 
thus ensuring improved significance of the findings.
A clinically important difference, however, cannot be 
derived from statistically significant findings alone. Here, 
the patient’s perspective should be taken into consider-
ation. As modern technology is now able to document 
extremely subtle changes, clinically important differ-
ences, despite significant statistical changes, can only be 
asserted if  the patient considers them significant. This 
further illustrates that neither subjective nor objective 
scar assessment means alone should be employed. Both 
clinical and research protocols should include both to 
profit from additional information and to further char-
acterize their findings.
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Take-Home Messages
 5 Choosing the right objective scar assessment tools 
is paramount and should be based on the scar 
parameters that are central to the research.
 5 Devices that work with standardized units of mea-
surement should be preferred to those that work 
with proprietary units or formats.
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 5 Maintaining a standardized environment for the 
measurements both regarding the instruments 
(regular cleaning and calibration are required; the 
proper configuration should be checked before 
measurements are performed) and the patients 
(standardized posture, identical location for the 
measurements) is crucial.
 5 Absolute values should be preferred to relative val-
ues to improve the informative value and the statis-
tical significance of the findings.
 5 The clinically important difference in objective scar 
assessment is rather a correlation between objec-
tive findings and subjective patient satisfaction, 
than a certain amount of improvement according 
to technical measurements. Modern assessment 
technology is oftentimes so sensitive that statisti-
cal testing reveals significant improvements before 
patients notice them.
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17.1   Clinimetrics
The discipline of “clinimetrics” (i.e., measurement in 
medicine) aims to improve the quality of measurements 
by assessment of the properties of existing tools or by 
development of new tools. Before implementation of a 
new measurement tool in either clinical practice or in 
research can be considered, two essential properties 
need to be evaluated: reliability and validity. All mea-
surement tools are required to produce reliable and valid 
scores. 
The general definition of reliability is “the degree to 
which the measurement is free from measurement error” 
[1, 2]. In addition, there is an extended definition of reli-
ability: “the extent to which scores for patients who have 
not changed are the same for repeated measurements 
under several conditions,” which makes clear that 
repeated measurements are a key point. The variation 
that may arise between repeated measurements decreases 
the reliability. This can be attributed either to the mea-
surement tool, the persons performing the measurement, 
the patients undergoing the measurement, or the circum-
stances under which the measurements are performed. 
The measurement error comprises both the systematic 
and random error of a patient’s score that cannot be 
attributed to true changes in the scar. So, parameters of 
measurement error are relevant for the measurements of 
changes in scar status. Moreover, these parameters are 
of great value for clinicians as they are expressed in the 
units of measurement, which facilitates interpretation. 
Finally, to determine whether changes are clinically rel-
evant, the minimally important change (MIC) can be 
calculated, which is defined as “the smallest change in 
score which patients, clinicians or relevant others per-
ceive as important” [2, 3]. To monitor the scar of an indi-
vidual patient, it is of paramount importance that the 
MIC is smaller than the measurement error of the tool.
Validity is defined as “the degree to which an instru-
ment truly measures what it purports to measure” [1]. 
Validity can be divided into three types: content validity, 
construct validity, and criterion validity. Content valid-
ity focuses on the correspondence of the content of the 
measurement tool with the construct that is intended to 
measure. Content validity is assessed qualitatively 
 during development by pretesting, expert opinion, and 
literature review. Construct validity is applicable in situ-
Background
Several types of problematic scars can be identified: 
hypertrophic scars, keloids, contractures, and adherent 
scars (. Fig.  17.1). All these scars require specialized 
treatment. However, the need for innovation and novel 
treatment is paramount to further reduce the burden of 
these scars and to ultimately attain scarless healing. 
Critical to the development of novel treatment modalities 
are objective assessment tools that evaluate whether scar 
treatment is effective and successful. Secondly, assessment 
tools can be used to monitor the scar’s response to 
interventions. One important aspect to take into account 
when using tools in clinical practice is to ascertain that the 
chosen tool is “clinimetrically approved.”
  . Fig. 17.1 Several types of  pathological scars. a Hypertrophic 
scar on the right upper arm, b keloids on the right scapula and 
shoulder, c contracture of  the right axilla, and d widespread 
adherent scarring on a patient’s back and spine. (Reproduced 
with permission from ‘Beyond the skin, new insights in burn 
care’” by M.  E. H.  Jaspers, 2017. ISBN: 978-94-6233-852-4. 
© All rights reserved)
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ations in which there is no gold standard, and therefore 
this type of validity refers to whether the measurement 
tool provides the expected scores, based on knowledge 
about the construct. Criterion validity focuses on the 
correspondence of the (new) measurement tool with the 
gold standard (i.e., criterion). In theory, the gold stan-
dard is a perfectly valid assessment, but this rarely exists 
in practice. Also in scar care, it is challenging to identify 
a suitable criterion. In light of this chapter and of using 
tools in the future, it is important to take this into 
account and to be aware of the reliability and validity of 
the gold standard or comparator instrument itself.
Over the years, the number of available tools has 
increased rapidly. However, it is important to realize that 
not every scar parameter can be assessed and that the 
use of technologies and corresponding terminology is 
not standardized yet. Hereby, an overview is provided 
for three important physical scar parameters that can be 
assessed by (noninvasive) objective tools: color, elastic-
ity, and perfusion.
17.2   Color
17.2.1  Erythema and Pigmentation
When looking at hypertrophic scars, one could ask the 
question: Which feature makes these scars so obvious 
and therefore problematic? Besides increased thickness 
or an irregular surface, the amount of erythema and 
pigmentation appear to have a major impact on the 
judgment of scar quality by both clinicians and patients. 
Moreover, the assessment of erythema could be impera-
tive to predict the end of the remodeling phase [4]. 
Therefore, color measurements are an essential part of 
scar evaluation, and the associated measurement out-
comes are common parameters in scar research.
It is beyond the scope of this chapter to state the 
underlying causes of the formation of erythema and 
pigmentation. However, it is important to realize how 
these aberrant scar features are constituted, to conse-
quentially assess them in the right way. Moreover, it is 
underlined that the terminology regarding color mea-
surements is not standardized yet. In clinical practice 
and in research, the measurement outcomes blood flow, 
scar color, erythema, and redness are used interchange-
ably or often replaced by the umbrella term “vascular-
ization,” which is not appropriate [5].
For the purpose of clarity, it is beneficial to provide a 
detailed description of every feature when assessed by a 
certain tool. Erythema is a complex characteristic that 
may be defined as the level of oxygenated hemoglobin 
measured at 660 nm, which shows to have a correlation 
with subjectively assessed redness [5]. Furthermore, scar 
color is also constituted by the amount of pigmentation, 
expressed by the outcome measurement melanin.
17.2.2   Reflectance Spectroscopy
Reflectance spectroscopy has been in use for over 
60 years to assess skin color. At present, many afford-
able handheld devices are available that can easily be 
used in daily clinical settings. The most commonly used 
principles for measuring scar color are tristimulus reflec-
tance colorimetry and narrow-band reflectance spectro-
photometry. Both principles determine color by 
measuring the intensity of reflected light of specific 
wavelengths. The main chromophores in human scar tis-
sue, hemoglobin and melanin, are primary determinants 
of the color. It has to be taken into account that these 
chromophores can be measured separately, but may 
influence each other. It is suggested that a scar with high 
hemoglobin values can mask the amount of melanin 
and vice versa.
17.2.2.1   Tristimulus Colorimetry
Tools based on the principle of tristimulus reflectance 
colorimetry are the Chroma Meter CR-400 (Konica 
Minolta Sensing Inc., Osaka, Japan) and the Skin- 
Colorimeter CL 400 (Courage and Khazaka electronic 
GmbH, Köln, Germany). This principle was developed 
to objectively represent color in a manner analogous to 
how color is perceived by the human eye. As well as with 
narrow-band spectrophotometry, white light is sent to 
the skin by LEDs in a probe. Light is scattered in all 
directions whereas the light reflected from the skin or 
scar is measured through three particular wavelength fil-
ters and expressed accordingly. This technique expresses 
XYZ-values, which can be calculated into RGB (red/
green/blue) values or the related three L∗a∗b compo-
nents: L∗ (brightness), a∗ (amount of red-green), and 
b∗ (amount of yellow-blue) [6, 7]. These components 
are based on the color system of the Commission 
International d’Eclairage (CIE) Lab system.
Concerning the clinimetric properties, the parameter 
LAB2 by the Colorimeter shows and ICC of 0.95 for the 
interrater reliability [6]. The Chroma Meter was first 
investigated on healthy skin, showing ICC values >0.92 
for all parameters (L∗, a∗, and b∗) during measurements 
by two observers, thereby reporting the interrater reli-
ability [8]. The latter study also reports standard error of 
measurement (SEM) values, which are between 0.38 and 
0.59 and thereby low. In addition, a preceding type of 
the Chroma Meter (CR-221) was evaluated on scar tis-
sue and shows ICC values >0.73 for a single measure-
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ment by one observer (test–retest) and ICC values >0.91 
when the measurements of four observers are averaged 
[9]. In this study, SEM values are between 1.26 and 4.33, 
which is rather high.
17.2.2.2   Narrow-Band Spectrophotometry
Narrow-band tools are based on the fact that hemoglo-
bin and melanin show different spectral curves for the 
absorption of light. The tools offer read-out of ery-
thema and melanin values as well as CIE L∗a∗b values. 
The erythema and melanin index values are based on the 
differences in light absorption of red and green by 
hemoglobin and melanocytes, respectively. The ery-
thema index is defined as: E = 100 ×  log (intensity of 
reflected red light/intensity of reflected green light) and 
the melanin index can be defined as: M = 100 × log (1/
intensity of reflected red light). It has to be taken into 
account that the index values can be measured sepa-
rately, but may influence each other.
In the DSM III ColorMeter (Cortex Technology, 
Hadsund, Denmark) this is achieved by two light- 
emitting diodes (LEDs) (green 568 nm and red 655 nm) 
that illuminate a surface and record the intensity of 
reflected light using a photodetector. The Mexameter 
MX 18 (Courage and Khazaka electronic GmbH, Köln, 
Germany) uses 16 light-emitting diodes that emit light at 
three wavelengths (green: 568 nm; red 660 nm; infrared 
880 nm), where after the reflected light is measured by a 
receiver unit. Erythema is measured by the green and 
red wavelengths, whereas melanin is determined by the 
red and infrared wavelengths. Readings are expressed 
between 0 and 1000, corresponding to white and black 
respectively.
Both tools are examined in several clinical studies 
and provide reliable data on scars [10]. The most com-
mon reliability parameter examined is the intraclass cor-
relation coefficient (ICC) for ratings performed by 
several observers (i.e., interrater reliability). Erythema 
measured by the Mexameter shows an ICC between 0.82 
and 0.97 and for the DSM II ColorMeter an ICC of 
0.84 is reported [6, 11]. In addition, the DSM II 
ColorMeter also offers read-out of CIE L∗a∗b values, 
which will be described in the next paragraph. 
Investigation of the parameter a∗ by the DSM II 
ColorMeter shows an ICC of 0.94 [6]. Unfortunately, 
information on parameters concerning the measure-
ment error of these color tools is lacking. Furthermore, 
attempts are made to assort the most valid parameter of 
each tool [6]. However, as previously mentioned, it is 
often difficult to appoint an adequate comparator 
instrument that exactly measures the same feature (i.e., 
construct) of a scar as the tool under study. This is 
underscored by the poor correlations reported between 
color-measuring tools and scar assessment scales [10, 
12]. Overall, the correlation between erythema assessed 
by a tool and redness assessed by a scar assessment scale 
is between 0.4 and 0.7 [5, 11, 12].
Ultimately, the DermaLab Combo (Cortex 
Technology, Hadsund, Denmark) will be mentioned 
here. This device offers a combination of measurement 
possibilities. The color probe uses the principle of reflec-
tance spectrometry to measure scar color and all above-
mentioned parameters can be reproduced: erythema, 
melanin, L∗, a∗, and b∗. As previously stated, the param-
eters erythema and a∗ can be used to indicate scar ery-
thema. A weak to moderate correlation is found between 
erythema values and redness scored by a subjective tool 
and in terms of reliability, the ICC varies between 0.66 
and 0.84 for measurements by two observers, whereas the 
test–retest reliability is even lower: 0.29–0.42 [13, 14].
Several studies show that erythema index scores 
decline over time [15, 16] and all clinical studies report 
that distinction between scar tissue and healthy skin can 
be made with color-measuring tools. Therefore, it is 
stated that objective color measurements appear reliable 
to determine change over time in a (heterogeneous) 
study population, which merits their scientific use. 
However, for the clinical follow up of an individual 
patient, SEM values need to be very low. Moreover, con-
cerning the validity, it is challenging to define the exact 
measured construct, which is becoming even more com-
plex given that the tools can reflect various parameters. 
This has to be taken into account when a color-measur-
ing tool is selected to monitor the scar’s response to 
interventions.
From a practical point of view, it is important to 
notice that pressure on the scars will change the color 
toward the white spectrum. Therefore, users are required 
to lightly put a color-measuring tool on the scar to 
reduce the influence of pressure. Another limitation, 
which also accounts for elasticity-measuring tools, is the 
small size of the probe’s measurement area. To compre-
hensively present the color or elasticity of a scar as a 
whole, the proposed solution is to work with a pre-
defined algorithm, covering several measurement areas 
within the borders of one scar. For example, by drawing 
an imaginary line through the horizontal and vertical 
axis of the scar, resulting in five measurement points: 
one on the intersection of both lines and four halfway 
the intersection and the border of the scar. In this way, 
also selection bias by the observer is avoided.
17.2.3   Spectrophotometric Analysis (SIA)
To provide information on color outside the visible spec-
trum, relating to deeper structures of the scar, infrared 
light can be used. Spectrophotometric intracutaneous 
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analysis (SIA) can be performed via a clinical device, the 
SIAscope, which utilizes a probe that exerts radiation 
ranging from 400 to 1000 nm and produces 8 narrow- 
band spectrally filtered images of the skin. These images 
are processed by software algorithms and allow subse-
quently visualization and quantification of blood, col-
lagen, and melanin. It already has been used to monitor 
changes in scar tissue in response to treatment [17].
17.3   Elasticity
The second physical parameter that causes poor func-
tional scar quality is a loss of elasticity, which is due to 
increased collagen synthesis and lack of elastin in the 
dermal layer. However, as will be emphasized in this 
paragraph, certain tools quantify the opposite of elas-
ticity, which is tissue hardness.
17.3.1   Cutometer
The Cutometer MPA-580 is designed to measure elastic-
ity (i.e., elevation) of the upper skin or scar layer using a 
predefined negative pressure setting, which mechani-
cally deforms the skin. Negative pressure (i.e., vacuum) 
is instantly created in the device where after the skin is 
drawn into the aperture of the probe (. Fig.  17.2). 
Subsequently, after a defined time, the skin is released. 
Inside the probe, the vertical deformation of the skin is 
determined by a noncontact optical measuring system. 
This optical measuring system consists of a light source 
and a light receptor and two prisms facing each other 
that project the light from transmitter to receptor. The 
light intensity varies due to the penetration depth of the 
skin. The resistance of the skin to the negative pressure 
(rigidity) and its ability to return to its original position 
(elasticity) are displayed as curves (penetration depth in 
mm/time) in real time during the measurement. This 
measurement principle allows data collection on the 
elastic and mechanical properties of skin or scar surface 
and enables objective quantification.
The Cutometer is a feasible device containing a 
probe, which is available in several aperture sizes (2, 4, 
6 and 8 mm Ø) to fit different skin sites and different 
study requirements (. Fig.  17.2). The smaller aper-
tures mainly measure the elastic properties of  the epi-
dermis. With a larger aperture (6 and 8  mm), the 
measurement also comprises the dermal component, 
which is designated for scar assessment. As with the 
color-measuring tools, it is important to ensure light 
contact is made between the scar and the probe to 
avoid alterations in outcome measure. Measurements 
can be monitored as live curves on the screen of  a con-
nected laptop. The software of  the Cutometer MPA 
580 allows calculation of  many parameters of  interest 
from the different portions of  the measurement curve. 
The two most relevant parameters are labelled as R 
and U (. Figs. 17.3 and 17.4).
R-Parameters:
 5 R0: Behavior of the skin/scar to force (rigidity), 
maximum amplitude of the curve in mm
 5 R1/R4: Ability of the skin/scar to return to its 
original state, minimum amplitude after relaxation
 5 R2: Viscoelasticity: Resistance to mechanical force 
versus ability of returning in %
 5 R3/R9: Tiring effect (fatigue) visible with repeated 
suction/relaxation
 5 R5: Net elasticity: Elastic portion of the suction part 





  . Fig. 17.2 Left: measuring principle of  the Cutometer. Right: different aperture sizes of  the probes. Reused with permission from Courage 
+ Khazaka electronic GmbH. © All rights reserved
Objective Assessment Tools: Physical Parameters in Scar Assessment
154
17
 5 R6: Portion of the viscoelasticity of the curve in %
 5 R7: Portion of the elasticity compared to the com-
plete curve in %
 5 R8: Complete relaxation after the pressure is 
removed in mm
U-Parameters:
 5 Uf (maximal skin extension): Deformation at the 
end of the vacuum period
 5 Ue (elasticity): Extent of skin stretching within the 
first 0.1 s of the vacuum period
 5 Ua (pliability): Difference between the maximum 
deformation and the deformation after 1 s of normal 
pressure
 5 Ur (retraction): Relaxation of the skin within the 
first 0.1 s after the ending of the vacuum, that is, the 
ability of the skin to return to its initial position after 
deformation and is related to the function of elastic 
fibers
 5 Uv (viscoelasticity): Difference between the defor-
mation after the 0.1  s and the maximal deforma-
tion
The different parameters and their terms (i.e., elasticity, 
skin extension, pliability, retraction, and viscoelasticity) 
suggest that each parameter measures a different aspect 
of skin or scar deformation. However, the parameters 








R1 = Uf - Ua
R1 = Uf - Ua
R2 = Ua/Uf
R3 = last max. amplitude






R9 = R3 - R0
F0 = surface A






















  . Fig. 17.3 The R-parameters 
of  the Cutometer. Reused with 
permission from Courage + 
Khazaka electronic GmbH.  














  . Fig. 17.4 The U-parameters 
of  the Cutometer 
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gle parameter is sufficient to use in the evaluation of 
scar elasticity (see below) [18].
17.3.1.1   Clinimetric Properties
The reliability of a single measurement performed by a 
single observer is good for extensibility (Uf) and elasticity 
(Ue) and ranges r = 0.74–0.76. For viscoelasticity, pliabil-
ity, and retraction the reliability is low to  moderate: 
r = 0.35–0.69. The Coefficient of Variation (CV = S.E.meas/
mean  ×  100) for measurements on scars, based on the 
measurements of four observers, shows the lowest varia-
tion for extensibility (22.5%), whereas the highest varia-
tion is calculated for viscoelasticity measurements (36.0%) 
[18]. The concurrent validity was estimated by calculating 
the correlation between subjective evaluation of pliability 
and each of the Cutometer parameters. The correlations 
were moderate (r > 0.46) and statistically significant for 
each parameter except for viscoelasticity for which the 
correlation was low.
In general, it is stated that the reliability of the 2 mm 
probe is worse than the reliability of larger probes, 
because the small probe only reflects low values (small 
skin deformation). This is easily explained by the fact 
that the ICC or correlation is highly influenced by a 
wide range in measured values and by a heterogeneous 
population. So, when higher values or a range of values 
within a population are measured, this positively affects 
reliability as expressed by relative parameters. Of all 
parameters, either maximal skin extension (R0/Uf) or 
elasticity (Ue) appears to be influenced the least by vari-
ations in force applied to the probe and therefore it is the 
most reliable parameter to detect change in scar elastic-
ity over time or after treatment.
17.3.2   DermaLab
The DermaLab elasticity probe (Cortex Technology, 
Hadsund, Denmark), which is the successor of the 
Dermaflex, consists of a light plastic probe that is much 
smaller than that of the Cutometer. This probe is 
attached to the skin using double-sided adhesive rings to 
form a closed chamber. Within this chamber, two nar-
row beams of light run at different heights parallel to the 
skin surface and serve as elevation detectors. A con-
trolled vacuum is created in the closed chamber in over 
30–60  s. In contrast to the Cutometer, the DermaLab 
probe measures the amount of suction required (in 
megapascal, MPa) to achieve an elevation of the skin of 
1.5 mm. In pronounced adherent scars, this may cause a 
problem, as the scar is sometimes too stiff  to be elevated 
sufficiently to reach the level of the detectors. The 
DermaLab shows an excellent ICC for test–retest reli-
ability on scars (0.76–0.91); however, on healthy skin the 
ICC is much lower (ICC 0.45) [14].
Both the DermaLab and the Cutometer show 
advances of being a “hub,” to which other measurement 
probes can be attached. The DermaLab Combo, for 
example, provides several probes, considering nine skin 
parameters (e.g., elasticity, color, transepidermal water 
loss, temperature), including ultrasound measurement 
of dermal scar thickness.
17.3.3   Tonometers
Tonometry works by exerting pressure on the skin and 
therefore quantifies predominantly firmness or hardness 
of tissue. Two types of tonometers can be distinguished: 
one type is based on air that flows through the system, 
which is blocked at a certain pressure (e.g., the Tissue 
Tonometer), and the second type provides an indenta-
tion load in the vertical direction (e.g., the Durometer). 
The Tissue Tonometer (Flinders Biomedical Engineering, 
Adelaide, Australia) is a weight-loaded device that exerts 
pressure directly on the area to be measured. The weight 
drives a blunt probe into the tissue with a tissue defor-
mation as a result. This tissue deformation can be mea-
sured in millimeters, with a sensitivity of 0.01 mm. The 
readings are directly proportional to the firmness of the 
tissue being measured.
The Tissue Tonometer shows good intra-observer 
reliability, but a moderate correlation (r  =  0.44–0.46) 
with the pliability score of a subjective scoring system 
(the VSS scale) is found. Additionally, the measurement 
requires a contralateral reference point, making it a rela-
tive measure [Lye 2006]. Another study, using a modi-
fied Tissue Tonometer, shows excellent interobserver 
reliability (ICC  =  0.95) for healthy skin, accompanied 
by a low SEM of 0.025 mm [19]. A significant difference 
between scars and normal tissue was also demonstrated 
in the latter study. The Durometer (Rex Gauge Company, 
Inc., Glenview, Ill.) also shows good ICCs for the 
interobserver reliability (0.82–0.91) in one study, how-
ever, this is on sclerodermal skin [20].
Important to mention is that tonometers are influ-
enced by the hardness of underlying tissue, which may 
limit the compression of the skin. This has to be taken 
into account when measuring locations where bone 
structures are situated directly under the area of inter-
est. Possibly, measurements in these areas are not reflect-
ing the condition of the skin/scar but instead of the 
underlying structure. Another shortcoming of tonome-
ters include the need to place the device accurately, 
which must be within 5° of upright position to measure 
correctly.
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17.4   Perfusion
Hypertrophic scars result from a wide array of derailed 
wound healing processes. It is suggested that new blood 
vessel formation, mainly apparent as angiogenic sprout-
ing of preexisting blood vessels, is an essential process in 
the development of hypertrophic scars. Therefore, 
 several treatment regimens (e.g., laser, pressure gar-
ments, and cryotherapy) work by destructing the micro-
vasculature and/or reducing the blood flow. This may 
result in hypoxia that would lead to fibroblast degenera-
tion and collagen degradation, both enhancing shrink-
age of the hypertrophic scar tissue. As a result, it is of 
interest to measure scar blood flow (i.e., perfusion).
17.4.1   Laser Doppler Imaging
Laser Doppler imaging, a noninvasive flow measure-
ment technique, can be used to quantify and visualize 
blood flow in scars [15, 21]. Laser Doppler imaging 
can be divided in the older technique, laser Doppler 
flowmetry (LDF), in which the fiber optic probe is in 
contact with the tissue, and the newer laser Doppler 
imaging (LDI) devices. The working mechanism is 
based on the Doppler principle. In LDF, a single-point 
measure of  the cutaneous blood flow in a scar is 
obtained. LDF systems are therefore more limited 
compared to the other systems and unsuitable to use 
in larger heterogeneous scars. However, there are cur-
rently modern and high performance LDF systems 
such as the moorVMS-LDF (Moor Instruments Ltd., 
Axminster, United Kingdom) or the PeriFlux 5000 
(Perimed AB, Järfälla, Sweden) that are ideal for labo-
ratory or scientific use. In LDI, laser light directed at 
moving erythrocytes in sampled tissue exhibits a fre-
quency change, which is photo detected and processed 
to generate a line-by-line color- coded map that is pro-
portional to the amount of  perfusion in the tissue. 
After completion of  a LDI measurement, data can be 
analyzed offline using software to calculate the blood 
flow automatically, where after it is expressed in perfu-
sion units (PU).
To assess blood flow in a scar, the moorLDI Imaging 
System (Moor Instruments Ltd., Axminster, United 
Kingdom) can be used. Previous studies show that 
hypertrophic scars sustain an elevated blood flow com-
pared to normal skin [15, 22]. Another clinical study 
also presents a statistically significant increase in blood 
flow values of scars compared to healthy skin [5]. In 
more detail, the latter study shows increased LDI blood 
flow values in 29/32 included patients. Interestingly, this 
study also compares the association between the out-
comes of LDI and colorimetry using the DSM II 
ColorMeter. The results indicate that blood flow and 
erythema values are not correlated. During measure-
ments of 32 hypertrophic scars, a widespread in ery-
thema values is observed, whereas the accompanying 
blood flow values are mostly beneath 300 PU and 
thereby low. These data are in agreement with a previous 
study, presenting that erythema (measured using the 
skin-colorimeter expressing L∗a∗b index values) is asso-
ciated with blood flow, but this correlation is not consis-
tent at different test moments [4]. As a result, it is 
concluded that LDI and colorimetry are non-inter-
changeable measurement tools.
LDI can be a valuable adjunct in the research setting, 
where it might be useful to monitor scar development 
and/or response to treatment that is directed at lowering 
blood flow. However, although new laser Doppler 
instruments became available over the last years, it is 
important to keep in mind that the tool has some limita-
tions in terms of feasibility (e.g., high cost, long assess-
ment time, and moderate ease of use). Therefore, LDI 
seems less suitable for the follow-up of scars in daily 
practice.
17.4.2   Laser Speckle Imaging
Laser speckle imaging (LSI) or laser speckle perfusion 
imaging (LSPI) are alternative perfusion monitoring 
techniques that generate high-resolution images of tis-
sue in a shorter assessment time than LDI. In addition, 
these devices provide the possibility to zoom in with 
increased resolution of a smaller area of interest. The 
moorFLPI-2 blood flow imager (Moor Instruments 
Ltd., Axminster, United Kingdom) and the PeriCam 
PSI (Perimed AB, Järfälla, Sweden) both use the laser 
speckle contrast technique to deliver real-time high- 
resolution blood flow images. The latter system contains 
an invisible near infrared laser (785 nm), spreading the 
beam over the area of interest by a diffuser, creating a 
speckle pattern. Subsequently, blood perfusion is calcu-
lated by analyzing the variations (i.e., interference) in 
the speckle pattern. High values reflect high blood flow 
and should thereby indicate immature or hypertrophic 
scars.
A clinical study comparing the ability of LSPI with 
LDI in determining and monitoring hypertrophic scar 
perfusion shows a positive correlation (r2 = 0.86) [23]. 
Moreover, in terms of feasibility, the LSPI device dem-
onstrates a faster scan time and higher resolution, which 
may be an advantage for usage in clinical practice. Also, 
reactions to mechanical or pharmacological interven-
tions can be studied nearly real time, allowing a dynamic 
way of studying scars. Perfusion rates within keloids are 
also assessed by LSI, showing significantly higher perfu-
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sion in keloids and adjacent skin compared with nonad-
jacent healthy skin [24]. However, a thorough clinimetric 
evaluation of LSI in scars is currently not available.
17.5   Conclusion
Color, elasticity, and perfusion are scar characteristics 
with a high clinical relevance. Two features, erythema 
and pigmentation, determine the color of the scar. 
Erythema is a complex characteristic that may be defined 
as the level of oxygenated hemoglobin measured at 
660 nm. Pigmentation is often referred to as the level of 
melanin, which can be excessively present (hyperpig-
mentation) or underrepresented (hypopigmentation). 
Reflectance spectroscopy is the most widely used mea-
surement technique to assess scar color. Perfusion of 
vascularization and scar color are often bracketed 
together but both represent totally different features. 
The mixture of terms can also be found in literature 
where vascularization is described as scar color, blood 
flow, the presence of microvessels, as well as the amount 
of redness [9, 12, 15, 25]. Conform definitions in several 
dictionaries and physiology textbooks, we would like to 
propose that vascularization is defined as the formation 
of blood vessels and capillaries in living tissue, which 
reflects a process. The presence of microvessels is a phys-
ical result of this process, and blood flow fulfils the func-
tional role of perfusion. Scar redness is likely to be a 
derivative of all features that is assessed subjectively. For 
the purpose of clarity, it would be beneficial to provide a 
detailed description of every feature when assessed in 
research as well as in clinical practice, as we feel that the 
various scar features cannot be generalized into the 
umbrella term “vascularization.” The term elasticity is 
most probably related to the lack of elastin in the der-
mal layer of scar tissue, but can also be considered as an 
umbrella term including extensibility, pliability, or sup-
pleness of the scar. The most reliable assessment tech-
nique here measures vertical elasticity or extensibility by 
means of suction.
All tools are able to differentiate between scar tissue 
and healthy skin; however, this can also easily be deter-
mined by subjective evaluation. Objective tools should 
be able to monitor an individual patient in clinical prac-
tice, thereby distinguishing small scar changes. Thus, the 
measurement error of the tool must be smaller than the 
desired scar change to be measured. Taking into account 
reliability, patient friendliness, and feasibility in terms of 
cost and portability, a recommended panel of devices 
for the assessment of color, elasticity, and perfusion of 
scars consists of the DSM III ColorMeter for scar color, 
the Cutometer for scar elasticity and laser speckle imag-
ing to assess scar perfusion.
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18.1   Background
With advances in medicine, we are able to modulate 
wound healing and scarring. In order to assess new and 
often costly treatments, the need for objective scar mea-
surement tools has become increasingly important. A 
combination of subjective and objective measures 
should be the aim of every researcher. In daily practice, 
time is a limiting factor, and the choice for objective 
measurements should always incorporate feasibility and 
cost. Objective assessments provide a quantitative mea-
surement of the scar. Quantitative assessment of scars 
requires devices to measure their physical and physio-
logical properties. These properties include, but are not 




 5 Elasticity or pliability
 5 Texture
 5 Surface
 5 Tissue anisotropy
Physiological parameters:
 5 Skin hydration
 5 Transcutaneous oxygen level
 5 Tactile sensitivity
In this chapter, an overview of the assessment tools to 
evaluate physiological scar parameters will be given. 
Physiological scar parameters are scar characteristics 
relevant to pathological scarring which cannot be seen 
with the bare eye. This also means that they can only be 
assessed with objective assessment tools. This overview 
lacks skin characteristics which are measured with digi-
tal imaging systems. These assessment tools will be dis-
cussed in a separate chapter.
18.2   Skin Hydration
Skin hydration is defined as the water content of the epi-
dermis and the dermis. Approximately 20% of water 
present in our body is accumulated in the skin. Of this 
amount, 60–70% is located in the dermis, and 15–30% is 
retained in the stratum corneum (SC). Functionally, the 
amount of water in the skin can be divided into free and 
bound water. In healthy skin, most of the water are 
bound to macromolecules. The ability of the skin to 
retain water is primarily related to the SC, which plays 
the role of the outer skin barrier, protecting the skin 
from water loss. The SC consists of cells called corneo-
cytes and various lipids (fats) between them. The reten-
tion of water in the SC is dependent mainly on the 
presence of natural hygroscopic agents within the cor-
neocytes and the SC intercellular lipids orderly arranged 
to form a barrier to trans-epidermal water loss [1]. The 
corneocytes are often compared to bricks and the inter-
cellular lipids to mortar, an appropriate metaphor for a 
layer of skin that serves as a barrier. The corneocytes are 
dead cells without nuclei. They contain various sub-
stances that hold water. For our skin to feel smooth and 
supple, the SC has to be at least 10% water; ideally, it is 
20–30%. The SC can absorb as much as five to six times 
its own weight and increase its volume threefold when 
soaked in water. But it is not simply the water content 
that matters. Water has an effect on the enzymes that 
control orderly shedding of corneocytes, a process der-
matologists call desquamation. Without water, the cor-
neocytes accumulate, so the skin becomes flaky instead 
of peeling off  nicely, and the SC gets disorganized and 
full of cracks instead of being tightly packed.
The glycosaminoglycan (GAG) polymer hyaluronan 
(HA, hyaluronic acid) forms a scaffold on which 
 proteoglycans and matrix proteins are organized. These 
supramolecular structures are able to entrap water and 
ions to provide the skin with hydration. HA occurs in 
both the dermis and epidermis, with the dermis contain-
ing the greater proportion. HA present in the epidermis 
may play a role in a epidermal barrier function and SC 
hydration [1]. The lack of interaction between water and 
surrounding molecules contributes to dry appearance of 
the skin. Water content can vary depending on varying 
factors as skin site, skin depth, body mass index, age, 
sex, diurnal hour, seasons, and climates.
18.2.1   Skin Hydration in the Epidermis
The epidermal thickness is variable. It had been reported 
to be between 40 and 240 μm thick, depending on the 
measuring area and method used. Water originates in 
the deeper epidermal layers and moves upward to 
hydrate cells in the outermost skin layer, the stratum 
corneum (SC). Aquaporins (AQPs), cell membrane- 
bound water channels present in the epidermis, are 
essential hydration-regulating elements controlling cel-
lular water and glycerol transport. Glycerol, thus pres-
ent in the outer epidermal layers, binds and holds water, 
important for maintaining optimal skin hydration. The 
epidermis contains two different levels of water, sepa-
rated by the interface between the stratum granulosum 
(SG) and the SC. The largest gradient of water in the 
epidermis occurs in the underlying layers of the SG (via-
ble epidermis), while the SC water content is 4–5 times 
lower [2]. This gradient isolates the SC from the body, 
helping to conserve important solutes and water within 
the viable epidermis. The presence of a water gradient at 
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the deeper part of the SC triggers important keratino-
cyte functions such as the production of natural mois-
turizing factors (NMF). Dehydration of the upper skin 
layers increases when the SC water is lost more quickly 
than that which is received from the lower layers of the 
skin (viable epidermis and dermis), thus affecting the 
natural flow of water. Water originates in the deeper epi-
dermal layers and moves upward to hydrate cells in the 
SC, eventually being lost to evaporation. Then, an evap-
oration barrier is needed to maintain body water homeo-
stasis. The SC functions as the main evaporation barrier 
[2, 3].
18.2.2   Dermal Water Content
The dermis is between 1 and 4 mm thick, and it consists 
mainly of connective tissue. Dermis thickens as it binds 
more water. In the dermis, the collagen fibers, the inter-
stitial space GAGs, and the proteoglycans can absorb 
large quantities of water, which leads to youthful skin. 
With skin fibrosis, the collagen fiber network is stretched 
by external mechanical forces, reduces its absorption 
capacity and water retention, and can lead to prolonged 
inflammation. Dermal hydration is highly related to the 
content and distribution of GAGs. The GAGs most 
often present in the human skin are hyaluronic acid (not 
attached to a protein core) and the proteoglycan family 
of chondroitin sulfates (GAGs attached to a protein 
core). GAGs bind up to 1000 times their volume in water 
[4]. GAGs in photodamaged or scarred skin are abnor-
mally deposited in the papillary dermis, rather than dif-
fusely scattered as in young skin. This aberrant 
localization interferes with normal water binding by 
GAGs, despite their increased quantity [4].
18.2.3   How to Measure Skin Hydration?
Many approaches exist to measure skin water content. 
One single method is often not enough to capture all the 
relevant information. Trans-epidermal water loss, stra-
tum corneum water content, and dermal water content 
are equally important and related to each other.
The skin acts as a barrier against the water evapora-
tion from the internal tissue. The water content in the 
skin preserves the softness and the smoothness of the 
skin surface. Diffusion of condensed water through the 
stratum corneum (SC) occurs and is highly elevated in 
pathological situations such as scaring; this can be mea-
sured by trans-epidermal water loss (TEWL). The 
results of these measurements are a good indicator of 
the recovery of the skin barrier and are a useful indica-
tor of the scar maturation process [5]. TEWL is strongly 
related with the moisture content of the skin and can be 
measured with open- or closed-chamber systems [6]. 
The open chambers are the oldest but still most widely 
used.
18.2.3.1   Trans-Epidermal Water Loss: 
Measuring Principle
Trans-epidermal water loss represents the outward per-
meation of condensed water through the stratum cor-
neum by means of diffusion [7]. TEWL can be measured 
by using an open-chamber method or closed-chamber 
method. Open chambers are open to the surrounding 
atmosphere and are therefore easily influenced by exter-
nal air convection and turbulence. Closed-chamber 
methods have been designed more recently, the measur-
ing chamber is enclosed from the surrounding atmo-
sphere, and measurements are therefore not influenced 
by external air convection and turbulence.
TEWL can be calculated by measuring the water 
vapor pressure (VP) gradient at the skin surface. In the 
open-chamber method, the VP gradient is calculated by 
measuring the difference in VP between two distinct 
points aligned perpendicularly to the skin surface (see 
. Fig. 18.1). VP is calculated as the product of relative 
humidity (RH) and saturated VP; this is dependent on 
temperature. RH is measured using capacitive sensors; 
temperature is measured with fast thermistors located in 
the cylindrical measuring chamber with open ends [7–11].
  . Fig. 18.1 TEWL measured by using an open-chamber method. 
Reused with permission from Courage + Khazaka electronic GmbH. 
© All rights reserved
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18.2.3.2   Open-Chamber Method
To date, the open-chamber method is still considered the 
most reliable method to measure water evaporation in 
scarred skin. Open-chamber systems measure water 
evaporation rate based on diffusion principles [9, 11]. 
The vapor density gradient is measured indirectly by 
two pairs of sensors (temperature and relative humidity) 
inside a hollow cylinder [7, 11]. The resulting data are 
analyzed by a microprocessor. Measurement values are 
given in g/m2/h. The physiological water vapor mantle 
surrounding the human skin is a gradient of water with 
a thickness of about 10  mm. The two sensors of the 
evaporimeter probe are typically placed 3 and 6  mm 
above the skin surface. Open-chamber evaporimeters 
have limitations in practical use and should ideally be 
used in a climatized room with control of convection, 
temperature, and humidity [9, 10]. Used outside a clima-
tized room, special attention should be given to air con-
vection, room temperature, and ambient humidity [9].
The most widely used systems are the Tewameter® 
TM300 (Courage+Khazaka, Cologne, Germany) and 
the DermaLab® (Cortex, Hadsund, Denmark). Both 
are available as stand-alone devices or as a probe 
attached to a Multi Probe Adapter System like the 
Scarbase Duo™ (Courage+Khazaka, Cologne, 
Germany) and the DermaLab Combo® (Cortex, 
Hadsund, Denmark).
Both the Tewameter® (. Fig.  18.2) and the 
DermaLab USB® TEWL (. Fig. 18.3) showed good to 
excellent reliability and validity with rather high mini-
mal clinically important difference (MCID) [12, 13]. The 
MCID is the smallest change in an outcome that a 
patient or a clinician would identify as important. An 
overview of the results is set out in . Table 18.1.
18.2.3.3   Semi-Open-Chamber Method
Recordings with open-chamber evaporimeters are not 
intrusive to the 10 mm physiological water vapor mantle 
over the skin and due to its specificity sensitive to ambi-
ent airflow. Open-chamber instruments perform best 
under standardized ambient conditions with an air pro-
tection shield or box controlling the ambient air condi-
tions, as described in standards [9, 10]. Closed-chamber 
methods are insensitive to ambient air but, unfortu-
nately, directly intrusive to the water vapor mantle. 
Accumulation of water vapor in the chamber during the 
measurement instantly and directly influences the diffu-
sion of water out of the skin. Thus, closed chambers 
interfere with the physiological skin barrier and thus 
cannot record physiological TEWL directly. For the 
same reason, measurements may only be made as an ini-
tial estimate and not continuously. In the DermaLab 
system (Cortex Technology, Hadsund, Denmark), a spe-
cial grid serving as a semi-open windshield has been 
incorporated directly in the top of the open probe of 
this instrument. This grid is open and allows evapora-
tion of water out of the probe chamber and at the same 
time protects the sensors in the probe against ambient 
  . Fig. 18.2 The probe of  the Tewameter® TM300. Reused with 
permission from Oscare. © All rights reserved
  . Fig. 18.3 DermaLab® USB TEWL-probe. Reused with permis-
sion from Oscare. © All rights reserved
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air convections. The system can be considered respectful 
to the water vapor mantle.
18.2.3.4   Closed-Chamber Method
Two types of closed-chamber methods are available – a 
condenser chamber method and an unventilated-closed- 
chamber method. With the unventilated-chamber 
method, the measuring cylinder is closed off  at the top. 
When placed on the skin, water vapor from the skin col-
lects in the chamber, and with time, the humidity in the 
chamber increases slowly at first, and thereafter linearly. 
Flux density (amount of water diffusing through the SC 
per unit distance and time) is calculated from the change 
in RH and temperature over time. Due to the accumula-
tion of water vapor and humidity in the chamber, these 
instruments cannot be used for continuous measure-
ments. Overall, the measurement time of unventilated- 
closed- chamber instruments is very short (<10 seconds). 
Various skin barrier impairment studies revealed that 
the open-chamber devices are more sensitive or discrim-
inative and are able to detect significantly smaller differ-
ences than the closed-chamber devices [14]. The 
VapoMeter (Delfin Technologies Ltd., Kuopio, Finland) 
is an example of a unventilated-closed-chamber system 
[15]. The VapoMeter is simple in principle; a humidity 
sensor in the closed chamber measures the gradual 
buildup of humidity. On its commercialization, it was 
postulated that TEWL measurements were not affected 
by ambient or body-induced airflows.
18.2.3.5   Stratum Corneum Hydration Level: 
Measuring Principle
Hydration of the skin surface is a good indicator of epi-
dermal function. Hydration is directly proportional to 
retention of electrical charge and is therefore often mea-
sured by dielectric capacitance or the conductance of 
the superficial skin layers [11]. Technical aspects such as 
type of probe surface, degree of direct galvanic contact 
with the skin, distance between the electrodes, and depth 
of measurement all vary when comparing the different 
technologies. Due to the higher TEWL, scar sites are 
dryer than control sites and seem to become dryer as 
they mature. Water content is very important in the eval-
uation of biophysical properties of scars. Evidence sug-
gests that a sufficient amount of water in the stratum 
corneum (SC) keeps the skin soft and flexible and 
ensures that the skin appears smooth and healthy. The 
water holding capacity of the SC also influences its bar-
rier function and mechanical properties [16]. 
Measurements of hydration are often influenced by 
environmental factors [7].
The Corneometer CM 825® (Courage+Khazaka, 
Cologne, Germany) is based on the capacitance method. 
It is a well-known and efficient instrument in measuring 
hydration of the SC. In the past, the measuring probe of 
the Corneometer used an analog signal, but now, digital 
technology is used, resulting in higher stability and less 
interferences [17].
The Skicon instruments (I.B.S.  Co., Hamama-T), 
based on the conductance method, are also widely used. 
A modern version of the Skicon (Skicon-200EX®) has 
been developed with a new concentric interdigital probe.
18.2.3.6   Corneometer CM825®
The measuring principle is based on the capacitance 
method (see . Fig.  18.4). Technical description of this 
type of instrument and its use has been published by 
  . Fig. 18.4 The measurement principle of  the Corneometer® 
CM825 is based on the capacitance method. Reused with permission 
from Courage + Khazaka electronic GmbH. © All rights reserved
  . Table 18.1 Comparison of  reliability, validity, and MCID for trans-epidermal water loss assessment on scars










0.86–0.88 0.78–0.93 DermaLab® TEWL is able to distinguish normal 
skin from spontaneously healed scars (p = 0.036)
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many authors. Both probes (analog and digital) contain 
an interdigital grid of gold electrodes, covered by a low 
dielectric vitrified material (see . Fig. 18.5). A resonat-
ing system in the instrument detects the frequency shift of 
the oscillating system related to the capacitance (and 
hence hydration) of the biomaterial in contact with the 
probe. Unlike the Skicon instruments, there is no direct 
galvanic contact between the electrodes of the 
Corneometer and the skin surface. To enable a constant 
pressure of the probe on the skin surface, a spring system 
is incorporated. According to the manufacturer, the pres-
sure of the old analog probe is in the range of 1.1–1.8 N; 
the new digital probe operates at a lower pressure (about 
1 N or less). The Corneometer is factory calibrated using 
an in vitro method. Corneometer® results obtained with 
different instruments in different laboratories can be 
pooled if a pretest validation demonstrates concordance 
between instrument.
Anthonissen et al. investigated the reliability of the 
Corneometer and concluded that the instrument can be 
used in clinical trials but only under very strict condi-
tions with standardized test protocol, preferably in com-
bination with the evaluation of other physiological 
parameters [18]. The results revealed excellent ICC val-
ues (ICCintra = 0.985; ICCinter = 0.984) with relatively 
low within-subject coefficient of variation (WSCV) 
(WSCVintra = 6.3%; WSCVinter = 10.6%) for, respec-
tively, intra- and inter-observer reliability. However, the 
Bland–Altman plot showed that more than 5% of differ-
ences were expected to exceed 4 a.u., the limit of what 
has been defined as a clinically acceptable difference. 
Results for day-by-day variability showed good ICC 
value (ICCday-by-day  =  0.849) and higher WSCV 
(WSCVday-by-day = 20.5%).
18.2.3.7   Skicon-200EX
The Skicon instruments manufactured by I.B.S. Co. are 
based on the conductance principle. These instruments 
measure the conductance (μS) of a single high-frequency 
current at 3.5  MHz. The measuring probe consists of 
75 μm large concentric interdigital electrodes with a gap 
of 200 μm between the electrodes. The total probe sur-
face is 0.8 cm2. The probe makes use of a spring system 
ensuring a constant pressure force of 0.78  N when 
applied to the skin. The electrode makes direct galvanic 
contact with the skin surface. The device is calibrated 
in vitro using various external calibration standards in 
the range of 2–2000 μS conductance [19].
18.2.3.8   General Recommendations for Skin 
Hydration Measurements
The applied probe pressure has a large influence on 
hydration measurements. Despite the existence of a 
spring to ensure constant probe pressure, Clarys et al. 
have demonstrated that the measured hydration levels 
increase with higher probe pressures. This phenomenon 
is exacerbated on dryer skin (e.g., scar tissue). It is there-
fore advisable to use complete compression of the spring 
when applying the probe on the skin surface. Use a pre-
cision balance to practice obtaining more or less identi-
cal values. Finally, try to transpose this to the in  vivo 
application of the probe on the skin surface [20].
Digital capacitance probes are very sensitive for eval-
uating dry/very dry skin conditions (e.g., scars), while 
digital conductance probes are more suited for evaluat-
ing very high levels of hydration [17].
Skin hydration has a positive correlation with ambi-
ent temperature and humidity; it is strongly affected by 
these two environmental parameters [7].
Results of TEWL or skin hydration measurements 
should be reported as differences or percent change 
rather than absolute values. This approach partially 
eliminates influencing factors.
In order to obtain reliable results for skin hydration, 
it is advisable to minimize, as far as possible, the influ-
ences of endogenous, exogenous, environmental, and 
instrument or measurement-related factors [7].
For the Corneometer®, the MCID is 7% on healthy 
skin and 4% on scars [18].
18.2.4   Dermal Water Content Measurement
18.2.4.1  Confocal Raman Spectroscopy
Raman spectroscopy is a spectroscopic technique used 
to observe vibrational, rotational, and other low- 
frequency modes in a system. Raman spectroscopy is 
  . Fig. 18.5 Probe of  the Corneometer® CM825 device. (©Oscare)
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commonly used in chemistry to provide a structural fin-
gerprint by which molecules can be identified. Confocal 
Raman spectroscopy can directly measure the water con-
tent from the skin surface down to the upper epidermis 
with high depth resolution (5 μm) [21]. Moreover, it pro-
duces a more absolute measurement value than other 
methods. Using confocal Raman spectroscopy, the water 
content is calculated from the ratio of integrated Raman 
signals for water and protein. The proportionality con-
stant is estimated from the Raman spectra of various 
solutions of proteins in the water. Nakagawa et al. con-
cluded that in  vivo measurement of the dermal water 
content with confocal Raman spectroscopy was highly 
reliable [22]. The benefit of using confocal Raman spec-
troscopy is that the depth increment between measure-
ment points can be freely adjusted. The most widely used 
depth resolution of the confocal Raman spectroscopy is 
5 μm. With confocal Raman spectroscopy, the smaller 
the region of interest, the higher the depth resolution.
18.2.4.2   Near-Infrared Spectroscopy
Near-infrared spectroscopy (NIRS) is a spectroscopic 
method that uses the near-infrared region of the electro-
magnetic spectrum (from 780 nm to 2500 nm). NIRS is 
based on molecular overtone and combination vibra-
tions. One advantage is that NIRS can typically pene-
trate much further into a sample than mid-infrared 
radiation. NIRS is not a particularly sensitive technique, 
but it can be very useful in probing bulk material with 
little or no sample preparation [23].
The molecular overtone and combination bands seen 
in the near-IR are typically very broad, leading to com-
plex spectra; it can be difficult to assign specific features 
to specific chemical components. Multivariate calibra-
tion techniques (e.g., principal components analysis, par-
tial least squares, or artificial neural networks) are often 
employed to extract the desired chemical information. 
Careful development of a set of calibration samples and 
application of multivariate calibration techniques is 
essential for near-infrared analytical methods. NIRS can 
measure overall skin water content as well as of the vari-
ous components constituting the skin, i.e., the stratum 
corneum, epidermis, and dermis. This technique has the 
ability to directly determine the changes in the various 
types of water (free, bulk, and protein-bound water), 
which are present in the various skin layers.
Another interesting advantage is that this technique 
does not require direct contact with the skin and can 
easily be integrated in smartphones. This technique 
also allows to determine the thickness of  separate skin 
 layers [24]. However, its lack of  sensitivity and frequent 
integration of  algorithms raises doubts about its reli-
ability, which still needs to be investigated in scar tissue.
18.3   Transcutaneous Oxygen Tension
Scar maturation has been related to transcutaneous oxy-
gen tension that can be measured with electrodes on the 
skin. Heat is induced to the electrode and causes oxygen 
and CO2 to diffuse through the skin. In hypertrophic 
scar, PO2 is lower than in healthy skin. An increase over 
time was correlated with clinical improvement. 
Upregulated levels of transcutaneous oxygen tension in 
treated scars correlated well with a downregulation of 
scar thickness assessed both clinically and by ultra-
sound. It is hypothesized that low levels of transcutane-
ous oxygen pressure (tcpO2) in evolving scars result 
from low oxygen diffusibility through scar tissue rather 
than from rapid metabolic consumption of oxygen by 
scar tissue [25].
18.4   Tactile Sensitivity
Tactile sensitivity of the skin can be divided in two 
parts. Discriminative touch is a sensory modality that 
allows a subject to sense and localize touch. Non-
discriminative touch is a sensory modality that allows 
the subject to sense that something has touched them, 
without being able to localize where they were touched. 
Scars are frequently accompanied with sensory deficits 
often remaining present months or even years after 
injury.
Tactile sensitivity of  the skin can be measured by 
esthesiometers. There are different types of  esthesiom-
eters depending on their particular function. The sim-
plest is a manual tool with adjustable points similar to 
a caliper. It can determine how short a distance 
between two impressions on the skin can be distin-
guished.
Another type of manual esthesiometer is used to test 
lower thresholds of touch or pain. The tool uses nylon 
monofilaments with varying calibrated diameters (see 
. Fig. 18.6). The force needed to cause the monofila-
ment to “buckle” determines the tactile reading (see 
. Fig.  18.7). The filaments are calibrated by force 
applied, rather than by gram/mm2 pressure ratings 
because sensation follows force (when the stimulated 
area is small).
The most commonly used is the Semmes-Weinstein 
Aesthesiometer and its variant the Weinstein Enhanced 
Sensory Test (WEST) that determines the touch percep-
tion threshold (TPT). Meirte et al. concluded that the 
Semmes-Weinstein monofilament test is a feasible and 
reliable outcome measure to evaluate TPT in burn scars, 
showing excellent intrarater and interrater reliability 
(ICC >0.90) [26].
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Take-Home Messages
 5 The stratum corneum acts as an evaporation bar-
rier to maintain body water homeostasis.
 5 In the epidermis, water originates from the deeper 
layers.
 5 In scars, the absorption capacity and water reten-
tion are reduced and may contribute to prolonged 
inflammation.
 5 In scars, TEWL is higher than in normal skin.
 5 One single method to measure skin water content 
is not enough to capture all the relevant informa-
tion.
 5 The open-chamber method is the most widely used 
to measure TEWL.
 5 The dielectric capacitance method is the most reli-
able method to measure SC hydration level in scars.
 5 Confocal Raman spectroscopy is a reliable tech-
nique to measure dermal water content.
 5 The Semmes-Weinstein Aesthesiometer is a reli-
able tool to assess tactile sensitivity in scars.
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19.1   Introduction
The skin, the largest organ of the body, consists of an 
epidermal layer and a dermal layer underneath. The thin 
epidermal layer functions as a barrier to the outer world. 
The dermis is much thicker, and its structural organiza-
tion is responsible for the functional qualities of the 
human skin. It consists for almost 80% of collagen, elas-
tin, and different types of cells, which render the skin 
strong and at the same time remarkably pliable. In scar 
tissue, visual aspects (discoloration and texture [1]), 
functional aspects (stiffness [1] and moisture retention 
[2]), and sensory functions [3] of the skin differ signifi-
cantly from those of healthy skin.
In clinical practice, objective assessment of cutane-
ous scars remains a challenging task. The use of scar 
assessment tools has increased significantly in the last 
decade. The clinical follow-up of scar treatment neces-
sitates precise measurement of thickness, surface area, 
and relief. Further, a better visualization of the precise 
3D microstructural organization is crucial in under-
standing the etiology of pathological scarring. As most 
aspects of clinical scar assessment scales are based on 
the visual appearance, the potential for optical tech-
niques as an objective assessment tool is high. With a 
so-called optical biopsy, it is possible to assess the micro-
structure below the surface of the skin with optical 
methods, negating invasive physical biopsies. 
Furthermore, a range of extensions for these techniques 
allow simultaneous structural, mechanical, and even 
chemical characterization.
This chapter aims to describe current progress in 
objective imaging techniques used in the clinical follow-
 up of scar progression on the one hand and some of the 
most powerful techniques for basic structural research 
of scar microstructures on the other hand. For the sake 
of brevity, we limit our discussion to techniques and 
devices that have been shown to be valid and reliable. 
For a complete overview of available devices, we refer 
the reader to an extensive review by Lee et al. [4].
19.1.1   Volumetric Analyses
The number of devices that measure scar volume has 
seen a rapid growth in the last decade, partly advanced 
by increased attention to wound and burn research.
Volumetric aspects of scars discussed here are sur-
face area, thickness, and surface topology. Although 
there exists significant overlap between these aspects 
and some devices measure multiple aspects (surface 
roughness can be considered as fluctuations in scar 
height/thickness; newer analysis methods of surface 
area are often intrinsically three dimensional and there-
fore include information on surface topology), we dis-
cuss them separately as the reliability (the consistency of 
the measurements) and validity (whether the device 
measures what it intends to measure) of individual 
aspects of a device aren’t necessarily similar.
Volumetric assessment has gone from manual paper 
tracing to high-tech 3D cameras.
Although manual tracing of scar surface area is reli-
able in the case of linear postoperative scars [5], for scars 
with irregular boundaries, the reliability decreases with 
scar size [6]. The LifeViz 3D camera (Quantificare SA, 
Valbonne, France) has been extensively tested in both 
the surface area and volumetric analysis mode by 
Stekelenburg et al., who reported it to be a reliable and 
valid tool [7, 8]. The LifeViz 3D works by comparing 
two photos from different angles, from a predefined dis-
tance. The Vectra 3D is a speckle pattern-based system 
that utilizes six cameras to construct a 3D image. Its 
interrater reliability was found to be excellent in a trial 
on raised scars [9]. A device with a similar working 
mechanism, MAVIS III (Photometrix, Pontypridd, 
United Kingdom), was assessed in a study on burn scars. 
The authors note that poorly delineated scars on curved 
surfaces pose a challenge in the boundary selection and 
subsequent analysis [10].
Rashaan et al. tested another stereophotogrammetry 
device, the Artec MHT (Artec 3D, San Diego, CA, 
USA), and found it to be highly reliable and valid in 
burn scars [11].
Other strategies that include laser scanning cameras 
and structured light scanners need additional clinical 
evaluation.
19.1.2   Surface Topology
Roughness, or surface irregularity, has a significant 
impact on a patient’s perception of scars [12]. 
Furthermore, the predictive validity of long-term scar 
quality was found to be significantly influenced by the 
“relief” item on the POSAS observer scale [13] (see 
7 Chap. 16 for more on scar assessment scales). Most 
scar assessment scales include such a texture item, and 
even though subjective analysis isn’t necessarily inferior 
to objective analysis, quantification of these aspect 
remains challenging.
Early attempts at quantitative evaluation of rough-
ness entailed the casting of a positive or negative mold 
of the scar surface and its subsequent optical or mechan-
ical analysis [14]. This process, although accurate, is 
overly cumbersome and time-consuming. Current con-
tactless techniques use a combination of illumination 
and analysis of disturbance patterns. The most fre-
quently used device, the Phaseshift Rapid In Vivo 
Measurement of the Skin (PRIMOS, Canfield Scienitifc, 
Inc., Parsippany, USA), has been shown to reliably mea-
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sure scar topology [15, 16]. PRIMOS projects patterns 
of light onto the skin surface. Fluctuations in the sur-
face profile cause disruptions in these patterns that are 
subsequently analyzed.
Antera 3D (Miravex, Dublin, Ireland) is based on 
photometric stereo, in which light from different angles 
produces shade based on surface topology. The reflected 
light is analyzed to form a surface reconstruction. 
Similarly, LifeViz Micro (Quantificare SA, Valbonne, 
France) is one of the devices in the LifeViz series men-
tioned earlier. Although they have been described in the 
context of clinical scar assessment [17, 18], their clini-
metric properties have not been analyzed for the surface 
roughness aspect.
The Visioscan VC 98 uses software analysis of gray-
scale values in UVA-illuminated photographs (Visioscan 
VC 98). Reliability in healthy skin relies heavily on the 
chosen outcome measure of the “surface evaluation of 
living skin” method [16].
The analysis of relief can be considered a structural 
analysis of scar volume. Indeed, most devices offer some 
volumetric analysis. Furthermore, the Antera 3D offers 
additional colorimetric analysis. The abovementioned 
devices show great heterogeneity in measured parameters, 
resolution, and field of view, and thus, it is difficult to make 
a qualitative comparison. In the future, further cross-polli-
nation between techniques can be expected. Askaruly et al. 
showed the potential of optical coherence tomography 
(OCT) to measure relief [19]. Although their study was not 
on scar tissue, the possibility of combining 3D surface 
analysis with structural analysis looks promising.
19.1.3   Thickness
Follow-up of scar thickness is especially important in 
both hypertrophic and keloid scars, where the aberrant 
deposition of ECM proteins leads to significant expan-
sion. Therapies are mostly focused on reducing the scar’s 
prominence over the surrounding tissue, and correctly 
analyzing the thickness of cutaneous scar is paramount.
Although not an optical technique, we discuss high- 
frequency ultrasound here as it’s by far the most com-
monly used technique. Its inferior resolution compared 
to optical equivalents is mitigated by its superior pene-
tration depth allowing thickness analysis, even in severe 
scar thickening. The working mechanism is based on 
reflection of sound waves of structures with different 
acoustic impedances and the analysis of the reflection 
time to determine the depth of the structure. The pene-
tration depth ranges from the upper dermal layers to 
full-thickness skin and subcutaneous structures, depend-
ing on the employed frequency.
Numerous ultrasound systems exist that are mar-
keted for dermatological applications; we succinctly 
limit our discussion to systems that have been applied to 
scars. The frequency used by these systems ranges from 
5 to 50 MHz and forms the most important limitation in 
scars, as this limits the penetration depth. For example, 
the most frequently described device, the Dermascan C 
(Cortex Technology ApS), utilizes a frequency of 
20  MHz which has a penetration depth described as 
inadequate in up to a third of burn scars in a study by 
Gankande et al. [20] (using the DermaLab Combo).
Reliability of these instruments has been tested in 
several studies and shows excellent inter-observer [20–
23] and intra-observer reliability [20, 21, 23–25].
From a validity standpoint, it is of interest to note 
that a golden standard does not currently exist. 
Comparison with scar assessment scales has yielded 
inconsistent results, possibly due to heterogeneity in scar 
scales and ultrasound frequency [23, 26]. Histology has 
several drawbacks that include deformation during the 
biopsy process dependent on resting skin tension, 
manipulation during fixation, and slicing [27]. Agabalyan 
et al. found poor correlation between 20Mhz ultrasound 
analysis and histological analysis of skin graft scars in a 
small group of patients [26]. Andrew et al. found biop-
sies to be significantly thicker after excision, advising the 
use of pinning during formaldehyde fixation to mitigate 
this effect [27]. Li et al. compared ultrasound measure-
ments with the use of a micrometer [24], theoretically 
bypassing the negative effects of sample preparation for 
histology. Although they achieve a high correlation, 
sonographic analysis was performed on porcine excised 
tissue in which it is conceivably easier to recognize the 
skin’s boundaries.
Scar height can be measured using volumetric analy-
ses like the 3D camera LifeViz 3D (Quantificare SA, 
Valbonne, France), although studies comparing this 
device with ultrasound measurements have favored the 
latter [23, 28]. It seems that the reliability is suboptimal 
due to the device having difficulty scanning over curved 
surfaces.
19.2   Experimental Techniques
Scarring involves the aberrant deposition of matrix mol-
ecules. The collagen content of scars, especially, differs 
from healthy skin in terms of amount, type, and, impor-
tantly, organization. In the past decades, quantification 
of the extracellular matrix (ECM) organization was 
mostly limited to two-dimensional images from fixated 
and stained tissue. Depending on the orientation of his-
tological slices relative to the skin surface, analysis of 
orientation will yield different results. For example, 
Verhaegen et al. found significantly different supramo-
lecular organization depending on which cross section 
was imaged (e.g., perpendicular to the surface or in the 
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parallel plain) [29]. Gaining a better three-dimensional 
perspective of ECM organization is paramount in eluci-
dating the etiology of pathological scars.
As the goal is not only to assess scar tissue based on 
texture, volume, and color but also to perform micro-
structural analysis, more advanced microscopic tools 
are required. An ideal optical scar assessment technique 
would have a resolution with which microstructural 
changes can be clearly identified, even in the deeper 
parts of the dermis. However, in optics, there exists a 
common trade-off  between spatial resolution and pene-
tration depth, and the marked thickening of hypertro-
phic and keloids scar complicates this trade-off. In this 
sense, a “perfect technique” does not exist. A technique’s 
suitability depends merely on whether the application 
matches its strength. In the following, we will discuss 
several microscopic techniques and their applications in 
scar assessment and research.
19.2.1   Optical Coherence Tomography
Colloquially known as “Ultrasound based on light,” 
OCT is a promising technique based on low-coherence 
interferometry. In short, light with a broad bandwidth is 
split into a sample arm and a reference arm. The inter-
ference pattern that arises from the combination of the 
reference arm and the sample arm, containing reflected 
light from different depth layers of the sample, creates a 
depth profile of the sample. Combining a lateral series 
of these profiles creates a cross-sectional image (B scan) 
or a three-dimensional reconstruction when a stack of B 
scans is combined. Scanning approaches with full-field 
illumination allow the acquisition of stacks of “en face” 
scans. Typically, penetration depths of 1–2 mm can be 
reached, at a resolution of 4–10 μm [30].
The capability of OCT to create high-resolution 
tomography first piqued the interest of the ophthalmo-
logical community, where it is now a staple technique in 
retinal assessment. Naturally, attributes like fast acquisi-
tion time, high-resolution images, noninvasiveness, and 
multifaceted structural assessment make OCT an inter-
esting technique for dermatology. Moreover, OCT 
devices are often manageable handheld scanners, 
increasing their usability in the clinic.
Polarization-sensitive OCT (PS-OCT) has been 
described as a quantification tool for collagen density 
and alignment by means of tissue birefringence [31]. 
Jaspers et  al. compared burn scars and healthy skin 
using a volume-based birefringence method, which 
showed strong correlation to histologically determined 
collagen content [32]. By applying speckle decorrelation, 
Liew et al. visualized the microvasculature of burn scars 
in three dimensions [33]. A similar strategy was used in 
the clinical follow-up of burn scars undergoing laser 
ablation [34], allowing the authors to distinguish mature 
and immature scars [35]. Comparable strategies have 
been applied to lymph vessels [36]. Combined vascular-
ity, lymph vessels, and birefringence analyses were used 
by Park et al. to longitudinally follow wound healing in 
a mouse model, showing angiogenetic changes and 
realignment of birefringent signals [37].
Simultaneous mechanical testing allows the correla-
tion of local structural changes to variations in stiffness. 
Es’haghian et  al. showed that combining a handheld 
OCT probe with a mechanical loading device permits 
concurrent imaging of the in  vivo scars and stiffness 
mapping [38, 39]. Vibrational perturbation of the skin 
and the analysis of resonance frequencies while imaging 
the layers of the skin have also received some attention 
recently for bulk measurements of mechanical proper-
ties [40, 41].
OCT has been described as a tool for measuring 
thickness of individual skin layers. Because the limited 
penetration depth makes full thickness imaging impos-
sible, its application is limited to the epidermal thickness 
[42, 43].
19.2.2   Confocal Microscopy
Higher-resolution images to assess structures with submi-
cron resolution in 3D can be obtained using various 
microscopic techniques. In confocal fluorescence micros-
copy, the addition of a set of pinholes to a traditional fluo-
rescence microscope allows for the selection and detection 
of a small focal volume. Selective labeling with a fluoro-
phore allows for the imaging of a particular substance of 
interest by excitation of the fluorophore by a lamp or laser 
and detection of the fluorescence emission signals. Images 
are obtained by scanning the laser or the sample, yielding 
images with a resolution of 0.4 λ/NA where λ is the wave-
lenght of the emitted light and NA is the numerical aper-
ture of the objective, which is an improvement of ~30% 
compared to traditional fluorescence microscopy. Another 
advantage over widefield microscopy is that the labeling 
with fluorophores can be sparser, allowing for a fairer 
comparison of relative quantities of structures.
Confocal microscopy has been used to determine the 
ratios of collagen of different scar types [44], cell- 
signaling molecules [45] or innervation [46] of different 
scar types and as an ex vivo tool in evaluation of micro- 
needling penetration depth [47]. Furthermore, the supe-
rior resolution allows for quantitative collagen 
orientation analysis [29, 48]. Devices like the VivaScope 
(MAVIG, Munich, Germany) [49] are based on reflec-
tance confocal microscopy (RCM), in which backscat-
tered light from unlabeled structures is analyzed, based 
on changes in refractive index. The in vivo applications 
of RCM lie predominantly in the diagnosis of various 
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skin cancers [50], as its penetration depth is limited to 
the epidermis and upper part of the dermis. However, 
attempts to analyze collagen production after micro- 
needling of acne scars have been described in vivo with 
a combination of dermoscopy and RCM [51]. The lim-
ited penetration depth seems a significant hurdle in scar 
research; however, combining the device with an OCT 
arm allowed Iftimia et al. to analyze both structural and 
birefringence properties in burn scars [52].
19.2.3   Nonlinear Optical Microscopy
19.2.3.1  Introduction
As discussed above, confocal microscopy allows for 
three-dimensional imaging; however in this technique, 
samples require specific staining and sometimes also 
fixation and slicing, which may affect ECM structure 
and organization. Nonlinear optical (NLO) microscopy 
involves label-free imaging of unfixed tissue in three 
dimensions and has strong potential in the visualization 
of the scar microstructure. Here, we discuss several types 
of NLO microscopy, namely, higher harmonic genera-
tion microscopy (HHG) and multiphoton excited auto-
fluorescence (MEA), and explain their strengths in 
label-free imaging of scars.
Nonlinear microscopy can be described as the con-
version of multiple photons into a single photon, based 
on the specific nonlinear behavior of certain molecules 
or structures. This process occurs only when the inten-
sity of the incident light is sufficiently high. To keep the 
average laser power on the sample sufficiently low, 
short- pulsed lasers are used (generally femtosecond 
lasers) [53].
MEA involves the absorption of two or more pho-
tons by an intrinsic fluorophore and the recording of the 
subsequent fluorescence emission, which is then at a 
wavelength shorter than of the excitation light. 
Alternatively, external fluorophores can be applied to 
the sample to label specific structures. In contrast to 
single-photon fluorescence, excitation wavelengths typi-
cally lie in the infrared region, allowing deeper tissue 
penetration of up to 1.6 mm [54].
Comparably, in the HHG processes, two or three 
photons are converted into a single photon. No energy 
transfer takes place however, and the emitted photons 
have exactly half  (second harmonic generation, SHG) 
or a third (third harmonic generation, THG) of the 
wavelength of the incident photons and exactly double 
or triple the energy, respectively. This allows the detec-
tion of the specific signal using narrow-banded filters, 
improving contrast between structures. Simultaneous 
registration of these signals using one system allows for 
label-free visualization of the most important structural 
proteins of the ECM.
19.2.3.2   Two-Photon Excited 
Autofluorescence (2PEF)
MEP involves two or three photons being absorbed by a 
fluorophore and the subsequent emission of a single 
photon of a shorter wavelength. Two-photon excited 
autofluorescence (2PEF) has been described extensively 
in skin research.
2PEF is applicable to fluorophores used in single- 
photon fluorescence. As this is a fundamentally different 
process, excitation wavelengths will not equate to exactly 
double the wavelength of the single-photon excitation. 
The emission spectrum however will be identical. 
Fluorophores naturally present in biological tissue have 
well- described excitation and emission spectra, and 
extrapolation to the two-photon excitation wavelength 
is usually warranted. Although penetration depths more 
than one millimeter have been described in the context 
of brain tissue [54], the density of the skin and the rele-
vant excitation wavelengths do not permit such deep 
penetration. Imaging systems are conventionally limited 
to several hundred micrometers in depth.
Both collagen and elastin, the most important struc-
tural proteins of the extracellular matrix (ECM), have 
convenient 2PEF profiles [55]. On the cellular level, the 
abundantly present cytoplasmic metabolites NADH 
and FAD are prolific emitters in their reduced and oxi-
dized states, respectively. An example of 2PEF imaging 
of dermal fibroblasts can be seen in . Fig.  19.1. 
  . Fig. 19.1 Combined two-photon excited fluorescence image (2PEF, 
green) and second harmonic generation image (SHG, red) of cultured 
human dermal cells and their derived collagen matrix, respectively. Col-
lagen fibers induce a bright SHG signal, whereas intrinsic fluorophores 
in the cytoplasm of the dermal cells outline the cells. In vitro images 
were acquired using a previously described setup [87]. Scale bar: 500 μm
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Simultaneous recording allows a redox ratio to be calcu-
lated. The feasibility of this strategy was shown in an 
in  vivo mouse model by Quinn et  al. [56], visualizing 
metabolic changes during wound healing. Another 
in vivo study used the same concept to investigate the 
depth- dependent metabolism of keratinocytes [57]. 
Melanin content has been used as an in vivo marker for 
several dermatological disorders [58].
19.2.3.3   Second Harmonic Generation (SHG) 
Microscopy
The introduction of SHG microscopy has sparked a 
slew of research in dermatology. Also known as fre-
quency doubling, it involves the interaction of two pho-
tons of the same wavelength with a nonlinear material 
and the subsequent creation of a single photon with 
double the frequency and energy. The ability of a mate-
rial for second harmonic generation, described by the 
nonlinear susceptibility coefficient χ(2), depends on the 
non-centrosymmetric structure. Biologically significant 
harmonophores include collagen [59], myosin [60], and 
microtubules [61].
In the case of fibrillar collagen, the repeating dipoles 
of peptide bonds and the structural alignment on all lev-
els of the molecular and supramolecular structure (par-
allel peptide bonds are assembled into parallel fibrils; 
fibrils are aligned into fibers) result in coherent amplifi-
cation of the emitted second harmonic signal refs. This 
also means that the structural alignment of collagen 
fibers influences the SHG signal intensity [62]. As this is 
not the case for non-fibrillar collagen types, SHG 
microscopy is specific for type I and II collagens and 
forms a highly specific tool for 3D imaging of unpro-
cessed skin samples as showed in . Fig. 19.2 Abnormal 
ratios of collagen I:III have been described in multiple 
fibrotic processes [63]. Although collagen type III, often 
deposited alongside type I, is a fibrillar collagen, it pro-
duces only weak SHG signals [64]. As the SHG signal is 
dependent on phase-matching conditions, most of the 
signal forwardly propagated. The thin scattered fibers of 
collagen type III and their associated reduction in phase 
matching appear to be distinguishable from type I by 
comparing forward- and backward-scattered SHG 
images [65, 66]. The opacity of collagenous tissues how-
ever makes the detection of this signal impractical, ren-
dering this technique possible only in thin specimens.
Multiple strategies to distinguish scar types using 
SHG images have been described. Most of these focus 
on software-based analysis of collagen fiber orientation 
and density [67–69]. Matrix organization and orienta-
tion have been described as abnormal in scars [29]. Non- 
software- based approaches rely on the dependence of 
the nonlinear susceptibility of collagen on the polariza-
tion of the incident light. Polarization-sensitive SHG 
(PS-SHG) probes the organization of collagen fibers by 
sequentially rotating the polarization relative to the 
optical axis and probing the SHG response. By analyz-
ing the SHG intensity at different angles of polarization, 
orientation vectors can be reconstructed [70, 71]. Note 
that because of the strong dependence of SHG on polar-
ization, software-based analyses should be performed 
on images from circularly polarized light sources.
Using unstained tissue allows simultaneous biome-
chanical testing during imaging. For example, Rosin 
et  al. assessed the scarring capacity of healing split- 
thickness skin grafts by microstructural SHG imaging 
of collagen and biaxial stretch testing [72]. The authors 
correlate the loss of waviness patterns to increased stiff-
ness.
The reduced phototoxicity (as no external fluoro-
phores are used) from these optical processes allows 
in  vitro and even in  vivo imaging, for example, skin 
equivalents [73], lab-grown wound models [74], and 
antifibrotic treatments [75].
Several research groups have made attempts to 
include SHG in clinical decision-making. Predominately 
applied to neoplastic lesions, consecutive follow-up of 
  . Fig. 19.2 Combined 2PEF (green) and SHG (red) image of  elas-
tin and collagen fibers, respectively. Unprocessed ex  vivo human 
skin, specifically the reticular dermis, was imaged using the setup 
described in [87]. A stack of  35 images was acquired in the Z-axis. 
Image processing in ImageJ resulted in the 3D projection seen here 
[88]. Scale bar: 500 μm
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scars and topical therapies has also been described. 
Commercial translation has already resulted in multiple 
devices marketed for in vivo dermatological applications. 
The Dermaspect (JenLab GmbH, Berlin, Germany) 
device entails a multimodal (2PEF, CARS, SHG) micro-
scope with an adjustable scan head for in vivo skin imag-
ing [76]. Innovations in laser technology allow for 
increasingly smaller and cheaper devices [77, 78].
19.2.3.4   Third Harmonic Generation (THG) 
Microscopy
The propensity of  a material for third harmonic gen-
eration depends not only on its nonlinear susceptibility 
coefficient χ(3) but also on whether partial phase 
matching can be achieved by a small inhomogeneity at 
the focus, making THG an interface-sensitive tech-
nique [79]. THG is less specific than SHG, increasing 
the number of  possible applications. By setting the 
focal volume of  the incident laser beam to several times 
the size of  a typical tissue structure, a geometry can be 
created where the phase-matching conditions enable 
efficient THG. As the THG contrast comes from inho-
mogeneities and tissue interfaces with a high χ(3), cell 
membranes and cell nuclei are clearly displayed with 
THG microscopy, since they contain lipids which are 
known to have a high χ(3) [80]. Not surprisingly, the 
multilayered structure of  the epidermis provides excel-
lent contrast. . Figure  19.3 shows a THG cross sec-
tion of  the epidermis in a drug penetration experiment. 
To illustrate the potential in dermatology, THG was 
shown to be a viable imaging technique for label-free 
tracking of  melanoma cells [81]. The THG contrast 
from melanin and structural features allowed differen-
tiation of  skin cancers [82].
In the context of scar tissue, the surface of elastin 
fibers is an adequate THG emitter [83]; thus, combining 
SHG and THG potentially allows for three-dimensional 
imaging of unstained, unfixed, and unsliced tissue.
Although an analysis of scar tissue has not been 
described yet, THG has strong potential as a label-free 
imaging technique because of reduced phototoxicity. 
Indeed, several articles describe the in  vivo “optical 
biopsy” technique in the skin [78, 84].
19.2.3.5   Coherent Anti-Stokes Raman 
Spectroscopy (CARS)
The structural information provided by SHG and THG 
can be supplemented by chemical information using 
another nonlinear process, Coherent anti-Stokes Raman 
Spectroscopy (CARS). Here, two lasers with different 
frequencies are focused on the sample, to probe the 
vibrational fingerprint of the molecules in the focal 
point. The CH2 content of lipids provides excellent con-
trast when imaging phospholipid-rich cell membranes 
and adipocytes. The OH signal from water molecules 
makes this technique especially applicable for research 
into transepidermal water loss [76, 85].
19.3   Future Perspectives
The enormous increase in available devices for volumetric 
analysis is indicative for the increased attention for quan-
tification tools in scar research. Technological advances 
and the need for point of care solutions have already 
resulted in smaller and manageable devices suitable for 
bedside use. This trend can be expected to continue with 
smartphone-based solutions already being investigated in 
wound evaluation [86]. Both researcher and clinicians 
should however be mindful of the fact that most devices 
are not adequately tested on their clinimetric properties.
This trend is also applicable to experimental tech-
niques. As image acquisition times decrease and devices 
get smaller, we can expect integration of different imag-
ing techniques, each bringing their own strengths in elu-
cidating the multifaceted issue of pathological scarring.
  . Fig. 19.3 Nonlinear microscopy image of  a cross section of 
ex vivo skin. The THG signal (green) depicts the layers of  the epider-
mis; collagen fibers in the papillary dermis give rise to the SHG sig-
nal in red. In this experiment, fluorescently labeled (magenta) 
hyaluronic acid (250 kDa) was applied to the skin’s surface to quan-
tify epidermal skin penetration. Scale bar: 500 μm
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The purpose of this chapter is to provide an overview 
and potential answers to the ethical considerations of 
the clinical management of patient scars. We will focus 
on two main aspects of this subject:
 1. Is there truly a need to invoke ethics when the clini-
cian is faced with managing a patient’s scar?
 2. What are the dilemmas that a clinician will confront 
in their daily practice when managing a patient’s 
scar?
20.1   Is there Truly a Need to Invoke Ethics 
When the Clinician Is Faced 
with Managing a Patient’s Scar?
The motivation for the clinical management of a patient’s 
scar from both the patient’s perspective and the clinician’s 
perspective is clear: first, to improve the appearance of 
the scar and, second, if needed, to improve any functional 
impairment that the scar may have caused. If successful, 
these goals will enhance the beauty and function of the 
patient’s skin and improve the patient’s quality of life. 
Therefore, like all therapies or procedures in medicine, 
the ethical considerations of scar management are based 
upon balancing the risks and benefits of any treatment.
There are multiple causes of scars – scars generated by 
unintended accidents, iatrogenic scars from surgical pro-
cedures, and even self-inflected voluntary scars created by 
the patient. The constant among these, regardless of the 
reason(s) of the scar, is that the skin has been injured and 
has undergone the known phases of wound healing – clot-
ting with platelet aggregation and activation, inflamma-
tion, reepithelialization, fibroplasia, neovascularization, 
granulation tissue formation, and then a long period of 
tissue remodeling with fibrosis and scarring. The scar is 
actually a witness to these events of “reparative” wound 
healing, rather than “regenerative” non- scarring wound 
healing that is seen in newts and lower animals.
Each cultural group has its own concept of beauty 
and of what it considers to be normal or aberrant. 
Moreover, the judgment of what is normal or not may 
be interpreted differently, not only by the society but 
also by the individuals. That is why when a patient bears 
a scar, it may take on different meanings, depending 
upon the societal and individual context of the scar.
Sometimes, a skin scar can carry a highly positive 
message. For example, the scar could be proudly exhib-
ited as a testimony of some glorious actions such as the 
mark of a successful warrior exploit or survival from a 
savage assault. A voluntarily induced scar could also 
represent a ritualistic marking that symbolizes both 
social allegiance and beauty. Examples include scarifica-
tions and tattoos.
Conversely, a skin scar could represent an echo of 
an emotional scar. In these situations, the meaning of 
the scar is well beyond a simple previous threat to the 
integrity of the body envelope. Rather, the scar becomes 
a permanent remembrance a traumatic event. The 
scar may represent and even support the revival of the 
patient’s spirit after a painful traumatic episode. The 
possibility of recognizing an aesthetic prejudice, which 
could be temporary and/or permanent, in the context of 
a judicial expertise, testifies to this aspect.
On the other hand, for patients whom are strictly 
compliant to societal standards and societal points of 
view of beauty, a scar in a visible location on the patient’s 
body may cause loss of self-esteem and self-confidence, 
regardless of its origin.
Another potential context of scar management 
would be a patient who generates and accumulates 
self- inflicted scars and psychologically believes that the 
healed scars form sort of protective bandage.
Therefore, there is no single approach to the manage-
ment of these various complex situations, except for the 
underlying understanding that patients who are scarred 
require attention, and a physician who listens to them 
assesses the proper context of the scar and considers 
carefully what the patient desires.
20.2   What Are the Dilemmas that 
a Clinician Will Confront in Their Daily 
Practice When Managing a Patient’s 
Scar?
At the same time, the surgeon may be pleased to observe 
a minimal scar as the result from his/her surgical pro-
cedure and may be faced with the disappointed patient 
who wants the scar to disappear completely.
In many cases – and especially after surgery – scars 
can make the physician feels uncomfortable, because 
the scar is an obvious evidence of the physician’s work 
and reminds the physician of his or her limitations and 
shortcomings. Totally scarless surgery is not possible. 
Beyond the disease that the patient would like to forget 
and beyond the pain and suffering that the patient went 
through, the physician needs to understand the disap-
pointment and distress of the patient when he/she learns 
that the scar is permanent and cannot be erased.
Experience has taught us that objective criteria (sur-
face area, surface texture, color, thickness, degree of 
fibrosis etc.) are not always sufficient to assess  adequately 
a scar and its functional and psychological repercussions. 
A too fast clinical examination and judgment may lead 
to the conclusion that the patient’s request for scar revi-
sion is superfluous, unnecessary, or even unreasonable. 
To avoid misunderstanding of the patient’s feeling and 
desire for scar revision, the physician must look beyond 
the simple appearance of the scar and has to harken back 
to the patient’s own history including his or her trauma 
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and the context of the scar. A large discrepancy between 
the perspective of the patient and the perspective of the 
physician might be an early indication of psychological 
difficulties and a call for further clinical attention [1].
When the patient adamantly demands scar revision 
by surgical intervention, it often comes from the patient’s 
point of view (and/or experience) that less invasive solu-
tions (topical steroids, silicone membranes, laser treat-
ment, etc.) are not satisfactory.
The origin of surgical ethics is uncertain [2, 3]. 
Reviews and studies on skin scar ethics are scarce [4]. 
Most of the articles involve issues related to the ethics 
of burn scars [5], the ethics in plastic surgery [6], or the 
ethics in major surgery [7]. Nevertheless, some reviews 
highlight the current problems associated with emerging 
approaches for scar management such as the use of fetal 
cells in skin regeneration [8].
According to Miles Little publications [9, 10], surgi-
cal ethics have generally been framed as general medical 
ethics applied to surgical situations. There are five cat-
egories of experience and relationship, which are espe-
cially important in surgery field. These include (i) rescue, 
(ii) proximity, (iii) ordeal, (iv) aftermath, and (v) pres-
ence. The sense of rescue and of relational proximity, 
the ordeal, and aftermath of surgery are things that the 
patient experiences. Understanding these feelings allow 
surgeons to know what may be asked of them in an ethi-
cal point of view. Recognition of the reality and valid-
ity of each category in the surgical process highlights 
the importance of presence that is the acts by which the 
surgeon demonstrates that he is present to the patient 
throughout the surgical process and its consequences. 
While communication skill trainings may never com-
pletely compensate for insensitivity, the ideal of pres-
ence as a virtue and as a duty can be taught by precept 
and by mentors.
As Albert Einstein said “If  you always do what you 
always did, you will always get what you always got.” 
Because each scar, each patient, and each context are 
unique, the search for an adequate and appropri-
ate surgical solution constantly forces us to innovate. 
Innovation in surgery has contributed to progress in 
medicine and has enhanced the overall patient’s quality 
of life. Nevertheless, surgical innovation itself  also raises 
numerous ethical issues, such as patient safety, informed 
consent, the proper use of healthcare resources, and 
conflicts of interest – especially in the case of developing 
new devices by an industry-physician partnership. None 
of these challenges are specific to surgery field, nor to 
scars, but there are features about surgery and scars that 
complicates the identification and resolution of these 
issues [11, 12]. Therefore, it is important, from an ethi-
cal point of view, to consider that innovation is not only 
the key to progress but also the greatest challenge to our 
professionalism [13].
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Take Home Message
Given that scar treatment needs to balance risks and 
benefits for the patient, it’s impossible to define a skin 
scar by its physical appearance only.
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21.1   Background
The healing of open cutaneous wounds involves the gen-
eration of vascularized granulation tissue that closes the 
gap in the skin. Thereafter, an effective epidermal bar-
rier is created over the granulation tissue. Wounds in 
which sutures have approximated the edges also undergo 
granulation, albeit less than in open wounds that must 
heal by secondary intention. In both cases, the adher-
ence of the wound edges becomes stronger over time: in 
general, wounded skin acquires 80% of the dermal 
strength of the surrounding normal skin by 3 months 
post-wounding [1].
21.2   Cutaneous Wound Healing 
and Mechanobiology
These wound-healing phenomena are the result of  a 
cascade of  complex biochemical events that can be 
categorized into four general overlapping phases: 
coagulation, inflammation, proliferation, and remod-
eling. Significantly, all four phases of  wound healing 
are influenced by both intrinsic and extrinsic mechani-
cal forces. For example, the formation of  granulation 
tissue in the proliferating phase is driven by intrinsic 
and extrinsic mechanical stimulation of  the fibro-
blasts, myofibroblasts, endothelial cells, and epithelial 
cells that are in and near the wound. Similarly, myofi-
broblasts contract the wound in the proliferative phase 
by mechanical forces that are themselves shaped by 
many extrinsic forces, including the natural tension in 
the skin. The remodeling phase can also be influenced 
by extrinsic mechanical forces [2]. During this phase, 
fibroblasts secrete collagen and fibronectin, which are 
key components of  the extracellular matrix (ECM). 
These cells then regulate the volume of  the ECM by 
secreting collagenase. This repeated synthesis and 
enzymatic breakdown of  ECM proteins remodels the 
three-dimensional structure of  the ECM. For proper 
remodeling, the synthesis and degradation processes 
must be carefully balanced: if  there is too much ECM 
synthesis, scars can become hypertrophic. Conversely, 
if  there is excessive ECM degradation, the scar can 
become atrophic. Multiple lines of  evidence show that 
this ECM remodeling process can become deranged 
by extrinsic forces on the ECM [3]. For example, 
wounds on the major joints tend to develop hypertro-
phic scars because the joint movements place strong 
cyclical tension on the wound. This tension provokes 
chronic inflammation of  the dermis, namely, the 
unceasing influx and activation of  inflammatory cells, 
the persistent generation of  blood vessels and nerve 
fibers, and the constant production of  collagen by the 
activated fibroblasts. This chronic inflammation 
blocks the conversion of  the granulation tissue into 
dermis-like tissue by the remodeling process and 
results in an immature hypertrophic scar that is red, 
elevated, hard, and painful.
These observations suggest that, to prevent patho-
logical scarring after surgery, it is necessary to ensure 
that the sutures cause the wound edges to adhere to each 
other without any tension, even when strong extrinsic 
forces are placed on the wound. This will allow the gran-
ulation tissue to convert smoothly into dermis-like tis-
sue, thereby yielding minimal scarring.
21.3   Surgical Techniques that Can Minimize 
Dermal Tension
The risk of pathological scarring can be greatly reduced 
by using subcutaneous/fascial tensile reduction sutures 
[4]. This is because dermal sutures do not effectively 
reduce tension on the dermis: rather, to achieve this, we 
must access much deeper structures, namely, the superfi-
cial and deep fascia, and suture them. This type of 
suturing will elevate the wound edges smoothly while 
placing minimal tension on the dermis. In other words, 
it will cause the wound edges to attach naturally to each. 
Only then should dermal and superficial sutures be used. 
It is very important to realize that dermal sutures on 
their own cannot reduce the tension on the dermis: this 
concept is the key to preventing the formation of patho-
logical scars after surgery.
Thus, in the case of benign tumor excision or scar 
revision surgery in high-tension areas such as the chest 
wall, the cutaneous mass should be completely excised 
along with a minimum of normal skin margin and all 
fatty tissues under the mass. Hence, all tissues above the 
deep fascia of the muscle are removed. The wound edges 
are then undermined under the deep fascia, and the deep 
fascia is sutured with 0 polydioxanone sutures such as 
PDS®II (Ethicon, Inc., Somerville, New Jersey). 
Thereafter, the fibrous membrane in the fatty tissues, 
namely, the superficial fascia, is sutured using 2–0 and 
3–0 PDS®II. This approach causes the wound edges to 
adhere naturally to each other. Our previous study 
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showed that deep fascia suturing reduced about 90% of 
the tension on the wound edge, while superficial fascia 
suturing reduced the remaining 10% [5]. After fascial 
suturing, dermal sutures using 4–0 PDS®II are started. 
This is followed by superficial sutures with 6–0 polypro-
pylene or nylon sutures such as Proline® or Ethilon® 
(Ethicon, Inc., Somerville, New Jersey) (. Figs.  21.1, 
21.2, and 21.3).
21.4   Z-Plasty
Another way to prevent pathological scar formation in 
high-tension areas is to use zigzag suturing techniques 
such as the Z-plasty [5]. This is particularly suitable for 
joint or limb surgery because the fatty tissue layers in 
these areas are thin: this means that it is difficult to find 
the superficial fascia and apply the subcutaneous/fascial 
tensile reduction sutures. Zigzag suturing is also good 
for long suture wounds because it effectively disrupts the 
tension on the resulting scar. As a result, zigzag suturing 
is an effective approach for releasing linear scar contrac-
tures. Another major benefit of Z-plasties is that seg-
mented scars mature faster than long linear scars. Thus, 
if  a scar or wound crosses a joint, zigzag incision and 
suturing will significantly reduce the risk of pathological 
scar recurrence or development (. Fig. 21.4).
In terms of Z-plasty design, the sides of each trian-
gular flap should be 7–10 mm long and the pitch between 
each z-plasty should be 2–4 cm, depending on the total 
length of the wound [5]. In our experience, this pitch 
yields the most satisfactory results (personal observa-
tions). Dermal sutures can be started after confirming 
that the triangular flaps are fully elevated and can be 
transposed with each other.
It should be noted that, because keloids have much 
stronger inflammation than hypertrophic scars, it is 
best to use both tension reduction sutures and 
Z-plasties during keloid revision surgery [5]. This sig-
nificantly reduces the risk of  recurrence (. Fig. 21.5). 




  . Fig. 21.1 The ideal closure method for minimizing the tension on the 
dermis. a The fatty tissues are removed along with the scar or tumor. b 
Undermining between the deep fascia and the muscle is performed. c 
The deep and superficial fasciae are then sutured to release the tension 
on the dermis. The red lines in a indicate where the tissue is incised and 
undermined. Dermal sutures themselves do not effectively reduce ten-
sion on the dermis. To achieve this, we must access much deeper struc-
tures, namely, the superficial and deep fasciae, and suture them
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  . Fig. 21.2 Chest wall scar revision. a Preoperative appearance of 
the scar. b View after the scar and fatty tissues were removed. c View 
after the deep and superficial fasciae of  the pectoralis major muscle 
were sutured. d View immediately after the dermal sutures and 
superficial sutures were placed. e View 2  years after surgery. The 
wound edges were undermined under the deep fascia, after which the 
deep fascia was strongly sutured. These deep sutures absorb 90% of 





  . Fig. 21.3 Abdominal wall scar revision. a Preoperative appear-
ance of  the scar and the design of  the incisions. b View after the scar 
and fatty tissues were removed. c View after the deep and superficial 
fasciae were sutured. d View immediately after dermal sutures and 
superficial sutures were placed. e View of  the postoperative taping 
fixation that was used to stabilize the wound and protect it from 
extrinsic mechanical forces. f View 2 years after surgery. The anterior 
sheath of  the rectus abdominis muscle was strongly sutured. The 
wound edges were smoothly elevated so that they attached naturally 
to each other. Dermal sutures could then be placed
a b c d e
  . Fig. 21.4 Knee joint scar revision. a Preoperative appearance of 
the scar and the design of  the incisions and Z-plasties. b View imme-
diately after the operation. c View 3  months after surgery. d View 
6 months after surgery. e View 1 year after surgery. In the case of 
limb surgery, it is difficult to place deep tissue sutures. Therefore, it is 
necessary to dissipate the tension on the wound by using zigzag line 
suturing methods such as the Z-plasty: this approach segments the 
scar and thereby releases its tension. This in turn causes the chronic 
tension-induced inflammation that is driving pathological scar 
growth to wane over time





  . Fig. 21.5 Anterior chest keloid treatment using tension reduc-
tion sutures, Z-plasties, and postoperative radiotherapy. a Preopera-
tive appearance of  the keloid and the design of  the incisions. b View 
after the scar and fatty tissues were removed. c View immediately 
after the deep and superficial fascial sutures were placed and the 
Z-plasties were designed. d View immediately after the dermal 
sutures and superficial sutures were placed. e View 2 years after sur-
gery. In cases of  keloid revision surgery, great care is needed to 
decrease the powerful chronic inflammation that is driving the 
growth of  the scar. A combination of  tension reduction sutures, 
Z-plasty, and postoperative radiotherapy can effectively prevent 
keloid recurrence after revision surgery
21.5   Conclusion
All four phases of  wound healing are influenced by 
mechanical forces. These mechanical forces provoke 
chronic inflammation of  the dermis and cause patho-
logical scars. Dermal sutures do not effectively reduce 
tension on the dermis: rather, to achieve this, we must 
access much deeper structures, namely, the superficial 
and deep fascia, and suture them. Another way to pre-
vent pathological scar formation in high-tension areas 
is to use zigzag suturing techniques such as the 
Z-plasty.
Take-Home Messages
 5 The risk of pathological scarring can be greatly 
reduced by using subcutaneous/fascial tensile 
reduction sutures.
 5 Dermal sutures do not effectively reduce tension 
on the dermis: rather, to achieve this, we must 
access much deeper structures, namely, the superfi-
cial and deep fascia, and suture them.
 5 A study showed that deep fascia suturing reduced 
about 90% of the tension on the wound edge, 
while superficial fascia suturing reduced the 
remaining 10%.
 5 Z-plasty is particularly suitable for joint or limb 
surgery because the fatty tissues layers in these 
areas are thin: this means that it is difficult to find 
the superficial fascia and apply the subcutaneous/
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Effective scar treatment has come a long way in recent 
years. Classifications allow us to differentiate between 
individual types of scars and allow us to propose 
scientifically proven therapeutic regimes to improve even 
severe pathological scarring. This has helped not only in 
improving functional and aesthetic results in the affected 
patients but also to ameliorate their oftentimes severely 
impaired quality of life.
However, efforts have long been underway to prevent 
pathological scarring altogether. Hopes are that through 
early intervention in fresh scars, excessive scarring can be 
limited or prevented altogether.
The use of  compression garments or silicone gel 
sheeting has long been established to steer the scar matu-
ration process away from excessive and proliferative scar-
ring disorders. Flavonoids, too, have proven a promising 
option for the prevention of  excessive scarring in recent 
years.
Through the advent of  newer techniques for the treat-
ment of  hypertrophic scars and keloids and fresh insights 
into the pathophysiology of  excessive scarring, new 
methods for scar prevention are currently making their 
way into routine practice.
Since fractional photothermolysis has shown its 
potential in mitigating proliferative scarring and aiding 
scar remodeling in mature scars, more and more research-
ers are attempting to alter these ongoing processes in 
fresh scars to prevent excessive scarring.
This chapter explores the different modalities for scar 
prevention (see . Table 22.1), their mode of  action, and 
the evidence supporting their use.






Gold standard for burn injuries after skin grafting 
or after deeper second-degree burns that have 
healed without surgery
Begin treatment as soon as the skin grafts are stable 
enough or after reepithelialization in wounds that have 
healed without surgery
Garments should be worn for as close to 24 hours per 
day as possible for 6 to 12 months, depending on the 
level of  scar activity
Garments should be replaced regularly, at least every 3 
months so as to ensure sufficiency
As an adjunct after earlobe keloid excision Pressure earrings should be worn for as close to 24 
hours per day as possible after surgery to minimize the 
risk of  keloid resurgence, starting on the day of  suture 
removal
Children with linear hypertrophic scarring or 
keloids, where intralesional treatment is not an 
option
Same treatment paradigm as in burn scarring. 
Especially in younger children, sudden growth can 




First-line therapy for linear and widespread 
hypertrophic scarring as well as minor keloids and 
first option for the prevention of  hypertrophic 
scarring
Sheets or patches should be applied to the desired area 
for 12 to 24 hours per day. Treatment times can vary 
depending on scar activity, but 3 to 6 months of 
treatment should be performed
Gels should be applied to the scarred area two to three 




Can be considered for the treatment of 
hypertrophic scarring or scar prevention
Treatment recommendations vary depending on the 
manufacturer
Patches are commonly applied for 6 to 12 hours 
overnight for 3 to 6 months
Pulsed dye 
laser (PDL)
Can be considered for the treatment of 
erythematous and pruritic postsurgical scars
No clear recommendations or fixed treatment 
paradigms exist; however, studies indicate that up to 
three treatment sessions are required for favorable 
results





In most studies, treatment is begun at the date of 




Should be considered in patients where excessive 
scarring is expected (after severe burns/trauma)
Expert committees recommend starting treatment one 
to three months after the original injury to modulate 
the scarring process
Again, no carefully researched treatment paradigms 
exist; however, based on the data available, 
low-density, high-energy treatment of  the deep dermis 
in combination with careful superficial smoothening 
seems favorable
Experimentally, the laser has been used 
intraoperatively for scar improvement
To aid with the wound healing, this laser has been 
used to treat the wound margins intraoperatively 
before placing the sutures. One to two passes of 
low-density, high-energy laser treatment were 
performed on the wound margins
Thus far, this research was mostly empiric and 
uncontrolled; thus, no recommendations regarding its 






Indications for this laser are similar to those of 
the CO2 laser
Treatment with the Er:Glass laser has less side effects 
than with the CO2 laser; however, its treatment effects 
are reduced as well, thus requiring more sessions for 
similar results
As with the CO2 laser, little research on the potential 
for immature scar treatment has been performed, so no 
clear recommendations can be made
  . Table 22.1 (Continued)
22.1   Techniques for the Treatment 
of Immature Scars
22.1.1  Pressure Therapy
Upon the discovery of the clinical effects of pressure 
garments on hypertrophic burn scarring by Silverstein 
and Larson in the late 1960s, the results of further 
research on the topic performed at Shriners Burns 
Institute in Galveston, Texas, were published in the 
early 1970s. This led to the onset of pressure garment 
therapy use to prevent hypertrophic scar formation in 
burn patients. Ever since, this method has become the 
gold standard for scar prevention in burn patients in 
many countries around the world. While the exact mode 
of action has not been fully understood, pressure gar-
ment therapy supposedly decreases capillary perfusion 
in the affected tissue, thus leading to localized tissue 
hypoxia which in turn increases the rate of fibroblast 
apoptosis, thus leading to a reduced production of col-
lagen. A recent preclinical study by DeBruler et  al. 
investigated the effects of early pressure garment appli-
cation after skin grafting in burned Duroc pigs and 
found an increased level of matrix metalloprotease-1 
(MMP1) in pigs that received pressure garment treat-
ment within 1 week of grafting [1]. While further 
research on the matter is required and influences on the 
levels of collagen I and III or transforming growth fac-
tor 1 could not be proven, increased levels of MMP1 
which is a known contributor in scar remodeling might 
help to explain the effects of pressure garment therapy.
Pressure garments come in the form of stockings, 
pants, sleeves, suits, bandages, girdles, and clip-on ear-
rings, and for locations that are hard to reach through 
circularly applied pressure, special pelottes can routinely 
be fitted to allow for effective treatment of nearly every 
anatomic location. Garments should be worn for as 
close to 24 hours per day as possible and are usually rec-
ommended for at least 6–12 months. In patients showing 
scar activity after 12  months, treatment is often pro-
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longed for up to 18 months. Being worn for such long 
times takes a significant toll on the garments which 
loosen drastically over time, thus requiring regular 
replacement to ensure sufficient pressure. In our experi-
ence, garment replacement is necessary at least every 
3 months. To allow patients to wash their compression 
garments regularly, at least two complete sets should be 
available at any given time. In patients with physically 
demanding jobs, wear times might be reduced even fur-
ther, and more pairs for regular changing might be 
required.
Pressure garment therapy is very taxing on the 
patient and compliance is often lacking. Especially dur-
ing the summer, patients experience sweating and skin 
maceration, as well as strong odor. In countries without 
comprehensive health insurance, treatment cost is 
another important factor. Even in patients where only 
small areas of the body are affected, treatment over the 
course of a year will easily cost between one and two 
thousand euros for a small pressure garment like a glove 
(. Fig. 22.1) or a sleeve alone, whereas larger pieces or 
even suits for the whole body will cost low to medium 
five-figure sums, especially when combined with other 
treatment modalities.
The current consensus on the pressure applied through 
garments recommends between 20 and 25  mmHg, as 
studies have shown a higher efficacy when compared to 
lower-pressure garments (10–15 mmHg).
Even though pressure garment therapy has now been 
in clinical use for over 40 years, hard clinical data on its 
efficacy is largely missing, and the existing literature is 
quite heterogenous.
Early adopters of the technique like Larson, Kischer, 
and Tolhurst reported favorable results on the reduction 
of hypertrophic scar formation. More recently, Van den 
Kerckhove et al. reported positive effects on scar thick-
ness when treating patients with garments with at least 
15 mmHg of pressure, and Engrav et al. demonstrated 
that scars under compression were noticeably softer and 
thinner in their clinical study in 2010 aided by objective 
measuring devices. However, a large meta-analysis by 
Anzarut et al. in 2009 was unable to discern differences 
in scars treated with pressure garments and untreated 
scars [2]. In 2013, Atiyeh et al. came to a similar conclu-
sion and questioned the widespread use and recommen-
dation, especially in the light of the often poor patient 
compliance and the resultant cost-effectiveness of this 
course of treatment. Especially in burn patients, this 
course of treatment, however, has become the accepted 
standard. This makes randomized controlled trials with 
an untreated patient population nearly impossible on 
ethical grounds, thus limiting the designs of further 
studies investigating this treatment method.
Thus far, based upon many different studies indicat-
ing the clinical efficacy of pressure garment therapy, 
current guidelines for the treatment and prevention of 
pathological scarring recommend its use while noting 
the less than robust level of evidence.
Furthermore, pressure garment therapy can be con-
sidered in children with linear hypertrophic scarring or 
keloids, where intralesional treatment is abandoned 
because of side effects or the associated risk of the treat-
ment and pressure garment therapy has empirically 
shown greater efficacy than in adults.
In patients that received surgical treatment for ear-
lobe keloids, pressure earrings have been shown to 
greatly reduce the risk of keloid recurrence and are thus 
regularly recommended as an adjunct. Pressure earrings 
are readily available from specialized orthopedic techni-
cians, and if  keloids are excised elsewhere on the ear, like 
on the helix, tragus, or other parts of the ear, special 
splints can be custom-made.
  . Fig. 22.1 Patient with severe burn scarring of  the left hand wearing a compression glove. The glove allows full function (full finger flexion 
and extension) while providing full coverage
 J. Poetschke and G. G. Gauglitz
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22.1.2   Silicone-Based Products
Silicone-based products come in a variety of forms. 
They are available as creams, oils, gels, or, most com-
monly, patches or sheets that can be applied to the 
affected areas. Their mode of action regarding the treat-
ment and prevention of excessive scarring has not yet 
been fully understood, but it is stipulated that the occlu-
sive effect of the silicone inhibits the transepidermal loss 
of water (TEWL), thus ensuring sufficient hydration of 
the skin. Thus far, no properties of silicone, which 
directly influence the process of scarring, have been dis-
covered.
Treatment with silicone-based products can be 
started after complete reepithelialization of the wounds. 
Sheets or patches should be applied for 12–24 hours per 
day throughout 3–6 months. Gel- or cream-based sili-
cone products are better suited for areas that are subject 
to constant motion (i.e., large joints) where wound 
dressings might prove unsuitable. To achieve the desired 
effect, applying the gel two to three times daily is recom-
mended.
Patches and sheets come in many different forms and 
thicknesses. Commonly, thicker sheets last longer than 
thinner ones. Larger sheets can be cut into the desired 
size. They should be cleaned with water and special 
cleaning solutions that come with the product regularly 
and can be put back on their carrier foil for storing in 
between applications. Reusing a single sheet is usually 
possible for 6–8 weeks, before the silicone disintegrates 
and becomes gelatinous in its structure, whereupon a 
fresh sheet should be used.
Side effects or allergies to silicone-based products are 
rarely observed. Skin maceration through the occlusive 
effect is possible, whereupon patients can reduce the 
application time of the silicone.
Silicone has been used in the treatment of immature 
scars since the early 1980s, where it was first used in the 
Adelaide Children’s Hospital for the treatment of burn 
scars. Ever since, it has become one of the pillars for 
early scar intervention. Different prevention and treat-
ment studies have reported outcomes documenting the 
efficacy of silicone for preventing scar hypertrophy. 
Cruz-Korchin compared patients after bilateral mam-
moplasty, after which the scars on one breast were 
dressed with silicone sheets for 12  hours a day for 2 
months while the other remained without preventative 
treatment. Results demonstrated scar hypertrophy in 
60% of the untreated breasts after 2  months, whereas 
only 25% of the scars in the treatment group showed 
hypertrophy. Ahn et al., in 1991, could demonstrate that 
surgical incisions treated with silicone gel bandages 
showed less proclivity for hypertrophy than an untreated 
control.
In 2001, Gold et  al. showed that patients suffering 
from abnormal scarring showed significantly less hyper-
trophic scarring when treated with silicone gel sheeting 
after skin surgery compared to an untreated group of 
patients.
However, a variety of studies have failed to docu-
ment significant effects regarding scar prevention of 
treatment through silicone-based products. In 1998, 
Niessen et  al. failed to show positive effects regarding 
scar prevention through silicone gel sheeting and even 
reported a higher rate of hypertrophic scar development 
than in their control group treated with nonocclusive 
micropore in their breast reduction scar model.
Cochrane Reviews in 2006 and 2013 noted the gener-
ally poor quality of prevention and treatment studies 
analyzing the effects of silicone regarding pathological 
scarring [3]. While seemingly reducing the risk of abnor-
mal scarring in high-risk patients and improving scar 
parameters such as color and softness in existing scars, 
significant bias was a main critique point in most studies.
Nevertheless, silicone gel sheeting is recommended 
as a first-line therapy for linear and widespread hyper-
trophic scarring, as well as minor keloids in national and 
international guidelines on the management of patho-
logical scarring, and has furthermore been noted as an 
important option for the prevention of excessive 
scarring.
22.1.3   Onion Extract
Products that contain onion extract have seen increas-
ing popularity for the treatment of  immature scars in 
recent years. They are available as creams or patches 
and commonly include adjuncts such as allantoin or 
heparin. Onion extract contains quercetin, a flavonoid 
that has anti-oxidative and anti-inflammatory proper-
ties. Experimental research has suggested that quercetin 
influences transforming growth factor beta 1 and 2 and 
SMAD signaling pathways, thus inhibiting fibroblast 
proliferation and collagen synthesis. In cell cultures, it 
has also been shown to induce matrix metalloprotein-
ase-1 expression, thus influencing extracellular matrix 
remodeling.
Scar treatment is begun after complete reepithelial-
ization of  the wound is complete. Onion extract patches 
are commonly used overnight, where they are applied 
for 6–12 hours over the course of  12–24 weeks, though 
no clear recommendations regarding the length of 
treatment exist to date. Gels are often applied multiple 
times throughout the day for weeks or months, accord-
ing to manufacturer recommendations, though there is 
a variance between different formulations and manu-
facturers.
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Regarding the efficacy of onion-extract-based prod-
ucts, different studies documented significant potential 
regarding the prevention of pathological scarring. 
Draelos et al. reported a significantly improved appear-
ance of fresh surgical scars treated with onion extract gel 
when compared with a control group in two different 
studies in 2008 and 2012. Parameters positively influ-
enced through the treatment included scar softness, red-
ness, texture, and global appearance. In 2006, Ho et al. 
evaluated the effects of onion extract gel on scarring after 
Q-switched Nd:YAG laser tattoo removal in a Chinese 
patient population and reported significantly less scarring 
in the treatment group than in the control group.
In 2018, a randomized controlled study by Prager 
et al. on 125 subjects with fresh postsurgical scars that 
were treated with an overnight patch containing onion 
extract, allantoin, and heparin demonstrated signifi-
cantly better rated scars by both patients and investiga-
tors after 12 and 24 weeks of treatment when compared 
to the control group [4]. Overall treatment comfort was 
good, and no safety concerns were identified.
Some studies have, however, come up with less posi-
tive conclusions. Chung et al. investigated the effects of 
an onion extract gel when compared with a petrolatum 
emollient on fresh surgical scars and found no difference 
between the treatments. Ocampo-Candini et  al. pub-
lished a randomized controlled trial documenting the 
development of Pfannenstiel scars after cesarean section 
under treatment with onion extract gel and found no 
significant improvement over their untreated control 
group when comparing POSAS scores.
Overall, this relatively new treatment option requires 
further intense scientific evaluation to improve the level 
of evidence regarding its efficacy. Due to the promising 
data that has been collected thus far, current guidelines 
support the consideration of onion-extract-based for-
mulations for the treatment of hypertrophic scarring as 
well as the prevention of excessive scarring after surgery.
22.1.4   Pulsed Dye Laser (PDL)
The pulsed dye laser is a nonablative laser with a wave-
length of 585 or 595 nm. Its target chromophore is oxy-
genized hemoglobin, and application of the laser will 
therefore lead to coagulation of capillaries, thus induc-
ing tissue hypoxemia. In scar tissue, this effect will 
induce a reduction of profibrotic processes and stimu-
late scar remodeling.
Alster et al. reported significant therapeutic benefits 
of the PDL for the treatment of keloids in 1995; however, 
other research groups failed to replicate their findings 
with some even showing high numbers of recurrence. 
Further clinical research, however, has established the 
laser potential for the treatment of erythematous and 
pruritic scars, for which it is routinely considered. 
Recently, however, more and more authors have started 
treating fresh postsurgical scars with the PDL to eluci-
date whether this can favorably alter the process of scar 
maturation. McGraw et  al. were the first to publish a 
study on the prevention of hypertrophic scarring with 
the PDL in 1999. They found that early treatment within 
the first few weeks after trauma or surgery resulted in a 
faster resolution of scar stiffness and erythema, as well 
as a decreased frequency of hypertrophic scarring. 
Furthermore, they noted an improved scar quality due 
to the good color match with the healthy skin. In 2003, 
Nouri et  al. published similar findings. In their study, 
they included 11 patients with 12 postoperative linear 
scars that were divided into a treated and an untreated 
half. Overall, three sessions of 585 nm PDL treatment at 
monthly intervals were performed, whereupon the cos-
metic appearance of the treated scars was reportedly sig-
nificantly better, when analyzed by a blinded examiner 
using the Vancouver Scar Scale. In 2006, however, Alam 
et al. found no significant difference in their randomized 
controlled trial, where fresh postsurgical scars were 
treated with one pass of PDL treatment upon suture 
removal. They noted that 6 weeks after treatment, both 
groups had improved while the result of neither group 
was superior. In 2011, Kim et al. examined the effect of 
three sessions of PDL treatment followed by three ses-
sions of fractional ablative erbium:YAG laser treatment 
on fresh thyroidectomy scars and noticed favorable 
effects after PDL treatment with 83% of patients express-
ing satisfaction with the result. Er:YAG treatment fur-
ther improved the observed results [5].
To date, further studies on the potential of the PDL 
as an option in the treatment of fresh postsurgical scars 
to quicken scar maturation and to prevent scar hyper-
trophy exist. However, most studies lack a long-term 
follow-up that encompasses the entirety of the natural 
length of scar maturation (12–18 months), thus inhibit-
ing judgment about whether the final results are supe-
rior to an untreated control or simply accelerate the 
process. Therefore, so far, no clear recommendations on 
the use of the PDL for scar prevention can be made, 
while the current literature indicates that positive results 
at the cost of low rates of side effects can be achieved.
22.1.5   Fractional Ablative Carbon Dioxide 
(CO2) Laser
While the 10,800  nm carbon dioxide (CO2) laser has 
been around for decades, the recent development of 
fractional lasers has led to a significant expansion of its 
therapeutic range.
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In fractional units, the laser beam is divided into an 
array of smaller columns, leaving untreated skin islets in 
between. The divided laser columns ablate tissue and 
can reach depths of up to 4  mm newer models, with 
maybe their most important effects taking place in the 
dermis. Through the heating of the surrounding tissue, 
fractional CO2 laser treatment activates heat-shock pro-
teins which in turn stimulate antifibrotic factors such as 
transforming growth factor beta 3 (TGF-β3) and matrix 
metalloproteinases, thus stimulating scar remodeling. 
Additionally, through classic tissue ablation, scar sur-
face irregularities can effectively be smoothened through 
use of the CO2 laser.
After the discovery of these effects through experi-
mental research, different clinical studies have since used 
the fractional CO2 laser to treat mature burn scars. 
Recent studies found that a single treatment can improve 
scar softness and surface irregularities by up to 30% all 
the while positively influencing patient quality of life. 
While further research is warranted, current guidelines 
for the treatment of excessive scarring are recommend-
ing the CO2 laser for treatment in severe widespread 
hypertrophic scarring.
Side effects of the treatment commonly include 
swelling and oozing of the wounds throughout the first 
days after treatment, as well as erythema, which com-
monly recede within 1–2 weeks after treatment. In the 
author’s experience, when treating severe scarring with 
higher fluences, posttreatment hyperpigmentation often 
occurs but tapers off  after 4–6 months after treatment.
Since the fractional CO2 laser has seen great success 
in the treatment of mature widespread scarring and 
experimental studies suggest that this laser is able to 
normalize the oftentimes greatly disturbed architecture 
of the dermal matrix, research is under way to establish 
the CO2 laser’s abilities regarding excessive scar preven-
tion through the treatment of immature scars.
In 2011, Ozog et al. examined the intraoperative use 
of the fractional CO2 laser. Before wound closure, one- 
half  of the wound margins were treated with one to two 
passes of Active FX (Lumenis Ultrapulse, Santa Clara, 
California, USA), before the wound was closed. Upon 
the final evaluation of the scars after 2–3 months post 
surgery, both patients and examiners rated the laser- 
treated scar halves superior to the untreated halves [6]. 
Jung et  al., also in 2011, treated immature thyroidec-
tomy scars 2–3 weeks after surgery with a fractional CO2 
laser. Patients were treated with two passes, 50  mJ of 
energy and 100 microbeams/cm2 with a coverage of 
12.7%. Analysis of the treatment effect after 3 months 
revealed significantly improved Vancouver Scar Scale 
scores, as well as significantly improved values measured 
with a skin durometer [7]. However, no comparison with 
an untreated control group was performed. In 2013, Lee 
et al. performed a split-scar study on 15 three-week-old 
scars. Two laser passes were delivered at 80 mJ with a 
density of 100 microbeams/cm2 achieving a total cover-
age of 15.6%. During the final observation, 3 months 
after treatment, a significant improvement of Vancouver 
Scar Scale values superior to those made in the control 
group was found. Especially, scar pliability and thick-
ness improvements were larger than those in the control 
group, while vascularity and pigmentation did not differ 
considerably.
Overall, more research on the fractional CO2 laser’s 
abilities regarding scar prevention is required. While ini-
tial research shows promising results and the molecular 
defects thus far discovered suggest that early interven-
tion could lead to a normalization of the dermal archi-
tecture in scar tissue, many issues remain to be elucidated. 
To exclude natural scar regression, which is an impor-
tant factor in hypertrophic scarring, as a factor, long- 
term follow-up of over 12–18 months is required, as well 
as including a control group.
Nevertheless, expert committees suggest that early 
treatment, 1–3 months after the original injury, should 
be considered, especially when excessive scarring is 
expected. Thus far, no study researching early laser 
intervention found evidence of increased scarring or 
other severe side effects, thus supporting the safety the 
laser is known for in mature scar treatment.
22.1.6   Nonablative Erbium Glass (Er:Glass) 
Laser
The 1550 nm erbium glass (Er:Glass) laser is a nonabla-
tive fractional laser. It does not remove tissue but merely 
applies heat in a controlled way and leaves the epidermis 
intact. Through the application of heat in the dermis, its 
effect there is similar to those of the carbon dioxide laser, 
albeit at a reduced rate of side effects. Since treatment 
with the Er:Glass laser does not leave wounds, downtime 
is greatly reduced. Patients commonly experience light 
swelling and posttreatment erythema for a few days.
Regarding its efficacy for early scar intervention, 
thus far, few studies exist. Tierney et al. compared PDL 
and Er:Glass laser treatment in 2-month-old scars after 
Mohs surgery in 2009. The study was performed in a 
split-scar fashion, and patients were blinded as to what 
side was being treated with which laser. Every scar 
received four treatment sessions at four-week intervals, 
and follow-up was performed 1 month after the last 
treatment session. Overall, patients preferred the results 
of the Er:Glass-laser-treated scars (83% of patients). 
Regarding the scar parameters, pigmentation, scar 
thickness, and overall aesthetic outcome were all supe-
rior in the Er:Glass group [8].
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In 2014, Ha et al. compared the effects of PDL treat-
ment to Er:Glass laser treatment in a split-scar study on 
2–3-week-old thyroidectomy scars. Overall, both groups 
saw significantly improved scar ratings 6 months after 
treatment. Patients reported that they found the PDL 
treated scars less apparent; however, pliability appeared 
superior in the Er:Glass-laser-treated scars [9]. In their 
2014 study, Shin et al. performed another split-scar study, 
this time comparing ablative fractional CO2 laser treat-
ment to Er:Glass laser treatment. After three treatment 
sessions in 2-month intervals, follow-up examinations 3 
months after the last laser session revealed significant 
improvement of the scarring in both groups without sta-
tistically significant differences between the groups over-
all. However, the CO2 laser group showed greater 
improvement of scar hardness, while the Er:Glass-laser-
treated scars proved superior regarding their color [10].
Overall, current research has shown promise regard-
ing the Er:Glass laser’s efficacy for early scar interven-
tion. However, thus far, few clinical studies are available, 
thus requiring further research on the matter. As with 
other laser modalities for the treatment of immature 
scars, further studies should focus on longer follow-up 
times as well as larger group samples to further improve 
the level of evidence.
22.2   Conclusion
Efforts to prevent pathological scarring have been under-
way for many decades. One of the most established meth-
ods is pressure garment therapy, which has been used in 
the prevention of widespread hypertrophic burn scarring 
since the early 1970s. Years of use have seen this modality 
become the gold standard, and thus, pressure garments 
are routinely prescribed for most burn patients in the 
developed world. However, upon further inspection of 
the evidence, hard clinical data on the efficacy of pressure 
garment therapy is only scarcely available. Furthermore, 
patient discomfort is often high, leading to infrequent 
treatment compliance. Other options for the treatment of 
immature scarring are tolerated better. Silicone gel sheet-
ing is often applied throughout the night, and its contin-
ued use has been shown to improve scar pliability and 
height in connection with little to no side effects. Clinical 
evidence, however, is not as explicit as frequent mentions 
in national and international guidelines for the treatment 
and prevention of pathological scarring might infer. 
Similar in their application to silicone-based products, 
onion- extract- based gels, creams, and patches have 
appeared on the market in recent years. Often combined 
with further active ingredients like allantoin and heparin, 
they are specifically marketed for use in fresh scars, where 
they show promise in alleviating scar redness and firm-
ness as well as improving further scar parameters. While 
additional research will determine the future role of this 
treatment modality, the low side-effect profile and the 
appearance of natural ingredients appeal to many 
patients. In the treatment of mature scars, and increas-
ingly so in the treatment of fresh scars, lasers cannot be 
ignored. While PDL treatment has been around for years 
and its use in immature scars to alleviate pruritus and 
erythema has been well researched and documented, 
researchers are more and more focusing on fractional 
lasers. Their effects on dermal matrix remodeling through 
the stimulation of heat-shock proteins and the resultant 
effects on transforming growth factor beta isotypes and 
the concentration of matrix metalloproteases have 
resulted in researchers trying to employ these effects to 
modulate the active scar process in favor of remodeling 
rather than excessive fibrosis. While initial research, both 
for the ablative CO2 laser and for the nonablative Er:Glass 
laser, has shown promising results, most recent studies 
lack sufficient follow-up observation time. To assess 
whether clinically measured effects are caused through 
treatment and not through natural scar regression over 
time, scar maturation must be waited for to make a final 
conclusion. To date, this presents the largest problems 
with most research on immature scars. Overall, however, 
patients today can rely on a variety of promising options 
for the prevention of excessive scarring. While not every 
patient requires a robust prevention regimen after surgi-
cal intervention, care should be taken to identify patients 
at risk for excessive scarring and to tailor a treatment 
algorithm according to their needs. After all, preventing 
a hypertrophic scar or keloid from forming saves patients 
from months or years of strenuous symptoms and treat-
ment. Furthermore, today, most algorithms for the pre-
vention of excessive scarring are well tolerated and go 
along with minimal treatment discomfort and side effects.
Take-Home Messages
 5 Pressure garment therapy is the gold standard 
for the prevention of widespread scarring, e.g., 
after burns. Even though it has been in use since 
the early 1970s, evidence for its efficacy is largely 
empiric. Additionally, side effects of pressure gar-
ment therapy often lead to low compliance which 
affects the treatment efficacy.
 5 Silicone gel sheeting has proven effective in soften-
ing scars, and its use shows little to no side effects. 
Its mode of action, however, remains largely 
unknown, and recent meta-analyses question its 
efficacy.
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 5 Onion-extract-based products are available as 
creams and patches. Early research has shown 
promise regarding the prevention of pathological 
scarring, but further research is needed to further 
elucidate its role in the treatment of immature 
scars.
 5 PDL treatment has been found to improve pruri-
tus, erythema, and stiffness in fresh postsurgical 
scars; however, the overall level of evidence for 
immature scar treatment is low.
 5 Fractional CO2 laser treatment has been shown to 
affect dermal matrix remodeling and is therefore 
increasingly used to modulate immature scars. 
While initial studies show promise and scar pliabil-
ity and height seem to improve through treatment, 
long-term follow-up is crucial in future studies to 
further strengthen the clinical evidence for this 
therapeutic option.
 5 Fractional nonablative Er:Glass laser treatment 
employs a similar mode of action, much like the 
CO2 laser, but does not ablate tissue. Thus, down-
time and side effects are greatly reduced.
 5 Scar prevention is imperative in patients with a 
history of  pathological scarring to avoid severe 
functional, aesthetic, and psychosocial impair-
ments.
 5 Most modern methods for scar prevention have a 
minimal likelihood of severe side effects, and treat-
ment discomfort is commonly very low.
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23.1   History
Silicone gel was first discovered to be useful in the 
treatment of  scars by Perkins in Australia and New 
Zealand when observations were made empirically 
that scars improved when silicone was used as part of 
a dressing. The observations although anecdotal were 
impressive enough that use spread to the UK, and at 
the University of  Strathclyde in Glasgow, Scotland, a 
biomedical engineering student, Karen Quinn, under-
took a series of  studies for her PhD thesis to determine 
the mechanism of  action and published a paper in 
burns [1]. She determined that neither heat nor pres-
sure nor silicone absorption or chemical effects were 
responsible for its effects in studies done together with 
surgeon from the Plastic Surgery Unit at Canniesburn 
(Professor Reid). By chance, I was visiting the 
Canniesburn Hospital for 2 weeks and had the oppor-
tunity to observe the use of  silicone gel, which was 
made by Dow Corning. They were already sponsoring 
some of  my studies at Washington University School 
of  Medicine, and I suggested a controlled clinical study 
which had not yet been done. The effects on immature 
hypertrophic scars were in some cases dramatic with 
each patient serving as their own control. We subse-
quently did a follow-up study on using silicone on very 
early scars to prevent hypertrophy with equally encour-
aging results. Although there was some skepticism, in 
part due to a lack of  a clear mechanism of  action, sub-
sequent studies by several other investigators con-
firmed the efficacy. I will detail some of  these studies 
later in this chapter.
23.2   The Role of the Epithelium in Scar 
Formation
Hypertrophic scars are due to an excess of  collagen 
deposition which is almost entirely from fibroblasts. 
The role of  excess inflammation, myofibroblasts, and 
other fibroblasts phenotypically that produce excess 
collagen, tension, and genetic factors all play a role in 
hypertrophic scar formation. Given that silicone is not 
absorbed into the skin and covers intact epithelium, the 
beneficial effects must be indirect through effects on the 
epithelium.
The epithelium serves an important barrier function. 
Water loss through the epithelium is limited by a func-
tional stratum corneum, and disturbances in barrier 
function are associated in many dermatologic condi-
tions with increased inflammation instigated by inflam-
matory growth factors and other inflammatory 
mediators produced by epidermal cells. Epithelial mes-
enchymal cell cross talk is well known.
23.2.1   Delay in Epithelization
When barrier function is disrupted by tissue injury, res-
toration of the stratum corneum lags behind epitheliza-
tion which is initially only one cell layer thick as 
epithelium rapidly migrates over an open wound, fol-
lowed by stratification, followed eventually by a multi-
layered stratum corneum. However, there is evidence 
that the immature stratum corneum does not become 
fully functional as a water barrier for weeks to months. 
During that time, there is a stimulus to restore homeo-
static barrier function by increased epithelial prolifera-
tion, as manifested by increases in thickness, alterations 
in differentiation markers in the immature differentiat-
ing epithelium, and increased inflammatory mediator 
synthesis [2].
In cell culture, prevention of water loss by a liquid or 
high-humidity environment results in a reduction in sol-
uble inflammatory mediators and consequently a reduc-
tion in collagen synthesis in a coculture setup with 
fibroblasts [3, 4]. In vivo, in models in rabbits, rats, and 
mice, prevention of water loss from an epithelium with 
an immature, deficient stratum corneum results in 
increase in inflammatory mediators similar to those uti-
lizing human cells in an in  vitro system [5]. There are 
multiple highly upregulated factors including IL-1, IL-8, 
and Cox-2. In total, over 1000 genes are either upregu-
lated or downregulated in an environment where tran-
sepidermal water loss (TEWL) is limited by a 
semiocclusive dressing versus no covering [6].
Humans are almost unique in their tendency to heal 
with excessive or hypertrophic scarring. In part this is 
due to the “tight-skinned” characteristic of the human 
skin which is tightly adherent to the underlying muscle 
layer due to the lack of a panniculus carnosus. Thus, 
human wounds heal only part by wound contracture, 
with both a delay in epithelization and also tension forces 
due to the constraints on skin contraction by adherence 
to the underlying deeper tissues. The rabbit ear [7] mim-
ics human skin in being firmly adherent to the underly-
ing cartilage which splints the wound and minimizes 
contracture. Healing is almost entirely due to epitheliza-
tion, and with wounds larger than 6  mm in diameter, 
healing is delayed beyond 2 weeks which in humans is the 
critical delay in healing sufficient to increase the risk of 
hypertrophic scars. In addition, during the healing pro-
cess, the fibroblasts in the granulation tissue are under 
tension because the contractile forces generated by the 
myofibroblasts are counteracted by the resistance to con-
traction by the stiff  underlying cartilage. Wounds on the 
rabbit ear heal with scar elevation (. Fig. 23.1) which 
both from gross visual appearance, and also histologi-
cally closely mimic human hypertrophic scars. Larger 
wounds with epithelization delayed beyond 2 weeks have 
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greater scar elevation, and like humans, older rabbits 
heal with flatter scars. The scars respond to interventions 
like local steroid and injections and blockers of fibrosis 
including TGFB antibodies and antisense to CTGF, in 
which both growth factors induce collagen synthesis and 
are upregulated in fibrotic processes. Silicone gel sheets 
and silicone cream both reduce scarring, and other semi-
occlusive agents such as paper tape, polyurethane films, 
cyanoacrylates, or stoma adhesive are also effective 
which implicates occlusion as the working mechanism of 
silicone gel, when combined with negative data ruling 
out absorption (chemical process) or heat or pressure.
We have used this model to investigate the working 
mechanism of silicone gel or other occlusive dressings in a 
series of experiments. In our model, silicone gel resulted in 
decreased inflammatory cytokines including IL-1, TNF, 
IL-8, and Cox-2 among others. The net effect of increased 
hydration is a decrease in osmolarity and several extracel-
lular fluid ions including calcium, sodium, and chloride. 
By controlling otherwise for potential ions and osmolarity, 
we found that Na concentration was the critical factor 
controlling signaling for the inflammatory cytokines 
affected by hydration. We also found that changes in extra-
cellular Na concentration resulted in changes in trans-
membrane Na flux which is mediated chiefly by the Na 
channel ENaC. Briefly, an increase in Na concentration 
due to increased TEWL caused by a deficient epithelial 
barrier results in activation of ENaC which controls levels 
of COX-2 resulting in increased prostaglandins [3].
The question remained of how increases in Na con-
centration are sensed resulting in activation of 
ENaC. We looked for changes in all of the candidate Na 
channels in epitheilia cells that could conceivably 
respond to changes in Na concentration and found only 
one channel, Nax, had a significant response. Nax is a 
member of the voltage-gated Na channels but lacks the 
extracellular domain responsive for voltage gating. It’s 
function previously has been unclear. NaX has been 
found to be Na concentration sensor in the central ner-
vous system, but its function and presence in other 
organs and cell types had not been extensively studied. 
With a series of knockdown experiments in  vitro, we 
established that NaX controls the entire signal transduc-
tion signaling seen with changes in Na concentration 
and hydration in  vitro in epithelial cells and also skin 
explants. Utilizing our model of hypertrophic scarring 
in the rabbit ear, we found treatment with antisense to 
NaX results in a very significant reduction in scarring, 
similar or greater to the effects of silicone gel. 
Furthermore blocking downstream signals including 
Cox-2, IL-B, and the S-100 proteins also reduced scar-
ring. Blocking ENaC with a clinically used pharmaco-
logic agent, amiloride, also resulted in decreased 
scarring. Experiments to elucidate the signal transduc-
tion pathways further have established that NaX 
responds or senses high salt with activation of a serine 
protease, prostasin, which activates ENaC. The impor-
tance of NaX in controlling changes in the epithelium 
includes profound changes in epithelial differentiation, 
cell migration, and cell proliferation in knockdown 
experiments in vitro [4].
In summary the application of silicone gel to an 
acute scar with a deficient epithelial water barrier due to 
an immature stratum corneum results in decreased water 
loss (TEWL). This prevents the increase in Na concen-
tration which otherwise results in an NaX-mediated 
complex signal transduction pathway which includes 
downstream activation of ENaC as well as hundreds of 
other genes, mirroring the kind of broad changes in 
gene expression found to be controlled by many cyto-
a b
  . Fig. 23.1 a A large scar in the rabbit ear created by full- thickness 
removal of  the skin followed by healing without dressings. b By cre-
ating small 6–8 mm in diameter full-thickness wounds with a circular 
punch, healing is complete in about 2 weeks and the scar is elevated 
allowing quantification. This rabbit ear model has been used for all 
of  our experimental studies
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kines such as TGFB. Other occlusive treatments are also 
effective, but the degree of occlusion is important (com-
plete occlusion results in excessive hydration with 
impacts on surface bacterial levels as well as undesirable 
physical changes in the epithelium).
23.2.2   Clinical Studies
The first controlled clinical study to demonstrate effi-
cacy of silicone gel utilized silicone gel sheets applied to 
portions of immature hypertrophic scars due to burns, 
trauma, or surgery, in an effort to treat immature hyper-
trophic scars (. Fig.  23.2). Treatment went on for 
3 months with application of the gel for 12 hours. We 
found that 24-hour treatment led to maceration and was 
poorly tolerated. One of the challenges was to quantify 
the improvement in scarring. Although photographic 
evidence is essential, rating scar severity remains chal-
lenging and is ultimately nonquantitative. In an effort to 
have a completely objective and quantitative method of 
measuring scar severity, we turned to measuring the scar 
stiffness. Scars are stiffer (less elastic) than normal skin, 
and as scars improve they become more pliable or more 
elastic. Utilizing an extensometer which measures the 
amount of stretch when the skin is subjected to a given 
force, we were able to calculate Young’s modulus and get 
an objective measure of scar stiffness. We first used an 
extensometer to measure the stiffness of burn scars and 
found that older scars were more elastic and there was a 
very good correlation with age of burn scar to stiffness 
of the scar over several years [8]. In our scar study, we 
found a highly statistically significant reduction in stiff-
ness that reached closed to its maximum after 2 months 
of treatment, with only minor changes by extending 
treatment for 3 months [9]. Furthermore, the improve-
ment was sustained after treatment was terminated. At 
the same time, there were a substantial reduction in scar 
erythema and flattening of the scar clinically which was 
obvious on photographs. We saw no response in a keloid 
and much more impressive results in immature scars, 
with minor effects or no effect on mature scars (scars 
older than 1 year without erythema).
In a follow-up study (. Fig. 23.3), we wanted to see 
if  we could prevent the development of hypertrophic 
scars by beginning treatment early on surgical incisional 
scars. Again, a portion of the incision was treated with 
an adjacent area untreated [10]. We again utilized pho-
tography but wanted to quantify the scar volumes for an 
objective quantitative measure. Dental alginate was used 
to make a negative impression which was then converted 
to a positive impression using dental plaster in similar 
fashion to the way dentists take dental impressions for 
models used in a variety of dental and oral surgical pro-
cedures. The positive molds there then burred down to a 
totally flat surface and volumes calculated by measuring 
the difference in weights. Treated areas of the scars were 
found to have significantly less volumes as long as the 
untreated scar developed some hypertrophy. Not sur-
prisingly, in scars that healed favorably, minimal or no 
differences were seen.
Initially, although these studies received considerable 
attention, even in the popular press, there was some 
skepticism by many clinicians, due in part to the lack of 
mechanism. Over the subsequent years, many studies 
have confirmed the observations we made relying on 
subjective evaluation of scar severity using a variety of 
scar severity scales such as the Vancouver Scar Scale and 
Patient and Observer Scar Assessment Scale (POSAS). 
In 2002, an international group developed an evidence- 
based analysis to develop guidelines for treatment [11] 
and found that there was strong evidence for the use of 
a b
  . Fig. 23.2 a Partial-thickness immature hypertrophic burn scar. The square marks the planned treatment area with silicone gel. b After 2 
months of  treatment, the treated area is flatter, more pliable, and less pink
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silicone gel both for the treatment and prevention of 
hypertrophic scars.
Since 2002, many more studies have been published 
on silicone gel with supportive data. Most of these stud-
ies were not prospective randomized trials and by the 
nature of the treatment virtually impossible to blind. 
The Cochrane group did an analysis and noted the defi-
ciencies of the studies and made the conclusion that 
solid evidence for silicone gel was lacking but failed to 
recognize the strengths of our early studies in which the 
patients served as their own control and quantitative 
objective data was collected.
23.2.3   Sheets Versus Creams
There are some limitations to silicone gel sheets. They 
are not completely self-adhering with some attachment 
method such as a covering bandage, although clothing 
can be used in some situations (such as a bra) to aid in 
fixation. In tropical climates with high humidity, the 
scar can develop a “heat” rash due to excessive moisture 
underneath the gel. The gel sheeting can pick up dirt and 
perspiration which makes cleaning or using new sheets 
essential. As a practical matter, patients have difficulty 
wearing the sheets 24  hours/day. Our original studies 
suggested that using the sheets to cover the scars needed 
to be utilized at least 12 hours/day to be effective.
Silicone gel creams have been alternative products 
that address many of the limitations of silicone gel 
sheeting. They can be used in tropical climates more eas-
ily, do not require any additional adherence methodol-
ogy, and are easier to apply 24 hours/day with twice-daily 
applications. The question arises whether they are as 
effective. One potential limitation is the chance that the 
cream will be rubbed off. Some silicone creams dry in 
place and are less likely to rub off.
We have addressed the question of efficacy of sili-
cone gel creams in our rabbit ear animal model of hyper-
trophic scarring and have found the cream to be as 
effective as sheeting in multiple studies. All of our stud-
ies investigating the mechanism of silicone gel that we 
referred to earlier utilized silicone gel cream because of 
its ease of use.
Multiple well-done clinical studies have been done 
over the last 15 years that have confirmed efficacy of sili-
cone gel. In Asian patients who are particularly high risk 
for hypertrophic scars, Chan [12] performed a random-
ized, double-blind controlled study in 50 Asian patients 
with a sternotomy wound following coronary bypass sur-
gery or cardiac valvular surgery. They found that silicone 
gel significantly reduced multiple scar attributes includ-
ing visual parameter pigmentation, vascularity, pliability, 
height, as well as symptoms of pain and itchiness com-
pared with control wounds (p ≤ 0.02 for all). No treat-
ment-related adverse effects were reported. To date, no 
comparison studies have directly compared the efficacy 
of sheeting to silicone gel cream. Due to the very thin film 
formed by silicone gel cream and the uncertainty of how 
effectively it remains in place when subjected to rubbing 
by clothing or movement, it is quite possible or even likely 
that sheeting might be more effective, but in practice this 
may be offset by the ease in 24 hours/day use.
Recently a meta-analysis of all prospective random-
ized controlled trials as well as additional controlled 
studies between 1990 and 2014 found a total of 11 stud-
ies that qualified involving 864 patient scars in which the 
silicone gel was used to prevent scars. They found a 
highly positive result from silicone gel or silicone gel 
sheeting particularly in patients at high risk, but even 
a b
   . Fig. 23.3 a A fresh surgical incision prior to treatment. One 
area of  the scar is going to be treated preventively with the other 
portion of  the scar serving as comparison. b After 2 months, the 
untreated scar is slightly elevated and pink in color. The area of  the 
scar treated with silicone gel sheeting is flatter and less pink in 
color
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when all patient were included, the results were statisti-
cally significant (p < 0.02) [13].
In summary, silicone gel sheeting has an almost 
40-year history, with widespread clinical use for 20 years. 
Our laboratory and others have found a compelling 
mechanism based on the semiocclusive properties of 
silicone gel, which normalize transepidermal water loss 
in scars with a deficient stratum corneum barrier func-
tion, and via the Na channels ENaC and Nax regulated.
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24.1  Onion Extract
Extractum cepae acts in an anti-inflammatory manner 
and is bactericidal. It is currently believed that the fla-
vonoids (quercetin and kaempferol) in onion extract 
play the main role in reducing scar formation through 
inhibition of  fibroblast proliferation and collagen pro-
duction. A study by Phan and others suggested that 
these inhibitory effects may be mediated through inhi-
bition of  transforming growth factor-β (TGF-β1, −2) 
and SMAD proteins by quercetin [5, 6]. Specifically, 
the authors demonstrated that basal expression and 
activation of  several key proteins in the IGF (insulin-
like growth factor)-1 signal pathways were significantly 
reduced when keloid fibroblast cells were exposed to 
quercetin. The authors also analyzed keloid fibroblast 
cells treated with quercetin by means of  immunoblot-
ting and electron microscopic approaches. Fibronectin 
expression was suppressed by quercetin suggesting a 
strong inhibitory effect of  this compound on produc-
tion of  fibronectin. Transmission electron microscopy 
was performed on keloid fibroblasts with and without 
quercetin. Keloid fibroblasts without quercetin showed 
markedly higher density of  ECM fibers in a homoge-
nous ECM, but no ECM deposition was seen in the 
fibroblasts treated with quercetin, indicating a strong 
effect of  quercetin in the suppression of  ECM produc-
tion and deposition by keloid fibroblasts. In a follow-
up study, Phan et al. treated keloid fibroblast cells with 
quercetin at different concentrations, and cells were 
then harvested and subjected to immunoblotting anal-
ysis. In the pathogenesis of  keloids, both IGF-1 and 
transforming growth factor-β (TGF-β) signaling sys-
tems are usually overactive, stimulating fibroblast over-
proliferation and production of  collagen and 
ECM. The data of  Phan and colleagues suggested that 
quercetin could potentially have an anti- scarring effect 
by inhibiting the signaling pathway of  IGF-1 and 
TGF-β systems.
It has been further demonstrated that several flavo-
noids inhibit the antigen-induced histamine release from 
human basophils, which may be of certain importance 
since there is evidence to the effect that histamine may 
accelerate collagen formation.
Today, an increasing body of  literature and clinical 
experience are available testing the ultimate clinical 
benefit of  onion extract-containing scar creams as 
monotherapy (. Fig.  24.1) or in combination with 
other measures (. Fig. 24.2). Study data on the effi-
cacy of  Extractum cepae for prevention and treatment 
of  hypertrophic scars or keloids, however, remains 
inconsistent, and the quality of  the studies is relatively 
poor.
Background
Multiple studies on hypertrophic scar and keloid 
formation have led to a multitude of therapeutic 
strategies in order to prevent or attenuate keloid and 
hypertrophic scar formation. Until today preventing 
pathologic scarring remains undoubtedly more effective 
than treating it later on. Thus, avoiding all unnecessary 
wounds in any patient, whether keloid/hypertrophic 
scar-prone or not, remains an obvious but imperfect 
solution. Since delayed epithelialization beyond 10 to 
14 days increases the incidence of hypertrophic scarring 
dramatically [1], achieving rapid epithelialization is 
mandatory for avoiding excessive scar formation. 
Particularly, wounds subjected to tension due to motion, 
body location, or loss of tissue are at increased risk of 
scar hypertrophy and spreading [2]. Thus, in case of any 
cutaneous injury, the goal for rapid primary closure of 
wounds under little to no tension cannot be overstated. 
In addition to gentle surgical techniques and suitable 
suture material, careful hemostasis, and intraoperative 
tissue treatment, the prevention of wound infections 
and delayed wound healing are extremely important for 
good scar healing. The incision should be made along 
the “Langer” lines of the skin and take esthetic subunits 
(especially in the face) into account. The patient himself  
or herself should expose fresh scars to little traction, 
pressure, and stretching, consistently protect them from 
the sun, and return early to the treating physician as 
growth increases. If there is a known tendency to 
formation of keloids and hypertrophic scars, early 
intralesional injection of triamcinolone acetonide into 
the fresh surgical wound after surgery may be considered. 
According to various studies, next to pressure garments, 
early and regular application of silicone-based products 
seems to lead to an improvement in scar quality and an 
accelerated reduction in redness. Current guidelines 
emphasize the importance of silicone gels and patches 
for preventive treatment (at the earliest from the 14th 
postoperative day for at least 2  months) to avoid 
excessive scars in high-risk patients.
Topical gels containing onion (Extractum cepae) 
extract have been available for more than 60 years treat-
ing, preventing, and reducing dermatologic scars and 
keloids [3]. Extractum cepae is reported to have anti-
inflammatory, antimicrobial, antiproliferative, and 
regenerative activities [4]. Several clinical trials have indi-
cated that Extractum cepae may prevent pathologic scar-
ring and improves preexisting scars. It has been 
introduced as a preventional approach for unpleasant 
hypertrophic scars in current German scar guidelines in 
2012 and in current international scar guidelines in 2014.
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Currently several onion extract-containing scar gel 
preparations do exists that are mainly based on combi-
nations with either allantoin alone or allantoin and hep-
arin.
Willital et  al. evaluated the efficacy of  Extractum 
cepae in combination with allantoin and heparin on 
early scars in an uncontrolled, multicenter, prospective 
observational study in 1268 subjects. In this study, the 
scar gel was used at least twice daily. The observational 
period was 4 to 5  months [7]. Data was recorded at 
start of  treatment, after 2–3  months, and after 
4–5  months. Even though the authors were able to 
show some benefit of  regular application of  an onion 
extract-containing gel and a considerably high patient 
satisfaction, the study was completely uncontrolled; 
did not use any consistent, recognized scar scale; and 
was thus highly susceptible to bias. For prevention of 
hypertrophic scars and keloids, a prospective, random-
ized, controlled non- blinded study on children with 
surgery on the thorax after 6-month use of  a scar gel 
containing onion extract, allantoin, and heparin 
observed a less frequent development of  excessive scars 
than in the untreated comparison group [8]. The ther-
apy in the comparative group, however, remained 
largely unclear with the statement “normal wound 
therapy.” This is of  particular significance, as in a fur-
ther comparative study on improving scar quality (ery-
thema, pruritus, burning, pain, hypertrophy) between 
scar gels containing onion extract and a topical agent 
based on petrolatum, a specific effect of  the ingredients 
could not be proven [9]. It must be considered, how-
ever, that the patient number in this study was low, the 
operations were not performed on specific predilection 
sites such as the thorax, and thus statistically signifi-
cant results could have been expected only with very 
high patient numbers. For treatment of  hypertrophic 
  . Fig. 24.1 Upper half  of  the scar has been treated twice daily for 
3 months with onion extract gel
a b




scars and keloids, the benefit of  a combination of 
intralesional triamcinolone and an onion extract com-
binational gel was reported as positive, with both 
monotherapy with triamcinolone alone and the combi-
nation with an additional topical agent containing 
onion skin extract resulting in statistically significant 
improvement. A calculation of  statistical significance 
with respect to the differences of  the therapy concepts 
was, nonetheless, not performed in the study [10].
In a prospective randomized controlled trial con-
ducted in China, the use of  onion extract was investi-
gated in the prevention of  scarring after laser removal 
of  tattoos [11]. Local experience according to the 
authors found that nearly 25% of  Chinese subjects with 
dark skin (Fitzpatrick types III–IV) developed scarring 
after laser removal of  tattoos. A total of  120 subjects 
with 144 professional blue-black tattoos were random-
ized into the onion extract group or the control group. 
Subjects in the onion extract group applied onion 
extract to the treatment areas after reepithelialization 
twice daily in between laser treatment sessions, and 
subjects in the control group did not apply anything. A 
total of  52 subjects with 61 tattoos completed the study 
in the onion extract group. Seven tattoos (11.5%) in 
seven subjects developed scarring, four subjects (7.7%) 
had permanent hypopigmentation, and three (5.8%) 
had permanent hyperpigmentation. The control group 
comprised 55 subjects with 68 tattoos. Sixteen tattoos 
(23.5%) in 14 subjects developed scarring, 4 subjects 
(7.2%) had permanent hypopigmentation, and 5 (9%) 
had transient hyperpigmentation. According to this 
publication, the rate of  scarring was statistically sig-
nificantly lower in the onion extract group than in the 
control group.
It is currently recommended to apply the gel several 
times daily (usually two to three times a day) with mild 
massage of the scar tissue. In firm, mature scars use 
under occlusion or in combination with ultrasound may 
also be considered. In prophylactic postoperative use, 
treatment may be started shortly after removal of 
sutures. In the treatment of open wounds, scar prophy-
laxis using an onion extract gel should be delayed until 
complete epithelialization of the wound. Treatment usu-
ally continues over several weeks to months. While side 
effects are generally very low, treatment containing 
onion extract might be slightly irritating in facial areas, 
particularly in younger children.
Recently, an onion extract- and allantoin-contain-
ing patch has been introduced to the market. This 
product features an occlusive active release liner with 
an adhesive layer separated by a micro-air cushion seal. 
The so- called overnight intensive patch may be cut to 
size for small scars or placed side-by-side for larger 
scars. Its efficacy has been elucidated in an intraindi-
vidual randomized, observer-blind, controlled study in 
adults with post-dermatologic surgery scars [12]. Two 
scars per subject were randomized to no treatment or 
overnight treatment with the OIP for 12 to 24 weeks. 
Scar quality was assessed in a total of  125 subjects 
using the Patient and Observer Scar Assessment Scale 
(POSAS) and Global Aesthetic Improvement Scale. 
The authors found a decrease in observer-assessed 
POSAS from baseline, which was significantly greater 
for treated than untreated scars at week 6 and 24. The 
decrease in patient-assessed POSAS was further sig-
nificantly greater for the treated scar than the untreated 
scar at week 12 and 24. Subject- and investigator-eval-
uated Global Aesthetic Improvement Scale scores were 
higher for the treated than the untreated scar at all vis-
its. According to the manuscript, all subjects consid-
ered the global comfort of  the OIP to be good or very 
good, and no safety concerns were identified. Also, no 
further studies have been published, testing this rather 
novel product, and current communications do con-
firm a high patient satisfaction due to the patient orien-
tation application and a certain benefit for early 
scarring.
24.2  Conclusion
Scarring following surgery or trauma is difficult to pre-
dict, and both physicians and their patients are highly 
concerned with minimizing scar appearance and value 
even small improvements in scarring as clinically mean-
ingful. Till to date, preventing pathologic scarring 
remains undoubtedly more effective than treating it. 
Next to specific surgical techniques and appropriate gen-
eral aftercare of fresh wounds, a multitude of scar gels, 
creams, patches, and ointments are available and are 
being promoted for scarless wound healing. Next to sili-
cone-based products, onion extract or cepalin has been 
highlighted as one potential anti-scarring agent over 
recent years. Although its underlying study data remains 
in part contradicting regarding its efficacy, onion extract-
containing scar creams appear to positively influence 
scar texture, height, and associated symptoms compared 
to placebo or untreated control. Based on the recently 
published German guidelines on scarring, onion extract-
containing scar creams may be considered as additional 
therapy for active hypertrophic scars and for postsurgical 
prophylaxis of excessive scarring.
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Take-Home Messages
 5 Preventing pathologic scarring remains undoubt-
edly more effective than treating it.
 5 Next to silicone-based products, onion extract- 
containing creams have been shown to positively 
influence scar maturation if  used shortly after 
wound healing.
 5 Data remains contradicting, but guidelines have 
incorporated onion extract in their recommenda-
tions on preventing unpleasant scarring.
 5 Onion extract-containing products are available as 
creams, ointments, gels, or patches.
 5 Therapy can be started after complete epitheliali-
zation of the wound and should continue for 12 to 
24 weeks.
 5 Onion extract-containing products are safe, and 
side effects beyond irritation of the treated skin 
are extremely rare.
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25.1   Background
Scar massages are used to improve skin qualities in 
terms of flexibility, adhesions, pruritus, and pain. The 
specific techniques are not always mastered by all the 
therapists. Indeed pathological scars can appear follow-
ing strong massage movements or too long sessions dur-
ing the inflammation stage. The techniques must be 
controlled and take into account the inflammation, the 
appearance, and the localization of the scar.
25.2   Introduction
Care of the burn skin and scars requires specific treat-
ments to reduce and control the inflammation stage and 
its consequences [1, 2]. Adapted rehabilitation technique 
restores flexibility and limits esthetic and functional 
sequelae. The treatment will progress and be adapted 
throughout the scar maturation process. Several specific 
manual massages are part of the treatment but have to 
be applied respecting the inflammation, the fragility, and 
the localization of the scar [3, 4, 5].
25.3   Indications of Manual Massages
Manual massages allow to improve cutaneous mobility 
compared with the deep plan and its elasticity. They are 
indicated on burn scars but also in case of traumatic or 
surgical scars [6].
They can be started as soon as the scar tissue is epider-
mized and solid and allows to support specific manual 
techniques. The massages are contraindicated when the tis-
sue is thin and hyper-inflammatory. When the skin is frag-
ile and presents a vitropression test less than 1.2 seconds, 
the massages will be realized at first around the scar [7, 8].
25.4   Description of the Techniques
25.4.1  Morice Orthodermic Stretching
Orthodermic stretchings such as they were described by 
René Morice are compatible with an inflammatory skin. 
Indeed the technique can be summarized by a fixed 
pulpaire pressure associated with a moderated stretch-
ing supported in the inverse direction of the retraction. 
This kind of massages is frequently used on the face and 
dorsal side of the hand.
 
25.4.2    Punctual Crushing
The punctual crushing is also used during the inflamma-
tory stage and allows to crush the edges of grafts or 
hypertrophic scars. The pressure is moderated, vertical, 
and realized with the pulp of one or several fingers. The 
pressure can be circular but without practicing however 
of friction or lifting fingers.
 
25.4.3    Static Fold
Statics folds are realized during the inflammation stage 
on a solid epidermis and when the vitropression test is 
close to 2 seconds. They improve various plans if  sliding 
and have an action on the suppleness of the skin. 
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According to the surface or area to be treated, they are 
realized between two fingers or more globally between 




25.4.4    Palpate-Rolling
When the vitropression test gets closer to 3 seconds, the 
static fold evolves in rolled fold. This also significantly 
softens the deep plans and fibrosis scars. Palpate-rolling 
has also an interest to raise adhesions. It is crucial to 
observe the scar tissue before, during, and after the 
 massage treatment.
25.4.5    Efficacy
The massages are widely used within the care and reha-
bilitation of burns and scars.
The techniques have a role in the improvement of the 
characteristics and evolution of the scar.
25.5   Conclusion
Treatment of skin and scar following burn injuries must 
be performed with caution and requires the input of the 
whole multidisciplinary team. It is necessary to align the 
treatment according to the stage of scar maturation. 
The inflammation of the scar is the main factor to con-
sider to guide the therapist’s treatment [9].
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26.1   Background
Botulinum toxin type A (BoNTA) and occasionally of 
serotype B has been used for treatment of conditions 
associated with muscle spasm, hyperhidrosis and 
improving appearance of static rhytides.
The same neuronal effects and a muscle tension 
reduction at the site of injury were initially attributed to 
the benefits of BoNTA in a scar formation. However, a 
more detailed research into effects of BoNTA on wound 
healing suggested a variety of biologic effects of the 
toxin. New possibilities emerged for using BoNTA to 
modify early tissue repair mechanisms to promote more 
favourable outcomes and less noticeable scars.
26.2   Chapter Introduction
The Botulinum toxin A (BoNTA), and to a lesser degree 
type B (BoNTB), is used in clinical practice for the treat-
ment of conditions associated with muscle spasms. The 
therapeutic indications include cervical dystonia, bleph-
arospasm, strabismus, chronic migraine, and severe axil-
lary hyperhidrosis. BoNTA is also approved for esthetic 
use in the treatment of facial wrinkles such as “crow’s 
feet” and frown lines. In addition, there are many unli-
censed off-label uses of BoNTA for the treatment of 
various other conditions.
The demand for BoNTA products is rapidly expand-
ing due to ever-increasing esthetic applications, and 
there is a plethora of BoNTA formulations available 
across global markets. This can make it difficult to iden-
tify an adequate product for any specific application.
The most popular and well-tested products are 
Botox (onabotulinumtoxinA) and Vistabel (specifically 
for esthetic applications) that are manufactured by 
Allergan (USA). Dysport (abobotulinumtoxinA), mar-
keted as Azzalure for cosmetic applications, is made by 
Ipsen Ltd. (UK) and Galderma Laboratories (USA). 
Xeomin (incobotulinumtoxinA) and its esthetic brand, 
Bocouture, are made by Merz Pharmaceutical 
(Germany).
Less known preparations include Evosyal made by 
Puretox (USA) and Linurase made by Phiderma 
(Canada). BoNTB preparations such as Myobloc 
(rimabotulinumtoxinB) are marketed by Solstice 
Neurosciences (USA). Other BoNTA products are avail-
able in Asian and Russian markets.
Although normally injected into the skin layer, sev-
eral products for the topical delivery of BoNTA have 
become available recently. Examples include ANT-1207 
(Anterios/Allergan), CosmeTox (USA), and RT001 
(Revance, USA).
Each BoNTA product has a Botulinum toxin com-
bined with a variety of other complex proteins, and each 
manufacturer uses a different assay to determine the 
potency of their batches. These differences make it dif-
ficult to compare clinical responses across products.
Recent studies have shown that BoNTA improves the 
appearance of established scars and can also positively 
affect the early stages of tissue healing for a more favor-
able mature scar. This chapter examines evidence of the 
BoNTA effects on early stages of scar formation and 
describes how this can be employed for controlling scar 
development as it occurs. Practical guidance on optimal 
doses of injections and on treatment protocols is described 
and evaluated. Choices of the BoNTA preparations used 
for immature scar treatment are also discussed.
26.3   Botulinum Exotoxin, Structure, 
and Mechanism of Action
Botulinum neurotoxin (BoNT) is an exotoxin of 
Clostridium Botulinum bacteria, which has several sero-
types. In clinical practice, the serotypes A (BoNTA) and 
B (BoNTB) are most used for therapeutic, experimental, 
and esthetic purposes; however, due to their superior 
longevity of action, preparations of BoNTA have 
become the most popular.
26.3.1   Structure of BoNTA
The BoNTA molecule is made of a heavy (100 kDa) and 
a light (50kDA) polypeptide chain, linked together by a 
disulfide bond. The neurotoxin complex also includes 
associated nontoxic proteins: three hemagglutinin (HA) 
proteins and one non-HA protein. These play a role in 
transporting and protecting the toxin core.
26.3.2   Neuronal Mechanism of Action 
of BoNTA and Effects on  
Immature Scars
BoNTA impairs release of acetylcholine by disabling a 
soluble N-ethylmaleimide-sensitive factor attachment 
receptor (SNARE) protein. The latter facilitates acetyl-
choline release by mediating docking and fusion of syn-
aptic vesicles with the inner surface of the axonal 
membrane at the sites of release.
BoNTA adheres by its heavy chain to cholinergic 
cell membrane surface structures such as ganglioside 
moieties, a vesicular protein (SV2) and synaptotag-
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min. Its light chain enters the neuronal terminal and 
reaches the cytosol (vesicles). It cleaves SNARE pro-
teins: synaptosomal- associated protein (SNAP)-25, 
syntaxin, and vesicle-associated membrane protein 
(VAMP) also known as synaptobrevin II. The acetyl-
choline release into the synaptic cleft is impaired and 
the cholinergic mediation of  neurons is blocked. 
Furthermore, BoNTA has also been shown to impair 
release of  other neurotransmitters, such as glutamate, 
substance P (SP), and calcitonin gene-related peptide 
(CGRP).
The absence of the necessary mediator leads to a 
“chemical denervation” and temporary atrophy of the 
neuromuscular junction with a subsequent block of 
muscle contraction or reduction of exocrine glandular 
secretion.
Several studies involving animal and human subjects 
have tried to determine how reducing muscle contractil-
ity in the immediate vicinity to a fresh wound improves 
the esthetic result in scars. To date, findings have been 
inconclusive.
Immobilization of underlying musculature, reducing 
tension of the wound and skin (similar to the use of a 
surgical Z-plasty), has resulted in more favorable scar-
ring according to Ziade M et al. (2013). Patients in this 
research were injected within 3 days following facial sur-
gery, and results were assessed using a visual analogue 
scale. However, no statistically significant differences 
were found between the two groups in this study when 
using other assessment methods [1].
In another example of effects of BoNTA on the early 
stages of wound healing, researchers Lee B-J et  al. 
(2009) [2] used a rat wound model. In this study, each of 
15 animals was its own control. The results showed sig-
nificant differences in wound size between BoNT-treated 
and untreated control wounds. Also observed were less 
infiltration of inflammatory cells, fewer fibroblasts, and 
a lower expression of transforming growth factor 
(TGF)-β1 (as compared to the control wounds).
TGF-β1 is a cytokine that has multiple mediatory 
actions in tissue healing, and it is involved in the forma-
tion of fibrotic tissue and hypertrophic scars. The find-
ing that BoNT-treated wounds show a lower amount of 
TGF-β1 may be the result of the chemoimmobilization 
of the muscle as well as of a direct effect of BoNTA on 
the expression of TGF-β1  in fibroblasts and fibroblast 
proliferation.
It is known that a muscle paralysis due to the inhi-
bition of  acetylcholine exocytosis is reversible by natu-
ral SNARE protein recovery. After application of 
BoNTA, it takes 2 weeks to 4 months for neurotrans-
mission to recover. Therefore, its period of  action is 
definitely within the timeframe of  early scar formation. 
Nevertheless, the effects of  BoNTA on tissues are more 
complex than just reducing tension and decreasing 
TGF-β1.
26.3.3   Nonneuronal Mechanisms of Action 
of BoNTA and Effects on Immature 
Scars
More research into Botulinum toxin demonstrates that 
its biological effects on various cells and tissues are 
much more complex than previously understood [3]. 
The BoNT receptors and intracellular targets are not 
unique for neurotransmission, as several of these recep-
tors and targets have been found in neuronal and non-
neuronal cells.
BoNTA, for example, can attach to some other cell- 
surface proteins and, through them, modulate the func-
tion of a variety of human cell types [3]. These proteins 
include E-cadherin, fibroblast growth factor receptor 3 
(FGFR3), and vanilloid receptors. Indeed, epidermal 
keratinocytes, dermal fibroblasts, sebocytes and vascu-
lar endothelial cells, adipocyte-derived mesenchymal 
stem cells, and many other cells including macrophages 
and neutrophils have receptors capable of binding and 
cleaving the BoNTA molecule. Therefore, the effects of 
BoNTA at the nonneuronal level have an impact on 
inflammatory and immunological cascades, neurosen-
sory signaling, cellular inhibition and proliferation, vas-
cular and tissue differentiation, and growth (or atrophy). 
Familiarity with these effects is useful in understanding 
how BoNTA is helpful for tissue healing and scar devel-
opment.
26.3.3.1   Effects of BoNTA 
on the Inflammatory Cascade
Both pro- and anti-inflammatory effects by BoNTA 
have been demonstrated in animal models and cell cul-
tures. Those effects are expressed on additional binding 
sites for BoNTA and its carrier proteins. These have 
been identified at the RMS 13 receptor sites of skeletal 
muscle cells, TIB-152 of lymphoblasts, Detroit 551 of 
fibroblasts, and SH-SY5Y of neuronal cells. BoNTA 
alone does not induce inflammatory responses; it only 
does so in a complex with the Neurotoxin Associated 
Protein (NAP). The latter is responsible for the release 
of pro-inflammatory cytokines such as IL-6, IL-8, 
MCP-1, and TNF- α at these sites [4]. This last reference 
suggests that it is NAP that determines the pro- 
inflammatory effects of BoNTA at the time of the toxin 
application.
The inflammatory phase of a wound healing lasts 
approximately 2–4  days. It is marked by an abundant 
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release of cytokines, growth factors (such as platelet- 
derived growth factor (PDGF)), interleukin-1 and inter-
leukin- 8 (IL-1 and IL-8), chemokines, and hormones. 
These all work to sustain activation of the target cells 
and promote migration of the inflammatory cells.
PDGF and transforming growth factor-β (TGF-β) 
released by Alpha granules of platelets attract neutro-
phils and macrophages. The latter scavenges the wound 
site, and the former produces transforming growth fac-
tor (TGF), tissue growth factor-α (TGF-α), and epider-
mal growth factor (EGF). These give rise to fibroblast 
and keratinocyte migration, signaling the start of the 
proliferative phase of healing.
Once the heavy and light chains of BoNTA have 
reached their targets, inflammation starts downscaling. 
They reduce lymphocyte proliferation and migration 
and decrease cytokine expression. This is seen a few days 
after wounds have been treated with BoNTA [2, 3].
BoNTA has also demonstrated the ability to decrease 
inflammatory enzyme cyclooxigenase-2 (COX-2) and 
prostaglandin E2 receptors [5] in animal models and cell 
cultures. It also decreases the infiltration of monocytes 
and macrophages while blocking expression of interleu-
kins- 1B (IL-1β). Moreover, it is able to suppress nitric 
oxide and tumor necrosis factor-α (TNF-α) via inhibi-
tion of specialist receptors on macrophages [6].
Inflammation in tissues is often associated with pain 
and itching. BoNTA reduces pain by local muscle spasm 
relief and by blocking cholinergic and other neuropep-
tide sensory transmission. However, it is now known that 
BoNTA has effects at sites distant to the injection loca-
tion, as well as at a central level. In addition to the local 
uptake of BoNTA in the synaptic terminal, a distinct ret-
rograde transport pathway results in accumulation of 
BoNT toward the neuronal soma. This retrograde chan-
neling facilitates remote action of BoNTA at the dorsal 
root ganglion and the spinal cord, and it is believed to 
explain the efficacy of BoNTA used for the control of 
pain [7]. In addition to neurons, the glial cells such as 
Swann’s and astrocytes are also receptive to BoNTA, 
which suggests yet another pain modulation mechanism.
BoNTA also has been shown to reduce infiltration 
by cutaneous lymphocytes and decrease acanthosis, pro-
cesses associated with intense itching (most commonly 
mediated by histamine). BoNTA affects chemotaxis of 
mast cells, affecting their migration and histamine 
release and IL-4 expression. The histamine acts as the 
main mediator of H1-H4 receptors, responsible for acti-
vation of the target molecules within the sensory neu-
rons that code pruritic signals. BoNTA also 
downregulates transient receptor potential channel type 
V1 (TRPV1) and type A (TRPA1), responsible for 
histamine- mediated and non-histamine-dependent itch, 
respectively [8].
It is believed that the ability of BoNTA to moderate 
a florid inflammatory response and control itch and 
pain may explain its off-label use in treating scar hyper-
trophy and keloid formation. A recent double-blind ran-
domized study concluded that BoNTA was as effective 
as steroids when injected into keloid scars, but patients 
additionally reported the alleviation of pain and itching 
after use of the former [9].
In experiments, BoNTA has demonstrated proper-
ties inhibiting the overgrowth of a variety of cells, 
including malignant proliferation in breast, prostate, 
and colon cancers. It has been theorized that this is the 
same mechanism as the one that provides its inhibitory 
effects on fibroblast proliferation. This has motivated 
the use of BoNTA on the unchecked growth of the cells 
leading to keloid deposition.
26.3.3.2   Effects of BoNTA on Fibroblasts 
and Keratinocytes
BoNTA has a direct effect on dermal cells such as fibro-
blasts and keratinocytes and through them can positively 
mediate dermal tissue remodeling. This is an important 
characteristic for reversing the effects of skin aging, assist-
ing in wound epithelization, and reducing scar formations.
Fibroblasts and their differentiated subset, myofibro-
blasts, are the main components of the proliferation 
phase in wound healing. The transforming growth 
factor- beta 1(TGF-β1) prompts some of the fibroblasts 
to differentiate into myofibroblasts, possessing a retrac-
tile protein alpha-SM (α-SM), similar to those in smooth 
muscle cells. Myofibroblasts create bridging connections 
and promote the approximation and retraction of 
wounds. They do this by creating a matrix that further 
promotes the migration of additional fibroblasts and 
keratinocytes [10]. BoNTA seems to interrupt the dif-
ferentiation of fibroblasts to myofibroblasts by blocking 
TGF-β1 signaling and in so doing reduces excessive 
wound retraction and scar thickening [11].
Fibroblasts are also responsible for angiogenesis in a 
healing wound. This is mediated by fibroblast growth 
factor (FGF) and vascular endothelial growth factor 
(VEGF), both of which also promote epithelization and 
collagen synthesis. Epithelial growth will happen either 
from the basement membrane or from the edges of the 
wound by migrating keratinocytes. BoNTA acts to 
increase migration, proliferation, and differentiation of 
keratinocytes and the expression of epidermal growth 
factor (EGF). Collagen type III is mainly produced in 
this stage, actively promoted by IL4 mediators. 
Subsequently collagen type III degrades, and it is 
replaced by collagen type I with reorganized orientation 
of the fibers. This adds strength to the resulting scar.
BoNTA influences the ratio of collagen I to collagen 
III by increasing or inhibiting its degradation by matrix 
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metalloproteinases (MMPs) [12]. Excess of collagen 
synthesis by fibroblasts can determine scar hypertrophy 
and keloid formation, whereas lack of collagen matrix 
can predispose to a weak scar with atrophy [13].
26.3.3.3   Effects of BoNTA on Vascular 
Endothelium
BoNTA has been shown to have protective effects on 
dermal flap survival in animal models even with 
adverse conditions such as nicotine exposure, oxidative 
stress, or preexisting diabetes. BoNTA reduced accu-
mulation of  reactive oxygen species and prevented oxi-
dative damage to endothelial cells. It increased the 
blood flow in dermal vasculature by dilating lumen of 
the blood vessels. The model skin flaps also had 
increased production of  vascular endothelial growth 
factor (VEG) and expression of  platelet endothelial 
cell adhesion molecules 1, CD31 and CD34 lympho-
cyte subsets, interleukin (IL)-1, and tumor necrosis 
factor (TNF) [14].
26.4   Clinical Application of BoNTA 
for Treatment of Scars
The time frames of the various stages of wound healing 
are not precise and can be overlapping. The vascular 
stage lasts for roughly 24 to 48 hours after trauma, and 
the inflammatory phase runs 2 to 4 days. The prolifera-
tive phase starts from roughly day 3, peaks around day 
7, and finishes after 2 to 4 weeks. Finally, scar matura-
tion (often referred to as remodeling) can take up to 
12 months.
The usefulness of BoNTA in the management of 
immature scars (by definition, less than a year old) can 
be summarized as follows:
 5 Reduces local muscle contractility, allowing better 
approximation of the edges of healing wounds
 5 Moderates the inflammatory response at the site of 
the injury via suppression of inflammatory cytokines 
and neuropeptides
 5 Reduces pain and itching in healing wounds (these 
effects can be both peripheral at the site of the scar 
and central through a retrograde uptake of the toxin)
 5 Inhibits excessive proliferation of fibroblasts and 
their increased differentiation under TGF-β1 into 
myofibroblasts and so downgrades the over- 
proliferative scarring and retraction of the wound 
bed
 5 Mediates MMP enzymatic activity in controlling 
expression of collagen fibers, optimizing collagen I 
to III ratios, and preventing fibrosis and scar 
thickening
26.4.1   Timing of BoNTA Injections
The most efficacious timing of BoNTA application 
remains to be determined. For example, some research-
ers advocate injecting the toxin before surgery [15, 16] 
for better titration of BoNTA dose and improving local 
circulation via inhibition of norepinephrine. In other 
studies, BoNTA have been applied intraoperatively [17] 
at the time of wound closure or within the first 24 hours 
[2, 18–20]. Several clinicians have reported using the 
toxin after 72 hours [1], while others injected BoNTA at 
the time of suture removal (7 to10 days) [21]. In another 
study, BoNTA was only used at the time of a scar revi-
sion [22].
As can be seen, there are a wide variety of protocols 
proposed in the literature for the timing of BoNTA 
injections. That said, in the context of the discussion in 
Sect. 2, there are good reasons to prefer a single, early 
application of BoNTA from the onset of an injury. This 
timing is the one that has the best potential of benefit-
ting from all the additional effects of BoNTA.
26.4.2   Choosing BoNTA Preparation
The majority of published studies have used BoNTA 
preparations, including ona-, abo-, and incobotulinum-
toxinA.  However, BoNTB had been reported to also 
have beneficial results in wounds healing in a study 
involving facial reconstruction surgery [17]. Most other 
published studies use BoNTA, namely, the brand prepa-
rations such as Botox, Dysport, and Xeomin. 
Quantitative reporting on conversions of BoNTA unit 
rate and levels of toxin spreading is mainly based on 
these three products. Given the availability of the data, 
it would seem prudent to continue using the well-tested 
products when planning a scar treatment.
26.4.3   Reconstituting BoNTA
Currently BoNTA preparations are manufactured in 
lyophilized powder form. There have been some attempts 
at creating liquid preparations; however, these are not 
widely available.
Normal saline is most commonly used for the recon-
stitution of the toxin. Gassner et al. (2000) [18] have rec-
ommended mixing BoNTA with lidocaine and 
epinephrine, the former for immediate efferent block 
and the latter for the reduction of toxin diffusion.
Preparing BoNTA with bacteriostatic normal saline 
(BNS) reduces the discomfort of injections. Various 
dilution proportions have been tried, but the most com-
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mon volume of saline used per 100 U of BoNTA was 1.5 
to 2.5 ml. For keloid and large surface scars, the volume 
of BNS can be doubled.
26.4.4   Dose of BoNTA for Scar Treatment
A dose titration for a novel application of any medicine 
is always a challenge, and the amount of BoNTA 
required for the treatment of scars seems to be much 
lower than traditional doses used for immobilizing mus-
cles and treating wrinkles. The most popular BoNTA 
doses tried in various studies have been 5 U [21], 7 U [18, 
19], and 10 U [2]. In the main, however, these studies do 
not provide a rationale for their choices.
One reference, however, performs a preliminary sys-
tematic study of BoNTA dosages to determine optimum 
outcomes. Quantities of 5 U, 15 U, and 25 U of BoNTA 
were used on the postoperative wounds of rhytidectomy 
patients [20]. For the specific approach of this study, the 
best results were obtained with the use of about 15 units 
of BoNTA. That said results might vary significantly if  
other parameters are adopted. Facets that could be 
investigated going forward could include modifying the 
injection protocol. For example, these results suggest 
that increasing the number of injection points might 
achieve a more uniform reduction in scar width.
This last study seems to correlate to in vitro experi-
ments demonstrating the dose dependencies of kerati-
nocytes and endothelial cell function when subjected to 
the effects of BoNTA [25]. Doses lower than 20  units 
were found to support proliferation of endothelial cells 
but higher than 20  units impaired keratinocyte and 
endothelial migration and growth, these being respon-
sible for epithelization and angiogenesis, respectively.
26.4.5   BoNTA for Treatment of Keloid 
and Hypertrophic Scars
The treatment of pathologically healed wounds such as 
keloid and hypertrophic scars is a difficult and often 
fruitless task. BoNTA has demonstrated some promis-
ing results for reducing stiffness, hardness, and pain 
characteristic for these types of scars; see . Figs. 26.1 
and 26.2.
Studies based on repeated monthly application of 
BoNTA, involving multiple injections of the toxin cov-
ering the entire surface of a scar, have shown some effec-
tiveness [23, 24]. In these cases, the maximum 
concentration of 35 U was diluted to enable full cover-
age of the scar area. The injection volume was reduced 
into a microdroplet to ensure distribution was mainly in 
the skin and the superficial muscle layer [24].
26.4.6   Summary of Practical Guidelines 
for the Application of BoNTA 
in the Treatment of Scars
In summary, a practical clinical approach for the treat-
ment of scars is to administer BoNTA reconstituted in 1.5 
to 2.5 ml of bacteriostatic normal saline (BNS). Injections 
should be made using a superficial intradermal technique. 
The expectation is that the toxin will travel in the vertical 
and horizontal plane, reaching superficial muscles and 
even distant central locations by retrograde uptake. 
Leaving a 1 cm margin from the freshly sutured wound 
(see . Fig. 26.3) and 1 cm between injection points (see 
. Fig. 26.4) would seem to be adequate based on reported 
BoNTA diffusion distances. The total dose of BoNTA 
should remain below 20 U. A one-off treatment is likely 
sufficient to promote better healing of the wound and to 
achieve more favorable scarring.
  . Fig. 26.1 A post-traumatic hypertrophic scar, restricting articu-
lation of  the patient
  . Fig. 26.2 The scar is reduced in size and more pliable following a 
single session of  BoNTA injections
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For scars already displaying features of keloid or 
hypertrophic change, reconstituting 20 U of BoNTA in 
3 to 5 ml of BNS is recommended. An example of this is 
shown in . Fig. 26.5. Injections, delivered in microdro-
plets, should be applied to cover the whole surface of a 
pathological scar (similar to a mesotherapy technique). 
Monthly repeated treatments, consisting of three to 
eight sessions, are advised.
26.5   Conclusions
The scope of using of Botulinum toxin for various con-
ditions is ever expanding, and the benefits it provides for 
tissue healing and immature scar management are gain-
ing recognition and acceptance. Clearly, the complex 
effects of BoNTA on various cells and tissues are still 
not fully understood, and we continue to discover more 
about its full range of biological effects and useful appli-
cations. This chapter concludes with a description of 
practical approaches for the use of BoNTA in managing 
scarring in a clinical environment.
  . Fig. 26.3 BoNTA is injected immediately after closure of  the 
facelift wound, about 1 cm anterior to the margin
  . Fig. 26.4 BoNTA injections spaced evenly 1  cm apart after 
upper blepharoplasty and eyebrow lift surgery
  . Fig. 26.5 BoNTA injections should cover the entire surface of 
the early keloid scar and the adjacent normal skin
Take Home Message
 5 Effects of BoNTA on wound healing are multifac-
eted and not restricted just to the underlying mus-
cles relaxation and a wound tension reduction. 
The toxin exerts influence on various cells and tis-
sues involved in tissue repair following an injury. 
BoNTA can alter inflammatory reactions, cellular 
proliferation, mediation and inhibition
 5 Early application of BoNTA, within 24–72 hours of 
initial injury seems to ensure a less conspicuous scar
 5 All well known commercially available BoNTA 
preparations seem to be effective for that purpose
 5 A dose of 15 -20 units of BoNTA demonstrated to 
be sufficient to benefit for a wound of a traditional 
rhytidectomy length (15–20 cm). The preparation 
injected in equal amounts of 1–5 U spaced evenly 
along the length of the wound 1cm from the bor-
der. Injection points can be spaced either along the 
both sides of the wound or a just unilaterally.
 5 Dilution of the BoNTA for wound treatment was 
1.5 -2 ml of Bacteriostatic Normal Saline for 100 u 
of the Botox (or equivalent in case of other prod-
ucts). For larger surface wounds BoNTA could be 
diluted in a double amount of saline to provide a 
sufficient volume for coverage, as the dose of up to 
20 u is still applicable in these cases
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The aim of this chapter is to give an overview of the dif-
ferent conservative therapeutic strategies that are mostly 
used in the rehabilitation of patients with severe scars 
after burn injury. These strategies include pressure ther-
apy, the use of silicones as a contact medium, massage, 
the use of moisturizers, splinting and positioning, exer-
cise, and mobilizations. The relevance of the conserva-
tive therapeutic strategies will be situated within the field 
of the available scientific literature or guidelines.
According to the World Health Organization 
(WHO), annually nearly 11 million people worldwide 
are burned severely enough to require medical attention. 
Aesthetic and functional outcomes have become increas-
ingly important, as overall mortality from burn injury 
has decreased. Hypertrophic scar formation is a com-
mon and bothersome complication after a severe burn 
injury or even after minor burns, due to its functional 
and aesthetic consequences. These scars, which usually 
develop after 6–8 weeks of wound closure, are typified 
by the following characteristics. The red to deep purple 
color of the scar reflects an enhanced microcirculation. 
The hypertrophic scar becomes more elevated, firm, 
warm to touch, hypersensitive, and itchy but the lesion 
remains within the confines of the original scar. The 
elevation, firmness, and retraction of the scar is proba-
bly due to an overabundant collagen deposition as a cel-
lular response of the fibroblast during the proliferation 
phase of wound healing. The contraction of the scar has 
been linked to the presence of fibroblasts with contrac-
tile properties, called the “myofibroblasts.” Generally, a 
period of at least 6–18 months is required for matura-
tion of burn scars at which time the redness (erythema) 
of the scar subsides, the scar no longer appears inflamed, 
and the scar contraction diminishes.
Many factors can influence the presence or severity 
of hypertrophic scarring after a burn injury. Genetic 
predisposition, race, anatomical location of the burn, 
age, and depth of the burn are some of the factors that 
are known as “uncontrollable or extrinsic factors,” 
whereas infection, type of wound healing (surgical inter-
vention or not), and tension are factors that can be con-
sidered as “extrinsic or controllable” factors. The 
prevalence of hypertrophic scarring ranges from 32% to 
72%. Female gender, young age, race or ethnicity, burn 
site (on face, neck, and upper limb), multiple surgical 
procedures, meshed skin grafts, time to heal longer than 
2–3  weeks, more than 20% total body surface area 
(TBSA), and burn severity are some of the identified 
risk factors.
The scar management treatments in patients with 
burns have gained a lot of interest recently. This increase 
in interest is entirely correct, as the quality of life of 
these patients can be significantly influenced if  one can 
improve the clinical parameters of scars. Burn scar- 
related symptoms show a proximal impact on health- 
related quality of life. Therefore, the scar management 
interventions have high interest in the improvement of 
quality of life of burn patients, especially those with vis-
ible scars and severe burns. Scar management in the 
treatment of burn patients includes a wide variety of 
aftercare methods and physio- and occupational thera-
peutic techniques such as pressure therapy, silicone ther-
apy, massage, moisturizers, splinting and positioning, 
exercise, and mobilizations.
Of all the noninvasive therapeutic treatments, pres-
sure therapy is one of the most successful, widely used, 
and evidence-based techniques in the prevention and 
treatment of hypertrophic (burn-related) scars [1]. In the 
late 1960s, Dr. Silverstein at Brooke Army Hospital in 
San Antonio observed that in a patient with burns, vas-
cular support garments for the treatment of a postphle-
bitic syndrome decreased scarring after a burn injury 
and Larson noted the same effect with pressure-exerting 
splints on scar tissue. The use of compression in the pre-
vention of burn scar hypertrophy was then further pop-
ularized at Shriners’ Burns Institute in Galveston at the 
beginning of the 1970s.
Furthermore, silicone therapy is also a popular and 
evidence-supported conservative treatment to prevent 
or treat hypertrophic scars [2]. The first silicone applica-
tions were individually made as a pressure device or pad 
to solve concavity problems under pressure garments. 
The pressure pads are individually made using elasto-
mer (medical grade with catalyst), putty, or foam, and 
Background
Since a few decades, the focus of treatment of burn 
patients has shifted from survival to optimizing the 
rehabilitation outcome of patients with severe scars. 
This outcome can influence both physical as well as 
psychological well-being and quality of life of the 
patient. Therefore, the interest in the field of 
conservative scar management of these patients has 
risen drastically. In this regard, the golden standard in 
all medical or paramedical treatments is aiming for 
evidence-based interventions. Also in this rather new 
domain of scar rehabilitation, caregivers strive to use 
the most efficient therapies. Unfortunately, for most of 
the daily used interventions, the number of proper 
scientific clinical trials is still limited and therefore the 
evidence-based level of many of them is often low. As 
a consequence, the recommended therapies are often 
based on recommendations or guidelines written by a 
group of specialists based on their expertise and 
available literature. This chapter focuses on the most 
relevant noninvasive strategies in the aftercare of 
patients with severe scarring after burn injury with 
special attention to compression therapy.
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fitted directly on the patient. They are usually worn in 
combination with classical pressure garments, masks, 
and splints. Silicone applications can also be applied 
directly to the scar without any intention to augment or 
establish pressure on the scar. In the 1980s, silicone gel 
sheets were effectively used for the first time in the treat-
ment of burn-related scars, however without clear stan-
dardized treatment protocols. Since the beginning of the 
1990s, publications and protocols about the use of sili-
cone sheets and gels as contact media in the prevention 
of hypertrophic scarring and contractures started to 
appear. They remain very popular as a conservative 
strategy ever since.
Concerning the other noninvasive treatment modali-
ties, such as massage, the use of moisturizers, position-
ing and splinting, exercise, and mobilizations, the 
number of published controlled trials (randomized con-
trolled trials [RCTs] of controlled clinical trial [CCTs]) 
for each category is rather low and within each category, 
different techniques or types of applications and prod-
ucts are used. In the field of rehabilitation, especially in 
burn rehabilitation, controlled randomized double- 
blind trials are practically and ethically extremely diffi-
cult to perform. Due to this shortcoming, except for the 
effect of pressure on the thickness of a scar, there is no 
real scientific consensus on the actual effect of the vari-
ous treatment modalities. Therefore, most recommenda-
tions are mostly made based on guidelines and consensus 
meetings of experts [3–8].
Pressure therapy is indicated to prevent and treat skin 
grafts and wounds that take longer than 14–21 days to 
heal, because of the higher risk of hypertrophic scar for-
mation. As soon as the healing skin tolerates compres-
sion and shear forces, pressure therapy is recommended 
for 23 hours per day until scar maturation. Continuous 
pressure on scars can be exerted by means of custom- 
fitted pressure garments, orthoses or transparent face 
masks, casts, or splints, measured by trained technicians 
or therapists. The optimal amount of pressure required 
remains controversial. Theoretically, pressures that 
exceed 24 mmHg pressure to overcome capillary pres-
sure are required. However, good clinical results have 
been reported with levels as low as 5–15 mmHg pressure. 
Many authors however state or show that 15 mmHg or 
even higher, 20  mmHg to 30  mmHg, is necessary to 
accelerate the maturation process and that the effects of 
pressures below 10 mmHg pressure are minimal [1, 9]. 
Higher pressure increases the effect, but can also induce 
complications such as paresthesia, blistering, abnormal 
bone growth, limb necrosis, etc. The generated pressure 
plays a crucial role and needs to be monitored regularly 
(e.g., by using a simple pneumatic pressure sensor, such 
as for instance the Kikuhime pressure sensor). The 
Kikuhime pressure sensor has been tested in clinical cir-
cumstances and was found to be reliable and valid in the 
assessment of the efficiency of pressure garment ther-
apy. The pressure of pressure garments needs to be 
checked every 2–3 months and, if  necessary, they need 
to be replaced or modified to achieve optimal results [1]. 
Frequent washing and proper hygiene with a minimal 
use of ointments, lotions, or moisturizers that contain 
unsaturated lipid acids can help in reducing the aging 
and wearing of the garments.
There are mainly two different types of pressure gar-
ments that are used in the treatment and prevention of 
hypertrophic burn scars: elastic tricot and powernet 
structures. The first type of elastic tricot garments are 
mostly woven knit structures with a biaxial stretch and a 
multidimensional structure. These elastic tricot gar-
ments usually tend to be delivered with less tension (or 
pressure values on the scar) but maintain the pressure 
longer than powernet garments. The powernet structure 
garments have mostly one-axial stretch and a plenary 
open structure. The second type, the powernet garments 
are a bit more comfortable pertaining to water vapor 
permeability in summer or warm climates, but are more 
fragile due to their open structure. Also therefore elastic 
tricot garments offer a far better protection against UV 
rays, a property that cannot be underestimated since 
pigment changes are one of the most important sequelae 
after a severe burn injury with a higher risk for UV- 
induced malignant changes as result. Although the exact 
value for this protecting factor of the garments (UPF) is 
not defined, for textiles of common daily worn clothing 
this factor is set on a value of 50.
Pressure is strongly recommended to decrease scar 
height and scar erythema [1]. The working mechanism 
of pressure therapy is not completely understood. First, 
pressure can control collagen synthesis [9]. The realign-
ment of collagen fibers and the reduction of develop-
ment of whorled-typed collagen nodules might induce 
thinning of scars. Secondly, pressure might reduce the 
vascular flow to scar tissue, which leads to a decrease of 
nutrient and oxygen supply for cellular activities. It 
might diminish fibrotic activity (TGF-β reduction), 
accelerate cell apoptosis of fibroblasts, and reduce scar 
redness [9]. In addition, application of pressure com-
monly reduces pain and itching and alleviates edema 
associated with active hypertrophic scars [4, 9]. Based on 
the evidence framework of Sharp et al., pressure therapy 
is strongly recommended and found to be evidence 
based to decrease scar height and recommended to 
diminish scar erythema [1].
Silicone gel sheets or gels are also used in the preven-
tion of scars after wound healing of more than 21 days 
and in the treatment of hypertrophic scars. Silicone gel 
sheets or gels can be used as soon as wounds are re- 
epithelialized and until complete maturation of scars 
[2]. The silicone gel sheets are typically worn 12–16 hours 
per day. The topical silicone gels are applied twice a day 
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[2]. Skin reactions such as allergy, dermatitis, itch, or 
skin breakdown may occur, but fewer when using sili-
cone gels compared to gel sheets. Progressive building-
 up of wearing the silicone and hygienic precautions of 
both the product and the skin are important actions to 
reduce the risks of adverse effects, especially in warm 
weather or climates. Besides there are no clear benefits 
to using gels versus gel sheets or non-silicone versus sili-
cone products with respect to the treatment effect [2]; 
the silicone-containing occlusive sheets have the most 
substantial amount of publications and references [3].
Silicones are recommended to improve scar erythema, 
thickness, and pliability [2, 3]. The universally accepted 
mechanism of action of silicone is hydration and occlu-
sion of the stratum corneum [6, 10, 11]. Based on the 
guidelines of Meaume et al., silicone is the current gold 
standard and the first-line, noninvasive option for the 
prevention and treatment of hypertrophic scars [6].
In daily practice, silicone applications are worn in 
combination with pressure garments, masks, or splints 
to achieve the best outcomes. Silicone applications can 
be prefabricated sheets or individually made by special-
ized manufacturers as a pressure device or pad to solve 
concavity problems (chin, breast, clavicle, neck, and 
face) or in soft tissue parts of the face and neck.
Therapists routinely use massage in the treatment of 
(hypertrophic) scars, which can be applied manually or 
with the use of a vacuum device. Different manual mas-
sage techniques, such as the GAF techniques by Jaudoin 
D. and the “massage dermo-épidermique” by Godeau 
J., are described to limit fibrosis of scar tissue and to free 
adhesions. Depending on scar age and/or inflammatory 
status of scar tissue, the applied technique can vary 
between applying a mild pressure combined with a 
“translation” of the epidermis and a moderate pressure 
to create a skinfold combined with small rotations in dif-
ferent directions. Also a mechanical suction device can 
be used for mature scars. This therapy is called “vacuum 
therapy” or “depressomassage.” Using this mechanical 
massage, a skinfold is created in a treatment head with 
negative pressure after which the skinfold can be manip-
ulated.
Massage therapy is used in the treatment of hypertro-
phic scars and skin grafts to improve pliability and to 
reduce pain and itching [3]. The mechanical disruption of 
fibrotic scar tissue explains the improvements in pliability. 
The gate theory of Melzack and Wall support the reduc-
tion of pain and pruritus. Following the literature, the 
applied massage therapies differ in the type of manual 
techniques and mechanical settings, with or without mois-
turizer, duration, and frequency. However, to our knowl-
edge, massage therapy is applied daily using progressive 
techniques to obtain the best outcomes. The manual or 
mechanical technique depends on the inflammation sta-
tus of the scar (immature scar versus mature scar).
Moisturizers and lotions are used in the treatment of 
hypertrophic scars, which are typically dry skin and 
often itchy. Hypertrophic scars show increased transepi-
dermal water loss compared to healthy skin [12, 13]. 
Hydration can restore the skin barrier function. Little is 
known about the ideal composition of moisturizers and 
frequency of application for burn scar treatment [13], 
but we believe in an application of a water-based, neu-
tral lotion or cream at least thrice a day.
Positioning and splinting are indicated in each burn 
rehabilitation phase. In the acute phase, positioning and 
splints aim to control edema and to bring pressure relief. 
In the intermediate phase, positioning and splinting are 
indicated for soft tissue or skin graft protection and tis-
sue elongation, whereof the last indication is also impor-
tant in the long-term phase. Positioning after a burn 
injury corresponds with an anti-comfort position. There 
is no universal position, but burn depth and location 
must be considered when determining optimal anti- 
contracture positioning. Positioning may be active, 
which is ideal for cooperative patients, or passive, which 
requires the use of splints. Three different types of 
splints are commonly used, a static, a static progressive, 
and a dynamic splint. Indication for one or the other 
type can be to protect a skin graft after surgery, to pre-
vent or to treat contractures, or to improve joint mobil-
ity. However there is no consensus on the ideal 
splint-wearing schedule. The longer a splint is worn, the 
greater the benefit for tissue lengthening. Some suggest 
a regime of 2-hours-on, 2-hours-off; others advocate 
active exercises during the day and splinting only at 
night. Schedules should be established and adjusted 
according to the changes in joint mobility and activity 
level of the patient [14].
Positioning and splinting protocols must be super-
vised regularly for effectiveness and require cooperation 
of both the patient and the burn team.
Exercising and mobilizations are important compo-
nents of the daily treatment of patients after a burn 
injury. After a severe burn injury, patients have an 
increased catabolism that leads to loss of lean body 
mass and causes muscle weakness and decreased func-
tional capacity. The prolonged bed rest and the lack of 
physical activity have an important impact on recovery 
after burn injuries in the rehabilitation process. Further, 
the hypertrophic scar formation leads to scar contrac-
tures and decreased range of motion. Therefore, the 
rehabilitation program starts with passive and active 
movements, strength training of upper and/or lower 
limb and progressively includes more challenging exer-
cises such as bed cycling, sit-to-stand-transfers, and 
walking with or without assistance. Depending on the 
patient’s cooperation, general condition, and cardiovas-
cular and neurological status, mobilizations start already 
after 24–48  hours after admission to the burn unit or 
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surgical procedure, but always in dialogue with the 
attending physician.
In the literature, little is known about the best reha-
bilitation schemes to follow for adult burn patients. 
However, the aim of exercising is to maintain and restore 
the physical capacity, muscle strength, and autonomy of 
patients [15]. Mobilizations are required for realignment 
and lengthening of scar tissue, preventing joint and liga-
ment stiffening.
Among experts, compression therapy is considered a 
first-line intervention in the aftercare of patients with 
severe scars related to burn injury while the use of all the 
other mentioned techniques are considered to be at least 
“best practice.”
27.1  Conclusion
Although strong evidence is lacking for many of the dif-
ferent noninvasive therapeutic approaches that are used 
in the rehabilitation of patients with severe scars, all the 
interventions discussed in this chapter, that is, pressure 
and silicone therapy, massage, hydration, positioning 
and splinting, exercise, and mobilizations, are recom-
mended and considered useful by the authors in the 
aftercare of these patients.
Take-Home Messages
 5 Pressure and silicone therapy have the best evi-
dence in topical scar management.
 5 Massage is useful to treat pruritus and stiffness of 
scars.
 5 Combination strategies are mandatory and need 
to be individualized to optimize results.
 5 Hydration of scars is useful, but cost-effectiveness 
of the product that is used is also important.
 5 Positioning and splinting protocols must be 
individualized and supervised regularly for 
effectiveness.
 5 Physical activity and exercise are crucial to 
maintain and restore the physical capacity and 
muscle strength of burn patients.
 5 Mobilizations are required for realignment and 
lengthening of scar tissue as well as preventing 
joint and ligament stiffening.
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28.1   Background
A total of 100 million patients develop scars in the 
developed world alone each year as a result of 55 million 
elective operations and 25 million operations after 
trauma. Excessive scars form as a result of aberrations 
of physiologic wound healing and may develop follow-
ing any insult to the deep dermis, including burn injury, 
lacerations, abrasions, surgery, piercings, and vaccina-
tions. By causing pruritus, pain, and contractures, exces-
sive scarring can dramatically affect a patient’s quality 
of life, both physically and psychologically. Spray or 
contact cryosurgery is a nonsurgical therapy for the 
treatment of hypertrophic scars and keloids.
Cryosurgery is an effective and safe therapeutic regi-
men in the treatment of hypertrophic scars and keloids. 
Because of its major advantage of a low relapse rate, the 
technique, either as monotherapy or in combination, 
has been established as the treatment of choice for 
keloids and hypertrophic scars.
The cryosurgery freezing process includes four 
phases, which are termed “Thermal history.” These 
phases include cooling rate, end temperature, hold time, 
and thawing rate. Each of these phases has an impact on 
the mechanism of injury on the frozen tissue. The tissue 
injury is induced by two synergistic arms – direct physi-
cal effects of cells freezing (intracellular ice formation) 
and by the vascular stasis that develops in the tissue 
after thawing. It is postulated that another factor in the 
effect on the tissue following cryosurgery is the immuno-
logic response which is still under investigation.
Contact cryosurgery method uses metallic probes, 
which are circulated by a cryogen gas. This probe 
removes heat from the tissue and thus the tissue gradu-
ally cools. When the cryosurgical unit is activated and 
the probe is placed in firm contact with the tissue, an 
area of frozen tissue or ice ball appears, which extends 
radially from the cryoprobe. The lateral spread of freeze 
approximates the depth of freeze by a ratio of 1:1.3. 
Although the depth of freeze is time related, as the dura-
tion of freeze extends toward 100 seconds the lethal zone 
flats, that is, the deeper tissue is not affected. It has been 
shown that repeated contact cryosurgical sessions can 
exhibit a beneficial effect on keloids and hypertrophic 
scars and additionally prevent relapses. However, 1–20 
treatment sessions using the contact cryosurgery were 
required to flatten those scars. In addition this method 
caused a high incidence of hypopigmentation. Therefore, 
the need for new, more potent, and quickly effective 
cryosurgical methods and instrumentation are war-
ranted. Har-Shai et al. have developed the intralesional 
cryoneedle [1–15]. This technique exhibits an increased 
efficacy in the treatment of hypertrophic scars and 
keloids when compared with the contact method, due to 
the enhanced freezing area of deeply located scar tissue. 
In addition, fewer cryosurgical sessions are required, 
and less hypopigmentation is evident following the 
application of intralesional cryosurgery (. Fig. 28.1).
28.2   The Technology: Treatment 
Technique – CryoShape [5, 10]
With the patient lying at a supine position, the skin sur-
face of the scar is cleansed with disinfecting solution 
and draped. The area of penetration into the scar and 
the underlying subcutaneous tissue are anesthetized 
locally, by a translesional approach, with Bupivacaine 
hydrochloride 0.5% (marcaine) [7]. Thereafter, the ster-
ile cryoprobe (CryoShape, Life by Ice Ltd. Haifa, Israel) 
(. Fig. 28.2) is forced into the long axis, core, and mid-
height of the scar in a forward rotary movement, which 
is parallel to the skin surface. The scar itself  is grasped 
between the index and thumb of the other hand, until 
the sharp tip of the needle penetrates the opposite distal 
edge of the scar, thus maximizing the volume of scar tis-
sue to be frozen. Attention is taken to prevent any pen-
etration of the cryoneedle into the healthy surrounding 
skin. Sterile gauzes are placed under the proximal and 
distal exposed parts of the cryoprobe and care is taken 
to assure that the vent nostril is positioned away from 
the patient to prevent accidental freezing of adjacent 
skin or tissue (. Fig. 28.3).
The proximal part of the probe is connected via an 
elongation tube to the cryogun (CryoPro Maxi 500 cc, 
Cortex Technology, Hadsund, Denmark), which is filled 
with liquid nitrogen to three-fourth of the cryogen vol-
ume and about 15 minutes beforehand in order to allow 
a sufficient pressure to build-up inside it (11 psi). A full 
pressurized cryogen can operate continuously for 1 hour, 
thus two to three medium-sized keloids can be treated 
successively without the need to refill.
The cryogun is grasped or placed on a steady surface, 
which is located higher than the scar to facilitate the liq-
uid nitrogen flow downward with no direct contact with 
the patient body. By activating the cryogun trigger, the 
pressure valve is opened and the cryogen enters the cryo-
needle, thereby freezing the scar. A forced steam of the 
liquid nitrogen gas flows out from the vent nostril dur-
ing the entire freezing process. The strength of the steam 
flow, which is observed by the naked eye during the 
entire freezing procedure, indicates an appropriate 
working pressure. Two ice balls appear shortly at the two 
cryoprobe penetration sites of the treated scar and with 
time they gradually spread toward each other until a 
complete freezing of the scar is clinically evident. The 
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length of the intralesional cryosurgery process depends 
upon the scar volume and ranges between minutes to 3 
hours without the need of time taking. Following the 
complete freezing of the scar, the cryogun trigger is 
released to stop the freezing process and the cryoneedle 
is left to thaw for 1–2  minutes and is withdrawn in a 
reverse rotary movement. After a complete thawing of 
the scar is clinically noticed, slight bleeding from the 
penetration points of the needle requires the application 
of a sterile dressing. If  active bleeding is evident, gauzes 
soaked with Tranexamic Acid will end the bleeding. The 
patient is instructed to wash daily the treated scar and to 
apply an antibiotic ointment until full healing is accom-
plished.
In cases where the scar is longer than the cryoneedle 
length (10 cm) or very wide, two or three parallel needles 
or successive insertions of the same needle are necessary 
to freeze the entire keloid in one session.
28.3   When to Use Contact or Intralesional 
Cryosurgery?
Contact cryosurgery can be used on very small HSK 
with a reduced volume in which the cryoneedle cannot 
be inserted into. All other HSK can be treated by the 
intralesional cryosurgery method. In very large or giant 
HSK, several cryoneedles can be inserted in parallel to 




















  . Fig. 28.1 A comparison between the contact and intralesional 
cryosurgery methods. Upper – Contact method: Ice ball induced by 
the contact cryoprobe. The interface between the ice ball and unfro-
zen tissue represents 0  °C isotherm. The volume of  tissue located 
between −22  °C isotherm and contact probe is the lethal zone in 
which cells undergo cryonecrosis. Cells situated in the warmer region 
between −22 °C isotherm and 0 °C isotherm  (recovery zone) gener-
ally survive the freeze. The melanocytes are located within the lethal 
zone. Bottom – Intralesional method: Ice ball induced by the intral-
esional cryoneedle. The interface between the ice ball and unfrozen 
tissue represents 0  °C isotherm. The volume of  tissue located 
between −22 °C isotherm and cryoneedle probe is the lethal zone in 
which cells undergo cryonecrosis. Cells situated in the warmer region 
between −22 °C isotherm and 0 °C isotherm (recovery zone) gener-
ally survive the freeze. The melanocytes are located within the recov-
ery zone
  . Fig. 28.2 The intralesional cryosurgery system composed of  the 
CryoShape cryoprobe which is connected to the cryogen
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  . Fig. 28.3 Upper – Preoperative view of  two large keloids on the 
anterior and post aspects of  the right and left lobules following 
piercing. Lower – Postoperative view 6 years following a single cryo-
session of  intralesional cryosurgery demonstrating complete involu-
tion of  the scars with no distortion of  the lobules and without 
hypopigmentation or recurrence
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28.4   How Many Cryosessions Are Needed 
for Contact or Intralesional 
Cryosurgery?
A total of 1–20 treatment sessions using the contact 
cryosurgery are required to flatten HSK scars. The inter-
val between sessions is between 2 and 3 months.
For the intralesional method, usually a single cryo-
session is needed to flatten the HSK. In few cases a sec-
ond cryo-treatment is needed. The interval between 
sessions is 6 months.
28.5   Combined Treatment
Intralesional cryosurgery can be combined with intrale-
sional excision of the HSK [14], topical silicone gel 
sheeting [8], intralesional injection of steroids, and pres-
sure garments. Following the flattening of the scars by 
cryosurgery, fractional CO2 lasers can be applied to fur-
ther smoothen the skin surface if  necessary [16].
28.6   Conclusion
This simple to operate technology can be applied as an 
office procedure, is safe, cost-effective, and possesses a 
short learning curve. This evidence-based novel intral-
esional cryosurgery method for the treatment of 
hypertrophic scars and keloids was recently intro-
  . Fig. 28.4 Sequential steps of  the intralesional cryosurgery proce-
dure and final result. Upper left – Preoperative view of  a large keloid 
of  the left upper ear following piercing. Upper right – Following pen-
etration of  the cryoneedle into the keloid, two ice balls are formed at 
the two penetration points of  the scar. Warm gauzes are placed 
opposite to the treated scar (posterior aspect of  the auricle) in order 
to prevent cryoinjury to the auricular cartilage. Lower left to lower 
right – One week following the cryo-treatment a blister is evident; 3 
weeks following treatment scar necrosis is evident; 6 months follow-
ing the treatment the helical keloid has reduced significantly without 
distortion of  the lobule and with almost no hypopigmentation; 4 
years following a single cryosession, the scar is flat with some extra 
pliable skin above it which can be excised via an intralesional 
approach. No recurrence is evident
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duced. This method was shown to be effective in the 
treatment of  hypertrophic scars and keloids, and has 
achieved significant superior clinical results when 
compared with the existing treatment modalities 
(. Figs. 28.3, 28.4, and 28.5). In addition, it was dem-
onstrated [4, 10] that this method has significantly 
reduced the patient concern and deformity scores in a 
scale from 1 (no concern and deformity) to 5 (severe 
concern and deformity) in 11 patients in whom keloids 
developed following aesthetic surgery. It was con-
cluded that intralesional cryosurgery provides the 
plastic surgeon with an effective instrument to treat 
such scars following aesthetic surgery, thus reducing 
the dissatisfaction of  patients.
The intralesional cryosurgery methods has two main 
advantages over the spray or contact cryosurgery tech-
niques. Usually only a single cryosession in needed, and 
it exhibits significantly less hypopigmentation due to 
better survival environment for the melanocytes, thus 
can be effectively applied on black/darker-colored skin 
[1–3]. These beneficial advantages have an important 
clinical application for the treatment of hypertrophic 
scars and keloids especially on the face, which is the 
most crucial area of concern to the patient. Furthermore, 
the common treatment modalities which were men-
tioned to treat such a scar would necessitate several 
treatments and a long therapeutic period while the final 
results are unpredictable.
In summary, the intralesional cryosurgery technique 
might be added to the armamentarium of treatment 
modalities to effectively treat keloid scars. This method 
is easy to use, safe, can be applied on any size and shape 
of scars, requires a short learning curve, consumes less 
liquid nitrogen, and can be applied as an office proce-
dure.
Take-Home Message
Intralesional cryosurgery, which is an evidence-based 
method, is probably the best treatment for a variety 
of  HSK (small, intermediate, large, and oversized) 
that achieves remarkable clinical results in a high 
proportion of  patients with minimal hypopigmentation 
and usually by a single cryo-treatment.
References
 1. Har-Shai Y, Amar M, Sabo E.  Intralesional cryotherapy for 
enhancing the involution of  hypertrophic scars and keloids. Plast 
Reconstr Surg. 2003;111:1841–52.
 2. Har-Shai Y, Sabo E, Rohde E, Hyams M, Assaf  C, Zouboulis 
CC. Intralesional cryosurgery enhances the involution of  recalci-
trant auricular keloids: a new clinical approach supported by 
experimental studies. Wound Repair Regen. 2006;14:18–27.
 3. Har-Shai Y, Dujovny E, Rohde E, Zouboulis CC. Effect of  skin 
surface temperature on skin pigmentation during contact and 
intralesional cryosurgery of  keloids. J Eur Acad Dermatol 
Venereol. 2007;21:191–8. Erratum in: J Eur Acad Dermatol 
Venereol. 21:292, 2007.
 4. Har-Shai Y, Brown W, Labbê D, Dompmartin A, Goldine I, Gil 
T, Mettanes I, Pallua N. Intralesional cryosurgery for the treat-
ment of  hypertrophic scars and keloid following aesthetic sur-
gery: the results of  a prospective observational study. Int J Low 
Extrem Wounds. 2008;7:169–75.
 5. Har-Shai Y. Intralesional cryosurgery – a new and effective tech-
nology for the treatment of  hypertrophic scars and keloids. 
Chapter II-10.1. In: Krupp S, Rennekampff  H-O, Pallua N, edi-
tors. Plastische Chirurgie, Klinik und Praxis. Landsberg: 
Ecomed Medicin, Verlag Group; 2008. p. 1–7.
 6. Har-Shai Y, Mettanes I, Genin O, Spector I, Pines M.  Keloid 
histopathology after intralesional cryoneedle treatment. J Eur 
Acad Dermatol Veanerol. 2011;25(9):1027–36.
 7. Mirmovich O, Gil T, Lavi I, Goldine I, Mettanes I, Har- Shai 
Y. Pain evaluation and control during and following the treat-
ment of  hypertrophic scars and keloids employing contact and 
intralesional cryosurgery  – a preliminary study. J Eur Acad 
Dermatol Veanerol. 2012;26:440–7.
 8. Stromps JP, Dunda S, Eppstein RJ, Babic D, Har-Shai Y, Pallua 
N. Intralesional cryosurgery combined with topical silicone gel 
sheeting for the treatment of  refractory keloids. Dermatol Surg. 
2014;40:996–1003.
 9. Chopinaud M, Pham A-D, Labbê D, Verneuil L, Gourio C, 
Benateau H, Dompmartin A. Intralesional cryosurgery to treat 
keloid scars: results from a retrospective study. Dermatology. 
2014;229:263–70.
  . Fig. 28.5 Upper – Preoperative view of  a large keloid scar on the 
anterior chest following acne. Lower  – Postoperative view demon-
strating a complete flattening of  the scar 10 years following a single 
cryosession with no recurrence or hypopigmentation
 Y. Har-Shai and L. Har-Shai
241 28
 10. Har-Shai Y, Har-Shai L. Intralesional cryosurgery for the treat-
ment of  upper lip keloid following deep chemical peeling. Eur J 
Plast Surg. 2014;37:679–82.
 11. Har-Shai Y, Zouboulis CC.  Intralesional cryosurgery for the 
treatment of  hypertrophic scars and keloids. Chapter 86. In: 
Abramovich W, Graham G, Har-Shai Y, Strumia R, editors. 
Dermatological cryosurgery and cryotherapy. London: Springer; 
2016. p. 453–74.
 12. Roitman A, Luntz M, Har-Shai Y. Intralesional cryosurgery for 
the treatment of  keloid scars following cochlear implant surgery 
and removal of  cholesteatoma. Eur J Plast Surg. 2016;39:307–12.
 13. O’boyle CP, Shayan-Arani H, Hamada MW. Intralesional cryo-
therapy for hypertrophic scars and keloids: a review. Scars Burn 
Heal. 2017;3:1–9.
 14. Har-Shai L, Pallua N, Grasys I, Metanes I, Har-Shai 
Y.  Intralesional excision combined with intralesional cryosur-
gery for the treatment of  oversized and therapy-resistant keloids 
of  the neck and ears. Eur J Plast Surg. 2018;41:233–8.
 15. Zouboulis CC, Har-Shai Y, Orfanos CE.  Cryosurgical treat-
ment of  keloids and hypertrophic scars. Chapter 85. In: 
Abramovich W, Graham G, Har-Shai Y, Strumia R, editors. 
Dermatological cryosurgery and cryotherapy. London: Springer; 
2016. p. 413–51.
 16. Har-Shai Y, Har-Shai L, Artzi O. Two-step treatment of  bulky 
keloids on the cheeks after deep chemical peeling: intralesional 
cryosurgery followed by pulsed dye and ablative fractional CO2 
laser.  Eur J Plast Surg., published online 20 March, 2020. 
https://doi.org/10.1007/s00238-020-01651-x
Open Access This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons. 
org/licenses/by/4. 0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appro-
priate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if  changes were made.
The images or other third party material in this chapter are included in the chapter’s Creative Commons license, unless indicated otherwise 
in a credit line to the material. If  material is not included in the chapter’s Creative Commons license and your intended use is not permitted by 
statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
Minimally Invasive Technologies for the Treatment of Hypertrophic Scars and Keloids: Intralesional…
243
© The Author(s) 2020







29.1  Background – 244
29.2  The Corticosteroids – 246
29.3  Pharmacology and Mechanism of Action – 246
29.4  Corticosteroid in Scar Treatment – 247
29.5  Topical Steroids – 247
29.6  Intralesional Injection – 247
29.6.1  Administration – 247
29.6.2  Side Effects and Complications – 248
29.7  Further Applications – 249
29.7.1  Enhancing the Effect of Intralesional Corticosteroid – 249
29.8  Conclusion – 249
 References – 249
244
29
29.1   Background
Hypertrophic scars and keloids represent the conse-
quences are the results of abnormal wound healing. 
Keloids are characterized by overproduction and depo-
sition of collagen and extracellular matrix (ECM). 
Keloids often manifest as growing and infiltrative lesions 
toward the neighboring intact skin beyond the original 
boundaries. Abnormal fibroblast activity is a histopath-
ological hallmark for keloid pathogenesis leading to 
prominent accumulation of dermal constituents. Due to 
sustained proliferation without regression, the patients 
often experience pruritus and pain which leads to func-
tional impairment affecting quality of life. Recent find-
ings have identified that elevated levels of growth factor 
and cytokines contribute to aberrant fibroblast activity. 
Among various singling molecules, transforming growth 
factor beta (TGF-β) family is a crucial mediator in scar 
formation.
Management of hypertrophic scars and keloids are 
yet ill categorized. Unlike keloids, hypertrophic scars 
may resolve partially without treatment, although treat-
ment is required depending on patient desire for further 
improvement. The use of steroid for the treatment of 
excessive scarring was first proposed in the 1950s. The 
early case reports showed that corticosteroids admin-
istered during wound healing halted the growth of 
granulation tissue. In vitro fibroblasts subject to des-
oxycorticosterone failed to reach maturation, and there 
were notable morphologic changes [1]. In the follow-
ing years, small numbers of patients with keloids were 
treated with systemic intake and regional injection of 
ACTH who showed inhibition of recurrence. In 1963, 
triamcinolone was first used for intralesional injection 
after surgical excision of keloids [1]. Since then, many 
groups have reported the successful application of 
intralesionally injected triamcinolone in scar treatment 
(. Figs. 29.1, 29.2, 29.3, and 29.4).
In the past decades, intralesional injection has been 
proposed as a standard therapy for hypertrophic scars. 
The international guidelines on management on keloid 
scarring have recommended the use of corticosteroids as 
a b
  . Fig. 29.1 a A 50-year-old man with keloid after total gastrectomy. b The patient underwent seven sessions of  intralesional injection of 
triamcinolone (10 mg/ml) in 4 weeks interval
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  . Fig. 29.2 a A 22-year-old woman with keloid on the chest. b The patient underwent four sessions of  fractional CO2 laser (eCO2 Lutronic, 
Goyang, Korea. 60 mJ, 15% density) combined with intralesional injection of  triamcinolone acetonide suspension of  10 mg/ml
a b
  . Fig. 29.3 a A 62-year-old women with keloid after knee replacement surgery. b The patient underwent seven sessions of  combination 
cryotherapy and intralesional injection of  triamcinolone (10~20 mg/ml) in 4 weeks interval
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a mainstay treatment [2]. Most commonly used cortico-
steroids for scar treatments are medium- to long-acting 
agents such as dexamethasone, methylprednisolone, and 
triamcinolone acetonide. Overall, corticosteroids inhibit 
all aspects of scar development including inflammation, 
fibroblast activation, and extracellular matrix accumula-
tions. Thus, the use of corticosteroids efficiently reduces 
volume of scar tissue and relieves symptoms such as 
pain and pruritus.
29.2   The Corticosteroids
Corticosteroids are the most commonly prescribed 
anti- inflammatory agent in the medical field. Specific 
and nonspecific effects of steroids include immunosup-
pressive, antiproliferative, and vasoconstrictive effects. 
Besides systemic administration, proper use of topi-
cal and intralesional injection requires awareness of its 
potencies and various formulations.
29.3   Pharmacology and Mechanism 
of Action
All corticosteroids have basic skeletal structure com-
prising carbon atoms with three hexane rings and one 
pentane ring. Modifications in the basic cortisol struc-
tures result in systemic agents with different potencies, 
duration of action, metabolism, and mineralocorticoid 
effects. For example, triamcinolone was synthesized by 
fluoridation of the hydrocortisone molecule at the 9th 
position to enhance anti-inflammatory properties.
The free fraction of the corticosteroid enters the cell 
and exerts its effects by binding to a cytoplasmic gluco-
corticoid receptor. The glucocorticoid receptor is located 
within the multi-protein complex consists of heat shock 
protein and immunophilins. Binding of corticosteroid 
to its receptor leads to translocation into the nucleus 
and release from the multiprotein complex. Within the 
nucleus, the receptor forms a dimer and directly binds 
to glucocorticoid response elements in the promoter 
regions of the target genes. Eventually, the intranuclear 
binding affects the rate of transcription which induces 
or represses specific target mRNA and protein synthe-
sis. Corticosteroid receptor also interacts with other 
crucial transcription factors regulating cell metabolism 
such as cAMP response element binding (CREB) pro-
tein. Cellular inflammatory response is modulated via 
nuclear factor-κB (NF-κB). NF-κB is an important 
transcription factor that induces the expression of genes 
regulating inflammatory mediators. Corticosteroids and 
its receptor inhibit the activity of NF-κB causing reduc-
tion of inflammatory process in cell. Additionally, the 
glucocorticoid receptor has an inhibitory effect on acti-
vator protein 1 (AP-1), which controls the expression of 
various growth factors and cytokine genes. Other key 
cytokines or proinflammatory molecule inhibited by 
glucocorticoids includes tumor necrosis factor-α (TNF- 
α); granulocyte-macrophage colony-stimulating factor 
(GMCSF); interleukins (IL). IL-1, IL-2, IL-6, IL-8; leu-
kotrienes; and prostaglandins.
a b
  . Fig. 29.4 a A 60-year-old woman visited 12 weeks after total thyroidectomy. b Postoperative lymphedema significantly resolved after 
single session of  intralesional injection of  triamcinolone acetonide (10 mg/ml)
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29.4   Corticosteroid in Scar Treatment
Unlike normal fibroblasts, keloid fibroblasts possess 
tumor-like properties, showing excessive proliferation 
and invasion of surrounding tissues. Enhanced migra-
tion and invasion of normal fibroblasts are critical fac-
tors for the development of keloids. TGF-β signaling 
has long been considered a pivotal fibrogenic factor in 
abnormal wound healing. Subsequently, anti-fibrotic 
strategies based on the blockade or elimination of 
TGF-β signaling emerged as an important pharmacolog-
ical target for treating keloids [3]. The clinical response 
to corticosteroids in scar treatments is mainly achieved 
by reducing the prolonged inflammatory response dur-
ing wound healing, inhibiting collagen and reducing 
excessive ECM synthesis by reducing fibroblast activity. 
Additionally, intralesional injection of corticosteroids 
enhances fibroblast and collagen degeneration.
In lesions treated with corticosteroids, thick colla-
gen bundles are dissociated and ECM constituents are 
markedly reduced. In vivo studies have shown that corti-
costeroid, especially triamcinolone, can retard synthesis 
of pro-collagen and TGF-β1 and TGF-β2 expression [4]. 
Administration of dexamethasone induced reduction in 
vascular endothelial growth factor and angiogenesis in 
keloid-derived fibroblasts [5]. Further study on the effect 
of corticosteroids on keloid pathophysiology is required 
in the aspect of modulation of chemotaxis immuno-
modulation controlling fibroblast activity and collagen 
metabolism.
29.5   Topical Steroids
Topical steroids are the most frequently prescribed of all 
dermatologic drugs, yet its usage has been limited in scar 
treatment. There are different formulations available 
in a wide range of potencies and a variety of vehicles. 
Topical corticosteroids are categorized into four major 
potency groups and seven classes. The classes are devel-
oped based on vasoconstrictor assays and clinical stud-
ies which range from class 1 ultra-high potency to class 
7 very low potency. Certain formulation is more potent 
such as ointment formulation, which can enhance percu-
taneous absorption through increased hydration of the 
stratum corneum. In selecting a topical glucocorticoid 
preparation for scar treatment, optimal potency should 
be selected based on scar extent, location, and thickness. 
Target site for topical steroids is the viable epidermis 
or dermis, and the clinical response to a formulation is 
directly proportional to the concentration of the drug 
achieved at the target site. When topical application is 
considered, it is important to monitor potential adverse 
skin reaction due to continuous application. When skin 
atrophy or purpura is noted, temporary discontinuation 
of a topical agent should be considered. For hypertro-
phic scar or keloid treatment, topical corticosteroids 
alone have failed to reduce pre-existing scar tissue or 
prevent scar development and not advocated as a pre-
ferred modality.
29.6   Intralesional Injection
Keloids and hypertrophic scars are often treated by 
intralesional injection of therapeutic drugs because the 
pathogenic target is accumulated collagen and ECM 
constituents within the dermis. Intralesional administra-
tion of corticosteroids allows bypassing the thick stra-
tum corneum barrier and directly treating pathologic 
dermal lesions with higher concentration of corticoste-
roids at the site. Triamcinolone acetonide and triamcino-
lone diacetate are the most widely used corticosteroids 
for intralesional administration. After its administration, 
micronized crystals of corticosteroids persist in the skin 
and released over a period of weeks, thus being the most 
desirable delivery system for the treatment of chronic 
inflammatory skin diseases. Triamcinolone agents are 
available as micronized suspensions of corticosteroid 
crystals, favored than dexamethasone or betamethasone.
29.6.1   Administration
Typically 27- or 30-gauge needles are the most preferred 
because it causes less discomfort when penetrating the 
skin and allow greater precision in injecting the desired 
quantity. Needles with thicker caliber can be applied for 
the long-standing lesions with dense tissue. The com-
mon therapeutic dosage would be between 10 and 40 mg 
per mL. Available triamcinolone suspension should be 
diluted to achieve the final concentration just sufficient 
to treat the target lesion. Because the injections are 
administered monthly, the authors favor lower dosage 
10 or 20 mg to prevent undesirable effects.
To reduce the discomfort on pain, 1% or 2% lido-
caine can be used to dilute triamcinolone in desired 
concentrations. Lidocaine alone may not induce reduc-
tion in pain due to its acidity and sodium bicarbonate 
can be added. Injection with lidocaine and bupivacaine 
mixture subcutaneously beneath and around the target 
lesion few minutes prior to the treatment can be benefi-
cial to minimize pain on administration and after the 
treatment. Other measures to reduce patient discomfort 
are to apply ice pack or spray cooling system prior to the 
injection. Topical lidocaine available in tape or cream 
formulation can be of benefit.
Before administration, it is important to gently shake 
to suspend the micronized suspensions evenly. Upon 
injection, the needle should be introduced to target the 
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dermis where the target tissue is deposited. Resistance is 
felt when correctly injected to the dermis and when the 
drug is administered in the upper dermis, slight blanch-
ing can be noted. Direct injection to the subcutaneous 
tissue should be avoided which easily induces lipoatro-
phy. Long-standing keloid tissue with firm texture should 
be pretreated with liquid nitrogen to induce edema and 
subsequent softening of the tissue. Alternatively, injec-
tion can be performed to the periphery of the scar tissue 
directing the needle toward the scar tissue. Most treatment 
algorithms require multiple serial injections of intral-
esional steroid. In clinical practice, keloids are treated by 
a monthly injection until the resolution of clinical symp-
toms. The clinical response may differ between hypertro-
phic scars and keloids. While hypertrophic scars tend to 
be more responsive than keloids and generally flatten with 
time, keloids may require repeated interventions [6].
Currently, intralesional triamcinolone is the major 
first-line therapy for treatment of both hypertrophic 
scars and keloids. Its efficacy is well confirmed by numer-
ous clinical trials and meta-analysis [7]. Intralesional 
triamcinolone injection effectively induced marked 
reduction in the size of the keloid. It was particularly 
efficient when administered after surgical removal of 
keloid lesions. Intralesional triamcinolone immediately 
after wound closure and at early postoperative visits, 
20 mg/ml and 10 mg/ml respectively, resulted in 76.5% 
recurrence-free resolutions during a follow-up period 
of 18  months [8]. Combination treatment regimen 
with intralesional injection, 20~40  mg/ml, and potent 
topical steroid application yield favorable results with 
85.7% recurrence-free on average of 32-month follow-
up period [9]. Given the results of the clinical studies 
encompass different lesions occurring on different ana-
tomical locations and durations, further clinical trials 
should be directed to overcome limitations of current 
repots including differences in timing of intervention, 
anatomical locations, inclusion and exclusion criteria, 
and inconsistent outcome measures.
29.6.2   Side Effects and Complications
Steroid-induced side effects include skin atrophy, telan-
giectasia, hypopigmentation, ulceration, and, rarely, sys-
temic complications. Fortunately, the most commonly 
encountered side effects of intralesional corticosteroid 
injection are localized. The incidence of localized side 
effects is often reported in one-third of patients. Skin 
atrophy usually occurs over several weeks to months 
after the injection and may resolve spontaneously 
without treatment. However, atrophic lesion caused 
by repeated injection with high dosage persists lon-
ger and may induce permanent change. Telangiectasia 
may occur frequently on the site of injection. In most 
cases, the lesions do not regress spontaneously and fur-
ther treatment is required. Laser or light devices such 
as pulsed dye laser or intensive pulsed light can be suc-
cessfully applied for its treatment. Foreign body reac-
tion to intralesional triamcinolone is rare but reported. 
Granulomatous reactions result from the failure of 
injected crystalized corticosteroid particle to disperse 
or incomplete absorption. Clinically, prolonged absorp-
tion of injected material presents as xanthoma-like 
lesions and resolves spontaneously over few months 
(. Fig. 29.5).
Systemic complications are rare but occasionally 
observed. In children, cases of Cushing’s syndrome fol-
lowing repeated injection of high dosage intralesional 
steroid is reported. In adults, the evidence for sys-
temic complication is limited with few reported cases 
of Cushing’s syndrome when patients are subjected 
to large doses due to extensive keloids. Monthly injec-
tion of large dosage of corticosteroids is often brought 
to account to cause menstrual irregularities. Although 
there is insufficient clinical evidence, it is unlikely that 
intralesional corticosteroid alone can cause adrenal 
complications.
Complications related to intralesional injections can 
be prevented by using the lowest concentration and the 
a b
  . Fig. 29.5 Localized side effect after corticosteroid intralesional injection. a Telangiectasia on the chest. b Permanent skin atrophy on the 
back
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smallest quantity of the drug needed. Increasing the con-
centration can be adjusted as needed after the repeated 
course of treatments. For patients with multiple or large 
lesions, alternating the treatment site or dilution to lower 
dosage is recommended. Additionally, scars across the 
joint area and periorbital area can be more susceptible 
to localized absorption of corticosteroids and higher 
concentration should be avoided. Although diabetes is 
not a contraindication to intralesional corticosteroid 
injection, patients should be approached with caution 
and appropriate monitoring should be considered.
29.7   Further Applications
29.7.1   Enhancing the Effect of Intralesional 
Corticosteroid
For long-standing hypertrophic scar lesions or large 
and firm keloids, the combination with cryotherapy 
can be highly effective. Cryotherapy with liquid nitro-
gen induces dissociation of  accumulated ECM tissue 
along with possible vascular suppression and apop-
tosis of  fibroblasts. Open spray technique is most 
commonly used in combination with intralesional 
injections. When used in combination, injections 
should be made after defrosting of  the lesion. There 
are several reports showing marked improvement of 
hypertrophic scars and keloids after either superficial 
or intralesional cryotherapy. To prevent hypopigmen-
tation from melanocyte destruction or other asso-
ciated side effects of  cryotherapy, shorter exposure 
(10~30  seconds) is recommended with fewer (two to 
three) freeze thaw cycles.
In addition to intralesional injection of triam-
cinolone, localized injection of antimetabolite agents 
are reported to be beneficial for scar treatments. 
5- Fluorouracil (5-FU) is an antimetabolite inhibiting 
DNA synthesis which increases fibroblast apoptosis 
and inhibit proliferation. The use of combination tri-
amcinolone and 5-FU has been demonstrated to be as 
efficacious as triamcinolone alone. Although there are 
possible side effects from 5-FU including injection site 
irritation or delayed wound healing, it lacks atrophy 
or erythema associated with corticosteroid injections. 
The pain upon administration was a major drawback in 
5-FU treatment, while its combination with triamcino-
lone relieved excruciating pain. Combination of intrale-
sional 5-FU injection with topical corticosteroids yields 
successful result in scar treatment [3]. Given the require-
ment for repeated treatment sessions and pain associ-
ated with intralesional injection of corticosteroids, other 
modalities such as lasers and efficient delivery systems 
are suggested.
29.8   Conclusion
The management of  keloids and hypertrophic scars 
continues to challenge clinicians, and there is no uni-
versally accepted treatment algorithm. Although there 
are myriad of  treatment options, selection of  treatment 
modality largely depends on the patient desire. The use 
of  corticosteroids has remained mainstay of  the treat-
ment for more than half  century. While potent topical 
corticosteroids can be of  limited use to address pruri-
tus, intralesional injection of  triamcinolone is the 
mainstay in treatment. Intralesional triamcinolone 
injection is thought to reduce scar formation by sup-
pressing inflammation, inhibiting fibroblast prolifera-
tion, and inducing collagen remodeling. Corticosteroid 
is cost-effective because it does not require additional 
equipment, and thus readily applied in patients’ regular 
clinical visits. Further studies are warranted to identify 
the optimal combination with other modalities for scar 
treatment.
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30.1   Introduction
30.1.1   Hypertrophic Scar and Keloid 
Information
Keloid is the most difficult pathological scar to treat and 
cure and it is characterized with uncontrolled growth, 
invasion into normal skin, and expansion beyond the 
original wound boundary with severe pain and itching 
[1]. In addition, high recurrence rate after various thera-
pies is a common feature of keloids. These characters 
similar to those of tumors render keloids more like a 
“benign skin tumor” rather than a fibrotic tissue per se. 
Because of this, anticancer therapies such as chemo-
therapy and radiotherapy have been applied to keloid 
treatment.
HTS is another type of  pathological scar, character-
ized with the deposition of  excessive amounts of  col-
lagen matrix along with significant angiogenic process, 
which eventually leads to a raised and red scar with 
severe tissue contracture and painful and itching symp-
toms. HTS eventually resolves by itself  after tissue mat-
uration. Nevertheless, this process can take 1–2 years or 
even longer with disturbing symptoms and functional 
disability, which needs to be intervened for improv-
ing symptoms and preventing patients from disability. 
With this perspective, anticancer therapy approaches 
such as chemotherapy and radiotherapy might be also 
applied [2, 3].
30.1.2   Chemotherapy for Keloids 
and Hypertrophic Scar
Intralesional injection is a routine procedure for keloid 
treatment, and steroid injection alone could lead to 
recurrence rate higher than 50% [2], indicating the 
necessity of involving others drugs as a combined drug 
treatment. Chemotherapy for keloid was tried as early 
as 1989 [1]. The common drugs for keloid chemotherapy 
include 5-FU, Bleomycin, and Mitomycin C, etc. [2, 3]. 
The usual delivery way is intralesional injection of che-
motherapy drug alone or combined injection of both 
chemo-agents and steroids.
In recent years, chemotherapy on HTS has been 
tried either as intralesional injection or combined with 
post- laser therapy with positive results [3]. Because of 
its self- resolving nature, chemotherapy for HTS remains 
an exploratory area for its balanced value between the 
efficacy and the side effect. Therefore, most studies of 
pathological scar chemotherapy focus on keloids and it 
will be the focus of this chapter as well.
30.1.3   5-FU and Its Combined Use 
of Steroids
Among the various chemotherapy agents, 5-FU, a 
pyrimidine analog with antimetabolite activity, might be 
the most commonly used drug for keloid chemotherapy. 
Dr. Fitzpatrick R.E. started intralesional injection of 
5-FU for both keloid and HTS since 1989 using the con-
centration of 50 mg/ml with positive results [1]. Later, 
Gupta and Kalra [4] and Nanda and Reddy [5] also 
reported their 5-FU applications in keloid treatment 
with a dose of 50 mg/ml, and the intralesional injection 
was administered weekly, lasting for 12–16 weeks with 
positive results. With this dose, pain is the most com-
mon side effect and ulceration could occur as high as 
21.4% [5].
5-FU intralesional injection was listed as an emerg-
ing therapy for keloid and HTS in “International clini-
cal recommendation on scar management” [2], but was 
listed as a formal therapeutic option for HTS and keloid 
with monthly injection interval in “Updated interna-
tional clinical recommendations on scar management: 
Part 2 – algorithms for scar prevention and treatment” 
[3]. In addition, a combined use of 5-FU with steroids 
not only enhanced the therapeutic efficacy, but also 
reduced pain suffering post-injection [1]. In the litera-
ture, high-dose (40–50 mg/ml) 5-FU injection is usually 
combined with steroid at a volume ratio varying from 
9:1 [1] to 7.5:2.5 [6].
According to published literatures [1–6], 5-FU is a 
safe drug with no obvious side effect for the use in a rela-
tively short time period (such as 2–6 months). However, 
whether it can be safely used for a long term at the 
reported dose (40–50  mg/ml) remains unclear because 
the accumulated effect of chemotherapy agents would 
be a concern if  they are continuously used for a long 
time.
30.2   The Rational of Using Low-Dose 5-FU 
Injection for Keloid Treatment
To address the potential concern of 5-FU’s side effects, 
our group proposed the application of low dose 5-FU 
for keloid treatment because of the following reasons:
 1. Keloid necrosis caused by high dose 5-FU injection 
should be avoided simply because any new wound will 
accelerate keloid development and worsen the clini-
cal situation. Inactivating keloid cells and remodel-
ing keloid tissue rather than destroying keloid tissue 
are the correct strategy for keloid therapy with intra-
lesional injection.
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 2. A sustainable and long-term therapy (2–3  years) 
is usually required for keloid treatment in order to 
completely cure keloids and prevent their recurrence. 
To do so, a low dose of chemotherapy agent is neces-
sary not only for safety concern, but also for proper 
working mechanism of tissue remodeling.
 3. Low-dose 5-FU will be sensitive enough for inducing 
endothelial cell apoptosis/death and destroying neo-
vascular structure during keloid development, and 
will also be enough to inhibit fibroblast activities such 
as proliferation, invasion, and matrix production.
 4. This therapeutic model provides good basis for other 
conjunctive therapies including surgery, laser, and 
steroid injection to remove or to flatten keloid tissue 
by partial keloid destruction or tissue remodeling. It 
also avoids host production of risk factors that will 
trigger keloid development and recurrence, in which 
growth factors and neovascularization play signifi-
cant roles.
30.2.1   Background
After careful literature review and exploratory test-
ing, concentrations ranging from 1.5 to 5  mg/ml were 
decided as the low dose of 5-FU for clinical use with 
at least monthly injection interval in order to avoid any 
significant systemic side effect and local side effect such 
as adverse effect on hemopoietic system and severe pain 
and tissue ulceration. According to our clinical experi-
ence in treating more than 10,000 cases during the past 
18 years of clinical practice, this method has been proved 
safe for patients with a therapeutic time period ranging 
from 2 to 5 years or even longer, and no severe side effect 
has ever been observed thus far. In addition, this dose 
also has the effective rate of more than 97.14% in term 
of relieving pain and itching symptom, softening and 
flattening keloid scar, and the recurrence rate is signifi-
cantly decreased after long term therapy [7]. However, 
drug resistance to 5-FU was observed in some patients, 
and for these patients a bit higher doses could also be 
applied but were always limited to less than 9  mg/ml 
concentration to avoid significant side effects.
Importantly, low-dose 5-FU injection aims to disrupt 
or destroy neovascularity of keloid tissue and inhibit 
fibroblast proliferation, rather than to destroy keloid tis-
sue; thus low-dose 5-FU will not be able to majorly flatten 
or soften keloid tissues, in which abundant collagen and 
other matrices need to be degraded with steroid’s effect. 
Therefore, combined injection with steroid is needed in 
order to flatten and soften keloid tissue. Nevertheless, 
injected low-dose 5-FU is able to timely demolish neo-
vascularity induced by steroid injection, and thus render 
treated keloids to become relatively malnourished post-
drug injection and thus less possible to reoccur.
Meanwhile, reduced vascularity also allows the lon-
ger stay of  the injected drug inside keloids due to the 
reduced drug absorption via tissue capillaries, and thus 
enhance the drug efficacy and reduce the side effects. 
The case 1 demonstrates how this strategy could be 
applied to treat keloid tissue with intralesional injec-
tion of  combined 5-FU and steroid at a low dose in 
order to gradually remodel the keloid into normal-
looking skin [8].
30.3   Clinical Protocol of Low-Dose 5-FU 
Injection Therapy
The protocol for intralesional injection of low-dose 
drugs includes the injection of 5-FU alone or 5-FU com-
bined with steroid. In general, the combined injection of 
5-FU and triamcinolone acetonide will be a preferred 
method, unless the keloid scar is heavily vascularized, 
which will need 5-FU injection first to demolish tissue 
vascularity before steroid injection. The key points of 
this protocol include the following:
 1. Drug preparation: Triamcinolone acetonide should 
be mixed with 2% lidocaine, and then 5-FU stock 
solution can be further mixed with them to maintain 
the concentrations of 5-FU between 1.5 and 5 mg/
ml and steroid between 3 and 9 mg/ml. Low concen-
trations of both drugs will enable better control of 
the side effects such as severe pain, tissue ulceration, 
and atrophy as well as the drug-induced angiogen-
esis. Also, the volume ratio between the drug and 
lidocaine should be 3–5:1 in order to reduce the pain 
suffering during and after the drug injection. As a 
routine, the concentrations should always start from 
relatively high (5-FU: 3–4 mg/ml; triamcinolone ace-
tonide at 8–9 mg/ml) and gradually reduced as below 
described.
 2. Injection procedure: To avoid pain, 1  ml syringe 
with 26–27G needles is generally recommended for 
the injection and multi-entrance manner should be 
applied. Briefly, each injection should deliver about 
0.2 ml volume and then change the injection sites to 
make sure for even distribution of the drugs. When 
performing, the keloid tissue should be held between 
two fingers with pressure in order to prevent drug 
from oozing into surrounding normal skin. In addi-
tion, before injection, blood withdrawal should be 
tested to avoid direct drug injection into a blood 
vessel. When injecting, the drug should be pushed 
hard into the tissue in order to create a pressure in 
the tissue between the fingers and whiten the injected 
tissue, this manner will make sure that the injected 
drugs will deeply infiltrate inside the keloids, but not 
to noninjected region, and thus to enhance the effi-
cacy and reduce the side effect.
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 3. Adjustment of drug concentrations and injectional 
interval: Here, an important concept is that this pro-
cedure does not try to destroy keloid, but rather to 
remodel the keloid tissue gradually via inactivat-
ing keloid fibroblast and degrading keloid matrices. 
Therefore, the drug concentration should be adjusted 
according to the status of treated keloids. The fol-
lowings are the general principles:
 A. Steroid concentration should be gradually 
reduced when keloids become softened and flat-
tened as overdoses of steroid will cause tissue 
atrophy. In addition, sudden withdraw of steroid 
is well known for causing reoccurrence of other 
steroid-treated diseases, such as autoimmune 
disease, and thus the principle of gradual ste-
roid withdrawal should also be applied to keloid 
treatment.
 B. 5-FU concentration should be reduced when tissue 
angiogenesis is significantly inhibited or keloid is 
significantly inactivated with improved symptoms. 
Vice versa, a higher concentration of 5-FU should 
be used when significantly enhanced angiogenesis 
is observed or keloid remains highly activated and 
less responsive to the drug treatment.
 C. Adjustment of drug injection interval: With the 
progress of drug treatment, injection interval 
should also be gradually prolonged as a way of 
gradual withdrawal of steroid and 5-FU, and 
thus to better prevent keloid recurrence. In gen-
eral, initial drug injection will be administered 
every 4 weeks for a few months. Afterwards, the 
injection can be adjusted for every 6  weeks to 
10 weeks for several months, and finally adjusted 
to every 12 weeks with further reduced drug con-
centrations for several repeats. According to our 
experiences, most keloid will be resolved eventu-
ally without a high recurrence rate.
 D. Long-term therapy for localized nodule: As 
shown in case 1, localized nodule is often 
observed as the last part of noncured keloid or 
as the first sign of reoccurred keloid, which needs 
to be continuously injected with an interval of 
every 6 to 12 weeks until a final resolution (also 
see case 3).
30.4   Low-Dose 5-FU-Based Injection 
Therapy for HTS and Keloids
The best candidate for low dose 5-FU injection is the 
keloid type that usually exhibits relatively soft and flat-
ten but red color with significant signs of inflammation 
such as severe pain, itching, erythema, and rapid inva-
sion into normal skin (. Fig. 30.1a). Keloid types that 
are more like tumors, such as cauliflower-shaped solid 
tissue with relative dark color, fit better for surgical 
therapy (. Fig. 30.1b), but 5-FU-based injection can be 
well employed as well for preventing keloid relapse after 
surgical removal.
In general, single or multiple keloids with small sizes 
(diameter less than 2 cm) and located at various parts 
of the body are the best candidates for drug injection 
treatment.
Large-sized keloids will not be ideal candidates for 
drug treatment by intralesional injection because of 
potential side effects of both 5-FU and steroids.
a b
  . Fig. 30.1 Keloids are generally divided into two types: a inflammatory type; b tumor-like type
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30.4.1   Important Concepts of Keloid Curing 
and Relapse Rate for Low-Dose 
5-FU-Based Therapy
Insufficient treatment might be the most important rea-
son for not being able to cure a keloid and preventing its 
 reoccurrence
A softened and flattened keloid along with disap-
pearance of the symptom does not necessarily indicate 
that a keloid is cured and the treatment is completed. 
Rather, the keloid is in a temporary inactivated stage 
under the drug pressure. Like cancer therapy, drug treat-
ment can remove most of disease cells but there will 
always be a portion of cells (residue cells) that survive 
after chemotherapy and become quiescent and drug 
resistant [9, 10]. Once the drug pressure is relieved, these 
cells become reactivated and enter an active stage with 
rapid proliferation and production of matrices, growth 
factors, and angiogenic factors, and eventually lead to a 
reoccurred keloid.
To prevent this from happening, a continuous drug 
pressure should be applied to any of these residue cells 
to inactivate or remove them once they become acti-
vated. In the literature, most studies report the success-
ful treatment of keloid with the criteria of flattening and 
softening of the treated keloid along with disappeared 
symptoms of pain, itching, and erythema as judged by 
Vancouver Score or Patient and Observer Scar Assess-
ment Scale (POSAS). But the cessation of drug injec-
tion improperly will likely lead to keloid to reoccur 
simply because these treatments did not really remove 
or remodel the residual quiescent keloid cells into nor-
mal skin cell phenotype. This might be the key reason 
why high recurrence rate remains after keloid injection 
therapy, to which less attention has been paid in the lit-
erature.
In our group, it has been observed that 2–3 years are 
usually required for completely curing keloids by 5-FU 
and steroid injection in most cases. More importantly, 
preventive drug injection at a later stage aiming to pre-
vent reoccurrence is essential and is performed by grad-
ual drug withdrawal via reduced doses and prolonged 
injection intervals. As shown in case 3, there was a large- 
sized keloid in a woman’s abdominal region, and a total 
of 6.5  years were spent to completely cure the keloid 
via combined injection of both 5-FU and steroids at a 
low concentration. During this process, the first 3 years 
were spent on treatment of the keloid, whereas the last 
3 years were spent on preventive therapy to timely treat 
the reoccurred keloid nodules.
30.5   5-FU-Based Injection Therapy 
for Recurrence Prevention 
of Surgically Removed Keloids
Although low-dose 5-FU injection has been proven 
effective for primary keloid treatment and reoccurrence 
control, the efficiency would be too low to be an ideal 
method. As described earlier, the conversion of a keloid 
tissue into a normal-like skin will be a long-term pro-
cess. On the contrast, preventing the conversion of nor-
mal wound cells into keloid cells would be much easier, 
in which 5-FU could play an important role.
Surgical excision has now become the first-line keloid 
treatment in our group because it is an efficient way of 
keloid treatment. In particular, keloids with a size larger 
than 2 cm in diameter and possible for primary closure 
after surgery are the best indication for surgical therapy. 
Most importantly, the use of low-dose 5-FU injection 
along with other procedures enables us to prevent the 
development of new keloids in a surgically created 
wound. Therefore, the “treatment model” of injection 
therapy will be shifted to the “prevention model” of 
surgical treatment, and 1-year time period will be usu-
ally long enough to achieve satisfactory results in most 
keloid patients as shown in cases 4 and 5.
There are three key issues that are essential for the 
success in this surgical procedure, including (1) anti- 
tension procedures by proper multilayer suturing and 
anti-tension device application; (2) wound irrigation 
with combined 5-FU and steroids during the surgical 
procedure; (3) post-surgery radiotherapy and combined 
5-FU injection. The procedures are described in the fol-
lowing sections.
30.5.1   Surgical Procedure for Keloid 
Excision
Briefly, after local anesthesia with 2% lidocaine injec-
tion, the keloid will be surgically excised followed by 
multilayer suturing (including fascia and dermal and 
epidermal layers). 5-FU wound irrigation was reported 
valuable for preventing keloid recurrence from surgical 
procedure [11]. Thus, wound irrigation with combined 
5-FU (about 3  mg/ml) and triamcinolone acetonide 
(about 8  mg/ml) should be performed, and excessive 
drug liquid should be extruded out of the wound before 
its closure. With the clinical experience over 3,000 cases, 
no failure of wound healing has even been observed 
when a wound was irrigated at this dose.
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After wound closure, tension-reduction device such 
as “zipline” should be applied immediately to guarantee 
a tension-free zone in the wound area. Afterwards, the 
patients should receive irradiation on the wound within 
24 hours post-surgery with a dose of 4–5 grays once a 
day for a total of 4 days using electron beam as the irra-
diation source.
30.5.2   Postsurgical Monitoring 
and Preventive Injection of 5-FU
After the procedure, the patients are advised to visit the 
clinic monthly to closely monitor the status of surgical 
site and silicone gel is generally needed for application 
on the wound site. In most cases, the above procedure is 
enough to keep the sutured wound quiescent and non-
activated, and the wound tissue will maintain erythema- 
free and symptom-free for pain and itching (see case 4). 
If  this maintains with no further signs of recurrence, the 
tension-reduction device can be removed after continu-
ous wearing for at least 6 months.
For high-risk patients, including those who have 
previous history of postsurgical reoccurrence, mul-
tiple keloids, or previous recurrence after surgery plus 
radiotherapy, early injection of low-dose 5-FU into the 
wound subcutaneous tissue should be applied as early as 
4 weeks post-surgery, which is maintained for another 
five injections every 4 weeks until the sixth month post- 
surgery. Afterwards, 5-FU injection should be given 
whenever there is sign of pain, itching, and erythema 
to make sure that early management of recurrence is 
applied (see case 5).
For non-risk patients, or patient without previous 
surgery, an indication for low-dose 5-FU injection will 
be the minor level of erythema and the feeling of pain 
and itching. The injection should be given one more 
time after disappearance of these early signs.
30.6   Anti-indications of Low-Dose 5-FU 
Injection Therapy Combined 
with Steroids
Children are generally not the candidates for 5-FU- 
based chemotherapy in both keloid and HTS. In addi-
tion, female patients are recommended not to prepare 
for pregnancy during the treatment time period until 
6 months after the cessation of the treatment. In addi-
tion, a blood cell count test is recommended every 
2 months to monitor potential adverse effects on hema-
topoietic system. Close monitoring of steroid side effects 
is needed, and the cessation of the therapy is needed at 
once in case any side effect is confirmed.
30.7   Representative Case Reports
30.7.1   Case 1. Remodeling of Keloid into 
Normal-Looking Skin [7] (. Fig. 30.2)
A 53-year-old woman with 28  years of  spontaneous 
formation and development of  her chest keloid with 
previous history of  cryotherapy and steroid injec-
tion. The keloid grew rapidly in the last several years 
with unbearable pain (++++)1 and itching (++++). 
Physical examination revealed a big keloid in her 
chest skin with dimensions 10 cm wide, 7 cm high, and 
0.3 cm thick along with severe erythema (++++), and 
hard tissue texture (++) (. Fig.  30.2a). The patient 
was first given nine intralesional injections of  5-FU 
(mostly 3.45 mg/ml) in 2% lidocaine every 2 weeks in 
order to control growth and abolish vascularity. The 
drug injections led to decreased erythema (+), thick-
ness (0.15 cm), hardness (+), reduced itching (+), and 
also pain disappearance.
Afterwards, the patient received three injections of 
triamcinolone acetonide in lidocaine (8.3 mg/ml) every 
other week, resulting in flattened and softened scar with 
no pain and itching despite the fact that some minor 
elevated scar areas remained (. Fig.  30.2b). Due to 
re- increased erythema (++) caused by injected steroid, 
the patient received four injections of a mixture of ste-
roid (7.58–7.35 mg/ml) and 5-FU (2.94–2.27 mg/ml) in 
lidocaine to achieve both drug effects simultaneously, 
and this further decreased erythema (+), while main-
taining flattened and softened scar without symptom 
(. Fig.  30.2c). Because of improved symptom and 
physical sign, the patient was given a much lower dose 
of combined drugs (steroid: from 2.83 to 2.40 mg/ml, 
5-FU from 2.27 to 1.42 to 0.96 mg/ml) for six times with 
3–8- week intervals in order to prevent relapse and to 
remodel the scar. During this time, relatively high dose 
of drugs remained necessary in some small re-growing 
areas. When followed up 4 months later, it was surprising 
to find that some keloid areas became grossly invisible 
and normal-looking skin had appeared (. Fig. 30.2d).
Encouraged by this result, another five injections of 
low-dose combined drugs (steroids: 3.77 mg/ml, 5-FU: 
1.42  mg/ml) were administered only to the remain-
ing elevated scar areas with an interval of 4–8  weeks. 
After another 9-month treatment, scar portion further 
decreased, and normal-looking skin further expanded 
with skin color, surface, and texture close to those of 
normal skin (. Fig.  30.2e). After 3  years of tissue 
remodeling therapy, the treatment was completed and 
1 Represents the level of  pain, itiching or thickness of  the scar, 
sort of  semi-quantitative analysis.
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no further relapse was observed at 14 months post-ther-
apy (. Fig.  30.2f). Blood cell counts maintained nor-
mal during and after therapy.
Two years after the cease of  the treatment, a small 
nodule with redness and pain and itching recurred at 
the left lower corner (. Fig. 30.2g, white arrowed), and 
further injections with 5-FU (about 3  mg/ml) mixed 
with triamcinolone acetonide (about 9  mg/ml) were 
given at intervals of  every 3–6 months for 2 more years 
and once a year for another 3 years. The complete cure 
of  the scar was observed at 9 years after the initiation 
of  the treatment except for an even smaller active nod-
ule (. Fig. 30.2h, white arrowed), which may deserve 









  . Fig. 30.2 Case 1: Remodeling of  keloid into normal-looking skin at various stages. Black arrows indicate the areas that are under con-
tinued tissue remodeling. White arrow indicates reoccurred keloid nodule. (See details in the text)
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30.7.2   Case 2. Intralesional Injection 
of Low-Dose 5-FU and Steroid 
for a Large-Sized Keloid
A 50-year-old female patient visited the clinic with a 
chest keloid spontaneously forming for 5 years, which 
developed quickly along with the symptoms of pain and 
itching. The keloid revealed a size of 15  cm in width, 
12 cm in length, and 0.5–1 cm in thickness with server 
erythema (. Fig. 30.3a). The patient was treated with 
intralesional injection of combined 5-FU and triamcin-
olone acetonide at low doses as described earlier. This 
big-sized keloid was divided into four regions, and the 
injectional therapy was given in a manner of region by 
region that lasted for 4 years and eventually resulted in 
a completely remodeled scar that was flattened and soft-
ened without erythema and symptoms (. Fig. 30.3b). 
Afterwards, the keloid was generally stable and inactive 
except for some minor nodules that needed occasional 
injection.
30.7.3   Case 3. Sufficient Therapy Is Essential 
for Curing Keloids
A 22-year-old female patient with a large-sized keloid 
(18 cm in length, 6 cm in width, and 0.5–1.5 cm in thick-
ness) in the abdominal area visited the clinic for her 
keloid treatment (. Fig.  30.4a). The total keloid was 
roughly divided into three regions for one-by-one treat-
ment. Due to high vascularity of the keloid, the patient 
was first given 5-FU injection alone at the dose about 
3 mg/ml every 3–4 weeks for three times to reduce the 
vascularity via inducing endothelial cell apoptosis. Once 
the scar became darker with less erythema, combined 
5-FU (2.6 mg/ml) and triamcinolone acetonide (7.5 mg/
ml) was used for intralesional injection every 4 weeks. 
At the seventh-month posttreatment checkup, the top 
two- thirds of the keloid had already became softened 
and flattened with the disappearance of pain and itch-
ing and reduced erythema (. Fig. 30.4b). The patient 
was further treated for the rest of the keloid in a similar 
way and the total keloid area became completely soft-
ened and flattened without symptoms and with further 
reduced vascularity at the 24th-month posttreatment 
(. Fig.  30.4c). Then, reduced drug dose (2.6  mg/ml 
for 5-FU and 4.5  mg/ml for steroids) and prolonged 
injection interval (6–8 weeks) were applied to focus on 
remodeling keloid and improving tissue texture. At the 
32th-month posttreatment, completely remolded keloid 
with tissue texture similar to normal skin and minimal 
level of redness was observed, except for a few isolated 
active keloid nodules which remained over-vascular-
ized at the bottom region (. Fig.  30.4d). Afterwards, 
the treatment focused only on activated keloid nodules 
with an injection every 6–8 weeks and whole keloid was 
completely remodeled when observed at the 68th-month 
posttreatment except for a few nodules located at the 
stich markers that remained activated at the 63th-month 
posttreatment (. Fig.  30.4e). Following that time 
point, the nodule treatment remained and most nodules 
were completely remodeled after another 15  months 
of treatment with 3-month interval. The whole keloid 
has been completely remodeled, which became stably 
inactivated with whitened color and soften tissue tex-
ture when observed at the 78th-month posttreatment 
(. Fig. 30.4f). Afterwards, the whole keloid never reoc-
curred, and the treated nodules also completely inac-
tivated after several more injections. After more than 
6  years of treatment with low-dose 5-FU, the patient 
delivered a completely healthy child at 2  years post-
a b
  . Fig. 30.3 Case 2: Intralesional injection of  low-dose 5-FU and steroids for the treatment of  large-sized keloids before a and after b treat-
ment. (See details in the text)
Minimally Invasive Technologies for Treatment of HTS and Keloids: Low-Dose 5-Fluorouracil
260
30
cessation of the treatment. This exploratory treatment 
indicates the importance of sufficient treatment for pre-
venting keloid reoccurrence.
30.7.4   Case 4. Low-Dose 5-FU for Preventing 
Keloid from Reoccurrence After 
Surgical Excision
A female patient who had a chest keloid (3 cm in width, 
2 cm in height, and 0.5 cm in thickness) with severe pain 
and itching visited the clinic to request keloid treatment 
(. Fig.  30.5a). The patient received surgical excision 
of her keloid, and then the wound was irrigated with 
combined 5-FU (2.6  mg/ml) and triamcinolone ace-
tonide (7.5 mg/ml) followed by primary wound closure 
with multiple tissue-layer suturing. A tension-reduction 
device was immediately applied on the closed wound 
and the patient was asked to keep wearing the device for 
at least 6 months after the surgery. The patient received 
radiotherapy within 24 hours post-surgery with a dose 
of 4 grays per time and per day for total 4  days. The 
patient was followed up every 4 weeks post-surgery with 
no sign of reoccurrence, and a linear white scar was 
observed at 13 months post-surgery without any sign of 
 reoccurrence (. Fig. 30.5b).
a b c
d e f
  . Fig. 30.4 Case 3: Sufficient therapy is essential for curing keloids with image presentation of  an evolved keloid treated with low- dose 
5-FU and steroid injection. (See details in the text)
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A female patient with multiple keloids on her neck, 
chest (. Fig. 30.6a), and left arm visited the clinic and 
requested keloid treatment. Her chest keloid (4  cm in 
width, 2 cm in height, and 1 cm in thickness) was heavily 
vascularized with severe pain, itching, and rapid growth 
(. Fig.  30.6a). The patient received surgical excision, 
wound irrigation, and closure and radiotherapy simi-
larly as in case 4. However, relapse signs of itching and 
pain occurred early at 1 month post-surgery. Thus, the 
patient was given injection of low-dose 5-FU alone 
(about 3  mg/ml) at 1  month, 8  months, 10  months, 
13 months, 16 months, and 19 months post-surgery and 
no further treatment after 19-month time point. At the 
24th month post-surgery follow-up, a whitened linear 
mature scar was observed at the operational site with no 
sign of relapse (. Fig. 30.6b).
30.8   Conclusion
Intralesional injection of low dose 5-FU combined with 
steroids for keloid and HTS treatment has been prac-
ticed by the authors since 2002 with more than 10,000 
cases and proven safe and effective. The use of low dose 
drugs is to keep this procedure safe and sustainable for 
long term therapy that is essential for reducing the post- 
therapy recurrence. Gradual adjustment of drug dose 
and injection interval time and the management of reoc-
curred keloids at the earliest possible time are the keys 
for the success of this procedure.
a b
  . Fig. 30.6 Case 5: Low-dose 5-FU for combined chemoradiotherapy to prevent keloid from postsurgical reoccurrence. a Before the sur-
gery; b 2 years post-surgery with multiple 5-FU injections. (See details in the text)
a b
  . Fig. 30.5 Case 4: Low-dose 5-FU for preventing keloid from reoccurrence after surgical excision. a Before the surgery; b 13 months post-
surgery. (See details in the text)
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Take-Home Messages
 5 Intralesional injection of low dose 5-FU (1.5–5 
mg/ml) combined with steroids has been used for 
keloid treatment with proved safety and efficacy.
 5 The working mechanism is to inactivate keloid 
fibroblasts and to gradually remodel keloid tissue, 
rather to cause keloid necrosis which is a trigger 
for keloid recurrence.
 5 The procedure can be used for treating primary 
keloids or for preventing recurrence of surgically 
removed keloids.
 5 Sustainable long-term treatment with adjusted 
drug dose and injection interval and early manage-
ment of reoccurred lesions are the keys for keloid 
successful treatment and recurrence prevention.
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On the following pages, the pulsed-dye laser (PDL) is 
delineated and its significance in the treatment of hyper-
trophic scars and keloids discussed.
31.1  Historical Development
Among the wide variety of  available treatment options, 
laser applications are considered more recent technolo-
gies. Medical use of  the physical properties of  light 
dates back to ancient times, when Egyptians, Greeks, 
and Romans used some form of heliotherapy thousands 
of  years BC. However, none other than Albert Einstein 
first described the stimulated emission of radiation, the 
base of  laser technology, in 1917 [1]. In 1955, 38 years 
later, the manuscript of  the first functioning precursor 
of  a laser, the MASER was published by Gordon, 
Zeiger, and Townes [2]. Schawlow and Townes, who 
filed the first US patent for a laser in 1960, altered the 
Microwave Amplification by Stimulated Emission of 
Radiation- device (MASER) to visible Light wavelengths 
(LASER).
In the same year, Maiman built the first functioning 
laser, which used a synthetic pink ruby crystal as active 
medium [3]. In the early 1960s, the laser was first used 
for medical purposes in humans [4], and Townes along 
with two others (Prokhorov and Basov) were awarded 
the Nobel Prize in Physics for their work based on the 
MASER (1964). In 1981, Schawlow (along with 
Bloembergen) shared this honor for his contribution in 
the development of the laser spectroscopy.
After the development of the first laser, different 
kinds of light amplification devices have been developed 
using all kinds of active media.
The first dye laser was introduced in 1966 by two 
teams more or less simultaneously: the Americans 
Sorokin and Lankard at the Thomas J.  Watson 
Research Center, as well as the German Schaefer at the 
University of  Marburg developed the apparatus. While 
Sorokin and Lankard published the invention [5], 
Schaefer’s manuscript was rejected. After resubmis-
sion, the journal Applied Physics Letter asked Sorokin 
to review the manuscript, who finally made a publica-
tion possible [6], and also acknowledged Schaefer as 
the first to describe the dye laser’s advantage of  adjust-
able wavelengths.
In 1983, Anderson and Parrish described the prin-
ciple of  selective photothermolysis, which enabled fur-
ther research to adapt and better understand the 
medical possibilities of  the laser and its tissue interac-
tions [7]. First results of  the use of  the pulsed-dye laser 
(PDL) in Naevi flammei were published in the same 
year [8]. Also in that year, hypotheses for the applica-
tion of  lasers for the treatment of  hypertrophic scars 
were made public [9].
Alster and colleagues were the first to issue their pos-
itive results in the treatment of hypertrophic scars 
(n = 14; [10]) and keloidal post-sternotomy scars (n = 16; 
[11]) with the 585 nm PDL.
Of note is that these positive results of the PD laser 
have so far failed to be reproduced in subsequent stud-
ies, and only minimal improvements in scar texture have 
been reported.
Background
Hypertrophic scars and keloids can be a major medical 
concern with varying impact.
Depending on the literature one chooses, preva-
lence between 30% and 70% for postsurgical hyper-
trophic scarring is reported; looking at burn injuries, 
the numbers even range from 60% to 90%. Keloids on 
the other hand, show a prevalence of  about 4–14% in 
Afro-Americans. Given the fact, that the number of 
people developing significant scars after surgery or 
trauma ranges in the lower hundred millions every 
year, one can easily imagine, that scars can be more 
than an unavoidable side effect after trauma and 
pathologic scars are not rare.
Besides the cosmetic appearance and the psycho-
logical impact (especially after burns), those patho-
logic scars tend to be responsible for physical and 
functional impairing symptoms like pruritus, ery-
thema, (neuropathic) pain, and in extreme cases even 
restriction of  movement. The therapy has a wide vari-
ety from topical applications to complete surgery – all 
being covered in this book.
Since the management of  cutaneous scars has and 
often still does rely on personal preference and experi-
ence, rather than large-scale and high-quality studies, 
to date no standard- of- care for the optimal therapy 
could be established, at least not based on solid scien-
tific evidence.
Many treatment modalities are accompanied by 
high recurrence rates and with variable effect, which 
emphasizes the value of and need for minimally inva-
sive technologies. This and the following chapters 
introduce and focus on several laser technologies as 
minimally invasive technologies in the treatment of 
hypertrophic scars and keloids.
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31.2  Technique of a Laser
The following section outlines the principle of a laser 
with a focus on the basics and the most relevant proper-
ties for a clinical understanding.
The mode of action of a laser is based on the emis-
sion of light by active medium molecules in an excited 
state, as described by Einstein [1]. This requires an 
energy source that is able to excite these molecules. To 
enhance this effect of excitation and reach higher energy 
levels, an additional resonator is used. These three com-
ponents are the key elements of a laser (. Fig. 31.1).
Atoms in the active medium, which can be of  solid 
(e.g., ruby crystal), liquid (dye), or gaseous (CO2) state, 
are excited by supplying them with energy from the 
energy source. Depending on the used active medium, 
the time of  decay varies until the atoms return to their 
ground state. The longer the time of  decay, the more 
time remains for an incoming photon to interact with 
the excited atom, which in turn makes it return to its 
ground state and emits an additional photon of  the 
same wavelength and frequency (. Fig. 31.1, Detail). 
This doubling ignites a chain reaction leading to the 
required high intensity of  a laser. The resonator, which 
can be embodied by (various numbers of) plane or 
curved mirrors, in between the photons are reflected, 
enhances this effect additionally. One of  these mirrors 
is subtotal-reflective, creating an exit for a part of  the 
photons. In lasers that use dye as active medium, the 
resonator holds another function. Being equipped 
with a dispersive element (grid, filter, prism), the wave-
length of  the emitted light becomes tunable, as 
described by Schaefer as adjustable wavelengths (see 
7 Sect. 31.2).
The main difference between laser and regular light 
lies in its coherence, which allows a monochromatic (just 
one specific wavelength), high energetic, low divergent 
emission of light. It can also be applied as continuous 
wave or in short pulses of up to a femtosecond (one qua-
drillionth of a second), which allows for a temporal 
selective application.
31.3  Tissue Interaction of Laser
The effect and clinical impact of a laser is determined by 
its interaction with the irradiated tissue. The interaction 
can basically be distinguished in reflected, scattered, and 
absorbed photons. While reflective light is predomi-
nantly relevant for diagnostic use of lasers, scattering 
limits the depth of focusing of the laser beam by attenu-
ation. The therapeutic effort is caused by the absorption 
of light, which can be used for various therapeutic 
effects. Due to the relevance for the present topic, we 
only deal with the photothermal effect; other effects can 
be comprehensively looked up in laser textbooks (see 
Further Reading).
Since every tissue component shows a different 
absorption coefficient, which equals the reciprocal of 
the distance that a photon can travel in that component 
until it is absorbed, therefore, every tissue component 
reacts differently to a specific type of light. While, for 
example, bilirubin and melanin show good absorption 
of visible light, water (H2O), the main component of 
human soft tissue, has its absorptive maximum in infra-
red wavelengths (. Fig. 31.2).
The penetration depth of a laser also depends on the 
wavelength; the higher the wavelength, the higher the 
penetration depth in the visible spectrum (blue to red).
The photothermal effect describes the 
 transformation of electromagnetic energy (light) to heat 
by absorption and thereby photoexcitation of matter. 
Photothermal therapy is the most common application 
of laser therapy.
  . Fig. 31.1 The working 
principle of  a laser is dis-
played (simplified). An energy 
source causes excitation in 
atoms of  the active medium 
that, amplified by the resona-
tor, leads to a chain reaction 
with the photons ultimately 
exiting through the subtotal-
reflective resonator. The 
detailed view shows photons 
interacting with excited elec-
trons of  the active medium 
and emission of  additional 
photons of  the same energy
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The absorptive properties of the irradiated tissue 
together with the properties of the used laser determine 
the exact location and effect of the irradiation. The 
more energy the irradiated matter absorbs, the more 
heat is produced, therefore explaining the correlation 
between the absorption coefficient and the different 
laser wavelengths.
Depending on the temperature reached, edema and 
apoptosis induction (≥ 45 °C), coagulation, and dena-
turation of proteins (≥ 60  °C), and even ablation and 
cutting by vaporization (≥ 100 °C) can be induced.
Another important aspect determining the amount 
of damage is the fluence. It is given in J/cm2 and describes 
the energy deposited on a certain area over a certain 
amount of time. This makes it an excellent parameter 
suitable for description of a treatment protocol.
31.4  Selective Photothermolysis
Selective photothermolysis describes a principle that 
enables selective damage to wavelength-specific pig-
ments within the skin without harming the surrounding 
or above lying tissues.
The photothermolysis-induced damage is not only 
transmitted by direct local interaction, but also by heat 
diffusion additionally irradiating surrounding tissue lay-
ers; this principle is of particular importance for calcu-
lating selectivity and precise interaction of the laser with 
adjacent tissue layers.
A basic condition for selective photothermolysis is for 
the desired target to have a higher absorption coefficient 
than the surrounding tissues. By pulse-wise-specific irra-
diation of the target tissue a higher thermal energy is 
deposited in the target pigment with the higher absorp-
tive coefficient than the surrounding tissue, and directs 
damaging temperatures only to the target pigment. Due 
to the pause in between the pulses, there is enough time 
for the target tissue to cool down by heat diffusion before 
applying another pulse. On the one hand, depending on 
the exposure time of the pulses, the amount of damage is 
relatively well-adjustable to the target area. On the other 
hand, the wavelength of the chosen and applied light 
determines the target area. For instance, light of around 
580 nm (red light) is predominantly absorbed by hemo-
globin, while water has its absorption maximum in the 
infrared wavelengths and melanin absorbs light through-
out the visible region of the electromagnetic spectrum 
with a decrease toward higher wavelengths. The selectiv-
ity of the physical properties allows for a certain approx-
imation of the beam to the target area including a 
pulse-dependent diameter of several millimeters around 
it. The downside of this specificity results in a relatively 
narrow therapeutic spectrum for each type of laser. Due 
to the monochromatic property of a given laser (emis-
sion of light of just one wavelength) and from a technical 
point-of-view, this leads to different therapeutic targets 
requiring individual lasers of a different spectrum. This 
latter fact has made the PDL with its active medium dye 
and the tuneability (see 7 Sects. 31.2 and 31.3) predes-
tined for exploiting this physical principle generating 
various targets with the same active medium.
31.5  The PDL and Its Application 
on Hypertrophic Scars and Keloids
The PDL is based on the principle of  selective photo-
thermolysis and was developed to damage and destroy 
small cutaneous vessels without harming epidermal 
  . Fig. 31.2 The wave-
length-dependent absorption 
coefficients of  H2O, oxygen-
ated hemoglobin (HbO2) and 
melanin are displayed; the 
wavelengths of  pulsed dye 
(PDL), Nd:YAG, and CO2 
laser are presented exemplary. 
The wavelength of  visible 
light ranges from about 400 
to 700 nm. (Design: Dr. med. 
univ. Hanna Luze, Graz, Aus-
tria. © All rights reserved)
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structures. Being initially developed with a wavelength 
of  577 nm, the current models mostly work on a spec-
trum of 585 or 595 nm. Small cutaneous vessels absorb 
energy at these specified wavelengths. Consequently, the 
vessels are destroyed, ultimately leading to hypoxemia 
by diminution of the vascular supply. Then, by alleg-
edly reported secondary effects, disulfide bonds are dis-
sociated, collagen production is reduced, and expression 
of enzymes such as matrix metalloproteinases is induced 
[11, 12], leading to a loosening and restructuring of  the 
fibrous structure in hypertrophic scars and keloids. 
However, there is no ultimate and scientifically proven 
consensus about the exact mechanisms promoted by 
PDL.
Hypertrophic scars and keloids often show signifi-
cant characteristics like erythema and pruritus, which 
can be caused by hyperemia. Destruction of small cuta-
neous vessels can therefore significantly reduce these 
symptoms.
The mentioned restructuring procedures may be 
responsible for the observed improvement of pliability 
and height [13].
The properties of PDL and its modes of action also 
suggest the application in the prevention of hypertro-
phic scars, since some authors suggest an early laser 
application after surgery [14, 15].
In support of this theoretical recommendation (early 
use after surgery) is that the PDL proved to be less effec-
tive in thicker scars (>1 cm) due to its restricted penetra-
tion depth.
Side effects are relatively rare and include edema, 
scab formation, and pigmentary disorders (tempo-
rary often, permanent rarely), but also range from 
 hypotrophic to hypertrophic scarring [16], but may 
be related to the therapeutic context of  PDL applica-
tion.
While most PDL work with 585 nm, more recently 
the 595 nm long-pulsed dye laser has been introduced. 
Longer pulses have been promoted on the basis of  a 
more effective destruction of larger vessels by higher 
deposition of energy, and less posttreatment hyperpig-
mentation. In contrast to that, 585  nm lasers have 
reportedly ameliorated the scar texture; it remains to be 
seen if  this also applies to the next generation of 595 
lasers.
All in all, no scientifically solid high quality stud-
ies exist, and the above-mentioned studies do not sup-
port the development of  definite recommendations 
for a PDL protocol on hypertrophic scars or keloids. 
The only common denominator seems to be the mini-
mum requirement of  greater than two PDL applica-
tions every 4–12 weeks across the scanned literature.
31.6  Selected Studies and Evidence
The first publications of hypertrophic scars treated with 
the PDL date back to 1994. Alster presented 14 cases of 
patients suffering from hypertrophic and/or erythema-
tous scars after trauma or surgery [10]. After treatment 
with one or two sessions of 585 nm PDL within a 6-week 
interval, they showed an improvement in erythema and 
scar flattening of 57–83% as evaluated by two different 
and independent observers. The fluence used in this 
study was 6.5–6.75 J/cm2.
One year later, in 1995, Alster and Williams described 
another series of patients (n = 16) that had developed 
keloidal or hypertrophic scars after a median sternot-
omy [11]. Those patients had half  of the scars treated 
with a similar protocol (mean fluence: 7.00 J/cm2, two 
sessions, 6–8 weeks apart) and afterwards evaluated by 
two independent, blinded observers. Significant amelio-
ration of pruritus, tenderness, burning, scar height, pli-
ability, and erythema was observed 6 months after laser 
treatment, as compared to untreated scars.
Subsequently, no study was able to reproduce these 
initially promising results. While several studies described 
changes in scar erythema, pliability, height, and volume, 
very few demonstrated a statistical significance (also due 
to the low number of scars treated). Significant improve-
ment in Vancouver Scar Scale scores and pigmentation 
could be shown by Bowes et al. [17] and Chan et al. [18] 
for patients treated with PDL compared to no treatment 
intra-individually, respectively. Alster further showed a 
significant reduction in pruritus by adding intralesional 
injection of triamcinolone [19] in contrast to Wittenberg 
et al. who could not observe a significant reduction of 
pruritus in hypertrophic scars treated with PDL over 
patients treated with silicone gel sheeting [20].
Another study by Asilian et al. could reach a signifi-
cant participant-subjective, inter-individual overall 
improvement from baseline and a reduction of erythema 
in patients treated with PDL, intralesional injection of 
triamcinolone, and 5-fluoruracil compared to the con-
trols treated with the intralesional injection alone [21].
Ouyang et al. (2018) reached significant improvement 
in height, vascularity, pliability, and Vancouver Scar Scale 
in 56 patients with fresh (immature), red hypertrophic 
scars [22], suggesting an early application and possible 
prevention strategy in conjunction with a recommenda-
tion of an international panel of experts [23].
To summarize, data on PDL treatment in hypertro-
phic scars and keloids is scarce. Studies were conducted 
with no or insufficient control groups, no standardized 
treatment protocols, small numbers of participants, or 
lack of differentiation between the scar types treated. 
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The exact mechanisms of PDL application in hypertro-
phic scars or keloids remain elusive and precise recom-
mendations cannot be made on the given evidence.
Nonetheless, PDL may serve as effective additional 
(second-line) therapeutic strategy given the relatively 
low side-effect spectrum; application in fresh pathologic, 
erythematous, itching scars and use for preventive strat-
egies can be considered. PDL use is limited by its low 
penetration depth (thick scars) and higher amount of 
melanin as concurrent absorber (darker skin types).
31.7  Clinical Relevance
Since most of the published research demonstrated 
inconclusive results of the use of PDL for hypertrophic 
scars and keloids, no solid recommendation can be 
derived from the given literature. Hypertrophic scars 
tend to involute over time, and without the evidence 
served by adequate control groups in published research, 
it remains difficult to support them. Since medical device 
regulations will require more published research in the 
future (notably for device registration in the European 
Union), future therapeutic registration or re-registration 
might add in encouraging industry to support more 
science- driven studies.
Active hypertrophic scars as seen with the clinical 
sign of erythema or symptom of pruritus can be treated 
by PDL with a low level of side effects but only if  used 
in conjunction with other more proven methods.
Limiting factors are thick scars (>1  cm) and dark 
skin types. As a result the PDL can play a role in the 
prevention of pathologic scars. Future studies should 
aim toward more standardized research with an 
 adequate selection of control groups (e.g., intra-individ-
ual comparison), and are still necessary to reach the 
actual potential of the PDL.
31.8  Conclusion
This chapter dealt with the minimally invasive treatment 
of hypertrophic scars and keloids with the pulsed-dye 
laser. Being the first chapter about laser technology, an 
introduction on lasers, their functioning, and an outline 
of the temporal development were given. We then 
explained the principle behind the PDL, called selective 
photothermolysis, and clarified its relevance in the treat-
ment of pathologic scars. Lastly, selected studies in terms 
of clinically applied PDL were presented, the evidence 
was analyzed, and the clinical relevance delineated.
The reader should now be able to sort the relevance 
of PDL for treatment of hypertrophic scars and keloids 
in the whole arsenal of treatment methods for patho-
logic scars.
Summarizing, we want to emphasize one more time 
that laser technology itself  is a rather new technology, 
which certainly holds many advantages  – not least its 
minimal invasiveness and low side-effect profile. With 
only few studies available, we refrain from giving abso-
lute recommendations. We rather want to encourage the 
reader, if  interested in this topic, to help creating more 
evidence and perform further research on this specific 
topic. PDL holds potential, that still is to be grasped 
comprehensively.
Take-Home Messages
 5 Pulsed-dye laser is based on a principle called 
selective photothermolysis.
 5 Its wavelength ranges from 585 to 595 nm.
 5 PDL’s main targets are cutaneous vessels that are 
coagulated by the irradiation.
 5 PDL should be applied a minimum of two times 
every 4–12 weeks.
 5 PDL application can reduce symptoms like 
pruritus or erythema.
 5 PDL should NOT be used for thick scars (>1 cm) 
and/or in dark skin types.
 5 PDL should only be used in combination with 
other treatment modalities to achieve the most 
effective treatment.
 5 The low risk and side-effect profile makes the PDL 
a valuable alternative for the prevention of 
pathologic scars.
 5 Long-term outcome and high-quality intervention 
studies are necessary to provide proper evidence 
for PDL application in hypertrophic scars and 
keloids.
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Keloids and hypertrophic scars are fibroproliferative 
disorders of the skin that are caused by abnormal heal-
ing of injured or irritated skin [1]. Both disorders have 
similar histological features: the epidermis and the pap-
illary layer of the dermis are almost normal apart from 
slight inflammation, and the only abnormality is in the 
reticular layer of the dermis [2]. While keloids typically 
exhibit marked hyalinized collagen deposition as a result 
of prolonged and strong inflammation, this feature is 
less pronounced in hypertrophic scars [3]. Thus, it is pos-
sible that hypertrophic scars and keloids are manifesta-
tions of the same fibroproliferative skin disorder and 
just differ in the intensity and duration of inflammation. 
These features may in turn be influenced by genetic, sys-
temic, and local risk factors. It is possible that keloids 
arise largely as a result of genetic and systemic factors 
that promote massive and extended inflammation, while 
hypertrophic scars are more likely to be due to local fac-
tors. Genetic factors may include single nucleotide poly-
morphisms [4, 5], while systemic factors may include 
hypertension [6, 7], pregnancy [8, 9], hormones, and 
cytokines. The most important local factor is skin ten-
sion on the edges of the scar [10–12].
Our understanding of the pathogenesis of keloids 
and hypertrophic scars has improved markedly in the 
last 10 years, and these previously intractable scars are 
now regarded as being treatable. This has dramatically 
improved the quality of life of patients with these heavy 
scars [3]. There are many therapeutic options for keloids 
and hypertrophic scars, including surgery, radiation, 
corticosteroids, 5-fluorouracil, cryotherapy, laser ther-
apy, anti-allergy agents, anti-inflammatory agents, 
bleaching creams, and make-up therapies. In terms of 
laser therapy, we have used long-pulsed 1064  nm 
Nd:YAG laser (Cutera Inc., Brisbane, CA) to treat 
keloids and hypertrophic scars and have reported its 
indications and limitations previously [13, 14].
32.2  Laser Therapies for Keloids 
and Hypertrophic Scars
Pulsed dye laser (PDL) has long been the therapy of 
choice for cutaneous vascular diseases, including telan-
giectasia, hemangioma, and vascular malformations 
[15–17]. It has also been used to treat keloids and hyper-
trophic scars because they have more blood vessels than 
normal skin. However, although PDL is effective for 
vascular diseases that affect the superficial skin layers 
(i.e., the epidermis and the papillary layer of the der-
mis), it does not penetrate deep enough to reach the 
deep dermal regions (i.e., the reticular layer of the der-
mis). Thus, PDL is not particularly effective for keloids 
and hypertrophic scars. By contrast, 1064 nm Nd:YAG 
laser reaches more deeply than PDL. As a result, it is 
increasingly being used to treat keloids and hypertrophic 
scars [13, 18–21]. It has been suggested that it acts by 
suppressing neovascularization and the dilatation of 
blood vessels.
Long-pulsed (not Q-switched) 1064  nm Nd:YAG 
laser plays an important role in our treatment algo-
rithms for keloids and hypertrophic scars. This laser 
was developed for the treatment of  vascular diseases, 
including inflammatory scars that exhibit neovascular-
ization. It is also used to remove hair and to rejuvenate 
the skin [13]. The depth that is reached is determined 
by the spot size, the laser power, and the fluence: the 
larger the spot size, power, or fluence, the deeper the 
laser beam penetrates. Therefore, a large spot size and/
or power are used for deep targets such as hair follicles 
and the blood vessels in the reticular layer of  the der-
mis. However, since larger power increases the risk of 
cutaneous burn injury, the power should be determined 
on a case-by-case basis.
32.3  Indications and Limitations 
of Long-Pulsed 1064 nm Nd:YAG Laser 
for Keloids and Hypertrophic Scars
Keloid and hypertrophic scar development is due to 
chronic inflammation of the dermis during the course of 
wound healing. This associates with prolonged angio-
genesis and collagen production. As mentioned above, 
long-pulsed 1064  nm Nd:YAG laser treatment may 
effectively treat keloid and hypertrophic scars because it 
reduces their vascularity. This reduction in vascularity 
may in turn decrease cytokine or growth factor levels in 
the tissue, which then promote collagen deposition. This 
notion is supported by the ability of several vascularity- 
suppressing treatments to improve inflammation and 
thereby ameliorate abnormal scars. One such treatment 
may be compression therapy, which is widely used with 
heavy scars, especially for hypertrophic scars that arise 
from burn wounds. This therapy may force the collapse 
of blood vessels in the scar, thereby decreasing cytokine 
or growth factor levels in the tissue. Moreover, it has 
been suggested that radiation therapy is effective for 
keloids because it suppresses angiogenesis. However, 
studies elucidating the mechanisms underlying long- 
pulsed 1064  nm Nd:YAG laser treatment efficacy in 
abnormal scars are warranted.
Our previous study [13] suggests that repeated ten-
sion on the edges of scars that is imposed by body move-
ments prolongs scar inflammation: we observed that the 
patterns of mechanical force distribution around keloids 
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and hypertrophic scars are largely consistent with the 
shape of the scar. In particular, our study suggests that 
keloids grow into the direction of the dominant prevail-
ing skin tension. This mechanism explains why keloids 
on different regions of the body adopt specific shapes, 
such as the butterfly on the shoulder, the dumbbell on 
the upper arm, and the crab’s claw on the anterior chest. 
These observations suggest that, if  scars will continue to 
be subjected to strong tension due to the daily move-
ments of the body, long-pulsed 1064 nm Nd:YAG laser 
will not be successful. Indeed, our experience suggests 
that scars on less stretched areas (i.e., the face and ante-
rior lower leg) respond better to this therapy than scars 
on highly stretched areas (i.e., the anterior chest wall 
and scapula). We also found that (1) less inflamed scars 
(i.e., the typical hypertrophic scar) (. Figs. 32.1, 32.2, 
and 32.3) respond better than highly inflamed scars (i.e., 
the typical keloid) (. Figs.  32.4, 32.5, and 32.6); (2) 
thinner scars respond better than thick scars; (3) small 
scars respond better than large scars; (4) single scars 
respond better than multiple scars (. Fig. 32.7); and (5) 
if  even a little scar redness and induration remains after 
long- pulsed 1064  nm Nd:YAG laser treatment, these 
scars are highly likely to recur.
32.4  Treatment Settings of Long-Pulsed 
1064 nm Nd:YAG Laser for Keloids 
and Hypertrophic Scars
The laser should generally be applied to the skin sur-
face with the following standard treatment settings: a 
spot diameter of  5 mm, an energy density of  75 J/cm2, 
an exposure time per pulse of  25 ms, and a repetition 
rate of  2  Hz. However, in the case of  the face 
(. Figs. 32.1 and 32.2) or pediatric patients, the treat-
ment should start with a lower energy density (60–70 J/
cm2) to reduce the possibility of  a burn injury. The best 
way to prevent such burn injuries is to cool the tip or 
air-cool the targeted skin before and immediately after 
irradiation. Each session should consist of  three passes 
unless the patient feels strong pain at the second pass; 
in this case, the session should be stopped. Even if  the 
patient feels no pain after the third pass, the session 
should be stopped. Local anesthesia is not necessary. 
However, if  the patient expresses concern, anesthesia 
cream or tape can be used. The intervals between the 
sessions should generally be 2–4 weeks depending on 
the patient’s schedule.
  . Fig. 32.1 Upper lip hypertrophic scar. Left: before treatment. 
Right: 1 year after treatment. Two years before her referral to our 
clinic, a 20-year-old female received an abrasion injury to her upper 
lip that turned into a hypertrophic scar. Long-pulsed 1064  nm 
Nd:YAG laser was used at the following settings: 5 mm spot diameter, 
65–70 J/cm2, 25 ms, and 2 Hz. After 1 year of  this treatment, the scar 
continued to exhibit a textural difference, but its redness and eleva-
tion had improved. (This figure is cited from Ref. [13] with approval 
from the publisher. © All rights reserved)
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Steroid tape is often used to decrease the inflam-
mation in keloids and hypertrophic scars; this prac-
tice is particularly common in Japan and several 
other countries [22]. We use fludroxycortide tape 
(Drenison®, Dainippon Sumitomo Pharma Co., Ltd., 
Tokyo, Japan) with or without 1064-nm Nd:YAG 
laser (Cutera Inc., Brisbane, CA, USA) to treat path-
ological scars, including keloids and hypertrophic 
scars in recent years [23]. A retrospective cohort 
study [23] was performed to determine whether add-
ing contact mode 1064-nm Nd:YAG laser therapy to 
conservative therapy (steroid tape) reduces the treat-
ment time for hypertrophic Caesarean- section scars. 
In the results, combination of  Nd:YAG laser and ste-
roid tape treatment effectively decreased the total 
treatment time of  hypertrophic Caesarean- section 
scars [23].
32.5  Follow-Up of Keloids and Hypertrophic 
Scars
It is important that patients with keloids and hypertro-
phic scars who undergo sequential treatments are fol-
lowed up over the long term and that they are 
appropriately educated about scar management [3]. This 
is true regardless of the treatment that is being used. 
This is because, if  patients develop pathological scars in 
the first place, they may be particularly prone to recur-
rence or the development of new pathological scars in 
  . Fig. 32.3 Abdomen hypertrophic scar. Upper: before treatment. 
Lower: 1 year after treatment. Four years before her referral to our 
clinic, a 50-year-old female developed hypertrophic scars on her 
abdomen after uterine myoma surgery. Long-pulsed 1064  nm 
Nd:YAG laser was used at the following settings: 5 mm spot diame-
ter, 75 J/cm2, 25 ms, and 2 Hz. After 1 year of  treatment, the scar had 
almost disappeared. (This figure is cited from Ref. [13] with approval 
from the publisher. © All rights reserved)
  . Fig. 32.2 Lower lip hypertrophic scar. Left: before treatment. 
Right: 1  year after treatment. One year before her referral to our 
clinic, an 11-year-old female received an abrasion injury to her lower 
lip that developed into hypertrophic scars. Long-pulsed 1064  nm 
Nd:YAG laser was used at the following settings: 5 mm spot diame-
ter, 60–70 J/cm2, 25 ms, and 2 Hz. After 1 year of  treatment, the scars 
continued to display textural differences and elevation, but there was 
clear improvement in their redness. (This figure is cited from Ref. [13] 
with approval from the publisher. © All rights reserved)
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response to minor stimulation. Thus, these patients 
should be educated in the self-management of both their 
abnormal scars and new wounds. In particular, they 
should be encouraged to apply steroid tape/plasters dur-
ing the early stages of scar development. This will rap-
idly reduce the inflammation in the scar and improve its 
appearance. Moreover, laser therapy, anti-allergy agents 
(including tranilast), anti-inflammatory agents, bleach-
ing creams, and make-up therapies can be used on a 
case-by-case basis [3].
32.6  Conclusion
Long-pulsed 1064 nm Nd:YAG laser has been used to 
treat keloids and hypertrophic scars. This laser was 
developed for the treatment of  vascular diseases, 
including inflammatory scars that exhibit neovascular-
ization. The depth that is reached is determined by the 
spot size, the laser power, and the fluence: the larger 
the spot size, power, or fluence, the deeper the laser 
beam penetrates. The standard treatment setting is a 
spot diameter of  5 mm, an energy density of  75 J/cm2, 
an exposure time per pulse of  25 ms, and a repetition 
rate of  2 Hz. Moreover, it is important that patients 
with keloids and hypertrophic scars who undergo 
sequential treatments are followed up over the long 
term and that they are appropriately educated about 
scar management.
Take-Home Messages
 5 It has been used long-pulsed 1064  nm Nd:YAG 
laser to treat keloids and hypertrophic scars.
 5 Long-pulsed 1064  nm Nd:YAG laser was 
developed for the treatment of vascular diseases, 
including inflammatory scars that exhibit 
neovascularization.
 5 The depth that is reached is determined by the spot 
size, the laser power, and the fluence: the larger the 
spot size, power, or fluence, the deeper the laser 
beam penetrates.
 5 The standard treatment setting is a spot diameter 
of 5  mm, an energy density of 75  J/cm2, an 
exposure time per pulse of 25 ms, and a repetition 
rate of 2 Hz.
  . Fig. 32.4 Anterior chest wall keloid. Left: before treatment. 
Right: 1 year after treatment. Eleven years before her referral to our 
clinic, a 29-year-old female developed butterfly-shaped keloids on 
her anterior chest. Treatment with steroid ointment and tape at other 
clinics did not improve these scars. Long-pulsed Nd:YAG laser was 
used at the following settings: 5  mm spot diameter, 65–75  J/cm2, 
25 ms, and 2 Hz. After 1 year of  treatment, the textural differences 
and elevation had improved but there was remaining redness on 
some parts. (This figure is cited from Ref. [13] with approval from the 
publisher. © All rights reserved)
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  . Fig. 32.6 Scapular keloid. Left: before treatment. Right: 3 years 
after treatment. About 30 years before her referral to our clinic, a 
52-year-old female developed a butterfly-shaped keloid on her scap-
ula. Steroid injections and tape at other clinics yielded little improve-
ment. Long-pulsed 1064 nm Nd:YAG laser was used at the following 
settings: 5 mm spot diameter, 70–75 J/cm2, 25 ms, and 2 Hz. After 
2 years of  treatment, the texture, redness, induration, and elevation 
of  the scar had clearly improved. (This figure is cited from Ref. [13] 
with approval from the publisher)
  . Fig. 32.5 Shoulder keloid. 
Left: before treatment. Right: 
30  months after treatment. 
About 20  years before her 
referral to our clinic, a 
52-year-old female developed 
butterfly-shaped keloids on 
her upper arm and shoulder. 
Long-pulsed 1064  nm 
Nd:YAG laser was used at the 
following settings: 5 mm spot 
diameter, 70–75 J/cm2, 25 ms, 
and 2  Hz. After 1  year of 
treatment, there were clear 
improvements in the textural 
differences and elevation but 
there was remaining redness 
on some parts. There was also 
some capillary dilation that 
was the result of  steroid injec-
tions in the past. (This figure 
is cited from Ref. [13] with 
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Hypertrophic fractional laser and keloid scars present a 
spectrum of disorders that are difficult to treat. Multiple 
treatments have been tried, to ameliorate the clinical 
sequelae of scarring, such as erythema, pruritus, func-
tional limitation, reduced range of movement, dyschro-
mias, hyper and/or hypopigmentation. Early international 
clinical recommendations on scar management first rec-
ognized the importance of laser therapy in this armamen-
tarium [1]. Within the years that followed, laser technology 
and the understanding of how it modulates the underly-
ing processes that leads to hypertrophic and keloid scar-
ring have experienced a quantum leap [2] and are still 
evolving. Lasers also present a considerable financial 
commitent, and it is possible, in the authors’ experience, 
that limited early results partially stemmed from limited 
availability of multiple lasers with consequent attempts to 
overstretch the indications for what was available.
This chapter presents a state-of-the-art insight into 
the use of fractional laser for the management of this 
complex problem. In particular, we focus on the man-
agement of complex scars such as those occurring post- 
burn injury and split-thickness skin grafting.
33.2  Method of Action
Light energy can be used to modulate or ablate specific 
targets in the skin through selective absorption of energy 
and specific heat energy dissipation properties [3]. The 
theory of selective photothermolysis, first described in 
1983, laid the foundations for subsequent developments 
and standard practices [3]. When used to induce a con-
trolled thermal injury, lasers initiate information pro-
cesses to increase vascular permeability and modulate 
matrix metalloproteinase production of collagen fiber 
deposition and tissue hypoxia caused by targeted vascu-
lar ablation [4]. Through these processes, wound healing 
specifically in the remodeling phase may be manipulated, 
resulting in scar maturation and obviation of symptoms 
[5]. Different types of lasers are useful in targeting the 
different components of this disease scar tissue and it is 
important that the laser practitioner has the essential 
range of appropriately powered tools required to pro-
duce an optimal effect.
The choice of fractional laser in the management of 
a hypertrophic spectrum scar depends upon whether an 
ablative or non-ablative effect is desired, the target chro-
mophore, the background skin type, the thickness of 
scarring, requirement for laser-assisted drug delivery 
(LADD), and the patient’s compliance with postopera-
tive downtime and regimes. The Azzopardi classification 
of chromophores also helps the practitioner rationalize 
the likely target and downstream metabolic effects [6]. 
Fractionated lasers with established effectiveness include 
CO2 and Er YAG (nanosecond modality). More recently, 
fractioned, picosecond Nd: YAG has emerged as a 
potent platform in this context.
33.3  Fractioned Laser Platforms
Fraction laser resurfacing creates microscopic columns 
of ablation in epidermis and dermis, termed microscopic 
treatment zones. The relationship of these zones to 
intervening blocks of normal tissue permit rapid heat 
dissipation yet deliver enough energy to allow immedi-
ate changes in scar pliability, and instigate scar remodel-
ing and neocollagenesis. The use of non-fractioned 
platforms such as pulsed dye and KTP (532 nm) are well 
documented and discussed elsewhere.
Fractioned CO2 (10,600 nm) and Er:YAG (2940 nm) 
are the two main ablative modalities in use, targeting 
water and collagen to produce mass transfer zones 
(MTZs) of defined diameter (70–100 μm) and depth, tis-
sue vaporization, and coagulation.
At the molecular level, fractional ablative laser 
treatment induces upregulation of  heat shock protein, 
upregulation of  matrix metalloproteinase, fibroblast 
apoptosis, downregulation of  transforming growth 
factors and basic fibroblast growth factors, and modu-
lation of  collagen-type ratios. These changes are evi-
dent beyond the microscopic treatment zones, yet the 
spared tissues contribute to rapid, normalized wound 
healing. A major difference however between CO2 and 
Er:YAG laser is the potential to achieve immediate 
coagulation and hemostasis: CO2 laser is 10 times 
more effective in this regard. This is critically impor-
tant when considering resurfacing of  extensive areas 
and when considering LADD, as in our experience, 
bleeding results in plugging and reduced LADD effi-
cacy. Moreover, the waveform characteristics of  a CO2 
laser have a significant bearing on the potential for 
side effects.
33.4  Fractioned CO2 Laser
Indications and timing: The latest version of  consen-
sus international guidelines for prevention and treat-
ment of  pathological scarring (2014) reserve the use of 
fractional laser therapy for scars refractory to pulsed 
dye laser; widespread hypertrophic burn scars that 
failed to improve with treatment with silicone gel or 
sheeting, pressure garments, and/or onion extract 
preparations for 8–12 weeks; minor keloids that failed 
to improve within 8–12 weeks with silicone gel sheet-
ing and intralesional corticosteroids; and major 
keloids resistant to improvement with intralesional 
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corticosteroids and 5-FU may be treated with ablative 
fractional laser or PDL therapy. This philosophy has 
been challenged by recent literature.
First, the use of  fractioned CO2 has since been suc-
cessfully used (to date, off-license) with extensive and 
well-documented success, as an adjunct facilitating 
transdermal delivery (see below) [7]. Pulsed dye is less 
effective in scars more than 1.2 mm depth, and do not 
allow for effective scar pliability that may substantially 
facilitate post-procedure physical therapy. From a 
basic sciences perspective, once it has been established 
that fractioned ablative laser may re-instigate appro-
priate scar remodeling, it would be more useful to tar-
get the scar during the remodeling phase once 
epidermal integrity is well established. Recent litera-
ture supports earlier intervention than the previous 6 
months to a year postinjury dogma, in concordance 
with our experience. In our experience, a treatment 
interval of  4–6 weeks is acceptable. Further, given the 
tendency of  corticosteroid to exacerbate telangiecta-
sias, use of  fractioned CO2 first (±LADD) followed by 
vascular-type laser to correct any resulting telangiec-
tasia may also be an acceptable and more time-efficient 
approach.
33.5  Settings for Ablative Fractional CO2 
Laser
Utmost caution is advised when deciding clinical set-
tings as these will vary between platforms. Many super-
pulsed lasers can only produce a shark tooth–type 
waveform. This results in the need to impart substan-
tially more energy for the therapeutic threshold to be 
achieved. This additional energy may be responsible for 
the increased risk of complications seen in the literature 
(both medical and legal) with these laser platforms. In 
contrast, lasers imparting a “top hat pattern” waveform 
impart only enough energy for the therapeutic threshold 
to be achieved. Further safety considerations include 
maintaining an inverse ratio of power to density, and 
ideally to avoid imparting a fluence that is above TRT, 
density sets the number of MTZs per unit area, which 
should not be above 10%. Ideally, for purposes of safety, 
pre- and post-cooling regime should also be considered. 
A cold-air blower provides excellent pre-and post- 
cooling as well as being an effective analgesic.
Further settings include the size, shape, pulse 
stacking, and depth. Shape and size of  the fractioned 
beam can be changed according to prevailing need. 
Whether the beam should penetrate beyond the scar 
thickness is still being investigated; however, injuries 
beyond the dermis may well lead to scarring and 
should be avoided [8].
33.6  Fractioned Erbium:YAG
The clinical efficacy of Er:YAG in keloid scars is lim-
ited. Cavale et  al. combined Er:YAG with twice daily 
topical  betamethasone under occlusion until therapeu-
tic maximum was achieved, resulting in 50% improve-
ment (median, n = 70), but recurrences also occurred in 
22% of lesions [9]. One factor which may explain this 
disappointing result is the limited ability of current 
Er:YAG technology to penetrated deeply, and lower 
hemostasis.
33.7  Fractional Non-ablative Laser
Fractional 1550 nm Erbium-doped fiber laser reported 
overall improvement in scar texture after four treat-
ments spaced 2  weeks apart, compared to the non- 
treated part of this split-scar study [10]. Literature 
reports that the response is mediated by heat shock pro-
tein, fibroblast proliferation, and consequent neocolla-
genesis [10].
A recent comparative RCT reports 1550  nm Er- 
doped fiber (70  mJ/23% coverage) to be superior to 
pulsed dye laser (7.5  mJ/10  mm/0.45  ms), with a 75% 
compared to 53% improvement reported [11, 12].
33.8  Picosecond, Fractioned, 1064 nm 
Nd:YAG
Management of hypertrophic and keloid scarring in 
darker skin types is a formidable challenge. Longer wave-
lengths, cooling devices, and lower treatment fluences 
have been shown to minimize complications [13, 14]. 
Recently, fractional picosecond 1064 lasers have reported 
good outcomes with very few side effects [15]. Compared 
to the conventional nanosecond domain QS Nd:YAG 
laser, the ps-Nd:YAG can produce significantly higher 
peak powers at the same energy level [16]. It is therefore 
expected that such technology works  principally through 
photomechanical rather than photothermal effects [17]. 
The inhibitory effect of the 1064-nm Nd:YAG laser 
against dermal collagen formation is documented in the 
literature [18–20]. More recently, the use of fractioned 
755 nm picosecond laser has been reported to be effective 
and safe in patients with Fitzpatrick skin types 4–6 [20].
33.9  Cautions and Contraindications
Caution is advised with any underlying process that 
impedes wound healing. History of herpes simplex virus, 
especially if  lasering is to be attempted in the peroral 
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area, should prompt prophylactic management. Oral 
antivirals or more recently bromelain should be consid-
ered [12, 21, 22]. Current depth of penetration for abla-
tive fractional devices is approximately 4  mm, and 
therefore management of deeper scars is less likely to be 
as effective [22].
33.10  Preoperative and Postoperative 
Regimes
No consensus exists with regard to preoperative prepa-
ration. Some prepare skin with chlorhexidine solution 
and moistening hair-bearing areas prior to treatment 
[23]. Others, including the authors, are content with 
cleansed, dry skin [24]. It is important to note that what-
ever preparation method is favored, that moist and 
humid surfaces result in reduced ablation, and increased 
heat latency since the primary target, water, is now in 
increased abundance.
Several factors influence the choice of  anesthesia, 
depending on the age of  the patients, available equip-
ment, and extent of  surface area treated. However, 
overarching principles governing the practice of  both 
authors include the use of  the safest, least-invasive 
modality first, pre-optimization, and dual effect of  skin 
cooling in increasing safety as well as providing an anal-
gesic effect. Within this context, pretreatment with top-
ical anesthetics of  increasing strength coupled with 
cold-air blowers may provide the mainstay of  analgesia 
requirements [25].
Where general anesthesia is required, it is possible 
to apply topical anesthesia immediately after fractioned 
CO2 lasering. However, the facilitation of  transdermal 
delivery will facilitate increased absorption (see below), 
and therefore it important to consider the maximum 
safe dose to avoid anesthesia-related toxicity. Use of 
ice- water packs immediately following treatment pro-
vides additional modalities for heat dissipation and 
analgesia [26].
Again, postoperative regimes vary widely, depending 
on resource, patient compliance, and experience. Use of 
antiseptic moisturizers, followed by a regime of moistur-
ization is strongly advised, along with hydrocortisone 
for pruritus. Sun protection is mandatory. Patients may 
resume normal activity almost immediately, including 
physical or occupational therapy. Showering is permit-
ted, with the exception of full immersion in standing 
(bath) water where ablative laser has been used. Some 
degree of edema is expected. Depending on the patient’s 
tolerance, compressive garments may be worn immedi-
ately after, but they may cause shear of treated tissue, 
and therefore it is sensible to recommend waiting for 
24–48 h before use.
33.11  Expected Outcomes
Benefits associated with CO2 laser treatment include 
increased scar pliability and reduced tightness, but it is 
important to impress on the patient that laser treatment 
creates the potential for increased scar pliability which is 
accomplished only by compliance with aggressive physi-
cal therapy postoperatively. Appropriate patient selec-
tion is therefore paramount, as is the availability of 
experienced and motivating physical therapists. Further 
benefits include reduced scar height and thickness. 
Pruritus has been observed to decrease in several studies 
presumably because nerve endings are no longer encased 
in tight scar tissues.
Similarly, fractioned CO2 laser may directly address 
the source of keloid formation, when this occurs in hair- 
bearing skin. Here, the hair follicle is encapsulated in the 
scar, which subsequently inflames, infects, and results in 
perpetuation of the insult-driving keloid growth. Scar 
remodeling results in amelioration of pliability, and in 
the authors’ experience it is not uncommon to result in 
resolution of the insult-driving keloidal growth as well 
as regrowth of hair in the site.
By inversely relating density to energy settings, it is 
also possible to attenuate relative scar height, resulting 
in flattening.
33.12  Potential Complications
The principal complications reported in the literature 
include burns, infection (viral, bacterial, mycotic) 
postoperative pain, and abnormal pigmentation: 
Post- inflammatory hyperpigmentation as well as 
hypopigmentation have been reported. In those being 
treated for burn injury memory flashbacks to the 
original incident have been reported in the literature, 
therefore it is essential that patients are forewarned. 
It is of  course important to discuss the potential of 
multiple treatments. A large prospective study per-
formed by Hultmann and colleagues puts the overall 
complication rate at 3.9% of  all treatments: in 
decreasing order of  incidence, hypopigmentation, 
blistering, hyperpigmentation, infection, cellulitis of 
the adjacent skin, superficial mycoses, and oral her-
pes simplex [27].
Practical recommendations for improving patient 
safety are judicious use of fluence (especially in darker 
skin types), use of pre- and post-cooling regimes, single 
pass, and avoiding stacking pulses, intentionally or oth-
erwise [8]. Multimodality treatment to one area within 
the same sitting is indeed possible, given the mastery of 
the underlying principles, correct understanding of the 
disease extent, the background skin type, and the 
patient’s potential for healing. However, it significantly 
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increases the risk for adverse events and therefore best 
avoided, except where mandated by individual risk–ben-
efit considerations and availability of experts with 
appropriate experience. The use of test-patching and ini-
tiation of treatment in non-cosmetically conspicuous 
areas are advocated. In addition, a readily available 
database of previous patient-specific settings allows set-
ting optimization to be delivered based on previous suc-
cesses or complications.
33.13  Fractioned CO2 Laser as a Method 
for Potentiating Transdermal 
Laser-Assisted Drug Delivery (LADD)
Ablative fractional laser breaches epidermal integrity, 
producing newly formed, uniform, and deep channels 
into hard dermal scars. It is well established (but at time 
of publishing as yet off  license) to harness this phenom-
enon as an effective method for trans-dermal drug deliv-
ery (. Fig.  33.1). The two-fold advantages may be 
summarized as follows: less pain and more even distri-
bution. First, traditional injection of volume into tight 
dermal scarring produces uneven distribution, creating 
blebs of volume while no treatment to adjacent areas. 
Volume injection into a tight scar also increases pain 
and discomfort [28]. Recent literature also points to var-
ious aspect of improvement this technique addresses, 
including pain tolerance, texture, dyschromia, and 
hypertrophy [26, 28, 29].
Pain relief: Intra-scar injection is often poorly toler-
ated pain-wise, especially when larger surface areas are 
being considered. Several studies have established that 
fractional Er:YAG pretreatment reduces up to twelve-
fold the time required for topical anesthesia to take 
effect. However, within these studies, it is impossible to 
assess whether mild adverse events reported (including 
residual pain, redness, or mild-moderate swelling) was 
due to the needle or laser, as the effect was measured 
only after the needle was inserted. Typical settings for 
this indication are fluence of 250 mJ/pulse, a pulse width 
of 300 microseconds, and an estimated pore depth of 
less than 20 mm [30–32].
More importantly, this data demonstrates that 
application of  local anesthesia post-procedure is likely 
to be more efficiently absorbed. While care needs to be 
taken with maximum dose due to altered absorption, 
post- procedure topical anesthesia may provide valu-
able pain relief, and is the standard practice of  one of 
the authors (EA) when treating larger areas of  sheet 
hypertrophic scarring post burns, with no side effects 
noted to date.
LADD has been used to potentiate transdermal 
delivery of  both corticosteroid [33–37] as well as 
5- fluorouracil [38] as well as combination treatment 
[38]. More recent evidence suggests that both are 
equally effective, but 5-FU does not lead to dermal 
atrophy or telangiectasia seen with corticosteroid 
delivery [39].
33.14  Consensus Practice
Established clinical consensus is that ablative lasers are 
significantly more effective per treatment for scar 
improvement than their non-ablative counterparts, 
especially for keloid and hypertrophic contracted scars, 
with significant gain in pruritus, pain, and physical 
mobility within days and up to 2 weeks posttreatment. 
Usually, rapid improvement in dyspigmentation is fol-






  . Fig. 33.1 In Laser Assisted 
Drug Delivery, is a recent 
advancement where laser energy 
is used to enhance trans-dermal 
drug delivery. For scarring a, 
typically, a fractioned ablative 
laser beam is used to create 
channels within the scar b. This 
is followed expeditiously with 
topical application c. The topical 
application is massaged in to the 
lasered area to enhance 
absorbtion d
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34.1   Background
HTS (hypertrophic scars) and keloids remain a serious 
and challenging issue regarding medical and therapeutic 
intervention. Clinical symptoms such as pain or pruri-
tus are followed by psychological deficits of stigmati-
zation or even discrimination for the affected people. 
Considering the multifactorial pathogenesis of these 
pathological scars, the injury to the skin reaches the 
reticular dermis and causes subsequent aberrant wound 
healing. A secondary intention of wound healing is char-
acterized by inflammation by promoting various tissue 
and immune cells. Hence, the vulnerable skin layer of 
HTS and keloids contains inflammatory cells, increased 
numbers of fibroblasts producing collagen and endothe-
lial cells for a nutritive angiogenesis. This may promote 
chronic inflammation, which in turn may cause the inva-
sive growth of keloids and explains clinical symptoms. 
The situation becomes even more complex with bacte-
rial superinfection or other inflammatory responses, as 
proinflammatory cells and cytokines are highly upregu-
lated. Pathophysiological parameters create a complex 
profile of HTS and keloids, which demand therapeutic 
attention and medical intervention.
34.2   Introduction
In this chapter, we are going to present medical needling 
as an ideal therapy for the treatment of hypertrophic 
scars and keloids. The past has shown difficulties in 
treating these types of scars that are characterized by 
a complex anatomy and a progressive degradation of 
the scar texture. Serious challenges for various therapy 
approaches are a rapid and uncontrolled growth, a lack 
of moisture and a rigid structure. Affected people are 
confronted with dysfunctional and aesthetic deficits 
in their daily life or suffer from further harm through 
stigmatization. For this indication, medical treatment is 
required that replaces surgical interventions and other 
ablative treatments. HTS and keloids are prominent scars 
that frequently occur in combination with persistent 
erythema. Widespread and deep damage of the skin lay-
ers is often followed by secondary wound healing, which 
enhances the formation of either HTS or keloids. Keloid 
scars occur when the skin overreacts to the injury, after 
which they continue to grow and get dark in color. The 
histopathology of keloid demonstrates an extensive tis-
sue proliferation beyond the margin of primary wound. 
Dark skin types are predisposed for the development of 
keloids that appear when a forced wound closure pro-
ceeds under tension. That is why keloids can cause great 
discomfort, tightness, or a limited range of mobility if  
they develop near a joint such as the knee or ankle. An 
excessive stretching of skin creates uncomfortable pres-
sure over the fibrotic tissue, which can cause itching. 
Because of their typical larger size, they tend to rub on 
clothing, causing unbearable irritation.
Whereas the development of HTS is fairly man-
ageable, keloids reveal specific features concerning the 
parameters of size and growth. Keloid scars develop 
uncontrolled or excessive fibrogenesis and are a tremen-
dous source of collagen that still causes clinical problems 
until now. Thus, keloid is an active tissue that demon-
strates signs of inflammation such as redness, itch, and 
mild pain. The permanent tendency to uncontrolled 
growth exceeds the original wound area and reaches 
massive proportions due to uncontrolled fibrosis. The 
last-mentioned issue is associated with a dysregulation 
of growth factors, which leads to an overproduction of 
scar tissue and an uncontrolled synthesis of the extracel-
lular matrix. Hence, therapeutic treatment of keloids dif-
fers from those of normal hypertrophic scars. Keloid is 
often recurrent, although it has been treated with either 
pharmacological agents or surgery. Dermatological 
approaches of scar removal are not based on ablative 
treatment methods. They include compression therapy, 
intralesional corticosteroid injections, and excisions. 
When injected into the keloid, appropriate medication 
helps shrink the scar for a short time. The patient is due 
to receive a series of injections once every month, which 
means a constant therapy in order to prevent renewed 
scarring. Moreover, the use of radiation therapy instead 
of laser therapy is a common practice. However, this 
method also means a radiation exposure, which is 
always a health hazard. Ionizing radiation should only 
be implemented when medical  indication is given or 
other alternatives are not reachable.
With regard to HTS, ablative treatments such as sur-
gical interventions show temporary success by reducing 
the scar tissue to the level of the surrounding skin. These 
circumstances support the risk of recurrence and a con-
tinuous degradation of scar texture and healthy skin. 
The majority of conventional treatments are based on 
ablative and radical principles that provoke short-term 
responses and only suited for the removal of HTS. For 
this reason, conventional therapy approaches show little 
success and permit poor access to an efficient treatment 
of keloids or HTS.
Against this background, the demand for less inva-
sive and effective functional and aesthetic treatments 
is steadily growing and remains a permanent issue in 
modern medicine. The focus is clearly defined by the 
patient’s satisfaction with the aim of maximal outcome 
and minimal risk at the same time. Medical needling 
seems to be an ideal method for what is postulated in 
many fields of modern medicine. PCI displays a simple 
regenerative technique that affects skin-related indica-
tions and in particular scars. Its success is manifested 
in skin regeneration particularly for severe and wide-
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spread scars with hypertrophic and keloid features. The 
method of PCI requires neither expensive apparatus nor 
the need of complex instruments and sets a new trend 
in plastic and aesthetic medicine. By stimulating com-
plex signal transduction pathways in the postneedling 
wound-healing cascade, the natural regeneration pro-
cess is modified and, hence, is more efficient. According 
to that, medical needling improves the appearance and 
quality of scars with comparatively low risk and stress 
for the patient. The postneedling cascade induces gene 
expression and the proliferation of skin and stem cells 
that are important for dermal remodeling. The expres-
sion of specific proteins and reorganization of the extra-
cellular matrix affect epidermal thickness and creates a 
stable and functioning skin barrier [1]. Furthermore, the 
PCI-induced synthesis of collagen and release of endog-
enous growth factors allow an association with scarless 
wound healing. Epidermal as well as dermal structures 
remain intact and histological findings show a complete 
re- epithelialization of the epidermis after treatment.
Current medical standards offer a diversity of non-
invasive treatments (e.g., silicone patches) and minimal 
invasive procedures (e.g., cortisone injections) or surgi-
cal options such as scar excisions, tissue transfer, and 
W- and Z-plasties. Keloids show a limited therapy spec-
trum, which is mainly based on nonablative treatments 
(radiation, injections). Ablative methods such as laser 
resurfacing, dermabrasion, and deep chemical peels 
are all together defined by the same principle and find 
use in the treatment of HTS: they lighten the scar by 
destroying the skin structure and provoke an inflamma-
tory response. As a result, the treated area is replaced 
by a thinner epidermis that shows flattened rete ridges 
and parallelly orientated scar collagen that is typical for 
fibrosis [2]. Furthermore, the skin is more vulnerable for 
bacterial or viral infections and external stress. These 
complications make a successful treatment of hypertro-
phic and keloid scars almost impossible, as they already 
have dysfunctional qualities. Complex structural and 
physical features of keloids have shown that common 
methods display temporary solutions that conceal the 
actual problem instead of improving the scar quality. 
In most instances, the scar quality of keloids or HTS 
would be much worse then. Compared to that, PCI 
has been proved to be a relatively simple, fast, and con-
trolled method, which can be safely repeated and used in 
body regions where ablative or semi-ablative treatments 
have limited usage. Current studies on medical needling 
show a positive effect on hypertrophic scars regard-
ing the parameters elasticity, moisture, transepidermal 
water loss, and erythema. In terms of dermal reorga-
nization, high levels of structural proteins – glycosami-
noglycans and proteoglycans – as well as an increased 
presence of physiological collagen are measurable after 
needling. PCI preserves dermal structures and promotes 
the formation of physiological collagen instead of scar 
collagen. For this reason, PCI overcomes shortcomings 
of other conventional methods that are available for 
treating problematic scars such as HTS or keloids. Study 
outcome has already shown the positive effect of medi-
cal needling on HTS in the past years and latest clinical 
data reveal similar results concerning keloids.
34.3   Method
Medical needling is based on a simple idea of punctur-
ing the affected area repeatedly with a roller covered with 
needles of a specific length. Approximately 20 years ago, 
Camirand and Doucet had the experience that treating 
hypertrophic scars with a tattoo gun affects the scar tex-
ture and achieves significant improvements regarding 
clinical parameters [3]. Based on these ideas, Fernandes 
developed the technique of percutaneous collagen 
induction. In 1997, he realized this scientific discovery 
by establishing a roller equipped with needles in order to 
produce thousands of neighboring micro- wounds in the 
dermis, which cause intradermal bleeding. Thanks to 
targeted research within the last 15 years, scientific data 
have been provided by Aust et al. at first, and underline 
the efficacy as well as safety of medical needling.
In Germany, medical needling is now a licensed 
therapy for the treatment of scars and other related 
 indications. The needling device is covered with needles 
of the desired length (0.5–3 mm) and needs to be rolled 
over the scar in three directions under constant pressure: 
vertically, horizontally, and diagonally. In the case of 
hypertrophic scars and keloids, surgical needling with a 
needle length of 3 mm is instructed in order to reach the 
scar collagen as deeply as possible. A straight guidance 
of the device is necessary in order to prevent shear forces 
and deeper damage. Relative to the extent of the scar size, 
this procedure requires 30–60  minutes of mechanical 
exposure. The penetration of the papillary dermis leads 
to thousands of micro-wounds and intradermal bleed-
ing through the parenchymal canals. Minimal lesions of 
the epidermis do not impair basal layers containing stem 
cells with regenerative capacity. The increased expres-
sion of specific growth factors and release of structure 
proteins induce a modified wound- healing cascade with 
a great regenerative potential. The scar is sufficiently 
needled when multiple and confluent ecchymosis as well 
as skin swelling are clearly indicated. After 24 hours, epi-
thelial cells close the channels and are reorganized into 
a natural protection barrier, which reduces the risk of 
potential postoperative complications such as infections. 
Therapy benefits are optimized by the application of 
nourishing products in first 24 hours. Swelling and local 
redness or edema of the treated area disappears after 
approximately 4–7 days. PCI is performed under general 
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anesthesia in an operation theatre. When smaller areas 
are treated, the performance can be done under local 
anesthesia. Preoperative formalities include an informed 
consent form signed by informed patients or parents of 
patients younger than 18  years of age. Pre- and post-
operative management is kept simple and includes the 
application of Vitamins A, C, and E as antioxidants [4]. 
According to latest research, maximal therapeutic out-
come regarding epidermal thickness and a better prog-
nosis for rapid healing can be expected. Postoperative 
monitoring is not substantially necessary. However, after 
surgical needling, a short down time of a few days needs 
to be considered, as the procedure requires general or 
local anesthesia. Therefore, a stay in hospital is only 
recommended, not obligated. Nevertheless, patients are 
able to get back to their daily life after a short time of 
recovery (. Fig. 34.1).
34.4   Effects of Medical Needling
The intradermal bleeding caused by the mechanical 
procedure induces second-messenger substances of 
significant signal transduction pathways, which lead 
to a modified physiological regeneration of the skin. 
Specific features of both skin layers are not only pre-
served in their functional structure but also promoted 
in a positive qualitative way. Epidermis and dermis 
remain functionally intact and protect subcutaneous 
structures. Moreover, single layers of the epidermis 
become thicker, which guarantees great stability and a 
reduced vulnerability. Treated skin reacts less sensitively 
to damaging physical factors such as UV radiation that 
is associated with postinflammatory hyperpigmentation 
[5]. Furthermore, medical needling is also suited for all 
skin types. Treating dark skin is not followed by any 
dyspigmentation or even hypopigmentation, although 
dark skin is indeed predisposed for color shifts due to 
the naturally increased amount of melanin. Molecular 
and cellular processes induced by PCI affect neither the 
amount of melanocytes nor the mechanisms of synthe-
sizing melanin. However, PCI specifically modifies the 
expression levels of the melanocyte-stimulating hormone 
(MSH) and Interleukin-10 (Il-10). MSH influences the 
activity of melanocytes and is downregulated within the 
postneedling cascade. On the other hand, high levels of 
Il-10 are evident, which is an antiinflammatory cytokine, 
and support immunological tolerance. As a targeted 
therapy, PCI concentrates especially on those areas that 
are aimed to be treated and also affects the surround-
ing healthy skin in a positive way. Due to the fact that 
needling does not create an open wound surface, there is 
a low risk for the development of viral or fungal infec-
tions, which could complicate a scar-free wound healing.
34.5   Needling Techniques
The needling treatment needs to be planned and pre-
pared in advance. This includes the examination and 
categorization of the scars according to specific fea-
tures. The selection of the appropriate length of nee-
dles depends on the type of scar, pain management, 
and expectation from the patient’s side. From this per-
spective, downtime repetition capacities and aesthetic 
achievements are considered. Massive scars with intense 
deficits would be HTS and keloids that are predomi-
nantly treated by surgical needling. This means a longer 
downtime but also maximum results. Considering input 
and outcome, maximizing the patient’s expected results 
is aimed to achieve.
In principle, medical needling can be classified into 
cosmetic, medical, and surgical needling. The differ-
ence depends on the length of the needles used and the 
intensity of the physiological effects as well as the post-
operative regime they require. First mentioned types of 
needling play a minor role for the treatment of HTS or 
keloids, as the desired effects cannot be achieved.
Cosmetic needling is performed as a purely cos-
metic treatment with needles 0.1–0.5 mm in length for 
 structural and superficial skin modifications. The nee-
dling procedure does not cause any intradermal bleed-
ing and hence any postinterventional reactions remain 
unnoticed. Using the minimal length of needles does not 
require any anesthesia and allows repeating the treatment 
daily. The patient does not experience any downtime and 
gets back to his daily routine without any complications. 
All together, the cosmetic needling is used as a penetra-
tion enhancer for topical skin care products.
Medical needling can be defined as PCI when the nee-
dles have a length between 1 and 2 mm. Needles of this 
length reach just beyond the basal membrane and lead to 
minimal petechial hemorrhages in the papillary dermis, 
which activate the TGF-ß signal cascade and give a skin-
  . Fig. 34.1 Roller device for medical needling
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regenerating effect. The needle length is proportional 
to the provoked bleeding, as it gets more intense when 
longer needles are used. However, intradermal lesions 
are so small that there is a minimal downtime without 
obvious edemas or bruises. Moreover, effective topical 
anesthetics can be used to make the process nearly pain-
less. Afterward, the treated area might be reddened and 
needs a few days to recover and normalize.
From the perspective of clinical efficacy, surgical nee-
dling proves to be more intense and impressive when the 
performance is done with a needle length of 3 mm. That is 
why HTS and keloids are indications for surgical needling. 
This procedure is carried out under general or local anes-
thesia and can also require a stay in hospital. The puncture 
depth does not only affect the epidermis and dermis but 
also the upper layers of the subcutis including the vascular 
system that is responsible for the desired and controlled 
bleeding after needling. This mechanical prodecure affects 
the skin structure and function by provoking stress and 
regenerative resources at the same time which is aimed to 
improve the natural skin barrier with intact skin layers. 
For this reason this step needs to be performed wisely and 
carefully observed. The relatively painful procedure under 
local anesthesia provokes primary inflammatory wound- 
healing reactions with temporary erythema, swelling, and 
bruising. The needling device needs to be rolled over the 
affected area until these signs of sufficient needling are 
apparent. The potential for aesthetic correction and reduc-
tion of the scar is on the highest level and provides maxi-
mal outcome. When selecting a needle length of 3 mm, 
the patient is expected to accept a protracted downtime 
in order to achieve maximal results in the phases of recov-
ery. According to that, longer recovery periods of weeks 
should be taken into account (. Figs. 34.2 and 34.3).
The selection of the needle length varies relative 
to the indication and its intensity of cicatrization. 
Moreover, there are important differences notable: The 
shorter the needles, the more often treatments need to 
be carried out in order to reach desired effects. Longer 
needles are indicated when treating prominent kind of 
scars such as HTS and keloids. Summing up, the com-
bination of the patient’s expectations and the desired 
result decides the amount of therapies and the selection 
of the three possible needle lengths.
34.6   Postinterventional Treatment 
Measures
Postoperative Wound Management – For optimizing and 
maximizing therapy outcome, it is instructed to treat 
the skin sufficiently and effectively under pre- and post-
operative circumstances. The application of vitamin A 
and antioxidants such as vitamin E and C is necessary 
to achieve best results. A specific skincare that combines 
the above-mentioned vitamins with a strongly recom-
mended gentle cleansing washing lotion containing tea 
tree oil should be performed every 2 hours as long as the 
needling canals are still open. While the skin remains 
bruised and swollen, direct exposure to sunlight should 
also be avoided. A moist wound-healing regime of 
vitamin- based creams prevents crust formation after the 
initial bleeding, which could eventually impair the final 
results. The loss of serous fluid through the puncture 
holes in the immediate postinterventional period can 
lead to crusting, which needs to be carefully averted by 
washing off  any surface serum. In consequence, prevent-
ing crusting reduces the risk of bacterial superinfections. 
Moreover, inflammation and secondary wound healing 
associated with the development of HTS or keloids can 
be avoided.
Managing Complications  – As needling does not 
produce open wounds, the postoperative complica-
tion rate is very low and postinterventional monitor-
ing is not necessarily needed. However, local edema 
  . Fig. 34.2 Technique of  surgical needling performed with a 
needle length of  3 mm. Desired bleeding and marked edema induce 
therapeutically effective collagen production during the postneedling 
wound-healing cascade
  . Fig. 34.3 A heavier bleeding caused by the 3  mm needling 
method
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can develop with longer needles, especially done on 
large areas. It is recommended to keep the patient in 
the clinic for a few hours after treatment. It needs to be 
considered that after extensive surgical needling under 
general anesthesia, the patient may experience burning 
pain in the treated area. Therefore, pain should be man-
aged with effective drugs particularly in the first hours 
postoperatively. The use of nonsteroidal antiphlogistic 
medication should be avoided, as the primary inflam-
matory response is desired. However, keloids and HTS 
require regular follow-up examinations in order observe 
wound- healing processes and to ensure that renewed 
scarring or proliferating tissue can be excluded. In the 
case of keloids, a further extension of the scarring is 
not that rare after treatment. Clinical data also reveal 
the  formation of necrotic tissue when there is an inad-
equate blood supply. Special attention needs to be paid 
to patients with diabetes that shows difficulties in wound 
healing anyway.
The intradermal bleeding caused by PCI is the essen-
tial driving force in medical needling. In this context, the 
endogenous potential of natural wound healing induced 
by PCI differs from the conventional inflammatory 
response to traumatic incidences starting minutes after 
injury. Therefore, the difference between the postnee-
dling regenerative cascade and the conventional wound- 
healing cascade becomes very clear. The PCI-induced 
regenerative process is based on completely different 
mechanisms that are associated with the desired bleed-
ing, as plenty of blood vessels are pierced at the same 
time. However, an open wound surface is not created 
within this procedure that would need to be refilled by 
regenerative fibers in the course of conventional wound 
healing. Refilling can rapidly escalate into an overpro-
duction of tissue fibers, which again supports the devel-
opment of HTS and keloids. The extent of the initial 
bleeding and the excretion of serous fluids can appear 
in different intensities and mainly depend on the area 
treated as well as the needle length that has been specifi-
cally selected. In consequence, facial skin regions show 
a higher bleeding capacity, as they tend to react more 
sensitively to mechanical stress. Further, these regions 
are more affected by swelling and bruising because skin 
seems to be thinner and therefore reacts more intensely 
to operative interventions than the skin of other regions. 
Eventually, PCI-related results are achieved by replacing 
scar typical collagen with normal collagen of healthy 
skin [6].
34.7   Induction of the Post-Needling 
Wound-Healing Cascade
The intended trauma through the repetitive punctur-
ing initiates a physiological wound-healing cascade. 
Platelets and neutrophils secrete growth factors such as 
the platelet-derived growth factor (PDGF), fibroblast 
growth factor (FGF), vascular endothelial growth factor 
(VEGF), tissue growth factor, and transforming growth 
factor-α and -ß (TGF-α, TGF-ß). The interactive coop-
eration of these factors provides blood coagulation, as 
well as the synthesis of dermal structures such as col-
lagen, elastin, and fibronectin. Furthermore, the differ-
entiation and migration of fibroblasts and keratinocytes 
contribute to regenerative processes. Fibroblasts have 
essential roles in synthesis of collagens I and III. Other 
cells that are represented in all tissues including the der-
mal layer are fibrocytes, dendrocytes, mast cells, and fur-
ther immune cells secreting collagen I and collagen III 
protein. Seen from a dermatological view, TGF-ß has 
specific functions that have a key role in the postnee-
dling wound-healing cascade. In general, wound heal-
ing can be divided into three phases interacting through 
numerous growth factors and other essential elements, 
into approximately month-long sequences: inflamma-
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  . Fig. 34.4 Wound-healing 
course schematic representation
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Right after the injury, the natural and typical reac-
tion of inflammation starts by activating immune cells, 
blood coagulation, as well as vasoconstriction [7]. The 
following stage of proliferation is marked by growth fac-
tors, especially focused on TGF-ß, which is important for 
the regulation of growth processes. Dysregulated signal 
transduction pathways can lead to a malignant degen-
eration of cells, which can result in the development of 
cancer or malignant tumor in the worst case. Keloids 
have indeed characteristics that are similar to tumor cells. 
The persistent presence of TGF-ß1 and-ß2, as well as the 
absence of TGF-ß3  in the conventional wound-healing 
process, indicates the formation of typical rigid scar tis-
sue. The activity of fibroblasts is necessary for the regen-
eration of the extracellular matrix and the synthesis of 
collagen. After the phase of regeneration, an intact skin 
barrier of renewed epithelial cells and a mechanically 
stable skin structure are evident. These are single steps 
described in a typical wound- healing procedure. On the 
contrary, the PCI-induced wound-healing mechanism is 
based on a modified principle of what is already known 
and described regarding wound healing. Special focus is 
manifested in the modified TGF-ß signal transduction 
pathway. Whereas TGF- ß1 and 2 are significantly down-
regulated in the postneedling cascade, TGF-ß3 shows a 
dominant activity 24 hours postinterventionally. Against 
this background, the traditional wound-healing para-
digm is converted into a regenerative phase marked by the 
synthesis of structural collagen of healthy and vital skin 
instead of scar tissue. This is why there is a low risk for 
the development of hypertrophic or keloid scars where it 
usually comes to an uncontrolled hyperplasia of collagen 
fibers and an uncontrolled growth of the connective tissue. 
Very common consequences are rigid and difficult scars.
34.8   Effects of Medical Needling Regarding 
Different Parameters
Scarless Wound Healing – In order to avoid secondary 
wound healing, a controlled activity of growth factors is 
necessary. The close relation between TGF and the for-
mation of collagen type I fibers represents a key role in 
repair and regeneration mechanisms. In this context, it 
needs to be considered that wounds healed by secondary 
intent tend toward an uncontrolled proliferation, which 
enhances the development of HTS or keloids. Type I 
collagen is the physiological desired collagen of lattice 
pattern structure in healthy and vital skin, whereas col-
lagens type III shows parallelly orientated fibers that is 
typical for scars. TGF-ß1 and 2 are at their highest lev-
els of activity when a dense collagen structure of type 
III in scars is built. Study results have proved that in 
keloids with excessive cell proliferation, the expression 
of procollagen I and III -mRNA as well as -protein is 
increased. In excessive cell proliferation of keloid tissue, 
there is a dominant presence of collagen III, although 
both collagen I and collagen III seem to be increased. 
Significant differences to normal skin are manifested in 
the shift of the collagen I and III ratio toward collagen 
III. However, a significant downregulation of TGF-ß1 
and 2 is evident in scar-free, embryonal wound healing 
determined by TGF-ß3. Second kind of wound heal-
ing is still active in juvenile tissue to a lesser extent, but 
not present in adult tissue that is rather predisposed for 
the development of scars. High levels of TGF-ß3 in the 
postneedling cascade do not only induce the synthe-
sis of collagen type I, but also manage the conversion 





















  . Fig. 34.5 Regulation of 
transforming and growth 
factor, TGF-ß3, and scarless 
healing. Microarray analy-
ses of  TGF-ß1, -ß2, and -ß3 
expression levels in treated 
and untreated animals show 
that the needling treatment 
stimulates TGF-ß3 to a greater 
extent than TGF- ß1 or -ß2. 
Moreover, the induction of 
TGF-ß3 gene expression con-
tinues even beyond the initial 
wound-healing phase, whereas 
the two other genes are down-
regulated during the second 
week postneedling
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34.9   Dermal Remodeling
Furthermore, PCI modulates the expression of relevant 
genes and molecules that are responsible for remodel-
ing the extracellular matrix. The skin appears thicker, 
more vital, and rejuvenated. Therefore, PCI displays a 
method that is focused on both quantitative and quali-
tative improvement of dermal function and appearance. 
The release of structural proteins, including fibronectin 
and glycosaminoglycan molecules, as well as the activity 
of specific enzymes, achieves dermal remodeling. These 
components of the postneedling cascade stimulate the 
proliferation of keratinocytes and other skin cells in the 
basal layer of the epidermis, which changes the physi-
cal and biological characteristics of skin. The entire 
connective tissue framework seems to be thicker and 
denser. Other endogenous factors contribute toward 
improved skin elasticity in terms of dermal remodel-
ing, as the amount of elastin is significantly greater 
after medical needling. A lack of elasticity is typical for 
HTS and keloids and one reason for their rigid struc-
ture, which puts the scar as well as the surrounding 
healthy skin under a great pressure. Hence, flexibility 
and mobility of the affected area are compromised, 
which might be a problem when regions close to joints 
are affected. Not only for this reason, TGF-ß3 reaches 
high levels of expression in the initial phases but shows 
a declining trend in the following phases of prolifera-
tion and regeneration. Based on Furguson’s work, the 
initial dominant influence of TGF-ß3 is important for 
the PCI-related wound-healing mechanisms. However, 
clinical expertise shows that giving TGF-ß3 additionally 
in phases of normally low levels can eventually impair 
regenerative processes. In conclusion, the method of 
medical needling influences the release and immediate 
effect of TGF, as well as the synthesis of collagen type I 
interacting within the process of dermal reorganization 
and remodeling. Once again, the signal transduction 
pathway of TGF seems to be one of the most important 
PCI-related factors. Therefore, the method of PCI has a 
regulatory function of promoting a controlled activity 
of growth factors and other regenerative factors as well 
as cytokines. With regard on HTS and keloids, the main 
focus is on managing growth and hypertrophy by a con-
trolled activity of growth, epithelial and vascular factors 
(. Figs. 34.6 and 34.7).
34.10   Improved Perfusion
Another factor showing high concentration during the 
postneedling regenerative cascade is VEGF. In terms of 
angiogenesis, its main function of creating new blood 
vessels and enhancing perfusion accelerates wound- 
healing processes. The method of PCI provides a con-
trolled and limited release of VEGF in order to prevent 
dysregulated activity, which can lead to degenerative 
processes. High levels of VEGF are initially observed in 
the postneedling cascade, which are again not kept con-
stantly high at all times. Hence, medical needling has a 
positive effect on subcutaneous structures conveyed by 
VEGF as an important indicator for active angiogene-
sis. The expression of this growth factor induces the vas-
cular system by supporting the proliferation and activity 
of vascular endothelial cells [8]. This process happens 
after the initial inflammatory response of a vasocon-
striction with the primary intention of stopping the 
bleeding as a typical reaction to an injury. The restricted 
perfusion is then followed by a massive vasodilatation 
in the wound-healing phase. The regulative effect on the 
vascular system explains the intense bleeding after the 
needling procedure, which is in fact an enhancer of the 
wound-healing progress. The better the blood perfusion 
of the skin tissue, the greater the bleeding after mechani-
  . Figs. 34.6 and 34.7 Regenerative effects on the epidermis through 
needling. One day after the treatment, Masson’s trichrome staining 
shows no injuries in either the epidermis or the dermis. Both skin 
layers are functionally intact; there are no signs of  ablation or cell 
damage. . Figure 34.6 Untreated animal (control). . Figure 34.7 
24 hours postneedling
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cal stress induced by PCI, which accelerates healing 
processes. The limited activity of VEGF for a desired 
period of time (postinflammation) has the advantage of 
a rapid wound healing due to a better perfusion and a 
primary wound closure in a timely and effective way. For 
this reason, the risk of secondary wound healing can be 
excluded, as delayed wound-healing processes are very 
improbable and also not expected after needling. In this 
context, the development of HTS and keloids is once 
again kept at minimal risk.
34.11   Dermal Thickness and Erythema
An effective wound-healing process implies active 
vascularization and causes a temporary reddening of 
the skin, which is not associated with persistent ery-
thema. After needling, the affected area is swollen 
and reddened due to a better perfusion in the course 
of  effective healing processes. However, the problem 
of  striking discolorations of  especially hypertrophic 
and keloid scars remains a serious one for the affected 
people, as the scar color differs extensively from the 
surrounding healthy skin. Discolorations can reach 
from slightly reddened skin or persistent erythema to 
dyspigmentation or even hypopigmentation, which is 
quite typical for HTS.  Untreated hypertrophic scars 
tend to a thin and vulnerable epidermis that is unstable 
and more transparent for local perfusion. This might 
support the appearance of  erythema through a thin 
skin texture with a long-term impact. After needling, 
the intense blood circulation is less prominent and tem-
porarily limited through a thickened epidermis. The 
entire tissue structure is more compact and makes the 
great optical difference between scar and surrounding 
skin less prominent. Either way, medical needling rep-
resents a skin- normalizing therapy method and creates 
a homogenous image of  initially reddened scars toward 
healthy skin. Based on outcomes of  objective measure-
ment methods with the Mexameter, medical needling 
achieves a normalization of  the skin color and an 
almost complete adjustment of  the scar tissue toward 
healthy skin after repetitive treatments. As the method 
is based on percutaneous collagen induction, the syn-
thesis of  collagen improves vital thickness, which is 
directly associated with less transparency and a low 
risk for the development of  erythematous hypertrophic 
scars (. Fig. 34.8).
  . Fig. 34.8 Patient 1, frontal shot, preoperatively (left) and one year postoperatively after needling (right). Areas treated include the entire 
face. Reduced erythema and hypertrophy of  the fibrosis
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34.12   Richness of Moisture
HTS and keloids are especially characterized by a lack 
moisture, which combines typical visible anomalies with 
symptoms of pain and itching. The current difficulty of 
HTS resides in skin dryness and an insufficient water 
content of the epidermis [9]. Dehydrated scar conditions 
are the main cause of pruritus, which is not only consid-
ered a sensation disorder but a relevant clinical param-
eter. In fact, itchy and dry scars are closely related to 
structural deficits of the typical scar tissue. Fibrous tis-
sue tends to have less skin appendages such as sebaceous 
and sweat glands and thus produces less moisturizing 
secretions, which leads to skin dryness, less flexibility, 
and a rigid scar texture. Moreover, a thin epidermis with 
parallelly orientated collagen fibers can impair the epi-
dermal barrier function, which is marked by transepi-
dermal water loss (TEWL). Severe and widespread burn 
scars, for example, hold the risk of an incomplete re- 
epithelialization of the epidermis due to a lack of stem 
cell reservoirs. It happens frequently that particularly 
those skin layers such as the basal layer of the epidermis 
are impaired by deeper and widespread damage of the 
skin. However, these components of the skin are able 
to provide stem cells that differentiate into functional 
skin or epithelial cells. Thus, a less functional epider-
mis enhances transepidermal water loss and a reduction 
of moisture. Therefore, patients suffer from dry, itchy, 
and painful scars followed by reddened and vulnerable 
skin. When protective features of epidermal layers are 
deficient, the skin reacts more sensitively to external 
factors and is more accessible for various pathogens, 
which can lead to progressive infections. In this context, 
medical needling ensures epidermal integrity in terms of 
regulating TEWL and reducing the risk of dehydration. 
Measurements with the Corneometer and Tewameter 
have shown that PCI improves the moisture content of 
the skin, which is closely related to the regulation of 
TEWL. Various studies on the effect of medical needling 
on moisture revealed remarkable improvements regard-
ing skin roughness and rigidity, which both depend on 
the water content of the skin (. Fig. 34.9).
Conservative treatments for scars with deficits in 
moisture and TEWL include silicone patches or diverse 
moisturizing creams that are established cosmetic ther-
apy methods. Provided that they are used permanently 
and several times a day over a longer period of time, 
they can improve the scar condition to a temporary 
extent. Concerning the water content of the skin, the 
fluid silicone gel preserves the moisture content, but 
does not affect the skin’s own potential to produce suf-
ficient moisture [10]. A permanent application of oily 
creams keeps the skin moist and smooth, but does not 
improve the scar in quality by itself. TEWL is least 
affected, as the epidermal barrier function is not influ-
enced by the silicone. Once again, short-term results are 
frequent and considering TEWL, there are less satisfy-
ing results. These kinds of methods have a preventative 
character and are rather suited for short-term solutions. 
In the case of HTS or keloids nonablative, conventional 
treatments can be used in addition to needling or other 
invasive therapy methods as complementary therapies. 
Ablative treatments achieve exactly the inverted effect 
in terms of destroying epidermal structures and holding 
the risk of degradation. On the contrary, the established 
method of medical needling preserves the epidermis and 
improves the epidermal barrier function. The signifi-
cant impact on the skin’s water balance is manifested by 
regulating moisturizing processes and the passive move-
ment of water (TEWL) through the epidermis.
  . Fig. 34.9 Patient 3, frontal shot, preoperatively (left) and one year postoperatively after needling (right). Areas treated include the face, 
perilabial, chin, and neck. Reduced erythema and greatness of  the scar. Less tension in the fibrotic area
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34.13   Conclusion
Based on the diverse profile of medical needling regard-
ing different parameters of HTS and keloids, this ther-
apy method is not only an innovative approach, but also 
rather an effective treatment method of problematic scars. 
The aim of improving the scar in quality and function 
is realized by a modified wound-healing cascade, which 
activates relevant signal transduction pathways for an 
effective regeneration. After needling, dysfunctional scar 
tissue gains vital features of healthy skin and shows func-
tional progression months and years after needling. The 
focus is clearly set on sustainability, which is the major 
challenge for an effective treatment of HTS and keloids. 
As underlying causes for the development of these types 
of scars are various and the clinical research potential 
on HTS and keloids is still not yet exhausted, medical 
solutions are required from modern medicine. Common 
therapy approaches are characterized by different moder-
ate success that does not provide long-lasting outcome. 
Improvements are temporarily restricted and rather accu-
mulate in the beginning of the therapy. HTS and keloids 
often tend to reach a nonresponder status in the course 
of repetitive conventional treatments. Surgical interven-
tions are less attractive for the affected people and are 
often followed by a structural degradation up to uncon-
trolled cell death. In terms of not confronting the patients 
with serious consequences and other complications, med-
ical treatment should be scientifically defined as effective 
and sustainable. PCI comes very close to what is expected 
from a medical point of view not only for the supplier 
side but especially for the demand side. Innovative and 
patient- friendly therapy approaches aim to be more con-
venient for patients relative to the required effort. In this 
context, medical needling seems to be a very promising 
therapy method that guarantees persistent effect on HTS 
and keloids. PCI displays a relatively simple and con-
trolled treatment of difficult scars that opens new path-
ways for modern medicine.
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Take-Home Messages
 5 HTS and keloids are pathological scars with a 
characteristic histological and clinical profile.
 5 Persistent lesions to deeper skin layers promote the 
development of HTS and keloids followed by an 
inflammatory response.
 5 Medical approach and success have been quite 
restricted to minimal outcomes and improvement 
in the past.
 5 The greater knowledge of pathomechanisms 
allows the establishment of targeted intervention.
 5 Medical needling overcomes deficits of conven-
tional treatment therapies combining minimal 
invasivity and long-lasting effects at the same time.
 5 Important clinical endpoints (erythema, pruritus, 
pain, and moisture) and not only clinical param-
eters are positively affected by PCI.
 5 Dysfunctional scar tissue gains vital and healthy 
features after treatment with PCI.
 5 Outcomes are up-to-date and underlined by evi-
dence-based clinical research.
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Local flaps are useful for reconstructing scar contrac-
tures on mobile areas such as the joints, the neck, the 
axilla, the digital web, and the mouth commissure. They 
are superior to skin grafts because the latter can con-
tract, thereby leading to secondary contractures. 
Moreover, the color and texture match of local flaps is 
better than that of grafted skin. Consequently, local 
flaps generally provide superior aesthetic outcomes. 
Thus, if  there is healthy skin adjacent to the scar con-
tracture, local flaps should be the first choice. Based on 
the type of movement needed to place the flap, local 
flaps can be classified as advancement flaps, rotation 
flaps, and transposition flaps. A more recent advance is 
to design these flaps as perforator flaps. The inclusion of 
perforators in the flap provides great freedom in terms 
of flap shape and the movement and rotation arc of the 
flap: the propeller flap method is a particularly good 
example of such flaps. Moreover, flap combinations 
such as the bilobed flap and the square flap method can 
expand the possibilities offered by local flaps.
35.2  Selection of Local Flaps
Several approaches that elongate the scar and thereby 
release linear contractures have been reported. Z-plasty 
is one of the best-known options when it comes to 
releasing linear contractures [1]. The theoretical final 
scar length for the 60° angle z-plasty is approximately 
1.73 times the original length of the scar. W-plasty also 
allows contracture release to some degree due to its so- 
called accordion effect: this reflects the fact that zigzag- 
shaped scars elongate in an accordion-like fashion over 
time [2]. However, these methods are mainly used for 
“linear” contractures. If  the scar is wide, the scar cannot 
be removed and then sutured primarily. In this case, the 
scar should be divided by a local flap to obtain contrac-
ture release.
In terms of local flap selection, it is necessary to 
choose between a skin-pedicled flap and an island flap. 
We showed recently [3] that 6 months after surgery, skin- 
pedicled flaps associate with greater scar extension rates 
than island flaps (. Fig.  35.1). Notably, skin-pedicled 
and island flaps, respectively, extended the scar by 1.53- 
and 1.28-fold 6 months after surgery. Thus, local flaps, 
especially skin-pedicled flaps, elongate the scar as effec-
tively as z-plasty. It should be noted that if  the scar is 
large, it is effective only by dividing the scar with the 
local flap. However, the flap size can be slightly smaller 
than the deformity size (although how much smaller 
depends somewhat on how extensible the flap type is): it 
is not necessary that the flap is as big as the open wound 
after scar division or scar removal.
In the case of  the local flap design, it can be affected 
not only by the ease of  the technique but also by the 
geometry of  the scar and open wound tissues. Thus, 
selecting between the skin-pedicled flap and the island 
flap should be performed on a case-by-case basis. 
However, the greater extensibility of  the skin-pedicled 
flap means that it should be the primary choice in the 
a
b
  . Fig. 35.1 Comparison of 
skin-pedicled and island flaps in 
terms of extensibility. a 
Skin-pedicled flap. b Island flap. 
Skin-pedicled flaps have a greater 
extension rate than island flaps 
because they include healthy skin, 
which can expand after surgery. 
By contrast, the inelastic scar 




case of  scar contracture release [3]. This greater exten-
sibility is probably because the entire perimeter of  the 
island flap is surrounded by new scar, whereas the 
skin-pedicled flap maintains a connection with nor-
mal skin. Since normal skin is highly elastic (much 
more elastic than scar tissue), it may promote the 
elongation and enlargement of  the skin-pedicled flap. 
Moreover, at a theoretical level, the circular shape of 
the island flap also limits its extensibility. However, it 
should be noted that island flaps have technical advan-
tages over skin-pedicled flaps: they are relatively sim-
ple to transfer to the recipient site, and they can 
employ the remaining healthy skin around the scars 
without any waste.
35.3  Transposition Flaps
The transposition flap is one of  the classical and most 
representative of  the local flaps. Its contracture- 
releasing effect is very high because the flap has a skin 
pedicle. The healthy skin of  the flap expands over time 
after surgery; as a result, the rectangular shape of  the 
flap becomes triangular (. Figs. 35.2, 35.3, 35.4, and 
35.5). This effect reflects the release of  tension via the 
skin pedicle.
If  the flap has to be large, perforators can be attached, 
and a supercharged transposition flap can be designed 
[4]. The perforator is then anastomosed to the recipient 
site. This perforator-supercharged transposition flap is 
  . Fig. 35.2 Transposition flap. 
Transposition flaps should be 
designed parallel to the 
contracture line. After surgery, the 
skin pedicle can expand over time
a b c d e
  . Fig. 35.3 Reconstruction of  a scar contracture on the cubital 
fossa. a Preoperative view. b View immediately after the operation. c 
Two weeks after the operation. d Two months after the operation. e 
Ten months after the operation. Bilateral transposition flaps were 
harvested. No flap ischemia was observed. The contracture was 
released by about 10 cm
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especially useful for reconstructing anterior neck con-
tractures (. Fig. 35.6).
35.4  The Square Flap Method
The square flap method was reported previously by 
Hyakusoku et al. [5] and is an effective way of elongat-
ing the skin, especially for scar contracture release 
(. Fig. 35.7). This method consists of a combination of 
a square flap, one 45° triangular flap, and one 90° trian-
gular flap. The angle of the triangular flaps of Limberg’s 
original method is 30° [6]. However, in the case of scar 
surgery, the 30° triangular flap can lead to blood flow 
failure because, in some cases, part of the scar must be 
included in the flap. Thus, the angles of the triangular 
flaps in the square flap method should be wider: the 
combination of a 45° triangular flap and a 90° triangu-
lar flap is ideal. One option is to design a four-flap 
z-plasty and a five-flap z-plasty. However, it is safer to 
include one square flap. Moreover, the biggest advan-
tage of the square flap method is that one of the flaps 
has a square shape. This square flap can advance down-
ward and can make a suitably large and pliable floor 
over the joints and web space. Thus, the method results 
in three-dimensional reconstruction [7]. In addition, the 
skin pedicle of the square flap can effectively release ten-
sion over time after the operation. This method is par-
ticularly indicated for scars on the joints, the neck, the 
axilla, the digital web, and the mouth commissure 
(. Figs.  35.8, 35.9, and 35.10). Theoretically, this 
method increases the original scar length by 2.8-fold [7].
a b c d e
  . Fig. 35.4 Reconstruction of  a scar contracture behind the knee. 
a Preoperative view. b Intraoperative view. c View immediately after 
the operation. d One year after the operation. e Two years after the 
operation. A transposition flap was designed next to the scar con-
tracture behind the knee. The contracture was released completely
a b c
  . Fig. 35.5 Reconstruction of  a scar contracture on the abdomen. a Preoperative view. b View immediately after the operation. c One year 
after the operation. A bilateral transposition flap was designed. The contracture sensation on the abdomen was relieved by the operation
 R. Ogawa
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35.5  Propeller Flaps
It has been reported that an island flap that can be rotated 
90° like a propeller is suitable for the reconstruction of 
the axilla and cubitus [8] (. Fig.  35.11). That was the 
first time this flap type was described. This original pro-
peller flap was made by using the intact skin in a cubital 
fossa as a subcutaneous-pedicled island flap to release 
post-burn linear scar contractures that adjoined the fossa. 
The subcutaneous pedicle was located in the center of the 
flap. In the 20 years following this seminal advance, pro-
peller flaps have been refined and modified, and various 
types of propeller flaps have been reported [9–13]. The 
most sophisticated of these is the  perforator- pedicled 
propeller (PPP) flap [9]. This type of flap can be harvested 
from any site on the body that bears a perforator. It 
employs a skeletonized vascular pedicle that allows the 
flap to be rotated by up to 180°. Moreover, if  the perfora-
tor pedicle is located at the edge of the flap, the flap can 
cover a defect that is a long distance away from the flap 
donor site. Depending on the case, the flap can be rotated 
in a clockwise or counterclockwise direction.
The PPP flap is now considered by many plastic sur-
geons to be a highly viable and particularly sophisticated 
perforator flap option. This largely reflects the fact that 
the human body has over 400 perforators whose diame-
ters exceed 0.5 mm. Thus, at least 400 types of propeller 
flaps can theoretically be harvested. This broad avail-
ability means that custom-made PPP flaps can be used 
to reconstruct defects on many parts of the body. Indeed, 
PPP flaps are particularly suitable for scars on the trunk 
and limbs. However, donor site limitations may reduce 
the suitability of this method for reconstructing the 
head and neck region.
Since the course and territory of perforators differ 
for each region, it is advisable to perform a careful pre-
operative assessment with Doppler ultrasound, color 
Doppler ultrasonography, or multi-detector low com-
puted tomography (MD-CT). This greatly facilitates the 
operation, thereby reducing the operative time [14].
It should be noted, however, that propeller flaps have 
one significant disadvantage: they are always island 
flaps. Thus, their contracture-releasing effect is lower 
than that of skin-pedicled flaps. Consequently, propeller 
flaps are generally only chosen when the available 
healthy skin adjacent to the defect is limited and a skin- 
pedicled flap is not possible (. Fig. 35.12).
a b c
  . Fig. 35.6 Reconstruction of  a scar contracture on the anterior 
neck by using a supercharged transposition flap. a Preoperative view. 
b Intraoperative view. c Two years after the operation. An anterior 
neck contracture of  a 71-year-old man was reconstructed with a 
supercharged transposition flap. A perforator of  the internal mam-
mary artery in the first intercostal space was attached to the flap and 
anastomosed with the facial artery and vein. The flap allowed full 






  . Fig. 35.7 The square flap method. Theoretically, the method 
lengthens the original scar length by 2.8-fold






  . Fig. 35.8 Reconstruction of  a scar contracture on the axilla. a 
Preoperative view. b Design of  the flap. c Intraoperative view. d View 
immediately after the operation. e Three months after the operation. 
f Six months after the operation. g One year after the operation. The 
square flap method was used to reconstruct an axillary scar contrac-
ture. The square flap gained a triangular shape one year after opera-
tion. This indicates that the skin pedicle of  the flap extended, thus 
effectively releasing the tension
a b
c
  . Fig. 35.9 Reconstruction of  a scar contracture on the digital 
web. a Design of  the flap. b View immediately after the operation. c 
Two years after the operation. The square flap method was used to 
reconstruct a digital web scar contracture. The skin pedicle of  the 




Local flaps generally provide superior functional and 
aesthetic outcomes. In terms of local flap selection, it is 
necessary to choose between a skin-pedicled flap and an 
island flap. It was suggeested that skin-pedicled flaps 
associate with greater scar extension rates than island 
flaps. Moreover, it should be noted that if  the scar is 
large, it is effective only by dividing the scar with the 
local flap.
a b c d
  . Fig. 35.10 Reconstruction of  a scar contracture on the cubital 
fossa. a Design of  the flap. b Intraoperative view. c View immediately 
after the operation. d Eighteen months after the operation. The 
square flap method was used to reconstruct a cubital fossa scar con-
tracture. The skin pedicle of  the flap extended, thereby effectively 
releasing the tension
  . Fig. 35.11 Propeller flap. The most sophisticated of  the propel-
ler flaps is the perforator-pedicled propeller (PPP) flap. However, its 
contracture-releasing effect is lower than that of  skin-pedicled flaps. 
Thus, propeller flaps are most useful when the available healthy skin 
adjacent to the scar is limited and a skin-pedicled flap cannot be per-
formed
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35 Take Home Messages
 5 Local flaps are superior to skin grafts because the 
latter can contract, thereby leading to secondary 
contractures.
 5 The color and texture match of local flaps is better 
than that of grafted skin.
 5 Local flaps, especially skin-pedicled flaps, elongate 
the scar as effectively as z-plasty.
 5 It should be noted that if  the scar is large, it is 
effective only by dividing the scar with the local 
flap.
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  . Fig. 35.12 Reconstruction of  a scar contracture on the anterior 
chest wall. a Design of  the flap. b, c Intraoperative view. d View 
immediately after the operation. e Eighteen months after the opera-
tion. The propeller flap was designed on the limited space between a 
scar contracture and an ulcer. Both open wounds were reconstructed 
by using a 90° rotated propeller flap
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36.1   Overview
Established scarring can have an impact on the function 
and aesthetics of the skin related to the volume of the 
fibrous tissue, the vascularity of the area, the colour 
mismatch with the adjacent normal skin and disruption 
of the skin adnexal structures. Resurfacing is a tech-
nique which involves the disruption of the epidermal 
surface of a scarred area with removal of a varying vol-
ume of the underlying scarred dermal element, followed 
by a controlled repair of the surface.
The aim of resurfacing is to improve the character of 
the scarred area with a resulting scar more closely 
matching the surrounding uninjured skin. This can be 
focused on improving the texture of the surface, the pig-
ment match or reduction of the volume of scar. 
Resurfacing will not address scar contracture or the 
absence of skin adnexal structures, with the exception of 
full- thickness excision and reconstruction with full-
thickness skin graft or flap repair. The character of the 
skin varies across body sites such that the specialist 
nature of the skin site must be considered when plan-
ning any intervention. A complex scar reconstruction 
may be undertaken as a combined procedure with strat-
egies designed to address the range of issues including 
resurfacing.
The timing and technique of the procedure are 
guided by the preceding clinical situation and specifi-
cally by the understanding of the conditions at the time 
of wound healing and subsequent scar development [1]. 
It is essential to understand that the opportunity to 
improve the scar depends upon the opportunity to bet-
ter control the wound healing at the time of the resur-
facing intervention.
There are a number of considerations to be taken 
into account when planning the interventions to improve 
the scar quality by control of the secondary wound heal-
ing:
 5 The mechanism of the initial skin injury and clinical 
pathway of healing, with specific reference to the ini-
tial techniques of wound repair, the time to healing 
and the presence of infection and other comorbidi-
ties influencing wound healing
 5 The time from the initial insult, considering if  the 
scar is fully mature or there are symptoms of the 
scar, or epithelial stability compromise, such that 
early intervention is being driven in an immature 
active scar
 5 The techniques available for the intervention in terms 
of the scar intervention and subsequent wound 
repair and post-intervention scar management
 5 Counselling that it is possible to improve the scar but 
not to eradicate the scar with the current stage of 
knowledge of wound healing
For the scar resurfacing intervention to translate into 
an improved scar outcome, it is important to under-
stand the clinical opportunities which offer an 
improvement on the initial treatments which have 
resulted in the unacceptable scar. For example, if  the 
plan is to repeat the same procedure, such as a surgical 
shave and split- thickness skin graft, then there has to 
be a significant difference in the clinical situation to 
advise that such a strategy offers the opportunity of 
scar reduction. This may be appropriate as in a mature 
scar there is control over the timing of  the intervention 
such that it is not associated with the inflammation of 
the acute episode. Alternatively, there may be the use 
of  a new method of  scar reduction such as laser or a 
method to reduce the time to healing such as a cell-
based therapies.
The chapter aims to outline strategies for scar 
improvement by disruption of the scar surface and con-
trol of the secondary healing process. In the context of 
this discussion, it is essential to articulate clearly the 
potential gains on a risk matrix that is realistic for the 
patient. The more severe a scar is, the greater the poten-
tial for improvement, as compared to a good-quality 
scar when the risk of worsening the scar may sensibly 
limit the interventions.
36.2   The Mechanism of the Initial Skin 
Injury and Clinical Pathway of Healing
It is well known that scar outcome is related to the 
mechanism of injury such that burn injury is frequently 
associated with an aggressive scar outcome. The surface 
area of the body involved in the injury is also a driver of 
the outcome with the challenges in healing large surface 
areas in a timely fashion. Further, the body site of the 
injury is also influential with areas such as the presternal 
and deltoid regions and areas of skin tension being 
associated with poor scar outcome.
The time to healing is a key element in the scarring 
process and can be affected by local and [1] systemic fac-
tors, infection, necrotic tissue, haematoma and comor-
bidities such as diabetes, nutritional deficiency, drugs 
such as steroids and retinoid in acne treatment. The 
clinical history is key in understanding what can be opti-
mised to improve the quality of healing and what fac-
tors may have been influential in the scar quality. 
Resurfacing is an elective procedure, and therefore, the 
preoperative optimisation of the patient’s condition is 
possible and needs attention. The history of infection is 
of importance in ensuring the intervention is covered by 
the appropriate antibiotics or the risk of triggering sec-
ondary problems such as herpes is considered with the 
appropriate prophylaxis.
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The knowledge of the initial intervention will also 
assist in the understanding of how resurfacing can be 
used in the post-acute phase to rehabilitate the scarred 
area [2]. Sharp dissection and haemostasis followed by 
careful approximation of the opposing surfaces with a 
suture designed to minimise inflammation are setting up 
the healing for the best outcome possible. In a wound 
such as a burn requiring cover of surface area, matching 
the repair to the defect in depth and body site with a 
focus on time to healing will again set up the best possi-
ble outcome. The concept of scar minimisation by 
meticulous attention to detail at the time of the initial 
intervention is covered in detail in 7 Chap. 23.
Despite the best efforts, the post-intervention period 
has influence on the outcome with infection control and 
techniques of wound support and post-healing scar 
management having an ongoing role.
The knowledge of the clinical pathway, both initially 
and the proposed interventions, is essential when con-
sidering the following question:
 5 Is it possible to re-wound the scar and control the 
healing in such a way as to significantly reduce the 
risk of scar recurrence?
36.3   The Timing of the Intervention
The natural history of scarring is such that in the major-
ity of cases, the scar severity will plateau between 6 and 
12  weeks with subsequent remodelling leading to a 
mature scar construct by 52  weeks. However, the scar 
will continue to improve over the subsequent years. In 
order to have control over the extent of scar re-excision, 
it may be prudent to wait until the scar is mature prior 
to intervention. The scar may well improve over time to 
the point that it is acceptable. The progress towards mat-
uration can be influenced by a range of non-invasive 
strategies highlighted in the chapters in section 
VIII. When considering resurfacing interventions, it is 
important to consider what aspects of the scar are of 
concern and how this could be influenced by time and 
conservative strategies.
However, there may be indications such as unstable 
epithelial surface, unsightly mismatched skin surfaces, 
or symptoms related to the scar such as itching which 
drives the decision for earlier intervention.
On the other hand, concern that a scar may be too 
old to consider treatment is unfounded, with improve-
ment in the quality being achieved after many years.
Timing is an element in the risk matrix that needs to be 
considered in the context of the patient’s symptoms and 
concerns. Early intervention may be explored related to 
specific techniques such as the re-suture a scar mismatch 
in height or laser to reduce pruritus, whereas in a florid 
vascular scar, more aggressive early intervention may add 
to the overall scarring pruritus, whereas in a florid vascu-
lar scar, more aggressive early intervention may add to the 
overall scarring [3]. The discussion with the patient needs 
to include the options such as time with the risks and ben-
efits. It is useful to have a scar assessment tool which 
assists in understanding the character of a scar and facili-
tates the discussion and clinical decision- making.
The assessment of the scar can be done in a number 
of ways, e.g. surface scanning focusing on specific 
aspects such as stiffness or colour [4], subjective stan-
dard assessment systems, validated questions [5] and 
clinical photography. When embarking on scar revision, 
the documentation of the scars is essential in tracking 
progress over time; the options are explored in detail in 
section VII.
36.4   The Techniques for Preparing the Scar 
Wound Bed for Resurfacing
The prerequisite to prepare the scar for resurfacing is the 
removal or disruption of the epithelial layer by tech-
niques including chemical, laser, dermabrasion and 
sharp dissection [6].
Chemical peels have been widely used aiming to 
remove the surface epithelium to a limited depth such 
that rapid healing by secondary intention is achieved 
with limited improved scar outcome.
There has been an expansion of the laser techniques 
used to remove or to disrupt the epithelial surface as 
explored in the chapters in section IX. Again, laser in 
isolation can be used with surface damage limited to a 
superficial level such that the healing by secondary 
intention is rapidly achieved. The use of fractional laser 
with discrete microthermal zones has been shown to ini-
tiate scar remodelling within the dermis. Further, the 
ablative lasers can be a tool used to prepare the wound 
bed for secondary interventions as described below.
Dermabrasion can be achieved with manually using 
abrasive sand papers, or mechanically with rotating 
brush or burr. The depth of tissue removal can be con-
trolled, and the contour can be guided using adjuncts 
such as injection or surface coating with agents such as 
methylene blue. Surface irrigation is necessary to miti-
gate against heat damage and to remove the debris from 
the surface.
The sharp dissection tools range from freehand scal-
pels to mechanised guarded blades allowing serial shav-
ing of the scar surface. Again, the depth of the tissue 
excision is dictated by the strategy of consequent wound 
healing [7]. In situations of superficial shave, the aim 
may be controlled healing by secondary intention. 




bulking of the scar volume such that the wound bed 
does not retain the capacity to heal within a timeframe 
that would limit the secondary scar risk [8].
The extent of the excision of the fibrotic dermal layer 
can range from total scar excision to minimal removal 
of the tissue. With the retention of the scarred bed, the 
overall scar result relies on the remodelling, driven by 
the interaction of the cells of the new epidermal layer 
and those in the retained scar construct.
36.5   The Techniques of Wound Repair 
for Resurfacing
In the situation of total scar excision, a full-thickness 
skin replacement is the ideal reconstruction and is con-
sidered in 7 Chap. 37, using flap repair, and 7 Chap. 39 
exploring the use of skin substitutes.
In some instances, an appropriate donor site for a 
full-thickness skin graft may allow full-thickness recon-
struction, or the use of tissue expansion can facilitate 
local flap repair with the most similar skin characteris-
tics. In complex scar reconstruction, the functional 
restriction may require the introduction of tissue from a 
remote uninjured body site using local or free tissue 
transfer explored in 7 Chaps. 37 and 40.
In a scar which has been prepared using limited 
removal of the epidermal surface, healing by secondary 
intention may be appropriate. In these cases, specific 
attention to detail is required to protect the healing wound 
surface [9]. The key to limiting the risk of worsening the 
scar is the time to healing. There are many strategies 
employed to facilitate healing with advanced technology 
dressing systems, both synthetic and biologically based.
When the scar has been de-bulked, then secondary 
repair of the surface should be considered as prolonged 
healing by secondary intention will be associated with 
an increased scar risk. The use of thin split-thickness 
skin graft can result in an improvement of the scar in 
terms of contour and colour. However, this can be 
unpredictable with some split-thickness skin grafts asso-
ciated with abnormal pigmentation. There is also the 
drawback of the donor site availability in terms of area 
and site specificity.
Matching the donor and recipient site is a key ele-
ment in improving the potential outcome from scar 
resurfacing. For example, the use of full-thickness skin 
grafts to release scar contractures of the palm of the 
hand will frequently afford an excellent functional 
release but is associated with significant mismatch in 
terms of the skin characteristics. The ability to match 
donor site is most frequently limited by the surface area 
required. The donor site itself  can be resurfaced such 
that a thick split-thickness or full-thickness harvested 
area is secondarily covered by a thin split-thickness skin 
graft aiming to reduce the overall donor site morbidity.
The use of tissue expansion techniques may also be 
used to address the donor site limitation. The concept of 
tissue expansion can be extended beyond the full- 
thickness skin construct, to the cells essential for re- 
epithelisation. The development of the processes of 
cultured epithelial autograft was specifically to address 
the need of large surface area skin cover in major burn 
injuries. The techniques of laboratory-based tissue 
expansion can provide epithelial cells as sheets or sus-
pension from a limited donor site which will retain the 
epithelial characteristics of the donor site. The draw-
back of such cell-based therapies is the reliance on the 
laboratory environment and the time taken to achieve 
the expansion via the tissue culture process.
The first steps of the cell-based expansion process 
have been incorporated into a medical device as a lab in 
a box, ReCell™. The technique of harvesting at the 
point of care of the cells of  the dermal-epidermal junc-
tion, for delivery as a cellular suspension, provides a 
method with an expansion ratio of up to 1–80. The 
technique uses the wound bed as the tissue culture envi-
ronment with the cellular suspension adhering to the 
prepared wound surface and the cells migrating and dif-
ferentiating into an intact epithelium. The use of the cell 
suspension from the dermal-epidermal junction allows 
the transfer of keratinocytes, melanocytes and papillary 
dermal fibroblasts in their normal ratio [10]. The use of 
such a cellular suspension in resurfacing is particularly 
useful in treating hypopigmentation. The melanocytes 
within the suspension will re-establish in the prepared 
wound, and re-pigmentation is seen over the subsequent 
6–12  weeks. The introduction of the cell suspension 
facilitates the epithelial repair reducing the time to heal-
ing and therefore the risk of secondary scarring.
There is also interesting basic science evidence that 
the interaction between the keratinocytes and fibroblasts 
has influence on the phenotype of the fibroblasts impact-
ing on collagen deposition [11].
The use of cell-based therapies is an opportunity to 
expand the surface area of wound cover possible for a 
given donor site with the appropriate cell phenotype. 
The seeding of the cells onto a de-bulked scarred wound 
bed reduces the time to achieve an intact epithelial sur-
face with the potential to introduce melanocyte and 
keratinocyte characteristics to match the area. The 
introduction of an uninjured cell phenotype has a theo-
 F. M. Wood
315 36
retical impact on the scar remodelling as the scar 
matures.
Whatever method of scar resurfacing is used, the 
objective remains constant, to improve the area of scar 
such that the scar blends better into the surrounding 
skin.
36.6   Post-Intervention Scar Management
The wound healing is only the first phase in the process 
of scar remodelling post resurfacing, and attention to 
detail at all stages is essential. The post-intervention 
dressing systems may involve a range of products 
focused on providing an environment of healing with 
infection control and protection of the fragile wound 
surface.
Further, the protection of the healed epithelial sur-
face and control of the environment are important as 
the dressings are removed and the surface exposed. At 
this stage, it may be prudent to consider the non- invasive 
conservative strategies for scar minimisation such as sili-
cones and massage as explored in the chapters of section 
VIII. At all stages, hygiene is an essential element to pre-
vent secondary infection and breakdown whilst the cell 
surface is fragile and immature.
For decades, pressure garments have been used in the 
attempt to control scar progression particularly post 
burn injury. The mechanism of action is debated, but it 
remains a widespread practise. The fabrics used vary in 
terms of the pressure delivery and the moisture wicking 
characteristics. A light pressure fabric can be used to 
protect the area in the early stages post healing if  well 
designed to avoid trauma and sheering.
Sun protection is also important not only to prevent 
sunburn of course but also to avoid the overstimulation 
of the melanocytes with the risk of hyperpigmentation 
in the resurfaced area. Simple advice such as wearing a 
hat and topical sunblock needs to be considered as part 
of the post-intervention information given to the 
patient. The advice will need to be tailored to the patient 
in relation to their environment.
36.7   Conclusion
The clinical decision to undertake a scar resurfacing 
procedure needs to bring together the needs of the 
patient and the characteristics and history of the scar, 
along with the tool box of potential interventions 
(. Table 36.1).
The choice of the specific resurfacing technique will 
then consider the triangle of care to specifically address 
the patient’s needs in the context of the clinician’s knowl-
edge and experience along with the technology environ-
ment available (. Fig. 36.1). The diagnosis of the scar 
with the inclusion of an assessment tool will give clarity 
to the clinical discussion with the focus on the aspects of 
the scar causing the concern.
Understanding the natural history of the scarring 
process will help in giving advice to the patient, explain-
ing the opportunities of conservative therapies and time 
to improve the scar. Then, choosing the technique that 
will give most benefit for least risk is the key to safely 
improving the scar. There are many ways of resurfacing, 
but understanding the need for bulk reduction, re- 
pigmentation or stabilising the epithelium of the scar 
will drive the clinical decision.
In the clinical counselling, being realistic that the 
scar may be reduced and blended to the surrounding 
skin rather than eradicated facilitates decision-making 
for the patient.
  . Table 36.1 Understanding the clinical details of  the scar 
and the impact of  the symptoms on the patient to drive the 
most appropriate clinical  intervention for the individual
Scar Assessment to guide intervention
Clinical history
• Mechanism of original scar process
• Timeframe of scar development
• Time to healing
• Technique used to achieve healing
• Presence of infection 











Techniques to prepare the
scar for resurfacing  





secondary wound healing 
• Cell based therapies 
• Advanced dressing systems
• Infection control 







 5 Clinical history of the patient and the scar is piv-
otal in the decision-making process.
 5 Scar assessment is key in tracking the impact of 
the scar intervention over time.
 5 Be clear on what elements of the scar need to be 
treated.
 5 Focus the intervention on the outcome required.
 5 The time to healing is a key element driving scar 
outcome.
 5 Meticulous attention to detail needs to be 
continued to the time of scar maturity.
 5 Education of the patient along the clinical journey 
is essential for a successful outcome.
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Scar Revision  . Fig. 36.1 The triangle of  care 
bringing together essential con-
siderations for clinical decision 
making
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Modern wound care demands a high focus on quality of 
healing. Skin substitutes can play an important role in 
achieving the best possible outcome for each patient. 
Although skin substitutes were primarily developed for 
use in acute wound care, they have since then started to 
play an important role in secondary scar revision sur-
gery. Initially, epidermal cell cultures were developed 
with a focus on efficient wound closure of large wound 
surfaces. Long-term results, however, indicated that sev-
eral structures that played a role in stabilizing the con-
nection between epidermis and dermis did not fully 
regenerate [1]. Thus the role and importance of the der-
mal component of skin regeneration became more 
apparent. This eventually led to the development of der-
mal substitutes. Various biomaterials were tested for 
their capacity to stimulate dermal regeneration, with 
various degrees of success. Synthetic as well as biologi-
cal materials were extensively tested. Where synthetic 
materials demonstrated to actively stimulate wound 
healing in chronic circumstances such as diabetic 
wounds, biological biomaterials proved to be more ben-
eficial for treating acute wounds. These biological mate-
rials were mainly composed of purified extracellular 
skin matrix components such as collagen, elastin, and/
or proteoglycans. Long- term clinical results of several 
of these materials have since then become available. 
Further development of the field resulted in the addition 
of cells to these synthetic and biomaterial constructs. 
Various cell sources were investigated, with specific 
attention to different sources of stem cells, as well as 
allogeneic versus autologous cell sources [2–4]. 
Alongside the clinical studies, outcome analysis on dif-
ferent skin and scar parameters was further developed. 
This provided insight into the different skin characteris-
tics that were influenced by the use of skin substitutes. 
Besides acute wound treatment, scar treatment using 
fat-derived mesenchymal stem cells is also subject of 
further research. Initial studies have demonstrated ben-
eficial effects on scar maturation after lipofilling. This 
technique aims at regeneration of the subcutaneous fat 
layer underneath the dermal layer of the skin. Nowadays, 
all these developments allow us to use these different 
biomaterials as acellular dermal substitutes in state-of-
the-art reconstructive surgery and acute wound treat-
ment. New advancements are found in the development 
of full skin constructs, using autologous epidermal as 
well as dermal cell sources. At present, autologous (i.e., 
from the patient) cells are still the mainstay in the suc-
cessful use of cellular substitutes. This is an advantage in 
terms of the absence of potential immunological reac-
tions, but at the same time, the long culture times needed 
to prepare these constructs are definitely a disadvantage 
of using cellular substitutes in the acute trauma setting. 
Furthermore, the long-term regenerative capacity of 
these cellular skin constructs still remains to be fully 
established.
37.2  Permanent Wound Coverage
Wound closure normally proceeds by migrating epi-
dermal cells from both wound edges and skin append-
ages such as sebaceous glands and hair follicles. As 
wounds grow deeper and larger, the skin loses its abil-
ity to provide enough epidermal cells to close the 
wounds in a reasonable time frame. This time frame of 
healing is considered to be adequate if  the wound is 
closed within 3–4 weeks. Prolonged exposure to patho-
gens and fluid loss represent immediate dangers in 
delayed healing and might potentially lead to bacterial 
contamination, sepsis, and death in the worst cases. 
Biological processes such as wound contraction are 
initiated that aimed at speeding up wound closure. 
This is paradoxically an undesired action in terms of 
the final quality of  the wound-healing process. 
Therefore, most large and deep wounds require surgi-
cal assistance to promote timely wound healing and 
adequate wound closure. The main purpose of  surgery 
is to bring a new source of  viable epidermal cells to the 
wound in order to speed up the wound closure. Skin 
grafts are the most well-known and most used meth-
ods for epidermal transfer and permanent wound 
 coverage.
37.2.1  Epidermal Cells/Cultured Epidermal 
Autografts CEA
The keratinocytes in the epidermal layer of the skin form 
the first barrier of the skin. A standard technique for clo-
sure of large wounds is transplantation of skin using a 
split-thickness skin graft (STSG). The protective proper-
ties of the epidermal layer are best conserved in the form 
of split-thickness skin grafts, which usually comprise the 
whole of the epidermis and a very thin layer of dermis 
(approximately 0.1–0.2 mm). Coverage of larger wound 
areas is possible using meshed STSGs, where expansion 
rates up to 1:6 are possible (. Fig. 37.1). However, scar 
formation in the mesh interstices is apparent, and there-
fore larger expansions with fewer donor sites were needed. 
This pushed Rheinwald and Green, as early as 1975, into 
being the first to show that keratinocytes could be 
extracted, in vitro cultured into sheets, and that they were 
suitable for grafting [5]. This can easily be considered the 
first step in the tissue engineering of the skin. The usage 
of cultured cells marked a leap forward in the treatment 
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of burn patients as larger areas of wounds could be cov-
ered with very small donor sites of healthy skin.
The development of cell culture techniques opened 
up the possibility to maintain viable cells outside of the 
human body. Initially, cultured keratinocyte layers (cul-
tured epithelial autografts or CEA) opened opportuni-
ties to cover large parts of the body without the necessity 
for substantial donor sites. This greatly improved the 
survival chances of severely burned patients. However, 
early studies of CEAs on wound beds showed insuffi-
cient regeneration of dermal–epidermal junctions 
between the epidermis and the underlying tissue, which 
even after many years resulted in a vulnerable and weak 
skin barrier [1]. Thus, it was discovered that substitution 
of dermal tissue is also of great importance in creating 
and maintaining a well-functioning new skin. These 
insights sparked the development of more complex skin 
substitutes.
Although CEAs have been used for over 40  years 
now, they did not provide the definitive solution for the 
treatment of large wounds. Specific downsides such as 
variable graft-take rates, high manufacturing costs, pro-
duction and transportation logistics, insufficient der-
mal–epidermal junction regeneration, and often having 
to compete with readily available split-skin grafts have 
limited most of the further development of CEAs [6].
A more recent development in the application of epi-
dermal cells is in the form of in situ cell therapy, called 
the ReCell® system (Avita Medical, Cambridge, UK). 
With only a small donor site of split skin (approximately 
1 cm2), this device allows the isolation of a single-cell 
suspension that can be sprayed on a wound bed. The 
cell suspension consists of  approximately 65% keratino-
cytes, 30% fibroblasts, and 3–5% melanocytes. This sys-
tem avoids the time-consuming and costly cell culture 
step. The cells in the cell suspension can adhere to the 
wound bed and promote tissue regeneration by both cell 
proliferation and growth factor stimulation. This tech-
nique is sometimes used in combination with expanded 
meshed autografts to accelerate wound healing. The 
combination of these two treatment options has shown 
to improve cosmetic outcomes of scars and pigment 
abnormalities. In situ cell therapy can also be used as a 
means to promote repigmentation of depigmented skin 
in patients with vitiligo and congenital melanocytic 




  . Fig. 37.1 a Microscopic image of  hematoxylin eosin staining of  human split skin. Note that only a very thin layer of  dermis is present. b 
Split-skin mesh graft with wide expansion to cover larger wound area. c Typical scar pattern showing mesh pattern of  the graft in the scar
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survival and proliferation or to growth factor and cyto-
kine secretion is presently still unclear.
37.2.2  Dermal Substitutes
Skin substitutes aiming at dermal regeneration are der-
mal constructs designed to either temporarily or perma-
nently replace dermal defects. In all cases, the aim of 
skin substitutes is to provide protection against microor-
ganisms, reduce pain, promote wound healing, and 
assist in recreating the barrier function of the skin [8]. 
This method has become increasingly important for the 
treatment of burns, open wounds, chronic wounds, and 
deep tissue donor sites, as it has been shown to improve 
and accelerate skin regeneration, reduce scar contrac-
ture, and minimize donor site morbidity. All these differ-
ent treatment indications resulted in the development of 
a wide range of skin substitutes with different character-
istics such as mono- or bilayered compositions, tempo-
rary or permanent fixture, and cellular or acellular skin 
substitutes.
37.2.2.1  Tissues
A biological approach used in the design of permanent 
skin substitutes was to start with real human tissue. One 
of the early developed acellular allogeneic skin substi-
tutes is Alloderm®. Alloderm® is harvested from cadaver 
donors as skin grafts, which are then washed with hyper-
tonic saline to remove cell remnants. After removal of the 
epithelial layer, the remaining dermal layer is treated to 
inactivate viruses and then freeze-dried to be used on 
demand. This provides a nonantigenic dermal scaffold 
with basement membrane proteins, which are known to 
promote wound healing and angiogenesis. After rehydra-
tion of the Alloderm®, coverage with an ultrathin split 
skin would suffice as a full coverage treatment option. 
Recently, Alloderm® has seen a rise in its use for breast 
reconstructive surgery, whereas the use of Alloderm® on 
wounds and burns remains limited. Glyaderm® is a simi-
lar product based on allogeneic dermis preserved in glyc-
erol instead of freeze-drying. Initial studies on burn 
patients have been performed with favorable results [9].
37.2.2.2  Dermal Scaffolds
Some of the most well-known and most used dermal 
scaffolds are Integra® and Matriderm®. Although both 
materials consist of bovine collagen combined with 
extracellular matrix components, their mode of applica-
tion is generally different. Integra® was the first dermal 
substitute of its kind in the early 1980s and was created 
with the apparent goal of minimizing fluid loss and bac-
terial contamination and promoting cell migration into 
the wound bed. It does so through its two-layered com-
position and its two-stage procedure. The deeper layer 
of Integra® is made out of a combination of bovine col-
lagen and glycosaminoglycan chondroitin-6-sulfate, 
whereas the top is made with a 0.2-mm-thick polysilox-
amine polymer membrane with vapor-transmitting 
characteristics similar to normal epithelium. This mem-
brane is intended to be placed on the full-thickness 
wound, and the outer silicone membrane will function 
as a temporary epidermal replacement and will need to 
be replaced by a split-skin graft after 2–3 weeks of suf-
ficient ingrowth of vasculature into the deeper dermal 
scaffold. Due to the combination with a silicone layer as 
temporary epidermal coverage, Integra® can immedi-
ately function as a barrier to limit fluid loss and protect 
from microbial contamination of the wound, while pro-
viding the required extracellular scaffolding for cell 
ingrowth and proliferation of fibroblasts and endothe-
lial cells. In the second stage, after vascular ingrowth, 
the silicone layer is replaced by a thin split-skin graft. 
This product has gained widespread use in the clinical 
treatment of deep partial-thickness and full-thickness 
burn wounds, full-thickness skin defects of other etiolo-
gies, chronic wounds, and soft tissue defects. The results 
of Integra® within burn care have been generally favor-
able and have shown improved quality of healing. 
However, the staged procedure leaves the wound open 
for a prolonged period of time and thus bears a risk of 
submembranous bacterial infections resulting in loss of 
the biomaterial. Other similar bilayered substitutes are 
Renoskin®, Pelnac™, and Hyalomatrix® [10].
Matriderm® is usually applied in a one-step proce-
dure as this dermal scaffold allows immediate coverage 
with a thin split-skin graft. It consists of an extracellular 
matrix scaffold made out of purified, freeze-dried bovine 
collagen mixed with 3% elastin hydrolysate. An autolo-
gous split-skin graft can be applied directly onto the 
Matriderm®. Clinical research showed a somewhat 
slower take of the graft, which reflects the interposition-
ing of the unvascularized scaffold between the wound 
bed and the split-skin graft. Nevertheless, the outcome in 
terms of scar quality was shown to be superior over split-
skin graft treatment even after a 12-year follow-up [11].
Both Matriderm® and Integra® have been used for 
acute and reconstructive purposes and as a means to 
improve scar quality. These dermal scaffolds initially lack 
cellular compounds and do require the body to incorpo-
rate the exogenous matrix into the wound environment 
through cell migration and remodeling, which is mediated 
by macrophages and fibroblasts. Fibroblasts, similar to 
keratinocytes, also secrete various cytokines and growth 
factors. But besides promoting cell proliferation, inducing 
angiogenesis, and modulating the inflammatory process, 
they also produce a new extracellular matrix, which helps 
to reconstruct the three- dimensional dermal structure of 
 F. W. Timmermans and E. Middelkoop
321 37
the skin. Other one-layered scaffolds are Novomaix® 
(freeze-dried collagen with elastin fibers) and Permacol® 
(a porcine collagen matrix which is now primarily used in 
hernia and abdominal wall surgery) [10].
37.2.3  Cellular Dermal Substitutes
Cellular dermal and composite skin substitutes are the 
most recent products of skin substitute research. Dermal 
skin substitutes are primarily created to guide dermal 
regeneration and are used in combination with autolo-
gous split-skin transplants. This treatment is aimed at 
providing an underlying layer of dermal tissue where 
normally fibrotic scar tissue would be formed. One of 
the disadvantages of an acellular dermal scaffold is the 
relatively slow ingrowth of blood vessels and other cells 
into the scaffold, which can hamper the take and even 
minimize the survival of the covering split-skin auto-
graft. The general understanding is that the inclusion of 
dermal cells in the scaffolds improves these outcomes 
and at the same time promotes the wound-healing pro-
cess. DenovoDerm™, Hyalograft 3D®, Dermagraft®, 
and TransCyte® are a few of these known cellular der-
mal skin substitutes. The first two are, respectively, made 
of autologous fibroblast seeded in bovine collagen and 
hyaluronic acid scaffolds, and the latter two are respec-
tively made of allogeneic fibroblasts seeded in a polygla-
ctin and nylon scaffold. Other experimental studies have 
looked into using adipose-derived regenerative cells in 
combination with Integra®, and some attempts have 
been made to create skin substitutes with nanotechnol-
ogy. However, the effectiveness and safety of these meth-
ods still need to be demonstrated outside of the 
experimental stages of development.
Most of the cellular dermal substitutes are produced 
using living neonatal fibroblasts. Examples include 
TransCyte® and Dermagraft®. TransCyte is produced by 
culturing neonatal fibroblasts on a nylon mesh, where the 
cells deposit collagen, other matrix proteins, and growth 
factors. After freezing, the cells are no longer alive, but 
the matrix proteins and growth factors remain and can 
actively promote healing, e.g., for deep partial thickness 
acute wounds. Dermagraft®, however, is composed of 
living allogeneic neonatal fibroblasts cultured on a poly-
glactin scaffold. The neonatal cells provide the extracel-
lular matrix compounds and growth factors needed for 
efficient tissue regeneration. The allogeneic compounds 
in the skin substitute will subsequently stimulate granula-
tion tissue formation that enables secondary closure or 
eventual coverage with a split-skin graft. Compared to 
the autologous counterparts, allogenic skin substitutes 
have thus far predominantly been successfully used for 
the treatment of chronic diabetic ulcers.
37.3  Full-Skin Substitutes
Several research groups have developed full biological 
skin substitutes comprising of both dermis and epider-
mis, while containing either allogeneic or autologous 
fibroblasts and keratinocytes. Apligraf® was the first of 
this kind to become commercially available. Apligraf® 
consists of cultured allogenic human foreskin-derived 
neonatal fibroblasts in a bovine type I collagen matrix 
over which allogenic human foreskin-derived neonatal 
epidermal keratinocytes are then cultured and allowed 
to stratify. The allogeneic character of this skin substi-
tute ultimately results in the rejection of the keratino-
cytes, which eventually requires an autologous split-skin 
coverage for definite would closure. Therefore, Apligraf® 
is less suitable for large acute wounds but has found its 
main use in the treatment of chronic wounds. Orcel® is a 
similar product with a similar composition. The allo-
genic cells are considered to survive up to 2–3 weeks in 
the wound bed, and the overall effectiveness of these 
composite skin substitutes is thought to be based on the 
excretion of a mix of growth factors and cytokines.
Some novel autologous composite skin substitutes 
are DenovoSkin™ and Permaderm®. Both of these 
composite skin substitutes are made with a bovine col-
lagen scaffold. Another described full-skin substitute is 
the TissueTech Autograft System™, which is essentially 
the combination of a dermal skin substitute (Hyalograft 
3D®) with a CEA (Laserskin®). A major advantage of 
autologous composite skin substitutes is its one-stage 
character. Except for the initial skin biopsy from which 
the autologous cells are harvested and cultured, no sec-
ondary procedures such as split-skin transplantations 
are required. Most of these are newly developed skin 
constructs, which are still undergoing trials, and none 
are commercially available at present. Besides regulatory 
obstacles (see below), other downsides to the further 
development of autologous composite skin substitutes 
are the high production costs, long preparation time, 
and the necessity for a well-organized production-to- 
clinic transfer. Nevertheless, these are important devel-
opments, since in the end, these advancements may lead 
to clinically applicable regenerative full-skin substitutes, 
comprising of not only dermal and epidermal structures 
but also vasculature, skin appendages, and even nerves.
37.4  Subcutaneous Fat
In recent years, there has been an apparent shift from 
merely thinking about reconstructing the dermis and 
epidermis, to the inclusion of the subcutis. It has become 
more clear that the subcutaneous fat layer plays an 
essential role in the gliding and mobile functions of the 
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skin. This characteristic is especially important in ana-
tomical locations where the skin is relatively thin, such 
as the back of the hand or the tibia. Scars in these areas 
can easily fuse to underlying tendons or bones if  subcu-
taneous fat is missing. Recent studies have noted benefi-
cial effects on scar quality of lipo-injection with the 
patient’s own fat, harvested by liposuction. Lipofilling 
of these scars showed an increase of elastic fibers at the 
dermopapillary layer, which could account for the 
improvement of scar quality [4, 12–14]. The sustainabil-
ity of a mere single treatment of autologous fat grafting 
in mature adherent scars showed to promote a lasting 
improvement in scar elasticity and tactile pliability [15]. 
Although there is not enough solid clinical evidence yet, 
the data gathered so far indicate that fat grafting could 
become a new treatment modality in improving scar 
quality and outcome after burns. Further research 
should aim at elucidating the best indications, timing, 
and techniques as well as frequencies of application.
37.5  Regulatory/Safety Issues
Further development of cell therapy and tissue engi-
neering for better clinical outcomes with regard to 
wound healing and the reduction of scar formation is a 
common recommendation in studies on the use and 
development of skin substitutes. However, new regula-
tions have become effective during the last decade, which 
designate cell-based therapy as advanced therapy medic-
inal products (ATMPs). Practically, this means that cell- 
based therapies in Europe are under direct assessment 
of the European Medicines Agency (EMA, a monitor-
ing institute of the European Union), which is dedicated 
to the scientific evaluation and supervision of market 
access of medicinal products. In the USA, the Food and 
Drug Administration (FDA) is the relevant authority, 
where the Office of Cellular, Tissue, and Gene Therapies 
(OCTGT) exerts the tasks to evaluate and supervise 
market access of ATMP products.
The European Regulation (EC) No. 1394/2007 pro-
vides the overall framework on production and use of 
ATMPs within the European Union. According to this 
regulation, an ATMP is a “medicine for human use that 
is based on genes, cells or tissue engineering.” When 
elaborating on the definition of tissue-engineered prod-
ucts, such products may contain or consist of engineered 
cells or tissues, with the purpose to regenerate, repair, or 
replace a human tissue, and it may contain viable or 
nonviable cells or tissues of human or animal origin. 
This means that most of the skin substitutes with living 
cells (both autologous and allogeneic), adipose tissue, 
and matrices containing human and/or xenogeneic 
material fall under the regulatory issues associated with 
this regulation. Scaffolds made of isolated and/or puri-
fied animal or human-derived proteins, however, are 
classified as medical devices. One of the main features of 
these regulations is that the production of ATMPs for 
human use must take place under Good Manufacturing 
Practice (GMP) conditions. This is translated into high 
standards of production facilities, which is only possible 
in a select few centers and represent a considerable 
administrative burden for importing and exporting 
ATMPs across international borders. These strict regu-
latory and production requirements imply intensive col-
laboration between centers for the further development 
of ATMP’ and for successful commercial exploitation 
of these novel treatment options.
37.6  Conclusion
Acellular skin substitutes have gained a solid position in 
the treatment options for acute and chronic wounds as 
well as scar revisions, with improved outcomes in skin 
quality over standard split-skin graft treatment. 
Autologous cellular skin substitutes still hold a promise 
for the future. Tissue repair and regeneration through 
the use of autologous cells promote superior healing 
over the known methods. There are still some drawbacks 
in the production and application of tissue-engineered 
skin constructs, but further research, automated pro-
duction process, and harmonizing our treatment prac-
tices will bring us closer toward a scarless future.
Take Home Messages
 5 Acellular dermal substitutes have proven their effi-
cacy in reaching better scar quality compared to 
split-skin grafting for acute and reconstructive 
treatment.
 5 Acellular dermal substitutes can be used in a one- 
step procedure, providing immediate wound 
coverage, or two-step approach, which allows 
prevascularization of the dermal component prior 
to epithelial grafting.
 5 Epidermal cell sprays can be used to treat pigment 
disorders in scars and/or to increase 
epithelialization rate during acute wound healing
 5 Fat grafting is used successfully on adherent scars 
as autologous fat injection to improve scar 
elasticity and regenerate a gliding layer underneath 
a scar.
 5 Cellular dermal and full-skin substitutes are in 
clinical trials for treatment of acute and 
reconstructive wounds.
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38.1   Objectives of the Chapter
The objective of the chapter is to present the different 
reconstruction techniques, distinctly describing the ones 
recruiting autologous skin and subcutaneous tissues, 
transferred from surrounding color-matching donor site 
areas as well as techniques suitable for a complete face 
transplantation from a living human donor, with this 
homologous transfer being realized using microsurgical 
revascularization.
The aim is to minimize as far as possible the con-
sequences of facial scars, which induce a loss of the 
dynamic aspect of the face and loss of the specific mim-
ics of each human character to express different emo-
tions. Consequences of the different surgical strategies 
are described, including local, regional, and systemic 
potential complications.
38.2   Techniques
 1. Skin Resurfacing
Used in postburns scars involving retractions and 
loss of skin capacity, the resurfacing using dermal 
substitute and partial thickness skin grafts is the 
easiest technique to perform. Excision of the scars 
is done via a long meticulous surgical debridement, 
preventing to severe venous and arterial pedicles, 
resecting the hard thick scar tissue, which may be 
strongly adherent to the muscular and aponeurotic 
structures of the face around the orifices, mouth, 
nose, and ears. The neck is extensively freed from 
retracting scars, allowing a restauration of the move-
ments up and down and laterally on each side. Cov-
ering using dermal substitute has become more and 
more popular in burns surgery since the initial works 
on Integra [1].
 2. Pedicled-Expanded Deltopectoral Flaps
Among the commonly used donor sites, the del-
topectoral site was conceived as one of the most suit-
able donor tissues for the reconstruction in the face 
and neck for its adjacent site and match in color and 
texture [2]. This technique uses an island flap, which is 
prepared and expanded to the size of the surface to be 
covered over the face and the distance of the flap ped-
icle to the distal end of the flap. This is a two-staged 
procedure. The size and projection of the silicone 
expander should precisely be determined before the 
first surgical step. Thanks to a limited incision outside 
the future face flap which will be drawn over the dor-
sal skin, a large expander will be inserted in a cavity 
created subcutaneously between the subcutaneous fat 
and the underlying muscle aponeurosis. The expander 
is chosen based on its capacity of inducing a predeter-
mined skin projection, surface of the projected area, 
and length and width. The expander is connected 
via a silicone tubing to a valve which is also inserted 
under the skin at a limited distance from the expander 
edges. After a period of 2 weeks, the expander filling 
will start, and the amount of liquid determined on the 
rate of filling and the needed projection to obtain the 
desired skin expansion. Usually the skin expander is 
overexpanded to 1.5 of its volume, in order to obtain 
an even skin expansion. Possible complications may 
include extravasation of the expander (in case of rigid 
silicone angle), a too rapid expansion inducing a local 
devascularization and stretch marks, the long dis-
tance from the back to the face and the postop edema 
sometimes causing flap tip necrosis
But a good skin compliance, normal contours, 
and emotional expression are usually noted after the 
reconstruction.
 3. Prefabrication
In 2000, the main author proposed the neofabrica-
tion of a cervico-deltopectoral flap used as an island 
flap after skin perfusion boosting. This technique, 
called prefabrication, was developed on the principle 
that when a vascular carrier (a fascia including an 
artery and a vein) is inserted between the expanded 
skin and the silicone balloon, the expanded skin ter-
ritory can be extended and its neovascularization 
amplified. The technique was published in 2000  in 
The Lancet, opening the way to the creation of flaps 
larger than the normal anatomy allows it [3].
Technically, the radial forearm facial flap 
(20 cm × 6 cm) is harvested with the radial artery and 
the vein, which are microsurgically branched on the 
facial vessels artery and vein using a limited incision. 
The fascia is inserted subcutaneously over the clavic-
ular bone anteriorly, the trapeze muscles posteriorly, 
and the deltoid muscle laterally. A transfixient suture 
is needed at the distal end of the fascia in order to 
prevent any gliding possibility.
Depending on the surface to cover, the amount 
of expansion and size and capacity of the expander 
may vary. When the complete face should be cov-
ered, a 2-liter skin expander will be inserted between 
the vascularized fascia and the underlying structures. 
The valve and tubing are positioned posteriorly on 
the back.
A progressive filling of the skin expander is real-
ized twice a week, with a regimen allowing to get the 
surface of the face (25 cm × 30 cm) on the shoulder 
after 3–4 months. An arteriogram is realized before 
the second stage in order to confirm the viability of 
the fascia and its capacity to revascularize the extra 
skin obtained thanks to the skin expansion. This 
arteriogram shows all the new arterial ramifications 
emerging from the radial transplanted artery, a sign 
which was interpreted by the radiologists as a certi-
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tude that the fascial vessels were inducing the new 
flap vascularization.
During the second step, a flap large enough to 
cover the entire face (if  needed) is designed over the 
expanded skin. The dissection starts from lateral to 
medial over the shoulder, with a particular attention 
not to harm the vascular pedicle. Once the flap is 
harvested and the flap pedicled on the arteriovenous 
pedicle, all facial scars are removed deep to the fas-
cia, in order to get a maximum surface covered by the 
new flap. Orifices (mouth, eyes, nostrils) are opened 
in front of the anatomical corresponding zones.
Long-term results are good, with the transplanted 
skin depth remaining adapted to the volume of the 
face, thanks to the precompression realized during 
the skin expansion (. Figs.  38.1, 38.2, 38.3, 38.4, 
38.5, 38.6, and 38.7).
This technique allows to get a precompressed 
large piece of skin, well vascularized and conform-
able. The whole face can be covered with a large 
viable piece of skin. There is no need for complemen-
tary drugs.
 4. Superthin Flaps
The “superthin flap” concept was introduced by 
Ogawa et al. in 1994 [4], based on the subdermal vas-
cular network (SVN).
  . Fig. 38.1 Before and after prefabricated flap on the neck of  a young male presenting a contractile postburn scar





Superthin flaps were used in different clinical 
situations. Twenty-one expanded flaps were used to 
reconstruct 21 face or neck scar cases in 9 males and 
12 females. In the first operation, an expander was 
inserted on the fascia of the pectoralis major muscle, 
and then about 1000 cc of saline was injected dur-
ing a 2-month period. In the second operation, the 
flap was thinned primarily and applied to the recipi-
ent site. Three weeks after the second operation, the 
pedicle of the flap was cut down and sutured.
In 2007, the authors reported an expanded 
“superthin flap” for reconstruction of the face and 
neck for the first time in a patient.
In their series the authors reported different flap 
sizes, ranging from 4 cm × 14 cm to 10 cm × 22 cm. 
Expanded volume ranged from 800 cc to 1200 cc. 
All flaps survived completely, and scar tissues were 
replaced with normal skin. Flaps did not shrink 
after the operations, and contractures did not 
recur. The main advantages of  the expanded flaps 
are the potential to create large thin flaps with a 
texture and color matching with the recipient area. 
The donor site can be closed primarily; and micro-
surgery is not required. However, the disadvantage 
of  the method is the requirement for two or three 
operations.
The advantages and limits of the techniques are 
using skin expansion with or without microsurgery. 
This technique may be considered safe in terms of 
skin manipulations, the obtained tissue being con-
formable enough to redrape the whole face without 
lymphatic accumulation. Edema can be maintained 
at a low level, especially when using complementary 
compressive techniques comparable to the ones used 
in postburn-grafted faces. However, the second stage 
(flap positioning) after skin expansion is crucial in 
order to prevent distal regions of the flap to be par-
tially devascularized and become distally necrosed, 
a complication issuing to a potential tissue loss. The 
transferred tissues are coming from areas where the 
dermal component is thicker than desired for facial 
tissues like the eyebrows or lips, but the global aspect 
of the transplanted face is compatible with a nor-
mal life, thanks to a daily adapted makeup and some 
retouching on the eyebrows and the lips. The skin 
has been submitted during skin expansion to a pres-
sure which limits the depth and gives a thin texture. 
However, in most of the cases, complementary surgi-
cal retouches will be needed for refining the red lips, 
nasal skin depth and nostrils, columella, and eye-
brows, reshaped using liposuction, fat transfer, and 
mucosal surgery
 5. Facial Allotransplantations
Historical Aspects
The Pioneers
The first clinical case was realized in November 
27, 2005, in Amiens (France); the patient presented a 
disfiguration after a severe dog bite. She was submit-
ted to the world’s first partial face transplant This 
disruptive approach established loss of quality of 
  . Fig. 38.4 One year postoperative aspect
  . Fig. 38.3 During the second procedure, the orifices (mouth, 
nose,) must be reopened adequately
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life and social exclusion due to scarring as a medical 
consideration comparable to a life-threatening situ-
ation, as it imposed an immunosuppression for life.
In 2015, 12 partial and 5 full facial transplants 
were recorded in the literature. Procedures included 
partial and near-total facial myocutaneous flaps 
and complex osteomyocutaneous grafts [5]. Fif-
teen patients received fully vascularized grafts, and 
2 patients died of transplant- related and infectious 
complications
Facial transplantation was proposed to restore 
quality of life and enable social reintegration. 
Results publishing the first facial transplants created 
some polemics all over the world. The main discus-
sions were concerning the long-term aesthetic and 
functional outcomes where more precisely defined 
outcomes are expected. In addition, significant 
technical, medical, and ethical issues remain to be 
solved, such as the secondary late failure and need 
for a second transplantation, recently reported by 
two authors [6, 7].
In 2018, Ozkan et al. [8] presented their long-term 
experiences with a series of five face-transplanted 
patients in terms of surgical aspects and postopera-
tive outcomes. Possible salvage strategies in case of 
difficulties were also described. Five patients, four 
receiving full-face transplantation and one under-
going partial transplantation were included. The 
  . Fig. 38.5 Preoperative aspect face and profile female 28 years old
  . Fig. 38.6 Arteriogram before the second procedure. Note the 
good vascularization of  the pedicle and the branches covering the 




patients were aged between 19 and 54  years. Two 
had extensive burn scars to the face, and three had 
suffered gunshot injuries. The posttransplant induc-
tion immunosuppressive regimen included ATG plus 
tacrolimus, mycophenolate mofetil, and prednisone.
Patient files included their etiologies, preopera-
tive preparations, surgical techniques, immunosup-
pressive regimen, postoperative courses, revisional 
surgeries, together with challenges including acute 
rejection episodes, and immunosuppressive drug 
complications.
No re-surgery due to vascular compromise was 
required in any case. One of the five patients was 
eventually lost due to complicated infectious and 
metabolic events 11  months posttransplantation. 
The other four patients were still alive, with a mean 
follow-up time of 53  months, and had satisfactory 
functional transplants and cosmetic appearance.
Potential complications may be linked to compli-
ance and psychological maturity of the patients, the 
risk of opportunistic infections, and malignancies.
These situations need be resolved for it to be 
accepted as a safe procedure.
Advantages and Limits of the Homologous 
Transplantation
After more than 50 transplants, the concept of 
“face transplantation” has emerged even if  several 
considerations should be mentioned: the immu-
nological science used for these transplantations is 
derived from the ones used in organ transplantation, 
and the antirejection regimen should be adapted to 
the rejection levels of the transferred tissues, their 
rejection capacities depending on their structure and 
vascularization (skin, muscle, aponeurosis), etc. The 
number of cases already realized all over the world is 
limited, and each case has his/her own multifactorial 
problems, linked to their own medical history, the 
preoperative difficulties during transplantation, the 
rate of opportunistic infections, and the compliance 
of the patient [9].
The ethical discussions ended with a mandatory 
preliminary authorization for transplantation in 
most of the countries where they were realized. This 
frame has limited the number of cases but opened a 
disruption in the “no-harm” principle, due to the risk 
of potential complications induced by immunosup-
pression in a non- vital medical situation. However, 
the intense need for more social inclusion of these 
abandoned patients has transformed the conserva-
tive approaches into more progressive possibilities.
38.3   Critical Analysis of the Literature
The scarce literature concerning large face reconstruc-
tion is the reflection of  the limited number of  patients 
presenting a scar incompatible with a minimal social 
life or the difficulty to find surgical teams able to sus-
tain a complex program including microsurgery, mul-
tiple actors, and adapted rehabilitation and care. The 
choice between the two strategies may be led by other 
considerations, like the ethical problem of  submitting 
the patient to immunosuppression for the rest of  his/
her life. Several authors have considered this as a prog-
ress opening the way to a large diffusion; others have 
simply refused to consider that facial tissues would 
be compared to any organ transplant performed on a 
daily basis all over the world like the kidney, pancreas, 
lung, or heart.
In conclusion, extensive facial scars remain a difficult 
challenge for reconstruction. Even in highly sophisti-
cated teams, the capacity of a homologous facial trans-
plantation needs to be prepared. The technique demands 
  . Fig. 38.7 Four years postoperative, the quality of  life has 




a permanent immunosuppression, and even if  the ethi-
cal problem was more or less solved, the  opportunistic 
infections remain a risk, and the long-term conse-
quences are unknown in terms of life-threatening issues. 
The techniques imposing a long-term preparation like 
skin expansion plus or minus microsurgical revascular-
ization are more usual. The specificity of the transferred 
tissues is less fine than with a complete homologous 
transfer and will need complementary techniques (fatty 
tissue removal or fat injections, makeup, etc.). A more 
EBM-based approach is needed to compare the results 
and mainly quality of life after allotransplantation ver-
sus auto transfers.
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Take Home Message
Face disfiguration represent difficult cases where 
the technical capacities of  restoring a normal face 
using long and complex surgical techniques have to 
be weighed to the motivation and understanding of 
the patient. Psychological testing should be realized 
before proposing surgery, in order to prevent disil-
lusions and bad feelings afterward and to drive the 
patient toward the right choice to do. All potential 
complications have to be explained, as well as the 
length and risks of  each procedure, keeping in mind 
that some strategies will need several procedures and 
that the final result will only be visible a long time 
after the last procedure.
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Since the end of the nineteenth century, fat grafting has 
become one of the most promising treatments for aes-
thetic and reconstructive purposes. Its very first appli-
cation dates back to 1889 when Van der Mullen used 
fat grafting to treat a diaphragmatic hernia; some years 
later, in 1893, Neuber A. treated posttraumatic depressed 
facial scars with a small-dimension autologous fat graft 
taken from the forearm. Neuber, indeed, noticed that 
the application of small pearls of fat, compared with the 
bigger ones, could bring to better aesthetic results. Later, 
in 1910, Lexer reported the application of the autolo-
gous fat grafting for facial rejuvenation; in fact, he uses 
the fat as a filler for periorbital and facial wrinkles. Dur-
ing his experience, Lexer noted that, in order to obtain 
a good aesthetic results, the fat should not be damaged 
during the taking procedure.
In the same period, authors reported their experi-
ence with the engraftment of fat tissue, and in 1911 
Brunning noticed that fat graft could be reabsorbed.
From 1912 to the Second World War, many stud-
ies have reported on the application of lipofilling for 
“aesthetic purpose” as treatment of the scars; but in 
the meantime, researchers such as Wasserman in 1926, 
and later Neuhof, Shapiro, and others, demonstrated 
that the fat grafting was a “living tissue” in which there 
were present preadipocytes which could later become 
mature adipocytes. They also noted that even if  there 
were a degenerative process for the first months after 
the implantation, later there was the presence of a 
regenerative process with a full transformation of the 
preadipocytes in mature adipocytes after 5 months.
But it has been only during the end of the twentieth 
century that the real features and potentiality of the autol-
ogous fat graft started to become clear. In fact, it was only 
during that period that researchers started to demonstrate 
the presence of stem cells, the adipose-derived stem cells, 
which could survive after the transplantation and regener-
ate the adipose tissue. Nowadays, it is a common opinion 
that there are three zones that arrange the autologous fat 
grafting: (1) the outer one called “surviving zone,” (2) the 
intermediate one called the “regenerating zone,” and( 3) 
the inner one called the “necrotic zone.”
As the name suggests, the intermediate zone or 
regenerating zone can replace the dead adipocytes 
in necrotic/center area; this process is allowed by the 
presence of the so-called stromal vascular fraction 
(SVF). The SVF indeed consists in a multiple cellular 
lineage composed by fibroblasts, pericytes, endothelial 
cells, and mesenchymal stem cells which composed the 
“adipose-derived stem cells” (ADSCs) and which can 
promote wound healing stimulating the reepitheliza-
tion and neo-angiogenesis.
But how can ADSCs do this?
39.1   Adipose-Derived Stem Cells: Their 
Biological Properties
Obtained by a lipo-aspiration procedure, ADSCs can 
be found in large quantities, representing a fraction 
of 1/500–1/1500  cells for a total of 5000 per cell each 
gram of fatty tissue taken, with stem potential 500 times 
higher than the medullary equivalent.
The adipose-derived stem cells have both a regenera-
tive and a volumetric effect due to multiple mechanisms:
 1. They produce a sort of filler effect because of the 
direct differentiation of the preadipocytes to mature 
adipocytes. This differentiation is promoted by an 
auto-paracrine stimulation too.
 2. They have an antioxidant effect and protect against 
damage due to ischemia reperfusion, reactive oxygen 
species (ROS), and hypoxia.
 3. They induce angiogenesis promoting the perfusion of 
the treated area, supporting existing vascular structures, 
and having a paracrine promotion of angiogenesis.
 4. They modulate inflammation suppressing the T- and 
B-cell proliferation via NFkB- mediated mechanism; 
they also produce IL6 and IL8. These cytokines can 
recruit monocytes and macrophages in the site of 
injury because of their chemoattractive role.
 5. They modulate the granulation tissue and other pro-
cesses as fibrosis and/or reepithelization. In fact, they 
upregulate type I procollagen a1mRna, and they stim-
ulate the migration of keratinocytes and fibroblasts.
 6. They secrete lymphangiogenic factors.
 7. They recruit systemic endogenous stem cells via a 
home chemokine gradient to the area of injury.
39.2   The Guidelines
As every procedure, the free fat grafting also has to fol-
low some guidelines. From 2007 to 2014, the US Food 
and Drug Administration and the American Society 
of Plastic Surgeons (ASPS) and American Society for 
Aesthetic Plastic Surgery (ASAPS) proposed many 
guidelines [1, 2], but it has been only in 2016 that there 
have been clear guidelines. In fact, FDA defined the adi-
pose tissue as a “structural tissue” because it is a “con-
nective tissue that stores energy in the form of lipids, 
insulates the body, and provides cushioning and support 
for subcutaneous tissues and internal organs”; but this 
definition restricted its use. Nowadays, the guidelines 
can be summarized as follows:
 1. The graft should be taken and used in the same patient 
at the same session. Delayed grafting is not allowed.
 2. The graft should be minimally manipulated. Based on 
the definition given by FDA, the minimal manipula-
tion is “a process that doesn’t alter the original features 
of the tissue, which maintains its utilities.” The graft 
shouldn’t be sizing. Even if  centrifugation is consid-
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ered a sizing procedure, nowadays the immediate cen-
trifugation at low speed (3000 rpm for 3–5 minutes) is 
allowed, but decantation and mechanical purification 
are preferable, because they don’t alter any features of 
the tissue (. Figs. 39.1 and 39.2).
 3. The manufacturing of the graft may not involve com-
bination with another article, except for water, crys-
talloids, or a sterilizing, preserving, or storage agent. 
Enzymatic process is not allowed. Separation and 
reinjection of the stromal vascular fraction are not 
allowed. Till some years ago, enzymes were permit-
ted to be used as collagenase in order to “upgrade” 
an adipose stem cell (ASC)-poor fat. In fact, the col-
lagenase could disrupt the link between the ASC per-
mitting to add some freshly isolated stromal vascular 
fraction in order to obtain a so-called ASC-enriched 
fat. Nowadays, this enzymatic process is considered 
manipulation, so it cannot be allowed. Also, today 
it is possible to prepare the adipose tissue with a 
tumescent solution, and the lipoaspirate obtained 
can be added with sterile saline without altering the 
tissue. This process guarantees the keeping of the 
original features of the tissue, but it doesn’t help us 
in increasing the engraftment of the free fat graft; so, 
as we will see later, we can use some ancillary proce-
dures to increase the survival of the fat grafting, as 
plasma-rich platelet.
 4. The graft has to be harvested with sterile technique; 
the contact with air has to be minimal. In order to per-
form this process, a so-called closed system has to be 
used that is featured by a sterile disposable canister 
for collecting, separating, concentrating, and trans-
ferring the fat graft (. Fig. 39.3).
 5. The graft has to be taken with small cannulas 
(3–4 mm) and injected with 2–2.5 mm cannulas in a 
retrograde way (retrograde fat distribution). Actually 
this is not a new guideline; indeed it was there already 
in 1893 when Neuber A. treated scars noticing that 
small-dimension fat graft could be more effective 
than bigger one (. Fig. 39.4).
39.3   The Procedure
Set up by Coleman in 1925, in order to improve overall adi-
pose cell survival, the procedure is featured by a tumescent 
technique lipo-aspiration with cannulas or micro cannulas 
from regions as, for example, the abdomen, medial thighs, 
hips, and trochanteric region. The fat taken can be centri-
fuged for 3000 rpm for 3–5 minutes or decanted in order 
to separate the oily part, which can be calcified if injected, 
from the seric part and the “real” fat. After being sepa-
rated, the adipose tissues are injected, with small cannulas, 
in other regions as, for example, the face. The lipofilling 
  . Fig. 39.1 Centrifugation
  . Fig. 39.2 Decantation
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procedure can be executed under general or locoregional 
anesthesia; it depends on the volume of adipose tissue that 
we have to take and on the area that has to be injected. The 
procedure is not free of peri- and postoperative complica-
tions such as infection, hematoma, or calcifications.
It also has to be also considered that the free fat graft-
ing can be physiologically reabsorbed. Unfortunately, 
the engraftment percentage is a subjective parameter, 
and it varies from 10% to 70% and in some comes till a 
total reabsorption. This feature can be brought to mul-
tiple sessions in order to obtain the correct volume.
39.4   The Free Fat Grafting and Scars [3–9] 
(. Figs. 39.5, 39.6, 39.7, and 39.8)
Considering its biological properties, we can propose the 
free fat grafting both to stimulate wound healing and to 
treat or prevent scarring, because it can act and improve 
more than one feature of a scar:
 1. The skin texture, thickness, and pliability
 2. The volume and contour
 3. The fibrosis
 4. The pain
  . Fig. 39.3 Closed system
  . Fig. 39.4 The cannulas





  . Fig. 39.5 Skin texture and color: a Pre-lipofilling after radiotherapy for sarcoma; b 40 days postop; c preop second lipofilling; d post-
second lipofilling at 1 year
  . Fig. 39.6 Fibrosis control in Dupuytren’s disease




  . Fig. 39.7 a Volume and contour: dog bite scar; pre-lipofilling; interoperative. b Volume and contour: postoperative results
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39.4.1   The Skin Texture, Thickness, 
and Pliability
As demonstrated in 2009 by Mojallal et al. in an experi-
mental mouse model, the transplantation of human adi-
pose tissue to nude mice brought to an improving in the 
thickness of dermis. These results were obtained, thanks 
to a stimulated neosynthesis of type I collagen fibers, 
with a consequent composition of a denser extracellular 
dermal matrix. This skin feature improved its texture, 
thickness, and pliability.
Some years later, in 2013, Klinger M. et al. performed 
a study on humans, and they noted that the areas treated 
with free fat grafting assumed features that were simi-
lar to normal skin in terms of elasticity and softness. 
In order to demonstrate these features, they also used 
a durometer evaluation that demonstrated a significant 
reduction of skin hardness.
But why do ADSCs behave this way? As we said 
earlier, ADSCs can modulate and reduce inflammation; 
studies demonstrated that there is also an improvement 
in melanin secretion. These last utilities can also mod-
ify the skin color, thereby reducing the erythema and 
improving normal color of the skin.
39.4.2   The Fibrosis
Related to skin thickness, fibrosis can be due to dis-
eases as, for example, connective tissue diseases or 
Dupuytren’s disease or treatment such as radiotherapy. 
We used lipofilling in the treatment of a specific con-
nective tissue disease called scleroderma or systemic 
sclerosis. This systemic connective tissue disease is fea-
tured by a progressive skin fibrosis especially on the face 
and in particular in the perioral region which brings to 
the so- called microstomia. The patients affected (usu-
ally female) report a bad lips sensation and progressive 
mouth dryness, difficulty in speaking, oral hygiene, and 
feeding. In our experience, the application of fat grafting 
  . Fig. 39.8 Pain and nerve release: posttraumatic nerve entrapment
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in perioral region has improved the symptoms reducing 
skin stiffness and improving opening the mouth.
Regarding the use of lipofilling in Dupuytren’s dis-
ease, this pathology is due to a fibrotic degeneration of 
the longitudinal fibers of palmar aponeurosis, with the 
consequent involvement of subcutaneous septa, the loss 
of subcutaneous fat, and the adherence of dermis to 
palmar aponeurosis. In this case the autologous adipose 
tissue is used as adjuvant therapy to prevent the forma-
tion of new fibrotic tissue (. Fig. 39.7).
Finally, regarding radiotherapy, the fibrosis is a sort 
of adverse event that rises years after the end of radio-
therapy treatment and that it is due to the presence of 
an important post irradiated fibro-necrotic tissue fea-
tured by local dystrophic fat lobules, smaller but thicker 
vessels, and a perivascular fibrosis. In this case the fat 
grafting reduces the necrotic areas and improves neoan-
giogenesis with a consequent increasing in skin quality. 
It is supposed that these results are due to the intrinsic 
ability of the ADSCs to secrete growth factors, as angio-
genic ones, as we said earlier.
39.4.3   The Volume and Contour
As we said earlier, the free fat grafting has a trophic/vol-
umetric effect. As Mojallal noticed the autologous free 
fat grafting has to be considered as a dynamic filler. In 
fact, the “fat filler” doesn’t have only an immediate effect 
of restoring volume, but it has the ability to produce 
adipogenesis with the consequent transformation of the 
preadipocytes in mature adipocytes. This can bring to 
an increased volume of the soft adipose tissue. The plas-
ticity that features the adipose tissue makes it a good 
filler to restore the contour too, not only in posttrau-
matic scars but also in postoperative deformities and/or 
congenital malformation or adult progressive and self-
limited deformation as, for example, in Parry- Romberg 
syndrome (the adult hemifacial atrophy).
39.4.4   Pain: The Analgesic Effect
According to Coleman who demonstrated the posi-
tive effect of free tissue transfer on neuralgias, Riyat 
et al. published in 2017 a review in which they noticed 
as the lipofilling had an analgesic effect, demonstrated 
with tests as, for example, POSAS or McGill Pain 
Questionnaire, on 966 patients. This effect seems to be 
due to multiple aspects: first of all, there is a mechanical 
release. To perform the injection, we have to insert the 
cannula under the scar in the space of the dermo-hypo-
dermal junction, and then we proceed to distribute the 
fat in a retrograde way to reproduce a sort of a weblike 
matrix. This procedure can mechanically release fibrotic 
adherence and nerve entrapment, but most of all, the 
presence of the adipose stem cells can stimulate the nerve 
repair mediated by the brain-derived neurotrophic factor 
(BDNF), an adipose-derived neurotrophin which is fun-
damental in nerve growth and repair. But this is not the 
only mechanism to improve analgesic effect: as we said 
earlier, fat tissues are featured by an anti-inflammatory 
effect which is mediated both by the TGFβ production 
that can modulate and suppress T-cell function and by 
the production of IL 10 a cytokine which is abundantly 
produced by ADSCs and is known to inhibit Cd4 and 
CD8 lymphocytes reducing the inflammation response.
39.4.5   The Possible Applications
Based on the aforementioned effects, we can propose 
the free fat grafting for the treatment and prevention of 
multiple kinds of scars such as the following:
 1. The treatment of atrophic and/or depressed scar, for 
example, in case of acne or previous removal of bulky 
neoformations. In case of atrophic and/or depressed 
scar, the free fat grating can be used both for a volumet-
ric effect, indeed it fills the empty spaces, and for regen-
erative effect, indeed it can improve the skin texture.
 2. The treatment of retracting scars which can limit not 
only the aesthetic point of view but also many func-
tions as the flexor extension of the neck or of the 
elbow. In this case we can associate fat grafting with 
surgery as z-/w-plasty or flaps.
 3. Unstable posttraumatic scars in order to obtain both 
scar stabilization and to improve wound healing.
 4. Fibrotic diseases such as Dupuytren’s disease and 
connective tissue diseases such as scleroderma, as we 
said previously.
 5. Fibrotic irradiated tissue.
 6. Fibrotic response to foreign bodies named peripros-
thetic fibrotic and, often, contracted capsule: this 
response can be described as a pathological and 
excessive deposition of collagen fibers around a 
mammary implant, in this case, the lipofilling.
 7. Postsurgical deformities.
 8. Nerve release in case of neuromas or posttraumatic 
pain.
39.5   The Ancillary Procedures to Increase 
the Overall Survival of Adipose Cells
39.5.1   The Plasma-Rich Platelet [10]
Known as PRP, it is a product obtainable by a blood 
draw of at least 20 cc. It is featured by a high concentra-
tion of platelet >300–350 × 103 platelets/μL, (three to 
five  times than normal) and the production of growth 
factors, including PDGF, TGF β, VEGF, IGF-1, FGF, 
and EGF, released by the α granules of the activated 
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platelets. These factors promote tissue repair, modulate 
inflammatory processes and neoangiogenesis, and ulti-
mately regulate homeostasis of tissue and regenerative 
process. The PRP is easily obtainable without morbid-
ity for the patient, and it can be associated to free fat 
grafting during the same session, in order to increase the 
percentage of engraftment and to improve the overall 
adipose cell survival.
39.5.2   The External Volume Expansion [11]
In order to improve on-site adipogenesis and overall 
adipose cell survival, a new technique called external 
volume expansion (EVE) is being used in these years. 
This procedure is based on tissue expansion combined 
with the mechanobiology principles which explain 
how mechanical forces, such as the ones produced by 
the application of the negative pressure therapy, can be 
transduced in the cells in order to stimulate processes 
as cellular shaping, proliferation, and differentiation. In 
fact, studies demonstrated that the EVE application can 
increase cell proliferation, deep dermis capillary density, 
and adipogenesis due to the edema and inflammation 
response which are proadipogenic factors.
39.5.3   The Future
Recently the fat graft has been proposed for the treat-
ment of keloids or hypertrophic scars. Keloid is a fibro-
proliferative disorder which is known as pathological 
scar, and it is featured by an excessive production and 
deposition of extracellular dermal matrix due to pro-
longed inflammatory and proliferative phases of wound 
healing. Nowadays, there is not a gold standard treat-
ment for pathological scars; it is actually based both 
on prevention with compressive garments or silicone 
gel or sheets both on topical injection of keloid with 
anti- inflammatory drugs as corticosteroids. Based on 
the anti-inflammatory properties of the free fat graft-
ing and on its ability to stimulate neoangiogenesis and a 
better skin quality, it has been proposed to use it in the 
 treatment of hypertrophic/keloid scars, for example, in 
postburn patient. Even if  the first impressions are abso-
lutely positive, unfortunately, as Lee G et  al. noted in 
2017, there is a lack of high-level literature about this 
field, so further studies are required.
39.6   Something to Discuss: The Oncological 
Point of View
Even if  the adipose tissue transfer has multiple benefit 
effects, recently it has been supposed that the pluripo-
tent adipose-derived stem cells and the neoangiogen-
esis stimulated by growth factors can bring to the onset 
of a new neoplasia or a recurrence if  the free fat graft 
is injected in a recipient site which is recently affected 
by a cancer, especially in a breast that has undergone 
a nipple- sparing mastectomy or a partial mastectomy 
(quadrantectomy). Many studies have been performed 
in order to demonstrate the safety of the fat grafting 
in such patients, but nowadays, even if  a correlation 
between lipofilling and neoplasm or its recurrence has 
not been demonstrated, it is preferable to propose the 
free fat transfer after 2 years free of disease.
39.7   Conclusion
In light of our experience, the free fat grafting is con-
sidered an effective and promising treatment for scars. 
The biological properties of ADSCs combined with 
an easy and quick procedure, a low morbidity for the 
patients, and a high compliance make lipofilling an ideal 
treatment to propose. Unfortunately, the treatment has 
some limitations. First of all it cannot be proposed to a 
very slim patients; in fact we need fatty areas to obtain 
ADSCs; secondly, as we said earlier, the percentage of 
reabsorption of fat grafting subjectively varies from 10% 
to 70% till the complete reabsorption in extreme cases. 
This negative feature can result in multiple treatment 
sessions in order to obtain the right volume, but unfor-
tunately it is not possible to set the number of sessions 
required since the beginning.
Fortunately, new studies and new research on cell 
therapy help us to avoid or reduce this problem, as we 
saw that the use of the external negative pressure ther-
apy and/or the combination of free fat grafting with the 
plasma-rich platelet can improve the fat engraftment 
and the overall adipose cell survival with consequent 
better morpho-functional results.
Take Home Messages
 5 The fat grafting contains stem cells called adipose- 
derived stem cells.
 5 The adipose-derived stem cells are pluripotent 
cells.
 5 The fat grafting is an easy procedure with low 
morbidity rate.
 5 The fat injection has both a volumetric and a 
regenerative effect.
 5 The fat injection stimulates neo-adipogenesis and 
neoangiogenesis, and it modulates inflammation 
and fibrosis.
 5 The fat grafting can be reabsorbed.
 5 We can use external volume expansion and/or the 
combination with plasma-rich platelet to improve 
engraftment and overall adipose cell survival.
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Soon after the discovery of radiation, radiotherapy was 
recognized as a treatment technique for tissue over-
growth. Also, hypertrophic scars and keloid disorder 
were treated both therapeutically and for prevention of 
recurrent growth following surgery.
Both patients and care providers might hesitate 
about radiation treatment considering the associated 
ominous reputation and tissue burden. While radiation 
treatment represents a significant burden, for the patient 
as well as financially and logistically, it is also safe and 
characterized by low recurrence rates, high patient satis-
faction, and, in combination with excision, excellent 
aesthetic results. Therefore, when other techniques fail 
in preventing keloid disorder recurrence, radiation treat-
ment is a valid option and should be considered.
This chapter will provide an overview of the history 
of radiation treatment for keloid disorder. The available 
techniques and suggested dosages, as well as the authors’ 
experiences and vision on indications and biological 
working mechanisms, are described.
40.2  Introduction
Soon after the discovery of X-ray technology, radiation 
was recognized as a possible treatment modality for 
excessive tissue growth. Like malignant tumors, aberrant 
scars are proliferative tissue overgrowths and were there-
fore also considered valid targets for treatment with 
radiation. L. Freund first described the positive effect of 
roentgen treatment on a hypertrophic scar in 1898. 
Harris then described the same effect on a keloid disor-
der in 1901, whereas Wickham recommended radium 
for the treatment of keloid scars. Already in 1909, 
Freund combined surgical excision of the keloid with 
postoperative radiation, where he left the wound open 
and waited 2–3 days before starting radiation treatment 
[1]. In the following period, various treatment protocols 
were described using external radiation with relatively 
good results. Folke Jacobsson described in 1948 that in 
625 cases treated, a total regression of 73.6% was 
achieved, most of which with radiation alone (The 
Treatment of Keloids at Radiumhemmet, 1921–1941).
External beam radiation therapy uses a radiation 
source which emits energy onto the target area. The dis-
advantage of this technique is that it gives a relatively 
high dose to the adjacent healthy tissue due to the large 
distance between the radiation source and the target.
Brachytherapy, where the radiation source is placed 
inside or adjacent to the area requiring treatment, was 
pioneered in medicine soon after the discovery of radio-
activity in 1896 and was widely used in the 1930s to treat 
various sorts of tumors. The benefit of brachytherapy 
over external radiation therapy is the ability to deliver 
radiation as very localized and enabling a higher dose 
with fewer side effects and fewer treatments needed for 
the same effect. Brachytherapy for the treatment of 
keloid scars is nowadays always combined with excision.
After an enthusiastic start, the usage of brachyther-
apy declined due to the problematic radiation exposure 
for staff  and patients while handling the radioactive 
materials. The advent of novel radiation delivery meth-
ods and the use of new radioactive sources in the 1950s 
and 1960s caused a renewed interest in brachytherapy. 
Current remote afterloading devices provide safety by 
manually placing a hollow catheter (. Fig. 40.1b) first 
and then loading the radioactive source later through 
the catheter. It was not until 1976 that Malaker et  al. 
introduced this technique for keloid treatment. Current 
methods focus on excision of the lesion followed by 
adjuvant radiation therapy. Although this method offers 
total scar eradication with an optimal aesthetic and low 
recurrence rates (mean, 10.5%), its use is limited due to 
significantly higher costs in comparison with other treat-
ment options, as well as availability of the technique in 
the hospital and the need for more advanced specialist 
care (e.g., plastic surgeon/dermatologist/radiation 
oncologist with interest in keloid scar treatment).
40.3  Types of Radiation Therapy
40.3.1  External Beam Radiation  
Therapy (EBRT)
The classic form of radiation therapy uses a radiation 
source which emits energy onto the target area. Regular 
X-ray radiation is probably the most widely available 
and least expensive radiation option. It does not pene-
trate too deep, so underlying structures remain undam-
aged. Due to the inaccuracy of the technique, however, 
more skin side effects are seen. In superficial radiation 
therapy (SRT), low-energy X-rays (the same range as 
diagnostic X-rays) emit photons at 20–150 kV reaching 
an effective depth of 3.5–16 mm. At higher energy of 
200–500 kV, an effective depth of 2 cm is reached (ortho-
voltage radiation). Electron beam radiotherapy uses a 
linear accelerator to create β-rays. It reaches a depth of 
2–6 cm and can be more accurately delivered.
40.3.2  Brachytherapy (Internal Radiation)
In brachytherapy, a hollow catheter is placed either 
interstitially during closure or superficially on the desired 
target area (see . Fig.  40.1a–c). After this  procedure, 
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the catheter is loaded with a radioactive source. The 
treatment regimen can either be low-dose rate (LDR) or 
high-dose rate (HDR). In LDR a low-dose- rate radioac-
tive source is used to treat for a longer time frame (20–
72 hours). It requires hospitalization in a lightly shielded 
chamber. In HDR the patient is transferred to a shielded 
chamber after the excision. Here, a high-dose-rate radio-
active source is loaded into the catheter remotely by per-
sonnel in a separate area for a short exposure 
(5–10 minutes). Because of the short treatment duration, 
HDR can effectively be used as an outpatient treatment 
option and is therefore preferred over LDR. The main 
advantage of brachytherapy to external beam radiother-
apy is the diminished exposure of surrounding tissue, 
which also provides the possibility to administer a higher 
dose in a shorter time frame. Additionally, because the 
applicator can be shaped to fit the desired area, uneven 
surfaces will receive the same dose, and deeper structures 
can be avoided. The most commonly used radioactive 
source is Iridium-192 which emits γ-rays.
40.4  Excision and Radiation Type
Radiotherapy should be reserved for recurrent keloid 
scars because of its invasive characteristic and signifi-
cant cost. It should be noted that both excision-only and 
radiation-only have higher recurrence rates compared to 
excision followed by radiation [2]. The keloid is prefera-
bly excised in an extralesional fashion [2] and closed pri-
marily. If  this is not an option due to the size of the scar 
or high tension on the wound edges, skin grafts can be 
used, or excision of the core of the keloid can be per-
formed.
Close cooperation with the local radiotherapy 
department is necessary to facilitate radiation therapy 
for keloids. Radiation equipment usually represents a 
significant cost to any hospital, and keloid treatment 
with radiation therapy will most likely only be per-
formed in a small fraction of treatments. This means 
physicians will probably be bound to techniques that are 




  . Fig. 40.1 a Keloid of  the earlobe. After excision, a hollow catheter is placed before closing the wound b. The catheter is fixed into place 
to ensure precise radiotherapy delivery c
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external radiation will be available, while brachytherapy 
may be more common in larger medical centers in devel-
oped countries.
When planning the procedure, two main consider-
ations should be timing and adequate dosage of the 
radiation therapy. The first dose should be administered 
as soon as possible after excision. A clear decrease in 
recurrence rate was seen in external radiation if  treated 
within 7 hours as opposed to the first 24 hours. HDR 
brachytherapy should be administered in the first 
24 hours after surgery and is also likely more effective in 
the first 7 hours [3]. Many protocols, therefore, opt to 
transfer the patient to the radiation department immedi-
ately after excision [2]. Choosing the right dosage is 
important and there is no “gold standard” (yet). The 
concept of biological effective dose (BED) is important 
in the radiation regimen to be formed. BED is the mea-
sure used to quantitatively indicate the biological effect 
of any radiotherapy treatment. Because it corrects for 
the dose per fraction given and the fraction number, it 
will allow comparison of all kinds of treatments and 
modalities. In keloid treatment, it would appear that 
administering less than a BED of 10–12 Gy is correlated 
with a higher recurrence rate [2]. Literature suggests 
there seems to be a strict threshold because doses of less 
than 10  Gy repeatedly report higher recurrence rates. 
This would also mean that a single fraction could be 
enough, possibly preventing an overnight stay and/or 
additional hospital visits. At present, there are not 
enough studies yet in support of this, and a recent study 
even found a higher recurrence rate in a 13  Gy 
 single- faction protocol [4]. In a multicenter comparison 
of HDR brachytherapy, 2  ×  6  Gy (BED of 19) treat-
ment gave an equally low recurrence and lower compli-
cation rates than using 2  ×  9 and 3  ×  6  Gy [4]. 
Administering more than a BED of 20 Gy seems unnec-
essary in HDR brachytherapy [4]. In the treatment of 
earlobe keloids with EBRT, a BED of 15–22.5 over two 
fractions (2 × 10 Gy) was found to be sufficient [5]. In a 
recent systematic review, HDR brachytherapy achieved 
the lowest mean recurrence rate, followed by LDR 
brachytherapy and external radiation therapy (HDR, 
10.5  ±  15%; range, 0–44; LDR, 21.3  ±  2.1%; range, 
19.4–23.6; external, 22.2 ± 16%; range, 0–72) [2].
40.5  Recurrence
When reviewing the literature, it should be kept in mind 
that recurrence is often defined differently. It can be 
described as any regrowth of tissue, mild or total relapse, 
or even regrowth extending beyond the borders of the 
original lesion. Symptoms like pain or itching or any 
other complaint in the operated area not related to radi-
ation may be counted as recurrence. With respect to 
radiation therapy, recurrence is usually correlated to the 
administered BED; the higher the BED, the lower the 
recurrence and vice versa. Since the opposite can be said 
of complications, a balanced approach should be made 
toward BED. Recurrence rate is also influenced by loca-
tion; in a recent meta-analysis, Mankowski et al. found 
the chest and trunk to have higher recurrence rates 
(34%) as opposed to the ears (12%) [5]. Furthermore, to 
properly assess recurrence, a follow-up of at least 1 or 2 
years posttreatment should be considered to avoid bias 
by missing recurrences.
40.5.1  Complications
Complications following radiotherapy of the skin are 
scored with the toxicity criteria of the Radiation Therapy 
Oncology Group (RTOG) and the European 
Organisation for Research and Treatment of Cancer 
(EORTC) [6]; see . Table  40.1. Since radiotherapy 
influences wound healing, wound-related complications 
like wound dehiscence, infection, and the failure of the 
wound to close (chronic wound) are additional entities 
to consider. The most commonly seen complications are 
erythema, temporary and permanent pigmentation dis-
turbances, and telangiectasia. Wound-related complica-
tions are rarely seen when administering doses as 
  . Table 40.1 Toxicity criteria of  the Radiation Therapy Oncology Group (RTOG) and the European Organisation for Research 
and Treatment of  Cancer (EORTC) [6]
Grade 1 2 3 4




Tender or bright 




desquamation other than 
skin folds, pitting edema
Ulceration, hemorrhage, 
necrosis
Late Slight atrophy; pigmentation 
change; some hair loss
Patch atrophy; moderate 
telangiectasia; total hair 
loss
Marked atrophy; gross 
telangiectasia
Ulceration
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discussed earlier. Reported recurrence and complication 
rates vary. A recent retrospective study comparing 
2 × 9 Gy, 3 × 6 Gy, and 2 × 6 Gy reported minor com-
plications in 57%, 40%, and 33.7%, respectively, and 
18.6%, 13.8%, and 3.3% major complications, respec-
tively. Recurrence was the same for all groups (25%) [4]. 
Pigmentation complications are more commonly seen in 
people with a darker skin (Fitzpatrick V–VI) who seem 
to benefit from brachytherapy in which the irradiated 
area is greatly reduced [7]. It should be noted that pig-
mentation differences are less prevalent in brachyther-
apy in comparison with cryotherapy [8]. Furthermore, 
HDR brachytherapy yields good results in patient-
reported outcomes such as the Patient and Observer 
Scar Assessment Scale [7].
40.6  Safety Concerns
When administering radiotherapy for benign diseases, 
concerns will arise about the risk of inducing secondary 
malignancy in the treated area. As of now, only a few 
cases have been described in external radiotherapy, and 
Ogawa et al. found the risk to be very low, with an esti-
mated incidence of 0.1–0.0335% [3]. No cases of late 
malignancy have been described while using brachyther-
apy. Of course, the possibility should be mentioned 
when discussing therapeutic options with the patient [3].
40.7  Additional Thoughts on  the 
Biomechanisms of Radiotherapy 
in Keloid Treatment
The working mechanism of radiation therapy to prevent 
the recurrence of the keloid scar is still the subject of 
research. Initially, the application was based on the prin-
ciple that radiation inhibits tissue growth, and since 
both keloid disorder and hypertrophic scars are consid-
ered tissue overgrowth reactions, they were treated as 
such. Early irradiation, within 7 hours of surgery, has 
been shown to result in lower recurrence rates as opposed 
to a later moment [2]. This suggests that interfering in 
the early stages of wound healing is paramount in pre-
venting recurrence of the disorder. Radiation is espe-
cially harmful to dividing cells; the fact that particularly 
the most proliferative cells are vulnerable explains its 
effectiveness in treating cell overgrowth.
Fibroblasts have been linked to keloid disorder for a 
long time, and ionizing radiation has been proven to 
influence keloid fibroblast proliferation [9]. Current the-
ories consider keloids to be an immunological problem 
where endothelial cells and neovascularization may play 
a pivotal role as well [10]. During surgery or trauma, the 
tissue is damaged, and blood vessels are severed. To pro-
vide the upcoming immune cells and fibroblasts with 
enough nutrients and oxygen, new blood vessels are 
formed along the wound edges, while the surroundings 
of the wound show redness as a sign of vasodilation. 
This process starts during the first hours following 
wounding [11]. Endothelial dysfunction has been linked 
to abnormal wound healing [10, 12, 13], so by suppress-
ing endothelial cells and therefore angiogenesis due to 
radiation, the formation of dysfunctional blood vessels 
could be prevented and inflammation decreased, ulti-
mately potentially suppressing keloid formation and 
preventing recurrence [1, 10].
In the classic definition, hypertrophic scarring is con-
fined within the boundaries of the original lesion, 
whereas a keloid scar grows beyond its boundaries. 
However, in close visual inspection of hypertrophic 
scars, we see that they also can extend beyond the bor-
ders of the original lesion. The extension beyond the 
scar borders is less compared to keloid disorder, and the 
ongoing process of scar formation stops earlier. In the 
case of keloid disorder, the vascularity is the highest just 
around the keloid as may be observed clinically during 
excision (. Fig. 40.2).
40.8  Conclusions
Radiotherapy is a last resort option for recurrent and 
therapy-resistant keloids and hypertrophic scars. It rep-
resents a significant burden, both financially and logisti-
cally as well as to the patient. On the other hand, It is a 
very efficacious treatment option (in preventing recur-
rence) while obtaining the most optimal esthetic result. 
It is a safe procedure and most patients experience no or 
minor side effects. The therapeutic goal should be to try 
and excise the entire keloid (extralesionally) and start 
radiation treatment as soon as possible, preferably 
within 7  hours. Between external radiation and LDR 
and HDR brachytherapy, the most preferable option is 
high-dose-rate (HDR) brachytherapy because of the
 5 Ability to customize the device per treatment area, 
therefore only radiating the target area while mini-
mizing radiation damage to the healthy surrounding 
tissue
 5 Lower total BED compared to external radiation to 
achieve the same effect
 5 Ability to deliver the desired BED in a short period 
of time, allowing an outpatient setting
The optimal dose appears to be around a BED of 
20–30 Gy; however, more research works are needed to 
determine treatment protocols. Physicians should adjust 
their therapies on the merit of experience and existing 
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literature in collaboration with the local radiotherapy 
department and in accordance with the wishes of the 
patient.
Take Home Message
 5 Consider excision and radiotherapy as a last resort 
for therapy-resistant keloids.
 5 HDR brachytherapy started <7 hours after surgery 
and a BED of ±20 is recommended.
 5 The chance of secondary malignancy seems very 
low.
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Atrophic scars represent some of the most difficult and 
insidious pathologies confronting the reconstructive 
surgeon. Deriving from the ancient Greek “a-trophos” 
(wasted), the term presents a vivid representation of the 
clinical picture and an area of scar management particu-
larly worthy of specific attention.
The atrophic scars typically develop as a result of 
an intracutaneous inflammatory process. Rather than 
exuberant inflammation, the process results in 
reduced matrix regeneration and focally reduced col-
lagen production. Focal contraction of  the scar tissue 
will result in uneven soft tissue defects. Clinically, 
these result in contour defects on the surface of  the 
skin [1].
Several pathologies may result in atrophic scars [2], 
This chapter is intended for the experienced laser practi-
tioner tackling three clinical conditions presenting to 
the reconstructive specialties, often as a last resort after 
exhaustive traditional management: acne, striae albae, 
and burns. It explores common principles, followed by 
state-of-the-art management and evaluation of the 
senior author’s experience.
41.1.1  Common Principles
These atrophic conditions wound both tissue and psyche. 
They tend to be underestimated causes of significant 
morbidity for the individual patient who often either 
loses all hope of amelioration or presents with unrealis-
tic expectation. Therefore, its appropriate management 
entails identification of their concern, their attitude 
toward the risk/benefit of the management proposed, 
and setting their expectations at an appropriate and real-
istic level. It is important to emphasize that current 
treatment modalities can improve but cannot completely 
remove atrophic scars. Scarring from acne vulgaris and 
burns has been associated to a range of mental health 
issues including depression as well as embarrassment, 
poor self-esteem, and general social impairment. Early 
and appropriate involvement of multidisciplinary opin-
ion is key [3, 4].
Appropriate clinical documentation not only helps 
set the baseline at presentation but also allows the 
patient to observe progress and build confidence. Both 
two-dimensional photography and three-dimensional 
photography are useful adjuncts in management, given 
reproducible conditions and serial repetition.
Further, an objective grading of  the condition is key 
to identify appropriate therapeutic options in mind. 
While classification systems are extensively discussed 
elsewhere, it is our experience that the use of  one over 
the other is not in itself  as important as consistency, 
and familiarity with one system, geared toward a thera-
peutic solution.
41.2  Atrophic Acne Vulgaris Scarring
Atrophic scarring is substantially more common than 
hypertrophic [5]. Being able to deconstruct the presenta-
tion into the component symptoms is crucial. Often the 
components of the presenting complaint are a mixture 
of contour and dyschromia, which can be general or 
specific to particular areas or even single scars. It is 
important to enquire about the physical consequences 
which the patient perceives, such as the inability to apply 
makeup, which are key areas of concern, past treatment 
regimes, and the frequency of recrudescence. Tendency 
to hypertrophic, keloid, or poor scarring is asked. 
Enquiring about postoperative social commitments is 
important, considering the variation in recovery times 
with the various treatments while sun exposure without 
adequate protection may dramatically alter the result 
and incidence of complications. Examination estab-
lishes skin type and excludes residual active inflamma-
tion, extent, and grade of disease. Application of the 
Goodman and Baron classification imparts some degree 
of objectivity in concluding one’s deliberations to focus 
on the appropriate therapeutic modalities (. Table 41.1).
Management of atrophic acne scarring depends on 
the infrastructure and equipment available to the practi-
tioner; therefore, a critical appraisal of traditional meth-
ods is presented first, followed by state-of-the-art 
methods and our experience thereafter. For ease of ref-
erence, these techniques are grouped by their main mode 
of action into resurfacing and tightening, dermal lifting 
techniques, and dermal volumization techniques.
41.2.1  Resurfacing and Tightening 
Techniques
41.2.1.1  Microdermabrasion
Microdermabrasion is a minimally invasive technique 
that improves texture but only addresses superficial 
scars, although its combination with aminolevulinic 
acid photodynamic therapy (ALA-PDT) is more effec-
tive, based on RCT evidence [7]. In principle, subsequent 
wound remodeling results in neocollagenesis and hence 
increased dermal thickness. Its main use is for well- 
defined superficial scars with distinct borders or broad- 
based scars with indistinct borders. Its main drawbacks 
are high operator dependence and a suboptimal safety 
profile. Further adverse effects may include dyschromia 
and scarring. For these reasons it has been largely 
replaced by laser.
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41.2.1.2  Chemical Peels and Microneedling
Chemical peels can improve pigmentation and tone and 
texture. Bhargava et al. reported that glycolic acid (35%) 
peels and salicylic (20%)  – mandelic acid (10%) peels 
were more effective for ice-pick than boxcar scars. Twice- 
weekly stronger strength peels seem to be more effective 
than daily low-strength creams. Trichloroacetic acid 
(35%) peels with a short downtime seemed to be particu-
larly effective in darker skin types. Yet others combine 
needling with TCA peels to good effect. Caution needs 
to be taken in view of several potential adverse effects 
including prolonged erythema and post-inflammatory 
hyperpigmentation. These side effects are more preva-
lent but by no means limited to deep peels. Paradoxically, 
very high concentrations of TCA have demonstrated 
high efficacy in atrophic scars, and boxcar scars in par-
ticular, and have been rebranded as chemical reconstruc-
tion of skin scars (CROSS). Skin needling is another 
method, based on the principle of percutaneous induc-
tion of collagen, creating dermal microclefts, with col-
lagenesis resulting from the cascade of growth factors 
unleashed by the wound-healing process. It appears to 
be more effective on rolling scars, and collagen deposi-
tion happens slowly, with the final result taking several 
repeat sessions and up to a year to be complete. Needling 
seems to confer added value as a method for transcuta-
neous drug delivery. Several such applications have been 
reported, such as combinations with TCA, platelet- rich 
plasma (PRP), and CROSS. Current best evidence sug-
gests that results are operator-dependent, frequency- 
dependent, and concentration-dependent and that depth 
and degree of post-inflammatory hyperpigmentation 
are unpredictable, requiring experience and expertise; 
for this reason, the authors have moved away from these 
techniques toward light and laser therapy.
41.2.2  Dermal Lift Techniques
41.2.2.1  Punch Excision
Punch excision is a simple and quick technique that con-
verts a discrete atrophic scar into a well-apposed, well- 
oriented surgical “healthy scar” which is easier to manage 
by both surgeon and patient. An appropriately sized 
punch biopsy is used to perform full-thickness excision. 
The wound is then sutured along relaxed skin tension 
lines (RSTLs). Observing the elongation of the circle 
into an ellipse with tension allows the practitioner to 
choose the optimal orientation for closure. It is also use-
ful to avoid closely spaced defects and thus excess trac-
tion. Punch excision is replaced by sharp elliptical 
excision to avoid standing cone formation, when the 
defect is larger than 3 mm. Once healed, the resulting sur-
gical wounds can be incorporated into laser remodeling.
Punch grafting replaces the punch excision with a 
similarly sized graft, of better quality in principle, but is 
laborious and often results in suboptimal color and tex-
tural mismatch. Punch elevation is another less com-
monly practiced technique reserved for boxcar scars 
with sharp edges and normal bases. The punch biopsy 
tool is used to excise the scar and its walls down to fat. 
This is followed by careful tissue elevation for the  surface 
to sit slightly proud of surrounding skin to allow for 
subsequent retraction. The punched base is then secured. 
While both techniques are described in the literature, a 
clear advantage of either compared to punch excision 
and suturing, or our preferred techniques illustrated 
hereunder, is not immediately evident.
41.2.2.2  Subcutaneous Incision
Subcutaneous incision (subcision) frees dermis tethered 
by fibrous bands causing rolling scars. This technique 
employs a needle (ideally tribevelled) by severing adherent 
bands in a subcutaneous plane. Given adequate infiltra-
tion with adrenaline-containing local anesthetic, risk of 
hematoma formation is minimized. The technique does, 
however, run the risk of subcutaneous nodule formation.
  . Table 41.1 Post-acne scars, qualitative global grading 




I Macular These scars are erythematous, hyper- or 
hypopigmented macules
They do not represent a problem of 
contour but that of  color
II Mild Mild atrophic or hypertrophic scars 
that may not be obvious at social 
distances of  0.5 m or greater and may 
be covered adequately by makeup or 
the normal shadow of  shaved beard 
hair in men or normal body hair if  
extrafacial
III Moderate Moderate atrophic or hypertrophic 
scarring that is obvious at social 
distances of  0.5 m or greater and is not 
covered easily by makeup or the 
normal shadow of  shaved beard hair 
in men or body hair if  extrafacial. Can 
be flattened by manual stretching of 
the skin (if  atrophic)
IV Severe Severe atrophic or hypertrophic 
scarring that is evident at social 
distances greater than 0.5 m and is not 
covered easily by makeup or the normal 
shadow of  shaved beard hair in men or 
body hair if  extrafacial. Cannot be 
flattened by manual stretching of  the 
skin
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41.2.3  Volume-Imparting Techniques
41.2.3.1  Filling Techniques
Both autologous (lipotransfer) and alloplast (nonani-
mal, cross-linked hyaluronic acid, NAHA) have been 
described to improve the volume underneath atrophic 
scars. The technique mandates prior release of the teth-
ered scarring, without which the defect may be exagger-
ated due to volumization surrounding a tethered defect. 
Additionally, the technique is prone to the same compli-
cations of the volumizing agent. There is some evidence 
that dermal fillers can be used to impart volume which 
can be useful for soft boxcar or rolling scars [8]. While 
this produces some improvement of the dermal volume 
to counter the atrophic nature of the scar itself, the 
results are dependent on the nature of the dermal filler. 
Injections of cross-linked hyaluronic acid stimulate col-
lagen formation by dermal fibroblasts and ameliorate 
skin quality [9]. Several studies claim advantages of dif-
ferent fillers, and this is extensively discussed elsewhere 
[10]. However, the emerging consensus is that dermal 
fillers offer very little on their own in the management of 
atrophic acne scars and work best as combination ther-
apy. Traditionally, fillers care combined with prior sub-
cision [8]. The combination of dermal fillers with 
high-pressure blast-effect devices is discussed further in 
this section as part of our current regime.
41.2.3.2  Dermal and Fat Autografting
Two less common techniques used for correcting volume 
deficit in atrophic acne scarring are dermal grafting and 
fat autografting. They are included for completeness, as 
the practitioner may occasionally encounter patients 
having been on the receiving end of this technique. In 
dermal grafting, harvested dermis is processed and 
implanted into recipient areas. This traditional tech-
nique’s limitations are that it is limited to atrophic scars 
at least 4 mm in diameter; necessitates pocket dissection 
for insetting the graft, which may simultaneously mean 
subcision; multiple incisions; and inclusion of epidermis 
may lead to inclusions and dermal cysts.
Lipotransfer involves harvesting, processing, and 
insetting adipose tissue, which then will be needed to 
survive by developing a blood supply from surrounding 
tissues. Evidence regarding its use in atrophic acne scar-
ring is controversial. A combination of fat grafting and 
condensed nanofat has been successfully used to treat 
atrophic scars [11]. Other studies claim that this tech-
nique may improve atrophic acne scars and texture [12]. 
Azzam et al. claim that fat grafting proved to be more 
effective in the treatment of acne scars than ablative 
fractional CO2 laser treatment. However, it should be 
pointed out that this study’s methodology suffered from 
limited validity. Follow-up was limited to 3 months after 
a single lesion of fractional CO2 laser therapy. Relatively 
low energies were used as well as a limited number of 
treatments. Currently, there is no evidence on the long- 
term success of this modality in the management of 
atrophic acne scarring [10].
41.2.4  Isotretinoin Treatment
Exposure to isotretinoic acid within 6 months was often 
cited a contraindication to treatment with a second 
modality [13], although more recently this view has been 
challenged. Historically, a few case series reported 
adverse events (development of keloids and hypertro-
phic scars, delayed healing) when patients recently com-
pleting isotretinoin treatment received dermabrasion 
and laser. “Spontaneous” keloids were also described in 
patients on isotretinoin. More recently, literature 
describes successful treatment of atrophic acne scarring, 
including fractional laser and dermabrasion; chemical 
peels in patients on isotretinoin challenge the traditional 
view of withholding treatment for 6–12 months. Rather, 
these adverse events result from individual variations in 
immunologic and inflammatory pathways. Early treat-
ment of acne scars is critical for improved quality of life. 
The risk/benefit implications of treating the patient early 
need to be considered in the light of informed consent.
41.2.5  State-of-the-Art and Combinatorial 
Approaches
Most of the studies published today attempt to perform 
head-to-head comparison between different treatment 
modalities, in the attempt to identify the better option. 
This is understandable from a cost–benefit perspective 
due to the prohibitive outlay of some therapeutic modal-
ities (. Fig. 41.1).
Here we concentrate on combinatorial approach 
(. Table 41.2) for the more taxing Goodman type 3–4 
acne scars. There is a clear trend in the literature that 
favors combination treatments, and trends are now 
starting to emerge about useful synergies especially for 
the more severe acne types [2, 14].
41.2.5.1  Fractional Radiofrequency (FRF)
Fractional radiofrequency (FRF) transmits bipolar cur-
rents through contact electrodes or paired microneedles. 
This results in controlled, loco-temporal thermal dermal 
injury, inducing a wound-healing response. Clinically, 
this results in improved texture, tightening, and some 
improvement of skin clarity. There is consensus in the 
literature that three to six treatments provide optimal 
effects, ranging from 25% to 75% improvement and 
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patient satisfaction. Radiofrequency with microneedles 
(RFM) delivers energy through microneedles (both 
insulated/non-insulated). The initial, mechanically 
induced microneedle wound-healing response [15] is fol-
lowed by controlled thermal energy, up to 3.5 mm deep. 
This results in focal epidermal ablation, and controlled 
thermal damage to dermis, and, consequently, neocol-
lagenesis, neoelastogenesis, and ground substance depo-
sition [16]. Clinically, this results in textural amelioration, 
dermal density, and scar grading, whereas transepider-
mal water loss and sebum measurements did not change 
[17]. Some hybrid devices achieve this with a mixture of 
RF and galvanic energy. Transient posttreatment effects 
include pain, redness, mild swelling, and some crusting 
for up to 5 days. Track marks (<6%) and post- 
inflammatory hyperpigmentation (<3%) have been 
reported. Lesions arising from ice-pick and hypopig-
mented acne scars do not respond optimally to this 
treatment modality from a revolumization perspective, 
but there may be benefit from resulting skin tightening. 
Due to the risk of cross-infecting unaffected areas, RFM 
is contraindicated in patients with any areas of active 
acne.
Pre- and post-therapeutic regimes are integral to a 
positive outcome. Makeup removal, and adequate dry-
ing of the skin, is essential to avoid short-circuiting and 
epidermal injury. In contrast to other authors [18], we 
have achieved acceptability with topical anesthesia only 
(lignocaine/tetracaine cream 70  mg/g). The patient is 
advised a rigorous regime of UV protection (≥50%) and 
emollients to accelerate healing and decrease the risk of 
PIH.
41.2.5.2  High-Pressure Dermal Filler 
Deposition
More recently, low-viscosity NAHA dermal fillers have 
been employed to replenish volume loss associated to 
volume loss. Early studies were performed using micro-
droplet applicators [19]. Even though these limited stud-
ies did report a beneficial effect, with recent improvements 
in high pressure, needle-less transdermal delivery sys-
tems have allowed the development of high-pressure 
transdermal hyaluronic acid delivery. The latter leads to 
a controlled “blast effect,” releasing tethered scars while 
improving delivery of the NAHA to a controlled surface 
area and depth. The combined physicochemical blast 
deposition effect is purported to be synergistic and pro-
motes sustained neocollagenesis [19]. Limited level 4 evi-
dence does not allow pooling of data, but consistent 
beneficial effects have been reported on difficult-to-treat 
anatomical areas and skin types. Patel et al. used jet vol-
umetric remodeling (JVR) technology to deliver cross- 
linked hyaluronic acid, using 40–45% pressure vs. levels 
4–5 filling, and demonstrated a beneficial effect on ice- 
pick and boxcar scars. Although level 4 evidence is based 
on small case series, remarkable results are reported, on 
  . Fig. 41.1 Morphological clas-
sification of post-acne scarring [13]
  . Table 41.2 Proposed combinatorial approach and treatment schedule for treatment of  atrophic acne scarring
Treatment Effect Repeats Typical interval duration Typical side effect duration
Bipolar radiofrequency Regeneration 5 45–60 days 5–7 days
Hyaluronic acid/high 
pressure
Dermal revolumization 3 45–60 days 1–2 days
Fractional CO2 Resurfacing/tightening 1/2 9–12 months 5–7 days
Schedule, temporal interval, and side effect duration are based on expert experience, using calibrated and maintained technology. 
Equipment settings vary between different manufacturers and versions
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a cohort of patients which are difficult to manage tech-
nically. Benefits include shortened procedure times and 
minimal downtime for a sustained improvement in the 
Goodman score. Murine model histological evidence 
supports the notion that the pneumatic injection of 
NAHA induces neocollagenesis and dermal thickening 
[20] (. Table 41.3).
41.2.5.3  Laser
Laser now enjoys a solid evidence base in acne treat-
ment. Traditional ablative laser therapy involved whole-
sale, partial thickness ablation of diseased dermis. While 
this produced impressive results, it was associated with 
significant and prolonged side effects. In our practice 
this has been entirely overtaken by ablative fractional 
laser (AFL). Several ablative and non-ablative lasers 
have been described for the treatment of acne and which 
are well-described elsewhere [10].
In fractional laser, the laser beam is split into multi-
ple hundred columns, which create noncontiguous zones 
of thermal injury. These microthermal zones result in 
noncontiguous columns of epidermal and dermal abla-
tion, resulting in epidermal regeneration and neocolla-
genesis. There is consensus in the literature that repeat 
treatment is necessary, when offered in monotherapy, 
but this may not always be the case when offered as part 
of a regime intended to address the separate aspects of 
atrophic acne scarring pathology. Fractional carbon 
dioxide laser addresses both scar elevation and recon-
touring (. Fig. 41.2).
The skin stretch test of Goodman et  al. [6] 
(. Table 41.1) is a good indicator with which to assess 
the amenability of scars for laser. Scars not correcting 
with a simple stretch test indicates that it will likely not 
correct with laser therapy but may require prior treat-
ment with either punch excision or high-pressure injec-
tion of hyaluronic acid or, in select cases, subcision.
In a first pass, a narrow size scanning pattern is tar-
geted at the scar base, with the aim of achieving lift 
(Deep Fx). The second pass targets the edges of sharp- 
edged scar (such as boxcar scars), contouring it to a 
smoother scar edge (Deep Fx). In the third pass, active 
FX is performed to feather out the troughs and crests of 
the scars. This is typically done at a fixed distance from 
the skin using a spacer. However, the authors prefer to 
use a “spray painting” technique, by holding the hand-
piece still further away from the skin, on increased den-
sity, resulting in a more efficient and effective resurfacing 
(. Table 41.4).
Using this technique, substantial improvement has 
been demonstrated histologically, and efficacy has been 
maintained for up to 3 years. The results appear to be 
more significant when compared to non-ablative modal-
ities, albeit at the cost of increased downtime. It is 
important to advise patients appropriately regarding the 
importance of pre- and posttreatment regimes 
(. Table 41.5).
Non-ablative laser can also be useful in the correc-
tion of acne scarring. This modality trades off  minimal 
downtime, against slower, lower degrees of improve-
ment, compared to ablative laser. Particularly useful is 
Erbium glass (1565 nm) fractioned laser which may be 
used to refine dermal texture and contour. In shallow 
atrophic depressions requiring low energy for adequate 
penetration, high density may stimulate neocollagenesis, 
while the corollary settings on elevations may induce 
flattening.
Picosecond laser may also be used to the same effect 
with some distinct advantages. Hyperpigmentation may 
be effectively treated on collimated beam settings, with 
the picosecond duration resulting in light-reduced 
inflammatory response. In fractionated mode, picosec-
ond laser results in light-induced optical breakdown 
(LIOB) which stimulates gentle neocollagenesis.
41.3  Striae Albae
Lineae albae present another difficult challenge, espe-
cially in darker-skinned individuals. Myriad treatments 
have been described, none entirely satisfactory. Several 
eponymous terms are used interchangeably, but we  prefer 
the one proposed by Nardelli’s “striae atrophicae,” as it 
embodies the current histopathologic understanding [23]. 
  . Table 41.3 Evidence summary for JVR on the face and neck, since 2011, in the literature (English language)
Ref. Technique Reported 
improvement – reduction 









[21] JVR/Histo/SP 50 54.7 6 Neck Korean (II–V) 12
[22] JVR/SP 27.6 (face)/21.2 (neck) 53.2 3–18 Face/neck I–IV 34
SP standard photography, JVR jet volumetric remodeling, Histo histological analysis. Search String “Pneumatic AND Hyaluronic”/
limits: English, human since 2010
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Compared to adjacent unaffected skin, striae albae pres-
ent histologic evidence of attenuated dermal papillae, 
with the latter nearly entirely substituted with collagen 
fibers running parallel to the skin.
Trofolastin demonstrates level 2 evidence of positive 
results for their prophylactic use in SD [24]. Tehranchinia 
et al. [25] observed some degree of improvement in 80% 
of patients after two treatment sessions within a 4-week 
interval. However, 76.7% of patients remained dissatis-
fied. The authors concluded that this modality resulted 
in minimal improvement with mild side effects. It also is 
apparent that Trofolastin’s mode of action is related to 
the deposition of hyaluronic activity [26]. Additionally, it 
is well established that fractional laser treatments induce 
long-term clinical and histological improvement of 
mature atrophic scars [26], including increased architec-
tural reorganization toward normalization, such as col-
lagen structure (from thick surface paralleled hyalinized 
bundles to uniform dense interwoven fibers with higher 
vascularization), and decreased inflammation. Unlike 
Taudorf et al., we do not perform stack pulsing. First as 
unless there is complete immobility, true stacking is 
a b
  . Fig. 41.2 Figure 1a repesents the face before fractional CO2 procedure and b is the patient 6 months later
  . Table 41.4 Suggested typical settings for post-acne AFL protocol
Cycle size Pulses Density (%) Pattern cycle (Hz) Energy (mJ) Aim
1 DFX 2 1 5–10 300 15–20 Base of  scar
2 AFX 2 1 9 350 40–60 Flange out Boxcar scars, 
Handpiece at 45°
3 DFX 1 15 300 17.5 Tighten surrounda
4 AFX 1 3 125 100– Re surface full face
DFX Deep Fx™, AFX Active FX™
aFor severe scarring (optional)
  . Table 41.5 Suggested pre- and posttreatment considerations
Phase Advice
Pretreatment
All patients Back to “normal shade” with 
complete loss of  holiday tan
SPF 50+ (every 2 h)
Fitzpatrick 3–6 Initiate Kligman regime from 8 weeks 
pretreatment, stop 2 weeks pre Rx
tretinoin (0.02%); hydroquinone (4%); 
vitamin c (3%); hydrocortisone (1%)a
Posttreatment
All patients Emollients plus SPF 50+ (every 2 h)
Antivirals PO
Consider antimicrobials as per local 
protocols (antifungals, antibiotics)
aWith particular attention to an airtight container, avoid 
mucosal, periocular, and perioral areas, and avoid pooling in 
nasolabial sulcus
Specific Attention Areas in Scar Management: Management of Atrophic Scars
360
41
impossible to achieve and, secondly, because stacking 
does increase risk of excessive thermal damage.
Clinical evidence supports the use of JVR with 
NAHA promoting sustained neocollagenesis and 
increased dermal depth, while the blast effect untethers 
the underlying scarring of lineae alba [27]. The combi-
nation of JVR to non-ablative fractional laser gives, in 
our opinion, a substantial improvement over both tech-
niques used alone. NAFL then provides an effective tool 
to address dermal recontouring, by stimulating collagen 
synthesis in troughs and the opposite effect in surround-
ing areas. While effects of individual treatments appear 
to be long-lasting, we have also observed that one-off  
treatments are rarely as effective as repeated cycles 
spaced 6–8 weeks apart.
41.4  Burn Atrophic Scars
Great strides have been registered in acute burn manage-
ment, resulting in increased burn survival, even with 
major and previously unsurvivable burns. As a result 
patients are presenting with increased requirements relat-
ing to morbidity and quality of life, arising both from the 
mechanism of injury and subsequent interventions 
required to safe life and limb. Atrophic burn scars form 
an important minority of burn scars. Often interspersed 
with hypertrophic counterparts, they result in wound 
instability and breakdown and contribute to poor cos-
metic outcomes. The postoperative course of a burn scar 
is summarized symptomatically in . Table 41.6.
A plethora of lasers have been described in the treat-
ment of atrophic scars (. Table 41.7), both non-abla-
tive and ablative with an approximate cutoff  of 200 nm. 
Fractional ablation, first described by Mannstein [28], 
produces arrays of microscopic thermal damage zones 
(MTZs) throughout the epidermis and dermis, affecting 
only a part of the surface area, with consequent remod-
eling and neocollagenesis for up to 6 months after treat-
ment with permanent results [29]. Less energy is required 
to achieve the desired depth (≤2 mm) of penetration in 
atrophic or flat scars, allowing higher fractionated densi-
ties to be used, depending on the device, (≤10%).
Non-ablative fractional resurfacing (NAFR), in 
 contrast, leaves the epidermis intact (ad dermis) whilst 
forming MTZs. A focused dermal injury instigates der-
mal remodeling and neocollagenesis [28]. The result is a 
bloodless cylindrical coagulation area within dermis. 
The clinical advantage is lower risk of infection and pig-
ment alteration, as the epidermis is intact.
Post-procedure discomfort after AFR is surpris-
ingly limited. Patients generally return to normal activ-
ity within 1 day, but downtime may be up to 7 days and 
requires several topical applications which may inter-
fere with clothing and social activity. In contrast, 
NAFR requires far less downtime, dyschromia, PIH, 
with lower analgesia requirements, at the expense of 
more treatment sessions being required. In consider-
ation of  these reasons, for flat or atrophic scars, there is 
  . Table 41.6 Therapeutic burn phases
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CO2 carbon dioxide, Er YAG erbium-doped yttrium alumi-
num garnet, Er,Cr-YSGG erbium, chromium-doped yttrium 
scandium-gallium-garnet, LADD laser-assisted drug delivery
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emerging consensus in the literature that NAFR is the 
treatment of  choice [30]. We also suspect that such wide 
variety of  data exists in part from the prohibitive cost 
of  each technology. Having access to the entire range of 
technologies in our center, we favor the use of  NAFR 
Er:YAG to raise the base of  atrophic scars on higher-
density settings.
While the optimal timing of fractional laser therapy 
is not yet determined, current trends in the literature 
over the past 5 years favor earlier intervention. Scars of 
any age can be considered for fractional resurfacing. In 
practice, the contrast between postoperative regimes 
required by laser and complex burn surgery poses prac-
tical limits on how early a laser intervention may be suc-
cessfully offered. Notwithstanding, younger scars are 
more susceptible to remodeling, and some studies now 
suggest that the ideal timeframe may be as early as 
4–12 weeks post-injury, repeated every 1–2 months until 
response plateaus or the therapeutic aims are attained 
and may help in scar remodeling, reduce contracture 
rates, and expedite rehabilitation [31].
Vascular Laser Lasers targeting abnormal scar prolifera-
tion have the potential to improve scar characteristics. A 
number of wavelengths are often used for this purpose, 
including millisecond range potassium titanyl phosphate 
(KTP) 532  nm, pulse dye laser (PDL) 595  nm, and 
neodymium:yttrium aluminum garnet (Nd:YAG) 
1064 nm. Although the primary target of PDL is hemo-
globin, its mechanism of action is not fully understood. 
After multiple treatments, PDL results in some softening, 
flattening, and smoothening [32]. However, melanin acts 
as a potential competitor; therefore, conservative settings 
need to be used in darker individuals.
Fractioned picosecond modality laser has the poten-
tial to produce light-induced optical breakdown, limited 
to the dermis, which may stimulate dermal inflamma-
tion, remodeling, and neocollagenesis. There is still 
some controversy regarding the timing of appearance 
and significance of microscopic epidermal necrotic 
debris (MEND). In one such study, this phenomenon 
was noted as early as 3 h (post-pico-532 nm) and within 
24 h (both 532 and 1064 nm wavelengths) [6].
Burn reconstruction really starts in the immediate 
postburn period with adequate first aid therapy that 
limits the zone of stasis and hyperemia and careful, 
multimodality management including judicious debride-
ment and maximal attention to dermal sparing. 
Fractional laser resurfacing for atrophic wounds is an 
integral part of this armamentarium. Additionally, our 
recent experience suggests that JVR (NAHA) is a useful 
adjunct in achieving revolumization of selected atrophic 
burn wound reconstructions. In particular, resurfacing 
with split thickness skin grafts often leads to a honey-
combed appearance, reduced elasticity, and a feeling of 
tightness, due to the minimal dermal component of a 
split- thickness skin graft. Our early experience with this 
technology has produced excellent results when used in 
tandem with fractional laser, where we have observed 
synergistic dermal “re-plumping” and substantial 
improvement of skin texture.
41.5  Conclusion
Atrophic scars present a significant challenge to the 
reconstructive specialist, with acne, linea albae, and 
burns being topics worthy of special consideration. 
Optimal treatment is not based on superiority of one 
particular treatment over another but rather by the spe-
cialist’s ability to precisely identify the component parts 
of the presenting complaint and bringing his entire 
armamentarium to bear. We believe, based on experi-
ence and balance of current evidence, that combined, 
repeat treatment produces the best results and that these 
must be carefully balanced against the relative costs: 
physical, social, and economic, in consideration of each 
patient’s individual needs.
Take Home Messages
 5 Atrophic scarring is the final common pathway 
resulting from reduced matrix regeneration and 
focally reduced collagen production.
 5 Addressing patient concerns, expectations, and 
attitude to risk/benefit is key.
 5 Techniques may be considered according to their 
principal mode of action: resurfacing and 
tightening, dermal lifting techniques, and dermal 
volumization techniques.
 5 Acne scars affect physical, psychological, and 
social well-being. Involvement of multiprofessional 
advice is important.
 5 In appropriately selected patients, combined 
RFM- JVR- AFL treatment, tailored to individual 
needs, is more likely to produce appropriate results.
 5 Repeat treatment is likely to be needed.
 5 Color laser may lead to substantial improvement 
in dyschromias.
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42.1  Scar Treatment Options for Different 
Anatomical Localizations
42.1.1  Face
When planning treatment for facial scars, physicians 
need to take all the aspects of the scarring into consider-
ation. If  functional impairments like impaired opening 
or closure of the eyes and mouth are present, the initia-
tion and success of suitable therapeutic options are 
required more promptly than it would be with merely 
aesthetic impairments so that permanent damage 
beyond the scarring itself  can be avoided.
If  swift therapeutic success is required, surgical inter-
vention remains the gold standard. Common indica-
tions for surgical intervention in facial scarring include 
microstomia, which is often the result of facial burns, 
acid attacks, or the ingestion of caustic fluids. It hinders 
sustentation and oral hygiene and impairs speech. 
Techniques for commissuroplasty to widen the oral 
opening through the advancement of mucosal flaps 
after scar excision have been published as early as 1831 
by Dieffenbach and have since been modified and refined 
by Converse in 1959, Friedlander in 1974, and others 
(. Fig. 42.1). Often, commissuroplasty is aided postop-
eratively by splinting to avoid fresh scar contractures.
Lagophthalmos is another indication for swift surgi-
cal intervention. It, too, is often caused by thermal or 
chemical injuries. If  left untreated, corneal ulcers, infec-
tions, and pain are common ailments associated with 
this affliction, and permanent damage to the patient’s 
vision is a large risk.
Background
Scarring can have a variety of different detrimental 
effects on the affected patients. While small scars are 
often little more than an aesthetically unpleasing 
blemish, scarring has the potential to drastically affect 
patients’ lives.
Ultimately, not only the scar type but also the 
dimension of  the affected areas and their location 
play a large role regarding the impairments they 
might cause.
Different aspects come into play when certain 
areas of  the body are affected by severe scarring, and 
they should be taken into consideration when plan-
ning the treatment.
Severe facial scarring causes a multitude of  issues. 
It is incredibly stigmatizing for affected patients and 
will likely cause significant psychological suffering. 
This oftentimes has detrimental effects on the 
patients’ social life leading to isolation and thus fur-
ther psychological problems. Facial scarring can have 
a variety of  functional impairments, too. It can cause 
impaired closure of  the eyelids leading to lagophthal-
mos or leading to ectropium or entropium, all of 
which can endanger the patients’ vision and result in 
pain and unease.
Microstomia is another common consequence of 
facial scarring, leading to a reduction of  the mouth 
opening, thus greatly impairing the intake of  food 
and beverages as well as hindering speech or oral 
hygiene all the while causing significant discomfort.
On the head, scarring can lead to hair loss or cica-
tricial alopecia which, while problematic in men, too, 
can be downright devastating in women, where hair 
loss and baldness remain stigmatizing.
The chest is another aesthetically important area 
where scarring can lead to a significant psychosocial 
burden, especially in women.
While scarring of  the hands can be aesthetically 
unpleasing, too, its most problematic consequence is 
the functional impairment it can cause. Especially in 
burn patients, the functional consequences of  the 
scarring can be so severe that not only the patients’ 
ability to work but to maintain their self-reliance 
throughout their daily lives is also at risk. Even with 
immediate physiotherapy and occupational therapy 
after surgical treatment, functional impairments 
often remain and are exacerbated by the incipient 
process of  scarring thus leading to a lasting need for 
further treatment.
Similar problems arise with scarring on the feet. 
Since walking around throughout the day places a 
great load on the scars which are often less durable 
than healthy skin, instable scarring is a common prob-
lem around the feet. Scars can lead to deformities of 
the toes, too, like mallet, hammer, or claw toes which 
can lead to progressive joint damage and painful clavus.
In general, scarring around functionally important 
areas of  the body like the hands, feet, and joints can 
cause dire impairments throughout the demands of  the 
patient’s everyday life. Problematically, if  left untreated, 
joint damage, a permanent reduction of  one’s range of 
movement, and thus progressive worsening of  the 
patient’s condition long after the initial trauma are 
potential consequences.
Therefore, physicians need to make sure that their 
proposed treatment not only improves the scarring but 
that it is also suitable to reduce the risk of  secondary 
damage.
In this chapter, we aim to provide an overview of 
therapeutical options for the treatment of  scarring in 
different anatomical localizations.
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Ensuring sufficient closure of the eye is therefore a 
priority. Consulting an ophthalmologist is important in 
determining if  surgical intervention is necessary and 
when it is best performed as well as to assess the extent 
to which reconstructive surgery is necessary.
A variety of treatment options exist for the recon-
struction of the eyelids. Where full-thickness defects 
that affect both the anterior and posterior lamella of the 
eyelids can require complex reconstructions based on 
local flaps, oftentimes, only the anterior lamella is 
affected. Here, reconstruction with full-thickness skin 
grafts remains the standard (. Fig. 42.2). In lower eye-
lid reconstruction, lateral canthopexy is routinely per-
formed to avoid sagging of the lateral corner of the eye, 
thus leading to ectropion. This technique often results in 
good function and cosmesis.
Lasers, too, play a vital role in the treatment of facial 
scarring. Ablative laser treatment has been used for 
years to treat atrophic acne scars and has proven reliable 
and effective. Since the advent of fractional lasers, side 
effects and after-treatment downtimes have been reduced 
significantly while maintaining a good treatment effi-
cacy. In the treatment of acne scars, the fractional CO2 
laser has proven more effective than its Er:YAG coun-
terpart [1]. Through the radiance of heat into the sur-
rounding tissue, the CO2 laser stimulates heat shock 
proteins which trigger a cascade of molecular pathways 
leading to increased levels of scar remodeling factors 
like transforming growth factor beta 3 (TGF-β3) and 
matrix metalloproteases. Since treatment with the 
Er:YAG laser results in almost no heat transfer to the 
surrounding tissue, those effects are less pronounced.
Widespread hypertrophic scarring as the result of 
burns, scalds, or chemical agents is becoming a frequent 
indication for the use of fractional ablative lasers, too. 
Through its ability to penetrate deep into the scar tissue 
to stimulate remodeling within the deep dermis all the 
while being an effective tool for superficial ablation of 
the irregular, ropelike and tuberose scars that often 
result from the aforementioned trauma, the CO2 laser 
has become an oft-used and reliable tool for facial scar 
revision. While studies have shown significant improve-
ment of scar texture and firmness after just one session 
[2], commonly, repeated treatments are necessary to 
achieve satisfactory results. Furthermore, the scar 




  . Fig. 42.1 A 7-year-old child with severe microstomia due to burn 
scarring. Scar revision was performed with bilateral commissuro-
plasty (Converse plasty). Images were taken before a, intraopera-
tively b, and 4 weeks after surgery c. As a result of  the surgery, the 
teeth are visible again, when the mouth is opened, thus facilitating 
dental hygiene
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for months so that final results can only be expected 
after 6–9  months. Thus, while able to loosen contrac-
tures and greatly improve facial scarring, other tools 
should be chosen where immediate scar relief  is required.
Medical needling is another option that aims to 
improve scarring through percutaneous collagen induc-
tion. It has been shown to significantly improve acne 
and burn scars in connection with a low-risk profile and 
minimal side effects [3]. Satisfactory scar treatment, 
however, often requires multiple sessions, and thus far, 
clinical studies have often relied solely on subjective 
means of evaluation thus leading to a continued demand 
for evidence.
Ultimately, it seems best to combine different thera-
peutic paths. While surgical intervention is paramount 
for the treatment of severe functional impairments, it is 
rarely able to improve pliability and texture of scars thus 
normalizing the look and feel of scarred skin. Here, the 
combination of surgical intervention with fractional 
ablative laser treatment might provide a more holistic 
approach to the treatment of severe facial scarring 
resulting in improved overall results and lasting patient 
comfort and satisfaction.
42.1.2  Hair
Scarring in areas of hairy skin will often result in hair 
loss. This is particularly problematic in widespread scar-
ring. While small scars can easily be excised even on the 
immobile parts of the scalp, larger scars resulting in pro-
nounced hair loss are often difficult to treat.
On the scalp, the scarred, hairless tissue is excised 
and replaced by healthy surrounding skin. Ideally, local 
flaps from the scalp can cover the wound defect after 
excision; sometimes though, pre-expansion through 
skin expanders is necessary to provide the required tis-
sue. Side effects of this course of treatment are frequent 
and include expander malfunction, infection, and dehis-
cence or “breaking” of the skin over the expanders. If  
successful, however, the scarred tissue can be excised 
completely, and permanent hair loss of the scarred areas 
can be revised.
If  neither local flaps, skin grafting, nor tissue expan-
sion are an option after scar excision, free-flap recon-
struction can be considered. Here, fasciocutaneous flaps 
should be considered since the healthy skin architecture 
seems preferable for receiving a hair transplant as 
opposed to muscle flaps that have been covered with 
split-thickness skin grafts. After successful reconstruc-
tion and consolidation, fasciocutaneous flaps can easily 
be thinned to provide a natural contour and integrate 
well into the surrounding tissue, and consequently, hair 
transplantation can be attempted to restore a natural 
appearance. Hair transplantation can also be performed 
on scars or skin grafts; however, this will require both 
sufficient thickness of the subcutaneous tissue and ade-
quate tissue perfusion so that the hair grafts are likely to 
take.
Hair transplantation is the standard therapy for alo-
pecia of the eyebrows or eyelashes, too. While surgical 
techniques for reconstruction of the eyebrows are avail-
able, too, local flaps or composite grafts from the scalp 
will look different than natural eyebrows. Furthermore, 
in composite grafts, less so in pedicled flaps, the risk of 
reduced perfusion might lead to renewed hair loss, thus 
compromising results. Overall, for this indication, hair 
transplantation might lead to more natural results.
If  hair transplantation is considered, patients should 
be aware that multiple sessions are required to achieve a 
satisfactory hair density. Furthermore, it is paramount 
that sufficient donor sites are available [4].
a
b
c  . Fig. 42.2 A patient with pro-
nounced facial scarring and lag-
ophthalmos after sustaining burn 
injuries. Recurring conjunctivitis 
and a corneal ulcer led to the 
indication for surgical revision of 
the lagophthalmos. The scars 
were released, and the anterior 
lamella of  the upper and lower 
eyelid were reconstructed using a 
full- thickness skin graft from the 
upper arm of  the patient. Image 
a shows the preoperative site, 
while b and c show the postopera-
tive results where full closure of 
the eyelids can be achieved
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42.1.3  Hands
Normalizing function in scarred hands is paramount to 
avoid lasting impairments. Scarring of the hands is com-
mon in burns and scalds and often leads to widespread 
scarring, either through the trauma itself  or through the 
resultant surgical treatment and skin grafting. 
Oftentimes such scarring will lead to contractures of the 
web spaces, thus greatly affecting thumb or finger abduc-
tion and diminishing grip strength. Closure of the fist is 
commonly impaired, too, as contractures of the dorsum 
of the hand and fingers inhibit full flexion.
Such problems are often addressed surgically to 
allow for swift improvement of the functional impair-
ments and to allow for early mobilization through phys-
iotherapy and occupational therapy.
Loosening of contractures of the web spaces has 
been described through many different techniques such 
as single or multiple Z-plasty, butterfly, or jumping man 
flaps as described by Shaw or Trident flap plasty accord-
ing to Glicenstein or Hirshowitz (. Fig.  42.3). Many 
other techniques have been described as well, but their 
common goal is to loosen the contracted linear scar and 
deepen the affected web space.
It is important when planning web space scar revi-
sion that adjacent web spaces are never treated at the 
same time, to avoid perfusion problems to the finger in 
between, should one of the neurovascular bundles get 
damaged during surgery. Therefore, when planning to 
operate on multiple web spaces on one hand, pairings of 
web space 1 and 3, 2 and 4, or 1 and 4 are possible, while 
other combinations should be avoided.
Postoperative regimens vary, but commonly, load- 
free assisted exercising can be started shortly after sur-
gery. Ideally, compression gloves with silicone spreaders 
for the affected web spaces are prescribed for overnight 
use for a year after surgery.
Volar flexion contractures are often treated through 
multiple Z-pasties, thus lengthening the scar and resolv-
ing the contracture.
Especially in widespread dorsal contractures, treat-
ment remains difficult. Ensuring full closure of the fist is 
central to ensure good hand function; however, scarring 
is often rigid and restrictive.
To ameliorate these impairments, different tech-
niques should be considered. One option is to replace 
the scarred tissue. After scar resection, full-thickness 
skin grafts or dermal substitutes like Integra® in combi-
nation with split-thickness skin grafts can be used to cre-
ate a thicker, more flexible, and pliable skin in commonly 
stressed areas like the dorsum of the hand. Studies have 
shown that this might lead to improved pliability and 
functional results, both in acute and secondary burn 
reconstruction [5]. This, however, requires adequate cov-
erage of functional structures like neurovascular bun-
dles or tendons so that the grafts will take reliably. 
Otherwise, local or more likely free-flap coverage will be 
required. That course of action will, however, likely lead 
to multiple surgical revisions as flaps are often bulky and 
require subsequent thinning and contouring.
Laser therapy should be considered when improv-
ing the skin quality and rigidity is required. Fractional 
ablative CO2 laser treatment has proven effective in 
releasing contractures and improving scar firmness, 
and different authors have described swift improve-
ments in range of  motion and scar quality in patients 
with burned hands [6, 7].
After scar revision on the hands, dedicated hand 
therapy is imperative to achieve lasting improvements 
regarding hand function and strength. After severe 
a b c
  . Fig. 42.3 A patient with severe impairment of  the abduction of 
the thumb following burn injuries to the right hand with consecutive 
scarring of  the first web space a. After double opposing Z-plasty in 
the first web space and serial Z-plasty along the radial side of  the 
index finger b, abduction of  the thumb is drastically improved c
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trauma and scarring, patients often require months of 
therapy to reach satisfactory results and to enable self- 
reliance throughout their daily lives.
The ideal time for scar revision should be carefully 
weighed, too. Especially in the pediatric patient popula-
tion, where scar contractures might inhibit physical and 
functional development, timely intervention is indicated 
to avoid lasting damages that can be hard or even impos-
sible to reverse.
In general, if  possible, the conservative treatment of 
scarring through compression gloves, silicone finger 
spreaders, and hand-therapy should be exhausted, espe-
cially throughout the phase of scar maturation to avoid 
unnecessary surgery or even exacerbation of the scar-
ring through stimulation of the scarring process.
42.1.4  Feet
Severe scarring of the feet can lead to a variety of prob-
lems for the affected patients. Common causes of scar-
ring located on the feet include burns and scalds but also 
complex physical trauma.
Oftentimes such injuries cause contractures of the 
toes that will lead to painful malposition and toe defor-
mities that can greatly impair walking.
Unstable scarring around the feet is a frequent prob-
lem, too, and chronic wounds and tears open under the 
daily stress those scars are exposed to.
These common problems results in a high urgency 
for scar therapy regarding the feet. The goal is to pro-
vide stable skin that is flexible and resistant to the daily 
strain the feet are exposed to.
Scars resulting from burns or scalds are commonly 
located on the dorsum of the foot, and resultant contrac-
tures of the toes can often be released through excision 
and Z-plasty or other local flaps, not unlike contractures 
on the dorsum of the hand. Similarly, though, more 
severe scarring or unstable scars might require excision 
of larger scarred areas and then skin grafts or a combi-
nation of a dermal substitute (like Integra® or 
Matriderm®) and skin grafts. Full-thickness scars that 
require excision onto the extensor tendons might even 
require free flaps for successful defect reconstruction.
Severely contracted joints might require capsulot-
omy for release, and sometimes, temporary Kirschner 
wire transfixation is indicated to achieve lasting rehabili-
tation of the affected joints [8].
The data on laser treatment for severe scarring of the 
feet is scarce. In light of the capabilities of fractional 
ablative lasers, however, it seems prudent to consider 
this line of therapy as an adjunct in more severe cases or 
as a primary therapy option in mild to moderate cases 
where its capabilities to loosen contractures and to 
soften the scarred skin might yield promising results or 
at least ease subsequent surgery.
Complications of  surgery around the foot include 
hyperkeratosis, which is especially common around 
the load-bearing areas like the heel or the ball of  the 
foot, where scarring can often result in this cumber-
some problem, which is associated with significant 
pain, thus hindering walking and resulting in severe 
discomfort. Authors have noted that hyperkeratosis 
oftentimes forms protectively around a scarred area to 
minimize pressure on said area. Especially early on 
during the wound healing phase after local or free 
flaps to the heel or the sole of  the foot, hyperkeratosis 
can often hinder the healing process by overgrowing 
the wound margins and thus inhibiting complete 
fusion of  the wound margins. Therefore, after surgical 
treatment of  the foot, medical foot care presents an 
important adjunct, not only to ensure patient comfort 
but also to facilitate wound healing and to minimize 
complications.
As with treating scarred hands, surgical or laser- 
based interventions should always go along with conser-
vative means like compression garments, scar massages, 
and physiotherapy to optimize treatment results. This 
should be continued until the scar activity has subsided.
42.1.5  Joints
Scarring over joints can be particularly cumbersome to 
deal with. The constant tension that the healing tissue is 
exposed through the movement of the respective limb 
will encourage scar hypertrophy after trauma but also 
after scar revision. This should be taken into 
 consideration when planning the treatment of scars that 
run over joints.
Plenty of treatment options are available, but ideally, 
a combination is chosen to avoid recidivism of problem-
atic scarring.
Linear hypertrophic scarring can be released through 
Z-plasty or other comparable techniques relying on 
local flaps. While hypertrophic scars commonly show a 
great tendency for regress without treatment after an ini-
tial phase of growth activity and a consecutive constant 
phase so that invasive treatments are not considered a 
first-line treatment option, an exception can be made if  
hypertrophic scars are under constant tension.
As this stress can be considered a major cause of 
the scar hypertrophy, resolving it through surgery or 
fractional ablative laser treatment can result in 
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 subsiding hypertrophy and symptoms thus constitut-
ing a causal therapy.
Supportive measures that should be considered to 
avoid renewed hypertrophy include intralesional triam-
cinolone acetonide or 5-fluorouracil injections, silicone 
gel or sheets, and pressure therapy.
Widespread scarring can be treated through serial 
excision. Here, the scar is excised in two to three con-
secutive operations every 3–4 months. This allows the 
remaining skin to stretch thus facilitating complete 
scar removal that would not have been possible in one 
single step. To avoid stretching of  the scar, wound clo-
sure should be performed in a layered fashion. The 
subcutaneous and corium sutures should provide large 
tensile strength that remains over an extended period. 
Many studies, most recently by Gupta et  al., have 
shown that superior scar appearance results can be 
achieved by using intradermal polydioxanone (PDS) 
sutures when compared to polyglactin 910 (Vicryl) 
sutures [9].
Alternatively like in other problematic areas, frac-
tional ablative lasers have shown great potential to ame-
liorate scar contractures and should be considered a 
treatment option and be discussed with patients [10]. 
Successful treatment, however, will likely require 
repeated treatment sessions.
42.2  Conclusion
When treating pathological scarring, taking the ana-
tomic location of the scar into account is imperative 
when choosing the right form of treatment.
Facial scarring can be extremely disfiguring and 
beyond the aesthetic implications often results in severe 
functional impairments like microstomia and lagoph-
thalmos, among others. Treatment should be initiated 
quickly to avoid secondary damage to the affected 
organs. Commonly, surgical intervention remains the 
gold standard. Contractures are loosened through local 
flaps (e.g., Z-plasty), and skin defects after scar excision 
can be treated through split- or full-thickness skin 
grafting. Fractional laser treatment as an adjunct has 
become an important factor in improving facial scar-
ring as they are able to improve scar firmness and 
smoothen their irregular surface. Similar effects are 
sought through the use of  medical needling, though 
objective clinical data on its efficacy are largely lacking. 
Alopecia is a problem when scars affect the scalp. Often, 
the healthy skin is expanded through skin expanders 
over several weeks so that the scar can then be excised 
with the expanded skin now covering the defect. 
However, such treatment is often difficult because of 
expander malfunction and infections. Other options 
include free-flap reconstruction after scar excision, fol-
lowed by hair transplantation. Especially in hair loss of 
the eyebrows and lashes, hair transplantation remains 
the gold standard, and achieving a near natural result 
in the hands of  an experienced surgeon is often possi-
ble. Scarring of  the hands can result in the loss of  self-
reliance in affected patients. Oftentimes, the web spaces 
are contracted thus limiting abduction of  the thumb or 
spreading of  the fingers. This can be addressed through 
deepening of  the web spaces, for example, through dou-
ble opposing Z-plasty. Afterward, compression gloves 
with silicone spreaders are fitted to ensure permanence 
of  the achieved results and to inhibit renewed contrac-
tures. If  contractures on the dorsum of the hand inhibit 
closure of  the fist, complex reconstructions can become 
necessary if  larger areas of  scarred tissues need to be 
replaced. Laser treatment can assist in improving scar 
quality. Overall, a combination of  treatment options 
should be considered. Physiotherapy and occupational 
therapy as well as compression garment therapy should 
be included into the treatment algorithm to improve 
functional results and to inhibit renewed pathological 
scarring. On the feet, scars often lead to toe deformities 
which impair walking and make wearing regular shoes 
uncomfortable or impossible. Here, surgical interven-
tion is indicated. Since the feet are exposed to a lot of 
strain throughout the day, scars are often unstable and 
repeatedly crack and tear, leading to chronic wounds 
and strong patient discomfort. Here, excision and skin 
replacement through skin grafts, often together with 
dermal substitutes or even free flap reconstruction, can 
become necessary.
Overall, it is important to remember that scarring is 
a multifaceted problem. Through their firmness and 
contraction, they cause functional problems, their irreg-
ular appearance and color can be aesthetically displeas-
ing, and all of these effects can put an enormous strain 
on the quality of life of the affected patients. Treating 
such scarring, especially in exposed areas or where func-
tion is greatly impaired, should therefore address the 
complexity of this problem. This is oftentimes only pos-
sible by combining surgical, laser-based, and conserva-
tive treatment paradigms into an individual treatment 
plan for the affected patients. This ensures not only 
immediate but also long-term improvements and inhib-
its renewed scarring.




 5 Common functional impairments after scarring of 
the face include microstomia and lagophthalmos 
that require swift surgical attention to avoid sec-
ondary damage to the affected organs.
 5 While surgery remains the standard for severe 
functionally impairing scars of the face, fractional 
lasers have become a staple in improving scar 
firmness and surface irregularities and should be 
used in combination with surgery to improve 
overall results.
 5 Hair loss in scarred areas can be addressed in a 
variety of ways. Expanding healthy, surrounding 
tissue can help create enough tissue so that the scar 
can be excised in its entirety and the resultant 
defect can be covered with the expanded skin.
 5 If  this is not possible, the scarred tissue can be 
replaced by fasciocutaneous free flaps, and these 
flaps can then be contoured afterward and receive 
hair transplants.
 5 Hair transplants are the gold standard for hair loss 
of the eyebrows and eyelashes.
 5 Improving function in scarred hands is imperative 
to maintain self-reliance in affected patients. 
Contractures of the web spaces can easily be 
treated through local flaps to deepen the web 
space, and results are commonly good when 
assisted by compression garment therapy 
afterward.
 5 Scarring of the feet can be severely impairing for 
affected patients. Contractures that result in toe 
malposition or deformities should be addressed to 
ensure that the patients can walk and wear shoes 
comfortably.
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Scars are a normal process of dermal healing following 
laceration, skin incision, or tissue loss. Frequently, they 
are associated with burns, penetrating wounds, or surgi-
cal cuts. Morphologically, they appear erythematous 
and firm with elevated fibrous masses that are evolving 
within the margins of the wound and might revert later. 
They can cause cosmetic disfigurement, functional 
impairment, and psychological negative outcomes, 
affecting the patients’ quality of life. These patients 
often seek medical advice to recover the color, texture, 
pliability, and relief  of the associated pain [1]. In this 
chapter, we discussed how scars evolve differently in the 
skin of color, explored the available treatment modali-
ties, and recommended planned treatment modalities in 
keloid management based on the published evidence.
43.2  How Scars Evolve Differently in Skin 
of Color?
Injury to the tissue could significantly produce inflam-
mation, which is in turn associated with infiltration of 
neutrophils, monocytes, and macrophages, and release 
of pro-inflammatory cytokines, which induce fibroblast 
migration and proliferation, resulting in disproportion-
ate extracellular matrix (ECM) deposition besides colla-
gen accumulation [2]. This process is exaggerated when it 
affects the deep dermis, which would be complicated by 
the formation of a permanent scar. The scope of scar 
types varies from atrophic, flat, to raised dermal scars [3].
The pathogenesis of hypertrophic scars might be 
returned to atypical ECM metabolism following an odd 
and exaggerated fibroblastic stimulation. Histologically, 
it exhibits organized overexpression of types I and III 
collagen, deposition of fibronectin, and overexpression 
of pro-inflammatory interleukins (IL), such as IL-4, 
IL-6, IL-13, and IL-21, as well as downregulation of 
IL-12 and interferon (IFN)-γ expression [2]. The inci-
dence of hypertrophic scars associated with a burn is up 
to 78%. The risk factor for hypertrophic scar includes 
dark skin, neck or upper limb age (younger), site, female 
gender, healing time, the severity of the injury, and the 
increase in a number of operations.
Keloids are different from hypertrophic scars in a 
variety of ways: they propagate outside the margins of 
the wound zone and invade the adjacent skin with no 
regression, conversely to hypertrophic scars that develop 
within the edges of the original wound and frequently 
regress in months. Keloids are a common fibro- 
proliferative disorder that could happen due to abnormal 
healing process succeeding cutaneous injury. Keloids 
could evolve in any race; however, persons with more pig-
mented color (Fitzpatrick IV, V, and VI) are more vulner-
able. In Hispanics, African-Americans, and Asians, 
keloids develop in up to 6–16% of those populations. The 
tendency for keloid expansion was also observed in 
patients suffering from dermatological diseases which 
lead to a protracted inflammatory reaction [1].
The presentation of keloid and hypertrophic scars 
can vary in patients with skin of color. Scars can be 
hyperpigmented or very large in patients with darker 
skin. Although keloid and hypertrophic scars appear 
usually within 1 year after trauma or surgery, few cases 
of people with skin of color who developed spontane-
ous keloid scars were reported within the literature as 
well.
Under the microscope, keloids appear as a twirling 
nodular arrangement of collagen fibers, characteristi-
cally with hyalinized, coarsened collagen bundles. 
Moreover, they have an acellular collagen center with 
adjoining hyper-proliferative fibroblasts. Their center 
covers dense fibers of immature collagen that are feebly 
supplied by blood vessels without lymphatic or elastin.
Several mechanisms have been hypothesized for the 
development of keloids, for example, deviant collagen 
production, abnormal growth factor regulation, and 
genetic vulnerability. Elevated levels of transforming 
growth factor beta (TGF-β) are suggested to be involved 
in keloid development; nonetheless, several other media-
tors are tending to be elaborated. Still, there is a lack of 
confirmed hypothesis that could elucidate keloid patho-
genesis. Immune cells were also suggested to be involved 
in keloid scar formation.
Inherited genes increase predisposition for keloid tis-
sue development; however, still, exact genes involved 
have not been acknowledged. Remarkably, keloid is 
exclusive to humans, and the animal model of keloid 
scars is absent. A large Japanese genome-wide associa-
tion study (GWAS) discovered four single-nucleotide 
polymorphisms (SNPs) in three chromosomal segments 
in patients with keloid scars. These SNPs include 
rs8032158, situated in intron 5 of chromosome 15 that 
downregulates NEDD4 gene, which chiefly affects 
keloid severity. A study of admixture mapping recog-
nized potentially mutual genetic regions between a 
group of Black, Chinese, and Japanese patients on chro-
mosome 15q21.2–22.3, within which NEDD4 inhabits.
In analogous studies among relatives, one on chro-
mosome 2q23 and the other on chromosome 7p11 were 
recognized in Japanese patients and African-American 
patients, respectively. Notwithstanding evidence of 
familial keloid formation, there was a changeability in 
phenotypic presentations and scar severity between 
families; hence, polygenic inheritance pattern is mostly 
included in keloid inheritance [4].
Although there are no clear evidence regarding the 
influence of inherited genes on the higher frequency or 
severity of scar among patients with skin of color, it was 
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previously observed that the ethnicity of families with 
multiple affected members is mainly African-American 
and Indian. Variations in the age of onset, severity of 
the scars, and response to treatment in the same ethnic 
group may highlight the role of multiple gene mutations 
in the pathogenesis of the scar. Nevertheless, the pattern 
of gene involvements in scar pathogenesis is an area of 
further research.
43.3  Management of Scars in the Skin 
of Color
The prevention of scars can be achieved by proper clean-
ing and debridement of wounds, avoidance of unneces-
sary invasive procedures in high-risk population, and 
prophylactic measure. Modalities that prevent wound 
stretch – such as silicone gel sheets or tapes – and intra-
lesional corticosteroids exhibited promising results inn 
scars prevention; however, the evidence is still weak.
To identify the most suitable management strategy, a 
thorough clinical examination should be done. This 
assessment must contain a full medical history, a detailed 
keloid scar history, any family history of keloids, and a 
psychosocial assessment. Moreover, a detailed examina-
tion should be conducted, including location, color, 
contour, size, pliability, and symptoms, i.e., pain and 
itching. Keloid is an untreatable disease, but nonethe-
less, physicians might be able to manage the manifesta-
tions of keloid, counting reducing scar size and redness 
and mitigating inflammation; this might reduce the 
recurrence rate of such lesions and may even yield com-
plete extinction of lesions. Deterrence of signs and 
symptoms’ exacerbation and impediment of recurrence 
after therapy are the main treatment goals of keloids.
Clinically, it is challenging to forecast if  a scar will 
progress into either a hypertrophic scar or keloid. 
Increasing skin tension in specific locations and orienta-
tions while closing the wound and the existence of infec-
tions and foreign bodies may amplify the chance of 
keloid development. The more susceptible sites on the 
body for keloids include the earlobes, mandibular angle, 
posterior neck, shoulders, upper arms, upper back, and 
anterior chest. Bleeding, ulcerative, or firmly attached 
scars should undergo histopathologic investigation as a 
differential diagnosis of keloids. The possible differential 
lesions might be keloidal scleroderma, scar sarcoidosis, 
dermatofibroma, dermatofibrosarcoma protuberans, 
morphoeic basal cell carcinoma, and metastatic skin 
nodules.
Several therapeutic modalities are used in the man-
agement of keloid; though, due to unknown resolution 
rates and high recurrence rates, it is challenging to sup-
port any specific therapy. While several strategies exist, 
owing to the absence of level I evidence, none of them is 
universally demarcated as the standard. Presently, the 
treatments used have at best inadequate or indefinite 
effectiveness, with possible adverse drug reactions. 
Furthermore, many of these treatments require long 
treatment durations, might worsen the lesions, or could 
not prevent recurrence [3]. Multiple treatments for 
keloid, with varying efficacies, have been stated to date. 
Traditionally, a number of treatment regimens, for 
example, cryotherapy, interferon, and verapamil, have 
been applied for treating keloid, with unreliable success 
levels. Though, more novel treatments such as intrale-
sional steroid injections, imiquimod, silicone gel, radio-
therapy, lasers, electrical stimulation (ES), bleomycin, 
5- fluorouracil (FU), surgery, and photodynamic therapy 
(PDT) have also been tested, not all have revealed effi-
cacy in ethnic pigmented skin. These treatment modali-
ties were reviewed in detail (. Fig. 43.1). However, due 
to the lack of studies on ethnic skin, some included 
studies presented data on pigmented, as well as nonpig-
mented keloid skin.
43.3.1  Nonsurgical
43.3.1.1  Intralesional Steroid Injections
Intralesional injection of corticosteroid (alone or with 
other agents) is one of the commonest treatment meth-
ods for hypertrophic scars and keloids. They are injected 
each 4–6  weeks as insoluble triamcinolone acetonide 
(0–40 mg/mL) until pain, scar, and pruritis subside. The 
response of patients to the treatment ranges from 50% 
to 100%, while the recurrence rate ranges from 9% to 
50%. However, 63% presents with complications like 
localized ulceration, dermal atrophy, and telangiectasia 
or hypopigmentation. Noteworthy, pain might be man-
aged through applying a local anesthetic. Corticosteroids 
alone represent the most efficient for young keloids, 
while older keloids are further resistant [2].
43.3.1.2  Silicone Gel/Sheet
Using silicone gel/sheets is assumed to diminish mobil-
ity and decrease the scar tension. How silicone gel works 
is uncertain; however, it may serve as an impermeable 
membrane to preserve hydration of the skin. A former 
RCT with 21 patients compared silicone gel with no 
therapy. Gold et al. found a reduction in hypertrophic 
scarring and keloid incidence following silicone gel use. 
However, the limitations of this trial were short follow-
 up period (only 12 weeks), and the blinding and tech-
niques of randomization were not stated.
In another RCT by De Oliveira and colleagues, 26 
patients suffering from keloids or hypertrophic scars 
had a mixture of silicone gel sheeting and non-silicone 
gel sheeting, while the control group received no treat-
ment. They found no statistically significant difference 
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in the symptoms or size of scar by taking any of the 
treatments; however, both scar types were combined in 
their analysis, and the follow-up period was <6 months. 
These findings were in parallel with the results of 
O’Brien and Pandit study that was carried out among 13 
trials including 559 subjects, observing the efficacy of 
silicone gel in the management of abnormal scarring in 
vulnerable groups. These studies collectively highlighted 
the demand for further controlled trials to approve the 
safety and efficacy of silicone gel sheeting.
43.3.1.3  Radiotherapy
Radiotherapy is preferred in elder adults who failed to 
respond to other treatments. It is used only in elderly 
patients because of the theoretical risk, however, there is 
a low risk of carcinogenesis. In resistant keloids, we 
could use ionizing radiation with intralesional excision. 
It acts via inhibiting collagen synthesis and inducing 
apoptosis of proliferating cells, which might rebuild a 
balance between keloid degeneration and collagen syn-
thesis. It is given in doses of 15–30 Gy, ranging from 3 to 
40 Gy among the studies, along six periods with accu-
rate dosimetry and proper protection in the postopera-
tive duration [2].
Doornbos et al. retrospectively analyzed 203 patients 
with keloid lesions using radiotherapy postsurgical exci-
sion. They elucidated the correlation between dose and 
response, with bigger doses decreasing the recurrence 
rate more efficiently. Conversely, Klumpar et al. found 
no significant dose–response correlation. Moreover, 
some investigators as Ragoowansi et  al. and Maarouf 
et al. have supported the use of immediate postoperative 
radiotherapy [3]. Large-scale clinical trials are required 
to investigate a dose–response correlation among differ-
ent races. Using radiotherapy as an adjuvant has 
revealed good scar resolution rates from 67% up to 98%. 
Yet, the retrospective study design, different follow-up 
intervals, and lacking universal clinical evaluation have 
weakened this success rate.
43.3.1.4  Photodynamic Therapy (PDT)
The cytotoxic effects of PDT (with methyl-amino levu-
linate and amino levulinic acid) were investigated in dif-
ferent keloid lesional sites. One study concluded that the 
success of PDT depends on the photosensitizer precursor, 
the location, and the number of fibroblasts at the lesion 
site. A beneficial effect of topical application of methyl-
amino levulinate PDT was initially observed in a patient 
with resistant keloid. There is a case series with 20 keloid 
patients who were examined for the effect of PDT. The 
results showed that PDT reduced pain and pruritus 
scores, reduced flow of blood, improved pliability and 
reduced levels of collagen in keloid, and resulted in a 
decrease of volume of keloid without recurrence over the 
follow-up period (9  months) [5]. These findings direct 
potential utility of PDT in the management of keloid and 
necessitate a further high-quality clinical trial to confirm 
the safety and efficacy of photodynamic therapy.
43.3.1.5  Electrical Stimulation
Electrical stimulation (ES) was investigated in relieving 
the keloid symptoms, such as pruritis and pain. Lately, 
a new in vitro system examined the efficacy of  various 
ES types on collagen expression in keloid fibroblasts 
and revealed that ES could inhibit formation of  colla-
gen I in keloid. Two case series confirmed the efficacy 
of  degraded wave ES in few patients with painful 
keloids, and the regimen exhibited significant amelio-
  . Fig. 43.1 Treatment modali-
ties for a scar in colored skin
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ration of  the symptoms [6]. Moreover, Sebastian and 
colleagues investigated the efficacy of  PDT with and 
without ES and reported that the excitation improved 
the cytotoxic effects of  PDT.  Large-scale studies are 
needed to confirm the effectiveness of  PDT-ES combi-
nation therapy.
43.3.2  Surgical
Surgery is needed in patients with hypertrophic scars 
with contractures, particularly when affecting joints that 
result in function loss. Hypertrophic scars may impede 
movement when they do abnormal forces on adjacent 
tissues or cross the joints. The elbow, knee, and shoulder 
are most commonly affected joints by contractures fol-
lowing burn injury. Surgery must be approached with 
caution as surgical scars may themselves increase the 
risk of keloid in pigmented skin. Recent studies showed 
no difference between surgical cutting modalities in 
terms of scar characteristics [7].
Surgical excision of keloids must be executed with 
substantial precaution, owing to the high recurrence 
risk. Excision could result in a bigger lesion and 
increased possibility of recurrence. The link between 
scarring and mechanical stress scarring is due to keloid 
scars occurring primarily in sites of excessive stress and 
mobility, for example, the shoulder, scapular region, and 
sternum. Therefore, it has been encouraged that cases 
subjected to surgery in these specific locations must have 
a long time of local skin support and splintage.
43.3.2.1  Surgical Excision and Adjuvant 
Therapy
The essential method in keloid treatment is surgical 
removal and primary closure, then injection of local ste-
roid. Initial surgical excision followed by postoperative 
injection of steroid and silicone sheeting showed a 15% 
recurrence rate. Other modalities, for example, wearing 
a body corset or supportive bra, can furthermore 
decrease the risk of keloid in the mid-sternal region or 
upper trunk. Precautions to be considered while per-
forming the first keloid surgery include not putting ten-
sion on the adjacent skin while closing the lesion. All 
possible causes of residual inflammation, i.e., entrapped 
hair follicles or dermal sinus tracts, should be excised to 
avoid recurrence. In case of large-sized keloid, serial 
excision would be well thought out to diminish skin ten-
sion. The injection of corticosteroid may be performed 
with surgery, then once every month for about 
4–6  months. Surgeons should avoid local Z-plasties, 
W-plasties, and skin flaps beyond the defect to avert 
recurrence of bigger keloid. Of note, the use of silicone 
as a prophylactic method has so far been recommended 
in many studies except for Niessen et al.’s study. Topical 
steroid tape has also exhibited effectiveness in prevent-
ing recurrence, although it has the potential for unfortu-
nate compliance because it is dependent on its continuous 
application by the patient [1].
43.3.2.2  Cryosurgery
Smaller keloid lesions have been treated by cryosurgery; 
however, substantial pain and occasionally prolonged 
healing times posttreatment limit its usage. The hypoth-
esized mechanism of action is through ischemic damage 
that results in cellular anoxia producing necrosis of tis-
sue. Furthermore, it modifies collagen synthesis and 
stimulates differentiation of keloid fibroblast near nor-
mal phenotype, thereby reducing keloid scar size [8].
Intralesional cryosurgery is a technique advanced 
from simple cryosurgery, which was first announced, by 
Shepard and Dawber. A simple cryosurgery, including 
pray technique or liquid nitrogen contact, etc., might 
produce vascular injury causing necrosis of tissue, 
anoxia, sloughing, and consequently scar flattening. 
This procedure could take two to ten treatment sessions 
with an interval of 20–30  days between each session. 
The success rate was reported ranging from 32% to 74% 
following two or more therapies, with superior response 
rates among hypertrophic scars over keloids. There are 
complications such as pain and immediate blistering 
with long-term risk of dermal atrophy that could be 
hyper- or hypopigmented. Conversely, intralesional 
cryosurgery includes introducing a recent intralesional 
cryoneedle (Cryoshape™) inside the scar over the long 
axis. This probe is formed of an elongated uninsulated 
needle having double lumen with a safety vent and a 
sealed, cutting, distal tip prepared to augment the pen-
etration of firm, dense scar. The probe proximal end is 
linked with liquid nitrogen that is pressurized to circu-
late within the needle that results in an ice ball forming 
around the cryoneedle leaving the adjoining scar tissue 
totally frozen, thus resulting in an apparently normal 
collagen regarding its structure and organization with a 
decrease in myofibroblasts and mast cells in the scar. 
This technique was first described in 1993 by Weshahy 
and later popularized by Har-Shai et al. and has revealed 
superior efficacy over simple cryosurgery, with a reported 
clinical effect ranging from 20% to 75% reduction in the 
scar volume. The main complications are peritreatment 
edema and epidermolysis, temporary hypopigmenta-
tion, and pain (while this pain is lower than simple cryo-
therapy). The main advantage of intralesional over 
simple cryotherapy was melanocyte sparing feature that 
accounts for a lower incidence of dyschromia as the 
temperature of skin surface is less influenced in intrale-
sional cryotherapy [2].
A hospital-based clinical trial was performed on 30 
patients with keloid using cryotherapy. The findings 
demonstrated that cryosurgery was an essential treat-
ment regimen for recent keloid, chiefly in smaller lesions. 
Also, they found that both thicknesses and duration of 
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keloid were the main agents in defining treatment out-
come by cryosurgery. These findings were supported by 
Tziotzios and colleagues who recommended cryosurgery 
for reduction of scar size. Recently, a case study investi-
gated the efficacy of cryosurgery plus surgical excision 
combination in 12 participants with keloid after 
12  months. They demonstrated that shaving linked to 
cryosurgery was beneficial in the management of bulky 
keloid lesions because all cases showed improvement 
signs. Yet, it is arduous to follow this treatment modality 
owing to the small sample size [3].
43.3.3  Response Rates and Side Effects 
in Skin of Color
It is well-recognized that skin type significantly affects 
scar response to various modalities of treatment. 
Previous reports have shown that African-American 
patients had lower vascular response to topical cortico-
steroid than Caucasian patients. Relatively low response 
to bleomycin was reported among patients with skin of 
color. Patients with skin types IV–VI showed low 
response rates to different types of laser as well.
In terms of safety concerns, patients with skin of 
color are more reliable to higher incidence of adverse 
events than patients with lighter skin types. The risk of 
hypopigmentation after cryotherapy is more prominent 
in patients with darker skin due to cold sensitivity of 
melanocytes. While excessive melanin in patients with 
skin of color can absorb more laser and lead to hyper-
pigmentation, the high prevalence of melasma among 
patients with darker skin may contribute to post-laser 
hyperpigmentation as well. Hereditary hemolytic dis-
eases are more prevalent among African-American, and 
they may impair healing after laser excision of the scars.
43.3.4  Recurrence Rate
Keloid scars are associated with high rate of recurrence, 
especially when treated with surgical excision alone. 
However, there are no current published data that 
address the effect of skin type on the rate of recurrence 
after scars treatment.
43.4  Management of Scars in Asian Skin
Recent guidelines on the management of scars in Asian 
patients recommended that scar prevention should be 
initiated in the immediate postoperative period owing to 
the high risk of developing poor scars. The recom-
mended first-line therapy was silicone-based products 
(silicone gel and silicone gel sheets) based on their easy 
administration and strong supporting evidence. Several 
second-line therapies were recommended in case of fail-
ure of the first-line treatment, including intralesional 
steroid or 5-flourouracil injections, as well as radiother-
apy. Despite lack of strong evidence, laser treatments 
have been increasingly accepted in these patients; how-
ever, further studies are needed to confirm its efficacy 
and determine the optimal wavelength and amount of 
energy required. Surgery is generally considered a last 
resort in resistant keloids. It can be combined with 
radiotherapy “sandwich technique,” which has shown 
relatively low recurrence rates in Japanese patients [9].
43.5  Conclusions
Keloids are considered a challenging medical condition 
for both patients and medical health professionals owing 
to its high recurrence rate. The existing body of evidence 
has tried to investigate the pathophysiology and molecu-
lar basis involved in scar development using a reliable 
and reproducible model of a keloid. These endeavors 
would optimize the treatment and improve the outcomes 
of the disease. Currently, it is crucial to robust the pub-
lished evidence, merged with clinical outcome, to deliver 
patients with the best therapeutic regimens for scars. 
Moreover, additional large-scale, long-term, and high- 
quality RCTs are indispensable to conclude the safety 
and efficacy of these treatment options further, and also 
comparative studies are compulsory to identify the best 
treatment modality for scars in the pigmented skin. 
Finally, standard guidelines and protocols are manda-
tory to standardize the progress of such promising treat-
ment modalities on a global scale.
The current body of evidence has emphasized the 
requirement for additional long-term clinical trials with 
larger sample size to assess the efficacy of the 
 aforementioned treatments strongly. Several studies 
were short- term clinical trials with small numbers of 
patients included, and the others were case series. 
Besides, lacking stratification of patients into categories 
according to the type of lesion, i.e., keloid or hypertro-
phic scars, location, a degree of severity, or ethnicity of 
the patients, was present in some of these studies. The 
different types of scars are diverse at the molecular level 
and morphologically. Furthermore, the difference in 
skin color, site, number, and size of the scar could 
respond differently to the same modality of treatment. 
Therefore, this variability ought to be taken into consid-
eration when designing those studies. Likewise, the mea-
sures used to assess scar characteristic and response to 
treatment were variable among the studies. Therefore, it 
is a compulsory requirement to use universal tool for 
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assessment and implantation of measures to monitor 
cellular and metabolic activities in the tissue of keloid 
which, in turn, would support tailoring specific modal-
ity of treatment with each category of patients to ensure 
the best response of disease to treatment.
Keloid is unique for human tissue. This esoteric 
nature made keloids’ preclinical studies scramble owing 
to the absence of animal models. Nonetheless, the 
advent of an in vitro organ culture model of keloid was 
fundamental in facilitating the study of disease molecu-
lar biology, pathophysiology, and the response among 
variable therapeutic modalities. This model was found 
to be a valuable tool for investigating new treatments 
and optimizing the treatment that would exhibit the 
optimum safety and efficacy in a diminution of the 
keloid scar mass size. Hence, it is considered as a pro-
spective approach for new therapies assessment.
Take-Home Messages
 5 Pigmented skin has a higher chance of developing 
hypertrophic and keloid scars following wounds.
 5 Thorough history taking and clinical examination 
are essential for accurate assessment and 
management of abnormal scars in pigmented skin.
 5 Several therapeutic modalities for keloid 
management are available; however, there is lack 
of evidence to identify one strategy as the gold 
standard.
 5 Nonsurgical modalities for keloid management 
include intralesional steroid injections, 
radiotherapy, photodynamic therapy, and 
electrical stimulation.
 5 Surgery is needed in patients with hypertrophic 
scars with contractures, particularly when affecting 
joints that result in function loss.
 5 Combination therapies of surgical and nonsurgical 
modalities have shown some promising results; 
however, further research is needed.
 5 Large-scale clinical trials and clinical practice 
guidelines are needed to direct the development of 
effective treatments for keloid management.
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Aims of the Chapter
 5 To provide demographic data on the elderly and the 
definition of elderly in medicine
 5 To bring elements of skin aging and dermatoporosis
 5 To describe the consequences of age on healing and 
major comorbidities in elderly that impair healing
 5 To address the main problems raised by scars in the 
elderly  – these scars are not the hypertrophic scar, 
the keloids, or the scars due to cosmetic aspects but the 
recurrence of a wound on a scar, the Marjolin’s ulcer, 
the hyperkeratosis, the unstable scars, and the adhesion 
to the deep plane of old scars
44.1  Introduction
The population is getting older all over the world. This 
means that more people are living with chronic illnesses, 
which reduce their independence and force them to take 
various medications. Healthcare professionals should 
take this into account when managing scar and scarring 
problems in older patients. Until now, research works pri-
marily focus on the treatment and prevention of wounds 
in the elderly  – acute (dissecting hematoma, skin tears, 
etc.) or chronic (pressure ulcers, leg ulcers, diabetic 
wounds of the foot, etc.) – but too little was done concern-
ing the problem of scarring itself and even less on scars 
associated with the loss of skin function along the time.
44.2  Epidemiology of the Elderly: A Factor 
to Consider
According to the United Nations’ report on the aging of 
the world population, adults over 60 years will outnum-
ber younger people by 2050 [1], and in Europe alone, 
more than 20% of the population will be over 65 years in 
2025 [2]. As this population ages, many older people will 
live with chronic conditions, reduced independence, 
polypathology, and polypharmacy, a situation health-
care professionals should take into consideration when 
dealing with dermatological, scarring, and scar condi-
tions. While governments encourage the growing trend 
in Europe to promote an adapted elderly management, 
the specific wound healing and scarring care provided by 
surgeons, physicians, and caregivers is increasingly 
important but scarcely discussed [3].
44.3  Definition of Elderly in Medicine: 
Should We Make Distinctions?
If the WHO defines elderly as over 65 years of age, the 
increase in life expectancy in good health means that 
when we talk about elderly people in the medical envi-
ronment, these are subjects of more than 75–80 years, 
and the distinction between the healthy elderly and the 
polypathological elderly becomes important. The state 
of health of the elderly is multifactorial. It depends on 
genetic, environmental, social, psychic factors, and the 
existence of multiple pathologies. It is not necessarily 
linked to age. For 30 years the concept of fragile old 
man/woman has been developed [4]. It obeys to several 
definitions and criteria which vary accordingly to the 
numerous publications of which it is the subject and 
makes it a dynamic medical concept. Only 10–20% of 
the nonagenarians or centenarians are considered frag-
ile. These are the so-called geriatric patients who require 
specific management. Most people over the age of 75 are 
not frail and considered “fit” with good functional 
autonomy and good social integration and few patholo-
gies. Conversely, the frail elderly present functional limi-
tations and a decline in their ability to adapt and 
anticipate. To distinguish these two types of elderly pop-
ulation, standardized geriatric assessments have been 
developed using validated scales of autonomy, nutrition, 
cognition, etc. [5]. This evaluation is not only performed 
by geriatrician if  one wishes exhaustive but can also be 
realized by nonspecialists and paramedics: nurses, phys-
iotherapists, social workers, dieticians, occupational 
therapists, and speech therapists. The objective of such 
assessments is to provide a supportive plan adapted to 
each patient, a compromise between what is desirable 
and feasible or reasonable and what is not (. Table 44.1).
44.4  From Skin Aging to Dermatoporosis
Skin aging leads to alteration of the skin and conse-
quently to the loss of its physiological barrier role. Skin 
aging leads to alteration of the skin and consequently 
to the loss of its physiological barrier role. It is the con-
sequence of intrinsic (genetically programmed) and 
  . Table 44.1 Main factors of  frailty in the elderly
Age over 85 years
Loss of  autonomy for an activity of  daily life or more
Impairment of  cognitive functions
Reduced nutritional reserves
Inadequate social support (loneliness, poverty)
Sedentary lifestyle, confinement, postural instability
Poorly compensated sensory disturbances
Kidney and liver failure
Depressive symptoms
Polymedication
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extrinsic factors. These extrinsic factors are numerous, 
and include more specifically drugs aggravating the 
physiological xerosis (hypolipidemic oral, allopurinol, 
hydroxyurea and cimetidine) [6], deficits in essential 
fatty acids, in vitamins (B group vitamins, E, PP, C, A), 
zinc, magnesium as well as malnutrition frequent in the 
elderly patient and environmental factors such as smok-
ing and exposure to ultraviolet (UV). For some patients, 
skin aging can become can constitute a real functional 
organ failure, far from cosmetics considerations. The 
term “dermatoporosis” was recently proposed by Saurat 
[7, 8] to cover all the manifestations and implications of 
this chronic skin syndrome linked to skin fragility and 
insufficiency.
The clinical manifestations of dermatoporosis 
(. Fig. 44.1) include morphological markers of fragility 
(skin atrophy, Bateman’s purpura, spontaneous stellar 
pseudo-scars, hyperpigmentation), as well as the func-
tional expression of skin fragility (skin tears, poor heal-
ing, dissecting hematoma). The first signs appear around 
the age of 60, while the disease itself, with its related com-
plications, is observed between the ages of 70 and 90.
On a microscopic scale, skin aging is manifested by a 
thinning of the dermo-epidermal junction and an exten-
sion of the keratinocyte renewal time. In the dermis, 
there is observed a decrease in the number of fibroblasts 
and thus the density of fiber collagen and glycosamino-
glycans, with thinning of the dermal thickness. Associated 
with this quantitative drop is a qualitative drop in resid-
ual fibers. During aging, a decrease of hydrophilic char-
acter of the glycosaminoglycans, responsible for the 
hydration of the dermis, is observed. This chemical mod-
ification can explain the dermal thinning and xerosis 
seen in the elderly. These changes also affect the micro-
vascularization, with thinning of the vessel wall, which 
may explain the tendency to hematoma and purpura 
(Batman’s purpura) typically observed in the elderly.
44.5  Consequences of Age on Wound 
Healing
Physiological healing has three main stages, directly 
impacted by aging: the first stage is hemostasis and 
inflammation, second stage is cell proliferation, and 
third stage is tissue remodeling. With age, platelet adhe-
sion to the damaged endothelium is increased, decreas-
ing the healing time. The local inflammatory answer to 
injury is reduced, following a decrease in the expression 
of molecules of adhesion. The proliferation phase is also 
impaired by slowing the renewal keratinocyte evokes 
above and also a decrease in response to growth factors. 
Finally, tissue remodeling, the final stage of wound heal-
ing, is also impaired in the aging subject due to an imbal-
ance between metalloproteinases and their physiological 
inhibitors, in favor of metalloproteinases and therefore 
the destruction of collagen [9]. The different healing 
phases are therefore altered by these phenomena in the 
elderly: reduction of the wound contraction, cell prolif-
eration, neovascularization, delay of the inflammatory 
phase, and slower epithelialization [10].
Apart from these deleterious aspects, elderly healing 
presents some advantages. Thanks to a decrease in 
inflammation, pathological scarring such as hypertro-
phic scars and/or keloids is rarely observed in elderly. 
After skin excision for tumor, sometimes needing a con-
sistent loss of substance, the aged patient skin laxity 
generally allows an easy reapproximation of the edges 
and the suture may be realized without tension, issuing 
to good scarring. However, suturing itself  can be 
impacted by the increased skin tears risks due to the der-
matoporosis.
44.6  Frequent Comorbidities Altering 
Wound Healing in the Elderly
Many comorbidities frequent in the elderly can decrease 
wound healing. Undernutrition and diabetes can delay all 
type of wound, while arterial or venous diseases and edema 
(linked to heart, kidney or liver failure) can delay healing 
of lower limbs wounds. Elderly patients are also more 
  . Fig. 44.1 Dermatoporosis: Bateman purpura, skin tears, hyper-




exposed to treatments that can delay healing, especially 
systemic corticosteroid therapy and cancer chemotherapy.
44.7  What Scarring Problems Are Usually 
Observed in the Elderly?
Traumatic and surgical acute wound healing is rather 
good even in very old patients, and hypertrophic or keloid 
scars are rare, at least in the Caucasian population [11].
The poor quality of the scar is usually not a major 
problem (appearance, color, shape) [12] except in 
exposed regions (face) or when impacting the function 
(heel, eyelid, and periorificial areas).
Pruritus and/or pain may appear very lately after the 
trauma/surgery and occur after 20 or 30 years. They are 
linked to dermatological problem (dry skin) or neuro-
genic disorders. These situations may be treated symp-
tomatically with appropriate cosmetics [13]. A few of 
them need surgery, but war, posttraumatic, and post- 
surgery scars are not usually reasons to go to see a doctor.
Atrophic and adherent scars can be improved by 
injecting fat under the scar, a recent technique present-
ing the advantage of being scarcely invasive when anti-
coagulation is not needed or should be stopped 
(. Fig. 44.2).
The reappearance of a wound on a scar should be con-
sidered differently. The recurrence of a tumor may be at 
the origin of the scar. A biopsy or the recurrence of a 
chronic ulcer (arterial or venous, pressure, or diabetic foot 
ulcers) is needed to diagnose a malignant transformation.
It can also lead to the reassessment of the patient 
and indication of preventive treatment of compression 
or discharge (cushion, shoe, soles).
Post-irradiation scars in cancer treatments (breasts 
for example) pose the problem of radiodermatitis and 
radionecrosis which evolves and worsens over time, in 
particular in the elderly who were irradiated at a time 
when the administered doses were high.
Some scars from childhood linked to operated ortho-
pedic malformations are associated with joint deforma-
tions of osteoarthritis because of mechanical forces 
pressure or friction exerted on those scars or because of 
underlying medical problems in the region: arterial dis-
ease or neuropathy.
Marjolin’s ulcer [14], a rare and aggressive skin 
cancer, develops late on scars from burns (. Fig. 44.3) 
or from delayed wound-healing problems: chronic 
osteitis, burns, pressure ulcers, lupus scar, skin graft, 
and radiodermatitis. Squamous cell carcinoma are 
more frequently observed than basal cell carcinoma, 
melanoma, or sarcoma. The occurrence of  a wound 
on a scar aged of  more than 20 years always requires a 
biopsy [15].
Hyperkeratosis is common especially on scars on 
plantar aspect of the foot, the heel, next to the Achilles 
tendon, or on the toes and the lateral aspects of the foot, 
due to a thickening of the stratum corneum reaction to 
friction or to mechanical conflict, especially in case of 
loss of sensibility (diabetes, nerve damage). Cracks can 
appear and constitute entry doors exposing to the risk 
of deep infection (. Fig. 44.4).
Unstable scars may appear because of their location, 
sometimes due to a poor quality of the dermal compo-
nent (absent or fibrotic) or insufficient preventive mea-
sures taken against external agents (shoes, stockings, 
bandages, prosthesis, etc.).
These wounds finally closed after a succession of clo-
sure and multiple reopenings, source of discomfort, and 
risk of cancer transformation (. Fig. 44.5). The treat-
ment of these unstable scars becomes more and more 
complex due to the underlying diseases and comorbidi-
  . Fig. 44.2 Atrophic scar/defect: In this stage 4 pressure ulcer, the 
healing process led to a neoskin adherent to the underlying struc-
tures like aponeurosis, muscle, tendon, and bone. The possibility to 
inject adipose tissue under the skin should be discussed   . Fig. 44.3 Marjolin’s ulcer on an old burn scar
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ties. Biopsies often need to be done to rule out a malig-
nant degenerescence.
Adherence to the depth is a problem that worsens with 
age. Healing occurring on a wound with loss of  deep 
substance (dermis, fat, gliding capacities) and not cor-
rectly repaired (for exemple using negative pressure 
therapy, skin substitute or flap) may lead to an atrophic 
scar adherent to the deep plans. These adherent scars 
can disrupt normal skin movements and mobilisation 
of  the patient, specially when located near an articula-
tion. These adherences are exposed to skin reopening 
due to the loss of  elasticity of  age-related skin.
44.8  Conclusion
Epidemiological studies are lacking and the literature is 
poor on the subject. Hypertrophic and keloids do not 
seem to be a frequent problem in the elderly. The absence 
of inflammation and tension on the scar is undoubtedly an 
explanatory factor that perhaps merits more basic 
research. However, persistent functional problems lead 
aged patients to consult. Chronic wounds or sites of a 
long-lasting healing process are associated to an increased 
risk of malignant transformation, that must be take into 
consideration by the clinician. Regarding scars, elderly 
patients are usually less concern by the cosmetic aspects 
and its impact on the quality of life. The existence of 
underlying diseases can reopen certain scars or pressure 
ulcers and therefore the treatment must be adapted accord-
ing to the comorbidities. The geriatrician sometimes has a 
role to play in establishing the therapeutic plan.
Take-Home Messages
 5 The number of elderly people is increasing.
 5 The tension on the scars is often less because the 
skin of the elderly is less elastic (modification of 
the extra cellular matrix).
 5 Keloid and hypertrophic scars are rare in the 
elderly.
 5 Scars problems are more often malignant 
degenerescence, hyperkeratosis, atrophy, instability, 
or adherence to the depth.
 5 A biopsy must be performed if  the scar reopens or 
persists in an elderly patient.
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45.1   Introduction
Demand for cosmetic surgery procedures continues to 
grow at a rapid pace around the world, with a 9% increase 
in treatments performed in 2017 compared to the previ-
ous year. This translated into 20 million more cosmetic 
surgery procedures [1]. According to the International 
Society of Aesthetic Plastic Surgery (ISAPS), the USA, 
Brazil, Japan, Italy, and Mexico account for 41.4% of 
the world’s cosmetic interventions. Breast augmentation, 
liposuction, eyelid surgery, rhinoplasty, and abdomino-
plasty were the most popular treatments.
All surgical procedures have inherent risks, and aes-
thetic surgery is not an exception. One of the risks is 
poor scarring, and this can occur from postoperative 
infection, wound dehiscence, tissue necrosis, or simply 
from abnormal healing tendencies. Unfavorable scarring 
is not uncommon following cosmetic surgery; the inci-
dence can vary from 5% after breast augmentation to as 
high as 8% after abdominoplasty [2, 3]. The impact of 
excessive scarring can be disturbing to a patient and can 
incite significant morbidity and psychological distress. 
The experience can also be disheartening for the sur-
geon, as the patient will likely blame them for scars. For 
example, in the UK, approximately a quarter of medi-
cal malpractice claims after cosmetic surgery are related 
to poor scarring and, on average, generate roughly 
£300,000 in awards [4]. The cost of remedial scar treat-
ment can be quite expensive, taking time and resources 
of both the patient and the surgeon.
Given the risks of poor scarring, it makes sense for 
cosmetic surgeons to take as many precautions as pos-
sible to avoid inferior outcomes. This chapter explores 
preventative measures to preclude the occurrence of 
unacceptable scars, as well as treatment strategies for 
when they nevertheless develop.
45.2   Patient Selection for Cosmetic Surgery
All cosmetic procedures are elective, and identify-
ing patients at risk for poor scarring is a key starting 
step. It is important to develop a selective approach 
in offering aesthetic treatments to reduce unfavorable 
outcomes and to mitigate potential problems. Patients 
must be included in the decision-making process, 
beginning with providing a clear explanation of  the 
risks for their specific case. The surgeon must take the 
time to explain and to provide realistic management 
of  patient expectations. Only after clearly describing 
the risks and answering questions can patients make a 
valid informed decision.
The scar risk and acceptance matrix (. Table 45.1) is 
an example of a simple clinical tool that can be used to 
quantify the risks of cicatrix formation. This is a com-
munication tool that can help a patient’s understanding 
and, when used in a clinical practice, only requires a few 
minutes of consultation time. The parameters taken into 
account for this calculator are the preexisting medical 
conditions that might affect healing, life style risks, the 
patient’s constitutional tendencies to poor scarring, and 
the patient’s expectations about scar appearance.
Each row of the matrix can contribute an inte-
ger value from 1 to 5 according to the descriptions in 
each column. Adding the results from each row gives a 
total score, with low values corresponding to low risk. 
Patients with medium and high risk should be well 
counseled before their procedure, and the preventative 
measures (to be described later in this chapter) should 
be taken before surgery. A very high-risk score might 
justify declining treatment. The following subsections 
describe each row of the calculator in more detail.
45.2.1   Evaluating Medical Risks
Reviewing a patient’s medical history is key for identify-
ing patients who might be at risk for the types of com-
plications that can lead to poor scarring. The following 
examples illustrate some of the issues to consider.
 5 Individuals with cardiovascular disease and hyper-
tension might be at higher risk of bleeding or inad-
equate tissue perfusion.
 5 Chronic lung disease and poor peripheral circulation 
can cause inadequate oxygenation of skin. This in 
turn could lead to a potential necrosis at the surgical 
site.
 5 Autoimmune and connective tissue diseases can give 
rise to excessive fibrosis and scar thickening. They 
can also lead to suboptimal collagen deposition, 
resulting in atrophic or widened scars.
 5 Immunosuppressed or diabetic patients will have 
a greater chance of postoperative infection and a 
problem healing.
 5 Allergies to certain medications or substances, like 
latex or adhesive dressings, might compromise an 
otherwise successful surgery.
 5 Some medications and supplements can promote 
postoperative bleeding or predispose to hyperpig-
mentation.
 5 Patients, who have previously developed unsightly 
scars, might be prone to keloid and hypertrophic or 
atrophic healing.
Aesthetic (Cosmetic) Surgery
Aesthetic surgery’s principal purpose is to improve 
physical appearance and self-esteem.
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In summary, a good understanding of the patient’s med-
ical history and how this could affect the scar formation 
process is important for the surgeon’s treatment plan, 
which also helps the patient understand their specific 
risks. A discussion of these issues is an important part 
of helping the patient to make an informed decision.
45.2.2   Assessment of Constitutional 
and Genetic Risks
Being either under- or overweight increases surgical 
risks, and this also has an effect on postoperative recov-
ery [5]. Patients with one of these characteristics may 
suffer from nutritional or metabolic abnormalities (or 
both). Accounting for this before proceeding with a cos-
metic surgery is strongly advisable.
Also of note is the specific case for patients who have 
undergone bariatric surgery to control their weight. 
These patients often develop a condition of malabsorp-
tion and a significant metabolic shift.
For some individuals, there will be inherent famil-
ial or racial risks that can contribute to excessive scar-
ring. Although, no specific genetic mechanisms have yet 
been identified, individuals with the skin type 4–6 on the 
Fitzpatrick scale are at higher risk for more noticeable 
scars [6]. Both the MYH9 gene (coding for a non-muscle 
myosin) and apolipoprotein1 (APOL1) have been impli-
cated in non-diabetic kidney disease and keloid scarring 
in people of African descent (see . Fig. 45.1). There is 
a hypothesis that a haplotype MYH9-APOL1 is likely 
responsible for keloid formation [7]. Brown et  al. [8] 
found a genetic association between HLA-DRB1∗15 
status and the risk of developing keloid scarring in indi-
viduals with a pale complexion.
In a practical clinical consultation, the surgeon can 
simply enquire about ethnicity and make an examination 
of the patient’s skin. Pigmentation tendencies and any 
previous scars or marks (for example from vaccinations 
or injections) will help estimate risks. . Figure  45.2 
illustrates a tendency to form a keloid scar following 
mesotherapy injections for improving fine décolletage 
lines.
Note that age plays a role in constitutional scarring 
tendencies. Older patients with thinner and dryer skin 
have almost no chance of developing keloid scarring, 
whereas teenagers with higher sebaceous and cellular 
activity have a higher chance of developing pronounced 
scars.
As already stated, poor scarring can negate the ben-
efits of the cosmetic surgery. A careful explanation of 
the risks is essential before embarking on a procedure. 
  . Table 45.1 Scar risk and acceptance matrix
Score 1 2 3 4 5
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sebaceous activity
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Hopes for no poor 
scarring
Expects scarring, 
which can be 
easily disguised
Expects scarring but only 
a minimal
Expects no scar 
at all
A cumulative score of  5 or below is indicative of  low risk for unfavorable scarring and low probability of  patient distress with a scar. 
Scores 6–10 indicate medium risk, scores 11–15 predict high risk, and scores 16–20 very high risk
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The patient needs to be fully informed and should have 
the time to weigh the risks versus the benefits of a pro-
cedure. Procedural planning and early preventative 
interventions can change the balance toward a more 
acceptable final outcome.
45.2.3   Modification of Lifestyle
A patient’s lifestyle choices can have important effects 
on their postoperative recovery, including scarring. It is 
important to assess these types of risks and to advise the 
patient on the steps to be taken before and after surgery. 
Furthermore, as some patients may not fully follow pro-
posed lifestyle modifications, it is wise for the surgeon 
to plan on compliance tests and to enter these into the 
patient’s medical record prior to surgery.
It is well known that smoking tobacco products has 
a detrimental effect in the perioperative period by expos-
ing tissue to the effects of nicotine, carbon monoxide, 
hydrogen cyanide, and nitric oxide. These all impair 
wound healing. There are numerous retrospective and 
prospective cohort studies of levels 2 and 3 evidence 
demonstrating the relationship between smoking and 
delayed postoperative healing.
That said, there are studies with level 1 evidence 
showing ameliorating effects on surgical outcomes when 
preoperative smoking is discontinued for 4 weeks or lon-
ger prior to surgery [9]. When embarking on a smok-
ing cessation protocol, patient compliance should be 
checked with a carbon monoxide breath or urinary coti-
nine test just prior to surgery.
Heavy use of alcohol can cause vasodilatation and 
increase perioperative bleeding. Patients should be 
advised to refrain from drinking alcoholic beverages 
for 2 weeks before and after their surgery. A blood test 
for gamma-glutamyl transferase (GTT) can establish 
whether a patient is abstaining and compliant with the 
recommendation.
A balanced diet and supplements of vitamin D, zinc, 
and iron have a positive impact on postoperative healing.
Substance abuse can have complex effects that 
potentially include reducing a patient’s compliance to 
preoperative protocols, and this can also decrease their 
immunity. These types of issues are serious enough; 
however, it should be noted that in some regulatory con-
texts, individuals suffering from addictions might not be 
considered capable of giving a valid consent to cosmetic 
surgery.
Physically fit, active, and psychologically stable indi-
viduals tolerate surgery better and recover faster [10].
In summary, it is important that the patient be 
informed that their surgical outcome will depend on life-
style. This should be particularly emphasized for those 
who need to make changes prior to surgery.
  . Fig. 45.1 Unilateral keloid scar formation after gynecomastia and mastopexy surgery in a patient of  African origin with skin type 6




45.2.4   Psychological Assessment 
and Expectations Management
Evaluating a patient’s psychological state of mind can 
be challenging for cosmetic surgeons; however, it is an 
essential component of every presurgical consultation. 
It is important to evaluate a patient’s motivations for 
surgery for several reasons. First, it can give an indica-
tion of whether they will be apt to follow the key pre- 
and postsurgical advice they have been given to optimize 
their surgical outcomes. Second, it can help identify 
those patients who may have unreasonable expectations 
and give an indication of the likelihood of them becom-
ing combative or litigious (regardless of the outcome). 
Finally, it is a required step in determining whether a 
patient suffers from body dysmorphic disorder (BDD), 
which, depending on the regulatory context, could 
potentially legally disqualify them from surgery.
Psychological assessment and expectations manage-
ment is a difficult process, especially since most surgeons 
are not trained in how to do this. There are some common 
sense steps that can be used without too much difficulty. 
The first is to look for indicators of psychological imbal-
ance during the consultation process. For example, note 
whether the patient is overly concerned with minor cos-
metic defects. If this is the case, then even the most nomi-
nal scarring will likely be unacceptable to the patient.
Show the patient before- and after-photos for a 
broad spectrum of surgical outcomes, and ask them for 
feedback on which ones correspond to their hopes and 
expectations. If  the patient indicates a strong preference 
for an unrealistic outcome for their body type and age, 
the surgeon should factor this observation into the score.
The consultation process should be used to determine 
the history of psychological treatments, as well as the 
patient’s history of past cosmetic procedures. Although 
a patient may hide their psychological care, a physical 
examination will turn up scars that may be easily asso-
ciated with past cosmetic surgeries. This can be used to 
begin a conversation about the patient’s satisfaction with 
past procedures, and what revisions they have undergone.
Finally, the surgeon should always ask the patient for 
permission to contact their general practitioner (GP) for a 
confirmation of their medical history. If the patient refuses, 
this might be a warning flag, although it may simply be 
due to negative social perceptions of aesthetic surgery. 
However, if the patient’s medical condition or medical his-
tory might possibly contraindicate a surgical procedure, it 
is essential that the patient obtain a letter from their GP 
indicating that undergoing surgery would be safe.
Realize that no psychological evaluation will be 100% 
effective. Some patients with psychological issues such 
as BDD will have learned how to game doctors with 
credible answers. Nevertheless, the surgeon must make 
a good effort at trying to provide the patient with an 
honest assessment while also avoiding harming patients 
who are at risk. There are some practical tools that can 
be considered for this.
First, consider making a video recording of all con-
sultations with every patient. This will be the primary 
record of what was discussed, including facts presented 
about surgical risks, and indications of the patient’s 
expectations.
Make liberal use of before- and after-photos. It can 
be quite difficult to understand a patient’s perspective, 
and it is equally difficult for a patient to understand the 
likely outcomes without concrete examples. Particularly 
important is the patient’s appreciation of scarring pat-
terns and their acceptance of their inevitability. The 
before- and after-photos present an excellent opportu-
nity for gauging the patient’s sentiments on scarring.
Asking the patient for permission to contact their 
GP is an important step of the consultation process. 
The GP can often provide relevant information about 
the patient’s medical history that is relevant to the safety 
of a surgical procedure.
Finally, it is worthwhile to be abreast of psychologi-
cal risk factors for various segments of the population 
and to fold such statistics into the patient’s overall eval-
uation. For example, some patients might not be open 
about their true motives for cosmetic interventions, and 
in some contexts, their aims might be controversial [11]. 
Recognized factors associated with a poor psychosocial 
outcome of aesthetic surgery include [12] the following:
 5 Being of a young age and of male gender
 5 Having unrealistic expectations of the procedure
 5 Having had previous unsatisfactory cosmetic treat-
ments
 5 Exhibiting minimal deformity
 5 Motivations based on relationship issues
 5 A history of depression, anxiety, or personality dis-
order
For cases where the surgeon has a serious doubt about a 
patient, it makes sense to defer surgery while collecting 
more data. The surgeon can insist on a letter from the 
GP stating their opinion that it would be safe for the 
patient to undergo surgery. In highly borderline cases, 
it might make sense to ask the patient to undergo a psy-
chological assessment before proceeding with treatment.
45.3   Prophylactic Measures in Cosmetic 
Surgery to Reduce Excessive Scarring
Scarring is an inevitable result of all surgeries; however, 
as already discussed, patients will be more critical and 
less accepting of scars from cosmetic procedures than 
for those obtained after surgeries for illness or injury. 
Even after extensive preoperative counseling, patients 
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typically do not fully appreciate the realities of scarring. 
This means that cosmetic surgeons should make every 
effort to minimize scarring by utilizing all available tools 
and methods to optimize healing. This section reviews a 
range of current options.
45.3.1   Choice of Surgical Techniques
Careful planning is the best approach to achieving suc-
cess for any surgery, and this is especially true for elective 
cosmetic procedures. The following discussion provides a 
list of points that should be planned for prior to surgery.
Meticulous surgical field preparation and antibacte-
rial prophylaxis are crucial in mitigating risk of infec-
tion. Infiltration with local anesthetic and adrenaline, 
combined with a careful hemostasis, will help reduce 
bleeding during and after the operation. Both infection 
and hemorrhage can be detrimental to wound healing 
and should be avoided at all cost.
The surgeon must take care not to damage vascular 
dermal plexus when undermining skin and take into 
account blood supply via a vascular pedicle when lifting 
flaps and cutting through tissues. Inadvertently damag-
ing local circulatory pathways will lead to skin necrosis 
and devastating consequences.
Incisions should be made bearing in mind the natu-
ral skin tension vectors. Avoiding crossing these will 
diminish the likelihood of wound dehiscence, scar wid-
ening, or hypertrophy. Similarly, avoid areas with tight 
skin such as the presternal, upper shoulders, and over 
the extensor surfaces of joints [13].
Try to strategically hide scars by placing incisions as 
much as possible in the natural creases of the skin or 
where imperfections can be disguised by clothing.
Finally, a cosmetic surgeon must handle tissues gently, 
approximate edges of the wound carefully, and make use 
of fine instruments and suturing materials. While closing 
tissue incisions, a surgeon should bear in mind how the 
tensile strength of the wound will evolve during the heal-
ing process. The tension strength of the wound, related 
to cross-linking of collagen, will only be 3% of that of a 
normal skin after roughly 1 week, 30% after 3 weeks, and 
80% after about 12  weeks [14]. This should be reflected 
in the choice of suturing techniques and materials. Non-
absorbable sutures can be removed after 7–10  days, but 
appropriate additional scar holdup is required during the 
first 3 months with adhesive tapes, dressings, and garments.
45.3.2   Methods to Control Better Healing
Postsurgical techniques to influence and optimize scar 
formation are varied. Some methods are well estab-
lished, while others are still experimental. A brief  review 
of modalities currently in use is summarized here.
 5 Compression garments to reinforce tensile strength 
across a wound and to reduce stretching and friction
 5 Adhesive tapes and plasters
 5 Topical flavonoids
 5 Botulinum neurotoxin type A (BoNTA)
 5 Platelet-rich plasma (PRP)
 5 Microneedling + topical applications
 5 Imiquimod
 5 Bioengineering and recombinant DNA
The first step in postsurgical scar optimization is the use 
of compression therapy. Although the effects are poorly 
understood, compression keeps wounds reinforced and 
prevents both stretching and friction. A wide range 
of compression and support garments are available. 
Pressure levels should be sustained at 15–40 mmHg for 
at least 23 h/day over a period of 6 months. This pres-
ents, however, a problem of patient compliance due to 
restrictiveness of such a regime.
This can be managed with the use of various adhesive 
tapes and plasters to cover the already closed wounds. 
These keep the scar undisturbed and protected and can 
be more comfortably used over a longer period of time. 
A randomized controlled study of 70 patients using a 
paper tape on their wounds showed this to be an effec-
tive strategy [15].
More specialized dressings and skin substitutes can 
be utilized to promote epithelization by creating matrix 
for a cellular migration, providing a protective barrier, 
and sustaining a moist environment. Silicone gel and 
sheets have been shown to reduce unfavorable scarring 
in randomized controlled studies [16, 17], but a meta- 
analysis of 13 trials involving 559 patients demonstrated 
only weak evidence that silicone can reduce the inci-
dence of abnormal scarring in high-risk individuals [18]. 
That said, silicone softens the scar and makes it more 
comfortable for patients, and because of this, it may be 
worthwhile. It is recommended to use silicone dressing 
for at least 12 h a day for 2 months from 2 weeks after 
the surgery.
Topical flavonoids such as Contractubex (Merz 
Pharma, Frankfurt, Germany) or Mederma skin care 
gel (Merz Pharmaceutical, Greensboro, CA, USA) 
are used to keep scars soft and supple from the second 
week after surgery for up to 6 months. Their efficacy has 
been found to be controversial, but the dietary bioflavo-
noid quercetin can also improve scarring by suppress-
ing fibroblasts proliferation via inhibition of SMAD 
intercellular transduction protein [19]. This reduces the 
actions of the transforming growth factor β (TGF-β) 
and reduces fibroblasts activity.
In clinical practice, cosmetic surgeons can use botu-
linum neurotoxin type A (BoNTA) immediately after 
wound closure. Injections of 15U of the preparation 
have been shown to improve scarring following 6 weeks 
after a facelift [20].
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Platelet-rich plasma (PRP) has gained some popu-
larity for skin anti-aging, chronic wound management, 
and scar therapy. Treating a wound bed with PRP has 
shown substantial benefits for better wound healing, 
an increased survival of  fat grafts, and the accelera-
tion of  cartilage and bone grafts uptake in a system-
atic review of  15 randomized controlled trials and 25 
case- controlled studies [21]. Platelet-rich fibrin also 
proved to be useful in aesthetic and reconstructive 
applications.
Also note that the repeated microneedling at a con-
trolled depth and topical application of retinol and 
marine collagen reversed both atrophic and hypertro-
phic scars to a more even appearance after a year of 
treatment [22].
Attempts have been made to use Imiquimod 5% 
cream to prevent keloid recurrence after surgical exci-
sion. This topical immune-response modulator stimu-
lates a proinflammatory cytokine interferon, which 
increases collagen breakdown. Imiquimod also alters 
the effects of apoptosis-associated genes. The prepara-
tion was used daily for a fortnight after a surgery. Later 
it was applied three times a week under a dressing for 
1 month. The efficacy for this prophylaxis is still ques-
tionable, as the result of this double-blinded, placebo- 
controlled pilot study showed no significant difference 
in keloid deposition rates in the two groups [23].
Interesting research in tissue bioengineering is 
attempting to bring new methods to improved wound 
healing, with an objective of even achieving scarless 
regeneration. Promising results have been obtained using 
therapies based on TGF-β. A preparation of a recom-
binant version of this cytokine marketed as Juvista by 
Renovo Laboratory (Manchester, UK) has shown a 70% 
improvement in wound healing and scar appearance in 
a phase 2 trial. Other therapies developed by the same 
company include formulations of mannose- 6- phosphate 
(M6P; marketed as Juvidex) and another preparation 
based on estradiol (marketed as Zesteem) [24].
In another study, a preparation of recombinant 
human TGF-β3, called avotermin, was injected before 
the skin was cut and again 24  h after wounding in 
healthy participants. A dose of 50 ng/100 μl of the drug 
per linear centimeter achieved 10% scar improvement 
in three double-blinded, placebo-controlled studies. 
However, the investigators had commercial interests in 
TGF- β3, which may weaken their claim. Nevertheless, 
they demonstrated a strict adherence to established pro-
tocols and research standards and conducted a rigorous 
statistical analysis [25].
Whatever methods be used to prevent unfavorable 
scarring, they must be initiated early enough to influ-
ence the processes of tissue healing. Failure to do so 
might lead to florid scarring that might subsequently be 
more difficult to treat.
45.4   Treatment of Scars Following 
Aesthetic Surgery
Pronounced scarring following surgery is common. Up 
to 40% might display hypertrophic scar features, and 
6–16% of these will evolve into a keloid scar (especially for 
patients of African descent). Scar atrophy can result from 
wound infection and inflammation, but it is less common.
If, after all other precautions, a scar begins to display 
features of pathological healing, or is simply too notice-
able, treatment plans are still available and can do much 
to remediate the situation. Management of scars after 
aesthetic surgery does not differ from any other scar 
treatment. The therapeutic approach can be divided into 
surgical and non-surgical methods.
45.4.1   Surgical Treatments
Traditionally, keloid and hypertrophic scars are excised, 
and tissue is manipulated to allow for more favorable 
healing afterward. Excision with a linear, tension-free 
closure should be used. If the defect is a large one, or 
the wound is in a high skin-tension area, a split- or full- 
thickness skin grafting with Z-plasty or W-plasty skin 
closure flaps is recommended (. Fig.  45.3). That said, 
hypertrophic scars tend to spontaneously regress for up 
to 12 months. This suggests that surgical revisions should 
probably not be made until after a 1-year time window.
  . Fig. 45.3 Skin flap closure with W-plasty following a forehead 
lift with hair line advancement surgery
Management of Scarring Following Aesthetic Surgery
392
45
Hypertrophic scars rarely recur after excision, and as 
such, they require no adjuvant treatments following the 
removal. Keloid scars on the other hand can redevelop 
after excision. This will occur in more than half  of all 
cases, and so will likely require additional therapeutic 
interventions. This should be undertaken immediately 
after their excision.
The most commonly used methods for controlling 
keloid scar recurrence include corticosteroid injections 
or radiotherapy. In recent years, a mixture of 5 fluoro-
uracil (5FU) with triamcinolone has become popular. 
The cocktail is made of 3 ml of 5FU 50 mg/ml and 1 ml 
of the steroid containing 40  mg/ml triamcinolone. An 
amount of 1–2 ml of this mixture is used for postopera-
tive tissue infiltration at the level of excision plane and 
below it. The treatment can be repeated after full epithe-
lization of the wound. Postoperative pressure should be 
applied for 6 months afterward, and silicone gel should 
be used for 2 months.
45.4.2   Non-surgical Treatments
A broad range of treatments with no cutting of scars 
is available for cosmetic surgeons. Therapeutic choices 
vary from injectable preparations to interventions based 
on a variety of technologies. Whatever method is being 
employed, it should be done in a timely fashion with 
stepwise escalation to the next option if  the current one 
is ineffective.
The first choice of non-surgical treatment for early 
keloid formation scars is intra-lesional corticoste-
roid injections. In most cases, steroid injections act as 
a second- line modality for hypertrophic scars if  less- 
invasive options, such as silicone dressings and support 
tapes, fail.
Corticosteroids suppress inflammation in the wound; 
they reduce collagen and glycosaminoglycans synthesis, 
while increasing collagen degradation. Glucocorticoids 
inhibit fibroblasts proliferation and enhance their degra-
dation. The most commonly used preparation is triamcin-
olone 40 mg/ml. A dose of 10 mg or 40 mg is injected into 
a scar, every 1–2 months. Usually two to three sessions are 
all that is required. Scars become flatter and softer with 
alleviation of symptoms, but a recurrence rate is common 
and can be as high as 50%. Side effects of corticosteroid 
injections are telangiectasia and dermal atrophy. Topical 
corticosteroid preparations in the form of creams can be 
massaged into post- blepharoplasty scars. Corticosteroid 
tapes are sometimes applied after aesthetic surgery for 
breast reduction. However, efficacy of topical corticoste-
roids for scar reduction has never been proven.
Laser treatment modality is next in line after corticoste-
roids. Pulsed-dye laser (PDL) with a wavelength of 585 nm 
is most commonly used for treating scars as a stand-alone 
intervention or in addition to other treatments. Pulse-shots 
at a fluency of 3.5–5.5 J/cm2 are fired to cover the entire 
scar, making sure the shots do not overlap. Treatments 
are repeated four to six times every 3 weeks. Hyper- and 
hypopigmentation, blistering, and small bruises are pos-
sible after the treatment but tend to be transient.
It is sometimes possible to destroy scar tissue by sub-
jecting it to subzero temperatures. For example, cryo-
therapy with liquid nitrogen is an option. Rarely used 
to improve scars caused by cosmetic surgery, it can be 
nevertheless be useful for pretreatment before repeat-
ing injections of corticosteroids in smaller scars. This is 
especially the case if  laser is unavailable or has proven to 
be ineffective.
Recalcitrant scars can be subjected to radiotherapy. 
This method is mostly combined with the surgical exci-
sions but is rarely used in aesthetic practice. The methods 
of radiotherapy choice include superficial X-rays, elec-
tron beam therapy, and low or high-dose-rate brachy-
therapy. They all can be utilized, but not for breast or 
tummy tuck scars due to their potential for carcinogenic 
side effects.
Atrophic tissue healing is another type of pathologi-
cal scarring, leading to a volume loss and an indented 
surface formation. The treatment objective is to restore 
the tissue deficit and to reinforce thinning and hollowing 
of the scar surface. For the former, corrections are made 
with fillers and fat grafts. The latter can be achieved 
with stimulating therapies such as microneedling, 
Sculptra injections, free-floating PDO, or gold threads. 
An example study using a controlled depth micronee-
dling approach proved to be effective for both atrophic 
and hypertrophic scars [22]. Early keloid scars can also 
respond to this type of intervention (. Fig. 45.4). This 
suggests that all pathological scars may have similar 
pathways for regression.
Another promising modality for treatment of scar-
ring is botulinum neurotoxin type A (BoNTA). Keloid 
can be treated successfully with diluted BoNTA and the 
technique for that is described in 7 Chap. 8.
45.4.3   Long-Term Management of Patients 
with Scars After Cosmetic Surgery
Even with a conscientious effort made by both the 
patient and the surgeon to control and optimize scar-
ring, some patients will find it difficult to accept their 
outcomes. These patients may be especially psychologi-
cally vulnerable if  their scars are located in areas easily 
seen. Examples include the eyelids after a blepharo-
plasty or in front of the ears after pretragal incision used 
during rhytidectomies.
The surgeon has some responsibility to help these 
types of patients come to terms with their scars. The 
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process will likely involve a combination of approaches, 
including counseling, cognitive behavioral therapy, cam-
ouflage makeup, and medical tattooing. A multidisci-
plinary approach to the psychological rehabilitation of 
the patient will likely be needed to succeed. The surgeon 
should be empathetic to the patient’s perspective and be 
prepared to help with what can often be a lengthy and 
arduous process.
45.5   Conclusion
Scarring after cosmetic surgery is the same as that from 
accidents, disease, or other types of surgical procedures. 
The context, however, is completely different. Patients 
primarily choose aesthetic surgery for non-essential 
health reasons. Because of this, when poor scarring 
occurs, cosmetic surgeons are at much higher risk for 
patient dissatisfaction and potential legal action.
A wide variety of therapeutic and prophylactic 
methods are available for the management of posttrau-
matic and postsurgical cicatrix. Thus, the main point of 
this chapter is that surgeons should put into place pre-, 
intra-, and postsurgical processes to mitigate scarring 
risks.
Finally, regardless of the objective severity of cos-
metic surgical scars, this is an important component of 
a patient’s perception of the success of the procedure. 
Surgeons should take an active role in providing patients 
with information and compassionate support.
  . Fig. 45.4 Keloid scar following rhytidectomy was improved by using microneedling and topical retinol
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Take-Home Messages
 5 Always bear in mind that a scar following aesthetic 
surgery impacts a patient far more than its objec-
tive evaluation and it negatively contributes to the 
overall perception of otherwise successful treat-
ment.
 5 Carefully evaluate the potential risk of scarring 
and take appropriate measures to reduce it prior 
to surgery.
 5 Manage patient expectations by providing suf-
ficient explanation of the range of potential out-
comes.
 5 Avoid offering elective cosmetic surgery to people 
at high risk of very poor scarring or to those with 
highly unreasonable expectations.
 5 Plan and execute an appropriate surgical tech-
nique.
 5 Employ prophylactic measures and treatments in 
a timely fashion.
 5 Take active measures to minimize the formation 
of keloid and hypertrophic or atrophic scarring 
should they occur.
 5 Keep careful records (written and video) of the 
consultation process, surgical techniques, and 
postsurgical treatments, making specific mention 
of the management of scarring.
 5 Provide emotional and medical support to a 
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46.1   Introduction/Background
A child is not a miniature adult. Although physiological 
healing process is not different in children, their growth 
potential gives them some specificities in terms of heal-
ing and scaring. Disturbance of healing process or inap-
propriate wound treatment will lead to pathologic scar. 
Pathologic scars can disrupt growth in children.
46.2   Healing Specificities in Children
46.2.1   Fetal Healing
Experimental and clinical studies point that fetal heal-
ing is scarless [1]. Fetal healing mechanisms are still 
poorly known, although many endogenous and exog-
enous factors seem to differ from those of  adult heal-
ing mechanisms. The main difference probably lies at 
the level of  the immune system and the inflammatory 
response. All these studies concern different animal 
species and any extrapolation towards human species 
should be cautious.
Macrophages are known to be the major agents 
of the inflammatory response and tissue regeneration 
process in adults. In early gestation, healing process is 
accomplished with poor influx of macrophages, while 
the influx of macrophages in the wound is more impor-
tant at the end of gestation [2]. The embryo seems to be 
able to heal without macrophages, and therefore with-
out undergoing inflammatory response. Nevertheless, 
the embryo is able to respond to inflammatory stimuli 
[3]. Explanation for this paradox could be the imma-
turity of the inflammatory system, but we need further 
exploration to understand this ambiguity.
Collagen is scarce in the healing wound due to the 
lack of response of the fibroblasts to transforming 
growth factor beta 1 (TGFβ1). TGFβ1 induces glycos-
aminoglycan synthesis all along gestation: glycosamino-
glycan is much more important than collagen in the scar 
matrix in fetus [4].
Amniotic fluid provides the fetus with an environment 
rich in growth factors necessary for its development. High 
concentration of hyaluronic acid in the amniotic fluid has 
been supposed to be the extrinsic and intrinsic factor of 
non-inflammatory fetal healing [5]. Further experimen-
tal studies need to prove that the quality of fetal wound 
healing is due to intrinsic factors [6]. Even if scarless fetal 
healing mechanisms are uncertain, absence of inflamma-
tory response seems to be the key point.
Nevertheless, at the end of gestation, inflammatory 
response appears and scar becomes visible. Further 
exploration of fetal healing and better knowledge 
should allow for promising clinical applications.
46.2.2   Pediatric Peculiarities in Healing
Very few data on this subject is available in the literature. 
Nevertheless, “healing behavior” is peculiar and varies 
all along childhood [7].
 5 0–6 months
Infants before the age of 6  months heal very 
fast and with very discreet scar. It happens as if  
the inflammatory response was immature, therefore 
attenuated. Perhaps some phenomena of prenatal 
period are perpetuated after birth.
 5 2 years – teenage
On the contrary, the inflammatory expression of 
the scar dominates this period, and the phenomena 
of remodeling seem amplified, major, and disabling. 
The few comorbidities of healthy organisms and the 
physiological mechanisms linked to growth are an 
undeniable asset for the good evolution of the child’s 
wounds. Scarring is often very fast but can be explo-
sive. Hypertrophic scaring could be considered as 
physiological at this age, as it is constant.
 5 6 months – 2 years
The evolutive pattern of scar is unpredictable at 
this age, sometimes still discreet, sometimes already 
very inflammatory.
46.2.3   How to Manage Wound Healing 
in Children
As the inflammatory response is constant and “explo-
sive,” the healing process must be carried out over a 
short period of time to prevent excessive production of 
collagen.
Except for children under palliative care, most of 
the wounds can undergo surgery: mechanical cleans-
ing, suturing, grafting, flaps. Before, instead of or after 
surgery, we use dressings or negative pressure wound 
therapy (NPWT).
Management of pain is essential and difficult: pain 
and fear are often entangled; level 2 painkillers are not 
recommended before 12  years old. Therefore, level 3 
painkillers are often necessary but to be administrated 
in health institutions. Inhalation of 50–50% N2O–O2 
mixture and any adjuvant technique of analgesia may 
be useful (hypnoanalgesia, video distraction, virtual 
reality, etc.) [8, 9].
Surgical techniques have to be adapted according to 
age, psychomotor development, thickness of teguments, 
and potential of growth. Thinner sutures are used with 
young children. Rapid absorbable sutures that generate 
an inflammatory response are to be avoided on exposed 
areas. On the contrary, intradermal slow absorbable 
sutures are a good option to avoid marks. Cyanoacrylate 
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tissue adhesive may be used but is appropriated for very 
superficial wounds (. Fig. 46.1).
Dressings have to be painless at removal, easy to 
apply. It is better to realize dressing with hand rather 
than with forceps because it is quicker and less fright-
ening. Topics should be elementary; healing is rarely a 
problem in pediatric practice as child’s body continu-
ously synthesizes tissue for growth. Therefore, NPWT 
is most often rapidly effective, preparing wound to be 
grafted. Flap indications are therefore less frequent in 
pediatric practice than in adult practice.
46.3   Pathological Scars
Scar is the result of the healing process. Ideal scar is thin, 
flat, white, supple, elastic, and painless, but it exists and 
is perfectly identifiable under microscope (. Fig. 46.2).
Pathological scars are due to dysregulation of heal-
ing phenomena, especially due to the dysregulation that 
occurs during the modeling phase. This results in pro-
longed or definitive inflammation and are called hyper-
trophic or keloid scars [10].
46.3.1   Clinical and Histological Aspects
At the beginning of their evolution, it is not possible to 
distinguish hypertrophic scars from keloid scars: both 
remain very inflammatory beyond the normal period, 
red, hot, tense, and itchy. Only the evolution can distin-
guish them (. Fig. 46.3).
 5 Hypertrophic scar: despite a marked and prolonged 
inflammation period, the inflammatory signs will 
eventually be amended, leading to scar enlargement 
and fibrosis resulting in a thick scar. Histologically, 
collagen is abundant, is immature (collagen III in 
excess), is organized in more flat bundles than in a nor-
mal dermis, and contains nodules. Secretion of trans-
forming growth factor β (TGFβ) and platelet derived 
growth factor (PDGF) is abundant. Fibroblasts are 
numerous, responsible for the secretion of collagen in 
excess. Mast cells are numerous, secreting histamine 
which is probably responsible for pruritus.
 5 Keloid scar: evolution goes on forever, leading to exten-
sion of lesions beyond the initial limits of the scar, with 
persistence of inflammatory signs. Sometimes, telangi-








  . Fig. 46.1 a–d: Good-quality intradermal suture; e and f: good- quality epidermal suture; g and h: cyanoacrylate tissue adhesive; i: poor-




we found the same characteristics as for hypertrophic 
scar but with a complete disorganization of the col-
lagen arrangement: there are no more beams but col-
lagen fibers randomly connected and poorly oriented.
46.3.2   Easing Factors
Most often, pathological scars occur on a particular field. 
Although the causal link is not always obvious, there are 
several factors that contribute to the same scar.
 5 There is no male or female predominance. The sex 
ratio for pathological scars is equal to 1.
 5 There is no evidence of hereditary factor. However, 
some authors have questioned about the hereditary 
characters of keloid scars [11].
 5 Nevertheless, the ethnic origin seems to be decisive. 
A preponderance of keloid scars is observed in sub-
jects with pigmented skin (Black, Asian, Métis, etc.). 
Some studies submit biological hypotheses related to 
the characteristics of pigmented skins, but there is no 
evidence at the moment.
 5 The age of  the patient is a determining factor. 
Hypertrophic and keloid scars are exceptional in 
the elderly and are very common in young people 
and around puberty. It is therefore essential for 
pediatric surgeons to be familiar with this scar 
pathology.
 5 The location of the wound plays a clear role: the 
scapular region, the ear area, and the midline of the 
trunk (presternal and medio-abdominal) are particu-
larly concerned by the development of pathological 
scars.
 5 The types of wounds, such as deep burn, soiled 
wounds, and presence of foreign bodies in the 
wound, will prolong the cleansing phase and there-
fore the inflammatory phenomena.
 5 Hormonal factors: the preponderance of pathologi-
cal scars at the time of puberty, the impact of preg-
nancy on scars, and the regression of hypertrophic 
scars at the time of menopause seem to evoke the 
role of estrogen. Some studies have looked at the use 
























  . Fig. 46.3 Pathological scars: a: evolution diagram; b: hypertrophic scar; and c: keloid scar
  . Fig. 46.2 “Ideal” scars
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Although all these factors may have been suggested 
as favoring pathological scars, only the age, the ethnic 
factors, and the location of the wound are really the 
determining factors. Mechanism of occurrence of these 
pathological scars is not yet totally understood.
46.3.3   Prevention and Treatment [13]
Treatment is often disappointing. Many treatments have 
been proposed, but they are quickly abandoned as they are 
ineffective. The physio-pathological approach of mecha-
nisms has helped rationalize treatments, particularly by 
acting on inflammation. Nevertheless, the results often 
remain below the expectations of the patient and the phy-
sician.
Prevention, especially in high-risk population such 
as pediatric patients, is often effective.
 5 Prevention of pathological scars
 5 To be really preventive, treatment must be applied as 
soon the wound is healed: a few days after primary 
closure or as soon as epimerization is achieved in sec-
ondary closure.
 – Reduce inflammation
 – Decrease healing time by activating mechanical 
cleansing.
 – Decrease healing time by using surgical means 
of cover (grafts, flaps).
 – Use non-absorbable or slow absorbable intra-
dermal sutures for which inflammatory response 
is less intense.
 – Massage of recent scars reduce edema and 
mechanically dissociate molecular aggregates. 
Therefore, massages have a real mechanical 
action. Massages are most often made with an 
emollient cream because they are better toler-
ated. However, massages would be just as effec-
tive as without cream.
 – Pressure therapy will also reduce edema, induc-
ing a relative tissue hypoxia, thereby minimizing 
local inflammation. Silicone sheets act in a same 
way on inflammation [14] (. Fig. 46.4).
 – Reduce tension on the scar
 – Use Langer’s or Borges’s lines in surgery.
 – Reduce tension on scar by using strips and 
splinting adjacent joints.
 5 Treatment of pathological scars
Some treatments are well established, even if  their effi-
cacy is disappointing. Other treatments are rather per-
spectives and subject to current studies. However, the 
evolution of these scars is sometimes so hopeless for the 
patient that minimally invasive techniques deserve to be 
tempted, even if  their efficacy is very inconsistent.
Several techniques can be associated either simulta-
neously or successively.
When a scar becomes inflammatory, the earlier the 
treatment will be initiated, the more effective it will be.
Preventive techniques can be used as treatment tech-
niques, but they will not be so effective.
 5 Massages
 5 Pressure therapy (. Fig. 46.5)
 5 Silicone sheets
 5 Steroids have been used for a long time to treat 
pathologic scars.
  . Fig. 46.4 Silicone sheet on hypertrophic scar
a b c d




They can be used as topic (cream or ointment) or 
in situ injections.
Local application may be dangerous in children, 
as the dose of absorbed steroids is difficult to evalu-
ate. An overdose in steroids can lead to a partial or 
complete Cushing syndrome, which may occur due 
to abusive local application of corticoids.
For this reason, we prefer local injections of ste-
roids in pediatric practice, using steroids of delayed 
action with minimal general effects. Injection is pro-
ceeded with dermo-jet or syringe and needle after 
local anesthesia (. Fig.  46.6). Nevertheless, it is 
often more comfortable to do so under general anes-
thesia in day surgery unit. Injections can be repeated 
until at least 2 months between two injections so as 
not to overload the scar with steroids. The only con-
traindication is the local infection. Most of the time, 
flattening of the scar and disappearance of func-
tional signs (pain, pruritus) are observed.
However, it is necessary to be cautious because 
steroid overload results in epidermal thinning and 
appearance of telangiectasia.
 5 Cryotherapy [15] may be used with inconsistent 
results: it may be used by contact or with freezing 
needles (. Fig. 46.7).
 5 Surgery will induce more inflammatory reactions. 
Therefore, surgery on its own will not solve the prob-
lem: it must be a step in a therapeutic scheme, associ-
ating several techniques, and must be proceeded only 
at the end of the scar maturation, when the inflam-
matory phenomena have calmed down.
Intralesional excision is the only way to prevent 
recurrence, but it does not mean that it consistently 
gives the expected result. The volume of the scar will 
decrease, which will improve comfort and release 
functional effects, and perhaps the residual scar will 
be more receptive to the complementary treatments 
that are necessary to avoid recurrence.
An injection of delay-steroids can be performed 
in the dermis of the banks of the excision wound 
before closing by non-absorbable sutures. Pressure 
therapy will be prescribed systematically as soon as 
healing is achieved (10 days).
 5 Radiations (X-rays, radium, iridium) may be pro-
posed, but they are not to be used in pediatric prac-
tice because of carcinogenic risk.
 5 Anti-neoplastic substances [16] have been the subject 
of research in recent years: Interferons, mitomycin 
C, bleomycin, 5-fluorouracil [17] are all molecules 
that are used as injections in situ, either alone or in 
combination with corticosteroids. These treatments 
have to be used very carefully and when there is no 
other therapeutic possibility in pediatric practice 
because of their interaction with growth.
 5 Laser therapy has been tried on pathological scars 
[18] and is easy to use in pediatric practice under 
contact local anesthesia.
 5 Finally, it may be wise, in some situations, to allow 
time for inflammatory phenomena to decrease spon-
taneously before initiating aggressive therapies. This 
implies to support the patient because the evolution 
often seems hopeless.
Multiple treatments are proposed for these pathological 
scars due to their uncertain efficacy and the difficulty in 
achieving results that satisfy the patient (and the physician).  . Fig. 46.6 Intralesional injection of  steroids
a
b c
  . Fig. 46.7 a–c: Cryotherapy
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46.4   Defective or Disgracious Scars
Some scars are defective or disgracious and do not dis-
turb the healing process: hypotrophic or enlarged scars, 
adherent scars, dyschromic scars, tattooed scars, granu-
loma, technical defects, etc.
All scars that present defects but no pathology of the 
healing process can be corrected by surgery, irrespec-
tive of the technique used: surgical recovery, adipocytes 
transplantation (Coleman technique), dermabrasion 
with or without vaporization of autologous keratino-
cytes, etc. However, it will be necessary to wait at least 
until the end of the maturation phase to consider sec-
ondary surgery.
Deciding what is the best time to practice this sur-
gery is sometimes difficult in pediatric practice. Apart 
from functional indications for which the question 
hardly arises, the indications are most often aesthetic. It 
is then necessary to ensure the child’s actual motivations 
and that this is not a parental request.
If  the child is voluntary, a “contract” must then be 
passed with the child or teenager emphasizing three key 
points:
 5 The disgracious scar will be replaced by a scar that 
hopefully will be of better quality. There is no magic 
rubber for scar.
 5 Postoperative scar management (e.g., strips, silicone, 
possible splint, and refraining from sportive activi-
ties) is constraining but necessary for a good result.
 5 If  the patient is not able to undergo scar manage-
ment, surgery is useless.
All these scar anomalies can be corrected, but it is of 
course essential to prevent and avoid them.
46.5   Scars and Growth
During the first 2 years after healing, the scar matures. 
Contraction of the scar is current and normal due to the 
action of myofibroblasts. After this period of time, the 
scar is quiet and more or less definitive.
In pediatric practice, the patient will grow with 
the scar. This may induce tractions because the scar is 
fibrous and does not grow as much as the patient. If  
this is not corrected, it may induce bending because of 
asymmetric growth.
Psychomotor development may be disturbed by scars. 
Physicians should be aware that psychological impact of 
scars evolves over time all along childhood and teenage. 
Therefore, pediatric patients with scars have to be fol-
lowed all along their growth period to detect the need 
for scar surgery, whether it is for functional purpose or 
for aesthetic and psychological purpose.
46.6   Conclusion
Healing physiology is not different in children but the 
importance of inflammatory mechanisms makes the 
resulting scar different. Hypertrophic scar is physiologi-
cal in pediatric practice and has to be prevented.
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Excessive scarring of the genitalia is uncommon despite 
the fact that approximately 30% of men are circum-
cised worldwide with minor complication rates and no 
mention of scarring. After burn injury, severe scarring 
is commonly seen in the perineal or suprapubic area 
but rarely occurs to the outer genital organs. Skin anat-
omy, inflammatory response, and hormonal metabo-
lism differ between the genitals and the extragenital 
skin and might therefore account for differences in 
wound healing and scarring. Owing to the high regen-
erative potential of genital skin, the management of 
genital wounds aims at the stabilization of the local tis-
sue with infection control and demarcation of necrotic 
tissue. Reconstruction of tissue defects and scars com-
prises plastic surgical skin tissue transfer, including flap 
surgery and the restoration of the urinary and sexual 
function in an interdisciplinary context.
 z The objectives of this chapters are as follows
 5 To give an overview on the epidemiology and cause 
of genital scarring
 5 To point out specific features of genital skin anatomy
 5 To inform on the pathophysiology on skin wound 
healing, lymphology, and scarring of the outer geni-
tals in women and men
 5 To describe management of genital wounds and tis-
sue defects
 5 To give an overview on conservative and surgical 
treatment of genital wounds and scars
47.1   Epidemiology and Etiology of Genital 
Wounds
Since the ancient times, male circumcisions have been 
practiced by many communities mainly as a purity or 
religious ritual (. Fig.  47.1). Female genital mutila-
tion (FGM)/cutting is still a common practice in many 
African countries, no matter the religious background 
of the people. Little is known on the incidence and 
severity of scarring in the genital area despite the fact 
that 30% of all men on the earth are circumcised [37].
Aside from circumcisions and ritual cuttings, other 
types of  injuries, infections, tumors, skin diseases, 
and malformations can lead to abnormal wound heal-
ing and scarring of  the genital skin. Due to the mul-
titude of  causes for genital trauma with subsequent 
scarring, a general incidence for genital scars is diffi-
cult to provide. As a consequence, I will first describe 
different origins for genital tissue defects with special 
focus on cutaneous wound healing and scarring of 
the outer genitalia, that is, the vulva, the scrotum, 
and the penis. For wound repair of  the urinary system 
or the vagina and uterus, I would like to refer to the 
corresponding urological or gynecological literature 
and textbooks.
 z Causes for genital scarring and fibrosis
 5 Trauma, for example, burns, injuries to the pelvic 
area, autoerotic injuries, genital self-mutilation
 5 Sequelae of any type of infections, for example, 
Hidradenitis suppurativa/acne inversa, Fournier 
gangrene, viral infections, and sexually transmitted 
diseases
  . Fig. 47.1 Ritual act of  cir-
cumcision: relief  in the tomb of 
Ankhmahor at Saqqara (sixth 
dynasty, 2345 BC; © CC BY-SA 
3.0). This work is licensed under 
a Creative Commons Attribu-




 5 Dermatological diseases, for example, various 
inflammatory autoimmune diseases (e.g., Behçet’s 
syndrome or Crohn’s disease with ulcerations, pyo-
derma gangraenosum), bullous skin diseases, lichen 
sclerosus et atrophicus (LSC), lichen planus
 5 Religiously/culturally motivated, for example, cir-
cumcisions, FGM/-cutting, or self-inflicted proce-
dures, for example, piercings, tattoos, foreign body 
insertion
 5 Iatrogenic/surgical interventions, for example, aes-
thetic surgery, cosmetic procedures, including foreign 
body application; circumcision for phimosis; treat-
ment of malformations; genital reassignment surgery
 5 Tumors followed by oncological surgery with/with-
out radiation therapy
 5 Lymphatic disorders: congenital (Milroy’s or Meigs’ 
disease) or acquired (e.g., after tumor surgery, lymph 
node excision, irradiation; infectious: filariasis)
The literature search for causes of genital wounds that 
result in scarring yields some information on burns or 
combat injuries with concomitant affection of the geni-
tal organs. The incidence of burn injury to the genita-
lia is rare with around 1.5% [15] but associated with a 
higher mortality rate with 17% in comparison to non-
genital burns (4.7%) [12]. In contrast to perineal and 
inguinal scar contractures that are a common sequela 
after burns to the lower abdomen and groin area, exces-
sive scarring is rarely attributed to the outer genital 
organs (. Fig. 47.2).
The shift from high velocity to more explosive weap-
ons during the end of the twentieth century and the use 
of improvised explosive devices resulted in more geni-
tal injuries in military conflicts than noticed before [1]. 
Genitourinary trauma accounted for only 5.3% of all 
combat-related injuries being mostly associated with 
severe polytraumatic incidents (62.1%). There are no 
reports on scarring after this type of injury.
Infections are quite common in the genital area. 
With several body orifices being anatomically located 
in close relation, a multitude of  commensal microbia 
is constantly present. In case of  small lesions, lacera-
tions, or immune incompetence of  the host, germs can 
penetrate into deeper tissue layers and cause severe 
infections, for example, abscesses or gangrenes with 
high mortality rates. Predisposed patients develop 
chronic infections of  the sweat glands and hair folli-
cles in the groin and genital area, also called hidrade-
nitis suppurativa or acne inversa. Without appropriate 
treatment, they develop fistulas with recurrent infec-
tions and subsequent scarring to the perineal crease. 
The annual prevalence of  hidradenitis suppurativa 
is around 1% with an estimate of  70 million patients 
worldwide [14].
Fournier gangrene is a life-threatening necrotizing 
fasciitis of the genitalia with an incidence of 1.6/100,000 
patients that affects mostly men (10:1) [18]. The only 
sufficient cure is the radical surgical debridement of the 
entire infected and necrotic tissue with accompanying 
antibiotic treatment. Massive tissue losses can be the 
consequence with plastic surgical reconstruction after 
successful elimination of the infection. Because the tis-
sue defects have a tendency to spread over the groin area 
as well, scar contractures are found as remnants of this 
type of genital infection (. Fig. 47.3).
  . Fig. 47.2 Inguinal scar contracture with impairment of  the 
abduction of  the right leg but without involvement of  the big labia 
after severe burn injury
  . Fig. 47.3 Inguinal hypertrophic scarring with scar contractures 
after hidradenitis suppurativa and recurrent inguinal infections that 
culminated into a Fournier gangrene with vast tissue excision and 
postoperative scarring. The resulting scar contractures impaired the 
abduction of  the left leg. Please note the instable scar with recur-
rent ulceration between the prepubic area and the left inguinal crease 
adjacent to the contracture (arrow). Aside from severe scarring, a 
buried penis grade III is present. No scarring of  the penile skin or 




The incidence of autoerotic or self-inflicted genital 
injuries has not been determined but is extremely low 
and patients present sporadically. Genital lesions can 
derive from blunt, strangulating, or penetrating trauma 
and go as far as to incomplete or total amputations. 
Self-inflicted genital injuries can derive from neurotic, 
psychotic, and various other types of mental disorders 
or associated diseases and are seen in gender dysphoric 
conditions.
It appears that the genital skin tends more to chronic 
ulcers or fistulas seen in various dermatological dis-
eases or infections than to healing with excessive scar 
formation. Despite reports on scarring after Behçet’s 
syndrome, it seems that the genital skin heals with atro-
phic rather than hypertrophic scarring. Of note, exces-
sive swelling of the outer genitalia is another feature 
that occurs typically after trauma or surgery and that 
differs to skin wound repair of other body areas. Genital 
lymphedema can be idiopathic and associated with con-
genital malformations but is also present after cancer 
therapy and infections, for example, filariasis. Chronic 
genital lymphedema can ultimately lead to severe fibrotic 
conditions and elephantiasis.
The genitalia differ in several regards from other 
body sites. Urogenital and anal orifices and the sur-
rounding skin are colonized by resident microbia in a 
moist environment, there is abundant highly elastic skin 
around the external genital organs that is loosely fixed 
to the pelvic bone, and the cutaneous microstructure, 
inflammatory reaction, and hormonal responsiveness 
are different compared to other tissues. In the following 
sections, all these features and their influence on genital 
wound repair and scarring will be elucidated in detail.
47.2   Genital Skin Anatomy 
and Microstructure
For a better understanding why genitalia behave dif-
ferently to skin from other body sites, the macro- and 
microstructure of the genital skin and organs, including 
lymphatics, are important and will be described in the 
following paragraphs. The knowledge of the anatomy 
is the prerequisite for the appropriate conservative and 
surgical treatment.
47.2.1   Development of Genital Organs 
and Homology Between Sexes
Female and male outer genitals derive from the same 
embryological origins with different development 
depending on the sex of the infant. The develop-
ment of the external genitalia is presented in detail in 
. Fig. 47.4, which depicts the common origin of respec-
tive  anatomical entity at the embryonic stage and further 
differentiation into male and female genitalia during the 
fetal period. . Table 47.1 summarizes the homologous 
anatomical and microscopic structures.
47.2.2   Anatomy of Male and Female 
Genitalia
The main anatomical differences between genital and 
skin of  other body areas are the lack of  fat tissue to the 
scrotum, penis and labia minora, the absence of  hair 
to the penile and small labia skin, and the reduced or 
missing cornified epidermal layer of  the epithelium of 
the prepuce and the small labia. With regard to biome-
chanics, the genital skin is highly elastic and flexible 
because it lacks a firm attachment to underlying struc-
tures, for example, bones or cartilage. A subcutane-
ous smooth muscle layer, also called Dartos muscle or 
Tunica dartos that is found in the scrotum and big labia, 
is reminiscent of  the subcutaneous carnosus muscle in 
fur bearing animals and enables a gliding between the 
skin and the underlying connective tissue. Of note, the 
anatomic relict of  the carnosus muscle in humans is the 
Scarpa fascia that is found in most other parts of  the 
body underneath the subcutaneous fat layer. The geni-
talia are devoid of  fat and the Scarpa fascia. Instead, 
the Dartos fascia is found here. An illustration of the 
genital anatomy for both sexes is shown in . Figs. 47.5 
and 47.6.
 z Summary: Differences Between Genital and 
Nongenital Skin
Genital skin differs from other regions:
 5 No subcutaneous fat tissue, no Scarpa fascia; instead 
tunica dartos with smooth muscle cells (scrotum and 
big labia) or dartos fascia with loose attachment of 
the skin (penis)
 5 No tight attachment of the skin to underlying bone 
or cartilage
 5 Little or no keratinizing epithelia—mucous surfaces 
of small labia, glans, and prepuce
 5 Reduced hair growth—skin of scrotum and big labia
 5 Moist environment due to mucous surfaces and a 
multitude of mucous secreting glands
 5 Constant microbial contamination—cutaneous, gen-
itourinary, and intestinal flora
47.2.3   Microstructure of the Genital Skin
The skin is the largest organ of the human body that 
protects us against biological (e.g., microbial), chemical 
(e.g., acids, bases), physical (e.g., irradiation, pressure), 
thermal (heat, cold), and other threats, including exsic-
 U. Mirastschijski
409 47
cation. We sense our environment by touching things 
and we are simultaneously protected by pain receptors 
in the skin. We regulate our body temperature via the 
cutaneous vasculature, and we communicate with other 
people via mimics or smell—all provided by our intact 
skin. To ensure its protective function, the skin possesses 
an intricate architecture that can vary depending on the 
body site, for example, eyelid, back, palms, oral cavity, 
or genitals. The general micro-structure of the skin com-
prises three different entities, that is, the epidermis, the 
dermis (cutis) consisting of the upper/papillary and the 
lower/reticular dermis, and the subcutaneous fat layer. 
Epidermis and dermis are separated from each other by a 
basement membrane that is also the limit for vasculature. 
The epidermis is free of vessels and nourished by means 
of oxygen diffusion. The subcutaneous fat is  separated 
from the deeper fat by a superficial fascia, called Scarpa 
fascia. In the genitalia, this superficial fascia is called 
Colles (women) or Dartos fascia (men). This anatomical 
structure is of importance because it serves as a fixation 
point between fat layers whereas it provides elasticity and 
sliding properties to the genital skin.
The cutaneous surface of moist environments is 























































hair follicles. Instead, different types of glands, for 
example, apocrine and eccrine, secrete fluids that mois-
turize the surface and protect the mucous epithelium 
(. Figs. 47.7, 47.8, and 47.9).
47.3   Pathophysiology of Genital Wound 
Healing, Lymphedema and Scarring
Cutaneous scarring with tissue fibrosis is the result of a 
postnatal wound healing process. The longer the dura-
tion and the excessive the inflammatory response in the 
healing course, the more likely is the development of 
aberrant scarring and severe tissue fibrosis. However, 
scar formation varies depending on the body site, the 
skin architecture and anchorage to underlying struc-
tures.
Little is known about the pathophysiological pro-
cesses of genital cutaneous wound repair except for the 
general clinical statement that genital wounds heal fast, 
with enormous swelling and almost invisible scarring. In 
the following, I will describe features that are different 
between the genitalia and the skin of other areas of the 
body and that influence acute wound healing or chronic 
scarring (. Fig.  47.10). It is beyond the scope of this 
chapter to include urethral, vaginal, or anal epithelial 
repair; tissues that derive from different developmen-
tal origins and with differential healing behavior (e.g., 
ulcerations, adhesion or fistula formation) compared to 
genital skin.
47.3.1   Skin Architecture and Biomechanics
The genital skin has to master many challenges, for 
example, fast volume changes during sexual activity, sex 
steroid sensitivity with permanent hormonal changes, 
the presence of several body openings with constant 
commensal microbial presence, and infectious threats 
deriving from sexual contacts. In that context, it is 
breathtaking to understand the extraordinary adaption 
of the genital skin to its multiple tasks. To encounter 
aforementioned challenges, it is excellently equipped 
anatomically and physiologically to address specific fea-
tures of the genital microenvironment.
Notably the male genital skin has to manage fast 
volume changes that occur during sexual activity and 
for thermal regulation of the testes. These physiological 
tasks are addressed by several means: (i) abundance of 
skin tissue on both the penile shaft and the scrotal sac, 
(ii) the Dartos fascia on the penile shaft and the Tunica 
Dartos with the Dartos muscle in the scrotum, and (iii) 
a high amount of elastic fibers in the dermis. In all three 
items, the genitalia differ from skin of other body areas 
that is firmly attached to the underlying structures by a 
rather immobile fat layer. High skin elasticity and abun-
dance of tissue are the prerequisite for tension-free acute 
wound healing with unapparent scars—optimal repair 
conditions present in the genitalia. A drawback is the 
tendency of the outer genitals to enormous swelling and 
edema after surgery or trauma. The good side is that due 
to its elasticity and intricate lymphatics, the swelling of 
the genital tissue resolves as fast as it occurs in healthy 
subjects.
  . Table 47.1 Homology of  male and female genitalia
Male Female Microscopic structure of the skin
Glans penis Glans clitoridis Multilayered, nonkeratinizing epidermis, dermal tissue with abundant innervation
Penile foreskin Clitoral prepuce Outer face of  foreskin: epidermis with cornified layer;
Inner face: nonkeratinizing epidermis; mucous epithelium; no subcutaneous fat tissue
Frenulum penis Frenula clitoridis (pair) Nonkeratinizing, mucous epithelium, no fat tissue
Penile shaft skin Small labia Penis: epidermis with cornified layer
Labia: outer surface with thin cornified layer; inner surface: no cornified layer
Both sexes: no hair; no subcutaneous fat tissue; many elastic fibers;
Penis: highly flexible attachment to underlying tissue via Dartos fascia (fascia penis 
superficialis)
Scrotal skin Big labia Hair bearing epidermis (labia: only outer surface), epidermal cornified layer
Labia: subcutaneous fat layer and smooth muscle cells






  . Fig. 47.5 Anatomy of  the male external genitalia. Of  note, no fat tissue is present in the penis or scrotal tissue underneath the skin. 




47.3.2   Moist Environment and Bacterial 
Colonialization
Urethral, vaginal, and anal orifices are transition zones 
between mucous membranes and keratinizing skin. As 
depicted previously, parts of the genitalia are covered 
by little or nonkeratinizing squamous epithelia. The 
secreted fluids of multiple glands prevent the exsicca-
tion of mucous membranes and provide a moist micro- 
environment. It is an established fact that moist wound 
healing contributes to faster wound closure and reduced 
scarring.
The proximity of the genital skin to different orifices 
is Janus sided. Aside from the beneficial moist milieu, 
bacterial load and stringent body fluids such as urine 
bear constant threats to the fragile mucosal skin lack-
ing the protective epidermal cornified layer. And again, 
the genital mucosal skin is well prepared to address both 
biological and chemical challenges. In contrast to other 













  . Fig. 47.6 Anatomy of  the female external genitalia
Multilayered, non-keratinizing
squamous epithelium
Skin type found in moist environments,
e.g. glanspenis/clitoridis, innerside of
the prepuce, oral cavity
Skin type found over the entire body;














  . Fig. 47.8 Histological section from the abdominal skin stained 
with hematoxylin-eosin. (By courtesy of  Dr. D.  Jiang and Dr. 
Y. Rinkevich, Helmholtz Center Munich. © All rights reserved)
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genital skin are equipped with a fast immune response 
to bacterial presence. By secreting antimicrobial pep-
tides (AMPs) and defensins and with glandular mucous 
fluids, bacteria are held at a distance. The immune 
response is fast and so is the resolution with quick con-
version of M1 to M2 macrophages and reduced expres-
sion of proinflammatory cytokines [38]. Upon injury, 
skin cells increase the interleukin (IL)-1α production 
15-fold in comparison to vaginal epithelial cells with 
only threefold increase. IL-1β and tumor necrosis fac-
tor (TNF)-α were only secreted by cutaneous epithelia 
in contrast to mucous epithelial cells [9]. With regard 
to profibrotic mediators, TGF-β is significantly elevated 
in normal skin keratinocytes but not in mucosal epithe-
lia and without induction of fibrotic processes in the 
underlying connective tissue. In summary, the reduced 
inflammatory response of mucosal epithelia to injury 
is sufficient to ensure wound closure without inducing 
serious scarring.
47.3.3   Hormonal Influences
47.3.3.1   Increased Aromatase Activity 
and Intracrine Estrogen Production
Hormone responsivity of  tissues has profound impact 
on wound healing. Estrogens accelerate wound clo-
sure whereas testosterone delays healing [10]. Skin is a 
major source of  extraglandular sex steroid hormones 
that are produced from circulating dehydroepiandros-
terone (DHEA, [24, 28]) (. Fig. 47.11). The intracel-
lular enzyme aromatase converts DHEA downstream 
into the weaker estrogen Estrone or via testosterone 
into the more potent 17β-estradiol. Both estrogens act 
via the estrogen receptors (ERs) α and β, and stimulate 
keratinocyte and fibroblast migration [11]. In genital 
fibroblasts, aromatase expression is androgen depen-
dent. Interestingly, estrogens stimulate fibroblast con-
tractility without increasing alpha-smooth muscle actin 
expression or myofibroblast differentiation [31]. Upon 
a
b c
  . Fig. 47.9 Microstructure 
of  the skin from different body 
areas: a arm, b penis, and c 
small labia. Note the dense 
dermal structure with multiple 
vessels in a and lose collagen 
bundles in b and c with high 
similarity of  penile and labial 
skin. Scale bar in all sections 
500 μm. (Elastica-van-Gieson 
stainings; by courtesy of  Dr. 





mechanical wounding, aromatase activity increases 
400-fold in keratinocytes with increased intracellular 
bioavailability of  estrogens. Testosterone reduces aro-
matase activity, albeit this effect is not present in case 
of  low oxygen levels in tissues. Estrogens reduce the 
cellular inflammatory response via downregulation of 
the proinflammatory cytokine macrophage migration 
inhibitory factor (MIF) [6], by reduced TLR-4 medi-
ated MAPK activation, by the reduction of  macro-
phage infiltration into wounds and by dampening the 
proinflammatory signaling of  IL-6 and TNF-α [5]. 
Of  note, estrogens are also important antioxidants 
that reduce cellular oxidative stress and apoptosis and 
increase keratinocyte migration and collagen synthe-
sis by dermal fibroblasts [38]. In menopausal women, 
cutaneous estrogen insufficiency manifests by atrophic 
skin changes and a diminished defense against reactive 
oxygen species.
• Non-keratinizing mucous epithelia
• Elastic fiber rich dermal tissue
• Absence of fat tissue 
• Dartos muscle / fascia




and scarring  
Biomechanics
• Reduced mechanical tension
due to lack of firm tissue fixation 




• High hormonal sensitivity of
genital skin due to
differential expression of
sex steroid receptors 
• Reduced inflammatory







• Increased epidermal water
evaporation due to absent /
reduced keratinizing epithelia
• Abundance of mucus
secreting glands
• Constant exposure to
microbia from the urogenital
tract and intestines










Fast wound healing 
Atrophic scarring,
Tissue shrinkage 
  . Fig. 47.10 Factors that influence genital wound repair and differ from skin from other body regions
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47.3.3.2   Androgen and Estrogen Receptor 
Expression in Genital Skin
Estrogens act via estrogen receptors and testosterone via 
androgen receptors (ARs) that are expressed by many 
cell types. For instance, AR expression differs between 
genital and nongenital skin with upregulation in genital 
fibroblasts. In general, it appears that sex steroid hor-
mone expression is higher in stromal cells than in epithe-
lial cells, implying higher responsiveness of fibroblasts 
to hormonal influences. Aside from receptor expres-
sion, the binding capacity and metabolism of sex ste-
roid hormones differs between different skin regions. 
Testosterone binding capacity of the AR is higher in 
genital compared to nongenital skin cells [39] from both 
sexes—independently of age—and testosterone degra-
dation is up to 30 times faster in genital skin compared 
with nongenital skin [30].
Sex hormone receptor expression in genital skin dif-
fers between prenatal and adult genital skin due to the 
terminal differentiation of the external genitalia that is 
dependent on hormonal influences. In fetal skin, ARs are 
very similarly expressed in both sexes with the absence 
of ARs on the preputial skin, penile shaft/labia minora, 
and scrotal skin/labia majora. ARs are expressed in the 
tissue of the glans and inner prepuce of both sexes and 
in the stromal tissue of the labia.
ER was present in fetal female genital skin except for 
labia minora and majora [16] and prominent ER stain-
ing was found in the entire developing fetal penis includ-
ing skin, glans, inner prepuce, and stromal cells [4]. 
Interestingly, ARs and ERs were colocalized in penile 
tissues.
Less detailed information is available with regard to 
adult genital skin. In women, ARs are found in kerati-
nocytes and fibroblasts of the labia majora and minora 
and in the adjacent extragenital skin. ER immunoposi-
tivity was found in the labia minora and nongenital 
skin. There are no differences in sex hormone receptor 
expression between pre- and postmenopausal women. 
Progesterone receptors are not present in genital skin. In 
men, ARs were located to basal keratinocytes and stro-
mal fibroblasts of the penile foreskin. No AR expres-
sion was found in nongenital cutaneous keratinocytes or 
 fibroblasts but in fibroblasts of hair follicle papillae or 
in cells of pilosebaceous ducts and glands, skin struc-
tures that are influenced by androgens in their function 
and structure. The highest intensity of AR staining was 
noted in genital skin. ERs were similarly expressed in 
postnatal penile skin with localization to basal epithelia 
and stromal cells adjacent to the urethra and the urethra 
itself  with age-dependent reduction [27]. Aromatase is 
not colocalized with estrogen receptors, and levels of 
aromatase, ERα, and ERβ decrease with age [27].
In summary, ARs and ERs are highly expressed in 
genital skin in contrast to skin of other body areas with 
fast binding and degradation of testosterone or conver-
sion into estrogen by increased aromatase activity. A 
summary of hormonal differences between genital skin 
and nongenital skin is given in . Table 47.2.
47.4   Acute Wound Repair of Genital Skin 
After Trauma
Depending on the type and severity of the injury, two 
main clinical symptoms characterize traumatized geni-
talia, namely enormous bleeding and swelling. When 
the hematoma resolves and the swelling disappears, 
wounds heal with almost no visible scarring even after 
major trauma. An example for invisible genital scarring 
is the fact that one-third of the male world population 


















  . Fig. 47.11 Simplified 
description of  intracrine sex 
steroid hormone production by 
skin cells. Dehydroepiandros-
terone (DHEA) is released by 
the adrenal cortex and further 
processed directly into estrogens 
by aromatase or into testos-
terone by 17-β-hydroxysteroid 
dehydrogenase (17-β-HSD). 
Estrone is reversibly oxi-
dized into 17β-estradiol by 
17β-OHSD. Testosterone can 
be either directly converted into 
the estrogen 17β-estradiol by 
aromatase or irreversibly con-
verted into dihydrotestosterone 




scarring to the preputial skin. Despite major trauma 
after female genital mutilation/cutting, the genital skin 
heals uneventfully if  the girl survives postinterventional 
bleeding and infection. Cutaneous genital infections are 
disastrous and can rapidly lead to septic conditions with 
high lethality. Fournier gangrene is one example of nec-
rotizing fasciitis of the genital skin with a mortality rate 
of 80% without surgery [18]. Obviously, the loose archi-
tecture of genital skin provides optimal means for rapid 
subcutaneous bacterial spreading leading ultimately to 
multiple organ failure and death.
The aforementioned characteristics of  the outer 
genitalia with regard to architecture, fixation, micro- 
environment, hormonal influences, and reduced 
inflammatory response orchestrate the fast resolution 
of  the acute wound healing process with reduced scar 
formation. Albeit the apparently scar-free wound heal-
ing properties of  genital skin, there is one exception. 
The ventral part of  the prepuce ends in the so-called 
frenulum that is fixed to stromal tissue of  the ventral 
side of  the glans bridging to the penile shaft. In case 
of  excessive tissue removal during circumcision, the 
frenulum can shrink and pull the glans in direction of 
the penile shaft that is painful, gives discomfort during 
erection, and can cause reduced sensation of  the glans 
penis (. Fig. 47.12).
47.5   Chronic Inflammatory Diseases 
of the External Genitalia and Tissue 
Fibrosis
Several skin diseases with autoimmune background 
can affect the outer genitalia with chronic inflamma-
tion leading to tissue shrinkage and atrophy. Chronic 
lymphedema after tumor surgery and/or irradiation, 
with infectious background or due to congenital malfor-
mation of lymphatic organs, leads to tissue fibrosis and 
stiffening and to verruca-like epidermal changes in the 
long run. In the following, the most common chronic 
diseases and changes to the genital skin will be described 
in detail.
47.5.1   Lichen Sclerosus et Atrophicus/
Balanitis Xerotica Obliterans
Lichen sclerosus et atrophicus (LSC), also called bala-
nitis xerotica obliterans in men, is the most common 
chronic dermatitis localized to the mucous membranes 
and skin of  the genitalia. LSC is found in females and 
males with a ratio of  up to 10:1 and has a double peak 
in females with occurrence in prepubertal and post-
menopausal age. In men, LSC is the most common 
  . Table 47.2 Hormonal differences between genital skin and nongenital skin
Genital skin Nongenital skin
Androgen receptor Higher expression in labia majora and minora
Upregulated in fibroblasts and basal keratinocytes
Colocalization with ER
Only present in hair follicles and pilo-sebaceous 
duct keratinocytes
Low expression in extra-genital skin
Estrogen receptors Highly expressed in penis and labia minora
Restricted to basal keratinocytes and stromal 
fibroblasts
Expression decreases with age
Lower expression compared to vulva or vagina
Expressed by keratinocytes and fibroblasts
Absence in skin appendages or blood vessels
Testosterone Higher AR-binding capacity of  testosterone
30 times faster degradation
Reduced effect on aromatase activity in low-oxygen 
conditions
Higher rate of  conversion into DHT
Higher 5-α-reductase activity with irreversible 
formation of  DHT
Estrogens No conversion of  17β-estradiol into the weaker estrone
Stimulate fibroblast contractility without 
alpha-smooth-muscle actin (ASMA) expression
Threefold increased metabolism of 
17β-estradiol into estrone
Aromatase Higher activity in fibroblasts with conversion of 
testosterone into 17β-estradiol
Dose-dependent reduced activity by testosterone
Aromatase expression androgen dependent
Expression in skin fibroblasts, keratinocytes of 
the outer root sheath and in terminal hair 
follicles and in cells of  sebaceous glands and 
ducts
AR androgen receptor, ER estrogen receptor, DHT dihydrotestosterone
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cause of  acquired phimosis [3] and affects the glans 
and the prepuce (. Fig.  47.13). Typical symptoms 
are a thickening of  the foreskin that impairs retrac-
tion. Whitish plaques can extend over the entire glans 
with affection of  the urethral meatus followed by ste-
nosis and voiding problems. In females, the anogenital 
area is frequently affected forming an 8-shaped efflo-
rescence around the vulva and the anal orifice with 
opaque plaques and papules. In chronic disease, these 
atrophic lesions can lead to a complete destruction of 
the vulva with resorption of  the small labia, narrow-
ing of  the vaginal introitus and burying of  the clitoris. 
The patients’ quality of  life is severely reduced due to 
chronic pruritus, pain, and obstipation resulting from 
painful defecation in women and painful erection and 
hygienic problems in men. Of note, LSC is associated 
with squamous cell carcinoma formation in 5% of 
women [17] and up to 30% of  men [3]. Other LSC-
associated diseases comprise autoimmune thyroiditis, 
vitiligo, or pernicious anemia. The etiology of  LSC is 
not fully understood. An autoimmune origin with T- 
and B-cell-driven response to a yet unknown antigen is 
discussed because dense T-lymphocytic infiltrates with 
concomitant vasculitis and extensive tissue destruc-
tion are found in LSC-tissue sections. The glycoprotein 
extracellular matrix protein 1 (ECM 1) has been tar-
geted as putative autoantigen because the symptoms 
of  the autosomal recessive disorder lipoid proteinosis 
resemble acquired LSC with thickening and scarring 
of  skin and mucosa [2]. Another related dermatosis, 
the Lichen planus, presents with similar symptoms and 
etiology that makes the initial differentiation between 




  . Fig. 47.12 Examples for 
scar formation to the male 
genitalia. a Invisible scar after 
circumcision. Note differential 
pigmentation of  the outer 
penile skin and the remaining 
inner part of  the prepuce. b 
Scar after excessive circumci-
sion with shortening and scar-
ring of  the frenulum (arrow). 
c Scrotal scar (arrow) after 
multiple excisions of  silicone 





47.5.2   Behçet’s Disease
Aphthous stomatitis (oral ulcers) and genital ulcers are 
common features of Behçet’s disease. The etiology of 
the autoimmune vasculitis is unknown. The most com-
mon site for genital ulcer formation is the scrotum in 
men and the big labia in women. Interestingly, scrotal 
and big labia ulcers heal with normal, nonhypertrophic 
scarring whereas skin lesions on the small labia heal 
without scars similar to oral ulcers [22].
47.5.3   Chronic Inflammation due to Foreign 
Body Reaction
The size of the penis is of central importance for many 
men who build their self-confidence on the penile length. 
In that context it is not surprising that a plethora of dif-
ferent substances were used for penile enlargement over 
centuries. Vaseline, paraffin, liquid mercury, silicone 
(. Figs. 47.12c and 47.14), or cod liver oil were injected 
in to the scrotum or under the penile skin for girth 
enhancement with catastrophic complications such as 
granuloma formation, infections, swelling, and local tis-
sue necrosis [33]. Alternatively polymethylmethacrylate 
(PMMA) microspheres or autologous fat are used as fill-
ers or silicone implants for permanent enlargement [19, 
20]. The placement of permanent, alloplastic foreign 
body material in an environment populated by a variety 
of commensal microbes is risky due to the inherent dan-
ger of infection. In case of granuloma, tissue necrosis, or 
implant infection, the foreign material must be removed 
with subsequent tissue loss. Foreign body materials can 
initiate a chronic inflammatory process with cutaneous 
thickening and subcutaneous tissue fibrosis leading ulti-
mately to a shrinkage of the entire penile shaft. Details 
of the surgical treatment after  foreign body injection are 
shown in . Fig. 47.14.
47.5.4   Congenital and Acquired Genital 
Lymphedema and Tissue Fibrosis
Lymphedema is defined as low- (<1 g/100 ml) or high- 
(>1 g/100 ml) protein fluid retention in the interstitial 
space [8]. Congenital malformation of  lymphatic ves-
sels can cause chronic lymphedema. Acquired lymph-
edema occurs after surgery (. Fig. 47.15) for various 
reasons (cancer, gangrene, foreign bodies, etc.), irradia-
tion, or filariasis. The swelling is due to an imbalance 
of  the production and absorption, including drainage 
of  the lymph that can be caused by an obstruction, dis-
ruption, or insufficiency of  the lymph vessels. Chronic 
lymphedema affects the surrounding tissue with fibro-
sis and the skin with rhagades and recurrent infections, 
blister formation, wart-like epidermal excrescences, 
and scarring.
47.6   Treatment of Genital Wounds 
and Scars
The manifold the causes for wounding and scarring to 
the genitalia are, the diverging are the treatments as 
well. The choice of  the appropriate surgical technique 
is orientated on the depth, magnitude, and location of 
the defect and the quality of  the surrounding tissue. 
Needless to say that the delicate genital anatomy of 
both sexes and the variety of  tissue defects or scars that 
can extend over to adjacent body areas require highly 
skilled surgeons with expertise in reconstruction of  the 
genitalia. Aside from defect closure, restoration of  the 
voiding and sexual function are central to each recon-
structive procedure and require often an interdisciplin-
ary setting.
  . Fig. 47.13 Patient with Lichen sclerosus et atrophicus to the 
penile glans and after several circumcisions and reconstruction of 
a buried penis. Note central ulceration (thin arrow) surrounded by 
opaque and shiny skin changes of  the glans including meatal stenosis 





  . Fig. 47.14 Penile skin necrosis after silicone oil injection. a Tis-
sue necrosis over the entire penile shaft preoperatively. b, c Intraop-
erative situs b after meticulous excision of  all foreign body material 
and granuloma c. d Postoperative result after full-thickness skin 





47.6.1   Treatment of Acute Wounds 
and Tissue Defects
Small acute wounds and tissue defects are commonly 
closed primarily due to the abundance, elasticity, and 
loose fixation of the genital skin and tissue. For instance, 
primary closure of scrotal defects after up to 50% tis-
sue loss is feasible, otherwise local or distant flaps (e.g., 
bilateral gracilis flaps; . Fig. 47.16) or skin grafts are 
used to reconstruct the scrotal sac [18]. Superficial skin 
loss to the penile glans recovers by conservative treat-
ment, and deeper tissue defects need skin grafting, for 
example, with oral mucosa or thin split-thickness skin 
[34]. Penile shaft defects can be elegantly closed using 
preputial flaps in case the patient is not circumcised. 
Otherwise, split-thickness or full-thickness skin grafts 
are the current state-of-the-art for penile shaft recon-
struction. Drawback of free skin grafts is the lack of 
cutaneous elasticity and sensation. In case of abundant 
scrotal tissue, local neurovascular flaps (e.g., midline 
raphe scroti artery, MiRA-flap) can restore—at least in 
part—tissue texture and sensation [26].
The reconstruction of the female genitalia is similar 
as in men with primary closure of small lesions and flap 
surgery in case of larger tissue losses. An elegant proce-
dure for reconstruction of the big labia is the anterior 
obturator artery perforator flap (aOAP) that is har-
vested from the groin area [29]. Interestingly, the flap tis-
sue heals with minimal scarring once it is transferred to 
the vulva in contrast to its harvest site in the groin that 
is prone to hypertrophic scarring (personal communica-
tion with Prof. Dr. Uwe von Fritschen, Desert Flower 
Center, Helios Klinikum Emil von Behring, Berlin).
47.6.2   Treatment of Genital Wounds 
and Scars After Burn Injury
The golden standard for treatment of  partial-thickness 
(deep second degree) and full-thickness (third degree) 
burns is debridement of  the necrotic tissue with skin 
grafting. Due to its high regenerative potential, a more 
conservative approach is the current clinical practice 
for genital skin until full demarcation of  the necrotic 
tissue. As mentioned earlier, the genitals are capable of 
ba
  . Fig. 47.15 Penile lymphedema a Penile lymphatic vessels and 
lymph drainage on the dorsal side of  the penile shaft (arrow). b 
Fournier gangrene on the base of  a chronic acne inversa with mas-
sive tissue resection of  the prepubic and groin area after necrotizing 
infection with a multiresistant Staphylococcus aureus and different 
enterobacteriaceae. Note massive swelling of  the penile shaft (arrow) 
with burying of  the glans due to loss of  dorsal lymphatic vessels and 
drainage pathways after debridement
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compensating for rather large tissue losses with only 
minor scar formation [15]. In contrast, severe scarring 
and scar contractures are common to the groin and 
perineal area that can impair the movement of  the 
lower extremities (. Figs.  47.2 and 47.3). After scar 
excision, local skin flaps, for example, Z-plasties, are 
usually used for wound closure and tension release. 
In case of  insufficient local tissue, distant, pedicled, 
or free flaps with microvascular anastomosis are stan-
dard procedures and belong to the repertoire of  a plas-
tic–reconstructive surgeon (. Fig. 47.17). For further 
detailed information, the recently published textbooks 
for genital [25] or burn [13] reconstructive surgery are 
recommended.
47.6.3   Gender Reassignment Surgery
Genital gender reassignment surgery comprises the for-
mation of a female vulva, including big and small labia, 
a clitoris with a clitoral hood and a vagina in male-to- 
female transsexuals and the formation of a penoid with 
functional elongation of the urethra and a scrotum in 
female-to-male transsexuals. Highly specialized surgeons 
perform these extraordinary procedures in an interdisci-
plinary context with astonishing results. Notably scar-
ring is minimal despite extensive surgical intervention to 
the genitalia with relocation of ontogenetically homol-
ogous entities. My profound fascination for absent or 
minimal genital scarring derives from patients after gen-




  . Fig. 47.16 Plastic–reconstructive surgery of  the scrotum with 
bilateral gracilis muscle flaps covered by a split-thickness skin graft. 
a Preoperative site with almost complete loss of  the scrotal tissue. 
Both testes are exposed (white arrow) with lymphedematous swelling 
of  the penis (arrowhead). b Intraoperative situs after debridement. 
Both gracilis muscles (white arrow) are mobilized and rotated into 
the defect by tunneling underneath the perineal crease. Harvest areas 
are depicted with arrowheads. c Postoperative site after 1 week with 
almost complete skin graft take. d Situation after 3 weeks with little 
scarring and a skin texture resembling the natural scrotal appear-




  . Fig. 47.17 Scar contractures to the inguinal and perineal region 
after burn injury. a Preoperative situs with scar contractures span-
ning over both groins that impair the range of  motion of  both legs. 
Of  note, the genital area, including the big labia, is devoid of  scar-
ring. Previous reconstructive surgery included local tissue transfer 
for scar release to the right groin (arrow). b Postoperative situs after 
multiple Z-plasties
ba
  . Fig. 47.18 Male-to-female transsexual patient after genital reas-
signment surgery. Note construction of  all vulvar structures with big 
and small labia, a clitoris covered completely by the clitoral prepuce 
and the vaginal entrance. a. ventral aspect, b. caudal aspect (By cour-
tesy of  Dr. Jürgen Schaff, PSC Munich)
 U. Mirastschijski
423 47
47.6.4   Treatment of Chronic Genital Skin 
Diseases
Chronic genital ulcers can originate from autoimmune 
diseases, infections, pressure sores, etc. Describing 
details on the systemic rheumatologic treatment of 
autoimmune disorders is beyond the scope of this chap-
ter. More information on diagnosis and therapy of der-
matologic autoimmune disorders is provided in excellent 
reviews [7, 32].
LSC in women responds well to topical corticoste-
roid ointments whereas phimoses in men require surgi-
cal intervention. Circumcision with complete removal 
of the penile foreskin is the gold standard that leads to 
relapse-free recovery from LSC [3, 7].
47.6.5   Lymphedema Treatment
Depending on the underlying cause of  noninfectious 
genital lymphedema, the treatment is primarily con-
servative with a complex decongestive physiotherapy 
(CDP), according to Földi [8]. To ensure permanent 
lymphatic drainage, compression therapy is recom-
mended not only in patients with lymphedema but 
also in patients after genital reconstruction. Surgical 
intervention in secondary genital lymphedema is con-
troversially discussed and should be limited to selected 
patients in the hands of  experienced surgeons and 
physiotherapists [23, 36].
The treatment of filariasis is antimicrobial; in case 
of genital elephantiasis, surgical removal of penile and 
scrotal tissue is indicated for debulking although clinical 
studies on the postsurgical outcome are scarce [21].
47.7   Postoperative Management for Scar 
Prevention
Postoperative excessive scarring of  the genitalia is 
rare and limited to free partial-thickness skin grafts 
to the penile shaft. In contrast, hypertrophic scarring 
and scar contractures are common to the perineal and 
inguinal area with postoperative compression therapy 
and mobilizing physiotherapy being imperative. With 
regard to the genitals, lymphedema formation is more 
common and an issue for intensive postoperative care. 
Standard or tailor-made individual compression gar-
ments are available and recommended for 3–6 months. 
Compression panties for women are available in dif-
ferent sizes. With regard to male compression therapy, 
the issue is more problematic due to difficulties in han-
dling penile compression stockings and the fixation to 
the penile base. Our group has developed such a penile 
compression stocking in cooperation with highly quali-
fied orthopedic technicians who produce individually 
tailored pressure garments for men after skin grafts or 
flap surgery with postoperative lymphedematous swell-
ing. After a short training period, all men were capable 
of  handling the stocking by themselves (. Fig. 47.19). 
a b c
  . Fig. 47.19 Postoperative treatment after reconstruction of  a 
genital and perineal defect after Fournier gangrene. a Preoperative 
site after multiple debridements. b Postoperative situation 4  weeks 
after defect closure with split-thickness skin grafts. c Adjuvant treat-
ment with tailor-made pressure garments to prevent excessive scar-
ring. Note separate compression panty for the perineal area and a 




We recommend the prescription of  at least two pairs 
of  garments to ensure daily changes and washing for 
better hygiene.
47.8   Conclusion
Hypertrophic scarring to the genitalia is uncommon, pos-
sibly due to the high regenerative potential of genital skin, 
the abundance and elasticity of the local tissue, and the 
rapid and reduced immune response to traumatic events. 
Chronic inflammatory diseases such as lichen sclerosus et 
atrophicus or chronic lymphedema lead to tissue fibrosis 
with epidermal thickening and to a shrinkage and atrophy 
with complete destruction of the genitalia in the long run. 
In contrast to the genital skin, hypertrophic scarring and 
scar contractures are frequently seen in body areas adja-
cent to the genitalia, for example, the groin or the perineal 
crease. The reconstructive procedures for scar release or tis-
sue defect coverage should aim not only at defect closure 
but also at the functional restoration of micturition and 
sexuality and should exclusively be performed by experi-
enced specialists preferably in an interdisciplinary setting.
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48.1   Background
There is no getting around it: a severe burn injury is a 
major life event that can dramatically disrupt a person’s 
life. The traumatic nature of the event, the long hos-
pitalization and co-occurring high pain intensity, and 
the suddenly changed appearance can have a profound 
impact on those affected. Along with medical advances, 
more people with severe burns survive their injury and 
live with scars in a society where a high premium is 
placed on physical appearance and attractiveness. Scars 
resulting from burns can have a conspicuous look and 
may capture attention from the environment. When 
scars are hypertrophic, they are typically firm, raised, 
red, and have a rough surface. Hypertrophic scars can 
be difficult to conceal when they are located at visible 
body parts. Also, scars in less visible areas can pose a 
burden on someone’s life in specific situations such as 
the swimming pool, or when the weather is warm and 
more revealing clothing is indicated at that time.
Living with scars may become even more compli-
cated in the current society. Professionals and academics 
are concerned about the changing notions of normal-
ity related to appearance and the increasing demands of 
beauty. A recent paper [1] mentioned that an increasing 
amount of people in the UK consult the plastic surgeon 
or use cosmetic products to look as good as possible. 
Pictures on social media are manipulated to present 
persons in the best possible way. Body image and the 
perception of bodies are changing and result in increas-
ing engagement in beauty practices that are justified by 
the new concept of normality. Unsurprisingly, living in 
a world that values beauty can be challenging for those 
with a visible difference. It can be particularly challeng-
ing for the individual himself  or herself  when there is a 
high personal standard placed on beauty. Also, society 
may be less acceptant toward those with a visible dif-
ference. Therefore, even minor scarring may increase 
the call for plastic surgery and cosmetic interventions. 
Underlying psychological problems may therefore be a 
point of attention.
This chapter has the general purpose to provide 
information about the psychological impact of  a 
burn injury and psychological difficulties that may 
be encountered when living with scars. Because sur-
vival rates have increased, more people live with the 
physical and psychological consequences of  burns. 
Consequently, appropriate psychosocial support and 
interventions that help burn survivors deal with scars, 
from a personal view and the view from the outside 
world, become increasingly important. Also, an under-
standing care environment including all professionals, 
that is, medical doctors, nurses, and physiotherapist, 
can improve outcomes. Learning objectives of  this 
chapter include to know the prevalence rates of  diverse 
psychiatric disorders that can develop in the aftermath 
of  burn injury, to be aware of  signals that may require 
an in-depth examination of  underlying problems, to be 
aware that psychological problems can affect the per-
ceptions of  scar outcomes, to have some knowledge of 
risk factors, and, finally, to have knowledge regarding 
psychological treatment options to support people liv-
ing with scars.
48.2   Psychological Problems After a Burn 
Injury
A burn event happens suddenly and can be life threat-
ening. This may elicit a broad range of psychological 
reactions. Although it is documented that a substantial 
group of patients has pre-burn existing psychological 
problems sometimes being the cause of the injury, for 
example, self-harm during psychosis or suicide attempts, 
one may also develop severe and long-term psychologi-
cal problems in response to the trauma or the adjust-
ment process to a changed appearance. In the acute 
phase of burn injuries, there is a large focus on physical 
recovery. Along with wound healing and with the stabi-
lization of the physical condition comes the realization 
that scars may be permanent and that appearance has 
changed. Facing this change may elicit feelings of grief  
and diminished body and self-esteem.
Severe psychological disorders may be encountered 
such as posttraumatic stress disorder (PTSD), depres-
sion, and anxiety. These disorders can become chronic 
when persons do not receive appropriate treatment. 
PTSD is included in the Diagnostic and Statistical 
Manual of Mental Disorders, 5th Edition (DSM-V) as a 
stress disorder and can develop in response to a trau-
matic event. PTSD comprises four symptom clusters: 
intrusions (intrusive thoughts and memories), avoid-
ance of  trauma-related stimuli, alterations in arousal 
and reactivity, and negative alterations in cognitions and 
mood. Initial higher levels of acute stress symptoms 
may be expected and can be regarded as normal reac-
tions to a distressing event. For a substantial propor-
tion of the patients, the high initial stress levels largely 
decrease within the weeks or months following the 
trauma. Severe symptoms of acute traumatic stress are 
reported in approximately 25% of patients admitted to 
a burn center. In a subgroup, however, they persist and 
become chronic. Prevalence rates of full PTSD after 
1 year postburn are around 10% and another 15% may 
display severe symptoms that do not meet all criteria, 
that is, partial PTSD.
Depression is a disorder typically characterized by a 
negative mood and diminished interest or pleasure dur-
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ing a period of 14 days or longer. One to 4 years after 
the burn event, about 10% fulfilled criteria of major 
depression with a postburn onset. Generalized anxiety 
disorder (GAD) entails the presence of excessive anxi-
ety and worry, is experienced as challenging to control, 
and is accompanied by physical or cognitive symptoms. 
GAD was also found to occur in about 10% of burn 
survivors after 1 year. This implicates that over time, the 
majority of people involved in a burn injury appear to 
adjust well and they will recover from initial high stress 
and depressive symptoms but a substantial subgroup 
will have long-term problems [2]. Clinical attention and 
screening is needed for PTSD, depression, and anxiety.
48.3   Psychological and Social Impact 
of Living with Scars
After a burn injury, when wounds are healing and scars 
start to develop, one has to adjust to this new situation 
in which appearance has changed. There are two per-
spectives that have a mutual influence: the individual 
perspective and the social perspective. The first refers to 
how people look at themselves and the latter perspective 
entails the social perspective.
48.3.1   Body-Esteem and Self-Esteem 
Concerns
People sustaining a burn injury can be faced with notice-
able visible differences resulting from large wounds that 
lead to scarring. Besides an altered appearance caused 
by these scars, functional limitations can occur if  they 
are located across joints. Both the visible and functional 
characteristics can diminish satisfaction with appear-
ance and can cause negative self-perceptions and diffi-
culties with social interactions that place people at risk 
to develop depression and (social) anxiety disorders. 
These psychological problems may be debilitating to 
daily functioning in key areas of living such as occupa-
tional functioning.
Important psychological concepts such as self- 
esteem and body-esteem can be damaged when a person 
is forced to live with visible differences [3, 4]. Self-esteem 
is a generic cognitive representation of the self. It is a 
multidimensional concept comprising the view of the 
person on the different abilities and characteristics. It 
influences how external information is processed, for 
example remarks or looks from other people. Body- 
esteem refers to the evaluation of one’s own body and 
can be viewed as a part of self-esteem [5]. After acquired 
disfigurement, there is a change in body-esteem that a 
person needs to adjust to.
It is reasonable to expect that persons with more 
severe scarring have greater difficulty integrating the scars 
in daily life than a person with minor scarring. But objec-
tive characteristics such as severity of the burn injury 
in terms of body area affected, the number of surgeries 
needed, or the number of affected body parts are only 
modestly related to psychological well-being, indicating 
that psychological factors may be more important. One 
such factor, importance of appearance, showed to mod-
erate the relationship between severity characteristics and 
body-esteem. This indicates that for those who attach lit-
tle value to their appearance, scars have a lower impact on 
their body-esteem. For people who highly value appear-
ance, scars negatively affect their body-esteem [6]. These 
aspects will be addressed in more detail below.
48.3.2   Social Self-Consciousness 
of Appearance
Scars can elicit negative reactions from the environ-
ment. This is well described after burns. Feelings of 
 stigmatization is one of the documented social prob-
lems of living with scars. This feeling may result from 
reactions from other people such as prejudices, discrimi-
nation, being ignored, intrusive behaviors such as star-
ing, intrusive questions and remarks, or even bullying 
[7]. People who have to deal with these reactions may 
develop a feeling of self-conscious and may perceive 
stigmatization which may affect self-esteem in a negative 
way. This in turn can induce avoidant behavior or some-
times (symptoms of) social anxiety. However, the impact 
of these reactions may differ across individuals. Some 
persons are more prone to feel stigmatized because of a 
stronger attentional bias toward stimuli that elicit fear. 
Psychological therapies can help dealing with these reac-
tions and build self-esteem to increase quality of life.
48.4   Factors Impacting Adjustment
48.4.1   Burn Severity and Scarring
In general, the objective severity of scarring showed to 
be a poor predictor of psychological adjustment. Both 
small and large defects can elicit body image concerns and 
diminish satisfaction with appearance. Therefore, it has 
been argued that a person’s subjective perception is a better 
starting point to assess how persons adjust [4]. However, 
the body of knowledge that shows (in)direct associa-
tions between injury severity and psychological problems 
is growing. One in-hospital study documented that there 
were no differences across groups with minor and severe 
burns, but dissatisfaction with appearance increased over 
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time in the group with more severe burns [6]. Another 
study found that persons with severe burns showed to 
ruminate more often—rumination is considered a cogni-
tive strategy in which perseverative negative thinking and 
impaired disengagement from negative stimuli is present—
which in turn predicted the level of depressive symptoms 
[8]. However, permanent scarring can act as a reminder to 
the burn event and has the potency to maintain psycho-
logical problems. Particularly when persons developed 
posttraumatic stress symptoms in response to the burn 
event, changes in appearances can trigger re-experiencing 
the traumatic event, which is an important symptom of 
posttraumatic stress disorder [9]. This indicates that more 
severe burns, possibly associated with more functional 
problems, can partly drive psychological adjustment. This 
does not exclude the fact that less extensive scarring can 
also elicit appearance-related concerns. Paying attention to 
the role of the scars in personal life is therefore warranted.
48.4.2   Facial Involvement
The face is a key figure in identity and it plays a key role 
in personal communication and expression of emotions. 
Sustaining a severe facial burn can be a devastating expe-
rience as it affects issues that are central to identity and 
social interactions. It is commonly expected that persons 
with facial disfigurement have more problems compared 
to persons with scars located at body parts that can be cov-
ered with clothes. Although there is evidence that living 
with facial burns may be more distressing than non-facial 
burns, the evidence is not that straightforward. One of 
the explanations put forward as to why people with facial 
burns may adjust relatively well is that they get used to 
negative reactions and are therefore better able to antici-
pate these unwanted reactions. Still, it is well established 
that persons with facial injury are presented with certain 
social challenges. Unwanted social reactions include star-
ing, intrusive questions and remarks, and prejudices. A 
study comparing persons with facial burns to persons with 
the face not involved found higher problems in several 
domains of functioning such as: emotions, that is, they 
perceived more anger and sadness, and they had more 
social problems due to appearance issues [10]. Examples 
are available illustrating that facial differences is given 
meaning by others, for example, a woman who is pitied 
because she is seen as a victim of abuse [11]. Due to these 
responses, the risk to develop social anxiety and avoid-
ance, low mood, and difficulties with relationship may 
increase and remains a concern across the lifespan. This 
is illustrated by a quote from a 60-year-old man who was 
injured during childhood: “There is a part of me that hasn’t 
quite made the hurdle to 100% adjustment. I’m comfortable 
at home and work, and among my circle of friends. Going 
out among strangers brings good and bad days” [12], p. 368.
48.4.3   Concealed Scars
Scars that can be covered with clothes trigger dilemmas 
such as when to show the scars or how to present your-
self  in certain social situations, how to deal with stares 
in the swimming pool and at the beach. This can lead to 
avoidance of these situations because of the reactions of 
others. Hidden scars can also affect intimacy and sexual-
ity, topics still surrounded with taboo. Scars can impact 
the ability to enjoy intimacy because one may not feel 
attractive and avoid being touched.
48.4.4   Gender
It is suggested that women are more frequently con-
cerned about their appearance and therefore find it 
harder to cope with visible differences. Little research 
provides direct support for this assumption but, in gen-
eral, there is evidence that women (with facial burns) or 
with more severe burns have higher depression scores 
and are less satisfied with appearance [13]. These find-
ings do not exclude the fact that also (young) men can 
be troubled by (facial) disfigurement and can question 
their physical attractiveness. There is, however, evidence 
supporting that women were more concerned about the 
change in appearance. Men predominantly reported an 
increased awareness of their whole body and not spe-
cifically their appearance. This may indicate there is, in 
general, a higher risk for women to develop appearance 
concerns compared to men because appearance is more 
valued by women.
48.4.5   Importance of Appearance
How persons view themselves is closely related to how 
they feel. The role of scars in psychological problems 
after burns is therefore not straightforward. A per-
son’s appraisal of his or her appearance constitutes an 
important factor of self-esteem. There is evidence for 
the importance that persons attach to appearance in the 
adjustment process after burns. Importance of appear-
ance showed to predict distress of living with burn dis-
figurement [6].
48.5   Interference of Psychological 
Problems with the Perception 
of the Scar
There is ample evidence that scar evaluation by health 
care providers does not match that of the patient and 
is a poor predictor of satisfaction with the treatment 
by patients. This may be frustrating for both the patient 
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and the health care provider. Understanding why these 
differences occur may diminish disappointment for 
both. Psychological problems such as depression can 
alter the way scars are perceived. As shown in a study 
[14], many patients with burns were well able to score 
scar characteristics within the same range as the profes-
sional. Persons scoring lower on self-esteem, however, 
rated their scars more troublesome, compared to the 
professional’s view. This particularly concerned hyper-
trophy, possibly due to the fact that this characteristic 
is most conspicuous. This indicates that the psychologi-
cal state influences how scars are viewed. Particularly 
the discrepancy between the patient’s and professional’s 
view may be a starting point to evaluate psychological 
factors.
Bradbury [11] underlines the importance of  recog-
nizing psychosocial issues in surgical decision-mak-
ing. Having a realistic view on surgical outcomes in 
terms of  what can be expected and psychosocial fac-
tors that may interfere with expectations and decisions 
is important. She proposed a three-staged approach 
in which individuals working with patients with vis-
ible differences all have some knowledge on influenc-
ing psychosocial factors, which forms the first stage of 
attention. If  indicated, patients can be referred to, for 
example, a clinical nurse specialist trained in counsel-
ing skills. In the event therapy is needed, referral to 
a psychologist should be considered. It is emphasized 
that understanding psychological needs surrounding 
surgery is imperative to ensure that personal needs 
are met.
48.6   Management
Over the last decades, a number of  interventions has 
been described that have the objective to help people 
dealing with challenges that result from living with a 
visible difference. Social skills training was among the 
first intervention programs aimed at expanding the 
arsenal of  responses to a variety of  reactions of  people. 
Other therapies include cognitive behavioral therapy 
(CBT) in which dysfunctional cognitions, appraisals, 
beliefs, and assumptions are identified and changed in 
order to learn more useful ways of  dealing with the vis-
ible difference [11]. CBT showed to have the strongest 
evidence of  effectiveness and can support patients to 
come to terms with the visible difference, it can help in 
decision- making, and showed to be effective in over-
coming social anxiety [3]. An online program called 
YPFaceIt, which includes elements of  CBT and social 
skills training, has shown improvement in persons with 
a visible difference [15], although more research in 
larger groups is needed.
Besides psychological therapies, peer support groups 
have shown to be beneficial to well-being of burn sur-
vivors. Talking to a person who experienced a similar 
event and is faced with the same challenges increases 
empowerment. This was illustrated in the next quote: 
“When you meet someone who really knows what you’re 
going through, you can discuss things in a different way” 
[16]. It is assumed that peer support groups can facilitate 
social sharing, which is a specific type of social support 
in which illness-related emotions are shared.
48.7   Conclusion
In sum, a burn injury can have devastating consequences 
in terms of psychosocial well-being. To predict who will 
adjust well after a burn injury comprises a complex-
ity of factors that should be taken into account. It is 
an interplay of resilience and vulnerability factors; it 
involves a dynamic process over time. Some indications, 
however, may be points of attention for professionals 
in burn care. How persons cope with the consequences 
strongly depends on the significance they place on the 
value of their physical appearance. Objective factors 
such as gender, burn extent, and the extent to which the 
scars are visible all showed to have some relation but 
are poor direct predictors of dealing with the impact of 
scars. However, there are relationships that are worth 
considering. If  there is a considerable deviation between 
the professional’s and the patient’s view on outcome, it 
is worth starting a dialogue with the aim to identify the 
causes. There is also a higher risk for women to struggle 
with visible differences as they, more frequently than 
men, value appearance and beauty; appearance may 
make up a larger part of their self-esteem and self-worth 
when compared to men. In men, functional problems 
may cause more problems.
The challenge for the health care provider is to be 
aware of signals that point to underlying psychologi-
cal difficulties and judge to what extent another (surgi-
cal) intervention adds to the well-being of the patient. 
A staged approach of professionals with knowledge of 
psychosocial problems associated with visible differ-
ences should become more custom as it is now. It is only 
when the patient receives understanding, and whether 
it is clear for all parties what is going on in the patient, 
that compliance, decision-making, and outcome can be 
improved. Interventions focusing at psychological com-
ponents may be indicated and can make a difference in 
the final outcome.
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Take-Home Messages
 5 Pay attention to the role of the scars in personal 
life.
 5 A changed appearance can have psychological and 
social consequences.
 5 Pay attention to signals that indicate underlying 
psychosocial problems.
 5 Be aware of underlying psychosocial issues in sur-
gical decision-making.
 5 Consider a stepwise approach to recognize psy-
chosocial issues.
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Medical makeup is a solution to hide scars and burns 
on the face as well as body, to both men and women. 
The objective is to reduce the psychological impact and 
to improve the patient’s self-image.
Various studies have highlighted the positive effect 
of medical makeup on the patient’s quality of life. 
With medical makeup, patient’s self-confidence gradu-
ally comes back.
49.1   Definition
The priorities for medical makeup are different from 
those for cosmetic makeup, which is primarily con-
cerned with fashion and trends. With medical makeup, 
first and foremost, camouflage solutions must be found 
that do not risk aggravating skin lesions, the objective 
being to reduce the psychological impact and to improve 
the patient’s self-image. The aim is therefore not to cre-
ate the “most beautiful makeup” but to find corrective 
products that are compatible with medical prescriptions, 
skin sensitivity, the expectations of the patient, and their 
ability to put on the makeup. Medical makeup is offered 
to both men and women and helps hide lesions on the 
face as well as the body.
49.2   Characteristics
 5 Makeup referred to as “medical” is formulated to 
guarantee complete safety even for damaged skin [1].
 5 Products are hypoallergenic and non-comedogenic 
and must contain a high sun-protection factor.
 5 The quality of textures is important to make it easier 
to apply the makeup and also to achieve a natural 
result.
 5 It is essential that the makeup be long lasting and 
resistant to water and sweat so that it lasts all day 
long. That being the case, the description of the 
product on the packaging should be checked to make 
sure they have all these qualities.
 5 The anhydrous forms, and stick and compact types 
are resistant because their outer oily phase is less mis-
cible with water. For the other formulas, the addition 
of polymer increases the adhesion of the product to 
the skin and thus limits its migration into the water.
 5 By using makeup products that are resistant to water 
and perspiration, the makeup hold may be greater 
than 10 hours.
 5 However, one last important point should be empha-
sized: the makeup must be easy to remove so as not 
to cause a secondary irritation.
49.3   The Benefits of Medical Makeup
Various studies have highlighted the positive effects of 
medical makeup on the patient’s quality of life, particu-
larly in the case of treatment for scars.
49.3.1   Psychological Impact
By learning how to conceal their skin imperfections, 
patients:
 5 Find it easier to look at themselves in the mirror
 5 Regain a more realistic body image
 5 Enjoy taking care of themselves again
 5 Grow in self-confidence
The patient’s self-esteem is boosted and they find it eas-
ier to look to the future.
49.3.2   Social Impact
After having concealed highly visible lesions, patients:
 5 Are less likely to notice the sometimes “intrusive” 
looks from other people
 5 Find other people look at them more approvingly again
 5 Maintain or return to social activities
 5 Are able to continue working if  they wish to do so
Their relationship with others is improved, thus avoid-
ing or putting an end to their sense of isolation.
49.4   Medical Makeup
49.4.1   Step-by-Step Process
49.4.1.1   Evaluation of Needs
The first step is to evaluate the needs and expectations 
of patients.
What products does the doctor recommend: emol-
lient, sun protection, etc.?
 5 What does the patient want to conceal?
 5 Does the patient want a highly corrective or a lighter 
type of makeup?
 5 Does the patient usually apply makeup?
 5 Always remember to adapt the advice according to 
sex, age, habits, and preferences.
 5 And to give advice that the patient can easily replicate.
49.4.1.2   Makeup Base
Applying an emollient cream is essential for correcting a 
skin imperfection. Skin must be moisturized and supple 
to be able to spread the foundation easily. If  the skin is 
not moisturized, the pigments contained in the makeup 
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will stick to raised areas of the skin, the correction will 
not be even, and the makeup will not last for the entire 
day. If  sun protection is required, apply this after the 
emollient cream, using it as the makeup base [2].
49.4.1.3   Color Correction
Thick makeup often gives the impression of a mask 
effect and sometimes gives burn patients’ faces a frozen 
look. The makeup must therefore be lighter so that the 
patient does not feel their personality has been stripped 
away after having it applied [3].
49.4.2   Using Color Correction Is the Best 
Solution to This Issue
By experimenting with color, we can reduce the intensity 
of imperfections, which means less foundation needs to 
be applied therefore obtaining a more natural result.
49.4.3   Complementary Colors
The principle is to superimpose two complementary col-
ors in order to neutralize them.
As we can see from the chromatic circle (. Fig. 49.1):
 5 Green is the opposite color to red
 5 Yellow is the opposite color to purplish blue
 5 Coral is the opposite color to dark blue
Therefore:
 5 A green corrector neutralizes imperfections that are 
predominantly red: inflammatory scars, rosacea, 
psoriasis, etc.
 5 A yellow corrector neutralizes imperfections that are 
predominantly purplish: ecchymosis, angioma, blue- 
toned dark circles, varicose veins, etc.
 5 A coral corrector neutralizes imperfections that are 
predominantly dark-blue: tattoos, nevus of Ota, etc. 
(. Fig. 49.2)
After having applied a corrector, the imperfection 
becomes slightly grey; therefore, it is not necessary to 
apply as much foundation.
49.4.4   The Value of Colors
The light amplitude of a color is known as its “value,” 
from the lightest to the darkest; adding white or black to 
a color is all that is required to change its intensity. For 
example, with orange, as we can see from the chromatic 
circle, its dark value is brown and its light value is beige [4] 
(. Fig. 49.3).
In practice, if  we want to correct a brown imper-
fection, it is necessary to apply an orange-ish shade to 
obtain a bright, light beige color, before applying foun-
dation.
Therefore:
 5 A coral corrector neutralizes imperfections that 
are predominantly brown: hyperpigmented scars, 
melasma, brown-toned dark circles, lentigos, etc.
After having corrected the colored lesions using the 
complementary colors or the value of colors, we simply 
need to cover this with a little foundation to even out the 
complexion.
  . Fig. 49.1 Complementary color circle. Source: Eau Thermale 
Avène. © All rights reserved





49.4.4.1   Corrective Foundations
Corrective foundations offer several advantages for 
medical makeup.
 5 Their high pigment concentration allows for correc-
tion using less product.
 5 Their excellent resistance means that there is no need 
to reapply the product during the day.
 5 Their resistance to water and sweat means they can be 
used in any situation, both on the face and body.
 5 They have a high sun protection factor.
There are two types of corrective foundations:
 5 Fluid for mild imperfections
 5 Compact for severe imperfections
49.4.5   Compact Foundation Creams
These are the most suitable for concealing severe imper-
fections and particularly for a long-lasting effect and a 
water, sweat resistance finish.
 5 For post-surgery patients: it is better to use a “com-
fort” texture with a supple formula that is easily 
applied, even on the most sensitive skin.
 5 For remote post-surgery patients: we select a “com-
fort” texture for the face and a “matt-finish” texture 
for the body as there is no transfer and excellent 
resistance [5] (. Figs. 49.4 and 49.5).
It is better to apply these products with a sponge and 
therefore the finish can be adapted depending on the 
intensity of the imperfection.
 5 For a high-coverage result or after using a color cor-
rector, apply by dabbing.
 5 For a transparent result, apply by smoothing.
Do not forget to regularly clean the sponge with soap and 
water, or simply by washing it in the washing machine.
  . Fig. 49.4 Legs before (a) after (b) make up Source: Eau Ther-
male Avène. © All rights reserved
a
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49.4.6   Fluid Foundation Correctors
These are more suitable for mild to moderate imperfec-
tions and as they have a lower pigment concentration, 
they are ideal for scaly skin. They can be applied using 
the tips of the fingers, but if the skin is very dry or scaly, a 
sponge is more effective to “blur” the scales. As for foun-
dation brushes, they are chosen for a more transparent 
finish and for men who really like this method of applica-
tion.
49.4.6.1   How to Decide on a Shade 
of Foundation
People often select the color of their foundation accord-
ing to the color on the inside of their wrist, but this 
body area is quite fair and therefore this rarely achieves 
a natural result. The most effective method is to test the 
product on the jawline to check that there is no demar-
cation between the face and neck. For the body, test the 
product next to the imperfection that you are going to 
apply makeup to. In case of hyperpigmentation, opt for 
a shade that is slightly darker than the skin tone; this 
will help with correction.
Powder
This is essential to set the makeup and to ensure long- 
lasting hold. Opt for a powder suited to the skin tone 
and apply it with a large brush for a more natural effect. 
When scars are very raised, finish by applying the pow-
der in the opposite direction to get rid of excess product 
so that the makeup is less visible. If  skin is very scaly, it 




Eyebrow corrector pencils are extremely useful for 
concealing localized scars around the eyebrows or to 
completely redefine and rebalance the eye area. The eye-
brows are so important in makeup that it is said they act 
as a “frame for the eyes.”
Lips
In case of scarring around the mouth, a lip pencil is 
generally applied after having concealed the scar with 
foundation and a little bit of powder. The lip pencil is 
therefore used to define the contours of the mouth [6]. 
In the case of cheilitis, you can suggest using a lip balm 
before applying lipstick, which can be used instead of lip 
gloss to treat dry lips at the same time.  . Fig. 49.5 Face make up: before (a) and after (b). Source Eau 






Ensure Makeup Lasts longer
Spray a fine mist of thermal water 20  cm away from 
the makeup and leaving it to evaporate, this dries the 
makeup and makes it last longer. This is a very useful 
technique for body makeup, which is more subject to 
friction than the face.
Makeup Removal
An essential step! Most of the time, makeup remover is 
put on a cotton pad and rubbed against the skin with 
varying levels of force. If  the pressure from the cotton 
pad is not strong enough, the makeup is not removed 
and if  it is too strong, this could cause an irritation. The 
most suitable method is to remove makeup with just the 
tips of your fingers. The makeup remover must contain 
gentle surfactants, be fragrance-free, and in the form of 
a lotion or gel-like lotion so that it can be applied using 
gentle massage with the tips of the fingers. After hav-
ing loosened the makeup and impurities, gently remove 
the rest with paper tissues before rinsing with a thermal 
water spray to achieve perfectly cleansed skin.
In brief:
 1. Evaluation of needs: to evaluate the needs and expec-
tations of patients
 2. Makeup base: to prepare the skin before the makeup
 3. Color correction: to neutralize the color imperfection
 4. Corrective foundation: to unify the tone of the skin
 5. Powder: to set the makeup
 6. Corrector pencil: to correct scars or depigmentation 
on eyebrows and lips
 7. Fine mist of thermal water: ensure makeup lasts 
longer
 8. Makeup removal: to remove the makeup without 
creating irritation
49.5   Medical Makeup Classes
Because each patient needs personnel advice, it is impor-
tant for them to learn how to hide their imperfections 
from medical make-up specialists or nurses similarly 
trained. Usually, these classes or workshops are in 
hydrotherapy centers specializing (in skin disorders), 
functional rehabilitation centers, or hospitals.
At first, patients can have individual advice, and they 
can also join a workshop with other patients to learn 
how to do it by themselves. This last solution is the best 
way to become autonomous and generally men should 
opt for this more than women, because usually men do 
not use makeup and they need to be more careful in 
applying it.
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Take-Home Message
Medical makeup can be applied to all imperfections, 
ranging from mild to severe. It can be applied to the 
face and body and should be offered to men as well as 
women. Various studies have highlighted the positive 
effects of  medical makeup on the patient’s quality of 
life [7]. It improves patients’ personal relationships 
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50.1   Background
Scars can cause significant impact on patients’ quality 
life. Let alone cosmetic aspect, scars can result in func-
tional and structural comorbidity. However, the treat-
ment of scars is often challenging due to heterogeneity 
of etiologies and clinical presentations. Traditionally, 
surgical revision had been a mainstay for scars requir-
ing structural remodeling to release the contracture of 
underlying tissue and relieve restricted range of motion. 
Nowadays, varieties of therapeutic options have been 
successfully introduced including physical therapy, sili-
con sheet, cryotherapy, corticosteroids, and laser modal-
ities. Corticosteroids are often referred to as first-line 
treatment but its topical application is often ineffective. 
The major rate-limiting step for drug absorption is pas-
sage through the stratum corneum, which serves as the 
physiological barrier. Considering the pathogenic foci in 
scars are usually deep seated in the dermis, intralesional 
injection is considered as the best treatment option to 
bypass the thick stratum corneum barrier and deliver 
higher concentration of corticosteroids at the site. Yet 
the procedure inevitably accompanies excruciating pain. 
Corticosteroid is often associated with localized adverse 
events on repeated sessions causing skin atrophy, hyper 
or hypopigmentation, and telangiectasia. Treatment of 
keloid is even intriguing with varying success rates, and 
recurrence rates are high with conventional measures.
Target site for topically applied drug is the viable 
epidermis or dermis and the clinical response to a for-
mulation is directly proportional to the concentration 
of the drug achieved at the target site. Transcutaneous 
absorption is limited by inherent skin barrier properties, 
minimizing the absorption to only 1–5% [1]. The innate 
barrier function of the skin, in particular the stratum 
corneum, provides the rate-limiting step in percutane-
ous penetration of drugs and other agents. Many dif-
ferent strategies have been developed to increase the 
permeability of the skin transiently for drug delivery. In 
skin with intact stratum corneum, only small (<500 Da 
in molecular weight) and lipophilic drugs succeed in 
partitioning into and diffusing through this dense lipid- 
rich layer. Transdermal patches have been used since 
1970s but it is limited to drugs with low molecular mass. 
Accordingly, there is considerable interest in develop-
ing novel drug delivery methods. To enhance topical 
delivery of drug, currently available physical techniques 
include stripping, microneedling or sonophoresis, or 
iontophoresis to overcome the skin barrier.
The advent of lasers, particularly fractional laser 
systems, significantly advanced scar treatments in 
past decades [2]. Laser-assisted drug delivery was first 
described in 1987 and initially practiced with fully abla-
tive lasers [3]. Laser-assisted delivery has been reported 
and evaluated in animal models for variety of skin dis-
eases including premalignant lesions to inflammatory 
conditions. Ablative lasers can be effectively used to 
induce absorption of medications beyond the epidermal 
barrier. In precancerous skin lesions such as actinic ker-
atosis, ablative fractional laser (AFL) is used to induce 
penetration of photosensitizer prior to photodynamic 
therapy. Chemotherapeutic agents and immunomodula-
tors like 5-fluorouracil (5-FU) or imiquimod have been 
successfully used. Laser-assisted drug delivery has also 
shown to enhance absorption of topical anesthetics, 
nonsteroidal anti-inflammatory drugs, and corticoste-
roids [4].
50.2   Laser Systems Used for Laser-Assisted 
Delivery
Ablative lasers system has been employed to improve 
skin penetration of active molecules. Laser devices have 
traditionally been used in continuous mode, in which 
the entirety of the water-containing epidermis is com-
pletely ablated. Elimination of the physical barrier of 
stratum corneum allows transcutaneous delivery of 
large molecules, although it requires significant recovery 
time after removing large areas of stratum corneum. To 
overcome significant drawbacks from ablative fractional 
resurfacing, the concept of fractional photothermolysis 
(FP) was proposed in 2004 [5]. Fractional photother-
molysis (FP) is a technique whereby an ablative laser 
is administered in a fractionated pattern instead of 
full ablation. Fractionated systems create discreet col-
umns of ablated tissue, known as microthermal zones 
(MTZs), sparing intact portion of skin. The untreated 
skin surrounding MTZs serves as a reservoir of growth 
factors and stem cells promoting tissue regeneration 
and wound-healing response. Accordingly, ablative frac-
tional lasers (AFLs) have provided an emerging option 
with a lower side-effect profile. AFL emerged as a prom-
ising tool in the treatment of scars with minimal pain 
and rapid wound healing in few days [2]. Moreover, frac-
tional laser-assisted drug delivery is employed with high 
precision by controlling the area and degree of ablation 
through laser settings. MTZs facilitate penetration of 
topical molecules from the surface to the layer of inter-
est (. Fig. 50.1). Due to its predictable tissue response, 
it can be an effective alternative to injection or topical 
formulations of drugs targeting cutaneous diseases.
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50.3   Carbon Dioxide (CO2) Laser and 
Erbium:Yttrim-Aluminum-Garnet 
(Er:YAG) Laser
Carbon dioxide (CO2) laser and erbium:yttrim-alumi-
num-garnet (Er:YAG) laser are the two types of laser 
devices most commonly studied in regard to laser-
assisted drug delivery. CO2 laser (10,600 nm) heats cells 
instantly, resulting in vaporization and coagulation of 
irradiated cells. Subsequently, denaturation of extracel-
lular proteins and heat-induced shrinkage of collagen 
is noted in a subjacent residual layer. Histologic studies 
of scar tissue after ablative fractional CO2 laser treat-
ment demonstrated complete re-epithelization within 
48  hours. Er:YAG laser (2940  nm) system delivers 
energy more precisely without extensive thermal dam-
age to the surrounding tissue, permitting quicker wound 
healing and recovery of dermis. CO2 devices generate 
larger degrees of heat diffusion to the surrounding tis-
sue while Er:YAG system exerts less hemostatic effect. 
Differences between fractional CO2 laser and fractional 
Er:YAG laser are similar to their full-field counterparts 
in that the CO2 systems cause more residual thermal 
damage. Studies have reported that fractional Er:YAG 
laser causes significantly less residual thermal dermal 
damage, with a faster healing time and less post-pro-
cedure erythema compared to fractional CO2 laser [4]. 
When applicable, the combined-mode Er:YAG/CO2 
laser system can offer synergistic benefit of ablative and 
coagulation effect. Both lasers have been successfully 
applied for scar treatment with favorable clinical out-
comes. Fractional CO2 and Er:YAG provided compa-
rable outcome, yet fractional CO2 system was associated 
with a higher degree of procedural pain in few stud-
ies [6]. However, it is difficult to determine superiority 
between the two modalities due to clinical heterogeneity 
and lack of comparative study design.
50.4   Mechanism of Ablative Fractional 
Laser-Assisted Drug Delivery
Ablative fractional lasers irradiate high-fluence laser 
beam forming multiple, discrete columns of thermal 
damage. Ablative fractional photothermolysis (AFP) 
systems generate MTZs by vaporizing full thickness 
zones of scar tissue that may extend to deep dermis. 
Surrounding the denatured columns created by MTZs 
is a collateral area of thermal denaturation that is suf-
ficient to coagulate collagen. Moreover, thermal irradia-
tion stimulates neocollagenesis for collagen remodeling. 
Studies have demonstrated that the increased expres-
  . Fig. 50.1 Schematic diagram of  ablative fractional laser (AFL)-
assisted drug delivery. AFL irradiation creates microchannels 
extending from the skin surface to the dermis. Microthermal zones 
(MTZs) vaporize accumulated scar tissue (orange) and influence 
collagen remodeling (green). Microchannels transverse stratum cor-
neum and topically applied molecules can reach target tissue in the 
dermis and permeate into the skin
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sion of heat shock proteins (HSPs) induces anti- 
inflammatory effect after ablative laser treatment for 
scars. Additionally, the altered expressions of matrix 
metalloproteinases (MMPs) and tissue inhibitors of 
metalloproteinases (TIMPs) are noted along with 
increased expression of growth factors. Collectively, 
the differential expression of anti-inflammatory media-
tors and cytokines attribute to improvement in clinical 
appearance of scars.
MTZs facilitate penetration of topically applied 
drugs and other bioactive agents by acting as an alterna-
tive pathway for cutaneous drug delivery. Increased pen-
etration of molecule can be explained by Fick’s first law 
of diffusion. The diffusive flux of molecule goes from 
regions of high concentration to lower concentration, 
with a magnitude that is proportional to the concentra-
tion gradient. The degree of flux (J) is described as a 
product of partition coefficient (K), diffusion coefficient 
(D), and concentration difference across the barrier (ΔC) 
divided by the diffusion distance (L). Partition coeffi-
cient (K) indicates the equilibrium solubility of the drug 






The diffusion coefficient reflects the measure of inher-
ent diffusivity of a molecule and determines the diffu-
sion rate once the molecule permeates the membrane. 
The diffusion distance represents the length of a path 
for the diffusion. MTZs generated by AFL impact flux 
in various aspects of Fick’s first-law variables. Firstly, 
increased permeability via MTZs enables increase in K 
compared to intact skin. Secondly, larger molecules with 
higher diffusivity can permeate directly into epidermis. 
Lastly, the distance of the diffusion is decreased from 
the skin surface and enables delivery to deeper layer. As 
a result, pretreatment with AFL facilitates traditionally 
challenging uptake of large hydrophilic molecules. The 
use of AFL increases the transdermal drug delivery of 
large molecules by 8- to 15-fold [4].
50.5   Technique and Parameters
50.5.1   Main Parameters: MTZ Density 
and Depth
AFL system irradiates target scar tissue with high pre-
cision by controlling the area and degree of ablation 
through laser settings such as power, pulse duration, 
percentage of skin coverage, and ablation pattern. For 
AFL-assisted drug delivery, the density and depth of 
microablative columns should be determined by opera-
tor for the given clinical characteristics of the scars. 
MTZs formed by AFP system can be adjusted to tar-
get specific depth and diameter by increasing the fluence 
and induce regulated disruption of epidermal barrier. 
In general, relatively modest energy fluence and density 
are considered applicable for laser-assisted delivery. Low 
energy levels are classically all that are needed to impair 
the physical barrier of stratum corneum. By calibrating 
laser settings, it is possible to influence the delivery rate 
and drug biodistribution, which may lead to improved 
clinical efficacy with shortened incubation time. Studies 
of the effect of laser parameters on the transdermally 
absorbed molecules are limited.
50.5.1.1   MTZ Density and Coverage
The MTZs consist of sharply confined tissue denaturation 
with a diameter of about 100 μm at intervals of about 
200 μm. In animal models, increased density of MTZs 
achieved overall drug delivery, yet there was threshold 
density to achieve maximum diffusion. Fluorescent label-
ing demonstrated that the absorption of topically applied 
photosensitizers, immunomodulators, and lidocaine 
reached maximum biodistributions of 5%, 10%, and up 
to 20%, respectively, while further increase only resulted 
in deposition to stratum corneum [3]. More importantly, 
complications, such as scarring and hypopigmentation, 
have been observed at coverages in excess of 45%.
50.5.1.2   MTZ Depth and Energy
The depth of ablation represents how deep the MTZs 
extend into the skin and for a given laser beam diameter 
is mainly controlled by laser pulse energy. Microbeams 
of AFL irradiation typically induce MTZs ranging from 
100 to 300 μm in diameter and it can extend down to 
the deep reticular dermis. The optimal depth threshold 
is yet undetermined as studies report drug deposition 
as both dependent on and independent of laser channel 
depth. It is expected that increase in the laser fluence and 
irradiation time increases the cellular uptake of large 
molecules across the skin in a dose-dependent manner. 
The usual threshold in the literature is approximately 
200–250 μm in diameter. Hydrophilic or semi- lipophilic 
molecules (methotrexate, prednisone, and diclofenac) 
are generally dependent on MTZ depth while lipophilic 
molecules (lidocaine, ingenol mebutate, and imiquimod) 
do not show obvious depth-dependent uptake [6]. The 
variation between optimal depths for penetration can 
be related to the location of vascular plexus in different 
types of skin used for evaluation.
50.5.2   Clinical Application in Scar 
Treatment: Drugs and Bioactive 
Molecules
Delivery of every molecule will vary based on its inher-
ent properties such as size, diffusion coefficient, and 
individuals’ predisposed skin barrier conditions. In 
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stratum corneum, corneocytes are embedded in a lipid 
matrix and bioavailability of hydrophilic drugs is low. 
While lipophilic or semi-lipophilic molecules can pene-
trate lipid barrier of the outmost layer of the epidermis, 
large or hydrophilic molecules are able to transverse the 
stratum corneum after AFL pretreatment.
50.5.2.1   Corticosteroid
Corticosteroid has been a mainstay in the scar treat-
ment. It is mostly known to inhibit inflammatory 
mediators and promotes remodeling of extracellular 
matrix. To exert its clinical effect, corticosteroid should 
penetrate cell membrane to bind the nuclear receptor. 
Sustained release of corticosteroid can be beneficial 
because wound regeneration of the inflammatory stages 
is known to persist for several days after laser irradia-
tion. Triamcinolone acetonide is the most widely used 
and available as micronized suspensions of corticoste-
roid crystals. Currently, intralesional injection of corti-
costeroid has been well advocated in the treatment of 
both hypertrophic scars and keloids. After its adminis-
tration, micronized crystals of corticosteroids persist in 
skin and are released over a period of weeks. However, 
local injection of triamcinolone actinide is often painful 
and consistent dosing is difficult to achieve throughout 
the scar.
Combination treatment of AFL and topically 
applied corticosteroids demonstrate encouraging results. 
Application of triamcinolone immediately after AFL 
can induce synergistic effect of deep penetration into the 
scar tissue to induce collagen remodeling. Use of rela-
tively low-dose triamcinolone (10  mg/mL) is sufficient 
to induce clinical improvement in various types of scars 
including burn, trauma, or surgical scars. AFL-assisted 
delivery of topical triamcinolone potentially offers 
an efficient, safe, and effective adjunctive treatment. 
Corticosteroids available as topically applied formula-
tions demonstrated mediocre effect in scar treatment. 
There are only few reports used to alleviate symptoms 
or appearance of hypertrophic scars immediately after 
surgical procedure [7]. Nevertheless, the combination of 
AFL and topical corticosteroid application yields suc-
cessful result for the treatment of keloid without any 
adverse event [8]. AFL-assisted corticosteroid applica-
tion is a promising tool with minimal pain and rapid 
wound healing in few days. Beyond the specific action 
of the lasers on scar remodeling, the channels that they 
create can be used to deliver active molecules to poten-
tiate its efficacy (. Fig. 50.2). On the other hand, the 
presence of MTZ-induced channels is transient mostly 
at presence for 3 to 7 days. Accordingly, disrupted physi-
cal barrier of stratum corneum is restored within a week 
after AFL. Thus, further study is required to determine 
the optimal dosage of triamcinolone suspension and 
potency of topically applied formulations.
50.5.2.2   Other Agents for Scar Treatment
When routinely applied, topical corticosteroids do have 
risk to cause localized adverse effects such as skin atro-
phy, pigmentary changes, or telangiectasia. To spare 
such undesired skin reaction, drugs with immuno-
modulatory function has been applied in various skin 
conditions.
5-Fluorouracil (5-FU) is a pyrimidine analog anti-
metabolite that results in an irreversible inhibition of 
thymidylate synthase, commonly used for premalig-
nant skin lesions. Laser-assisted delivery of 5-FU has 
been tested in animal models using various types of 
laser systems. Pretreatment with AFL resulted in more 
than 50-fold and 30-fold increase in penetration using 
Er:YAG and CO2 system, respectively. In a study com-
paring the effect of 5-FU and triamcinolone to treat 
hypertrophic scars, lesions subjected to 5-FU demon-
strated comparable results in terms of scar texture and 
height [9]. Appropriate dosing of 5-FU should be evalu-
ated due to concern for increased systemic absorption 
with laser-assisted drug delivery, which can expand the 
adverse effect profile unlike bland topical application.
Atrophic scars result from loss of dermal or subcu-
taneous tissue during the wound-healing process. Fillers 
are high-molecular-weight biopolymer developed to 
provide structural support for volume restoration of 
skin. On this account, it is unable to permeate through 
intact epidermis and employed by injection. Laser sys-
tems, AFL in particular, can improve atrophic scars 
by promoting new collagen synthesis after irradiation. 
Concomitant use of AFL and topically applied poly-
L- lactic acid (PLLA) fillers proved to be successful in 
treating patients with atrophic scars from various eti-
a
b
  . Fig. 50.2 a A 16-year-old woman with Fitzpatrick skin type IV 
with hypertrophic scars after facial reconstruction surgery. b Patient 
underwent five sessions of  fractional CO2 laser (eCO2 Lutronic, Goy-
ang, Korea. 60 mJ, 10% density) combined with topical application 
of  triamcinolone acetonide suspension of  10 mg/mL
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ologies including acne and trauma. Histologic evalua-
tion on cadaveric skin demonstrated the penetration of 
PLLA to the dermis, albeit large molecular size [10]. 
Additionally, sustained release by prednisolone encap-
sulated in PLLA microsphere provided continuous 
delivery enough to suppress prolonged inflammatory 
response [6]. Likewise, several bioactive molecules and 
peptides such as polydeoxyribonucleotide (PDRN) are 
evaluated for potential application for scar treatment. 
Recently, enhanced percutaneous delivery of adipocyte 
and hematopoietic stem cells by AFL systems has been 
evaluated in scar management.
50.5.3   Other Modalities to Enhance 
the Effect of Laser-Assisted Delivery
50.5.3.1   Emerging Devices
AFL-assisted drug delivery of therapeutic agents emerg-
ing devices is one of the latest strategies to enhance 
cutaneous bioavailability of topically applied molecules. 
Notwithstanding that MTZs can empower to bypass the 
skin barrier, passive uptake through MTZs can be inade-
quate as the channels are rapidly restored within few days. 
Furthermore, within few hours after ablation, the depth of 
columns is gradually shortened by accumulated fibrin and 
interstitial granulation tissue. Therefore, several physical 
maneuvers have been suggested to enhance the delivery 
of active molecules. Ultrasound may temporarily reduce 
the intact biding of stratum corneum. Acoustic waves by 
ultrasound may induce cavitation, which increases the 
penetration of molecules. In animal model, active filling 
of MTZs was observed by altering the pressure during the 
topical application of test molecule [6]. Similarly, com-
bination of sonophoresis and iontophoresis with AFL-
assisted drug delivery can induce favorable results.
Radiofrequency (RF) devices locally generate heat 
depending on the local electrical resistance and current 
density. RF devices deliver thermal energy to the dermis 
and subdermal tissue, which induces collagen contraction 
and remodeling by disrupting its structural bond, thereby 
most commonly applied to the treatment of facial rhyt-
ides and skin tightening. Advances in laser and energy-
based devices expanded clinical indications of RF devices. 
Fractionated RF systems are used to improve scar tex-
ture, and bipolar fractional microneedle RF systems have 
shown the resolution of atrophic acne scars. Furthermore, 
ablative fractional RF associated with acoustic pressure 
generated by ultrasound was used to increase the delivery 
of triamcinolone into hypertrophic scars [8].
The use of non-ablative fractional lasers (NAFL) 
needs to be examined as a less invasive method of laser- 
assisted drug delivery. NAFL systems create a similar 
array of microablative columns as does AFLs; the MTZs 
consist of columns of thermal injury with intact overly-
ing stratum corneum. NAFL systems heat tissue with-
out vaporization, thus being less associated with patient 
discomfort. Although the epidermis is not fully vapor-
ized, barrier function of the skin in the treated area is 
transiently impaired allowing for enhanced drug deliv-
ery. NAFLs applied alone have confirmed its therapeutic 
efficacy in skin rejuvenation and various types of scars. 
NAFL-assisted drug delivery of minoxidil or corticoste-
roids can be applied to treat alopecia areata. Fractional 
erbium glass laser (1550 nm) was reported to effectively 
enhance percutaneous delivery of photosensitizers [4].
50.5.3.2   Limitations
Further investigations are required to establish the safety 
and efficacy of laser-assisted delivery of molecules as 
a transcutaneous drug delivery system. The majority 
of the existing studies have been performed on animal 
models and additional human studies are needed. Drug 
permeation through AFL-generated MTZs inevitably 
raises concern about systemic absorption and potential 
systemic toxicity. Transdermal delivery is considered 
relatively safe as the dosage required for the therapeutic 
effect of a drug is lower than the oral dose and avoids 
the drug metabolism in the liver. Although most applica-
tions of laser-assisted drug delivery have been intended 
for local effects in the skin, some reports have demon-
strated that systemic absorption does occur. Along with 
increased transcutaneous absorption, a decreased dose 
should be considered to minimize side- effects that could 
be local or systemic. Further clinical studies are needed 
to fully evaluate the safety and efficacy of laser-assisted 
drug delivery for scar treatment.
50.6   Conclusion
Laser-assisted drug delivery is an evolving technology 
with many possible applications as a highly targeted 
customizable method for distribution of drugs within 
the skin. Current studies have demonstrated that laser 
pretreatment of the skin can increase the permeability 
and depth of penetration of topically applied drug mol-
ecules. Fractional laser systems can be successfully uti-
lized in the treatment of various forms of scarring with 
a very favorable safety profile. Fractional photother-
molysis, both ablative and non-ablative, can improve the 
texture of various scars by promoting collagen remod-
eling. AFL-assisted drug delivery systems offer distinct 
advantage by enabling the topical medication to pen-
etrate deeper and reach target pathogenic site even for 
the systemic drug administration. Corroborative efforts 
with multidisciplinary measure and novel combinations 
of existing treatments can help ensure optimal clinical 
and cosmetic results.
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Take-Home Message
 5 Lasers are safe and effective means of enhancing 
the delivery of topically applied agents through 
the skin.
 5 Ablative fractional laser-assisted drug delivery is 
increasingly used to enhance percutaneous uptake.
 5 Microthermal zones generated by fractional laser 
create precise, uniform columns of tissue vaporiza-
tion, which facilitates delivery of various drugs.
 5 Ablative fractional laser-assisted corticosteroid 
delivery may take advantage of the newly formed 
channels to penetrate uniformly and deeply into the 
scar tissue. Combination of valuable scar treatment 
options can create synergistic therapeutic response.
 5 Laser-assisted drug delivery provides a new oppor-
tunity for a minimally invasive modality in scar 
treatment.
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51.1   Background
After skin injury, the wound-healing process has to occur 
as soon as possible to prevent excessive blood loss and/
or infection. In chronic wounds, this normal healing pro-
cess fails, which results in a pathologic cycle of inflamma-
tion and protease release, leading to the development of 
a pathologic scar. Also, in the healing of large and deep 
wounds, scar formation is evident. Nevertheless, in some 
natural cases, such as fetal skin, humans and animals are 
able to heal scarless due to the fast wound-healing pro-
cess and/or specific fetal characteristics [1].
Scars caused by burns, chronic ulcers from diabe-
tes, infections, skin cancer surgery, and other genetic 
or somatic disease could require effective treatment to 
avoid functional and psychological troubles and even in 
some severe cases to prevent mortality. Most of the cur-
rent treatments do not prevent scarring. They first aim 
to reduce local inflammation.
Herein, we will discuss about emerging technolo-
gies in scar management using allogeneic cell therapy. 
Allogeneic cell transplants offer the possibility of large 
prefabrication, cryopreservation for instantaneous use, 
and repeated applications. They also allow the use of 
fetal cells that show interesting properties. Furthermore, 
they are applicable for genetic skin diseases inducing 
severe scars such as dystrophic epidermolysis bullosa. 
Current research exploring allogeneic cell therapies for 
scar treatment show that they are mostly locally deliv-
ered by grafting and/or by intradermal injections.
51.2   Allogenic Cell Therapy Studied in Scar 
Management Field
Allogeneic cell therapies combined with scaffolding 
biomaterials have been employed in tissue engineering 
approaches for wound care and scar management. We 
will describe here the cells and their scaffold used in 
scar management. The common cell types used for scar 
treatments are fibroblasts and keratinocytes as commer-
cial products for skin regeneration (. Table 51.1). The 
emergence of three-dimensional (3D) printing is gaining 
commercial interest for large-scale production. Research 
works on mesenchymal stromal cells (MSCs) therapy 
for scar management are also increasing and show very 
promising results.
51.3   Human Allogeneic Epidermal Sheets
Epidermal sheets consist of human keratinocytes that 
are differentiated in vitro to give rise to a stratified epi-
dermal layer. They can be combined with other biocom-
patible substrates (bovine collagen, hyaluronic acid), 
acellular natural human or porcine materials, or nylon 
or polyglactin meshes. An example of one product using 
allogeneic keratinocytes is Cryoskin® that is available 
from frozen cells on a carrier dressing [2]. A single blind 
study shows the efficacy of this cell therapy for the accel-
eration of healing of chronic nonhealing neuropathic 
diabetic ulcers. In general, the clinical outcome of the 
epidermal sheet grafts is usually not satisfying because 
of the nonpermanent character, ultimate rejection, and 
absence of a dermal component.
51.4   Cellular Dermal Substitutes and 
Human Dermal Fibroblasts Therapy
In contrast to epidermal sheets, the dermal substitutes 
are composed either of autologous or of allogeneic der-
mal fibroblasts. The scaffold for the cells consists mostly 
  . Table 51.1 Human allogenic cell types used in skin 
regeneration
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of biomaterials, like benzyl-esterified derivatives of 
hyaluronic acid (Hyaff-11), polyglycolic acid, or poly-
glactin. TransCyte® is a comparable product containing 
a nylon mesh coated with porcine dermal collagen that 
is seeded with neonatal fibroblasts and fixed to an outer 
silicone membrane.
The major indication of application consists in 
transient wound cover after surgery. One of the most 
successfully bioengineered products is Dermagraft®, 
an allogeneic cell culture using neonatal dermal fibro-
blast grown on a biodegradable scaffold. This product 
showed the capacity to secrete several growth factors, 
to stimulate angiogenesis, and re-epithelialization from 
the wound edge, even after cryopreservation and thaw-
ing. In diabetic foot ulcers, its efficacy and its safety were 
demonstrated [2].
In addition, some other clinical trials are ongoing 
using a medicinal product comprised of viable alloge-
neic dermal fibroblasts suspended in HypoThermosol®-
FRS for remodeling scar contractures from burn 
patients and from dystrophic epidermolysis bullosa 
patients. Fibroblasts are from neonatal foreskin, cryo-
preserved, thawed, and expanded in culture under 
good manufacturing practice at Intercytex Ltd., UK 
(7 ClinicalTrials. gov, Identifier: NCT01564407 [burn 
patients], ISRCTN67757229 [recessive dystrophic epi-
dermolysis bullosa patients]).
51.5   Human Skin Equivalent
Skin equivalent is only composed of a culture of kera-
tinocytes growing on dermal substitutes containing 
fibroblasts. An example of an allogeneic skin equivalent 
product is Apligraf® consisting of cultured keratino-
cytes on a dermal layer of fibroblasts within a bovine 
type 1 collagen matrix (7 http://www. apligraf. com/
professional/). Apligraf® obtained its Food and Drug 
Administration (FDA) approval for diabetic foot ulcers 
and venous leg ulcers applications. This product has 
been well tolerated in over 150,000 patient applications.
Clinical trials showed that the healing rate of the 
venous ulcers treated with Apligraf® as well as the heal-
ing time was improved. Healing occurs with less fibro-
sis, which might be because of the construction of the 
graft itself  containing neonatal cells and growth factors/
cytokines, stimulating a more fetal-like scarless wound 
healing. Another product used in clinical trials for the 
treatment of venous ulcers is OrCel®, a bilayered cellu-
lar matrix containing adult epidermal keratinocytes and 
dermal fibroblasts. Donor dermal fibroblasts are cul-
tured within the porous Type I bovine collagen sponge 
while keratinocytes, from the same donor, are cultured 
on the coated, nonporous side of the collagen matrix.
Recently, OrCel® obtained its first FDA approvals 
for treatment of acute surgical excisions, such as contrac-
ture release sites in patients suffering from dystrophic 
epidermolysis bullosa undergoing hand reconstruction 
surgery (7 https://www. accessdata. fda. gov/cdrh_docs/
pdf/p010016b. pdf) and also in burn patients undergo-
ing excision and grafting [2]. In vitro skin cells used to 
make OrCel® skin equivalent are extensively expanded 
that give rise to a low human leukocyte antigen class II 
(HLA-II) level of the allogeneic cells. Therefore, OrCel® 
skin equivalent is well tolerated by the recipient after 
grafting into wound bed. The company reported in both 
clinical trial and commercial experience no clinical signs 
of tissue rejection using the cryopreserved OrCel® prod-
uct. Resorption appears to take place gradually, with no 
remnants of the donor cells or matrix being detectable 
by 2 weeks of posttreatment. Their working hypothesis 
is that extracellular secretion of cytokines and growth 
factors by the living cells in OrCel® is the major factor 
for accelerating wound healing.
51.6   Bioprinting of Skin
The use of three-dimensional (3D) bioprinting has 
emerged as a flexible tool in regenerative medicine to 
bioengineer skin substitutes. There are many kinds of 
bioprinting technologies, but the four more commonly 
used are inkjet-based printing, extrusion-based print-
ing, laser-assisted printing, and digital light processing 
(DLP)-based printing—dynamic optical projection ste-
reolithography (DOPsL). Cell viability can be affected 
by several factors, including bioprinting technique used.
Jorcano laboratory has developed one bioprinter 
prototype able to print skin cells, soluble factors, and 
biomaterials in a desired pattern with the help of high- 
precision Cartesian robots. The printing skin mimics the 
structural and molecular structure of the human skin 
[3]. It is the first functional printer to be introduced 
to the marketplace. To date, there is no allogeneic 3D 
printed skin used in patients, but this technology raised 
great hopes for the treatment of scar in the future.
51.7   Injections of Mesenchymal Stromal 
Cells (MSCs) for Skin Regeneration
MSCs were known to contribute to skin regeneration 
and to accelerate cutaneous wound healing. MSCs were 
first isolated from bone marrow in the 1970s by their 
ability to adhere, proliferate, and develop on a plastic 
surface, displaying fibroblastic morphology. MSCs are 
multipotent adult progenitor cells that can differentiate 
to lineages of mesenchymal cells, including osteoblasts, 
chondroblasts, and adipocytes. These can be isolated 
from various adult or perinatal tissues such as adi-
pose tissue or umbilical cord. MSCs have shown posi-
tive therapeutic effects in many tissue repair situations 
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through the secretion of trophic factors. In addition, 
allogeneic MSCs are well tolerated after injections due 
to their immune-modulating effects [4].
Many studies have demonstrated that MSCs exhibit 
a number of trophic functions to enhance skin regen-
eration, such as promoting angiogenesis, modulating the 
inflammatory response, and limiting tissue fibrosis [5]. In 
in vivo studies, these cells have been used successfully to 
limit scar formation. Transplanted allogeneic or xenoge-
neic MSCs transiently survive in the implantation site; 
their therapeutic potential in wound healing is associated 
with their secretion of trophic effects on resident cells. 
One of these in vivo studies using a rabbit model showed 
that intradermal injection of MSCs can regulate inflam-
mation and prevent the formation of hypertrophic scars. 
The MSCs underwent apoptosis rapidly in the injected 
site, between 24 and 72 hours postinjection. They dem-
onstrated that apoptosis has an important role in the acti-
vation of the inflammatory regulatory abilities of MSCs 
through TNF-alpha stimulated protein 6 (TSG-6) [6].
An in vivo study showed the efficacy of MSCs and 
dermal fibroblasts combined to minimize skin hyper-
trophic scarring [7]. They showed that transplanted 
xenogeneic MSCs influenced positively fibroblast prolif-
eration, migration, and extracellular matrix deposition 
and reduced inflammation following wounding. This 
effect was superior to MSC or fibroblast transplantation 
alone. This study suggests that MSCs, even if  eventu-
ally rejected quickly after injection, transplanted with 
fibroblasts normalize matrix regeneration during wound 
healing. This promising study provides insight into 
allogeneic cell therapies as a viable method for antifi-
brotic treatment and demonstrates that even transiently 
engrafted cells can have a long-term impact via matrix 
modulation and effect on other tissue cells.
One of the first randomized, controlled clinical 
trial will study the safety and efficacy of MSCs in skin 
scar for the treatment of Cesarean section [8]. Eligible 
patients received transdermal hydrogel MSCs once a 
day for six consecutive days. Their outcomes should be 
available soon (7 ClinicalTrials. gov, NCT02772289).
51.8   Promising Embryonic(-Like) Stem Cells 
Therapy for Scar Treatment
Embryonic stem cells (ESCs) and induced pluripotent 
stem cells (iPSCs) are defined as pluripotent cells able to 
self-renew. In the field of skin, those stem cells showed 
some promising results regarding fibrosis care.
Many in vitro and/or in vivo studies are ongoing on 
embryonic stem cells and induced pluripotent stem cells 
(iPSC) as potentially promising in scar management [9]. 
As fetal cells, ESCs are thought to possess antifibrotic 
ability. An in vitro study showed the capacity of ESC- 
derived macrophages to secrete scarless-like secretome 
to regulate the altered keloid niche and reverse the pro-
fibrotic phenotype of keloid fibroblasts [10]. Because 
iPSCs are similar to ESCs in many features, they have 
been evaluated in scar tissue repair. An in  vitro recent 
study documented that iPSC-conditioned medium 
may efficiently suppress hypertrophic scar fibroblast 
activation [11].
51.9   Conclusion/Discussion
The allogeneic cell therapy for scar management shows 
many advantages: large prefabrication, cryopreserva-
tion for instant use, and repeated applications. They also 
allow the use of fetal cells such as embryonic stem cells. 
Furthermore, they are applicable for genetic skin disease 
inducing wound healing without genetic modifications.
Most of current and emerging therapeutics for scar 
management are using allogeneic fibroblasts and kera-
tinocytes as epidermal sheet, dermal substitute, or skin 
equivalent. The immune rejection of these adult cells is 
commonly reported, mostly shown for allogeneic kera-
tinocytes due to different HLA expression and cytokine 
production. Fetal cells are of particular interest for skin 
repair due to the high expansion ability, low immu-
nogenicity, and intense secretion of bioactive factors. 
However, the main cellular effect seems in promoting 
wound healing through secretion of endogenous and 
exogenous factors rather than cell survival.
Regarding the viability of allogeneic cells, most of the 
studies on the literature agree on the fact that  allogeneic 
cells do not survive for a long time after transplanta-
tion. But most of their therapeutic potential seems to 
be based on their secretion of trophic factors such as 
growth factors, cytokines, and extracellular vesicles at 
least for MSC therapy and also for dermal fibroblasts 
therapy. Extracellular vesicles (exosomes, microvesicles, 
and apoptotic bodies) are secreted by most cells of 
the organism. These extracellular vesicles are of grow-
ing interest among investigators, specially from MSCs 
across multiple fields, including dermatology as a drug 
[12]. As MSCs or stem cells, extracellular vesicles dem-
onstrate immunomodulatory properties, accelerate skin 
cell migration and proliferation, control wound scar-
ring, and improve angiogenesis. Several clinical trials 
should appear in the future years testing the safety and 
the efficacy of stem cells and derived products for skin 
scar treatment.
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52.1   Background
Cutaneous wound healing following injury is a com-
plex biological process involving the orchestration of 
the immune system, inflammatory pathways, mecha-
notransduction pathways, and various types of partici-
pating cells. In adult humans, the wound repair process 
results in the replacement of the damaged functional 
tissue with a patch of cells (i.e., mostly fibroblasts) and 
disorganized collagen-rich extracellular matrix that is 
commonly defined as a scar [1]. While scarring occurs 
in almost all tissues, it is most apparent in the skin. 
Cutaneous scarring poses a significant psychological 
and physiological burden on patients, and an estimated 
$12 billion are spent annually on scar treatments in the 
USA alone [2]. Additionally, dysfunctional healing and 
hypertrophic scarring often causes lifelong disability, 
which has a significant additional economic impact [1, 
2]. Over 40 million patients undergo surgical procedures 
annually, which often lead to the formation of hyper-
trophic scars (HTSs) resulting in substantial morbidity 
and disfigurement of the skin. Similarly, scar forma-
tion occurring as a result of burns and other forms of 
trauma leads to severe functional disabilities costing 
the economy over $4 billion per year [2]. Keloidal scars, 
which are characterized by excessive fibrosis in areas 
of the skin with acne or other minor injuries, represent 
another major fibrotic skin disorder. Several other skin 
fibrotic diseases such as Dupuytren’s disease, psoriasis, 
and scleroderma lead to cutaneous scarring as well [2].
In current practice, cutaneous scars are treated using 
corticosteroid injections or cryotherapy, surgical revi-
sions, topical silicone gels, sheets and pressure garments, 
radiation, and laser treatments [3]. These traditional 
treatment modalities have shown mixed success and 
most methods lead only to partial alleviation of scar 
formation. Further, many of these treatment modali-
ties are associated with other practical issues such as 
patient discomfort and pain, multiple and frequent vis-
its to the doctor’s office, or even higher recurrence of 
scars [3]. Recent progress in the identification of key sig-
naling pathways involved in fibrosis and scar formation 
has led to the emergence of new therapeutic agents for 
scar treatment, with promising results in animal studies. 
Agents targeting collagen synthesis pathways, cytokines, 
growth factors, and cytotoxic agents are under investiga-
tion for scar therapy. Of these, drugs that inhibit expres-
sion of transforming growth factor (TGF)-β1/TGF-β2 
or augment TGF-β3 had shown initial promise, but have 
been shown to be ineffective in later clinical trials as dis-
cussed below [3, 4]. Similarly, treatment of scars with 
interleukin-10 (IL-10), an interleukin that is involved 
in regulating inflammatory pathways, has shown some 
promise in treating psoriasis, but has failed to show any 
significant benefit for other types of scars [5].
A paradigm shift in our understanding of the scar 
pathophysiology emerged when the role of mecha-
notransduction in fibrosis was explored. The role of 
mechanical stress in scar formation had been described 
as early as in the 1800s, with the description of Langer’s 
lines of skin tension used for surgical incisions to mini-
mize scarring. But recent work elucidating the role of 
mechanical cues activating inflammatory pathways and 
scar-promoting cells highlighted mechanotransduction 
as a central focus of scar pathophysiology [6]. In the past 
decade, aberrant activation of mechanosensitive skin 
cells have been shown to underlie abnormal wound heal-
ing and scar formation in various skin diseases including 
hypertrophic and keloidal scars, Dupuytren’s disease, and 
scleroderma [6]. Offloading of mechanical forces during 
healing of human skin incisions following abdominal 
surgeries has been shown to be effective in reducing scar 
formation in Phase I clinical trials [7]. In particular, focal 
adhesion kinase (FAK), a molecular mediator of mech-
anotransduction, has been identified to play a key role 
in fibrosis and scar formation (. Fig. 52.1) [8]. Animal 
studies have shown that pharmacological inhibition of 
FAK can lead to significantly reduced scar formation 
and accelerated wound healing [9].
In this chapter, we will review the latest pharma-
cological therapies that are being evaluated for scar 
management in the currently available literature. This 
includes agents that have recently completed clinical tri-
als and drugs that target cellular mechanotransduction 
pathways.
52.2   Objectives of the Proposed Chapter
This chapter describes the evidence-based new drug 
therapies introduced in recent scientific literature for 
scar mitigation and prevention. Although the underlying 
pathophysiology of hypertrophic scar formation follow-
ing injury is far from completely understood, over the 
past decade, advances in our understanding of the cel-
lular and molecular mechanisms by which fibrotic scars 
develop have paved the way for devising new approaches 
in scar therapies.
52.3   Description of the State-of-the-Art 
Historical Evolution: Recent Data
Traditional scar revision technologies include surgi-
cal treatment, topical silicone gels, sheets and pressure 
garments, radiation, and laser treatments [3]. In current 
practice, intralesional corticosteroidal therapies and 
antiproliferative 5-fluorouracil therapy are also com-
monly used to pharmacologically mitigate hypertrophic 
scars, although their effectiveness is mainly supported 
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by case studies and preliminary clinical studies [3]. These 
treatments are often associated with adverse reactions, 
such as dermal atrophy or hypopigmentation, leading 
many patients to seek alternative treatment modalities 
after prolonged use. Recent studies have investigated 
new pathways to reveal drug targets such as modulators 
of wound inflammatory cytokines, growth factors, and 
mechanomodulatory mediators as potential targets for 
scar-mitigating therapies [6].
52.4   Transforming Growth Factor-β (TGF-β)
TGF-β expression is involved in almost all stages of the 
wound-healing process, including wound inflammation, 
angiogenesis, extracellular matrix synthesis, and tissue 
remodeling. Various studies have established the impor-
tant role this wound-growth factor plays in dermal fibro-
blast differentiation into myofibroblasts and subsequent 
scar formation across a range of fibrotic diseases [3, 4]. 
Studies exploring the scarless and regenerative ability 
of the fetus have pointed toward the possibility that dif-
ferent isoforms of TGF-β could contribute to different 
stages of wound healing. While TGF-β1 and TGF-β2 
are expressed highly in postnatal adults, TGF- β3 is the 
dominant isoform in fetal wound healing, leading many 
researchers to identify either TGF-β3 as a therapeutic 
target to upregulate or TGF-β1/GF-β2 as targets to 
inhibit for scarless wound healing [3, 4].
Despite strong preclinical outcomes, current TGF-β 
clinical trials have had disappointing results. Juvista, 
a new recombinant TGF-β3 product developed by 
Renovo, had shown promise in early phase efficacy tri-
als but failed to meet primary endpoints in Phase III 
trials [3, 4]. Renovo also pursued a trial with Juvidex 
(mannose- 6 phosphate), an inhibitor of TGF-β1/TGF-
β2 [3]. Juvidex failed to meet its primary goal in a Phase 
II trial but it did meet a number of secondary endpoints 
[3]. Other researchers have also explored the clinical 
potential for a recombinant human antibody to neutral-
ize TGF-β1 to combat systemic sclerosis, but their clini-
cal studies did not prove any difference in efficacy from 
control during their Phase I/II trials [3]. TGF-β therapy 




















  . Fig. 52.1 Focal adhe-
sion kinase (FAK)-mediated 
 mechanotransduction. Mechan-
ical forces activate FAK, which 
activates several downstream 
effectors and transcriptional 
factors that mediate cellular 
mechanotransduction [6]. 
Source: Mechanobiology in 
Health and Disease, 1st Edi-
tion. Elsevier. © All rights 
reserved
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dual importance in both normal wound healing and 
also in excessive fibro-proliferation during scar forma-
tion. TGF-β receptors are upregulated during fibrosis, 
and while blocking TGF-β expression seems to prevent 
fibrosis, it can also lead to chronic, nonhealing wounds. 
Albeit, TGF-β continues to be an attractive pharmaco-
logical target for a wide variety of fibrotic diseases, and 
newer strategies modulating TGF-β pathophysiology 
await further investigation.
52.5   Interleukins (IL)
Neutrophils and macrophages, two of the major cell 
types during the inflammatory phase of wound heal-
ing, secrete cytokines such as interleukins (ILs). IL-10 
has been shown to regulate inflammatory cell function 
during wound healing by sequestering pro-inflamma-
tory IL-6 or IL-8 and by regulating the Th1 cell cyto-
kine production [3, 5], leading some research groups to 
explore the therapeutic effect of administering IL-10 to 
the wound bed during early wound healing. The previ-
ously mentioned Renovo also demonstrated the ability 
of IL-10 to potentially improve scar healing in human 
patients during Phase I/II trials administering Prevascar, 
their recombinant human IL-10 (rhIL-10) product [3]. 
However, they were unable to pursue Phase III trials 
after failing the aforementioned Juvidex and Juvista tri-
als. Treatment with rhIL-10 has also been explored in 
several other clinical trials to potentially combat vari-
ous inflammatory diseases such as Crohn’s diseases and 
rheumatoid arthritis with disappointing results, but has 
shown promise in treating psoriasis.
52.6   Mechanotransduction Pathway 
Inhibitors
During wound healing, mechanical stress plays an 
essential role in promoting pro-fibrotic cellular events 
through mechanisms that stimulate inflammatory path-
way components leading to exuberant fibro-prolifera-
tion. Manipulation of the wound mechanoenvironment 
with new medical devices that can modulate local bio-
mechanics, therefore, has gained a rapidly growing mar-
ket for scar reduction of surgical wounds [6–8]. Based 
on long-standing surgical principles clinically used to 
minimize scar development, these polymer-based medi-
cal devices offload mechanical force to release tension 
imposed upon healing surgical incisions. In particular, 
incisions created at high-tension body locations such as 
the central chest, shoulders, knees, ankles, and/or the 
back are prone to forming HTS than other body sites. 
For example, abdominoplasty wounds can develop into 
wide scars due to their natural high-tension closure, and 
application of a stress-shielding device on these wounds 
has demonstrated clear efficacy in mitigating scar for-
mation [6]. This technology successfully led polymer 
stress-shielding devices to the market, and numerous 
patients have seen benefits in the clinic.
Despite success on surgical incisions, polymer mech-
anomodulatory devices are difficult to use on large-
sized excisional wounds, burn injuries, and wounds that 
formed in contoured body areas. Alternatively, nonin-
vasive therapeutics that pharmacologically target key 
mechanotransduction (cellular machinery that trans-
duces mechanical stimuli to biochemical signals) path-
ways have also received highlight in recent literature. 
Currently, a prototype of such therapeutic agents is at 
the early preclinical development stage with transla-
tional potential.
Small molecule-mediated suppressors of pivotal 
mechanomodulatory proteins have been studied as anti-
cancer agents for many decades. A non-receptor protein 
tyrosine kinase, focal adhesion kinase (FAK), is a key 
upstream mediator of the Integrin mechanotransduc-
tion pathway and an important inducer of cell adhesion, 
proliferation, migration, and angiogenesis [8, 9]. FAK 
is known to be deregulated in cancer and is thought 
to be a rational target to block tumorigenic activities 
using pharmacological inhibitors [10]. Because emerg-
ing studies have shown that FAK transduces mechanical 
stress signals to stimulate the activation of the FAK–
ERK–MCP-1 signaling pathway and is an important 
regulator of cancer-promoting pathways [6–8], many 
pharmaceutical companies have taken effort to develop 
later- generation FAK inhibitors that display improved 
pharmacodynamic and pharmacokinetic properties. 
Clinical trials are ongoing in human cancer subjects, 
and the therapeutic potential to antagonize stromal 
solid tumors seems promising to date [10].
In currently available literature, small molecule- 
mediated inhibition of the kinase activity of FAK 
has been successfully used to prevent experimental 
bleomycin- induced lung fibrosis and mechanically 
induced skin HTS formation [6, 9]. FAK inhibition sig-
nificantly reduced scar-forming fibroblast migration, 
myofibroblast production of α-smooth muscle actin, 
and aberrant collagen extracellular matrix deposition in 
these studies (. Fig. 52.2) [9]. Because wound healing 
and cancer development share similarities in terms of 
overlapping mechanisms that promote transformation, 
proliferation, and survival of cells, FAK inhibitor ther-
apy that can be safely delivered to wound sites would 
be a new and promising approach to wound and scar 
management. In most circumstances, cutaneous scar 
development is a localized event; therefore, this provides 
rationale and support to develop targeted FAK inhibi-
tor delivery modalities in attenuating scar formation. 
Localized drug delivery has the advantage of circum-
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venting systemic toxicity while maximizing bioavail-
ability and local drug efficiency. Localized topical FAK 
inhibitor therapy ideally requires drug delivery vehicles 
that are biocompatible, eliciting no or low immuno-
genicity. Medicated self-adhesive patches that release 
therapeutic molecules upon dermal contact may not be 
suitable for large-sized open wounds, and other topical 
formulations in the form of topical cream, lotion, or 
ointment are easily subject to over- or under-dosing if  
application amount per treatment is not accurately mea-
sured. The latter is also problematic especially for thera-
peutic compounds with potential toxicological effects at 
the systemic level. Therefore, it is scientifically reason-
able to devise a dermal delivery vehicle that can deliver 
topical FAK inhibitor to wounds and/or scars in a con-
trolled manner. Biopolymers have strong advantages as 
drug delivery carriers because of their ability to carry 
bioactive compounds to target tissues and cells and to 
release compounds over a prolonged duration. Recent 
studies have used collagen-based bioscaffolds to develop 
biodegradable hydrogels that release FAK inhibitors in 
a regulated manner upon direct contact with the skin, 
which has proven preclinical efficacy in rodent wound 
models for HTS reduction [9]. Development of relevant 
drug delivery systems and extensive safety studies on 
potential adverse effects of each agent will be imperative 
to successful development of pharmaceutical therapies 
against fibrotic scar formation.
52.7   Supportive Articles in the EBM 
Literature
To date, currently available scar treatment modalities, 
especially for large-sized excisions and burn-related 
injuries, have not led to successful clinical outcomes, 
and the future market for new wound healing and scar 
mitigation therapies remains strongly promising. Recent 
progress in the identification of new signaling pathways 
and cellular components implicated in fibrotic scar for-
mation has advanced our knowledge toward developing 
nontraditional therapies for scar treatment. Promising 
results in preclinical studies have resulted in many publi-
cations from multiple research groups with some thera-
pies already completing human clinical trials. Scientific 
rationale for these newer therapies is strong; however, 
clinical development of some of these agents have faced 
failure during clinical trial phases. TGF-β-based thera-
pies, Juvista and Juvidex, both displayed strong preclini-
cal effects but failed during multiple human trials. IL-10 
products also showed disappointing clinical outcomes. A 
mechanomodulatory agent, specifically localized FAK 
inhibitor therapy, is in its early preclinical development 
stage with promising animal data recently published. 
The more we understand the cellular and molecular 
mechanisms underlying fibrosis and scar formation, the 




  . Fig. 52.2 Pharmacological blockade of  focal adhesion kinase 
(FAK) improves wound healing and reduces scarring of  murine 
burn wounds. (a, b) Mouse contact burn wound healing was accel-
erated with FAK-I hydrogel treatment. (c, d) Wound expression of 
α-smooth muscle actin (SMA) was significantly reduced with FAK-I 
hydrogel treatment [9]. Source: Journal of Investigative Dermatology 
(2018), Volume 138. Elsevier. © All rights reserved
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52.8   Clinical Relevance
Cutaneous scar development of the skin, particularly 
the formation of HTS and keloidal scars following 
wound healing, constitutes a major clinical challenge for 
health care, both in terms of individual suffering and 
economic burden.
Scar formation can occur at any site of dermal 
lesion resulting from burn-related trauma, or surgical 
wounds. Burn patients are particularly prone to severe 
disfigurement and functional impairment through often 
extensive scarring, and affected children are the most 
vulnerable patient group in regard to long-term suffer-
ing. HTS formation affects a variety of life quality deter-
minants. Cosmetic disfigurement by scar appearance 
may strongly diminish a person’s self- consciousness, as 
well as their ability to participate in social activities and 
professional life, and is often associated with serious 
physical impairments, especially in the context of scar- 
induced contractures. Moreover, scars frequently cause 
secondary illnesses requiring complex multidisciplinary 
treatment not only by plastic surgeons but also by der-
matologists, physical therapists, and psychotherapists. 
In children, abnormal scars can profoundly limit the 
potential of physical as well as emotional and psycho-
social development during childhood. Therefore, effec-
tive scar treatment approaches can critically determine a 
person’s long-term ability to lead a self-determined life.
From the perspective of health care professionals, 
researchers, and health economists, and for the society 
as a whole, scar formation is perhaps still an underesti-
mated yet growing burden for the public health. In the 
United States alone, about 500,000 patients are treated 
for burn injuries each year, resulting in expenses of 
about $7.5 billion. Conversely, treatment of scarring is 
a considerable economic factor, generating a $12 billion 
annual market with further potential to grow [1, 2, 6].
It is a long-standing clinical observation that the 
proneness to HTS formation and keloids is considerably 
influenced by individual genetic traits as well as eth-
nic risk profiles [6]. Studies showed that about 16% of 
patients with Hispanic or African ancestry are affected 
from keloidal scarring, as patients with darker skin color 
are approximately 15 times more likely to be affected 
than light-skinned individuals. As the individual recur-
rence risk of keloids also strongly depends on consti-
tutional determinants, progress in research toward their 
identification and, ultimately, targeted modulation can 
immediately affect therapeutic strategies of scar forma-
tion in the future. Consequently, scarring is a promising 
as well as challenging field of translational research into 
personalized medicine in the field of plastic and recon-
structive surgery. Beyond that, the search for novel phar-
macological treatments addressing molecular targets 
in the pathways of wound healing and fibrosis has the 
potential to improve the lives of numerous patients, and 
also to generate new products for health care of major 
economic value.
52.9   Conclusion
Wound healing and repair following injury is a complex 
and poorly understood process that leads to cutaneous 
scar formation, which constitutes a significant health 
care burden. Despite spending billions of dollars every 
year on scar management, traditional scar treatment 
modalities have not proved to be effective. Treatment 
modalities such as corticosteroid injections and radia-
tion can be largely uncomfortable for the patients. 
Surgical revisions, which are targeted at reducing the 
wide base of the scar, are associated with high recur-
rence rates in the absence of other therapeutic strate-
gies.  Identification of key signaling pathways that are 
dysregulated during abnormal wound healing has led to 
the emergence of a range of new pharmacological inter-
ventions that target growth factors, cytokines, and col-
lagen biosynthesis, and have showed promising results 
initially but have not led to successful outcomes in later 
clinical trials.
The clarification of the role of mechanotransduc-
tion in fibrosis has opened up a new avenue for scar 
therapy research. Offloading of mechanical forces of 
surgical incisions during healing has been shown to 
be effective in reducing scar formation, which further 
underscores the importance of mechanical signaling 
in scar development. Specifically, inhibition of focal 
adhesion kinase, a key regulator of mechanotransduc-
tion has been shown to be effective in attenuating scars 
and accelerating wound healing. Small molecule inhi-
bition of FAK blocks the activation of inflammatory 
signaling pathways, thus uncoupling mechanical force 
from pathologic scar formation. This strategy has been 
employed to reduce scar formation in burn wounds 
as well as excisional wounds in mice. Taken together, 
recent findings indicate that molecular strategies tar-
geting mechanotransduction pathways in general and 
specifically FAK pathway can effectively reduce fibrosis 
and show promise as an effective and versatile strategy 
for scar management.
 S. H. Kwon et al.
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Take-Home Messages
 5 The underlying pathophysiology of cutaneous 
hypertrophic scar formation following injury is 
incompletely understood; however, improved 
understanding of the molecular mechanisms by 
which fibrotic scars develop has paved the way for 
devising new approaches in scar therapies.
 5 Traditional scar management modalities include 
surgical revision, corticosteroid injections, and 
radiation treatment methods. These conventional 
therapies are often associated with practical issues 
and higher recurrence rates.
 5 Recent scientific evidence suggests that mechanical 
stress plays a crucial role in promoting pro-fibrotic 
cellular events via pro-inflammatory pathways 
leading to exuberant cutaneous scar formation 
and fibrosis.
 5 New medical devices that can modulate local bio-
mechanics has gained a rapidly growing market for 
scar reduction of surgical wounds.
 5 Pharmacological inhibitors of the mechanotrans-
duction pathways are promising evidence-based 
new scar therapies that block inflammation and 
pathologic scar formation.
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53.1   Introduction
A strategy of remodeling of an existed scar is by chang-
ing its tissue architecture that can eventually lead to a 
grossly non-visible or minimally visible scar. Since some 
years, mechanical or energetic manipulation of scarred 
skin has received considerable attention in attempts to 
improve scar quality. Next to techniques as dermabra-
sia, CO2 laser, or microneedling, microplasma technol-
ogy might represent a new technique in this field [1].
53.1.1   Fractional Microplasma 
Radiofrequency Technology
There are four formats of matter: solid, liquid, gas, 
and plasma. With energy, solid can be converted into 
liquid and liquid into gas. Similarly, gas can also be 
transformed into plasma with energy input. The frac-
tional microplasma radiofrequency technology (FMRT) 
employs the energy of radiofrequency to act on nitrogen 
of the air in the narrow space between the therapy tip 
and the treated skin, and thus to form a grid of high- 
energy focal-led plasma sparks, which result in ioniza-
tion of a portion of the atoms. With this physical effect, 
the FMRT can cause mild ablation of the epidermis 
with the formation of micro-channels in a fractional 
way (. Fig. 53.1).
The device we used in the past 13 years for patient 
treatment was a product from Alma Lasers (Caesarea, 
Israel) called PixelRF with both roller and stationary tips. 
. Figure  53.1 demonstrates its working mechanism of 
the device. In general, this device creates the depth of abla-
tive point in 100–150 μm, and the size of ablative point 
80–120 μm in diameter, and heating effect with a unipo-
lar can reach the depth of 1000 μm, depending on the 
radiofrequency power and pulse duration. However, the 
ablative depth could reach to the upper part of the dermis 
with increasing energy, and thus to remodel a superficial 
layer of dermis. By this way, the FMRT can remodel tis-
sue structure via ablative microchannel of epidermis and 
controlled thermal modification of the underlying der-
mis, with new collagen synthesis and collagen remodeling 
[2, 3]. With this type of working mechanism, the created 
micropore wound can be healed in 7 days (. Fig. 53.2) 
and thus repeated treatments can be applied.
Although this particular device was used because of 
its availability to the author at that time, the effect of 
wound/scar remodeling is also likely to be achieved by 
other devices such as CO2 fractional laser or others made 
by Lumenis, Cynosure, Alma, or Syneron, depending on 























  . Fig. 53.1 The schematic picture of  FMRT working mechanism. a Radiofrequency energy acts on nitrogen to create plasma particles. 
b Plasma particles penetrate epidermis in a fractional way. (Photo courtesy from Alma Lasers. © All rights reserved)
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53.2   Procedures: Clinical Protocol 
for Microplasma-Based Tissue 
Remodeling (. Fig. 53.3)
53.2.1   Pre-therapy Preparation
 1. Patients with skin lesions at the treating area should 
be advised not to receive the treatment before the 
cure of these lesions, including infectious skin lesions 
caused by both virus and bacteria, dermatitis, pso-
riasis, eczema, and urticaria.
 2. Patients should be advised for proper management 
of the micropore wound post-therapy and potential 
side effects with signed written informed  consent.
 3. Photography before the treatment. Be sure that it is 
taken before topical anesthesia and it is in the same 
conditions of environment such as light, focus, and 
positions.
 4. Topical application of 5% lidocaine hydrochloric 
gel under plastic wrap for 60–90 minutes before the 
treatment followed by thorough cleaning and steril-
ization with 70% alcohol.
 5. Non-treated skin should be protected with paper 
tape surrounding the treated skin if  the tip is larger 
than the area to be treated.
53.2.2   Microplasma Treatment
 1. Fractional microplasma radiofrequency treatment 
was performed with the device of Pixel RF (Alma 
Lasers, Caesarea, Israel).
 2. A roller tip was used with the power setting at 60–90 
watts, and 3–4 passes were usually made in different 
directions.
53.2.3   Post-therapy Wound Care
 1. Patients are advised for comprehensive instructions 
of post-procedure care.
 2. Sterile saline cleaning and erythromycin eye oint-
ment were topically applied daily for 6 days to pre-
vent infection.
 3. Patients are advised not to be exposed to sunlight to 
avoid post-therapy pigmentation.
 4. Patients are advised to protect the treating area by 
avoiding scratching or rubbing.
POWER TO ACHIEVE Acutea
• The histology shows a crater caused by ablative
effect of a single Pixel RF spike @45Watts
POWER TO ACHIEVE 3 daysb
POWER TO ACHIEVE 14 daysc
• The histology shows closure of the crater and healing/
rearrangement of the rate ridges area 14 days after Pixel RF.
• The histology shows re-epithelialization of
the crater 3 days after Pixel RF
  . Fig. 53.2 Histological demonstration of  microplasma working 
depth and healing process. a Acute wound immediately after micro-
plasma. b Healing at day 3. c Healing at day 14. (Photo courtesy from 
Alma Lasers. © All rights reserved)
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 5. Patients are advised to have the follow- up regularly.
 6. In the case of early wound remodeling, anti-tension 
type or device should be applied before and after the 
treatment.
53.3   Application Areas for FMRT-Mediated 
Tissue Remodeling
53.3.1   Microplasma Therapy for Post-scar 
Revision Skin to Enhance Cosmetic 
Result
Brief descriptions of the procedures for treating a linear 
scar for cosmetic reasons are as follows:
 1. In general, a patient will visit our clinics and seek 
a consultation through discussing what a patient is 
expected and what can be achieved from the proce-
dures. Then the patient will make an appointment 
for a scar revision surgical procedure.
 2. In the surgical procedure, the patient is given a local 
injection of 1–2% lidocaine for anesthesia. In most 
cases, a w-plasty procedure will be applied along 
with the surgical excision of a linear scar to prevent 
linear tension, which usually causes observable scar-
ring after the scar revision. To reduce wound ten-
sion, wound edge flap should be freed before wound 
closure. In addition, suturing of wound tissue at 
various levels also helps reducing wound tension, 
including subcutaneous, dermal, and epidermal tis-
sues. For patients who are prone to scarring, wound 
irrigation with triamcinolone acetonide (5  mg/mL) 
or 5-fluorouracil (2–4  mg/mL) or both combined 
should be applied before wound closure to prevent 
scar formation.
 3. After the surgical procedure, tension- reduction 
tape (such as 3 M tape) should be applied to keep 
the wound in a tension-free state. Patients are 
advised to have the tape changed every 2–3  days 
and maintained for at least 6 months post-surgery. 
The stiches are removed at day 5 or 6 post-surgery 
for head and neck regions, and stich removal can 
be postponed for 1 or 2 days at other regions. In 
case of  the scar-prone patients who were treated 
for hypertrophic scar or keloid, an injection of  tri-
amcinolone acetonide (5  mg/mL) or 5-fluoroura-
cil (2–4 mg/mL) or both combined with lidocaine 
into the healed wound can be administered at 1 or 
2 months post-suturing.
 4. In most cases, Pixel RF microplasma is applied to 
the healed incisional wound at 8 weeks post- surgery. 
Generally, the therapy should include 2–3 mm nor-
mal skin on both sides of the linear wound. The pro-
cedure is usually applied with a roller tip at 60–70 
watts with 3–4 passes (. Fig. 53.2).
 5. Pixel RF microplasma therapy should be repeated 
for 3–5 times with 8–12  weeks’ interval in general 
and patients should be closely followed up every 
4–8 weeks until a linear wound mark and stich marks 
are completely removed. By this procedure, the lin-
ear scar resulting from scar revision procedure can 
be largely removed and the fine linear scar becomes 
grossly less visible or non-visible.
a b c
  . Fig. 53.3 Microplasma procedure. a Paper taping is applied to 
protect untreated skin and 2–3  mm skin surrounding the healed 
wound tissue is also included in the procedure. b A roller tip is 
applied to perform the procedure. c The gross view of  the treated 
wound/skin tissue immediately after the procedure
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The following are the case presentations.
kCase 1
A 32-year–old female patient  visited our clinic to 
request for forehead scar treatment solely for cosmetic 
reason. Physical examination showed a red-colored lin-
ear scar with a length of 2 cm and a width of 0.2 cm. 
In addition, the linear scar was also a bit elevated and 
with a few stich marks scar on both sides (. Fig. 53.4a). 
The patient received a scar revision surgery along with 
w-plasty procedure. After the surgery, the patient wore 
3 M anti-tension paper tape vertical to the incision line. 
Later, silicone gel was also applied topically on the inci-
sional line, and then 3 M paper was used. At 8 weeks 
post-surgery, she received microplasma therapy with an 
energy of 65 watts and 4–6 passes of rolling therapy. At 
8  weeks after the first treatment, the follow-up photo 
showed significant improvement of the gross view of 
her forehead scar, although a fine linear scar remains 
when observed closely (. Fig. 53.4b). Then, the patient 
received another two treatments with 8 weeks’ interval 
between them. At 8  weeks after the third therapy, the 
follow-up photo shows no visible linear scar on her head 
(. Fig. 53.4c), and the patient was completely satisfied 
as the result match her original request of removing her 
forehead scar completely.
kCase 2
A 27-year-old female patient visited our clinic for cos-
metic treatment of a linear scar on her left face. Physical 
examination showed a mature flatten linear scar with 
a length of 6  cm and a width of 0.5  cm as shown in 
. Fig.  53.5a. The patient received a surgery of scar 
revision plus w-plasty. The follow-up photo at 8 weeks 
post- surgery showed an apparent linear scar resulting 
from scar surgical revision, with which the patient was 
significantly unsatisfied despite the fact that an original 
wide and flatten scar has been transformed into a fine 
a b c
  . Fig. 53.4 Case presentation of  microplasma remodeling of  a 
linear scar resulting from surgical scar revision procedure. a Before 
surgery. b The gross view of  a linear scar at 8 weeks after the first 
microplasma remodeling on a post-scar revision scar. c After 3 
microplasma remodeling, the gross view reveals complete scar 
remodeling and no visible linear scar at the time points of  8 weeks 
after the third remodeling
a b c d
  . Fig. 53.5 Case presentation of  microplasma remodeling of  a 
linear scar resulting from surgical scar revision procedure. a Before 
surgery. b The gross view of  a linear scar at 8 weeks post-surgical 
scar revision. c Gross view of  a remodeled linear scar at 8 weeks after 
the first microplasma remodeling. d After 3 microplasma remodel-
ing, the gross view reveals complete scar remodeling and no visible 
linear scar at the time points of  8 weeks after the third remodeling. 
However, erythema resulting from tissue remodeling remains visible
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linear scar (. Fig.  53.5b). At this time point, micro-
plasma tissue remodeling procedure was applied to the 
patient with an energy of 70 watts and six passes using a 
roller tip. Interestingly, at 8 weeks after the first therapy, 
the linear scar has already been significantly remodeled 
with the previous linear scar obscured; however, the 
linear scar remained obviously visible (. Fig.  53.5c). 
Thereafter, the patient was given another two micro-
plasma therapies with 8 weeks’ interval between them. 
At 8 weeks after the third therapy, the follow-up photo 
showed that a linear scar resulting from scar revision 
surgery was almost completely remodeled with no 
apparently visible linear scar (. Fig. 53.5d). Due to the 
thorough tissue remodeling process, in which the tissue 
structure of a healed linear wound has been significantly 
changed along with a regenerative skin repair, angiogen-
esis apparently occurred with manifestation of skin red-
ness (. Fig. 53.5d), which will disappear in 3–6 months 
after the discontinuation of the treatment. The patient 
was very satisfied with the end result, in which micro-
plasma tissue remodeling played a role significantly 
more important than the surgical procedure.
53.3.2   Microplasma for Early Wound 
Intervention to Prevent Scar 
Formation
With the success of remodeling healed linear wound tis-
sue, we wondered if  such a concept could be applied to 
tissue remodeling of an early incisional wound to pre-
vent scar formation. The scenario is that linear wounds 
of non-elected surgical procedures such as trauma and 
wounding are usually difficult to prepare an optimal 
condition for their healing, and thus these linear wounds 
are more likely to form an obvious linear scar than the 
wounds created by elected surgical procedure of scar 
revision.
Due to the non-optimal healing condition, the 
wound tissue remodeling procedure should be applied 
at an early-stage wound. In addition, improvement of 
wound healing conditions by other wound manipulation 
methods should also be applied comprehensively includ-
ing anti-tension, silicone product, drug local injec-
tion, or even re-suturing of an already sutured wound. 
Following are the general principles:
 1. When a patient with an acute linear skin wound visits 
the clinic, proper wound cleaning should be the first 
consideration. In case of severe wounds or appear-
ance of early signs of wound infection, antibiotics 
should be applied either locally or systemically or 
both.
 2. Anti-tension tape or device should be applied before 
and after stich removal, such as 3 M tape, Zipline™ 
or Neodyne™ or other tension reduction device in 
order to maximally reduce the tension-induced scar-
ring during wound healing process.
 3. Silicone product should be applied as early as pos-
sible, such as Dermatix™, Kelo-cote™ or other 
products. This should be applied along with taping 
or tension-reduction device and wound tension-free 
procedure should not be compromised by other pro-
cedures.
 4. Proper surgical procedures for wound closing is 
important as a thick scar will be too difficult to be 
remodeled for achieving a desirable effect. When 
decided to perform, proper debridement, wound 
edge preparation as well as fine suturing should all 
be included.
 5. The timing for microplasma procedure can be 
decided on the basis of the wound condition. If  an 
injured wound is properly managed with a condi-
tion similar to that of elected surgical procedure, the 
remodeling procedure can be performed at time point 
about 8 weeks post-wound closure to give a wound 
sufficient time to heal as a very fine linear immature 
scar, which can be completely remodeled with micro-
plasma procedure. If  a wound is improperly closed 
with a thick linear wound mark and obvious other 
stich marks, then the procedure should be applied as 
early as 1–4 weeks post- wound closure.
 6. The energy of microplasma remodeling can be 
adjusted according to the wound condition. For 
example, a wound of a child or a wound with fine 
closure technique, then the wound can be treated 
with a relative low energy; whereas a wound is closed 
unprofessionally or in a poor condition, a relatively 
high energy should be applied and the treatment 
should be repeated until a desirable result can be 
achieved.
 7. The comprehensive scar-reduction management 
should be continually applied after the remodeling 
and maintained for at least for 6 months post-wound 
closure.
The following are the case presentations.
kCase 3
A 52-year-old male (. Fig.  53.6)was wounded on his 
left-side face 3 days before, and he came to our clinic for 
assistance of the wound management in order to prevent 
severe scarring. Physical examination showed that there 
was a linear wound on his left-side face with a length 
of 3 cm. The wound had been closed unprofessionally 
by single layer suturing with tight knots that would be 
bound to form a thick linear scar with obvious stich 
marks after the healing of the wound (. Fig.  53.6a). 
To better prepare the wound closure, the stiches were 
removed and the wound was re-opened. After thorough 
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wound debridement, wound dermal and epidermal lay-
ers were properly positioned and closed with fine sutur-
ing (. Fig. 53.6b). The stiches were removed at day 5 
post-surgery and 3 M tape was applied. At 4 weeks post- 
surgery (31  days after wounding), the patient received 
his first microplasma remodeling. Eight weeks later 
(87 days after wounding), the follow-up photo showed 
significant improved gross view of the healed linear 
wound (. Fig.  53.6c). Then the patient was given the 
second microplasma remodeling. Eight weeks later 
(143 day after wounding), the patient was followed up 
with a photo demonstrating that linear wound mark was 
almost all removed via tissue remodeling (. Fig. 53.6d). 
The patient was very satisfied with the wound remodel-
ing result.
kCase 4
A 11-year-old female was injured on her left-side face 
and part of nose 5  days before she visited our clinic. 
She had concern of possible scar formation on her face 
after wound healing. Physical examination showed that 
there was a linear scar on her left-side face starting from 
suborbital region and extending to the left part of the 
upper region of the nose. In addition, she also had a 
curved linear wound at the left side of her left ala nasi as 
shown in . Fig. 53.7a. The patient was asked to remove 
her stiches and to apply 3 M tape for anti-tension pur-
pose. The patient was given COX-2 inhibitor (oral 
medicine) for 2  weeks to reduce wound inflammatory 
process. At day 12 post-wounding, there was an early 
sign of scar formation as raised tissue was observed on 
the upper wound of her face (arrow, . Fig. 53.7b). The 
patient was thus given an injection of low concentra-
tion steroid to inhibit potential scar formation. Four 
weeks later, several more injections were given with 
4 weeks’ interval between them. During the time period, 
taping and silicone gel were consistently applied. At 
3.5  months post- wounding, the patient was given the 
first microplasma remodeling. Eight weeks after the 
first therapy (5.5 months post-wounding), the scarring 
was significantly remodeled with obvious improvement 
of the gross view as shown in . Fig. 53.7c. Afterward, 
a b c d
  . Fig. 53.6 Case presentation of  microplasma intervention of  an 
early stage wound to prevent scar formation. a The patient has facial 
wound 3 days ago with unprofessional wound closure technique. b 
The stiches were removed and the wound was reopened. After wound 
debridement and proper position of  wound tissues, the wound was 
properly closed with fine suturing technique, which paved the way for 
further tissue remodeling. c Gross view shows remodeling of  a linear 
scar at 8 weeks after the first microplasma remodeling. d Gross view 
shows that post-wound linear scar is almost completely remodeled 
with no visible scar
a b c d
  . Fig. 53.7 Case presentation of  microplasma intervention of  an 
early stage wound to prevent scar formation. a The patient has two 
wounds on her face for 5 days. b Early sign of  scar formation was 
observed on her upper face scar at day 12 post-wounding. The arrow 
shows elevated tissue growth that would develop into hypertrophic 
scar, and thus a steroid injection was given. c Significant improve-
ment of  the linear scar was observed at 8 weeks after the first micro-
plasma remodeling. d Gross view shows almost complete remodeling 
of  the linear scar except for minor hyperpigmentation caused by 
microplasma treatment
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the patient was given three more procedures of micro-
plasma remodeling. The final follow-up photo demon-
strated that original scar was barely visible except for 
minor pigmentation. The patient was extremely satisfied 
with the results.
53.3.3   Microplasma Remodeling 
for an Existing Linear Scar
As described previously, scar revision surgery along with 
microplasma tissue remodeling is a preferred procedure 
to deal with the significant linear scars in majority cases. 
However, direct remodeling with microplasma is also a 
choice for linear scars under certain conditions. These 
include (1) a superficial linear scar; (2) an irregular 
shaped linear scar that is difficult to revise with surgical 
procedure; (3) a linear scar that formed in not too long 
time; and (4) the scar contains less dense collagen. These 
linear scars are more likely to be remodeled than other 
types of linear scars.
The following is a case presentation:
kCase 5
A 35-year–old female patient had an irregular linear 
scar caused by trauma in less than 1 year on the region 
between forehead and nose (. Fig.  53.8a). The linear 
scar was relatively irregular and superficial and was a bit 
raised above the skin. Microplasma remodeling proce-
dure was applied using a roller tip with 70 watts for 4–6 
passes. . Figure 53.8 shows the tissue remodeling results 
after the first (. Fig. 53.8b), third (. Fig. 53.8c), and 
fourth (. Fig.  53.8d) microplasma treatments, which 
demonstrated gradual improvement of the gross view of 
the linear scar, and the scar was barely detectable at the 
end of the treatment. The patient was very happy with 
the end result.
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Vacuum massage is also known as depressomassage, 
vacuotherapy, or Endermologie®. It is a non-inva-
sive mechanical massage technique performed with a 
mechanical device that lifts the skin by means of suc-
tion, creates a skin fold, and mobilizes that skin fold [1, 
2] as displayed in . Figs. 54.1 and 54.2.
Vacuum massage originates from cupping therapy, 
a traditional Chinese medicine therapy dating back 
2000 years or more. A local suction on the skin is cre-
ated using heat or mechanical forces in order to create 
vasodilatation. In the late 1970s, Louis-Paul Guitay 
suffered from severe skin burns after a car accident. 
During his rehabilitation, he had to endure hours of 
manual massages every day. This multi- month process 
was normal practice for burn victims with extensive 
scar tissue in the late 1970s. Massage sessions typi-
cally lasted 3– 4 hours a day and consisted of rigorous 
routines. The therapist rolled skin and tissue back and 
forth to regain elasticity. As days grew into weeks, Gui-
tay became dissatisfied with these incessant treatments. 
They were time- consuming, labor intensive, and he 
noticed his results varied drastically based on the skills 
of each individual therapist. Endermologie®, taken 
from the French term meaning “through the dermis”, 
was Louis-Paul Guitay’s way of standardizing mas-
sage therapy to maximize the effect of each treatment. 
He developed a mechanical device to copy the manual 
massage techniques by means of negative pressure. 
This method allowed him to perform the massage in 
a more consistent way and was less time consuming. 
From then onward, Endermologie® or vacuum mas-
sage has been frequently used to treat traumatic or 
burn scars.
Although vacuum massage was invented to treat 
burns and scars, very little literature is available on 
the effects of this intervention. Soon after its devel-
opment, the device was used extensively in Europe to 
treat trauma and burn scars [2]. In the course of its use, 
care providers soon noticed its ability to improve the 
appearance of cellulite, and consequently most stud-
ies mainly focused on lipodystrophy to investigate its 
working mechanism. The number of studies concern-
ing cellulite is three times higher than those of burns 
or scars.
The aim of this chapter is to present an overview of 
the available literature with the physical and physiolog-
ical effects of vacuum massage. This was done in order 
to find the underlying working mechanisms of Ender-
mologie® that could benefit the healing of burns and 
scars. Analyzing the physical and physiological effects 
of this treatment can increase insights in the influence 
on the scarring process and may clarify the outcome.
  . Fig. 54.1 Vacuum massage creates a skin fold and mobi-
lizes that skin fold   . Fig. 54.2 Vacuum massage on scars
 P. Moortgat et al.
477 54
54.1   Working Mechanism of Vacuum 
Massage in Relation to Pathological 
Scarring
In recent years, there has been an increasing interest in 
the mechanobiology of scars. The influence of mechani-
cal forces on skin has been examined since 1861 when 
Langer first reported the existence of lines of tension in 
cadaver skin [3]. Internal tension in the dermis leads to 
cell–extracellular matrix (ECM) and cell–cell interac-
tions transferring external mechanical forces into bio-
chemical signals inside the cell [4]. Khan et al. reclaimed 
the term “mechanotherapy” and presented the current 
scientific knowledge underpinning how mechanical load 
may be used therapeutically to stimulate tissue repair 
and remodeling. It has long been thought that the effec-
tiveness and efficiency of physical therapy would improve 
if  our understanding of the cell biology/biochemistry 
that participates in mechanics could be improved. 
Traditional physical therapy focuses primarily on reha-
bilitation, but recent developments in mechanobiology 
that illuminated the effects of physical forces on cells and 
tissues have led to the realization that the old therapy 
model should be updated. Recent studies showed how 
mechanotherapies target particular cells, molecules, and 
tissues. The role of mechanical force in various therapies, 
including micro-deforming soft tissue techniques, shock-
wave, vacuum massage, tissue expansion, skin stretching, 
and tension reduction (tissue targeting) therapies is the 
subject of numerous ongoing clinical trials [5–7].
All adherent cells including endothelial cells, fibro-
blasts, and myofibroblasts sense tension originate from 
the environment. Tension is transmitted via cell–ECM 
contacts, leading to reorganization of the cytoskeleton 
and the elicitation of specific signals that modulate gene 
expression. In skin, alterations of mechanical forces are 
continuously recognized by cells, and their functions are 
adapted according to the biological requirements. If  
mechanical tension is removed, those tissues undergo 
atrophy, indicating the important role of mechanical 
signals for maintaining proper functioning of the organ-
ism. Obviously, fibroblasts and myofibroblasts are cells 
implicated in scarring, which is strongly influenced by 
mechanical tension.
The precise mechanisms by which different cell types 
transmit mechanical signals are not fully understood. 
They might involve stretch-activated ion channels, direct 
interactions between structural and signaling compo-
nents, or activation of small GTPases. As outlined above, 
many cooperative interactions exist between integrins 
and growth factor signaling. In particular, fibroblast to 
myofibroblast conversion and alpha-smooth muscle actin 
(α-SMA) expression crucially depend on a combination 
of mechanical tension and TGF-β. Thus in scarring, gen-
eration of tension can induce myofibroblast formation, 
causing a self-perpetuating loop. A similar autocrine loop 
is discussed for the induction of collagen synthesis in 
fibroblasts by mechanical tension. In this case, TGF-β is 
induced by tension, which in turn activates collagen syn-
thesis via the classic pathways. In addition, fibronectin is 
induced by the application of cyclic strain to fibroblasts. 
In parallel, many proteases are downregulated, whereas 
protease inhibitors are upregulated. As a result of these 
events, modulation of mechanical tension results in alter-
ations of fibroblast and myofibroblast activity. . Tension 
directly modifies gene transcription, induces signaling 
from integrins affecting small GTPases, or induces/inhib-
its growth factor signaling, which then indirectly affects 
ECM protein synthesis by fibroblasts/myofibroblasts [8]. 
By a combination of these mechanisms, mechanical ten-
sion induces an activated, contractile fibroblast/myofibro-
blast phenotype characterized by high levels of synthesis 
of ECM proteins, low protease activity, and high produc-
tion of fibrogenic cytokines. Translated into a clinical sit-
uation, this means a retractile scar with adhesions between 
the dermal tissue and the underlying viscera.
The mechanotransduction theories provide possible 
evidence for several physical non-invasive treatment 
options. It was suggested that many of the physical scar 
management methods, including compression therapy, 
silicone therapy, adhesive tape, and occlusive dressing 
therapy, are related to mechanotransduction mecha-
nisms. Mechanical compression seems to induce apop-
tosis and to regulate cytokine release, thus reducing 
hypertrophic scarring. The effects of mechanical tension 
on TGF-beta1 and collagen synthesis leads to the 
hypothesis that brief, moderate stretch of scar tissue 
seems to downregulate hypertrophy and retraction of 
scars and could be the best option for splinting, posi-
tioning, and postural stretching [9].
54.2  The Effects of Vacuum Massage on 
Scars
54.2.1  General Effects [1, 10–12]
General effects are defined as the effects inherent to the 
intervention itself  or to the individual who performs the 
treatment. A number of studies mentioned the mea-
sured effects were dependent on the number of treat-
ments. The more the treatment, the higher the effect. 
After this ascertainment, Adcock et al. also discovered 
that the principal force applied to the tissue during the 
therapy depended on the particular type of maneuver 
performed, with the suction and the roller tension being 
of minor importance. Moreover, they observed a major 
decrease of tension in thicker tissue.
In four studies performed, the results showed a set-
back after a follow-up period without treatment, but 
one study demonstrated the opposite. All these results 
are shown in . Table 54.1.
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  . Table 54.1 Basic information available in the literature describing effects of vacuum massage on several skin layers








Moortgat et al. 
[16]
Burn scars CCT Epidermis/
dermis





Burn scars CCT Epidermis/
dermis
47 POSAS, Tristimulus colorimetry, 
trans-epidermal water loss
18
Adcock et al. [1] Pig skin RCT Dermis/
hypodermis
12 Histology 17
Adcock et al. [12] Pig skin RCT Hypodermis 4 Intra-dermal tonometry 16
Revuz et al. [11] Aging skin CCT Dermis 24 Subjective assessment of  skin laxity and 
skin loosening, stereophogrammetry, 
cutometer
16
Moseley et al. 
[18]
Scar like RCT Dermis/
hypodermis
10 Likert scale, tonometry 16
Lucassen et al. 
[19] 
Healthy skin Pre/post Dermis/
hypodermis
19 High frequency ultrasound 13
Watson et al. [2] Healthy skin RCT Epidermis/
dermis
5 Laser-Doppler imaging, 
lymphoscintigraphy, venous flowmetry
13




12 Descriptive histology 11




15 Quantitative histology 10




30 High frequency ultrasound, fringe 
projection, skin fold thickness
13




20 Subjective assessment of  pain, itch, 
tightness, erythema and skin 
smoothening, profilometry
13




9 Skin fold thickness 11
Marques et al. 
[10]
Healthy skin Pre/post Hypodermis 12 Gene profiling, micro-array 11
Scuderi et al. [23] Healthy skin RCT Epidermis/
dermis
10 Subjective assessment of  skin 
smoothening and skin tone
10
Majani et al. [24] Scars Pre/post Epidermis/
dermis
26 Subjective assessment of  skin 
smoothness, pain, tenderness, oedema 
and aesthetic improvement, histology
10
Marquez- Rebollo 
et al. [25] 
Scar like Pre/post Epidermis/
dermis
70 Number of  indurations 10
Gavroy et al. [26] Scars CCT Details not 
available
606 Test de glissement 7
Lattarulo et al. 
[27] 
Healthy skin Pre/post Epidermis/
dermis
34 Laser-Doppler imaging, tcpO2 7
Worret et al. [28] Scar like Pre/post Dermis 10 Subjective assessment of  pain, color and 
elasticity, quality of  life, cutometer
7
Delprat et al. [29] Scars Pre/post Details not 
available
132 Test de glissement 5
RCT randomized controlled trial, CCT controlled clinical trial, tcpO2 transcutaneous oxygen pressure
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54.2.2  Physical Effects [13–16]
An improvement of the tissue hardness and the elastic-
ity of the skin were the two most observed effects. 
However, most of the studies used subjective methods to 
quantify these effects. Other reported physical effects 
were decreased skin fold thickness, decreased face vol-
ume, improved skin laxity, increased epidermal thick-
ness, and improved skin roughness. Recent studies have 
shown that elasticity and redness, measured with subjec-
tive and objective assessment tools, were significantly 
improved after 1 year when the scar was treated for 6 
months. The results of one study also revealed that the 
vacuum massage had minimal value as additive treat-
ment to pressure garments and silicone when it con-
cerned redness. For elasticity, on the other hand, vacuum 
massage + pressure therapy and silicone seemed to per-
form better than pressure therapy and silicone alone. 
The results are set out in . Table 54.2.
54.2.3  Physiological Effects  
[2, 10, 13, 15, 17]
An improvement in blood perfusion was noticed in four 
studies. Fibroblast proliferation was enhanced together 
with an increase in collagen content. Two studies men-
tioned an improved venous and lymphatic flow together 
with increased transcutaneous oxygen pressure. 
Smoothening of the dermo-hypodermal junction and a 
decreased dermal interstitial space were also observed. 
One study mentioned altered gene expression profiles in 
adipose tissue. In another study, a significant decrease 
of trans-epidermal water loss (TEWL) was found and 
indicated a recovery of the skin barrier. After correction 
for baseline and age of scar, there was evidence for lower 
mean TEWL values in the vacuum massage group, sig-
nificant after 3 months (p = 0.006). Humbert et al. inves-
tigated the histological effects of vacuum massage and 
discovered an increased migratory ability of fibroblasts 
together with increased elastin and hyaluronic acid pres-
ence which indicated induced remodeling capacity. The 
upregulation of MMP-9 suggests degradation of the 
existing damaged ECM to induce remodeling. These 
findings were somehow confirmed by the study of 
Meirte et al., where an increased dermal thickness 
together with a decreased dermal density were already 
noticed in the first 2 hours after a vacuum massage treat-
ment. These results are shown in . Table 54.3.
54.2.4  Mechanical Effects
The suction forces generated by vacuum massage could 
elicit an array of mechanical forces within the tissues, 
associated with a relaxation of those mechanical forces. 
Once stress forces on a wound were relieved, apoptosis 
of myofibroblasts would occur. This finding implies that 
vacuum massage may release the mechanical stress asso-
ciated with scar retraction, and thus induce apoptosis. 
This can be another plausible theory for its mechanism 
of action to improve the outcome of (burn) scars.
54.3  Conclusion
Although vacuum massage initially had been developed 
for the treatment of burn scars, literature reveals little 
evidence for the efficacy of this treatment. Very few 
studies investigated the effects of vacuum massage on 
human models with scars. The heterogeneous popula-
tion and the wide diversity of study designs make it very 
hard to translate the previously mentioned results 
toward the burns and scars population in humans. 
Although the present study contributes additional evi-
dence for the working mechanism of vacuum massage 
as an anti-scarring agent, the results should be con-
firmed by studies on human models. Variations in dura-
tion, amplitude, or frequency of the treatment have a 
substantial influence on collagen restructuring and 
reorientation, thus implying possible beneficial influ-
ences on the healing potential by mechanotransduction 
pathways. Vacuum massage may release the mechanical 
tension associated with scar retraction, and thus induce 
apoptosis of myofibroblasts. Suggestions for future 
research include upscaling the study design, investigat-
ing molecular pathways and dose dependency, compar-
ing effects in different stages of repair, including 
evolutional parameters and the use of more objective 
assessment tools.
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 5 Vacuum massage is a way of standardizing mas-
sage techniques to optimize the treatment.
 5 Mechanotransduction is the presumed working 
mechanism behind vacuum massage.
 5 Improved tissue hardness and elasticity are the two 
most observed physical effects.
 5 The effect of vacuum massage is highly dependent 
on the type of maneuver performed.
 5 The more treatments are carried out, the higher 
the effect.
 5 Fibroblast migratory and proliferative capacities 
are enhanced by vacuum massage.
 5 Vacuum massage improves scar elasticity, which 
will probably lead to amelioration of function.
 5 Vacuum massage may release the mechanical 
stress associated with scar retraction.
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To influence the evolution of an excessive scar toward 
a normal scar, several physical treatments exist to man-
age hypertrophic scarring. Physical treatments include 
manual and mechanical massage, physiotherapy, ther-
mal therapy, and shock wave therapy. Manual massage 
has a wide array of beneficial effects on scars such as 
drainage of edema, reduction of pain, and pruritus 
and hydration of the skin [1]. Mechanical massage or 
vacuum massage uses gentle vacuum suction to lift the 
skin and to create a skin fold [2]. Since scars have a 
propensity to retract and create contractures in joints, 
splinting, taping, and posture stretching play a crucial 
role in the treatment. Thermal therapy includes high 
pressure showers, thread-like showers, and high pres-
sure water and aims to mobilize the skin, to improve 
flexibility and to reduce inflammation, pain, and pru-
ritus. All of these techniques are frequently used; how-
ever, there is only little supporting evidence [3].
The ideal non-invasive scar treatment should be 
safe, well tolerated by patients, have low associated 
complication rates, is easy to apply, cost-effective, 
and can be used in an outpatient setting. Shock Wave 
Therapy (SWT) meets all the aforementioned require-
ments [4–7]. The application of shock wave therapy in 
scar management (. Fig. 55.1) is still in its exploration 
phase; however, there are some interesting findings [3].
55.1   Working Mechanism of SWT 
in Relation to Skin Defects
SWT converts external mechanical stimuli into bio-
chemical cell reactions (e.g., gene transcription lead-
ing to collagen remodeling) in living tissue, supported 
by mechanotransduction pathways, which result in the 
activation of numerous cellular events, responsible for 
the positive effects of SWT on cell metabolism and cell 
cycle [8]. Moreover, as in some other mechanotherapies 
applied in clinical practice, the main action of SWT 
seems to focus on inducing tissue regeneration and 
matrix remodeling in vivo [9]. Fibroblasts are the major 
mechanoresponsive cells in connective tissue, and are 
therefore the main target of SWT [10, 11]. Fibroblasts 
play a crucial role in remodeling of the extracellular 
matrix (ECM) by synthesizing and organizing connec-
tive tissue components, and there is a strong believe 
that SWT has a modulating effect on these actions and 
could therefore be of interest in scar prevention and 
management.
Sukubo et al. (2015) described the beneficial effects 
of SWT on macrophage behavior. SWT does not acti-
vate resting macrophages and seems to modulate mac-
rophage activity in the inflammatory phase of wound 
healing. It inhibits the M1 (pro-inflammatory) activa-
tion in the initial inflammatory phase and enhances the 
M2 (anti-inflammatory) activation in the late inflam-
matory phase [12]. SWT can also regulate inflamma-
tion via TLR3 pathway in three phases. In an initiation 
phase, it induces a pro-inflammatory reaction mediated 
by cyclophylin A and IL6. There is a suppression of 
inflammation in the middle phase and in the limitation 
phase, there is a late anti-inflammatory effect mediated 
by IL10 [13]. Both findings indicate that SWT, applied 
in the wound healing stage or in the early stage of scar 
development, could prevent pathological scarring.
Non-randomized clinical data suggest that SWT is 
beneficial in terms of improved skin elasticity and revi-
talizing dermis in females with cellulite [14]. Fibrillar 
adipose tissue fibrosis looks very similar to dermal scar-
ring [15], so the outcomes of clinical trials investigating 
cellulite could be transferred to pathological scarring [2]. 
MR imaging has shown that fibrous septa, visualized in 
97% of the area with cellulite depressions, are markedly 
thickened in cellulite afflicted areas. Shockwave energy 
might weaken the fibrous septa, and thus the afflicted 
skin becomes smoother [14]. There is evolving experi-
mental data suggesting SWT activation pathways in 
adipose-derived stem cells [14].
Delayed wound healing might be considered as one 
of the main reasons to develop hypertrophic scars. SWT 
has repeatedly proven to be effective as a wound-healing 
modality by decreasing time to full wound closure [4, 5, 
16, 17]. From the mechanobiologic point of view, it has 
been described that the neoangiogenic capacity could be 
related to the inhibition of endothelial cell apoptosis, 
occurring in the very early phase after SWT stimulation 
(first 3  hours), as an initial response to the mechani-
cal stimulus. More in detail, it seems possible to detect 
some “preparatory” signals, such as downregulation of 
the genes involved in cell cycle, adhesion and apopto-
sis, probably correlated to an upcoming detachment of 
endothelial junction [9]. After a low-energy SWT treat-
  . Fig. 55.1 Shock wave application on a scar
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ment (800 shocks, 1 Hz, 0.03 mJ/mm2), mRNA expres-
sion and protein levels of vascular endothelial growth 
factor (VEGF) and endothelial nitric oxide synthase 
(eNOS) were significantly upregulated. Furthermore, 
the SW therapy enhanced phosphorylation of cave-
olin- 1 and the expression of HUTS-4 that represents 
β1-integrin activity. These results suggest that caveolin-1 
and β1-integrin are involved in the SW-induced activa-
tion of angiogenic signaling pathways [18].
We can summarize that the overall effect of SWT is 
an improvement of tissue homeostasis, accompanied by 
an improvement of the tissue self-healing abilities.
55.2   SWT Dose Effect Relationship
For a full treatment outline, the energy flux density 
(EFD), the number of pulses, the pulse frequency, and 
the number and interval of treatments are the most rele-
vant parameters [5]. Differences in these parameters can 
lead to varying outcomes, emphasizing the dose depen-
dency of these mechanotransduction events [9]. High-
energy SWT can suppress cell growth, while low- energy 
shock waves might enhance cell proliferation [19]. SWT 
applied with an EFD of 0.01–0.03 mJ/mm2 can modu-
late the inflammatory pathway in which macrophages 
are involved [12], and with an EFD of 0.08  mJ/mm2 
SWT can regulate inflammation via the TLR3 pathway. 
The EFD for soft tissue indications is typically in the 
range of 0.08–0.25  mJ/mm2 [4], while scars and fibro-
sis are treated with an EFD ranging between 0.15 and 
0.33 mJ/mm2. SWT settings of 0.22 mJ/mm2 and 1000 
pulses seem to be ideal for fibroblast viability and growth 
[20]. Fibroblast viability was also influenced by the num-
ber of pulses. The higher the number, the more risk for 
cell destruction [11]. Each cell type seems to be respon-
sive to SWT but probably with different optimal device 
settings and ranges of mechanical stimulation, thus 
developing different biochemical effects [8]. A study by 
Lee et al. showed that the EFD plays an important role 
in the targeting of specific mechano-signaling pathways, 
with 0.12 mJ/mm2 being the optimal dose for activating 
the mTOR-FAK pathway [21] and 0.10 mJ/mm2 showed 
the best results for inhibiting TGF-β1/Smad pathway 
[22] (. Table 55.1).
55.3   The Effects of Shock Wave Therapy 
in Soft Tissue Defects
55.3.1   The Effects of SWT in Wound Healing
Wound healing after SWT is characterized by an upreg-
ulation of the angio-active factors such as nitric oxide 
(NO) and vascular endothelial growth factor (VEGF) 
leading to induced angiogenesis [17], vasodilatation, 
increase in vascular and capillary density, and increased 
local blood flow. NO and VEGF are extremely impor-
tant, both in early stage and late stage healing [5, 7, 9, 
11, 17]. It has been suggested that an aspect of the early 
gene response of endothelial cells to SWT is character-
ized by a decreased apoptosis and stimulation of the 
extracellular matrix metabolism [5, 9]. SWT will lead 
to reduced tissue necrosis in wound healing by increas-
ing cellular proliferation and procollagen production 
[11, 23]. In terms of timing, vasodilatation is noticed 
at an early stage (first 3 days) and neovascularization at 
late- stage post intervention [17]. In a clinical trial inves-
tigating the efficacy of ESWT to heal chronic therapy-
refractory ulcers, the underlying molecular mechanisms 
were also studied in vitro [24]. Fibroblasts reorganized in 
a radial and star-shaped clustered manner and had large 
“stress” fibers. Cluster formation of fibroblasts was 
dose dependent, meaning that more applications lead to 
higher clustering. Shock waves also induce upregulation 
of 67 genes for keratinocytes and 652 genes for fibro-
blasts, suggesting that SWT mainly targets fibroblasts 
[24]. The upregulation of Vimentin on mRNA level 
leading to a visible reorganization of the cytoskeleton 
provided yet another proof for mechanotransduction as 
working mechanism for this intervention.
Besides “general wound healing,” SWT has specifi-
cally been proven effective in burns. First, SWT applied 
upon donor site healing burn wounds shows a signifi-
cantly shorter time to complete epithelialization [25]. 
Second, burn area perfusion has been evaluated with 
Laser Doppler Imaging before and after SWT and 
showed a significantly increased perfusion after extra-
corporeal shockwave therapy treatment [26]. The review 
of Antonic et al. suggested that SWT may decrease the 
need for surgical intervention and associated morbidities 
in patients with severely deep partial- or full- thickness 
  . Table 55.1 Suggested SWT settings for electro-hydraulic devices when treating wounds or scars






SWT for wound healing 0.03–0.20 mJ/mm2 500–1000 4–6 Hz 1× per week 1–3
SWT for scar treatment 0.15–0.33 mJ/mm2 800–1500 4–6 Hz 1× per week 8–12
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burns [4]. Joo et  al. demonstrated that ESWT signifi-
cantly reduced burn scar pruritus severity and activi-
ties-of-daily-living disturbances compared to a control 
group who received sham treatment. The EFD ranged 
between 0.05 and 0.20 mJ/mm2, which seemed useful for 
pruritus in burn scars [27]. The authors hypothesized 
that ESWT targeted “neurogenic inflammation,” which 
is an inflammation caused by the release of substances 
(e.g., SP and CGRP) from primary sensory nerve end-
ings. Nerve fiber loss and the depletion of neuropeptides 
might decrease inflammation, and thus may decrease 
itch [28]. A recent meta-analysis showed that ESWT had 
better therapeutic outcomes on acute and chronic soft 
tissue wounds when compared to Conventional Wound 
Therapy (CWT) [29]. The meta- analysis showed that 
ESWT statistically significantly increased the healing 
rate of acute and chronic soft tissue wounds 2.73-fold 
(odds ratio, OR  =  3.73, 95% confidence interval, CI: 
2.30–6.04, P < 0.001) and improved wound-healing area 
percentage by 30.45% (Standardized Mean Difference 
(SMD) = 30.45; 95% CI: 23.79–37.12; P < 0.001). ESWT 
reduced wound-healing time by 3 days (SMD = −2.86, 
95% CI:-3.78 to −1.95, P < 0.001) for acute soft tissue 
wounds and 19 days (SMD = −19.11, 95% CI: −23.74 
to −14.47, P  <  0.001) for chronic soft tissue wounds 
and the risk of wound infection by 53% (OR  =  0.47, 
95% CI: 0.24–0.92, P = 0.03) when compared to CWT 
alone. Serious adverse effects were not reported [29] 
(. Fig. 55.2).
55.3.2   The Effects of SWT in Scar 
Management
Fibrous tissue can be reduced by SWT (at the origin) 
during wound healing processes, but it can also be 
remodeled in a second phase of scar formation. Primary 
data show that height, pliability, vascularity, and pig-
mentation, all relevant scar parameters, show improve-
ment after SWT [6, 30]. The change in these physical and 
physiological parameters will probably lead to ameliora-
tion in function, which is, for example, demonstrated 
by an increase of passive ROM reported in a study on 
retracting hand scars [30]. Subjective pain measures also 
show a decrease in pain at the scar site after SWT [6, 30].
On a histopathological level, the effects of  SWT 
on fibrosis are plural. A downregulation of  alpha-
SMA expression, myofibroblast phenotype, TGF-β1 
expression, fibronectin, and collagen type I are mea-
sured. A significant increase in dermal fibroblast-like 
phenotype with low contractility and high migratory 
ability, small vessel density and precursors of  extracel-
lular matrix components, probably leads to new and 
thinner collagen fascicles and parallel orientation to 
the dermo- epidermal junction [30–32]. Synergistic 
alterations in pro- and anti- fibrotic proteins (TGF-β1 
and MMP-2, respectively) suggest a reduced capsule 
formation after silicone implantation [33]. One study 
compared ESWT to triamcinolone injections for the 
treatment of  keloids. ESWT showed comparable func-
tional outcome, together with comparable total sum of 
scores for POSAS patient scale and POSAS observer 
scale clinically. A significant reduction in collagen 
fibers and increased expression of  MMP-13 degrading 
enzyme could be seen when compared to intralesional 
steroid injection [34]. Zhao et al. demonstrated positive 
results on planimetric scar characteristics and inhibi-
tion of  TGF-β1/Smad signaling pathway with Radial 
Extracorporeal Shockwave Therapy [22], as well as 
decreased Scar Elevation Index, fibroblast density, and 
α-smooth-muscle-actin expression in hypertrophic scar 
tissues of  a rabbit model [35].
The most promising results in the research for the 
effects of SWT on scars were presented as preliminary 
data of an ongoing randomized placebo controlled trial 
investigating the effects of SWT in the management of 
hypertrophic scars. The results of the objective assess-
ments showed a statistically significant better perfor-
mance of the intervention group for elasticity assessed 
with cutometry [36] (. Table 55.2).
55.4   Conclusion
All the presented findings are fundamental knowledge 
for further investigation of SWT to reduce the fibrous 
component in regenerating and remodeling tissues. 
The dose dependency of the treatment effects remains 
understudied. Energy Flux Density, number of shocks, 
shock frequency, and treatment interval and number are 
all important parameters in the choice for the most suit-
able device settings, in relation to the indication. Future 
studies should include these parameters as covariates to 
determine the right-specific approach for each scar. The 
full potential of SWT in wound healing, scar treatment, 
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56.1   Introduction
In Japan, corticosteroid tapes and plasters have long 
served as a first-line therapy for keloids and hypertro-
phic scars. Pediatric patients are particularly responsive 
to this type of treatment. This may reflect the fact that 
children have thinner skin than adults and the steroids 
are therefore more easily absorbed. The postoperative 
application of corticosteroid tapes/plasters also signifi-
cantly prevents the development of keloids and hyper-
trophic scars after surgery.
External corticosteroid preparations are classified 
into five classes on the basis of  their vasoconstric-
tor activity and their clinical effect, namely, Group I 
(Strongest), Group II (Very strong), Group III (Strong), 
Group IV (Mild), and Group V (Weak). Steroid tape 
is available in the following three countries in different 
preparations. In the UK, the commercially available 
formulation comprises a fludroxycortide-impregnated 
tape (4  μg/cm2) [1]. Fludroxycortide tape is a Group 
III preparation. The USA has a steroid tape prepara-
tion that contains 4  μg/cm2 flurandrenolide, which is 
also a Group III preparation [2]. In Japan, two steroid 
tape formulations are available, namely, the Group 
III preparation found in the UK (4 μg/cm2 fludroxy-
cortide tape) and a 20  μg/cm2 deprodone propionate 
tape. Deprodone propionate tape is considered to be 
a Group I or II preparation [3] (. Fig.  56.1). In our 
experience, deprodone propionate tape (Eclar® plas-
ter) is the most effective tape for the treatment and pre-
vention of  keloids.
56.2   Difference Between Steroid Tapes/
Plasters and Steroid Injection
Corticosteroid injections rapidly reduce the volume of 
keloids and hypertrophic scars. However, the downsides 
of corticosteroid injections include pain (caused by the 
injection itself) and difficulties associated with contra-
indications such as pregnancy, glaucoma, or Cushing’s 
disease [4]. These problems can be overcome by using 
steroid tapes/plasters. Most pediatric and older patients 
can be treated by steroid tapes/plaster alone due to their 
thinner skin, which means that the steroids are easily 
absorbed.
Corticosteroid tapes/plasters can also be used in 
combination with other therapies such as corticoste-
roid injection. This is particularly suitable for adults 
with keloids and hypertrophic scars. The patients 
can apply the steroid tape/plaster every day in their 
homes and undergo the injection when they can go to 
the hospital. In our hospital, we succeeded in reduc-
ing the number of  hospital visits of  patients with 
pathological scars by adopting this approach. Indeed, 
many patients now only come to our hospital every 
3–4 months.
56.3   Typical Usage of Steroid Tapes/
Plasters
Steroid tapes/plasters should be changed every day. 
Important tips regarding the treatment of keloids and 
hypertrophic scars with steroid tapes/plasters are as fol-
lows. First, the patient should continue to use the tapes/
plasters until the elevated mass becomes flat and soft. 
The patient must also cut the tape according to the 
shape of the keloid or hypertrophic scar. Second, once 
a
b
  . Fig. 56.1 The steroid tapes and plasters that are available in 
Japan. a Fludroxycortide tape (Teikoku Seiyaku CO., LTD., Kagawa, 
Japan). b Deprodone propionate plaster (Hisamitsu Pharmaceutical 
CO., LTD., Saga, Japan)
 R. Ogawa
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the mass has become flat and soft, the use of steroid 
tape/plaster should be stopped, even if  the scar is still 
red. This reflects the fact that if  the patient continues to 
use the tape just because the scar is still red, capillarecta-
sia will occur. This is because the steroid treatment thins 
the structures supporting the blood vessels.
56.4   Difference Between Deprodone 
Propionate Plaster and Deprodone 
Propionate Ointment
At this stage, deprodone propionate plaster is the stron-
gest steroid tape/plaster in the world. Deprodone propio-
nate plaster was launched by Hisamitsu Pharmaceutical 
Co., Ltd., Saga, Japan in July 2001. Since the deprodone 
propionate in this plaster is at a concentration of 20 μg/
cm2, each 7.5 cm × 10 cm sheet contains 1500 μg of the 
steroid. The product sheet states that of the 910 cases, 24 
(2.64%) exhibited side effects to this plaster. The main 
side effects were capillary dilation (nine cases, 0.99%), 
contact dermatitis (five cases, 0.55%), skin atrophy (four 
cases, 0.44%), and hair folliculitis (four cases, 0.44%).
Deprodone propionate ointment is considered to be 
a Group III preparation: thus, it is 1–2 ranks weaker 
than deprodone propionate tape. This is because of 
differences in the action time and how much steroid 
is absorbed. When choosing between deprodone pro-
pionate ointment or deprodone propionate plaster, it 
should be noted that to cover the 75 cm2 area of  one 
deprodone propionate plaster, one must apply 0.125 g 
of  deprodone propionate ointment. This is because 
the product sheet states that 0.5 g of  the ointment can 
coat an area of  300 cm2. However, since the ointment 
consists of  0.3% of the active ingredient, 0.125  g of 
ointment will only contain 375 μg of  deprodone pro-
pionate. This is one- quarter of  the amount of  one tape 
(1500 μg). Therefore, deprodone propionate ointment 
will only have the same effect as 24-hr/day depro-
done propionate plaster if  the ointment is applied to 
the affected area 4 times a day and is covered with an 
occlusive dressing technique (ODT) using, for example, 
a polyurethane film.
56.5   Therapeutic Effect and Usage 
of Steroid Tape Preparations
In adults, deprodone propionate plaster is a more effec-
tive therapy for pathological scars than other steroid 
tapes. However, in pediatric patients, the therapeutic 
effect of  the other tapes is sufficient (. Fig. 56.2). This 
is indicated by our observational study [3] on the use 
of  fludroxycortide tape in 30 adults and 30 pediatric 
patients with hypertrophic and keloid scars. The adults 
were, on average, 37  years old (range 23–67  years), 
while the pediatric patients were, on average, 7.2 years 
old (range 2–15 years). Each patient had one scar that 
was treated with the tape. The scars were on various 
body sites, including the trunk and extremities. The 
scars were over 1  year old and the tape was used for 
at least 1 year for 24  hr/day. The results after 1  year 
of  treatment were judged by using the Japan Scar 
Workshop Scar Scale 2015 (JSS) [5]. The results sug-
gest that the fludroxycortide tape improved the scars 
of  20% of  the adult patients and 80% of  the pediat-
ric patients. After 1 year of  fludroxycortide tape usage, 
the 24 unresponsive adults were switched to 24 hr/day 
deprodone propionate plaster treatment. Of these 24 
cases, 17 (70.8%) exhibited scar improvements 1  year 
later. Thus, we conclude that adults require a stronger 
tape to obtain similar responses as children in terms of 
scar maturation. Thus, deprodone propionate plaster is 
better for adults, while fludroxycortide tape is sufficient 
a b c
  . Fig. 56.2 Effect of  fludroxycortide tape on a scapular keloid of  a 9-year-old boy. a Before treatment commenced. b Sixteen months after 
starting treatment. c Twenty-six months after starting treatment
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for pediatric patients (. Figs.  56.3, 56.4, and 56.5). 
The side effects in our study consisted of  contact der-
matitis in three adults. None of  the children exhibited 
any side effects.
Steroid tapes/plasters can also be used to prevent 
recurrence after keloid and hypertrophic scar resection 
(. Fig.  56.6). My empirical experience is that start-
ing 24  hr/day deprodone propionate plaster treatment 
1  month after surgery appears to suppress recurrence. 
Further research is needed to test this hypothesis. It 
should be noted that we currently routinely use depro-
done propionate tape combined with radiotherapy as a 
postoperative adjunct in surgically treated keloid cases 
to reduce the recurrence rate. In our experience, this 
combination reduces the postoperative keloid recur-
rence rate to less than 10% [6].
a b  . Fig. 56.3 Effect of  depro-
done propionate plaster on an 
upper arm keloid of  a 25-year-
old female patient. a Before 
treatment commenced. b Twelve 
months after starting treatment
a b
  . Fig. 56.4 Effect of  deprodone propionate plaster on an anterior chest wall keloid of  a 68-year-old male patient. a Before treatment com-
menced. b Twelve months after starting treatment
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56.6   Side Effects of Steroid Tapes 
and Plasters
Contact dermatitis is the most common problem associ-
ated with the use of steroid tapes/plasters. According to 
the product sheets, the frequencies of contact dermatitis 
during fludroxycortide tape and deprodone propionate 
plaster treatment are 16.7% and 0.55%, respectively. 
This is consistent with our impression in clinical prac-
tice. Thus, deprodone propionate plaster associates 
with a lower incidence of contact dermatitis. There are 
two types of contact dermatitis, namely, irritant con-
tact dermatitis and allergic contact dermatitis. One can 
reduce the possibility of the former by decreasing the 
frequency with which the tape/plaster is replaced and 
by reducing the duration of application. Thus, the risk 
of irritant contact dermatitis may be decreased by vari-
ous strategies, including replacing the tape/plaster every 
a b
  . Fig. 56.5 Effect of  deprodone propionate plaster on a shoulder keloid of  a 49-year-old female patient. a Before treatment commenced. 
b Thirty-six months after starting treatment
a b c
d e
  . Fig. 56.6 Effect of  surgery and postoperative deprodone propio-
nate plaster treatment on a shoulder keloid of  a 9-year-old boy. a 
Before treatment commenced. b Intraoperative view. c View imme-
diately after surgery. d Twenty months after surgery. e Thirty-six 
months after surgery
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24–48 hours, only wearing the tape/plaster overnight, or 
applying the tape/plaster for 1 day and then using oint-
ment on the next day. In the case of deprodone propio-
nate plaster, we have the impression that mild contact 
dermatitis is suppressed by the effect of steroid itself. If, 
however, allergic contact dermatitis develops, it often 
arises 1–3 months after the start of use. Since it can pro-
duce strong pruritus and reddens the skin, it can hamper 
the continuous use of the tape.
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Take Home Messages
 5 In Japan, corticosteroid tapes and plasters have 
long served as a first-line therapy for keloids and 
hypertrophic scars.
 5 Pediatric patients are particularly responsive to 
this type of treatment, because children have thin-
ner skin than adults and the steroids are therefore 
more easily absorbed.
 5 The postoperative application of corticosteroid 
tapes/plasters also significantly prevents the develop-
ment of keloids and hypertrophic scars after surgery.
 5 Deprodone propionate tape is the most effective 
tape for the treatment and prevention of keloids.
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57.1   Background
Suture management after closure has been considered as 
highly important in the prevention of enlargement and 
infection. The rupture of skin integrity, the surgical dissec-
tion, and subsequent trauma of the underlying structures 
may cause local inflammation, edema, dehiscence, and 
infection. In this context, new technologies were devel-
oped and recently validated. The aim of this chapter is 
to highlight the role of mechanotherapy in prevention of 
postoperative complications on the suture line. This chap-
ter is designed for surgeons facing surgical procedures at 
risk of infection or dehiscence or willing to reduce the 
scar enlargement after surgery on a visible area.
57.2   Introduction/Objectives
The tension exerted on the edges after cutaneous excision 
surgery has been demonstrated as a source of inflam-
mation and potential complications, like local infection, 
scar enlargement when skin edges are, even minimally, 
separated [1, 2]. Keloid generation as well as hypertro-
phic scarring has been related to mechanical forces in 
experimental and clinical studies confirming the impor-
tance of mechanical control in the prevention of path-
ological scars especially in Asia [3]. Several techniques 
have recently been described on the basis of the principle 
of immobilizing the suture edges after surgery [1].
Globally a better understanding of scar mechan-
ics has been under way for several years [2]. This has 
made it possible to multiply the compression strat-
egies offered  by compression garments or Orlen® 
(Professional Plastics, Fullerton, CA) plates, particu-
larly in burn scars [4]. Translational research has been 
stimulated and the optimization of mechanical devices 
exploiting mechanical forces has been developed, espe-
cially in the field of wound healing [5].
A recent study [6] on cadavers measured the forces of 
tension exerted on the edges of sutured skin and the under-
lying aponeurosis. These measurements can be considered 
as a basis for measuring the reapproximation forces of the 
edges in human clinical practice. A three- dimensional sim-
ulation model allowed for reproducing the in vivo tension 
experienced by the skin, the phenotype of fibroblasts from 
keloid scars, their matrix synthesis capacity under tension, 
and in vivo skin tension measured on volunteers. It has 
been demonstrated that the induction of tension modifies 
the expression of the genes linked to the mechanical ten-
sion of the fibroblasts. This mechanical regulation makes 
it possible to understand that an increased synthesis of 
collagen occurs in the scar via the fibroblasts when tension 
is exerted strongly on the edges. The therapeutic interest 
of this hypothesis serves as a basis for the development of 
medical devices opposing edge tension.
57.3   Description of the State of the Art, 
Historical Evolution, and Recent Data
Applying materials over the suture after surgery is a 
longtime practice.
In the 2000, the first international consensus [7] on 
scar management emphasized the positive role of sili-
cone but did not pay too much attention to the adhesive 
tapes, the first cheap device supposed to limit tension on 
the suture edges.
57.3.1   Silicone Devices
Silicone gels and tapes have been used since 1986  in 
prevention and treatment of hypertrophic scars and 
keloids. Although there have been multiple randomized 
controlled trials evaluating the efficacy of silicone gels 
[8], the overall quality of evidence is limited [9].
Silicone gels remain the most reported technique in 
the successive guidelines published since 2002. Silicone 
is not per se exerting any tension on the skin edges but 
may contribute to skin moisture.
57.3.2   Reinforced Suture Materials
During recent years a resorbable barb suture was 
developed, aiming at distribution of tension along the 
wound, providing a stronger wound edge approxima-
tion. The device was made of slowly resorbable material 
acting as a barber suture, due to obliquely distributed 
regular cuttings in the core of the device, preventing lon-
gitudinal movements on the suture line. The system was 
proposed as a drastic change in the suturing methods 
with a single- layer closure facilitated versus a 2-layer 
closure. Scar revision including large resection, preven-
tion of shearing forces consequence on flap edges, and 
situations where the suture line may be exposed to mild 
to moderate tension were indications for the device [10].
Adhesive sutures. Used since decades long term, these 
paper tapes are placed over the skin edges to maintain a 
minimal pressure. Forces exerted on the suture are low, 
the adherence of the paper embedded with glue being 
solubilized or detached either by the exudation liquids or 
by the movements. Reiffel could demonstrate some supe-
riority when adhesive sutures were placed longitudinally 
on the edges instead of transversally as a scale [11].
Self-adherent smart silicone has been proposed as a 
solution offering a permanent pressure exerted on the 
skin edges by a smart technology using adherent silicone 
covering the suture, isolating the suture from any external 
contamination. A mechanomodulating polymer device 
was utilized to manipulate the mechanical environment 
of closed cutaneous wounds in red Duroc swine, by 
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applying tension to the edges through physical means 
(silicone with pretensioning of axial fibers inserted in the 
layer) [12]. (EMBRACE®). During a surgical procedure, 
surgeons strive to make incisions that follow the relaxed 
tension lines on the body, so-called Langer lines. This 
strategy is used because tension is well known to increase 
scarring. The Embrace® device (Neodyne Biosciences, 
Newark, CA) is designed to shield the healing incision 
from the natural tension that is inherent in any break 
in skin that must be pulled together to close a wound. 
Previous preclinical and first-in-human data initially 
demonstrated that this mechanism of action was effec-
tive in scar mitigation in both pigs and humans.
A prospective RCT in scar appearance was con-
ducted on 36 healthy subjects during the post-operative 
period after abdominiplasty. Embrace® device was used 
fon the left part of the scar, and control (surgeon’s opti-
mal methods) on the right part. Result was significant 
on the scar appearance at 12 months after 5 weeks of 
application (Visual analog scale (VAS) p = 0.027, Patient 
and observer scar assessment scale (POSAS) subject 
p = 0.02, and surgeon p < 0.001) [13].
57.3.3   Adjustable Tensors
Another system to reduce skin tension across an incision 
line is the Zipline® system (ZiplineMedical-Stryker). The 
originality of the system is its ability to bring the two edges 
together and set the skin tension. This technique has been 
used since years in suturing the final epidermal layer as 
well as in restraining the suture edges movements dur-
ing the postoperative period, results being linked to the 
compliance of the patient to wear an hydrocolloid based 
adhesive, covering the adjustable tensors, with a potential 
risk of allergy. The system may be used as an alternative 
to superficial sutures.
The medical device (Zipline®) has been developed 
and is used clinically as a wound closure technique as an 
alternative to sutures in many surgical procedures.
The medical device is made up of two adhesive car-
boxymethylcellulose strips, which have a central reinforc-
ing core made up of polyurethane fibers, placed on the 
suture edges. These strips are interconnected by tensors 
formed of a polyurethane thread made up of nodes that 
are regularly distributed along the wire and finished by 
collars allowing easy grasping for tensioning. The entire 
set resembles a ladder with an adjustable length of bars. 
This tensor is firmly fixed and connected to the central 
core of polyurethane fibers of one of the two strips and 
placed transversely to bridge the scar zone. The tensor 
passes from the opposite side into a collar, and the nod-
ules serve as blockers to maintain the desired tension. 
The distance between the two strips at rest is 1.5 cm and 
can be reduced to 0.5 cm. This movement is reversible, 
allowing for a true adaptation of the tension based on 
local needs and the wishes of the surgeons. The system 
can be positioned immediately after surgery and main-
tained in situ during subsequent weeks (. Fig. 57.3).
The tension adjustment makes it possible to avoid 
even minimal edge spacing, which is a source of  bac-
terial penetration and secondary infection. Moreover, 
the separation movements exerted longitudinally by the 
natural movements of  the body are blocked, and this 
limitation serves as a transverse but also longitudinal 
immobilization. This is an essential factor in wound 
healing, limiting local inflammatory phenomena. Once 
the tension is stabilized, the loops are cut at their base.
In the author series of 21 clinical cases of skin excision 
[14], Zipline® was used after tumor resections, scar revi-
sion, or flaps. The tension exerted on the edges was variable 
and Zipline® was able to maintain the suture line outside 
of the transverse and longitudinal mechanical stresses. 
The results obtained in this series showed a maintenance 
of the linear scar measuring less than 0.5 cm permanently 
after 2 months of application. No local inflammation or 
secondary enlargement was observed after 2 months.
The anatomical sites were multiple and dependent on 
the necessities of the surgery. Most areas were located 
on the shoulders and back, regions known for their 
dermal fragility and problematic scarring. Maintaining 
a linear scar on these regions is difficult, especially in 
young women, after nevus resection. The skin’s natural 
mobility, its thickness, and the forces exerted produce 
areas of known risk.
All patients underwent cutaneous resection during 
surgery, with skin loss between 4 cm × 3 cm and 8 cm 
× 14 cm. The postoperative scars were either straight or 
slightly curvilinear, and the maximum effect seemed to 
be obtained when the system was applied to rectilinear 
scars (. Figs. 57.1, 57.2, 57.3, and 57.4). . Table 57.1 
summarizes the population studied and the amounts of 
skin resected during surgery. The system was applied for 
an average of 42 days, with three changes on average.
The evaluation of the scar was performed by three 
independent evaluators. The average follow-up was 6 ±3 
  . Fig. 57.1 Right arm presenting excessive fat volume (postbar-
iatric surgery)
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months. The results were considered positive when the 
scar remained linear without secondary enlargement 
after 6 months.
Zipline® could be proposed as a skin closure system 
and as an alternative to epidermal suturing. However, it 
has not yet been used as a tool to maintain mechanical 
tension after suturing during cutaneous resection.
The distraction forces exerted on a suture line are 
caused by the patient’s movements. The Zipline® sys-
tem creates an immobilization of the micromovement- 
generating forces on the suture edges, which are sources 
of disunion and scar enlargement. Thanks to the poly-
urethane core and its staggered arrangement on the 
adhesive strips, any type of movement can be prevented 
because it opposes both transverse and longitudinal 
forces. This compression can be considered dynamic, 
and it prevents the widening of the suture, regardless of 
the movement to which it is subjected.
Several clinical trials reporting the effects of Zipline® 
have recently been published [15–19]. These trials report 
the product’s good capacity to be used in the final clo-
sure of wounds. In our series, it appears that mainte-
nance in place for several weeks on the skin serves to 
limit postoperative mechanical tension and to minimize 
scars, even in areas in tension and after keloid excision.
Zipline® has been proposed in multiple disciplines like 
orthopedic surgery in mobile areas like knee or shoulders 
and in plastic surgery after cutaneous excision for scar 
revision, cutaneous tumor excision, and loss of cutaneous 
substances due to chronic wounds such as pressure sores.
57.3.4   Closed Incision Negative Pressure 
Therapy
Several recent studies demonstrate the value of isolating 
the wound from any source of external contamination 
and of keeping it under slight tension.
In recent years, the indication for negative pressure 
wound therapy (NPWT) has been extended to include 
treatment of closed surgical incisions (incisional NPWT, 
iNPWT). Some of the first studies were case series 
and observational studies [20] using one of the exist-
  . Fig. 57.2 Left arm presenting excessive fat volume
  . Fig. 57.4 Left arm 2 months after fat reduction and suture edge 
control
  . Table 57.1 Closed incision NPWT clinical indications
CiNPWT clinical indications Thoracic surgery Caesarian section Orthopedic surgery Postskin grafting Pilonidal sinus
PICO® x x x x x
Avelle® x x x
Prevena® x x x x x
Nanova® x x x
  . Fig. 57.3 Right arm 2 months after fat reduction and suture edge 
control
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ing NPWT devices (VAC®; KCI, San Antonio, Texas, 
USA) [21, 22] designed for open wounds. Two simplified 
NPWT devices became commercially available in 2010 
(Prevena™; KCI) and 2011 (PICO™; Smith & Nephew, 
Hull, UK). These NPWT devices consist of a single-
use battery-powered negative-pressure therapy device, 
an easy-to-place dressing, and either a very small and 
easily portable canister, or no canister at all. In the lat-
ter case, the liquid is removed by evaporation through a 
semipermeable dressing. The mechanisms of action of 
this closed incision management have been supported by 
biomechanical studies:
Biomechanical testing could experimentally dem-
onstrate that a pressure of 80  mmHg applied over a 
suture was enough to prevent 55% of tissue deforma-
tions compared to a situation when no NPWT dressing 
is applied [23]. Other authors suggested increased blood 
flow, decreased lateral and shear stress at the suture lines 
with decreased risk of wound dehiscence, and increased 
lymph clearance with reduced formation of hematoma/
seroma [24].
A recent meta-analysis was conducted by Strugala 
et al. [25] on the impact of prophylactic use of a specific 
design of NPWT device on surgical site complications. 
Articles were identified in which the specific single-use 
NPWT device (PICO⋄, Smith & Nephew) was compared 
with standard care for surgical site infection (SSI), dehis-
cence, or length of stay (LOS). Risk ratio (RR) ±95% 
confidence interval (CI) (SSI; dehiscence) or mean differ-
ence in LOS ±95% CI was calculated using RevMan v5.3.
Combining all 16 studies, there was a significant 
reduction in SSI of 58% from 12.5% to 5.2% with 
NPWT (RR 0.43, [95% CI 0.32–0.57], p  <  0.0001). 
Similar effects were seen irrespective of the kind of sur-
gery (orthopedic, abdominal, colorectal, or cesarean sec-
tion), although the numbers needed to treat (NNT) were 
lower in operations with higher frequencies of compli-
cations. There was a significant reduction in dehiscence 
from 17.4% to 12.8% with NPWT (RR 0.71, [95% CI 
0.54–0.92], p  <  0.01). The mean reduction in hospital 
LOS by NPWT was also significant (−0.47 days, [95% 
CI −0.71 to −0.23], p < 0.0001). The significant reduc-
tion in SSI, wound dehiscence, and LOS on the basis of 
pooled data from 16 studies shows a benefit of the PICO 
single-use NPWT system compared with standard care 
in closed surgical incisions (. Table 57.1).
Another study focused on the interest of CiNPWT 
after post-SSI revision of orthopedic implants [26] for 
total hip arthroplasty (THA) due to septic loosening 
in the presence of active fistula. They were treated with 
a PICO® device for NPWT, in combination with the 
standard treatment for prosthesis infection. Resolution 
of the infectious process and healing of the surgical 
wound without complications were considered promis-
ing results, confirming the interest of the system in most 
of the surgical disciplines (plastic surgery, thoracic and 
cardiac surgeries, and colorectal surgery) [27, 28]. The 
system has also demonstrated efficiency in stabilizing 
skin grafting.
57.4   Conclusion
The recent development of technologies proposing 
a mechanical restriction of micromovements on the 
suture line, with or without negative pressure, tends to 
demonstrate some evidenced benefits. These techniques 
are presently used in several surgical disciplines and 
proposed for at-risk situations in long and difficult pro-
cedures and also for minimizing the scar visibility and 
preventing enlargement as well as volume changes.
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58.1   Medical History
A 23-year-old healthy Caucasian patient suffered from 
a deep dermal burn (IIb) 2 years ago due to contact 
with an open fire. Despite initial professional burn care 
and aftercare using silicone-based products, the patient 
developed an elevated hypertrophic scar in an area of 
18 × 12 cm with an approximate height of 1 cm on her 
left lower leg. Repetitive treatments with cryotherapy 
and intralesional injections with triamcinolone aceton-
ide at the local university hospital did not result in sig-
nificant improvements; however, as a side effect of the 
treatment, brownish hyperpigmentations appeared in 
the treated area. At initial presentation in our clinic, the 
patient did not complain about any pain except some 
tension and pruritus but was severely disturbed by the 
appearance of the scar (. Fig. 58.1).
 ? Questions to Medical History
 5 What is the rationale for the formation of  postin-
flammatory hyperpigmentations after the initial 
therapy?
 5 Which therapeutic alternatives exist?
 5 Are there any medical precautions that should be 
considered for initiating any additional therapy?
 z Intervention 1
One pass using a Q-switched ruby 4 mm/4 J (Asclepion) 
under local anesthesia cream. Aftercare with fusidic 
acid and a class III steroid containing cream.
 z Interventions 2–6
Eight weeks later significant improvement of hyper-
pigmentation and some minor flattening (. Fig. 58.2), 
five additional sessions with fractional CO2 (Lumenis, 
UltraPulse, SCAAR FX 60–90 mJ, 1–3%, 300 Hz) under 
local anesthesia cream, additional 5-fluorouracil (5-FU) 
50 mg/cc for drug delivery on the scar surface. Wound 
dressings with gauze, fusidic acid, and a class III steroid 
containing cream. Repetitive treatments approximately 
every 4–6 weeks apart.
 ? Questions Interventions
 5 Why use the Q-ruby first before initiating therapy 
with fractional CO2?
 5 What is the rationale for the time intervals in 
between laser sessions?
 5 Potential risk of  laser therapy?
 5 Why combination with 5-FU?
 z Intervention 7
Another pass using a Q-switched ruby 4  mm/4  J 
(Asclepion) under local anesthesia cream. Aftercare with 
fusidic acid and a class III steroid containing cream. Final 
results 12 weeks after last treatment shown in . Fig. 58.3.
 z Discussion
Hyperpigmented scars are relatively common; however, 
most frequently scar therapy is directed toward reduc-
ing possible symptoms like pruritus, pain or tension, 
and reduction of excess scar tissue through various 
  . Fig. 58.1 Baseline situation: elevated hypertrophic scar in an area 
of  18×12 cm with an approximate height of  1 cm on the left lower leg 
at initial presentation. Surrounding erythema due to mild reaction to 
the local anesthesia cream applied prior to the laser therapy
  . Fig. 58.2 Presentation 8 weeks after initial Q-ruby laser treatment
  . Fig. 58.3 Presentation 12 weeks after last laser treatment
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approaches. Nevertheless, using nanosecond or picosec-
ond lasers with wave lengths of 532, 694, 755, or 1064 nm 
known from laser tattoo removal or treatment of benign 
pigmentated skin lesions do have potential to improve 
appearance of hyperpigmented scars. In our case, treat-
ment using a q-switched Ruby laser has been chosen as 
initial therapy simply due to the fact that the hyperpig-
mentation was the main concern of our patient. The 
hyperpigmentation was most probably a response to pre-
vious cryotherapy sessions; however, in darker- skinned 
patients, hyperpigmentations of scars are frequently seen 
without any previous therapy. Alternatively, a hydrochi-
none-containing cream may be used, but they are often 
less effective compared to respective laser treatments [1]. 
Caution should be paid to possible melanocytic lesions, 
which can easily be ruled out through dermatoscopy and 
should be excluded from laser therapy.
The use of fractional CO2 lasers for the improve-
ment of hypertrophic scars has been demonstrated in 
numerous studies. Combining deep fractional ablation 
with high fluences and a low density to stimulate der-
mal matrix remodeling with superficial smoothening of 
the scar through ablation of individual scar strands, fol-
lowed by extensive fractional surface ablation, has been 
shown to greatly improve widespread hypertrophic scar-
ring [2–4]. On a molecular basis, the heat radiated into the 
treated tissue results in the activation of heat-shock pro-
teins, predominantly from the HSP-70 family, as well as 
the alteration of remodeling factors like matrix- metallo- 
proteases and antifibrotic isotypes from the transform-
ing-growth factor beta family (TGF-β) [5, 6]. Although 
these processes have not yet been fully elucidated, clinical 
studies have shown a normalization of the dermal matrix 
architecture following fractional CO2- laser treatment [7, 
8]. Its combination with triamcinolone acetonide or 5-FU 
appears to further improve results and, in our experience, 
seems to minimize the total number of sessions necessary 
to achieve satisfying results [9, 10]. We usually allow the 
scar tissue to settle in between laser sessions for 4–8 weeks 
as scar tissue needs time for remodeling. While hypertro-
phic scars usually respond very well to fractional lasers, 
some caution should be paid when treating keloids as 
here, activation of the keloid with further enlargement is 
relatively frequently seen.
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Take-Home Message
 5 Different scar types do benefit from combina-
tional therapies. Interestingly, hyperpigmentations 
of scar do respond relatively well to QS-ruby or 
picosecond lasers.
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59.1   Introduction
Breast ptosis is one of the most common conditions 
treated by plastic surgeons with more than 100,000 
operations each year just in the USA. While its causes 
are not clearly defined, age, history of significant weight 
loss, higher body mass index (BMI), larger bra cup 
size, the number of pregnancies, and smoking history 
are known to be significant risk factors [1]. Treatment 
consists generally in mastopexy and/or breast augmen-
tation with implant fitting. The mastopexy procedure 
is generally considered a reliable aesthetic procedure 
with less than 2% of unsatisfactory breast shape [2]. In 
addition to operative risks related to any surgery per-
formed under anesthesia, some complications specific 
to breast plasty and breast implant may occur such 
as hematoma, infection, wound healing delay, wound 
dehiscence, necrosis of the areola, necrosis of the skin, 
disruption of the implant and silicon leakage, rare case 
of anaplastic large cell lymphoma, and poor quality of 
the scars, including hypertrophic scar or keloid [1]. The 
overall complication rate of mastopexy reaches 10% 
and the most represented complications are scar related, 
with 3% of hypertrophic or unaesthetic appearance [2]. 
The patients’ perspective is also essential when evaluat-
ing scar cosmetic appearance as it might differ from the 
ones of the surgeon [3, 4]. In particular, their expecta-
tions at short term (inflammatory stage) and long term 
(1  year) are of equal importance as they usually wish 
to regain a normal appearance skin as soon as possible 
and desire sustainable results [3, 4]. To minimize the aes-
thetic impact of surgical scars, many different strategies 
have been identified, such as compressing devices, sun 
protection, silicone dressing, or laser treatment [5, 6]. 
According to the recent guidelines, prevention of abnor-
mal scar formation should always be a first priority [5–7]. 
Preventive measures adapted to the patients’ risks and 
needs (possibly including combined therapies) and early 
intervention are well recognized for their positive out-
comes [5–7]. In particular, laser therapy seems to gain 
each year broader and broader application in this field 
[8]. Ten years ago, a new approach based on a preventive 
treatment of scars called Laser-Assisted Skin Healing 
(LASH) was developed by Pr Mordon (INSERM U703; 
University of Lille Nord, France), and clinically evalu-
ated by the teams of Pr Magalon (Department of Plastic 
and Reconstructive Surgery, APHM, Marseille, France) 
and Dr. Capon (Plastic and Reconstructive Surgery 
Department of Pr Martinot and Pellerin, CHRU, Lille, 
France) [9]. Performed immediately after surgery, a laser 
shot induces a controlled elevation of skin temperature, 
which activates the overexpression of chaperone pro-
teins (Heat Shock Protein 70) [9, 10]. These proteins then 
activate tissue regeneration by shortening the inflam-
matory stage of the wound healing process and hasten 
scar maturation [9]. This technique, performed during 
the earliest stage of the healing process for a maximum 
impact, gave promising results. In 2016, a new laser sys-
tem was marketed on the basis of this LASH technique. 
The 1210-nm laser diode (UrgoTouch®, Laboratoires 
Urgo Medical, Chenove, France) was an automated, 
portable laser providing a controlled elevation of skin 
temperature, due to its scar control system technology. 
The wavelength of the system allows its use on patients 
with all skin phototypes, including Fitzpatrick scale pho-
totypes V and VI. The performance and safety of this 
new device were assessed in a 1-year follow-up double-
blinded randomized controlled trial (RCT), undertaken 
on patients undergoing breast reduction: The “SLASH” 
study [11]. This high-quality-level study was conducted 
in France and coordinated by Pr Casanova at the 
University Hospital of Marseille. A total of 40 women 
(with phototypes II to VI) undergoing bilateral breast 
reduction were enrolled by the five surgeons involved in 
the study and treated with the portable 1210-nm laser 
on one randomly assigned breast, while the controlat-
eral one was used as the study control. The unique laser-
treatment session was performed on the suture incisions, 
in the operating room, while the patient was still under 
the general anesthesia. According to the results of this 
clinical study, based on both subjective assessments 
(with the validated modified Observer Scar Assessment 
Scale (mOSAS) score) and objective measurements (with 
software analysis of three-dimensional [3D] pictures of 
the scars) the 1210-nm automated laser system provided 
significant improvements of the cosmetic aspect of the 
scars at short term (6 weeks), medium term (6 months), 
and long term (12 months) (. Fig. 59.1). These aesthetic 
improvements, notably in terms of volume, surface, and 
roughness, were strengthened with the blind expression 
of patients’ preference for their laser- treated scars. Of 
note, in the subgroup of dark skin-type patients (photo-
types V–VI), the results also favored the laser treatment, 
with 53% and 16% mean reductions of the scar volume 
and surface, compared to the control scars.
I have personally used this laser treatment 
(. Fig.  59.2) in many different indications in my cur-
rent practice and I propose to report here two cases of 
breast hypotrophy and ptosis treated by mastopexy with 
implants associated with the laser treatment.
 V. Hunsinger et al.
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59.2   Case Report Number 1
kDescription
A 37-year-old woman with bilateral breast hypotrophy 
and ptosis was seen in consultation seeking for breast 
lift. Physical examination revealed 85C-sized breasts 
with grade 2 ptosis based on the Regnault classifica-
tion (Nipple areola complex [NAC] 2 cm below the sub-
mammary fold) and asymmetry (with a left breast more 
voluminous and ptosic than the controlateral one). The 
patient (1.70 m, 58 kg, BMI 20) had recently lost 15 kg 
and reported a previous 95C breast size. She had three 
children and no prolonged breastfeeding period. The 
patient had no history of surgery, allergy, or medica-
tions, but was a current smoker.
A bilateral breast lift with retropectoral implants and 
laser treatment was proposed to the patient. The ben-
efits and risks related to the procedure were explained, 
together with the necessity to quit smoking, before the 
patient gave her written consent.
kMethods
The surgery was performed in November 2017, under 
general anesthesia and orotracheal intubation. The 
patient had received antibioprophylaxy and periopera-
tive compression stockings and she underwent preop-
erative marking. A similar procedure was followed for 
both breast. Infiltration of local anesthetics (narope-
Laser-treatedControl
Laser-treatedControl
  . Fig. 59.1 On the left, a two-dimensional (2D) photograph of 
the inframammary scars of  a patient, 6  months after her breast- 
reduction procedure. The horizontal scar of  one breast was ran-
domly assigned to receive in the operating theatre, the day of  the 
surgery, the laser treatment while the other scar of  the controlateral 
breast was used as a control. On the right, 3D photographs of  inter-
nal or external extremities of  the scars treated or not with the laser in 
two different patients, 12 months after the procedure. (Reproduced 
from the double-blind RCT “SLASH” with the courtesy of  Pr. Casa-
nova, coordinator of  the clinical trial)
  . Fig. 59.2 The 1210-nm laser diode laser system UrgoTouch® 
procedure. The laser treatment (only one pass over the incision) is 
performed in the operating theatre, when patients are still under gen-
eral anesthesia. The target cutaneous zone is secured by the applica-
tion of  safety strips containing high-technology microchips. These 
microchips enable the laser shots and prevent any overdose. The ster-
ile strips are positioned along the sutures just before the laser shot. 
The laser shot duration is determined and controlled by the laser 
software itself, based on the patient’s skin temperature detected by 
the embedded pyrometer of  the device. This technology ensures the 
automatic discontinuation of  the shot when the target skin tempera-
ture (53 ± 3°C) is reached, ensuring both patient safety and repro-
ducibility of  the shots. Neither preliminary parameter settings nor 
adjustments are required for laser shots. A training to the laser is 
received before its first use
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ine 7.5  mg/mL  +  xylocaine/adrenaline 1%) was done 
in the targeted zone. The incision on each breast was 
made under the future nipple-areola complex flap, with 
a glandular transection, until it reached the pectoralis 
muscle. The retropectoral area was dissected to develop 
the submuscular pocket at the implant size and a sizer 
was used for the mastopexy. The breast was lifted using 
inverted- T scar and a superior NAC pedicle technique. 
The round micro-textured breast implants prefilled with 
silicone gel were then placed in its pocket (LSM RM 
345, Sebbin) and the satisfying shape and volume of 
the breast were checked. Surgical incisions were sutured 
according to local standard procedures, using common 
surgical sutures (Monocryl™ 3/0 and 4/0 and Vicryl™ 
rapide 4/0, Ethicon) compatible with the laser use, 
according to the laser manufacturer’s instructions.
The safety strips of the laser were positioned along 
the sutured incisions. The laser shot duration was 
determined and controlled by the laser software itself, 
based on the patient’s skin temperature detected by the 
embedded pyrometer of the device. The laser treatment 
procedure was rapid and went unremarkable. After the 
laser treatment, the sutured incisions were secured with 
2-octyl cyanoacrylate adhesive (Dermabond®, Ethicon) 
and covered by a dry dressing, before adding the postop-
erative compressive bra.
Postoperative care recommendations included 
daily shower and dressing change after cleaning of the 
sutured incisions with an antiseptic solution. The patient 
was asked to wear postoperative compression bra for 
4  weeks after the surgery and received a prescription 
for analgesics. Sport activity resumption was allowed 
3 months after the surgery.
kResults
No complication was reported during the procedure 
and the early postoperative course. One month after the 
surgery and the laser treatment, the cosmetic aspects 
of the scars were already satisfying and the patient was 
pleased with this short-term outcome (. Fig.  59.3). 
Pre-operative ptosis 1 month 18 months
  . Fig. 59.3 Eighteen months’ follow-up of  the patient: anterolateral, lateral, and anterior views of  the preoperative ptosis and of  the 
breasts 1 month and 18 months after the surgery and the laser treatment
 V. Hunsinger et al.
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At the 18-month postoperative visit, the horizontal, ver-
tical, and periareolar scars became very discreet and the 
patient expressed her complete satisfaction for her new 
breasts (. Figs. 59.3 and 59.4).
59.3   Case Report Number 2
kDescription
The second case report relates to a 26-year-old woman 
(1.64 m, 60 kg, BMI 22) seen in consultation for breast 
lifting after weight loss. The patient presented a bilat-
eral breast hypotrophy and grade 2 ptosis (NAC 1 cm 
below the submammary fold). The breasts were asym-
metric (more voluminous and ptosic left breast). The 
patient currently had B-cup breasts and wanted a breast 
augmentation to reach plain C-cups. The review of the 
medical and surgical history of the patient revealed a 
sleeve-gastrectomy in March 2013, no allergy, no par-
ticular familial medical history, and no current medica-
tions, but she was a current smoker. A bilateral breast 
lift with retropectoral implants and laser treatment was 
proposed to the patient. She was informed that she had 
to quit smoking and the benefits and risks related to the 
procedure were explained to her. The surgery was sched-
uled in January 2018, once the written consent of the 
patient was obtained.
kMethods
The surgery was performed under general anesthesia 
and laryngeal mask. The procedure was globally similar 
to the one reported in Case 1. The glandular transection 
reached the pectoral muscle plan. The submuscular area 
was dissected to develop the implant pocket. Inverted-T 
incision and superior NAC pedicle technique was used 
and the round micro-textured breast implants prefilled 
with silicone gel were positioned in their pocket (LSM 
RS 270, Sebbin, for the right breast, and LSC 72330, 
Sebbin, for the left breast). The shape and volume of the 
breasts were checked and judged satisfying. The surgi-
cal sutures and laser treatment were performed as previ-
ously described. After the laser treatment, the sutured 
incisions were secured with steri-strips and covered by a 
dry dressing, before adding the postoperative compres-
sive bra. The global procedure (including surgery and 
laser treatment) lasted 2 hours. The drains were removed 
the day after the surgery. Postoperative care recommen-
dations were similar to the ones given in Case 1.
kResults
No complication was reported during the procedure and 
the postoperative course. Two months after the surgery, 
the interest of an early laser treatment on the inflam-
matory stage of the wound healing process was notice-
able. At the 12-month postoperative visit, the scars were 
barely detectable. The cosmetic aspects of the scars 
were very satisfying and the patient was pleased with 
the results of the procedure, at both the short-term and 
long-term visits (. Figs. 59.5 and 59.6).
59.4   Discussion
To my knowledge, this is the first time the use of the auto-
mated 1210-nm laser diode UrgoTouch® is reported in 
mastopexy associated with retropectoral implant. The 
short- and long-term cosmetic results reached after a 
unique session, realized in the operating theater the day 
of the surgery, were very satisfying from both the sur-
geon’ and the patient’s point of view, and consistent with 
the results reported in the “SLASH” RCT conducted in 
the breast-reduction indication.
I first tried this laser treatment in October 2016 in a 
revision of breast and abdominoplasty in a patient of 
dark phototype skin presenting at my consultation with 
very wide scars. The aesthetic outcomes of the scars at 
10 months were very satisfactory and the patient said that 
she was happy with the result obtained. Subsequently, 
I have treated the scars of more than two hundreds of 
patients in different indications: secondarily to breast 
  . Fig. 59.4 Enlarged photographs of  periareolar and vertical scars of  each breast, 18 months post-surgery
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Pre-operative ptosis 2 months 12 months
  . Fig. 59.5 Twelve months’ follow-up of  the patient: anterolateral, lateral, and anterior views of  the preoperative ptosis and of  the breasts 
2 months and 12 months after the surgery and the laser treatment
  . Fig. 59.6 Enlarged photographs of  periareolar and vertical scars, 12 months post-surgery
 V. Hunsinger et al.
515 59
augmentation operations [12], breast plasty, ptosis cure, 
prosthesis repair, abdominoplasty, brachioplasty, body 
lift, or gynecomastia, without any particular compli-
cation. The laser procedure takes a minimum amount 
of time (a few minutes, depending on the length of the 
scars), and I agree with the surgeons of the “SLASH” 
study who have judged the portable laser very easy to 
use. Indeed, the absence of parameter setting or adjust-
ment really simplifies this type of procedure.
I always explain the limits of the procedure to my 
patients during the consultation prior to the surgery and 
laser treatment, in order to clear unrealistic expecta-
tions. Consequently, till today, none of my laser-treated 
patients were dissatisfied and their testimonials, col-
lected in postoperative consultation or on my medical 
office’s website, are all very positive. While this laser 
treatment can potentially be offered to all my patients, 
at the beginning I mainly proposed this procedure to 
patients with skin at risk or anxious by the scar result 
of their future operation, but now, it often happens that 
patients arrive at consultation demanding for it. The 
contraindications of the use of the laser 1210-nm laser 
diode UrgoTouch® are available in the manufacturer’s 
instruction for use.
 ? Reflective Questions
 5 Are there predetermining factors and risk for 
abnormal scarring?
 5 What are the guidelines for prevention and treat-
ment of  surgical scars and laser treatment?
 5 What are the contraindications for laser treat-
ment?
 5 What is the position of  laser procedure in your 
scar prevention strategies?
 5 How long does a laser treatment take? What for-
mation is required for laser use?
Take-Home Messages
 5 Different strategies have been identified to mini-
mize the aesthetic impact of surgical scars and pre-
vention of abnormal scar formation should always 
be a first priority.
 5 The performance and safety of the automated, 
portable, 1210-nm laser diode UrgoTouch® treat-
ment reported in real-life practice are consistent 
with the ones established in the randomised con-
trolled trial SLASH.
 5 An early and unique laser-treatment session with 
UrgoTouch® significantly improves the cosmetic 
aspect of the surgical scars.
 5 Patients treated with the laser procedure expressed 
their satisfaction both at short-term and long-term 
follow-up visits.
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60.1   Background
60.1.1   Incidence of Hypertrophic Scars
Hypertrophic scarring has a greater incidence in darker 
skinned individuals and predominately occurs in 
American Indian/Alaskan Natives, followed by African 
Americans and Asians [1]. The highest risk of pruritus 
occurs in the latter population. Additional risk fac-
tors include young age, female gender, and those with 
wounds in particular anatomic locations such as shoul-
ders, anterior chest, neck, upper arms, and cheeks. In 
the total patient population, hypertrophic scarring 
occurs in between 30% and 90% of burn patients, with 
a majority of these cases occurring in children [1]. The 
incidence rate of burn hypertrophic scars increases pro-
portionally with the time to healing, with a recent study 
demonstrating that scarring risk is multiplied by 1.138 
for every additional day needed for wound healing in 
pediatric patients, highlighting the need for rapid heal-
ing in scar prevention [2].
60.1.2   Prevention
Patients have a higher risk of development of hypertro-
phic scars in wounds that take longer than 3 weeks to 
heal. A study of 500 pediatric scald burns demonstrated 
that time to healing is a strong predictor of scarring, 
with similar results seen in a retrospective review of 59 
pediatric patients and 41 adults [3]. Therefore, acute 
wound care is critical in ensuring rapid healing. Care for 
burn wounds includes early tangential excision and cov-
erage with a split-thickness autografts, skin substitutes, 
or temporary xenografts or allografts. Since delayed 
healing may result from infection, topical application 
of antimicrobials may help prevent wound colonization. 
While time to healing is a strong predictor of scarring, 
patients can still develop hypertrophic scars despite heal-
ing earlier [2]. This highlights the importance of improv-
ing therapeutic strategies in addition to prevention.
60.1.3   Burn Depth
One of the ways to accurately treat burn scars is to reli-
ably treat them in a timely fashion and determine burn 
depth accurately. Many modes of burn depth assess-
ment have been used, including biopsy, thermography, 
and vital dyes, among other examples. The most widely 
used method for scald burns is the laser Doppler scan-
ner, which was shown to improve prediction of the level 
of burns that will or will not heal by reepithelialization 
at 3 weeks.
60.1.4   Chapter Objectives
In this chapter, we discuss management options for 
pediatric hypertrophic scars. In addition, we provide a 
palmar hypertrophic scar case with a 5-year follow-up 
and list the interventions, which consist of laser therapy 
in combination with serial casting, grafts, and local flaps 
for treatment of scar tension. Objectives of this chap-
ter include understanding risk factors for hypertrophic 
scar development, therapeutic options available, and 
rationale for particular treatment options in pediatric 
patients.
Clinical Case
A 3-year-old Filipino male initially presented to the 
clinic with a palm burn from a fireplace contact injury. 
The care of this wound consisted of once weekly dress-
ings with a closed dressing technique to minimize pain 
and allow for undisturbed wound healing. The child 
remained as an outpatient for the entire course of 
acute care. The deep wound took a full 3 weeks to heal 
and the patient developed a right palmar contracted 
hypertrophic scar (. Fig. 60.1). The patient presented 
with a raised, pruritic scar that remained confined 
within the boundaries of the wound area, as indicated 
in . Fig. 60.1.
 ? Questions to the Medical History
 5 What are the primary risk factors for hypertrophic 
scarring in this patient?
 5 Is ethnicity a primary predetermining factor for 
development of  hypertrophic scars?
 5 What are the features indicating that this is a 
hypertrophic scar as opposed to a keloid?
 5 Is this scar likely to progress over time?
  . Fig. 60.1 Right palmar hypertrophic scar
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Immediate Postintervention Situation
The patient presented with a scar contracture, which 
is one of the major detrimental effects of hypertrophic 
scars. Contractures of nonmatured scars can result in 
significant functional and developmental impairment 
and are frequently seen with scar hypertrophy. Conser-
vative approaches guided by physical or occupational 
therapists have proven to be beneficial in these patients. 
Initially, scar massage in conjunction with moisturiz-
ers is commonly employed [3]. This may decrease pain, 
pruritus, scar thickness, and erythema, and moistur-
izers themselves decrease transepidermal water loss. 
Currently, scar massage and moisturizing with water-
based lotions are the mainstay treatment for burn 
hypertrophic scars in children. Another approach is 
serial casting, which is used in burn patients to increase 
range of motion and prevent patient interference with 
the wound, an important concern in pediatric patients. 
With these considerations in mind, the patient was 
treated with conservative measures, including serial 
casting and scar massage three times a day. This treat-
ment commenced immediately after the skin had 
healed in a verified burn center with rehabilitation spe-
cialists trained to treat this condition.
Contractures particularly in pediatric patients are 
challenging to treat. Distraction techniques and train-
ing of parents are challenges, along with the fact that 
the treatments are repeated multiple times daily, making 
this a difficult task for the children and their caregivers. 
In addition to treatment by serial casting/splinting to 
maintain the position, surgical correction may be indi-
cated to restore function, especially if  the patient has 
a persistent hypertrophic scar (>1  year). Techniques 
include scar-lengthening flaps and skin grafts, which 
are often delayed until the scar has matured unless the 
contracture interferes with the normal development of 
the child (use of the hand).
Intralesional corticosteroids such as triamcinolone 
acetonide are an option for treatment of hypertrophic 
scars and keloids [1, 3]. Corticosteroids can reduce pru-
ritus and are effective in combination with cryotherapy 
in older hypertrophic scars and large keloids. In general, 
the corticosteroid is injected into the papillary dermis 
every 2–4  weeks until the scar is flattened. Although 
intralesional steroids are a common treatment for 
hypertrophic scars, they are rarely used for pediatric 
burn hypertrophic scars. They have limited utility due 
to the small dose that can be administered. In addition, 
the child needs to be sedated for the procedure in many 
cases. So, intralesional injections are usually reserved 
for small areas that are slow to settle after the majority 
of the burn hypertrophic scars have been treated.
At this point of treatment, the patient’s palmar 
contracture had stabilized. However, therapists were 
noting difficulty with grasping objects in the affected 
hand and significantly reduced palmar measurements 
compared with the other hand. As a result, the patient’s 
scar was treated by surgical revision and grafting after 
the initial conservative measures (. Fig. 60.2).
 ? Questions for Intervention
 5 What is the advantage of  serial casting in this 
patient?
 5 Are there any alternative conservative rehabilita-
tive strategies?
 5 Are these conservative strategies effective?
 5 In addition to the points mentioned earlier, what 
are other potential detrimental effects of  intral-
esional injections?
  . Fig. 60.2 Surgical revision and grafting of  the scar




Surgical revision is necessary in such refractory cases, 
and correction of linear hypertrophic scars can be 
done by tension-releasing techniques. Typical surgical 
techniques for hypertrophic scar contractures include 
Z- and W-plasties. Z-plasties are a scar-lengthening 
technique that can relieve tension and mitigate con-
tracture, improving range of motion, while W-plasties 
can minimize the appearance of prominent linear scars 
[4]. Several rounds of surgical releases, especially when 
combined with other techniques such as laser therapy, 
can facilitate successful rehabilitation of scars without 
excision. Lasers initiate an inflammatory response and 
induce moderate damage to local vasculature, resulting 
in  local hypoxia and remodeling [3, 4]. This, in turn, 
results in reduced scar erythema, pruritus, pain, and 
scar texture and stiffness [5]. Lasers can be further 
subdivided into ablative or nonablative types. Abla-
tive lasers reach their dermal targets by ablating the 
epidermis, which increases the risk of further scarring 
and other complications. As a result, traditional abla-
tive lasers are no longer used. However, an exception 
is the fractional carbon dioxide (fCO
2) laser, which is 
regarded as an ablative laser but can be considered as 
an alternative to the conventional ablative CO2 laser 
[5]. Alternatively, nonablative lasers can target dermal 
chromophores while preserving the epidermis, mini-
mizing complications. There are several types of lasers 
that are used in the treatment of hypertrophic scars. 
These include pulsed dye laser (PDL), alexandrite and 
diode lasers, intense pulsed light (IPL), erbium:glass 
(er:glass), infrared neodymium:yttrium aluminum gar-
net (Nd:YAG), and nonablative fractional lasers 1550 
or 1565 nm (NAFL). However, these nonablative lasers 
have a relatively shallow penetration depth, limiting 
their use to certain anatomical locations or shallow 
scars in the case of Nd:YAG and NAFL. Decision for 
which type of laser to use is dependent on scar char-
acteristics, pain, and scar texture and stiffness [5]. The 
procedure itself  is short and requires minimal addi-
tional rehabilitation, an advantage over surgical inter-
ventions, especially in younger patients.
A year after the initial surgical revision and graft-
ing, the patient had laser treatments combined with 
Z-plasties (. Fig.  60.3). This was followed by addi-
tional Z-plasties 5 years later. Several rounds of sur-
gical releases combined with laser therapy facilitated 
successful rehabilitation of the patient’s scar.
 ? Questions for Intervention
 5 Why was this surgical management of  this patient 
delayed?
 5 What are the reasons for a surgical intervention at 
this point in treatment?
 5 What is the purpose of  Z-plasties?
 5 What are the potential consequences of  laser 
treatment in this patient?
 v Answers
The primary risk factors for burn hypertrophic scars 
determined from the patient’s clinical history are young 
age and increased time to wound healing (>3 weeks). 
While there is a higher incidence in Asians compared 
to Caucasians, hypertrophic scarring in general primar-
ily occurs in darker skinned individuals and American 
Indian/Alaskan Natives [1]. Although hypertrophic 
scars and keloids have similar underlying mechanisms, 
they can be distinguished by certain clinical features. 
Hypertrophic scars are erythematous, pruritic, raised 
lesions that remain confined within the boundaries of 
the wound area, as indicated in . Fig. 60.1. In addi-
tion, the scar did not progress, unlike keloids, which 
continue to evolve over time.
The patient has limited range of motion and use of 
his hand due to scar contracture. Initial management 
with serial casting is beneficial in improving range of 
motion and softening the scar due to pressure. Casting 
provides pressure and stretch for an entire week giving 
caregivers a break, after which the cast is split and mas-
sage and stretching are resumed. The hand is placed 
back in the splint in between stretches, and the therapy 
  . Fig. 60.3 Treatment with Z-plasties and laser therapy
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is stopped after 2 or 3 weeks. Alternate options like com-
pression therapy are used to reduce scarring by decreas-
ing blood flow and collagen remodeling at the site of 
injury, and few studies have shown that it can possibly 
increase scar pliability and thickness. However, there is 
minimal evidence regarding effectiveness of these strate-
gies [3]. In addition, they may be difficult to attain due to 
the poor patient compliance. Techniques such as intral-
esional injections are avoided in these patients due to the 
need for repeated painful injections and side effects such 
as lipoatrophy, altered pigmentation, and blistering.
Surgical management was necessary to allow for 
normal developmental use of the hand. This was dic-
tated by review with a skilled rehabilitation team that 
followed the child’s developmental needs. Surgery is 
typically delayed until the scar has matured since early 
intervention is associated with high recurrence rates 
and morbidity [4]. Here, rounds of Z-plasties combined 
with other treatment modalities (e.g., lasers) help relieve 
tension and improve range of motion. Potential conse-
quences of laser therapy in this patient are hyperpig-
mentation and discomfort, the latter can be managed 
with topical anesthetics, oral or intravenous sedation, 
or nerve blocks to improve treatment tolerance [4].
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Take-Home Message
 5 Burn hypertrophic scars in children are challeng-
ing, with multiple modalities of treatment. Chil-
dren pose special considerations and, in addition 
to the scars, developmental stages and growth 
often dictate the treatments.
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61.1   Medical History
A 23-year-old Asian-origin young male  came after 
a long period of keloid of the left ear, secondary to 
a minor trauma during childhood. The patient was 
treated by three sequential surgical excisions followed by 
a recurrence, the last one being followed by YAG laser.
The patient abandoned the possibility to be ade-
quately treated by any therapy during 7 years and was 
examined at the clinic (. Figs. 61.1 and 61.2).
 ? Questions to Medical History
 5 Is Asian origin a predetermining factor for ear-
lobe keloid?
 5 Is keloid growing permanently or does it stop with 
age?
 5 Is there any guideline for surgical management of 
keloid?
kIntervention 1
A series of 10 5-FU injections (5  mL) at a dosage of 
50 mg/mL was administered at 3 weeks of interval.
The procedure was standardized as follows:
 5 EMLA cream application 2 hours before injection
 5 MEOPA (hilarant gas able to disconnect the patient 
from pain) administration during injection
 5 Hypnose adjuvant therapy during injection (hyp-
nose works to deviate the attention of the patient 
and present a growing interest particularly on 
patients submitted repeatedly to painful stimulation) 
(. Figs. 61.3 and 61.4)
 ? Questions: Procedure 1
 5 Why 5-FU injections instead of  corticosteroid 
injection?
 5 What is the rationale of  the dose (50 mg/mL)?
 5 How painful is the procedure?
  . Fig. 61.1 Earlobe keloid at presentation (anterior view)




A surgical excision was administered with reconstruc-
tion of the earlobe with a combined approach anteriorly 
and posteriorly to the earlobe. A compression was made 
at fashion to ensure the mechanical situation during the 
12 months postoperative period. The results were good 
with no recurrence. The scar presented redness after 3 
months postoperation and then this inflammation was 
resolutive with time (. Figs. 61.5 and 61.6).
 ? Late Postintervention Questions
 5 Why to choose not to apply any postoperative 
therapy?
 5 What about the loss of  substance of  the ear?
 5 Is there a need for complementary surgery?
 5 Is further surgery contraindicated?
 v Answers
The prevalence of earlobe keloid is higher in the Asian 
skin than in the Caucasian skin even if  the global 
risk of keloid is higher in the black- skin population. 
Keloids are, contrary to hypertrophic scars, growing 
permanently, reaching enormous sizes when left apart 
without adapted treatment.
Guidelines of surgical scar management mention 
the need for a combination of techniques, and most 
of them are being proposed after surgery (radiother-
apy, cryotherapy, laser). Cryotherapy has also been 
proposed as an alternative to surgery. In this case the 
preoperative management using antimitotic agents 
  . Fig. 61.4 Inflammatory aspect during 5-FU injections (posterior 
view)
  . Fig. 61.5 Aspect of  the ear 3 months postopertion, and some 
inflammation is still present
  . Fig. 61.6 Aspect at 14 months postoperation: the scar is stable 
and no recurrence occurred
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was proposed to limit the fibroblast postoperative pro-
liferation 5-FU is used at a high dose (50 mg/mL) as 
suggested by several authors without systemic compli-
cations and the rhythm of injections (every 3 weeks) 
limits the risk of local skin necrosis.
This strategy limits the risk of recurrence after sur-
gery and is proposed as a new option, in combination 
with preoperative injections and a close checkup of the 
local situation during 1 year.
The major inconvenience is pain induced by the in-
jection, and pain management needs combined thera-
pies (EMLA, MEOPA, Hypnose). During the surgical 
procedure the loss of substance of the earlobe had to 
be treated by reapproximation of the edges, a source 
of limited cosmetic difference compared to the contra-
lateral side, but the patient refused to be reoperated, 
considering the high risk of worsening of the scar and 
of recurrence of the keloid.
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Take Home Message
This clinical case reports the interest of  a combined 
strategy using sequential intralesional chemotherapy 
before surgery in order to limit the rebund effect in 
highly proliferative ear keloids.
 L. Téot
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A 47-year-old woman visited the outpatient clinic because 
of a scar on the right breast. She previously underwent 
deep inferior epigastric perforator (DIEP) flap breast 
reconstruction after nonskin, non-nipple- sparing mastec-
tomy, chemo- and radiotherapy, because of breast cancer. 
She had attended her oncological regular check-ups with-
out problems. She now complained of a painful scar on 
the right breast, which she also found unaesthetic.
 ? Questions (4 max)
 5 Q1. Which anatomic areas need to be examined as 
well during outpatient clinic consultation?
 5 Q2. Define the problems in terms of  anatomy.
 5 Q3. What could be a (non-)surgical approach of 
the problem?
 5 Q4. What should always be checked in postonco-
logical patients before surgery?
 W. B. van der Sluis
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 z Immediate Postintervention Situation
In one surgical session, a donor-site dogear correction, 
scar lipofilling, and contralateral breast reduction were 
performed. Liposuction was used to correct the excess 
of fat at the region of the abdominal scar. The same fat 
was used for lipofilling of the upper pole of the right 
breast and the right breast scar. Nipple tattooing was 
performed at the outpatient clinic.
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With 24  months of clinical follow-up, the patient was 
fully satisfied with the end result.
Argumented answers and explanation according to 
the five references (cited later): 20 lines
 5 Q1. Which anatomic areas need to be examined as 
well during outpatient clinic consultation?
 5 A1. The contralateral breast, the donor-site scar, and 
possible donor sites for future fat harvesting.
 5 Q2. Define the problem in terms of anatomy.
 5 A2. There is volume asymmetry between the left and 
right breasts. Right breast: lack of nipple, irregulari-
ties, and volume deficit of upper pole. Donor site: 
dogears, scar irregularities, and scar hypertrophy.
 5 Q3. What could be a nonsurgical approach of the 
problem?
 5 A3. Silicone application on all hypertrophic scars.
 5 Q4. What could be a surgical approach of the problem?
 5 A4. Donor-site dogear correction, nipple plasty or 
tattooing, scar lipofilling, contralateral breast reduc-
tion, or a combination of these strategies.
 5 Q5. What should always be checked in postoncologi-
cal patients before surgery?
 5 A5. If they have attended routine oncological checkups.
62.1   Conclusion
There are different surgical options for breast reconstruc-
tion: immediate or delayed prosthesis-based reconstruc-
tion, oncoplastic reconstruction, fat grafting, and free 
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or pedicled flap reconstructions [1–4]. Different tech-
niques leave different scars on the breast. Nonsurgical 
approaches for breast scarring after reconstruction are 
silicone application and/or corticosteroid injections. 
Physical examination should always include examina-
tion of the contralateral breast, the donor-site scar, and 
possible donor sites for reconstructive purposes. There 
is a great role for autologous fat grafting in these recon-
structive procedures. Other (minor) corrections can be 
performed simultaneously.
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Take-Home Message
 5 Scar problems after various types of breast recon-
struction are common. Many different corrections 
can be combined in one or multiple sessions.
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63.1   Medical History
A 28-year-old man became paraplegic after a car acci-
dent 10 years ago. He presented repetitive pressure 
ulcers on the sacrum and the ischions, with successive 
surgical procedures (flaps, negative pressure, and skin 
grafting) on both sides.
He was successfully treated on the left side using a 
rotation flap for an ischiatic pressure ulcer, allowing to 
restart verticalization. The seated position was allowed 
after 2 months, progressively allowing a 12-hour-a-day 
seated position. The flap was followed every month and 
a progressive crushing of the fat under the ischial tuber-
osity was noted for a long time, with transient signs of 
redness appearing 1 year after surgery (. Fig. 63.1) A 
Coleman technique using 300 cc of fat was proposed.
 ? Questions to Medical History
 5 What is the rationale of  using fat transfer in a 
patient who seems not to respect the postopera-
tive restrictions?
 5 How to calculate the volume of  fat to inject?
kIntervention 1:
One year later, a Coleman technique was proposed and 
administered, using 300 cc of fat obtained from the abdo-
men by liposuction. The fat was centrifugated 3000 t/min 
during 3 min, and then the substratum was extracted and 
used as a filler (. Fig. 63.2). The patient was authorized 
to remain seated 1 hour a day after 2 weeks and then pro-
gressively 1 hour more each month, till 12 hours a day.
 ? Question Intervention 1
 5 Is there a risk to inject a large fat volume under a 
suffering skin?
 5 Which postoperative protocol is given to the 
patient in order to prevent the recurrence?
kIntervention 2:
The patient was followed regularly, and a second injec-
tion was done 1 year after the first one (. Fig. 63.3), 
in order to compensate a recurrent diminished fat vol-
ume. The injected fat volume was increased to 450 cc. 
The patient was informed to limit his seated position 
to a maximum of  6  hours a day and to check every 
day the ischial area, the cushion was reanalyzed and 
changed.
The patient did not present any recurrence after 
2 years of follow-up.
  . Fig. 63.1 Paraplegic patient operated 1 year before using a rota-
tion ischial flap on the left side. The fat mattress under the flap skin 
begins to crush, exposing the patient to the risk of  recurrence
  . Fig. 63.2 Fat injection 300 cc, under the flap skin in the most 
exposed area when the patient is seated
  . Fig. 63.3 A second 450 fat injection was administered 1 year later
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 ? Question Intervention 2
 5 Has the patient been informed about the risk of 
recurrence?
 5 How to adapt the behavior of  the patient during 
the postoperative period in order to prevent the 
recurrence?
 v Answers
Fat transfer has been proposed since a long period 
of  time as a filler [1], and used alone or in combina-
tion with PRP [2]. However, the literature suggests 
that transplanted adipocyte stem cells bring some 
mechanical properties [3] and help to regenerate the 
subcutaneous tissues [4], a reason why injections 
can be  administered even under a lightly suffering 
skin. In this case the postoperative pressure applied 
over the flap and then over the fat injected area was 
too high and the patient was not correctly following 
the protocol. A second chance was given after some 
alarming signs of  suffering on the ischial area had 
appeared. The volume of  injected fat was increased 
and the  therapeutic education provided to the pa-
tient was enhanced. The patient was particularly en-
couraged to limit the daily seating, which he finally 
accepted, a crucial point to prevent another recur-
rence.
References
 1. Moseley TA, Zhu M, Hedrick MH. Adipose-derived stem and 
progenitor cells as fillers in plastic and reconstructive surgery. 
Plast Reconstr Surg. 2006;118(3 Suppl):121S–8S.
 2. Alser OH, Goutos I.  The evidence behind the use of  platelet- 
rich plasma (PRP) in scar management: a literature review. 
Scars Burn Heal. 2018;4:2059513118808773. https://doi.
org/10.1177/2059513118808773. eCollection 2018 Jan–Dec.
 3. Atashroo D, Raphel J, Chung MT, Paik KJ, Parisi-Amon A, 
McArdle A, Senarath-Yapa K, Zielins ER, Tevlin R, Duldulao 
C, Walmsley GG, Hu MS, Momeni A, Domecus B, Rimsa JR, 
Greenberg L, Gurtner GC, Longaker MT, Wan DC.  Studies in 
fat grafting: Part II.  Effects of injection mechanics on material 
properties of fat. Plast Reconstr Surg. 2014;134(1):29–38.
 4. Scioli MG, Bielli A, Gentile P, Mazzaglia D, Cervelli V, Orlandi 
A.  The biomolecular basis of  adipogenic differentiation of 
adipose-derived stem cells. Int J Mol Sci. 2014;15(4):6517–26. 
https://doi.org/10.3390/ijms15046517. Review.
Open Access This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons. 
org/licenses/by/4. 0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appro-
priate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if  changes were made.
The images or other third party material in this chapter are included in the chapter’s Creative Commons license, unless indicated otherwise 
in a credit line to the material. If  material is not included in the chapter’s Creative Commons license and your intended use is not permitted by 
statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
Take Home Message
Adipocyte stem cells have provided some evi-
dence in scar improvement. This chapter intro-
duces the use of  adipocyte derived fillers in scars 
presenting adherence to the underlying struc-
tures or depressions compared to adjacent areas. 
The use of  fat grafting prepared with simple 
techniques is now considered as a useful adjunc-
tive technique in resurfacing pathological scars.
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A 11-year-old male visited the outpatient clinic with his 
parents because of unpleasing esthetic result after surgi-
cal correction of unilateral cleft lip and palate in China. 
There are no additional operative data available. The 
cleft palate and lip were not part of a genetic syndrome. 
There were no other comorbidities.
He stated that he was not pleased with the aesthetic 
result of the cleft surgery and that the main problem for 
him was asymmetry of the perioral area. There were no 
functional complaints in the domains of speech, eating, 
and/or drinking.
 ? Questions (4 max)
 5 Q1. Define the problem in terms of  anatomy
 5 Q2. What is the Rose–Thompson effect?
 5 Q3. What would be the surgical approach to this 
problem?
 5 Q4. What (non)surgical methods can be chosen to 
optimize postoperative scarring?
 
Immediate postintervention situation: Correction of 
these deformities in children is best performed under gen-
eral anesthesia. Intubation is performed using an RAE 
(Ring-Adair-Elwyn) tube, which is a prebent tube that 
facilitates adequate reach of the operative area. The oper-
ative area is marked using skin marker that does not wash 
away or fade out during sterile exposition and surgery. 
The operative region is infiltrated with a mix of lidocaine 
and adrenalin.
The scar was excised using a concave excision pattern, 
making use of the Rose–Thompson effect. With one addi-
tional Z-plasty, adequate scar length was achieved. Recon-
figuration of misaligned lip mucosa was achieved in the 
same session. The subcutaneous plane was closed using 
resorbable sutures. The skin was closed using skin glue.
Argumented answers and explanation according to the 
five references (cited later): 20 lines
 5 Q1. Define the problem in terms of anatomy.
 5 A1. Postoperative scar contracture of philtral scar 
with subsequent effect on nose and lip esthetics. 
Also, misalignment of lip mucosa was observed.
 5 Q2. What is the Rose–Thomson effect?
 5 A2. The effect of scar lengthening by using concave 
excisions of the scar, which is subsequently closed in 
a straight line
 W. B. van der Sluis and J. P. W. Don Griot
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 5 Q3. What would be the surgical approach to this 
problem?
 5 A3. Use of the Rose–Thompson effect in combina-
tion with one or multiple Z-plasties or a combination 
of these strategies. An alternative approach might be 
using fat grafting of the scar; however, this probably 
provides a less predictable result.
 5 Q4. What (non)surgical methods can be chosen to 
optimize postoperative scarring?
 5 A4. Injecting the orbicularis oris with botulinum toxin, 
silicon application in the postoperative phase, using 
glue instead of sutures for tissue approximation.
Open Access  This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons. 
org/licenses/by/4. 0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appro-
priate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if  changes were made.
The images or other third party material in this chapter are included in the chapter’s Creative Commons license, unless indicated otherwise 
in a credit line to the material. If  material is not included in the chapter’s Creative Commons license and your intended use is not permitted by 
statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
Take-Home Messages
 5 Cleft lip scars influence lip, philtrum, and nose 
aesthetics.
 5 In secondary lip correction, cleft surgeons typi-
cally make use of the Rose–Thompson effect, one 
or multiple Z-plasties, or a combination of these 
strategies.
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ACC, see Anterior cingulate cortex
Acne inversa 407
Acne keloidalis nuchae (AKN) 30
Adhesive sutures 498
Adipose-derived stem cells (ADSCs) 334, 339, 341
Adjustable tensors 499, 500
Adjuvant radiation therapy 344
Adjuvant therapy 375
Advanced therapy medicinal products (ATMPs) 322
Aesthetic Plastic Surgery (ASAPS) 334
Aesthetic surgery, see Cosmetic surgery
Affymetrix-based microarray analysis 70
AFL, see Ablative fractional laser
Alexandrite and diode lasers 520
Allantoin 211, 212
Alloderm® 320
Allogeneic cell therapy 452, 454
 – cellular dermal substitutes 452, 453
 – embryonic(-like) stem cells therapy 454
 – human allogeneic epidermal sheets 452
 – human dermal fibroblasts therapy 452, 453
 – human skin equivalent 453
 – mesenchymal stromal cells for skin regeneration 453, 454
 – in scar management field 452
 – skin bioprinting of  skin 453
Allogeneic fibroblasts and keratinocytes 454
Alopecia 369
Alpha–smooth muscle actin (α-SMA) 21–23, 477
American Societies of Plastic Surgeons (ASPS) 334
Amiloride 205
Aminolevulinic acid photodynamic therapy (ALA-PDT) 354
Amniotic fluid 398
Androgen receptor (AR) expression in genital skin 415
Angiogenesis 5, 20, 105
Angiogenesis dilation 104
Antera 3D 171
Anterior chest wall keloid 275








Artery perforator flap (aOAP) 420
Asher-McDade (AMD) system 55
Atrophic acne vulgaris scarring 354
Atrophic scars 46, 354, 533
 – atrophic acne vulgaris scarring 354
 – burn atrophic scars 360, 361
 – common principles 354
 – dermal lift techniques
 – punch excision 355
 – subcutaneous incision 355
 – fat injection 532
 – isotretinoin treatment 356
 – management of  354
 – medical history 532
 – resurfacing and tightening techniques
 – chemical peels and microneedling 355
 – microdermabrasion 354
 – rotation ischial flap 532
 – state of  art and combinatorial approaches 356, 357
 – fractional radiofrequency 356, 357
 – high-pressure dermal filler deposition 357, 358
 – laser 358, 359
 – striae albae 358–360
 – vascular laser 361
 – volume-imparting techniques
 – dermal and fat autografting 356
 – filling techniques 356
Auto-erotic/self-inflicted genital injuries 408
Autologous fat graft 334
 – for facial rejuvenation 334
B
Bacteriostatic normal saline (BNS) 223
Balanced diet 388
Balanitis xerotica obliterans, see Lichen sclerosus et  
atrophicus (LSC)
Basic fibroblast growth factor (bFGF) 104
Behçet’s disease 408, 418
Biaxial stretch testing 174
Bilateral cleft lip 52, 53
Bilateral cleft palate 52
Bilateral gracilis muscle flaps 421
Biological effective dose (BED) 346
Blast effect 357
Bleomycin 373, 376, 402
Bock Quality of Life Scale 126
Body dysmorphic disorder (BDD) 389
Botulinum toxin 537
Botulinum toxin A (BoNTA) 390, 392
 – demand for 220
 – effects on immature scars 221
 – neuronal mechanism of  action of  220, 221
 – non-neuronal mechanism of  action of  221
 – fibroblasts 222
 – inflammatory cascade 221, 222
 – keratinocytes 222, 223
 – on vascular endothelium 223
 – structure 220
 – treatment
 – dosage 224
 – keloid and hypertrophic scars 224
 – practical guidelines for application 224, 225
 – preparations 223
 – reconstitution 223, 224
 – timing 223
 – usefulness 223
Brachytherapy 344, 345, 347




Breast reconstruction, scar after
 – anatomic areas examination 530
 – immediate post-intervention situation 529
 – non-surgical approach of  problem 530
 – problem in anatomy 530
 – surgical approach of  problem 530
Brisbane burn scar impact profile (BSSIP) 126–127
Broad thumb-hallux syndrome 32
Burn atrophic scars 360, 361
Burn injury 430, 462
 – factors impacting adjustment
 – appearance,importance of  432
 – burn severity and scarring 431, 432
 – concealed scars 432
 – facial involvement 432
 – gender 432
 – genital wounds and scars , treatment of  420–422
 – interference of  psychological problems with 432, 433
 – management 433
 – psychological and social impact of  living with scars
 – body-esteem and self-esteem concerns 431
 – social self-consciousness of  appearance 431
 – psychological problems after 430, 431
Burn scars 146
 – burn injuries and treatment 38
 – acute phase 38, 39
 – burn care 38
 – incidence 38
 – clinical relevance 42
 – factors predicting scar outcome
 – injury and treatment characteristics 41, 42
 – patient characteristics 41
 – patient, injury and treatment characteristics combined 42
 – prevalence and their consequences
 – contractures 40
 – hypertrophic scarring 39
 – maturation pattern 40, 41
 – reconstructive surgery 40
 – scar quality assessment 40
Burnt patient healing 47
C




Cell-based expansion process 314
Cell-based therapies 314
Cellular dermal substitutes 321, 452, 453
Cellular mechanosensors 12




Chemical reconstruction of skin scars (CROSS) 355
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 – pharmacology and mechanism of  action 246
 – in scar treatment 247
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 – of  steroids 402
Intralesional triamcinoloneacetonide 369
Intrusions 430
Invasive techniques in scar management
 – Local flaps (see Local flaps)
 – scar resurfacing (see Resurfacing)






Japan Scar Workshop (JSW) scar scale (JSS) 134
 – classification table 134
 – clinical suitability and usefulness of  136, 140
 – evaluation table 134, 136
jet volumetric remodeling (JVR) technology 357









Keloid dermal fibroblasts (KDF) 65
Keloid disease (KD) 62
Keloid fibroblasts (KFs) 69, 70
Keloidogenesis 33
Keloids 12–17, 187, 190, 373
 – distribution of  mechanical forces 16
 – epidemiology of  30
 – chest and shoulder keloid, Asians, Africans, and 
Caucasians 31
 – demographic risk factors 30–32
 – environmental risk factors 32, 34
 – genetic risk factors 32, 33
 – incidences of  30
 – in world 31
 – nerve fiber density 24
 – on specific regions of  body 15
 – symptoms, pain/itch 83
Keloid scarring 22, 46, 62, 105, 372, 392, 399, 462
 – characterized by 458
 – corticosteroid tapes/plasters (see Corticosteroid tapes/plasters)
 – elderly, scars in 382
 – epidemiology 47
 – genetics of
 – epigenetics 72
 – gene expression 66–68
 – genetic elements with 63
 – genetic susceptibility 62
 – HLA immunogenetics 62, 63
 – large scale population single-nucleotide polymorphism (SNP) 65
 – linkage 64
 – microarray analysis 71
 – MicroRNAs 65, 69
 – small interfering RNA (siRNA) 69, 70
 – JSS 134, 136
 – risk factors 47
Keratinocytes 6, 7, 222
Kikuhime pressure sensor 229
Kirschner wire transfixation 368





Langer lines 8, 210, 499
Large scale population single-nucleotide polymorphism (SNP) 65
Laser 358, 359, 368
Laser assisted delivery of therapeutic agents 444
 – ablative fractional laser-assisted drug delivery 445, 446
 – carbon dioxide (CO2) laser 445
 – drugs and bioactive molecules 446
 – corticosteroid 447
 – 5-fluorouracil (5-FU) 447, 448
 – emerging devices 448
 – erbium 445
 – laser systems used for 444
 – limitations 448
 – MTZ
 – density and coverage 446
 – density and depth 446
 – depth and energy 446
 – technique and parameters, MTZ density and depth 446
Laser assisted drug delivery (LADD) 280
 – clinical consensus 283
 – fractioned CO2 laser 283
Laser-assisted skin healing (LASH) 510
Laser Doppler flowmetry (LDF) 156
Laser Doppler imaging (LDI) 104, 156
Laser speckle imaging (LSI) 156, 157
Laser speckle perfusion imaging (LSPI) 156
Laser therapy 367, 402, 510
Leprosy 32




Light induced optical breakdown (LIOB) 358
Linear hypertrophic scarring 368
Linkage 64
Linkage disequilibrium (LD) 64
Lipofilling 337, 341
 – Dupuytren’s disease 340
Lipotransfer 356
Liquid nitrogen 236, 240
Local flaps 17, 366
 – classification 302
 – island flap 302
 – propeller flap 305, 307
 – scar contracture reconstruction
 – abdomen 304
 – anterior chest wall 308
 – anterior neck 305
 – behind knee 304
 – cubital fossa 303, 307
 – digital web 306
 – on axilla 306
 – selection 302, 303
 – skin-pedicled flap 302
 – square flap method 304, 305
 – transposition flap 303, 304
Long-pulsed 1064 nm Nd:YAG laser
 – abdomen hypertrophic scar 274
 – anterior chest wall keloid 275
 – follow-up of  keloids and hypertrophic scars 274, 275
 – genetic factors 272
 – indications 272
 – for keloids and hypertrophic scars 272
 – limitations 272, 273
 – lower lip hypertrophic scar 274
 – scapular keloid 276, 277
 – shoulder keloid 276
 – treatment settings 273, 274
 – upper lip hypertrophic scar 273
Low dose 5-Fluorouracil
 – chemotherapy 253
 – HTS 253
 – keloid treatment
 – anti-indications and steroid 257
 – application 253, 254
 – chemo-radiotherapy, post-surgical reoccurrence 261
 – drug concentrations adjustment and injectional  
interval 255
 – drug preparation 254
 – drug pressure 256
 – injection procedure 254
 – intralesional injection for large sized keloid 259
 – post-surgical monitoring and preventive injection  
of  5-FU 257
 – preventing keloid from reoccurrence after surgical  
excision 260
 – remodeling of  keloid into normal-looking skin 257, 258
 – reoccurrence prevention 256
 – sufficient therapy 259, 260
 – surgical procedure for keloid excision 256, 257
 – steroids 253
Low-dose-rate (LDR) brachytherapy 346
Lower lip hypertrophic scar 274
Lowe syndrome 32
Low-molecular-weight (LMW) HA 5
Lymphedema 418, 423
Lysyl oxidase (LOX) 5
M
Macrophages 398
Makeup, definition of 436
Male genitalia
 – anatomy of  408, 411, 412
 – scar formation 417
Manchester scar scale 126
Manual massages 216
 – efficacy 217
 – indications 216
 – morice orthodermic stretching 216
 – palpate-rolling 217
 – punctual crushing 216




Mastopexy 510, 513, 515
 – case reports 511–514
 – overall complication rate 510
Matriderm® 320, 368
Matrix metalloproteinases (MMPs) 8, 20, 22, 24, 222–223, 446
Matrix-metalloprotease 1 (MMP1) 195
Matrix remodeling 486







 – objective measurement instruments 112




Mechanobiology of cutaneous scarring 12
 – cellular and tissue responses to mechanical forces 12, 13
 – pathological scar animal model, mechanotransduction 16
 – pathological scars, development of  13–15
 – role of  12
 – scar prevention and treatment
 – stabilization materials 16
 – sutures 16, 17




Mechanotransduction 7, 16, 458, 477, 486
Mechanotransduction pathway inhibitors 460, 461
Mederma Skin Care gel 390
Medical makeup 436
 – benefits of
 – psychological impact 436
 – social impact 436
 – characteristics of  436
 – classes 440
 – color correction 437
 – compact foundation creams 438, 439
 – complementary colors 437
 – corrective foundations 438
 – corrector pencils
 – eyebrows 439
 – lips 440
 – definition of  436
 – ensure make-up lasts longer 440
 – evaluation of  needs 436
 – fluid foundation correctors 439
 – makeup base 436
 – male-up removal 440
 – powder 439
 – value of  colors 437, 438
Medical needling 290, 291, 366
 – ablative methods 289
 – benefits 289
 – cosmetic needling 290
 – dermal remodeling 294
 – dermal thickness and erythema 295
 – dermatological approach 288
 – effects 290
 – improved perfusion 294, 295
 – maximal outcome and minimal risk 288
 – medical needling 290, 291
 – moisture 296
 – needling techniques 290
 – postinterventional treatment
 – complications 291, 292
 – post-needling wound healing cascade 292, 293
 – postoperative wound management 291
 – procedure 289
 – scarless wound healing 293
 – surgical needling 291
Melanin 174
Mesenchymal stem cells (MSC) therapy 22, 452
 – for skin regeneration 453, 454
Metalloproteinases 381




MicroRNAs (miRNAs) 22, 65, 69
Microscopic epidermal necrotic debris (MEND). 361
Microscopic thermal damage zones (MTZs) 360
Microstomia 339, 364, 365
Microthermal zones (MTZs) 444
 – density and coverage 446
 – density and depth 446
 – depth and energy 446
Microwave Amplification by Stimulated Emission of 
Radiation-device (MASER) 264
Millard lip closure 53
 – postoperative scar pattern 54
 – pre-operative planning 53
Millard-Mulliken technique 53
Minimal clinically important difference (MCID) 162, 163
Minimal-invasive technologies for treatment of HTS and keloids
 – corticosteroids (see Corticosteroids)
 – cryosurgery (see Intralesional cryosurgery)
 – long pulsed Nd
 – YAG Laser (see Long-pulsed 1064 nm Nd:YAG laser)
 – low dose 5-FU (see Low dose 5-Fluorouracil)
 – medical needling (see Medical Needling)
 – PDL (see Pulsed-dye laser (PDL))
Minimally important change (MIC) 150
Mitomycin C 402
MMPs, see Matrix metalloproteinases
Mobilizations 231
Modified Vancouver Scare Scale 39
Moisturizers and lotions 230
MoorFLPI-2 blood flow imager 156
MoorLDI Imaging System 156
MoorVMS-LDF 156
Morice orthodermic stretching 216
Multiphoton excited autofluorescence (MEA) 173
Myofibroblast 20, 23, 25, 46
 – cellular origins of  21, 22
 – in pathological scarring and fibrosis 22, 23
 – phenotype, morphological and biochemical  
characteristics of  21
 – phenotype, regulation of  22, 23
N
Narrow-band reflectance spectrophotometry 105
Narrow-band spectrophotometry 152
Nasoalveolar molding (NAM) 53
Natural moisturizing factors (NMF) 161
Near-infrared spectroscopy (NIRS) 165
Necrotic zone 334
Negative alterations in cognitions and mood 430
Negative pressure wound therapy (NPWT) 398, 500, 501
Neuregulin-1 (NRG1) 70




Non-ablative fractional lasers (NAFL) 358, 448
Nonablative fractional resurfacing (NAFR) 360







Normal wound therapy 211
Novomaix® 321
Nuclear factor erythroid 2-related factor 2 (Nrf2) 70
Nuclear factor-κB (NF-κB) 246
O
Objective assessment tools 150
 – clinimetrics 150, 151
 – colour
 – erythema and pigmentation 151
 – reflectance spectroscopy 151
 – narrow-band spectrophotometry 152
 – tristimulus colorimetry 151, 152
 – elasticity 153
 – cutometer 153–155
 – DermaLab elasticity probe 155
 – tonometry 155
 – perfusion 156
 – laser Doppler imaging 156
 – laser speckle imaging (LSI) 156, 157
 – spectrophotometric analysis 152
Objective scar assessment
 – choosing the tools 144
 – dermal water content measurement
 – confocal Raman Spectroscopy 164, 165
 – near-infrared spectroscopy 165
 – interpreting therapeutic success with
 – clinically important difference 146
 – data assessment and evaluation 146
 – optimizing measurement process
 – configuring and calibrating assessment tools 145
 – patient preparation 145
 – performing measurements 145, 146
 – preparing the surroundings 144
 – physical parameters 160
 – physiological parameters 160
 – skin hydration 160
 – dermal water content 161
 – in epidermis 160, 161
 – measurement 161–164
 – tactile sensitivity 165
 – transcutaneous oxygen tension 165
Occlusive dressing technique (ODT) 493
Occupational therapy 364
Oculocerebrorenal syndrome of Lowe [OCRL] 32
Office of Cellular, Tissue and Gene Therapies (OCTGT) 322
Onion extract 194, 197, 198
 – allantoin 211, 212
 – fractional CO2 210, 211
 – heparin 211
 – keloid fibroblasts 210
 – quercetin 210
 – scar creams 210
 – tattoos 212
 – topical gels 210
Open chamber method 162, 163
Optical biopsy 170, 175




Paediatric patients, scars in 399, 400
 – defective/dysgracious scars 403
 – healing specificities in children
 – foetal healing 398
 – paediatric peculiarities in healing 398
 – wound healing management 398, 399
 – pathological scars 399
 – clinical and histological aspects 399, 400
 – easing factors 400, 401
 – prevention of  401
 – treatment of  401, 402
 – scars and growth 403
Pain 382
 – acute 88
 – analgesic effect 340
 – chronic 88
Pain pathway
 – ascending pathway 88
 – central sensitization 90
 – descending pathway 88–89
 – peripheral receptor activation 88
 – peripheral sensitization 89
Pain symptoms, subtypes
 – nociceptive 88
 – non-nociceptive 88
Palatal scarring
 – maxillary growth 56
 – palatal closure 55, 56
 – palatal closure, timing of  56




Pathological scars 12, 104, 150, 341, 392, 399
 – animal model, mechanotransduction 16
 – clinical and histological aspects 399, 400
 – development of  13–15
 – easing factors 400, 401
 – prevention of  401
 – treatment of  401, 402
Patient and observer scar assessment scale (POSAS) 39–41, 55, 105, 
126, 134, 206, 212, 347
Patient Scar Assessment Questionnaire 126
Patient-Reported Impact of Scars Measure (PSAQ) 126
Paxilin (Pax) 7
Pedicled expanded deltopectoral flaps 326
Pedicled/free flaps 421
Penile lymphedema 420
Penile skin necrosis 419
Percutaneous collagen induction (PCI), see Medical Needling
Perforator flaps 121
Perforator-pedicled propeller (PPP) flap 305, 307
Perfusion 294, 295
Perfusion units (PU) 156
PeriCam PSI 156
PeriFlux 5000 156
Peri-operative botulinum toxin 53




 – cellular dermal substitutes 321
 – dermal substitutes
 – dermal scaffolds 320, 321
 – tissues 320
 – epidermal cells/cultured epidermal autografts CEA 318, 319
Perry Romberg syndrome 340
Pharmacological adjuncts 94–97




Photodynamic therapy (PDT) 373, 374
Physical effects 479, 480
Physiological effects 479, 481
Physiological scars 104
Picosecond fractioned 1064 lasers 281
Picosecond laser 358
Pigmentation disorders 110
Pigmented skin 373, 375, 376
Pixel RF microplasma therapy 468
PixelRF 466
Plastic-reconstructive surgery 421
Platelet rich plasma (PRP) 340, 341, 355, 391, 533
Platelets 4, 292
Polarization sensitive OCT (PS-OCT) 172
Polarization Sensitive SHG (PS-SHG) probes 174
Polydeoxyribonucleotide (PDRN) 448
Poly-L-lactic acid (PLLA) 447
Polymethylmethacrylat (PMMA) microspheres 418
Positron emission tomography 88
Post traumatic nerve entrapement 339
Postacne AFL Protocol 359
Post-acne scarring 355, 357
Postinflammatory erythema (PIE) 104
Postinflammatory hyperpigmentation 110
Postoperative laser therapy 55
Posttraumatic stress disorder (PTSD) 430
Powernet structure garments 229
Pressure garment therapy 194–196








 – neurogenic 90
 – neuropathic 90
 – pruritogenic 90
 – psychogenic 90
Prutitic pathway
 – peripheral nerve fibers 91
 – peripheral receptor activation 90–91
 – spinal cord/itch specific neurons 91
 – thalamocortical level 91–93
 – thalamo-cortical level 91
Pulsed-dye laser (PDL) 194, 198, 361, 392, 520
 – application on hypertrophic scars  
and keloids 266, 267
 – clinical relevance 268
 – clinical studies and evidence 267, 268
 – historical development 264
 – laser light vs. regular light 265
 – mode of  action 265
 – selective photothermolysis 266




Q-switched ruby laser 506, 507
Quadrantectomy 341
Quadrige effect 119
Qualitative global grading system 355
Quercetin 210
R
Radial extracorporeal shockwave therapy 488
Radiation therapy
 – biomechanisms of  in keloid treatment 347
 – complications 346, 347
 – excision and 345, 346
 – recurrence 346
 – safety concerns 347
 – types of
 – brachytherapy 344, 345
 – EBRT 344
Radiation Therapy Oncology Group (RTOG) 346
Radiofrequency (RF) 448
Radiofrequency with microneedles (RFM) 357
Radiotherapy 340, 344, 392
 – skin color, scar management 374
RAE tube 536
Raman spectroscopy 164
Random skin flaps 121
Recalcitrant scars 392
ReCellTM 314, 319
Receptor tyrosine-protein kinase erbB-2 (ErbB2) 70
Recombinant human IL-10 (rhIL-10) 460
Reconstructive surgery, prevalence of 40
Reepithelialization 6
Reflectance confocal microscopy (RCM) 172
Reflectance spectroscopy
 – narrow-band spectrophotometry 152
 – tristimulus colorimetry 151, 152
Regenerative non-scarring wound healing 180
Rehabilitation programs 120
Reinforced suture materials 498
Reliability, definition of 131, 150
Remodeling phase 186
Remodeling, fetal wound healing 8
Renovo superficial scars 80
Reparative’ wound healing 180
Re-pigmentation 314, 316
Resurfacing
 – clinical pathway of  healing 312, 313
 – definition 312
 – initial skin injury mechanism 312
 – intervention timing 313
 – interventions 312
 – natural history of  scarring 316
 – post intervention scar management 315
 – preparing scar wound bed for
 – chemical peels 313
 – dermabrasion 313
 – sharp dissection tools 313, 314
 – timing and technique 312
 – wound repair techniques 314
Retracted scars 48
Retrograde fat distribution 335
Right palmar hypertrophic scar 518
Rose-Thompson effect 536, 537
Rotation flap 532
Rotation ischial flap 532
Rubinstein-Taybi syndrome (RSTS) 32
S
Sandwich technique 376
Scapular keloid 276, 277
Scar assessment scales 126–131
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 – domains 126
 – Manchester scar scale 126
 – measurement properties/clinimetrics 127, 131
 – POSAS 126
 – Scar Q 127
 – Seattle and Hamilton scale 126
 – VSS 126
Scarbase Duo™ 162
Scar colour 151
Scar erythema 104, 105
 – clinical treatments
 – laser treatments 106
 – medical needling 106
 – mechanisms
 – allergies 104
 – inflammation 104
 – mechanical stimulation 104
 – other chemical agents 104
 – radiation 104
Scar formation 4, 462
 – general mechanisms of  20, 21
 – innervation in skin healing 24, 25
 – mechanical tension 23, 24
 – myofibroblast
 – cellular origins of  21, 22
 – in pathological scarring and fibrosis 22, 23
 – phenotype, regulation of  22, 23
 – myofibroblast phenotype, morphological and biochemical 
characteristics of  21
 – therapeutic options 25
Scarless wound healing 4, 5, 293
Scar Q 127
Scar quality 40, 112
Scarred hypertrophy in burned patients 48
Scar redness, clinical measurement
 – compression therapy 106
 – Doppler ultrasound technique 105
 – 3D scanner 106
 – ultrasound and nuclear magnetic resonance 106
Scar Risk and Acceptance Matrix 386, 387
Scars
 – definition of  39
 – in elderly 382
 – epidemiology 380
 – frailty, factors of  380
 – frequent cormobidities altering wound healing 381
 – hyperkeratosis 382
 – hypertrophic or keloid scars 382
 – Marjolin’s ulcer 382
 – in medicine 380
 – post irradiation scars 382
 – skin aging to dermatoporosis 381
 – wound healing, consequences of  age 381
 – impact of  48
 – treatment for anatomical localizations
 – face 364–366
 – feet 368
 – hair 366
 – hands 367, 368
 – joints 368, 369
Scar symptoms
 – pain 88
 – pathophysiology and epidemiology
 – hyperpigmentation 110
 – hypopigmentation 110
 – maturation 111
 – pruritus 90
Scar thickness 104, 105
Scar tissues hyperproliferation 104
Seattle and Hamilton scale 126
Second harmonic generation (SHG) microscopy 174, 175
Secondary cleft lip reconstruction 55
Selective photothermolysis 266
Self  adherent smart silicone 498, 499
Self-inflicted scars 180
Semi-open chamber method 162, 163
Semmes-Weinstein Aesthesiometer 165
Sensory nervous system 24
Sex hormone receptor 415
Shock wave therapy (SWT)
 – dose effect relationship 487
 – for electro-hydraulic devices 487
 – in scar management 486
 – to skin defects 486, 487
 – in soft tissue defects
 – in scar management 488
 – in wound healing 487, 488
SIAscope 153
Silicone application 55
Silicone based products 194, 197
Silicone gel 341
 – epithelium
 – clinical studies 206, 207
 – delay in epithelization 204–206
 – sheets versus creams 207, 208
 – history 204
 – and sheets 194, 197, 200, 229, 230, 373, 374, 390
 – and tapes 498
Single-nucleotide polymorphisms (SNPs) 372
Skicon instruments 163, 164
Skin appendix formation 8
Skin bioprinting of skin 453
Skin capacity 118
Skin-colorimeter CL 400 151
Skin color, scar management 373
 – in Asian skin 376
 – non-surgical
 – electrical stimulation 374, 375
 – intra-lesional steroid injections 373
 – photodynamic therapy 374
 – radiotherapy 374
 – silicone gel/sheet 373, 374
 – scars evolve differently in 372, 373
 – surgical 375
 – cryosurgery 375, 376
 – recurrence rate 376
 – response rates and side effects 376
 – surgical excision and adjuvant therapy 375
 – treatment modalities for 374
Skin grafts 17, 121
Skin homeostasis 22
Skin hydration 160
 – definition of  160
 – dermal water content 161
 – in epidermis 160, 161
 – measurement 161
 – closed chamber method 163
 – Corneometer CM825® 163, 164
 – open chamber method 162, 163
 – recommendations for 164
 – semi-open chamber method 162, 163
 – Skicon 200EX 164
 – stratum corneum hydration level 163
 – trans-epidermal water loss 161
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Skin-pedicled flap 17, 302
Skin regeneration 4, 8
Skin resurfacing 326
Skin substitutes
 – full skin substitutes 321
 – permanent wound coverage (see Permanent wound  
coverage)
 – regulatory/safety issues 322
 – role 318
 – subcutaneous fat 321, 322
Skin using a split-thickness skin graft (STSG) 318
SMAD intercellular transduction protein 390
Small interfering RNA (siRNA) 69, 70
Sonophoresis 444
Spectrophotometric analysis (SIA) 152
Splinting 230
Split-thickness autografts 518
Split-thickness skin grafts (STSG) 17
Spontaneous keloids 356
Spray-painting technique 358
Square flap method 304, 305
Standard error of measurement (SEM) values 151
Statics folds 216, 217
Stereophotogrammetry device 170
Steroid tape 274, 492
Stony Brooks Scar Evaluation Scale 126
Stratum corneum (SC) 160, 161, 163
Stratum granulosum (SG) 160
Striae Albae 358–360
Striae atrophicae 358
Stromal vascular fraction (SVF) 334
Structural assessment of scars
 – clinical follow up 170
 – confocal microscopy 172, 173
 – future aspects 175
 – non-linear optical microscopy
 – coherent anti-stokes Raman spectroscopy 175
 – HHG 173
 – MEA 173
 – second harmonic generation microscopy 174, 175
 – third harmonic generation microscopy 175
 – two-photon excited autofluorescence 173, 174
 – optical coherence tomography 172
 – scar thickness 171
 – surface topology 170, 171
 – volumetric analyses 170
Subcutaneous fat 321, 322
Subcutaneous incision 355
Superficial radiation therapy (SRT) 344
Super-thin flap 327, 328
Surgical needling 291
Surviving zone 334
Suture edge tension control technologies 498–500
 – adhesive sutures 498
 – adjustable tensors 499, 500
 – closed incision negative pressure therapy 500, 501
 – reinforced suture materials 498
 – self  adherent smart silicone 498, 499
 – silicone gels and tapes 498












 – chemical peels 114
 – laser therapy 114
 – non-surgical treatment
 – topical treatments 114
 – surgical treatment
 – dermabrasion 115
 – excision 115
 – hypopigmentation
 – camouflage therapy 113
 – dermatography 113
 – laser therapy 112
 – surgical techniques
 – cell therapy 113
 – dermabrasion 113
 – excision 114
 – microneedling 114
 – non-surgical techniques
 – skin grafting 113
Thermal history 236
Thermal therapy 486
Thick hypertrophic scar 107
Third harmonic generation (THG) microscopy 175
1210-nm automated laser system 510
1210-nm laser diode UrgoTouch® 511, 513, 515
Three-dimensional (3D) bioprinting 453
Tissue engineering 318, 322
Tissue expansion techniques 314
Tissue hardness 153
Tissue inhibitors of metalloproteinases (TIMPs) 8, 20, 446
Tissue regeneration 80
TissueTech Autograft System™ 321
TNF-alpha stimulated protein 6 (TSG-6) 454
Tonometry 155
Topical flavonoids 390
Topical steroids, corticosteroid 247
Total body surface area burned (TBSA) 38, 41
Total hip arthroplasty (THA) 501
Touch perception threshold (TPT) 165
Trans epidermal water loss (TEWL) 204, 205, 208
Transcutaneous electrical nerve stimulation (TENS) 94
Transcutaneous oxygen tension 165
TransCyte® 321, 453
Transdermal patches 444
Transepidermal water loss (TEWL) 161, 197, 479
Transforming growth factor β (TGF-β) 210, 372, 390, 459, 460
Transforming growth factor-β (TGF-β1) 21, 210
Transforming growth factor beta 3 (TGF-β3) 199
Transposition flap 303
Triamcinolone 244, 246–249, 392
Triamcinolone acetonide 210, 247, 447, 507
Triamcinolone diacetate 247
Trident flap plasty 367
Tristimulus colorimetry 151, 152
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Tristimulus reflectance colorimetry 105
Trofolastin 359
Tumescent technique lipoaspiration 335
Tumor necrosis factor-α (TNF-α) 246
Tunica dartos 408, 410
Two-photon excited autofluorescence (2PEF) 173, 174
U
Unilateral cleft lip 52
 – Fisher lip closure 53
 – direct postoperative result 54
 – postoperative scar pattern 54
 – preoperative planning 54
 – pre-operative planning 53
 – Millard lip closure 53
 – postoperative scar pattern 54
 – pre-operative planning 53
Unilateral cleft palate 52
Upper lip hypertrophic scar 273
Urogenital and anal orifices 408
V
Vacuotherapy, see Vacuum massage
Vacuum massage 476, 478
 – general effects 477
 – mechanical effects 479
 – physical effects 479, 480
 – physiological effects 479, 481
 – working-mechanism of  477
Vacuum therapy 230
Validity, definition of 150
Vancouver Scar Scale (VSS) 39, 126, 206
VapoMeter 163
Vapor pressure (VP) gradient 161




Vesicle–associated membrane protein (VAMP) 221
Visioscan VC 98 (Visioscan VC 98) 171
Visual analog (VAS) scales 55
Vivascope 172
Volar flexion contractures 367
Volume-imparting techniques
 – dermal and fat autografting 356
 – filling techniques 356
Voluntarily induced scar 180
Von Recklinghausen's disease 32
W
Weinstein Enhanced Sensory Test (WEST) 165
Wound closure
 – cutaneous wound healing 186
 – dermal tension 186
 – granulation tissue 186
 – Z-plasty 187
Wound healing 12, 16, 22
 – children, management in 398, 399
 – consequences of  age 381
 – definition of  4
 – frequent cormobidities altering 381
 – last phase in 4
 – process 105
 – shock wave therapy in 487, 488







Zipline® system 499, 500
Z-plasties 17, 55, 187, 367, 368, 375, 391, 421, 520, 521, 536, 537
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